Part One

A pretty-good reference for the primary exam
# Table of Contents

About Part One 1.1

Download Part One 1.2

How to Pass 1.3

The SAQ 1.4

The Viva 1.5

## Curriculum

### Research Methods and Statistics

- Evidence-Based Medicine 2.1.1
- Study Types 2.1.2
- Clinical Trial Design 2.1.3
- Data Types 2.1.4
- Bias and Confounding 2.1.5
- Frequency Distributions 2.1.6
- Sample Size Calculation 2.1.7
- Statistical Tests 2.1.8
- Statistical Terms 2.1.9
- Risk and Odds 2.1.10
- Significance Testing 2.1.11
- Drug Development 2.1.12

### Pharmacology

- Pharmaceutics 2.2.1
  - Additives 2.2.1.1
  - Isomerism 2.2.1.2
- Pharmacokinetics 2.2.2
  - Modeling 2.2.2.1
  - Absorption 2.2.2.2
  - Distribution 2.2.2.3
  - Metabolism and Clearance 2.2.2.4
  - Elimination 2.2.2.5
  - Bolus and Infusion Kinetics 2.2.2.6
  - Drug Monitoring 2.2.2.7
  - Epidural and Intrathecal 2.2.2.8
  - TIVA and TCI 2.2.2.9
- Pharmacodynamics 2.2.3
  - Receptor Theory 2.2.3.1
<table>
<thead>
<tr>
<th>Receptor Types</th>
<th>2.2.3.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose-Response Curves</td>
<td>2.2.3.3</td>
</tr>
<tr>
<td>Mechanisms of Action</td>
<td>2.2.3.4</td>
</tr>
<tr>
<td>Variability in Drug Response</td>
<td>2.2.4</td>
</tr>
<tr>
<td>Adverse Effects</td>
<td>2.2.4.1</td>
</tr>
<tr>
<td>Drug Interactions</td>
<td>2.2.4.2</td>
</tr>
<tr>
<td>Alterations to Response</td>
<td>2.2.4.3</td>
</tr>
<tr>
<td>Pharmacogenetics</td>
<td>2.2.4.4</td>
</tr>
<tr>
<td>Drugs in Pregnancy</td>
<td>2.2.4.5</td>
</tr>
<tr>
<td>Toxicology</td>
<td>2.2.5</td>
</tr>
<tr>
<td>General Management</td>
<td>2.2.5.1</td>
</tr>
<tr>
<td>TCA Overdose</td>
<td>2.2.5.2</td>
</tr>
<tr>
<td>Organophosphates</td>
<td>2.2.5.3</td>
</tr>
<tr>
<td>Cellular Physiology</td>
<td>2.3</td>
</tr>
<tr>
<td>The Cell Membrane</td>
<td>2.3.1</td>
</tr>
<tr>
<td>Organelles</td>
<td>2.3.2</td>
</tr>
<tr>
<td>Excitable Cells</td>
<td>2.3.3</td>
</tr>
<tr>
<td>Transport Across Membranes</td>
<td>2.3.4</td>
</tr>
<tr>
<td>Fluid Compartments</td>
<td>2.3.5</td>
</tr>
<tr>
<td>Cell Homeostasis</td>
<td>2.3.6</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>2.4</td>
</tr>
<tr>
<td>Respiratory Anatomy</td>
<td>2.4.1</td>
</tr>
<tr>
<td>Airway and Alveolus</td>
<td>2.4.1.1</td>
</tr>
<tr>
<td>Chest Wall and Diaphragm</td>
<td>2.4.1.2</td>
</tr>
<tr>
<td>Variations in Anatomy</td>
<td>2.4.1.3</td>
</tr>
<tr>
<td>Control of Breathing</td>
<td>2.4.2</td>
</tr>
<tr>
<td>Mechanics of Breathing</td>
<td>2.4.3</td>
</tr>
<tr>
<td>Respiration</td>
<td>2.4.3.1</td>
</tr>
<tr>
<td>Compliance</td>
<td>2.4.3.2</td>
</tr>
<tr>
<td>Time-Constants</td>
<td>2.4.3.3</td>
</tr>
<tr>
<td>Resistance</td>
<td>2.4.3.4</td>
</tr>
<tr>
<td>Surfactant</td>
<td>2.4.3.5</td>
</tr>
<tr>
<td>Volumes and Capacities</td>
<td>2.4.3.6</td>
</tr>
<tr>
<td>Spirometry</td>
<td>2.4.3.7</td>
</tr>
<tr>
<td>Work of Breathing</td>
<td>2.4.3.8</td>
</tr>
<tr>
<td>Diffusion of Gases</td>
<td>2.4.4</td>
</tr>
<tr>
<td>Oxygen Cascade</td>
<td>2.4.4.1</td>
</tr>
<tr>
<td>Diffusing Capacity and Limitation</td>
<td>2.4.4.2</td>
</tr>
<tr>
<td>V/Q Relationships</td>
<td>2.4.5</td>
</tr>
<tr>
<td>West's Zones</td>
<td>2.4.5.1</td>
</tr>
<tr>
<td>Topic</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Basics of V:Q Matching</td>
<td>2.4.5.2</td>
</tr>
<tr>
<td>Dead Space</td>
<td>2.4.5.3</td>
</tr>
<tr>
<td>Shunt</td>
<td>2.4.5.4</td>
</tr>
<tr>
<td>Gas Transport</td>
<td>2.4.6</td>
</tr>
<tr>
<td>Oxygen Storage</td>
<td>2.4.6.1</td>
</tr>
<tr>
<td>Carbon Dioxide</td>
<td>2.4.6.2</td>
</tr>
<tr>
<td>Applied Respiratory Physiology</td>
<td>2.4.7</td>
</tr>
<tr>
<td>Positive Pressure Ventilation</td>
<td>2.4.7.1</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>2.4.7.2</td>
</tr>
<tr>
<td>Hypo and Hypercapnea</td>
<td>2.4.7.3</td>
</tr>
<tr>
<td>Position and Ventilation</td>
<td>2.4.7.4</td>
</tr>
<tr>
<td>Humidification</td>
<td>2.4.7.5</td>
</tr>
<tr>
<td>Cough Reflex</td>
<td>2.4.7.6</td>
</tr>
<tr>
<td>Non-Respiratory Functions</td>
<td>2.4.7.7</td>
</tr>
<tr>
<td>Altitude Physiology</td>
<td>2.4.7.8</td>
</tr>
<tr>
<td>Respiratory Changes with Obesity</td>
<td>2.4.7.9</td>
</tr>
<tr>
<td>Neonates and Children</td>
<td>2.4.7.10</td>
</tr>
<tr>
<td>Respiratory Pharmacology</td>
<td>2.4.8</td>
</tr>
<tr>
<td>Anti-Asthma Drugs</td>
<td>2.4.8.1</td>
</tr>
<tr>
<td>Cardiovascular System</td>
<td>2.5</td>
</tr>
<tr>
<td>Structure and Function</td>
<td>2.5.1</td>
</tr>
<tr>
<td>Cardiac Anatomy</td>
<td>2.5.1.1</td>
</tr>
<tr>
<td>Coronary Circulation</td>
<td>2.5.1.2</td>
</tr>
<tr>
<td>Cardiac Cycle</td>
<td>2.5.1.3</td>
</tr>
<tr>
<td>Electrical Properties</td>
<td>2.5.2</td>
</tr>
<tr>
<td>Cardiac Action Potential</td>
<td>2.5.2.1</td>
</tr>
<tr>
<td>Cardiac Output</td>
<td>2.5.3</td>
</tr>
<tr>
<td>Determinants of Cardiac Output</td>
<td>2.5.3.1</td>
</tr>
<tr>
<td>Venous Return</td>
<td>2.5.3.2</td>
</tr>
<tr>
<td>Myocardial Oxygen Supply and Demand</td>
<td>2.5.3.3</td>
</tr>
<tr>
<td>Pressure-Volume Relationships</td>
<td>2.5.3.4</td>
</tr>
<tr>
<td>Cardiac Reflexes</td>
<td>2.5.3.5</td>
</tr>
<tr>
<td>Peripheral Circulation</td>
<td>2.5.4</td>
</tr>
<tr>
<td>Starling Forces</td>
<td>2.5.4.1</td>
</tr>
<tr>
<td>Variations in Blood Pressure</td>
<td>2.5.4.2</td>
</tr>
<tr>
<td>Pulmonary Circulation</td>
<td>2.5.4.3</td>
</tr>
<tr>
<td>Cerebral Blood Flow</td>
<td>2.5.4.4</td>
</tr>
<tr>
<td>Hepatic Blood Flow</td>
<td>2.5.4.5</td>
</tr>
<tr>
<td>Circulatory Control</td>
<td>2.5.5</td>
</tr>
<tr>
<td>Baroreceptors</td>
<td>2.5.5.1</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Valsalva Manoeuvre</td>
<td>2.5.5.2</td>
</tr>
<tr>
<td>CVS Changes with Obesity</td>
<td>2.5.5.3</td>
</tr>
<tr>
<td>CVS Effects of Ageing</td>
<td>2.5.5.4</td>
</tr>
<tr>
<td>Cardiovascular Pharmacology</td>
<td>2.5.6</td>
</tr>
<tr>
<td>Inotropes</td>
<td>2.5.6.1</td>
</tr>
<tr>
<td>Adrenoreceptors</td>
<td>2.5.6.2</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td>2.5.6.3</td>
</tr>
<tr>
<td>Renal System</td>
<td>2.6</td>
</tr>
<tr>
<td>Renal Physiology</td>
<td>2.6.1</td>
</tr>
<tr>
<td>Functional Anatomy and Control of Blood Flow</td>
<td>2.6.1.1</td>
</tr>
<tr>
<td>Glomerular Filtration and Tubular Function</td>
<td>2.6.1.2</td>
</tr>
<tr>
<td>Handling of Organic Substances</td>
<td>2.6.1.3</td>
</tr>
<tr>
<td>Measurement of GFR</td>
<td>2.6.1.4</td>
</tr>
<tr>
<td>Endocrine Functions of the Kidney</td>
<td>2.6.1.5</td>
</tr>
<tr>
<td>Acid-Base Balance</td>
<td>2.6.1.6</td>
</tr>
<tr>
<td>Dialysis</td>
<td>2.6.1.7</td>
</tr>
<tr>
<td>Fluids and Electrolytes</td>
<td>2.6.2</td>
</tr>
<tr>
<td>Sodium and Water</td>
<td>2.6.2.1</td>
</tr>
<tr>
<td>Potassium</td>
<td>2.6.2.2</td>
</tr>
<tr>
<td>Acid-Base Physiology</td>
<td>2.7</td>
</tr>
<tr>
<td>Principles of Acid-Base Physiology</td>
<td>2.7.1</td>
</tr>
<tr>
<td>Compensation</td>
<td>2.7.2</td>
</tr>
<tr>
<td>Buffers</td>
<td>2.7.3</td>
</tr>
<tr>
<td>Nervous System</td>
<td>2.8</td>
</tr>
<tr>
<td>Blood-Brain Barrier</td>
<td>2.8.1</td>
</tr>
<tr>
<td>CSF</td>
<td>2.8.2</td>
</tr>
<tr>
<td>Spinal Cord Anatomy</td>
<td>2.8.3</td>
</tr>
<tr>
<td>Intracranial Pressure</td>
<td>2.8.4</td>
</tr>
<tr>
<td>Intraocular Pressure</td>
<td>2.8.5</td>
</tr>
<tr>
<td>Sleep</td>
<td>2.8.6</td>
</tr>
<tr>
<td>Pain</td>
<td>2.8.7</td>
</tr>
<tr>
<td>Autonomic Nervous System</td>
<td>2.8.8</td>
</tr>
<tr>
<td>Neuropharmacology</td>
<td>2.8.9</td>
</tr>
<tr>
<td>Neurotransmitters</td>
<td>2.8.9.1</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>2.8.9.2</td>
</tr>
<tr>
<td>Local Anaesthetics</td>
<td>2.8.9.3</td>
</tr>
<tr>
<td>Neuraxial Blockade</td>
<td>2.8.9.4</td>
</tr>
<tr>
<td>Acetylcholine Receptors</td>
<td>2.8.9.5</td>
</tr>
<tr>
<td>Opioids</td>
<td>2.8.9.6</td>
</tr>
<tr>
<td>Inhalational Anaesthetics</td>
<td>2.8.9.7</td>
</tr>
</tbody>
</table>
Endocrine

A Brief Overview of Hormones 2.9.1
Insulin, Glucagon, and Somatostatin 2.9.2
Control of Blood Glucose 2.9.3
Hypothalamus and Pituitary 2.9.4
Thyroid 2.9.5
Adrenal Hormones 2.9.6
Calcium Homeostasis 2.9.7
Histamine 2.9.8
Prostanoids 2.9.9

Musculoskeletal System 2.10
Skeletal Muscle Structure 2.10.1
Skeletal Muscle Innervation 2.10.2
 Neuromuscular Blockers 2.10.3

Nutrition & Metabolism 2.11
Basal Metabolic Rate 2.11.1
Fat Metabolism 2.11.2
Carbohydrate Metabolism 2.11.3
Protein Metabolism 2.11.4
Requirements and Starvation 2.11.5
Anaerobic Metabolism 2.11.6

Thermoregulation 2.12
Regulation of Body Temperature 2.12.1

Immunology 2.13
Inflammation 2.13.1
Innate Immunity 2.13.2
Adaptive Immunity 2.13.3
Hypersensitivity 2.13.4

Microbiology 2.14
Classification of Microorganisms 2.14.1
Antimicrobial Resistance 2.14.2
Antiseptics 2.14.3

Obstetrics & Neonates 2.15
Respiratory Changes 2.15.1
Cardiovascular Changes 2.15.2
Foetal Circulation 2.15.3
The Placenta 2.15.4

Gastrointestinal System 2.16
Oesophagus 2.16.1
Gastric Secretions 2.16.2
Control of Gastric Emptying 2.16.3  
Swallowing 2.16.4  
Physiology of Vomiting 2.16.5  
Liver Physiology 2.16.6  
  Functions of the Liver 2.16.6.1  
  Laboratory Assessment of Liver Function 2.16.6.2  
  Bile 2.16.6.3  
Haematology 2.17  
  Erythrocytes 2.17.1  
  Iron Homeostasis 2.17.2  
  Platelets 2.17.3  
  Transfusion 2.17.4  
  Haemostasis 2.17.5  
  Haemostatic Regulation 2.17.6  
  Coagulopathy Testing 2.17.7  
Equipment and Measurement 2.18  
  SI Units 2.18.1  
  Electrical Safety 2.18.2  
  Wheatstone Bridge 2.18.3  
  Neuromuscular Monitoring 2.18.4  
  Pressure Transduction 2.18.5  
  Pressure Waveform Analysis 2.18.6  
  Non-Invasive Blood Pressure 2.18.7  
  Cardiac Output Measurement 2.18.8  
  Pulse Oximetry 2.18.9  
  Oxygen Analysis 2.18.10  
  End-Tidal Gas Analysis 2.18.11  
  Blood Gas Analysis 2.18.12  
  Gas Flow 2.18.13  
  Principles of Ultrasound 2.18.14  
  Temperature and Humidity 2.18.15  
  Electrocardiography 2.18.16  
  Humidifiers 2.18.17  
  Supplemental Oxygen 2.18.18  
  Bispectral Index 2.18.19  
  Medical Gas Supply 2.18.20  
  Vapourisers 2.18.21  
  Breathing Systems 2.18.22  
  Circle System 2.18.23  
  Scavenging 2.18.24
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diathermy</td>
<td>2.18.25</td>
</tr>
<tr>
<td>Lasers</td>
<td>2.18.26</td>
</tr>
<tr>
<td><strong>Procedural Anatomy</strong></td>
<td>2.19</td>
</tr>
<tr>
<td>Subclavian Vein</td>
<td>2.19.1</td>
</tr>
<tr>
<td>Internal Jugular Vein</td>
<td>2.19.2</td>
</tr>
<tr>
<td>Intercostal Catheter</td>
<td>2.19.3</td>
</tr>
<tr>
<td>Antecubital Fossa</td>
<td>2.19.4</td>
</tr>
<tr>
<td>Tracheostomy</td>
<td>2.19.5</td>
</tr>
<tr>
<td><strong>Pharmacopoeia</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Toxicology</strong></td>
<td>3.1</td>
</tr>
<tr>
<td>Recreational Drugs</td>
<td>3.1.1</td>
</tr>
<tr>
<td>Toxic Alcohols</td>
<td>3.1.1.1</td>
</tr>
<tr>
<td>Antidotes</td>
<td>3.1.2</td>
</tr>
<tr>
<td>Naloxone</td>
<td>3.1.2.1</td>
</tr>
<tr>
<td>Flumazenil</td>
<td>3.1.2.2</td>
</tr>
<tr>
<td>Respiratory</td>
<td>3.2</td>
</tr>
<tr>
<td>Oxygen</td>
<td>3.2.1</td>
</tr>
<tr>
<td>Helium</td>
<td>3.2.2</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>3.2.3</td>
</tr>
<tr>
<td>Beta Agonists</td>
<td>3.2.3.1</td>
</tr>
<tr>
<td>Antimuscarinics</td>
<td>3.2.3.2</td>
</tr>
<tr>
<td>Phosphodiesterase Inhibitors</td>
<td>3.2.3.3</td>
</tr>
<tr>
<td>Leukotriene Antagonists</td>
<td>3.2.3.4</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>3.2.4</td>
</tr>
<tr>
<td>Pulmonary Vasodilators</td>
<td>3.2.5</td>
</tr>
<tr>
<td><strong>Cardiovascular Pharmacology</strong></td>
<td>3.3</td>
</tr>
<tr>
<td>Adrenergic Vasoactives</td>
<td>3.3.1</td>
</tr>
<tr>
<td>Non-adrenergic Vasoactives</td>
<td>3.3.2</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>3.3.3</td>
</tr>
<tr>
<td>Centrally Acting Agents</td>
<td>3.3.3.1</td>
</tr>
<tr>
<td>Calcium Channel Blockers</td>
<td>3.3.3.2</td>
</tr>
<tr>
<td>Direct Vasodilators</td>
<td>3.3.3.3</td>
</tr>
<tr>
<td>ACE Inhibitors</td>
<td>3.3.3.4</td>
</tr>
<tr>
<td>Angiotensin Receptor Blockers</td>
<td>3.3.3.5</td>
</tr>
<tr>
<td>Neprilsyn Inhibitors</td>
<td>3.3.3.6</td>
</tr>
<tr>
<td>Potassium Channel Activators</td>
<td>3.3.3.7</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td>3.3.4</td>
</tr>
<tr>
<td>Sodium Channel Blockers</td>
<td>3.3.4.1</td>
</tr>
</tbody>
</table>

**Pharmacopoeia**

**Toxicology**

- Recreational Drugs
  - Toxic Alcohols
- Antidotes
  - Naloxone
  - Flumazenil

**Respiratory**

- Oxygen
- Helium
- Bronchodilators
  - Beta Agonists
  - Antimuscarinics
  - Phosphodiesterase Inhibitors
  - Leukotriene Antagonists

**Corticosteroids**

**Pulmonary Vasodilators**

**Cardiovascular Pharmacology**

- Adrenergic Vasoactives
- Non-adrenergic Vasoactives
- Antihypertensives
  - Centrally Acting Agents
  - Calcium Channel Blockers
  - Direct Vasodilators
  - ACE Inhibitors
  - Angiotensin Receptor Blockers
  - Neprilsyn Inhibitors
  - Potassium Channel Activators
- Antiarrhythmics
  - Sodium Channel Blockers
Beta-Blockers 3.3.4.2
Amiodarone  3.3.4.3
Sotalol  3.3.4.4
Digoxin  3.3.4.5
Adenosine  3.3.4.6
Magnesium  3.3.4.7
Atropine  3.3.4.8

Renal
Diuretics  3.4.1
Intravenous Fluids  3.4.2

Neuropharmacology
Propofol  3.5.1
Barbiturates  3.5.2
Ketamine  3.5.3
Dexmedetomidine  3.5.4
Local Anaesthetics  3.5.5
Benzodiazepines  3.5.6
Antidepressants  3.5.7
Antipsychotics  3.5.8
Anticonvulsants  3.5.9
GABA Analogues  3.5.10
Inhalational Anaesthetic Agents  3.5.11
Nitrous Oxide  3.5.12

Analgesics
Opioids  3.6.1
COX Inhibitors  3.6.2
Tramadol  3.6.3
Paracetamol  3.6.4

Autonomic
Anticholinesterases  3.7.1
Antimuscarinics  3.7.2

Neuromuscular
Depolarising NMBs  3.8.1
Non-Depolarising NMBs  3.8.2
Dantrolene  3.8.3
Sugammadex  3.8.4

Haematological
Anticoagulants  3.9.1
Direct Thrombin Inhibitors  3.9.2
Antifibrinolytics  3.9.3
Antiplaletes 3.9.4
Antimicrobials 3.10
Penicillins 3.10.1
Glycopeptides 3.10.2
Aminoglycosides 3.10.3
Lincosamides 3.10.4
Metronidazole 3.10.5
Antifungals 3.10.6
Endocrine 3.11
Hypoglycaemics 3.11.1
Insulin 3.11.1.1
Oral Hypoglycaemics 3.11.1.2
Obstetric 3.12
Oxytocics 3.12.1
Tocolytics 3.12.2
Gastrointestinal 3.13
Acid Suppression 3.13.1
Antiemetics 3.13.2
Other Drugs 3.14
IV Contrast 3.14.1

Appendices

Definitions 4.1
Key Graphs 4.2
Laws and Equations 4.3
Structures for SAQs 4.4
Part One

Part One is a reference for trainees preparing for the CICM and ANZCA Primary Exams.

- Part One is:
  - Designed to cover the *assessed* sections of the CICM and ANZCA curricula *in enough detail to pass*
  - A rough guide for the expected depth of knowledge required on a topic
  - A tool to correct your written answers
  - A source of information you might find difficult to find elsewhere
- Part One *is not*:
  - A textbook
  - The definitive guide to the primary exam
  - A complete reference
  
  There will be both omissions and errors. If you find any, please let me know.

Layout

The book is divided into three sections:

- **Curriculum**
  Covers statistics, physiology, equipment and measurement, and anatomy.
  - Pages are laid out using the section title, topic titles, and order from the CICM curriculum
    - A grey block indicates a topic is from the CICM curriculum OR both curricula
  - When a topic is only examinable in the ANZCA curriculum, it has been slotted in somewhere sensible
    - A purple block indicates a topic is *ONLY* from the ANZCA curriculum
  - Topics covered by the page are listed at the beginning of each page

- **Pharmacopoeia**
  Covers drugs.
  - For the sake of consistency, the *general principles* of pharmacology are covered in the curriculum, whilst the specifics of different agents will be found in the pharmacopoeia. If lost, use the search box.

- **Appendices**
  Includes the key definitions, graphs, and equations you should know, as well as sample structures for SAQs.

Acknowledgements + Technical Stuff

Part One is built with a number of open-source tools:

- Written in John Gruber's elegant Markdown
- Built and made pretty by the GitBook toolchain
  - With plugins from:
    - Ben Lau for automatic timestamps
    - Michael Jerger for collapsible chapters
    - Rishabh Garg for top navigation
- Equations written in \LaTeX
- Graphs have been:
  - Written in PGF/Tikz using texworks
About Part One

- Converted to vector graphics with dvisvgm
- Refined with svgo
- (Some graphs have been taken from open-source sites such as Wikimedia Commons. These have been credited where used.)
- Additionally, chemical structures have been built in MarvinSketch

About the Author

Jake Barlow is an Anaesthetic and Intensive Care Registrar from Melbourne, Australia. Interested in all things critical care (with a particular fascination for physiology), as well as biotech, physical computing, teaching, analytics, and outcome prediction in intensive care. Send all comments, criticism, and complaints about Part One to him here.

Copyright + Legal

Copyright © 2015-2019 C. Jake Barlow

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Download Part One

Part One is also provided with:

- A PDF version for offline use

  Note that:
  - The image quality of graphs is reduced in the PDF version
  - The PDF version is automatically built whenever the site is updated

  Therefore:
  - The download link will always link to the most recent version
  - This page will appear in the PDF version

- A companion set of flashcards, made in Anki

Last updated 2018-07-16
How to Pass

The first part exam is:

- Painful
  The knowledge demanded is huge, and cannot be avoided.
- Eminently achievable
  Remember, it is not impossible - everybody before you has completed it.

Plan for Success

This is not an exam you want to have to sit more than once - try to give yourself the best chance of success the first time round:

- Commit yourself early
  Decide when you are going to sit:
  - Pick a date ~9 months in advance
    - 6 months is probably pushing it
    - 9 months is achievable
    - 12 months is almost too long - you will lose motivation and knowledge will fade.
  - Accept that the time between now and the exam is not going to be the best time of your life
  - Consider paying the money as soon as possible - lock yourself in
  - Your family and friends will forgive you, eventually
- Don't lose faith
  - There will be times that you question why you have to learn this
  - Those are very legitimate feelings
  - Accept that part of this exam is an academic hazing you must pass through on your path to fellowship

Be Strategic

The curriculum provided is overwhelming, and probably not achievable for most of us. Have a plan about how you will approach it:

- Have a timetable
  - Content to cover each week
    - I found setting a weekly goal would allow me to plan around day-to-day variations (finishing late, good days, bad days, etc)
    - A daily timetable was often mangled by life, creating unnecessary stress
  - Time to start viva practice
    - Aim to start before the written.
    - Topics that you can't explain, you probably don't understand fully
      - This may not be apparent until you try and explain it.
- Know the enemy
  - Syllabus
    - Read through it so you appreciate the breadth of knowledge required.
  - Know the style
    - This allows you to give answers efficiently - the key metric for both the vivas and the SAQs is marks per unit time.
      - Style of exam questions
        - Including the style of answers - see the SAQ.
- **Style of vivas**
  - Do practice vivas
    - Record yourself, so you know your tics
    - Do a dress rehearsal
      Make sure your suit still fits before the day.
- **Graphs**
  - Be able to draw them while talking about them.

- **Do past questions**
  I cannot stress this enough. This is the key to preparing for this exam.
  - Past questions:
    - Teach you appropriate structure
    - Teach you to write to time
    - Ensure you learn the content in the way it will be recalled
    - Ensure you don't waste time learning things that are unlikely to be examined
      When I sat the CICM exam, I had done almost all the past questions, which covered ~60% of the curriculum. There was 1 (out of 24) of the SAQs on a topic I had not answered an SAQ on before.
  - Do questions to time
    - Keeping to time is vital.
      - It is almost impossible to write a perfect answer in 10 minutes
      - In many cases you will need to move on to the next question despite still having things to say
      - Remember that the marking follows a sigmoid distribution
        - The first 30% of marks for a question are easy to get
        - The last 30% of marks are very difficult to get
        - Therefore, the most efficient use of your time is to aim to get ~60-70% of marks for each question.
  - **Remember the pass mark is 50%**
    - You are not expected to know everything
    - Breadth tends to be rewarded over depth
    - It is normal to sit the exam and have a question you have not thought about before

**Suggested Approach**

There are many equally valid ways to approach these exams. This is how I would do it, if I had to do it again:

1. **Read a general physiology and pharmacology textbook**
   This will help you understand the scope of the undertaking. I would recommend spending 2-3 weeks reading:
     In my opinion, this is the general physiology text. I believe that if you knew everything in this book, you would pass the physiology component of both exams.
     The first few chapters are a good introduction to pharmaceutics and pharmacokinetics, which will help you put later information from more complete texts into context.

2. **Start doing practice questions:**
   This is the key to the exam. I suggest:
   - Start doing one question at a time
     In the beginning, you will not know enough to write for 10 minutes.
     - After doing the question, check your answer against available past answers
       This forces active learning, and is far more efficient than reading. Look at:
       - Structure
         How did you structure your answer? What was the example structure?
Content
What did you miss? Are the numbers/graphs you used correct?
- Then study the curriculum areas that question covered, and make notes
  This would take me ~1-2 hours for a new curriculum area.
- Once you start doing questions which you know something about (having answered one similar previously), move up to three questions in 24 minutes.
  This teaches you to keep time, which is vital for success in the SAQ.
- Still check each answer afterwards, look over that area of the curriculum, and revise and refine your notes
- When you find yourself running out of time before you run out of things to write, give yourself 9 minutes per question
  I would suggest not going beyond this - you need to allocate your time strategically on the day, and writing to time is critical.
- As this gets easier, start doing 6 or more questions at a time to train your writing hand
- Do one or two full exams to time before game day

3. Do a lot of flashcards
Flashcards are less demanding than doing questions, and a simple form of revision.
- They are the absolute best way of rote learning facts (in my opinion)
- I used anki, but use whatever works for you
- My anki deck is available here

4. Do practice vivas
Start before the written. There is a lot of crossover of skills between the viva and the written. Both require a structured approach, and good content knowledge.
- Remember to take a break after the written exams, it is exhausting

The Bottom Line

- Pick a date, and commit to it
- Work out which times work best for you with respect to study
  Different times will be better for different things. I found:
    - Days off (including weekends) were best for learning new content
    - Work days were for revising
    - Post night shift was a write-off
- Maintain a positive attitude
  Study groups are good for this - share the suffering!
- Split large topics into manageable chunks
- Don't lose your head
  Set aside time for relaxation, and don't feel guilty about it.
- You don't have to know everything
  The pass mark is 50%

References

- This is based on a talk I gave at the 2016 VPECC Course, still raw from the CICM primary

Last updated 2019-08-01
The SAQ

A good response to a short-answer question is constructed from two things:

- **Structure**
  Developing a structured approach to answering SAQs is essential to succeeding in this section of the exam. A structured approach:
  - Is easily digested by the examiner
  - Reduces the amount of filler you need to write, meaning you can write more facts
  - Typically lends itself to bullet points rather than paragraphs
  - Allows you to recall more information than you would otherwise
    Especially if you learnt it in the same format. This is particularly important for pharmacology.

- **Knowledge**
  Obviously.

Additionally, a good response will:

- **Answer the question**
  This is stated repeatedly in examiner reports. If the question asks for a discussion of the respiratory changes of pregnancy, no marks will be awarded for cardiovascular changes.

- **Be legible**

- **Not be perfect**
  This is often-overlooked.
  - Examiner reports (and some model answers), assume a perfect response
  - This not feasible given the time allowed
  - It is also not actually expected - remember that the pass mark is 50%

The bottom line:

- A good response will cover the major points in reasonable detail
- Will generally focus on principles rather than specifics
  Marks become progressively harder to acquire:
  - The first one or two marks on a question should be easy
  - Going from an 8/10 to a 10/10 will require time which you likely cannot spare

### Answering the Question

- You have exactly **10 minutes** per SAQ
- You should practice to **8-9 minutes** per SAQ
  In many cases, the last question (or questions) goes unanswered. This demonstrates poor time management, as easy marks were thrown away by candidates reaching for harder marks on earlier questions.

- During reading time, you should evaluate each question to:
  - Decide what part of the curriculum it is assessing
  - Work out the context, if any
  - Decide what structure would be most appropriate

Last updated 2017-08-14
The Viva

The viva is the part of the exam most candidates seem most stressed about. However:

- If you make it through the written, you will most likely pass
  Very few people succeed in the written exams to fail at the viva.
  - The knowledge is there
  - Examiners want you to pass
    They will redirect you if you're off track.
    - This makes it easier to make up marks than on the written, where you can easily go off down the rabbit hole, haemorrhaging time and marks

Understanding the Viva

To do well at the viva:

- **Understand the viva is a performance piece**
  The viva is a ritualised conversation. Success requires you to know and understand the language and structure used, just like the SAQ.
- **Structure your answer**
  As with the SAQ, categorise your answer.
  - Have a good opening statement
    Don't answer more than is asked.
  - Start broad
    Often the viva will go into depth on only one or two areas of a topic. If you start going into detail on only parts of a topic, it makes it hard for the examiner to redirect you and scores you no marks.
- **Be confident**
  Enjoy it if you can.
- **Learn to think on your feet**
  The viva assesses knowledge in a different way to the SAQs.
  - The knowledge will be there, but it may require a different approach to access it
    This requires practice.
  - This is also important for delivering a sound answer based on incomplete knowledge
- **It's okay to say "I don't know"**
  But probably not on the first question.
  - If you don't know immediately, can you work it out from first principles?
- **Don't get angry**
  - With yourself
  - With the examiner
    Don't argue.
- **Don't apologise**
  Apologies:
  - Make you lose confidence
  - Don't get you marks
    Remember, marks per unit-time.
- **Don't talk over the examiner**
  They are interrupting you because what you are saying is gaining no marks. If you keep talking, you will:
  - Not be getting marks
  - Irritate them
Potentially losing future marks.

Last updated 2019-11-02
Evidence-Based Medicine

Describe the features of evidence-based medicine, including levels of evidence (e.g. NHMRC), meta-analysis, and systematic review.

What is Evidence-Based Medicine?

- Evidence-based medicine (EBM) is "the conscientious, explicit, and judicious use and appraisal of current best evidence in making decisions about the care of individual patients."
- The purpose of EBM is to provide a framework for acquiring knowledge and making optimal decisions around medical care. It means integrating individual clinical expertise with the best available external clinical evidence from systematic research.

There are five stages of EBM:

1. Ask an answerable question
2. Search
3. Critically appraise the evidence
4. Integrate the evidence with the patients unique circumstances and values
5. Evaluate the result

Levels of Evidence

Levels of evidence grade studies on likelihood of bias and internal validity. The NHMRC defines 6 levels of evidence, graded from I-IV (with three level III subtypes).

*In general:*

- Level I is evidence from a systematic review of RCTs
- Level II is evidence from at least one good RCT
- Level III-1 is evidence from a pseudo-RCT
- Level III-2 is evidence from a comparative study with concurrent controls, such as a cohort or case-control study
- Level III-3 is evidence from a comparative study without concurrent controls, such as a cohort study with historical controls
- Level IV is evidence from a case-series

Note that expert opinion is not part of NHMRC levels of evidence, though it is included on the Oxford Centre for Evidence Based Medicine system, used by the NHS.

<table>
<thead>
<tr>
<th>Level</th>
<th>Intervention</th>
<th>Diagnostic Accuracy</th>
<th>Prognostic</th>
<th>Aetiology</th>
<th>Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A systematic review of level II studies</td>
<td>A systematic review of level II studies</td>
<td>A systematic review of level II studies</td>
<td>A systematic review of level II studies</td>
<td>A systematic review of level II studies</td>
</tr>
<tr>
<td>II</td>
<td>A randomised controlled trial</td>
<td>A study of test accuracy with: an independent, blinded comparison with a valid reference standard, among consecutive persons with a defined clinical presentation</td>
<td>A prospective cohort study</td>
<td>A prospective cohort study</td>
<td>A randomised controlled trial</td>
</tr>
<tr>
<td></td>
<td>A study of test accuracy</td>
<td>A study of test accuracy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III-1</td>
<td>A pseudorandomised controlled trial</td>
<td>with: an independent, blinded comparison with a valid reference standard, among non-consecutive persons with a defined clinical presentation</td>
<td>All or none</td>
<td>All or none</td>
<td>A pseudorandomised controlled trial</td>
</tr>
<tr>
<td>III-2</td>
<td>A comparative study with concurrent controls</td>
<td>A comparison with reference standard that does not meet the criteria required for Level II and III-1 evidence</td>
<td>Analysis of prognostic factors amongst persons in a single arm of a randomised controlled trial</td>
<td>A retrospective cohort study</td>
<td>A comparative study with concurrent controls</td>
</tr>
<tr>
<td>III-3</td>
<td>A comparative study without concurrent controls</td>
<td>Diagnostic case-control study</td>
<td>A retrospsective cohort study</td>
<td>A case-control study</td>
<td>A comparative study without concurrent controls</td>
</tr>
<tr>
<td>IV</td>
<td>Case series with either post-test or pre-test/post-test outcomes</td>
<td>Study of diagnostic yield (no reference standard)</td>
<td>Case series, or cohort study of persons at different stages of disease</td>
<td>A cross-sectional study or case series</td>
<td>Case series</td>
</tr>
</tbody>
</table>

**Grades of evidence**

Evidence is graded to “indicate the strength of the body of evidence underpinning a recommendation” (e.g. in a clinical guideline). The NHMRC grades recommendations from A to D as follows:

- **A**: Body of evidence can be trusted to guide practice
- **B**: Body of evidence can be trusted to guide practice, in most situations
- **C**: Body of evidence provides some support, but care should be taken in its application
- **D**: Body of evidence is weak and recommendation must be applied with caution

**Study types: Systematic Reviews and Meta-analyses**

**Systematic Review**

Process of evaluating all of the (quality) literature to answer a specific clinical question. Does not necessarily involve statistical analysis. If it involves quantitative analysis of multiple trials, it is known as a **meta-analysis**.

**Meta-analysis**

Mathematical technique of combining the results of different trials to derive a **single pooled estimate of effect**. Can be done by:

- Pooling the results of each trial
- Pooling all of the raw data and conducting a reanalysis
- Meta-analyses usually use **random-effects models**, which assumes there will be a variety of similar treatment effects
- Individual trials are **summarised with an odds ratio**, and **weighted**, usually by sample size

**Stages of a [meta-analysis] and systematic review:**

1. Inclusion and exclusion criteria are predefined
2. Search: including online databases, reference lists, citations, and experts
3. Validation of potentially eligible trials (critique of interval validity, i.e. trial quality)
4. [Heterogeneity Analysis]
5. [Meta-analysis]
6. Reliability of result determined
   i.e. Consistency across studies, statistical significance, large effect size, biological plausibility.
7. Sensitivity analysis
   Repeating the analysis with an alternative model, excluding borderline trials or outliers. If the result is unchanged, then the findings are robust.

**Heterogeneity**

For the pooling of results to be valid, the trials need to be similar. Differences between trials is called heterogeneity, and is important because:

- Heterogeneity analysis affects the type of model that can be used (fixed or mixed effects)
- Highly heterogenous data is not appropriate for meta-analysis.

Heterogeneity is divided into:

- **Statistical Heterogeneity**
  The effects of the intervention are more different than would be expected to occur through chance alone.

- **Clinical Heterogeneity**
  Due to trial design it would be inappropriate to pool the results.
  - E.g., conducting a meta-analysis on the effects of the same drug in a paediatric and adult population may be inappropriate, as these two trials had different inclusion criteria.

- **Methodological Hetereogeneity**
  Where the methods used in different trials are too different to allow pooling of the data.

**Forest Plots**

Results of meta-analyses are presented in a blobbogram, or more boringly, a **Forest Plot**.

![Forest Plot Diagram](image)

Where:

- The **x-axis** plots the odds ratio, remembering that an OR of 1 indicates no difference
- The **y-axis** lists the studies included, and the overall summary statistic
- The **dot** (or square) indicates the point estimate (from its x-location) and the weight given to the study (by its size)
- The **horizontal line** indicates the upper and lower bounds of the confidence interval
- The **diamond** indicates the overall point estimate and (by its width) the confidence interval for the point estimate
- The result of the heterogeneity test should also be displayed
  - P < 0.1 indicates significant heterogeneity.

**Funnel Plots**
Funnel plots are a **graphical tool to detect publication bias**.

- Due to statistical power, larger studies should be a closer representation of the true effect
- Therefore, when evaluating an number of studies, one would expect that large studies cluster around the ‘true effect’, and smaller studies to scatter further
- A graph is then plotted of OR on the x-axis, and standard error on the y-axis
  - Publication bias is suggested when results cluster on one side of the funnel plot
  - No evidence of publication bias would have studies clustered around the true effect

### Strengths and weaknesses of meta-analyses

<table>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhanced precision of estimates of effect</td>
<td>Publication bias</td>
</tr>
<tr>
<td>Useful when large trials have not been done or are not feasible</td>
<td>Duplicate publication</td>
</tr>
<tr>
<td>Generate clinically relevant measures (NNT, NNH)</td>
<td>Heterogeneity</td>
</tr>
<tr>
<td></td>
<td>Inclusion of outdated studies</td>
</tr>
</tbody>
</table>

Because of these weaknesses:

- Positive meta-analyses should be considered largely hypothesis-generating, and should be confirmed by (a large) RCT
- Negative meta-analyses can probably be accepted

### References


Last updated 2019-07-18
Study Types

Describe the features of evidence-based medicine, including levels of evidence (e.g., NHMRC), meta-analysis, and systematic review.

Randomised Control Trial

A prospective randomised controlled trial is the **gold standard** of experimental research.

It involves allocating patients randomly to either an intervention or a reference (control) group, and measuring the outcome of interest. Allocation can be performed in three ways:

- Simple
  Individuals allocated randomly. This may lead to uneven group sizes.
- Block
  Allocation is performed within blocks such that group sizes will remain close in size
- Stratified
  Groups are randomised within a category (i.e. men and women are randomised separately).

**Strengths**

- Only study design which can establish causation
- Eliminates confounding
  Randomisation controls for both known and unknown confounding factors, as these should be randomly allocated between groups.
- Blinding can be performed in a standardised fashion
- Decreases selection bias

**Weaknesses**

- Costly
- Time-consuming
- Not appropriate for all study designs
  - Ethical concerns
    e.g. Adrenaline in ALS
  - Practical concerns
    Small patient population or uncommon disease may cause recruitment difficulties

Systematic Review

The process of evaluating all of the (quality) literature to answer a specific clinical question. This:

- Does not necessarily involve statistical analysis
  If it involves statistical analysis of multiple trials to generate a combined estimate of effect, it is known as a **meta-analysis**.

Meta-analysis
Mathematical technique of combining the results of different trials to derive a single pooled estimate of effect. Can be performed by:

- Pooling the results of each trial
- Combining all of the raw data and conducting a reanalysis
- Meta-analyses usually use **random-effects models**, which assumes there will be a variety of similar treatment effects
- Individual trials are **summarised with an odds ratio**, and **weighted**, usually predominantly by sample size

### Stages of a [meta-analysis] and systematic review:

1. Inclusion and exclusion criteria are predefined
2. Search: including online databases, reference lists, citations, and experts
3. Validation of potentially eligible trials (critique of interval validity, i.e. trial quality)
4. [Heterogeneity Analysis]
5. [Meta-analysis]
6. Reliability of result determined
   - i.e. Consistency across studies, statistical significance, large effect size, biological plausibility.
7. Sensitivity analysis
   - Repeating the analysis with an alternative model, excluding borderline trials or outliers. If the result is unchanged, then the findings are **robust**.

### Heterogeneity

For the pooling of results to be valid, the trials need to be similar. Differences between trials is known as **heterogeneity**. Heterogeneity can be either:

- **Statistical**: where the effects of the intervention are more different than would be expected to occur through chance alone.
  - Heterogeneity analysis affects the type of model that can be used (fixed or mixed effects) and highly heterogenous data is not appropriate for meta-analysis.
- **Clinical**: where, due to trial design, it would be inappropriate to pool the results. For example, conducting a meta-analysis on the effects of the same drug in a paediatric and adult population would be inappropriate, as these are two different populations.
- **Methodological**: Where the methods used in different trials are too different to allow pooling of the data.

### Forest Plots

Results of meta-analyses are presented in a blobbogram, or more boringly, a **Forest Plot**.

![Forest Plot Diagram]

Where:

- The **x-axis** plots the odds ratio, remembering that an OR of 1 indicates no difference
- The **y-axis** lists the studies included, and the overall summary statistic
The square indicates the **point estimate** (from its x-location) and the **weight** given to the study (by its size).

- The horizontal line indicates the upper and lower bounds of the **confidence interval**

- The diamond indicates the **overall point estimate** and (by its width) the **confidence interval** for the point estimate.

- The result of the heterogeneity test should also be displayed. \( P < 0.1 \) indicates significant heterogeneity.

**Funnel Plots**

A graphical tool to detect publication bias. Due to statistical power, larger studies should be a closer representation of the true effect. When evaluating a number of studies, one would expect that large studies cluster around the 'true effect' and smaller studies to have more scatter.

**Strengths and weaknesses of meta-analyses**

<table>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhanced precision of estimates of effect</td>
<td>Publication bias</td>
</tr>
<tr>
<td>Useful when large trials have not been done or are not feasible</td>
<td>Duplicate publication</td>
</tr>
<tr>
<td>Generate clinically relevant measures (NNT, NNH)</td>
<td>Heterogeneity</td>
</tr>
</tbody>
</table>

Because of these weaknesses, positive meta-analyses should be considered largely hypothesis-generating, and should be confirmed by (a large) RCT. Negative meta-analyses can probably be accepted.

**References**

Clinical Trial Design

Describe the stages in design of a clinical trial

1. Determine research question
2. Determine target population
3. Specify outcomes
4. Determine requirement for control group
5. Sample size estimation
6. Control for confounding
7. Control for bias
8. Data handling
9. Statistical analysis plan (pre-specified)

References


Last updated 2017-09-12
Data Types

Describe the different types of data

Data are a series of observations or measurements. Can be either qualitative or quantitative.

Qualitative Data

Using words as data rather than numbers, evaluating meaning and process. Common in the social sciences.

Quantitative Data

Uses numbers, or can be coded numerically. Divided into multiple types, each with multiple subtypes.

- **Categorical**
  Data exist in discrete categories without intrinsic order.
  - e.g. Medical specialty (intensive care, emergency medicine, orthopaedics, cardiology)
  - Descriptive statistics for categorical data can be reported using the absolute number for each category, percentages, or proportions

- **Ordinal**
  Data exists in discrete categories with an intrinsic order, e.g. age groups (0-5, 6-10, 11-15...)
  - Descriptive statistics for ordinal data are the same for categorical data, but they can also be summarised by the median and the range (e.g. median age group, age group range).

- **Numerical**
  Data is an actual number. Can be subdivided into discrete or continuous:
    - **Discrete**
      Can only be recorded as an integer (whole number), e.g. number of hospital admissions.
      - Dichotomous or binary data, which occurs when there are only two categories
    - **Continuous**
      Where data can assume any value (including fractions), e.g. white cell count.
      - Continuous data can be further subdivided into interval or ratio data:
        - **Ratio data**
          Are expressed with reference to a rational zero, which is where zero means no measurement.
          - e.g. Temperature in °K is a ratio variable, whilst temperature in °C is not
            This is because 0°K means no temperature, whilst 0°C does not; e.g. 50°K is half the temperature of 100°K, but 50°C is not half the temperature of 100°C.
          - Ratio variables can (unsurprisingly) be expressed as ratios, whilst interval variables can not
        - **Interval data**
          Do not have a rational 0 - this is just another point on the line (e.g. temperature in °C).

References

Bias and Confounding

Describe bias, types of error, confounding factors and sample size calculations, and the factors that influence them.

Bias

Bias is a **systematic deviation from truth**, and causes a study to lack **internal validity**.

In a research study, an observed difference between groups may be due to:

- A true difference between groups
- An error

Error can be due to:

- Normal random variation, i.e. chance
- A systematic difference, i.e. bias

Unlike error due to chance, the effect of bias cannot be reduced by increasing the sample size.

Types of Bias

<table>
<thead>
<tr>
<th>Type of bias</th>
<th>Description</th>
<th>Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selection</td>
<td>Where subject allocation results in treatment groups that are systematically different, apart from in the intervention being studied</td>
<td>Randomisation</td>
</tr>
<tr>
<td>Detection</td>
<td>Where measurements are taken differently between treatment groups</td>
<td>Blinding</td>
</tr>
<tr>
<td>Observer</td>
<td>Where the data collector is able to be subjective about the outcome</td>
<td>Blinding, Hard outcomes</td>
</tr>
<tr>
<td>Publication</td>
<td>When negative studies are less likely to be submitted or published than positive ones</td>
<td>Clinical trial registries</td>
</tr>
<tr>
<td>Recall</td>
<td>Altered reporting of symptoms by patients depending on which group they have been allocated to</td>
<td>Blinding</td>
</tr>
<tr>
<td>Response</td>
<td>When patients who enroll for a trial differ from the population, limiting generalisability</td>
<td>Random sampling</td>
</tr>
<tr>
<td>Hawthorne effect</td>
<td>When the process of actually doing the study improves the outcome</td>
<td>Control group, masking study intent from patients and observers</td>
</tr>
</tbody>
</table>

Confounder

A **confounder** is "a variable that, if removed, results in a change in the outcome variable by a clinically significant amount." It is a type of bias which will result in a distortion of the measured effect.

A confounding factor must be:

- **Associated with the exposure** but **not a consequence of it**
  - A confounding factor cannot be on the causal pathway between exposure and disease
  - It must be present unevenly between groups to cause distortion of the measured effect
- **An independent predictor of outcome**
  - The confounding factor must also be a risk factor for the disease, but independently from exposure.
Controlling for confounding

By Design

- **Randomisation**
  All confounders (known and unknown) are distributed evenly between groups.
- **Restriction**
  Restricts participants to remove confounders.
  - Results in reduced generalisability and does not control all factors
- **Matching**
  Pairing of similar subjects between groups.
  - May introduce additional confounding, and matching by multiple characteristics is difficult

By Analysis

- **Standardisation**
  Adjust for differences by transforming data.
- **Stratification**
  Analyse the data in subgroups for each potential confounding factor.

References


Last updated 2019-07-18
Frequency Distributions and Measures of Central Tendency

Frequency Distributions

Frequency distributions are a method of tabulating or graphically displaying a number of observations.

The Normal Distribution

The normal distribution is a gaussian distribution, where the majority of values cluster around the mean, and whilst more extreme values become progressively less frequent.

The normal distribution is common in medicine for two reasons.

- Much of the variation in biology follows a normal distribution
- When multiple random samples are taken from a population, the mean of these samples follows a normal distribution, even if the characteristic being measured is not normally distributed

This is known as the central limit theorem.

- It is useful because many statistical tests are only valid when the data follow a normal distribution

The formula for the normal distribution is given by:
From this, it can be seen the two variables which will determine the shape of the normal distribution are:

- $\mu$ (mu): The mean
- $\sigma$ (sigma): The standard deviation

The Standard Normal Distribution

The standard normal distribution is a normal distribution with a mean of 0 and a standard deviation of 1. The equation for the standard normal distribution is much simpler, which is why it is used.

$$f(x) = \frac{1}{\sqrt{2\pi}} e^{-\frac{(x-\mu)^2}{2\sigma^2}}$$

Any normal distribution can be transformed to fit a standard normal distribution using a z transformation:

$$z = \frac{x - \mu}{\sigma}$$

The value of $z$ then gives a standardised score, i.e. the number of standard deviations from the mean in a standardised curve. This can then be used to determine probability.

Binomial distribution

Where observations belong to one of two mutually exclusive categories, i.e.:

If $P(A) = x$ then $P(B) = 1 - x$

If the number of observations is very large and the probability of an event is small, a Poisson distribution can be used to approximate a binomial distribution.

Measures of Central Tendency

As noted above in the normal distribution, results tend to cluster around a central value. Quantification of the degree of clustering can be done using measures of central tendency, of which there are three:

- **Mode**
  
  The most common value in the sample.

- **Median**
  
  The middle value when the sample is ranked from lowest to highest.

  - The median is the best measure of central tendency when the data is skewed

- **Arithmetic mean**

  The average, i.e: $ar{x} = \frac{\sum x}{n}$

  The mean is common and reliable, though inaccurate if the distribution is skewed.

Measures of Dispersion

Measures of variability describe the degree of dispersion around the central value.

Basic Measures of Deviation
- **Range**: The lowest and highest values in the sample
  Highly influenced by outliers

- **Percentiles**: Rank observations into 100 equal parts, so that the median becomes the 50% percentile.
  Better measure of spread than range.

- **Interquartile range**: The 25th to 75th centile
  A box-and-whisker plot graphically demonstrates the mean, 25th centile, 75th centile, and (usually), the 10th and 90th centiles.
  - Outliers are represented by dots
  - Occasionally the range is plotted by the whiskers, and there are no outliers plotted

![Box-and-Whisker Plot](image)

**Variance and Standard Deviation**

**Variance** is a better measure of variability than the above methods. Variance:
- Evaluates how far each observation is from the mean, and penalises observations more the further they lie from the mean
- **Sums the squares** of each difference and divides by the number of observations i.e:
  \[ S^2 = \frac{\sum (x-x_\text{mean})^2}{n-1} \]
  - is used (instead of \(\Sigma x\)) because the mean of the sample is known and therefore the last observation calculated must be taken on a known quantity
    - This is known as a **degrees of freedom**, which is a mathematical restriction used when using one statistical test in order to estimate another
    - It is a confusing topic best illustrated with an example:
      - You have been given a sample of two observations (say, ages of two individuals), and you know nothing about them
      - The degrees of freedom is **two**, since those observations can take on any value.
      - Alternatively, imagine you have been given the same sample, but this time I tell you that the mean age of the sample is 20
      - The degrees of freedom is **one**, since if I tell you the value of one of the observations is 30, you know that the other must be 10
        Therefore, only one of the observations is free to vary - as soon as its value is known then the value of the other observation is known as well.
    - Different statistical tests may result in additional losses in degrees of freedom.

**Standard Deviation**

The standard deviation is the **positive square root of the variance**.

In a sample of normal distribution:
- 1 SD either side of the mean should include ~68% of results
- 2 SD either side of the mean should include ~95% of results
- 3 SD either side of the mean should include ~99.7% of results
Standard error and Confidence Intervals

Standard error of the mean is:

- A measure of the precision of the estimate of the mean
- Calculated from the standard deviation and the sample size
  As the sample size grows, the SEM decreases (as the estimate becomes more precise).
- Given by the formula:
  \[ SE = \frac{SD}{\sqrt{n}} \]
- Used to calculate the confidence interval

Confidence Interval

The confidence interval:

- Gives a range in which the true population parameter is likely to lie
  The width of the interval is related to the standard error, and the degree of confidence (typically 95%):
    - Indicates magnitude of the difference in a meaningful way
    - Indicates the precision of the estimate
    - The smaller the confidence interval, the more precise the estimate.
    - Allows statistical significance to be calculated
      If the confidence interval crosses 1, then the result is insignificant.

References

1. "Normal distribution". Licensed under Attribution 3.0 Unported (CC BY 3.0) via SubSurfWiki.
3. Course notes from "Introduction to Biostats", University of Sydney, School of Public Health, circa 2013.

Last updated 2019-07-18
Sample Size Calculation

Describe bias, types of error, confounding factors and sample size calculations, and the factors that influence them

Samples

A sample is a subset of a population that we wish to investigate. We take measurements on our sample with the aim to make inferences on the general population. An optimal sample (in quantitative research) will be representative, that is, it has the same characteristics of the population it is drawn from.

Sampling Error

Due to chance, the sample mean will not equal the population mean. This is called sampling error, and is a form of random error. A larger sample will more closely approximate the population mean, reducing random error leading to more accurate point estimates and narrower confidence intervals.

This is why large sample sizes are desirable in research. However, larger studies are also more costly and time consuming to run. Sample-size calculations are performed to find a happy medium.

Sample Size Calculation

All sample size calculations depend on:

- Acceptable risk of Type I error ($\alpha$), typically set at 0.05
  A smaller $\alpha$ (lower false positive risk) requires a larger sample size.
- Acceptable risk of Type II error ($\beta$), typically set at 0.20
  A smaller $\beta$ (lower false negative risk) requires a larger sample size.
- Expected effect size
  A smaller effect size requires a larger sample size, as the difference between groups will be smaller and harder to detect.
- Population variance
  A larger population variance requires a larger sample size, as there is more 'noise' in the sample.
- Study design
  Certain trial designs (e.g. multiple arms) require a larger sample size for a given effect size and power.
- Practical considerations
  - Cost
    Increasing sample size increases the cost of a study.
  - Participant availability
    Sample size is limited when the number of eligible participants for a study is small (e.g. rare diseases)

Different formulas for sample size calculations exist for different studies, and can be adjusted for particular study designs, such as multiple or unequal groups.

References

2. Course notes from "Introduction to Biostats", University of Sydney, School of Public Health, circa 2013.
Statistical Tests

Describe the appropriate selection of non-parametric and parametric tests and tests that examine relationships (e.g. correlation, regression)

Parametric Tests

Parametric tests are used when data is:

- Continuous and numerical
- Normally distributed
  - Remember that due to the central limit theorem - large data sets (n > 100) are typically amenable to parametric analysis, as sample means will follow a normal distribution
  - Non-normal data can be transformed so that they follow a normal distribution
- Samples are taken randomly
- Samples have the same variance
- Observations within the group are independent
  - Independent results are those when one value is not expected to influence another value.
  - A common example is repeated measures: when serial measures are taken from a patient or a hospital, the results cannot be treated as independent
- Paired tests are used when two dependent samples are compared
- Unpaired test are used when two independent samples are compared

Tests may be one-tailed or two-tailed:

- A two-tailed test evaluates whether the sample mean is significantly greater or less than the population mean
- A one-tailed test only evaluates the relationship in one direction
  - This doubles the power of the test to detect a difference, but should only be performed if there is a very good reason that the effect could only occur in one direction.

Common parametric tests include:

Z test

Used to test whether the mean of a particular sample (x̄) differs from the population mean (μ) by random variation.

Assumptions:

- Large sample
  - n > 100.
- Data is normally distributed
- Population standard deviation is known

Student’s T Test

This is a variant of the Z test, used when the population standard deviation is not known.

- The results from T test approximate the results of the Z test when n > 100

F Test
Compares the ratio of variances $\left( \frac{V_{\alpha_1}}{V_{\alpha_2}} \right)$ for two samples. If $F$ deviates significantly from 1, then there is a significant difference in group variances.

**Analysis of Variance (ANOVA)**

ANOVA tests for significant differences between means of multiple groups, in a more efficient manner than multiple comparisons (doing lots of $T$ tests).

There are several types of ANOVA tests used in different situations.

**Non-Parametric Tests**

Non-parametric tests are used when the assumptions for parametric tests are not met. Non-parametric tests:

- Do not assume the data follows any particular distribution
  
  This is required when:
  - Non-normality is obvious
    
    e.g. Multiple observations of 0
  - Possible non-normality
    
    Typically small sample sizes.
  - Data is ordinal
  - Are not as powerful as parametric tests (a larger sample size is required to achieve the same error rate)
  - Are more broadly applicable than parametric tests as they do not require the same assumptions

Non-parametric tests still require that data:

- Is continuous or ordinal
- Within-group observations are independent
- Samples are taken randomly

In general, non-parametric tests:

- Take each result and rank them
- Calculations are then performed on each rank to find the test statistic

Common non-parametric tests include:

**Mann-Whitney U Test/Wilcoxon Rank Sum Test**

Alternative to the unpaired $T$-test for non-parametric data.

Process:

- Data from both groups are combined, ordered, and given ranks
  
  Tied data are given identical ranks, where that rank is equal to the average rank of the tied observations
- The data are then separated into their original group
- Ranks in each group are added to give a test statistic for each group
- A statistical test is performed to see if the sum of ranks in one group is different to another

**Wilcoxon Signed Ranks Test**

Alternative to the paired $T$-test for non-parametric data.

Process:
As above (for the Wilcoxon Rank Sum Test), except absolute difference between paired observations are ranked
The sign (i.e. positive or negative) is preserved.
The sum of positive ranks is then compared with the sum of negative ranks
If there is no difference between groups, we would expect the net value to be 0

References


Last updated 2017-09-22
Statistical terms

Understand the terms sensitivity, specificity, positive and negative predictive value and how these are affected by the prevalence of the disease in question

Describe bias, types of error, confounding factors and sample size calculations, and the factors that influence them

All these terms refer to characteristics of diagnostic tests. The easiest way to approach this is via a 2x2 table, and has been recommended in previous exams as an approach to questions on this topic.

Types of Error

Draw a 2x2 table of disease state versus test outcome:

<table>
<thead>
<tr>
<th></th>
<th>Disease Positive</th>
<th>Disease Negative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test Positive</strong></td>
<td>True Positives</td>
<td>False Positives</td>
<td>All Test Positives</td>
</tr>
<tr>
<td><strong>Test Negative</strong></td>
<td>False Negatives</td>
<td>True Negatives</td>
<td>All Test Negatives</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>All Disease Positives</td>
<td>All Disease Negatives</td>
<td></td>
</tr>
</tbody>
</table>

- **True or false** refers to whether the test was correct
- **Positive or negative** refers to the test result

- A **Type I error** is a false positive, when we incorrectly reject the null hypothesis
  - The type I error rate can be decreased by decreasing α
- A **Type II error** is a false negative, when we incorrectly accept the null hypothesis
  - The type II error rate can be decreased by decreasing β, usually expressed as increasing power
  - Power is the chance of detecting a difference if it exists. Power is equal to 1-β.

Sensitivity and Specificity

**Sensitivity**

- **Sensitivity** is the probability those with the disease test positive, i.e. the true positive rate, and expressed mathematically as:

\[
Sensitivity = \frac{True\ Positives}{All\ Disease\ Positives} = \frac{True\ Positives}{True\ Positives + False\ Negatives}
\]

- It refers to the ability of a test to detect the condition
- A highly sensitive test will likely be positive if the condition is present
- Therefore, a negative result on a sensitive test gives a high likelihood the disease is not present
  - The mnemonic for this is SNOUT - Sensitive, Negative, rule OUT

**Specificity**

- **Specificity** is the probability those without the disease test negative, i.e. the true negative rate, and expressed mathematically as:

\[
Specificity = \frac{True\ Negatives}{All\ Disease\ Negatives} = \frac{True\ Negatives}{True\ Negatives + False\ Positives}
\]

- It refers to the ability of a test to detect absence of the condition
- A highly specific test will likely be negative if the condition is not present
Therefore a positive result on a specific test gives a high likelihood the disease is present

- The mnemonic for this is SPIN - Sensitive, Positive, rule IN

Positive and Negative Predictive Values

- Positive and negative predictive values describe the proportion of test results which are true
- A high value indicates accuracy of the test
- Because of how they are derived, they are dependent on population prevalence of the disease

- **Positive Predictive Value (PPV)** is the probability that the disease is present when the test is positive:
  \[
  \text{Positive Predictive Value} = \frac{\text{Disease Positives}}{\text{All Test Positives}} = \frac{\text{Disease Positives}}{\text{Disease Positives} + \text{False Positives}}
  \]

- **Negative Predictive Value (NPV)** is the probability that the disease is absent when the test is negative:
  \[
  \text{Negative Predictive Value} = \frac{\text{Disease Negatives}}{\text{All Test Negatives}} = \frac{\text{Disease Negatives}}{\text{Disease Negatives} + \text{False Negatives}}
  \]

**Remembering the Difference**

- Rote learning these formulas is hard
- Remember that:
  - Sensitivity and specificity are the same for any given prevalence of disease
    Therefore they look at columns (disease positive or disease negative).
  - PPV and NPV are not
    Therefore they look at rows (test positive or test negative).

**Likelihood Ratios**

The weakness of PPV and NPV as tools of evaluating the utility of a test in clinical practice is that they do not take into account the population prevalence, i.e. the prior probability, of a condition.

A classic example is the urine hCG, which has a high positive predictive value for pregnancy. Tested on an exclusively male group however, the true positive rate will be 0 (since there are no pregnancies), and so all test positives will be false positives.

Therefore:

- The actual utility of a test in decision making is dependent upon the prior probability of the disease being present
- Likelihood Ratios relate the pre-test odds to the post-test odds

  They are useful because (unlike the above values) they do not assume that the patient you are applying them to is identical to the sample from which the statistic was derived.

- The likelihood ratio multiplied by the pre-test odds gives the post-test odds of the disease being present
  - A positive likelihood ratio is used when the test is positive:
    \[
    LR(+) = \frac{\text{sensitivity}}{1 - \text{specificity}}
    \]
  - A negative likelihood ratio is used when the test is negative:
    \[
    LR(-) = \frac{1 - \text{sensitivity}}{\text{specificity}}
    \]

**References**
2. Course notes from "Introduction to Biostats", University of Sydney, School of Public Health, circa 2013.

Last updated 2019-11-02
Risk and Odds

Understand the concepts of risk and Odds Ratio

Risk

- **Absolute Risk** is the risk of an event occurring in the exposed group
- **Relative Risk** (or risk ratio) is the risk of an event occurring in the exposed group relative to the unexposed group.

\[
Relative Risk = \frac{\text{Risk in Exposed}}{\text{Risk in Unexposed}} = \frac{\frac{\text{Exposed individuals with outcome}}{\text{Number of exposed}}}{\frac{\text{Unexposed individuals with outcome}}{\text{Number of unexposed}}}
\]

- **Absolute Risk Reduction** is the decrease in risk provided by an exposure:

\[
ARR = \text{Risk in Exposed} - \text{Risk in Unexposed}
\]

Is a clinical useful measure of the value of an intervention, however is better expressed as:

- **Number Needed to Treat (NNT)** is the number of individuals who must receive a treatment to prevent one event:

\[
NNT = \frac{1}{ARR}
\]

- **Relative Risk Reduction** is the decrease in incidence provided by treatment. It is not as useful a measure of the value of an intervention, but drug companies like it because the numbers are bigger than absolute risk reduction.

Odds

- **Odds** are the probability of an event happening compared to the probability of it not happening, usually expressed as a fraction
- **The Odds Ratio** is the ratio of the odds of the outcome occurring in the exposed compared to the odds of it occurring in the unexposed

\[
OR = \frac{\text{Odds of the outcome in the exposed}}{\text{Odds of the outcome in the unexposed}}
\]

- An OR < 1 suggests the risk is lower in the exposed group
- An OR > 1 suggests the risk is higher in the exposed group
- An OR = 1 suggests that the groups are equivalent

In general, the OR overstates risk compared to the RR.

- It is approximately equal to the RR when the outcome is rare (< 10%)
- It is used when:
  - The denominator is uncertain, i.e.:
    - In retrospective designs, such as case-control studies when patients with the disease were identified, and then exposures ascertained
  - When it statistically appropriate (ORs are much easier to use in statistical tests), i.e.:
    - Multivariate regression
    - Systematic Reviews

Risk versus Odds
Relative Risk and Odds Ratios are both methods of comparing the likelihood of an outcome occurring between two groups. The difference, and particularly the concept of odds ratios, are commonly confused. Relative risk tends be much more intuitive than odds ratios. Imagine a trial has been performed, where group A was exposed group:

- In group A, the mortality was 50%
- In group B, the mortality was 25%

The relative risk is intuitive:

\[
RR = \frac{\text{Risk of death in exposed}}{\text{Risk of death in unexposed}} = \frac{0.5}{0.25} = 2
\]

The odds ratio is not:

\[
OR = \frac{\text{Odds of death in exposed}}{\text{Odds of death in unexposed}} = \frac{1/1}{1/3} = 3
\]

A RR of 2 is intuitive, but the OR of 3 is not. Now, imagine another trial where:

- In group A, the mortality was 90%
- In group B, the mortality was 10%

\[
RR = \frac{\text{Risk of death in exposed}}{\text{Risk of death in unexposed}} = \frac{0.9}{0.1} = 9
\]

\[
OR = \frac{\text{Odds of death in exposed}}{\text{Odds of death in unexposed}} = \frac{9/1}{1/9} = 81
\]

The relative risk is 9, but the OR is 81!

So why use odds ratios at all? Odds ratios are:

- Required when research subjects are selected on the basis of outcome rather than the basis of exposure
- Used by many statistical tests because the log odds ratio is normally distributed, which is a mathematically useful property

Relative Risk has a weakness as well - it is dependent on how the question is framed. Using the first trial above, we calculated that RR for death was 2 and the OR was 3. Rather than calculating mortality, an alternative method could be to look at survival:

- In group A, the survival was 50%
- In group B, the survival was 75%

\[
RR = \frac{\text{Risk of survival in exposed}}{\text{Risk of survival in unexposed}} = \frac{0.5}{0.75} = 0.66
\]

\[
OR = \frac{\text{Odds of survival in exposed}}{\text{Odds of survival in unexposed}} = \frac{1/1}{3/1} = 1/3
\]

Note that the relative risk is not 0.5 (as you may initially assume), however the odds ratio is just the inverse of the previous value.

References

2. Course notes from "Introduction to Biostats", University of Sydney, School of Public Health, circa 2013.

Last updated 2019-07-18
Significance Testing

Understand concept of significance and testing of significance

Significance testing is:

- The process of determining whether a difference between groups in a study is due to a real difference, or chance alone
- Performed using p-values
- Does not imply clinical significance

For a result to be statistically significant, there must be a 'real' difference between groups.

- This difference does not have to be clinically meaningful
  - e.g. A drug may reliably cause a 5mmHg decrease in SBP - this is unlikely to cause a meaningful drop in cardiovascular mortality but may be statistically significant

P Values

The p-value is the probability of obtaining a summary statistic (e.g. a mean) equal to or more extreme than the observed result, provided the null hypothesis is true.

The p-value is commonly (mis)used in frequentist significance testing.

- Prior to performing an experiment, a significance threshold (α) is selected
  - Traditionally 0.05 (5%) or 0.01 (1%)
  - These values define the "false-positive rate".
  - When multiple tests are being performed on one set of data, the chance of a false-positive will increase
    - To reduce the chance of a false positive occurring, the significance threshold for each test can be reduced. One method of this is the Bonferroni correction, where α is divided by the number of tests being performed.
  - Then the experiment is performed, and a value for \( p \) is calculated
    - If \( p < \alpha \), it suggests that the results are inconsistent with the null hypothesis (at that significance level), and it should be rejected.

Problems with P-values

P-values are, when employed correctly, are useful. However, they do have several weaknesses:

- Assume the null hypothesis is true
  - The p-value assumes that there is no real difference between groups.
    - This may not be the case
    - Not all hypotheses are created equal
      - There may be significant prior evidence supporting (or refuting) \( H_A \) - this will be ignored when interpreting a p-value.
        - Any study with significant results must therefore be interpreted in the context of:
          - Biological plausibility of those results
          - The previous evidence on the topic
        - It is a common misconception that the p-value estimates the chance that the result is true
          - This is not the case. The p-value measures how inconsistent the observed results are with the null hypothesis.

- A threshold of 0.05 is not always appropriate
  - The cost of being wrong must be included when interpreting a p-value. If this is a true result, what are the potential benefits?
    - If this is a false positive, what are the potential harms?

- Vulnerable to multiple comparisons
  - Conducting repeated analyses will eventually find a 'significant' result. At an \( \alpha \) of 0.05, we would expect 1/20 analyses to be
a false positive. Conducting 20 analyses would therefore generate one false positive result.

- Does not quantify effect size
  A significant $p$-value simply suggests a difference exists, it does not measure how big this difference is.
  - A result may be statistically significant but clinically unimportant, e.g. an antihypertensive medication causing a decrease in SBP by 2mmHg may be statistically significant, but clinically unimportant.

- Related to sample size $p$-values are affected by sample size:
  - A large effect size may be hidden by an insignificant $p$-value if sample size is small
  - Similarly, a tiny effect size may be detected (i.e. a significant $p$-value) if sample size is large

- Does not account for bias
  Like other statistical test, the $p$-value cannot account for bias or confounding.

References


Last updated 2019-07-18
Drug Approval and Development

Describe the processes by which new drugs are approved for research and clinical use in Australia, and to outline the phases of human drug trials (Phase I-IV)

Drug Approval

The Therapeutic Goods Administration (TGA) approves medicine for both research and clinical use in Australia.

Research

Drug trials are approved for research purposes under two schemes:

1. Clinical Trials Exemption
   Drugs must be evaluated by an expert committee to evaluate all aspects of pharmacology, toxicology, mutagenicity, teratogenicity, organ dysfunction, and other side-effects.
2. Clinical Trials Notification
   A drug which has been approved in another nation with similarly stringent requirements (New Zealand, Netherlands, UK, Sweden, US) may be used in a trial with oversight by a local ethics committee.

Clinical Use

The TGA classifies medicines into:

- **Registered Medicines**
  Assessed by the TGA for quality, safety, and efficacy.
  - All prescription (high-risk) medicines. Assessed on:
    - **Quality**
      - Composition of drug substance
      - Batch consistency
      - Stability data
      - Sterility data (if applicable)
      - Impurities
    - **Non-clinical**
      - Pharmacology data
      - Toxicology data
    - **Clinical**
      - Efficacy: results of clinical trials
  - Most OTC (low-risk) medicines
  - Some complementary medicines

- **Listed Medicines**
  Assessed by the TGA for quality, safety, but not efficacy.
  - Some OTC medicines
  - Most complementary medicines

Phases of Drug Development

- "Phase 0"
  - Pre-clinical R&D
In vitro and animal testing

**Phase I**
- First administration in humans
- Basic pharmacokinetic and toxicology data
- 20 - 100 human subjects

**Phase II**
- Administration to select patient groups
- Aim to establish dose-response curve
- Evidence of efficacy

**Phase III**
- Full-scale evaluation of benefits, potential risks and costs analysis
- 2000-3000 patients, usually treated in groups of several hundred for relatively short durations (3-6 months), regardless of the length of time the drug will be used in practice \(^3\)
- May not reveal uncommon or long-term risks

**Phase IV**
- Post-marketing surveillance

---

**References**


Last updated 2017-09-16
Additives

Describe the mechanisms of action and potential adverse effects of buffers, anti-oxidants, anti-microbial and solubilizing agents added to drugs.

Additives are components of a drug preparation which do not exert the pharmacological effect.

Additives include:

- **Preservatives**
  - Benzyl alcohol
    - Antimicrobial when > 2%
    - Can be used as a solvent when > 5%
    - Toxic

- **Antioxidants**
  - Sulfites
    - Hypersensitivity
    - Neurotoxic if given intrathecally

- **Solvents**
  - Water
    Appropriate for dissolving polar molecules.
  - Non-aqueous solvents
    Used to dissolve non-polar molecules, or to produce more stable preparations of semi-polar molecules. Examples include:
    - Propylene glycol
      - Hypotension
      - Arrhythmia
        - With rapid injection.
      - Pain on injection
      - Thrombophlebitis
    - Mannitol
      - Diuresis
    - Soybean oil
      - Pain on injection
      - Allergy

- **Emulsion**
  Formed when drops of a liquid are dispersed throughout another liquid in which it is immiscible. Emulsions are:
  - Unstable
    Emulsifiers are used to enhance stability.
  - Prone to contamination
    Due to the water component.
  - Prone to rancidity
    Due to the oil component.

- **Buffers**
  Maintain pH in a particular range in order to:
  - Maximise stability
    Preserve shelf life.
  - Maintain solubility
Maximise preservative function

References

Isomerism describes groups of compounds which have the same chemical formula but different chemical structures. Isomerism is relevant because different isomers may have different enzymatic and receptor affinities, altering their pharmacokinetic and pharmacodynamic properties.

Types of Isomerism

Isomers can be divided into:

- **Structural Isomers**
  Identical chemical formula but different arrangement of atoms. Structural isomerism is subdivided into:
  - **Static**
    Further subdivided into:
    - Chain isomer
      The carbon skeleton varies, but position of functional groups is static.
    - Position isomer
      The carbon skeleton is static, but the position of functional groups varies.
      - e.g. Isoflurane vs. enflurane
  - **Dynamic** (also known as tautomer)
    The molecule exists in a different molecular structures depending on the environment.
    - e.g. Midazolam has pH dependent imidazole ring opening. When the pH is less than 4 the ring remains open, maintaining water solubility. Midazolam is supplied at pH of 3.5, and so is water soluble on injection but (due to its pKa of 6.5) becomes 89% unionised at physiological pH therefore able to cross lipid membranes.

- **Stereoisomers**
  Atoms are connected in the same order in each isomer, but different orientation of functional groups. Stereoisomers are not super-imposable, meaning the different isomers can’t be rotated so that they look the same. Stereoisomers are divided into:
  - **Geometric Isomers**
    Have a chemical structure (e.g. a carbon-carbon double-bond) prevents free rotation of groups, so different locations of chemical groups will create an isomer. Geometric isomers are known as cis- or trans- depending on whether the subgroups are on the same or opposite sides (respectively) of the chemical structure.
    - e.g. Atracurium
  - **Optical Isomers**
    Optical isomers are chiral. This means they have no plane of symmetry. Optical isomers:
    - Were initially named based on how they rotated under polarised light:
      (Note this is different from D- and L- molecules, where the D-isomer refers to the molecule synthesised from (+)glyceraldehyde).
      - **Dextrorotatory**
        (d- or (+) isomers) molecules rotate clockwise under polarised light.
      - **Levorotatory**
        (l- or (-) isomers) molecules rotate counter-clockwise under polarised light.
    - Unfortunately, different molecules were found to rotate in different directions depending on the temperature. Therefore, a different classification scheme (R/S) is also used:
      - Based on chemical structure
      - "Priority" is assigned to each atom in the structure
      - Highest priority is usually those with the highest molecular weight, but other rules exist for ambiguous or very
large molecules

- The molecule is arranged in space such that the lowest priority atom is facing "away"
- An arrow is then drawn from the highest priority to the lower priority atoms:
  - If this arrow travels clockwise it is the R (Rectus) isomer
  - If this arrow travels counter-clockwise it is the S (Sinister) isomer
- Optical isomers are divided into:
  - **Enantiomers**
    Possess one chiral centre.
    - e.g. levobupivacaine is less cardiotoxic than racemic bupivacaine.
  - **Diastereoisomers**
    Possess multiple chiral centres, and may have multiple stereoisomers. Since not all are mirror images, these are not enantiomers.
    - For a molecule with $n$ chiral centres up to $n^2$ isomers are possible, though some of these may be duplicates.

**Preparations**

Drugs can be provided as:

- **Racemic solutions**
  A racemic solution is one which where the different enantiomers are present in equal proportions.

- **Enantiopure preparations**
  A drug produced with a single isomer, which may be more efficacious or less toxic (and definitely more expensive) than the racemic preparation.

**References**

2. CICM. The Mock Exam.
3. ChemGuide. Geometric isomerism
4. ChEBI. Misoprostol, European Molecular Biology Laboratory.
5. ANZCA July/August 2000

Last updated 2019-07-18
**Modeling**

Explain the concept of pharmacokinetic modeling of single and multiple compartment models.

Pharmacokinetics describes what the body does to a drug. Pharmacokinetic models are mathematical concepts used to predict plasma concentrations of drugs at different time points.

**Basic Pharmacokinetic Terms**

Key concepts in pharmacokinetics include:

- **Volume of distribution, $V_D$**
  The volume of distribution is defined as the theoretical volume into which an amount of drug would be distribute to produce the observed plasma concentration.
  
  - Units are ml.kg$^{-1}$
    
    $$ V_d = \frac{\text{Total bioavailable drug}}{\text{Plasma concentration}} $$
  
  - It is a way to describe what proportion of a drug is confined to plasma, and what proportion distributes to other tissues.
  
  - It does not correspond to any particular volume, however a $V_D$ of:
    
    - Less than 40ml.kg$^{-1}$ indicates a drug is confined to plasma
    - Up to 200ml.kg$^{-1}$ indicates a drug is confined to the ECF
    - Up to 600ml.kg$^{-1}$ indicates a drug is dissolved into the TBW
    - Greater than 1L.kg$^{-1}$ indicates a drug is highly protein bound or lipophilic
  
  - Agents which cross the blood brain barrier typically have a $V_D$ of 1-2L.kg$^{-1}$.
  
  - Subtypes of the volume of distribution are used to describe drug distribution at different times or with different models
    
    - These include:
      
      - $V_1$
        Volume of central compartment.
      
      - $V_{pss}$
        Volume of distribution at steady state.
      
      - $V_{pbe}$
        Volume of distribution at peak effect.
    
    - Which volume to use depends on the pharmacological question
    
    - e.g. Intubating dose for opioid should use a volume between $V_1$ (very small) and $V_{pss}$ (very large) - $V_{pbe}$ is ideal as it will allow a target concentration to be selected for the time at which intubation will occur relative to drug administration.

- **Half-life ($t_{1/2}$)**
  The time it takes for a process to be 50% complete. With respect to drug clearance, it is the time it takes for concentration (typically in plasma) to fall by 50%.

  - A process is considered to be complete after 4-5 half-lives
    
    Concentration will decrease by 50% after each half-life, so after 5 half-lives concentration will be 3.125% of its starting value.
  
    - This also applies to wash in - it will take ~4-5 elimination half-lives of a drug for a constant-rate infusion to reach its final concentration.
  
    - Half-life is mathematically related to many other key pharmacokinetic terms:
      
      $$ t_{1/2} = 0.693 \times \tau = \frac{0.693}{k} = \frac{0.593 \times V_D}{C_l} $$
      
      - $\tau$ is the time constant.
- $k$ is the rate constant for elimination
- $V_D$ is the volume of distribution
- $Cl$ is the clearance

- Various types of half-life are described:
  - $t_{1/2\alpha}$ describes the rapidity of the distribution phase following drug administration
  - $t_{1/2\beta}$ describes the rapidity of the elimination phase occurring after drug distribution equilibrium

  This only evaluates clearance from plasma, and so is a composite of both excretion from the body (e.g. renal and hepatic clearance) and ongoing distribution to peripheral tissues.

  - The elimination half-life is generally not useful to predict drug offset, as this is affected by many factors

  However, it does set an upper limit on how long it will take plasma concentration to fall by 50%.

- **Time-constant (T)**

  The time taken for a process to complete if it continued at its initial rate of change. Time constants are related to half-life, but are better suited when modeling change in exponential processes.

  - Time constants are discussed in more detail under respiratory time constants
  - Elimination will be virtually complete after three time constants

  A time constant is the inverse of the rate constant for elimination, i.e. $\tau = \frac{1}{k}$

  - Illustration of the relationship between half-life and time constant:

    ![Illustration of the relationship between half-life and time constant](image)

- **Clearance**

  The clearance is volume of plasma completely cleared of a drug per unit time.

  - In a one compartment model, this can be expressed as: $Cl = k. V_D$ in mL.min$^{-1}$.

    As the time constant is the inverse of $k$, clearance can also be expressed as:

    - Since $k$ and $V_D$ are constants, clearance is also a constant
    - Total clearance is a sum of the clearance of each individual clearance organ

- **Rate of elimination**

  Amount of drug removed by the body per unit time.

  - Rate of elimination is the product of the clearance and the current concentration:

    $$Rate\ of\ Elimination = Cl \times C, \text{in mg.min}^{-1}$$

    This is not the rate constant for elimination

---

**Compartmental Modeling**

The simplest model imagines the body a single, well-stirred compartment.
In a one compartment model, the concentration of a drug \( (C) \) at time \( t \) is given by the equation:

\[
C = C_0 e^{-kt}
\]

Where:

- \( C_0 \) is the concentration at time 0
  - As drug can only be eliminated from the compartment, this is also the peak concentration.
- \( k \) is the rate constant for elimination
  - This is the fraction of the Vd from which the drug is removed per unit time. The rate constant determines the slope of the curve.
  - A high rate constant for elimination results in a steep curve and therefore a short time constant

**Steady state**

At steady state, input is equal to output. Therefore concentration at steady state is:

- Proportional to the concentration of the infusion and infusion rate
- Inversely proportional to the clearance:

\[
\frac{Input}{Output} = \frac{CI}{Cl}
\]

\[
C_{ss} = \frac{CI}{Cl} \cdot I
\]

- Concentration of drug can therefore be determined by the amount infused and the clearance
- Note steady state requires peripheral compartments to be saturated, and so will only occur after an infusion of many hours

**Multiple Compartment Models**

- Models with multiple compartments have a better fit with experimental data than single compartment models
- Three-compartment models are typically used, as additional compartments typically offer no extra fidelity but are mathematically more complex
- A three-compartment model can be conceptualised as a plasma (or central) compartment, a well-perfused compartment, and a poorly-perfused compartment
  - This doesn’t mean that they should be thought of in this way - they are a mathematical technique used to calculate plasma concentration at a given time.
Plasma concentration in multi-compartment models is:

- Predicted through the net effect of several negative exponential equations. This is covered under two-compartment models below.
- Dependent on the effects of:
  - **Distribution**
    Distribution describes the movement of drug from the central compartment (V₁) to the peripheral compartment(s).
    - Rapid fall in plasma concentration of a drug after administration is generally due to distribution
    - Distribution is an important method for drug offset in short-acting drugs.
  - **Redistribution**
    Redistribution refers to the movement of drug from the peripheral compartment(s) back into plasma.
    - Drugs which have a large V_D in a peripheral compartment tend to distribute quickly along this concentration gradient, and redistribute slowly back into plasma
    - Drugs which tend to distribute slowly tend to redistribute quickly once administration has ceased
  - **Excretion**
    Excretion is the removal of drug from the body.

### Clearance in Two-Compartment Models

Removal of drug in two-compartment models is via:

- Distribution from the central to the peripheral compartment
- Elimination from the central compartment
- This produces a bi-exponential fall in plasma concentration
  Consists of two phases:
  - **Phase α**
    Distribution phase: A rapid decline in plasma concentration due to distribution to peripheral tissues.
  - **Phase β**
    Elimination phase: Slow decline in plasma concentration due to:
    - Elimination from the body
    - Redistribution into plasma

![Graph showing bi-exponential decline in plasma concentration](image)
This curve is given by the equation 

\[ C' = A e^{-\alpha t} + B e^{-\beta t}, \]

where:

- \( C' \) is the concentration of drug in plasma
- \( A \) is the \( y \)-intercept of the distribution exponent
  
  Used to calculate distribution half-life.
- \( B \) is the \( y \)-intercept of the elimination exponent
  
  Used to calculate elimination half-life.
- \( \alpha \) is the rate constant for distribution

The value of \( \alpha \) is dependent on the ratio of rate constants for distribution and redistribution (i.e. \( \frac{k_{12}}{k_{21}} \)).

- If distribution greatly exceeds redistribution, the gradient of \( \alpha \) will be very steep and plasma concentration will fall rapidly after administration
- \( \beta \) is the rate constant for elimination

- Note that the distribution and elimination curves appear straight because the \( y \)-axis is log-transformed
  
  If plasma concentration was plotted on the \( y \)-axis, then each of these curves would be a negative exponential (wash-out curve)

**Effect Site**

Pharmacokinetic models typically display the plasma concentration.

- Clinically however, we are interested in drug concentrations at the site of action (e.g. the brain)
  
  - Concentration at the effect site (also known as biophase) is given by \( C_e \)
    
    - This cannot be measured, and so is a calculated value
    - Effect site concentration be different from plasma concentration (\( C_p \)) prior to reaching steady state
  
    The delay between plasma and effect site concentrations is an example of hysteresis.
- The effect site can be modeled as an additional compartment in three-compartment models
  
  The effect site is modeled as a compartment of negligible volume contained within \( V_1 \), but does have rate constants
  
  - Effect site volume changes as \( V_1 \) changes
  - The \( k_{e1} \) is the rate constant for drug diffusion from plasma into the effect site
  - The \( k_{e0} \) is the rate constant for elimination of drug from the effect site

  This is a theoretical elimination pathway - drug is not usually metabolised at the effect site.
  
  - The \( t_{1/2ke0} \) describes the effect-site equilibration time
    
    It describes how rapidly the effect site reaches equilibrium with plasma.
    
    - A large \( ke0 \) (rapid drug flow) gives a short \( t_{1/2ke0} \)
    - After one \( t_{1/2ke0} \), 50% of the final effect site concentration will be reached provided plasma concentration remains constant
  
  - A shorter \( t_{1/2ke0} \) indicates that the effect site concentration will reach equilibrium with plasma more rapidly, and therefore a more rapid clinical effect following administration is seen

  - Note that:
    
    - The \( t_{1/2ke0} \) is not the time to peak effect
      
      - Neither is \( ke0 \)
    - For an infusion run at constant plasma concentration the peak effect will be seen at 3-5x the \( t_{1/2ke0} \)
    - The time to peak effect is a function of both plasma kinetics and the \( t_{1/2ke0} \)
      
      - e.g. adenosine has such a short elimination \( t_{1/2} \) the effect site concentration will reach its peak rapidly regardless of the \( ke0 \)
Non-Compartmental Models

Compartment models are not appropriate for describing the behaviours of all drugs. Non-compartmental models are used when drug:

- Clearance is organ-independent
- Elimination does not occur solely from the central compartment

These models use AUC, which is calculated by measuring the plasma concentration of a drug at different time intervals, and

plotting the area under the curve (AUC). This can be used to:

- Determine clearance
  \[ C' = \frac{\text{Dose}}{\text{AUC}} \]
- Determine Bioavailability
  Difference between the AUC of the same dose of drug administered IV and via another route.

Footnotes

The formula for half-life can be derived from the equation for a wash-in exponential as follows:

- Wash in exponential is given by: \( C' = 1 - e^{-kt} \)
- \( y = 0.5 \) can then be substituted and the equation solved for \( t \) as follows:
  \[
  0.5 = 1 - e^{-kt} \\
  -0.5 = e^{-kt} \\
  \ln(-0.5) = -kt \\
  \ln 2 = kt \\
  \frac{\ln 2}{k} = t \\
  \frac{0.693}{k} = t
  \]

References

Last updated 2019-07-18
Absorption

Describe absorption and factors that will influence it.

Absorption is dependent on the route of administration. Routes of administration are selected based on:

- Effect site of the drug
- Drug factors
  - Bioavailability
  - Available preparations
- Patient factors
  - Ability to take or absorb oral medications
  - Preference

Key Concepts

Bioavailability is the proportion of drug given which reaches the systemic circulation unchanged, compared to the IV form. It is affected by:

- Formulation
- Physicochemical Interactions
  - Interactions with other drugs and food.
- Patient Factors
  - Malabsorption syndrome
  - Gastric stasis
- First-pass metabolism

First-pass (pre-systemic) metabolism is the extent to which drug concentration is reduced after its first passage through an organ, prior to reaching the systemic circulation. First pass metabolism is:

- Typically used when referring to passage of orally-administered drugs through the liver
  - May also refer to metabolism by the:
    - Lungs
      - First pass of intravenously injected drugs prior to entering the arterial side of the circulation, e.g. fentanyl.
    - Vascular endothelium
- Relevant in:
  - Understanding differences between PO and IV dosing
    - Alternative routes of administration for drugs with low PO bioavailability
  - Delivery of prodrugs via PO mechanisms
    - Increases active drug concentration.
  - Understanding enzyme interactions
  - Understanding the effects of hepatic disease
    - Porto-systemic shunts decrease first pass metabolism
    - Altered bioavailability of drugs with high hepatic extraction ratios

Routes of administration

Intravenous

- Rapid Onset
- 100% bioavailability
  Some drugs may still undergo metabolism in the pulmonary circulation, such as fentanyl, lignocaine, propofol, and catecholamines.

**Oral**

- Absorption is through gut mucosa, through either:
  - Transport mechanisms
  - Unionised (lipid soluble)
    - Acidic drugs are absorbed more rapidly in the stomach
    - The small bowel absorbs both acid (despite being ionised) and alkaline drugs due to high surface area
- Lowest bioavailability of any route due to:
  - First-pass metabolism
  - Gut metabolism of drugs
  - Bacterial metabolism of drugs
- Drugs must be lipid soluble enough to cross cell-membranes and water soluble enough to cross interstitium

**Factors affecting GIT Absorption**

- Drug Factors
  - Molecular Weight
  - Concentration Gradient
  - Lipid Solubility
    - pH and pKa
  - Pharmaceutical Preparation
  - Physiochemical Interactions
    - Food
    - Other drugs

- Patient Factors
  - GIT blood flow
  - Surface Area
    - Small bowel has the largest surface area of any GIT organ
  - pH
  - Motility
  - Digestive Enzymes
  - GIT bacteria and subsequent metabolism
  - Disease
    - Critical Illness
    - Bowel Obstruction
    - Emesis/Diarrhoea

**Epidural**

- May be via bolus or infusion
- Onset determined by proportion of unionised drug available
  Lignocaine has a more rapid epidural onset than bupivacaine as it has a pKa of 7.9 (compared to 8.4) and therefore a greater unionised portion at physiologic pH.
- Additional factors include additives and intrinsic vasoactive properties of the delivered drug

**Subarachnoid/Intrathecal**
- Very small dosing
- Minimal systemic spread
- Extent of subarachnoid spread is dependent on volume and type of solution
- Appropriate positioning of the patient, with higher-specific gravity solutions, is required to avoid superior spread of the block
- Additional factors include additives and intrinsic vasoactive properties of the delivered drug

**Inhalation**

- Systemic absorption dependent on particle size
  - Large particles reach the bronchioles
  - <1 micron diameter particles may reach the alveolus
- Rapid diffusion to circulation due to high surface area and no first-pass metabolism

**Transdermal**

- Systemic absorption dependent on:
  - Dose requirement
    - Large dose requirements cannot be effectively given transdermally
  - Fick Principle
    - Amount of drug given
    - Amount of drug in skin
      - Regional blood flow
      - Histamine release
    - Surface Area
    - Skin thickness
    - Lipid solubility
      - pH of skin and emulsion
      - pKa of drug
    - Molecular weight
  - Advantages
    - Convenient
    - Painless
    - No first pass metabolism
    - Steady plasma concentration once established
  - Disadvantages
    - Slow onset
    - Variable plasma concentration initially
    - Overdose and abuse potentials

**Subcutaneous**

- Absorption dependent on regional blood flow

**Sublingual**

- Rapid onset
- Bypass portal circulation (drains into SVC)

**Rectal**

- Variable absorption
Distal rectal absorption bypasses portal circulation
- Proximal rectal absorption does not and may result in hepatic first pass metabolism
- Small surface area for absorption

Intramuscular
- Bioavailability close to 1
- Absorption dependent on regional blood flow
- Potential local complications:
  - Abscess
  - Haematoma

References
2. Chong CA, Denny NM. Local anaesthetic and additive drugs.

Last updated 2019-07-18
Drug distribution is dependent on many factors, all of which can be related to Fick's Law of Diffusion:

- **Concentration gradient**
- **Tissue mass**
- **Molecular Weight**
  Larger molecules are less able to cross cell membranes, and so a greater portion will remain in the compartment they are delivered to.
- **Lipid Solubility**
- **Ionisation**

  Ionised drugs are polar, and so are less lipid soluble.
  - Ionisation is a function of:
    - **pKa**
      The pKa is the pH at which a weak acid or weak base will be 50% ionised.
      - As solvent pH changes, the proportion of ionised vs. unionised drug will differ
      - How depends on whether the drug is an acid or base:
        - Bases are ionised Below their pKa
        - Acids are ionised Above their pKa
    - **pH**
      In combination with pKa, affects the ionised portion.
  - **Unionised drugs:**
    - Cross cell membranes more readily than the ionised form
    - Are typically hepatic metabolised
    - Are typically not renally eliminated
  - **Ionised drugs:**
    - Are typically renally excreted without undergoing metabolism
    - Are poorly lipid soluble and do not cross cell membranes readily
    - May be ion trapped
      This occurs when an unionised drug moves across a membrane and becomes ionised due to a change in pH. The now-insoluble drug is trapped in the new compartment. This is relevant in:
        - **Placenta**
          Foetal pH is lower than maternal pH, which can trap basic drugs (e.g. LA, opioids) in foetus.
          - This becomes more significant with a greater divergence of pH (e.g. placental insufficiency)
        - **Renal elimination**
          Urinary alkalisation is used to accelerate elimination of acidic drugs, as they become ionised and trapped in urine.
Protein binding

Proteins and drugs may be bound together by weak bonds. These include ionic bonds, van der Waal’s forces, and hydrogen bonds.

- Drugs may bind to proteins in:
  - Plasma
    - **Albumin**
      - Binds acid and neutral drugs.
      - High capacity
      - Two major binding sites (six total)
        - Site I (warfarin)
        - Site II (diazepam)
    - **α1-acid glycoprotein**
      - Binds basic drugs.
      - Single binding site
      - Low capacity
      - Typically results in lower total binding (compared to albumin) of alkaline drugs, despite its increased affinity.
    - Lipoprotein
      - For lipid soluble drugs.
  - Tissue
  - Receptor

- Protein binding is important as:
  - Only unbound drugs are able to:
    - Cross cell membranes
    - Interact with receptors
    - Undergo metabolism
    - Reduced protein binding increases clearance of drugs with low extraction ratios.
    - Be filtered by the kidney
  - Highly tissue bound drugs:
    - Have a long duration of action
    - Have a high volume of distribution, prolonging their elimination
    - May build up in tissues, leading to adverse effects
      - e.g. Corneal deposition, lung fibrosis.

- Protein binding is affected by:
  - Affinity of drug for protein
    - Ionised drugs do not bind to protein
    - pH.
  - Competition between drugs for binding sites
  - Amount of protein
    - Disease
Due to:
- Hypoalbuminaemia
  Negative acute phase reactant.
- Increased α1-acid glycoprotein
  Acute phase reactant.
- Competition
  Source of pharmacokinetic interactions.

- Protein binding typically:
  - Correlates with lipid solubility
  - Is important only when it is very high
  - Results in a decreased \( V_{DSS} \) when plasma binding is high
  - Results in an increased \( V_{DSS} \) when tissue binding is high
  - Is important in duration of action as it also relates to affinity for tissue proteins

- **Regional blood flow**
  Affects concentration gradients between blood and tissue, and is affected by cardiac output. Regions include:
  - Vessel Rich Group
    - Brain
    - Heart
    - Liver
    - Kidneys
  - Vessel Poor Group
    - Connective tissue
      - Bones
      - Ligament
      - Teeth
      - Hair
  - Muscle groups
  - Fat

---

**References**


Last updated 2019-07-18
**Metabolism**

Describe the mechanisms of drug clearance and metabolism.

Removal of drug from the body requires either:

- Metabolism of active drug to an inactive substance
  Typically by the liver, but other organs (kidney, lungs) also metabolise some substances.
- Excretion of active drug
  Often by the kidneys, but may also be in bile, or exhaled.
  - Removal of drugs from the body is achieved predominantly through renal excretion of water-soluble compounds
  - As many drugs are lipophilic, metabolism to water soluble compounds is required to clear drugs from the body

**Clearance**

Clearance describes the elimination of drug from the body. Clearance is:

- The volume of plasma completely cleared of a drug per unit time
  Measured in ml.min\(^{-1}\).
  - Discussed further in modeling
  - Does not include redistribution
  - Is calculated from the area under the concentration time curve:
  \[ C' = \frac{Dose}{AUC} \]

Total clearance is the sum of clearances from individual organs, e.g.:

\[ C'_{total} = C'_{renal} + C'_{liver} + C'_{lung} + C'_{organ-independent} + C'_{other}, \text{ where:} \]

- \([U]\) is urine concentration in mmol.L\(^{-1}\)
  Function of glomerular filtration, reabsorption, and secretion.
- \([V]\) is the urine flow in ml.min\(^{-1}\)
- \([P]\) is the plasma concentration in mmol.L\(^{-1}\)

- \(HBF\) is the hepatic blood flow in ml.min\(^{-1}\)
- \(ER\) is the extraction ratio

**Kinetics**

Drug clearance can follow either first order or zero-order kinetics:

- **First-order Kinetics**
  A constant proportion of the drug in the body is eliminated per unit time.
  - Most drugs are eliminated by first order kinetics, as the capacity of the elimination system exceeds the concentration of drug
- **Zero-order kinetics**

  A constant amount of drug is eliminated per unit time, independent of how much drug is in the body.

  - Occurs when there is saturation of enzyme systems

  It is also known as saturation kinetics for this reason.

    - e.g. Phenytoin follows first order kinetics at lower doses, but zero-order kinetics at doses within the therapeutic range
      
      This is clinically relevant as the narrow therapeutic index means that toxic levels may occur rapidly with a small increase in dose.

    - e.g. Ethanol also follows zero-order kinetics within the "therapeutic range", as it is a very weak (doses are in grams) positive allosteric modulator of the GABA<sub>A</sub> receptor

  - Zero-order kinetics is concerning as:

    - Plasma concentrations will **rapidly increase** with only modest dose increase
    - There is essentially **no steady state**: if drug input exceeds output, plasma levels will continue to rise

---

**Michaelis-Menten**

The Michaelis-Menten equation describes the transition from first order to zero order kinetics as drug concentration increases:

- Metabolism increases proportionally with concentration as long as the concentration of drug leaving the organ of metabolism (e.g. in the hepatic vein) is less than half of the maximal concentration of drug that organ can metabolise
Hepatic Metabolism

The principle organ of drug metabolism is the liver. Hepatic metabolism:

- Usually decreases the function of a drug, though:
  - Prodrugs have increased pharmacologically activity after liver metabolism
  - Some drugs have active or toxic metabolites
- Can be divided into two phases

Phase I

Phase one reactions:

- Occur in the endoplasmic reticulum
- Improve water solubility by exposing a functional chemical group
- Typically occur prior to phase II reactions for most drugs
- Include:
  - Oxidation
    - Loss of electrons.
      - Main phase I reaction
      - CYP450 driven
  - Reduction
    - Gain of electrons.
      - CYP450 driven
  - Hydrolysis
    - Addition of a water molecule, which may result in two new compounds.
      - Esterase driven
      - Therefore rapid, high capacity, organ-independent elimination.
        - Butylcholinesterase
        - Non-specific plasma cholinesterase
        - RBC esterase

CYP450 System

CYP450 enzymes are:

- A superfamily of enzymes vital in drug metabolism
- Named after the wavelength of light they absorb when:
  - Reduced
  - Combined with CO
- Located in:
  - Liver
    - Endoplasmic reticulum of hepatocytes.
  - Lungs
  - Kidney
  - Gut
  - Brain
- Over 1000 enzymes, with ~50 functionally active
- Classified by the degree of shared amino-acid sequence into:
  - Families
CYP1, CYP2, CYP3...
- Subfamilies
  CYP1A, CYP1B...
- Isoforms
  CYP1A1, CYP1A2...

<table>
<thead>
<tr>
<th>CYP2B6</th>
<th>CYP2C9</th>
<th>CYP2C19</th>
<th>CYP2D6</th>
<th>CYP2E1</th>
<th>CYP3A4</th>
<th>CYP3A5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propofol</td>
<td>Propofol, Parecoxib, Warfarin</td>
<td>Diazepam, Omeprazole, Clopidogrel, Phenytion</td>
<td>Codeine, Metoprolol, Flecainide</td>
<td>Volatile anaesthetic agents, paracetamol</td>
<td>Common benzodiazepines, Fentanyl, Alfentanil, Lignocaine, Vecuronium</td>
<td>Diazepam</td>
</tr>
</tbody>
</table>

Key CYP enzymes include:
- **CYP2E1**
  Metabolises volatiles and paracetamol.
- **CYP3A4**
  Responsible for 60% of metabolic activity.
- **CYP2D6**
  - Important because genetic polymorphism leads to significant inter-patient variability
  - May result in significant over- or under-metabolism of drugs, and therefore significant inter-individual variability in response.
    - 5-10% of the population are poor metabolisers
    - 2-10% are intermediate metabolisers
    - 1-2% are ultra-rapid metabolisers
    - Bulk of the population (70-90%) are extensive metabolisers
  - Clinical effect will depend on the type of drug
    - Pro-drugs
      - Extensive/ultra-rapid metabolisers will convert more drug to the active form, and see a greater effect
      - May lead to overdose.
      - Poor metabolisers will excrete more pro-drug prior to metabolism, and see a reduced clinical effect
    - Active drug
      - Extensive/ultra-rapid metabolisers will inactivate more drug, and see a reduced effect
      - Poor metabolisers will see a prolonged clinical effect
  - Clinical effect may be altered by enzyme interactions
    - e.g. Oxycodone use by an ultra-fast metaboliser, in combination with a CYP3A4 inhibitor (e.g. diltiazem) will result in a significant increase in the clinical effect of oxycodone
- Drugs metabolised by CYP2D6 include:
  - Analgesics
    - Codeine (prodrug)
    - Oxycodone (metabolised to the significantly more potent oxymorphone)
    - Methadone
    - Tramadol (metabolised to form with greater MOP selectivity)
  - Psychiatric drugs
    - SSRIs
    - TCAs
    - Haloperidol
  - Cardiovascular drugs
    - Amiodarone
    - Flecainide
    - Mexiletine
Phase II

Phase II reactions:

- Involve conjugation with another compound, producing a highly polar metabolite. This increases water solubility and therefore renal elimination.
- Typically occur in the hepatic endoplasmic reticulum.
- Include:
  - **Glucuronidation**: Addition of glucuronic acid.
  - **Sulfation**: Addition of a sulfa group.
  - **Acetylation**: Addition of an acetyl group.
    - Also occurs in the **lung** and **spleen**.
  - **Methylation**: Addition of a methyl group.

**Extraction Ratio**

**Extraction ratio** is the proportion of a drug that is cleared from circulation during each pass through the organ, typically the liver:

\[
ER = \frac{\text{Drug Absorbed}}{\text{Drug reaching systemic circulation}}
\]

Extraction ratio is dependent on:

- Blood flow
- Hepatocyte uptake
- Enzyme capacity
  - Described by the **Michaelis Constant**: The concentration of a substrate which causes an enzyme to work at 50% of its maximum capacity.

Drugs can have either a high or low extraction ratio:

- **High extraction ratio**
  - These drugs have a rapid uptake and high capacity, so elimination is **perfusion dependent**.
    - Free drug is rapidly removed from plasma, bound drug is released from plasma proteins and a concentration gradient is maintained.
    - Metabolism of drugs with a high extraction ratio is:
      - **Independent of protein binding**
      - **Dependent on liver flow**
        - Typically doubling liver blood flow will double hepatic clearance.
      - There is a **high variability** in plasma concentration between individuals due to the variation in liver blood flow.
      - Drugs with high extraction ratios are generally independent of enzyme activity - decreasing enzyme activity from 99% to 95% has a minimal effect on hepatic clearance.
      - The **key exception** is **first pass metabolism**, as the above change will result in a five-fold difference in dose reaching the systemic circulation.
        - Therefore drugs with a high extraction ratio have low PO bioavailability.

- **Low extraction ratio**
  - Elimination is **capacity-dependent**.
    - Amount of free drug available for metabolism is greatly affected by the degree of protein binding.
    - Metabolism is:
      - Largely **independent of flow**
Drugs have good PO bioavailability.
- Dependent on hepatocyte function and protein binding

## Factors Affecting Hepatic Metabolism

<table>
<thead>
<tr>
<th>Drug Factors</th>
<th>Patient Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid solubility</td>
<td>Age</td>
</tr>
<tr>
<td>Ionisation</td>
<td>Obesity</td>
</tr>
<tr>
<td>Protein binding</td>
<td>Pregnancy</td>
</tr>
<tr>
<td>Enzyme competition</td>
<td>Genetics: Slow vs. fast acetylators</td>
</tr>
<tr>
<td></td>
<td>Hepatic flow/Extraction Ratio</td>
</tr>
<tr>
<td></td>
<td>Enzyme Inhibition/Induction</td>
</tr>
<tr>
<td></td>
<td>Hepatic disease</td>
</tr>
<tr>
<td></td>
<td>Smoking, ETOH</td>
</tr>
</tbody>
</table>

## Organ Independent Metabolism

Mechanisms of organ independent metabolism include:

- **Hofmann Degradation**
  - Spontaneous degradation or metabolism of substances occurring in plasma.
  - e.g. Cisatracurium undergoes Hofmann degradation

- **Plasma Esterases**
  - Plasma esterases are non-microsomal enzymes which hydrolyse ester bonds. They:
    - Are typically synthesised in the liver and erythrocytes
    - Have a high capacity
      - This, combined with the organ-independent elimination, means drugs metabolised by plasma esterases have a reliable offset.
    - e.g. Suxamethonium is hydrolysed by plasma esterases

## References

2. Essential pharmacology for the ANZCA primary exam

Last updated 2019-07-18
Elimination

Describe the mechanisms of drug clearance and metabolism.

Drugs can be eliminated in:

- Urine
- Bile
- Sweat
- Breast milk
- Tears
- Exhaled gas

Renal Elimination

Drugs can be:

- Filtered at the glomerulus
  
  Filtered drugs are:
  
  - **Not protein bound**
    
    Only free drug present in filtered plasma will be excreted.
    
    - Concentration of filtered drug will be the same as in *unfiltered* plasma
    
    - **Highly protein bound** drugs are *poorly filtered*
      
      There is only a weak concentration gradient favouring dissociation from plasma proteins.
  
  - **Small**
    
    - Substances less than 7,000 Da are freely filtered
    
    - Substances greater than 70,000 Da are essentially impermeable
  
  - **Hydrophilic/lipophobic**
    
    Lipophilic drugs may be filtered at the glomerulus but will be freely reabsorbed during their passage down the tubule, such that only trivial amounts are eliminated in urine.
  
  - Secreted in the tubules
    
    - **Active** process allows secretion against concentration gradients
    
    - Separate mechanisms for acidic and alkaline drugs
      
      - Saturatable process
        
        Saturation may occur of a basic transporter whilst still allowing excretion of acidic drugs, and vice versa.
  
  - Reabsorbed in the tubules
    
    - **Passive diffusion** down a concentration gradient.
      
      - Hydrophilic molecules can only be reabsorbed by a specialised transport mechanism
        
        - Acidic drugs will be become ionised in an alkaline urine (and vice versa), reducing their solubility
          
          This is the physiological justification for urinary alkalisation.

Hepatic Elimination

Biliary elimination occurs for drugs unable to be filtered by the glomerulus. These are typically:

- Large
  
  Greater than 30,000 dalton.
- Lipid soluble
Enterohepatic recirculation

Drugs excreted in bile may:

- Be hydrolysed in the small bowel by bacteria and then reabsorbed
- Then pass through the portal circulation and get metabolised again
- This process may occur many times

References


Last updated 2019-07-18
Bolus and Infusion Kinetics

Explain the concepts of intravenous bolus and infusion kinetics. To describe the concepts of effect-site and context sensitive half time.

Continuous Infusions

Plasma concentrations of an IV infusion are influenced by:

- Distribution
- Metabolism
- Elimination

Onset of Continuous Rate Infusions

Without a loading dose, the concentration of drug infused at a constant increases in a negative exponential fashion:

- Plasma concentration initially rises rapidly
- Distribution into peripheral compartments is the main method for drugs to leave plasma
  This is because at the start of an infusion there is a large concentration gradient between plasma and peripheral compartments.
- Elimination becomes more important in prolonged infusions
  As peripheral compartments fill the concentration gradient between plasma and compartments falls, and redistribution becomes relatively less important.
- Steady state is achieved when concentrations in compartments are equal, and input is equivalent to clearance

\[ C^t = \frac{\text{Infusion Rate}}{\text{Clearance}} \]

- Concentration at steady state is determined by the ratio of infusion rate to clearance:
  - Therefore, at steady state with drugs with 100% bioavailability:
    \[ \text{Infusion Rate} = C_{\text{target}} \cdot Cl \]
  - For drugs given by a route with less than 100% bioavailability:
    \[ \text{Route Dosing Rate} = \frac{C_{\text{target}} \cdot \text{Dose Interval}}{\text{Bioavailability}} \]
  - If the dosing is given intermittently, then:
    \[ \text{Dosing Rate} = \text{Dose} \cdot \text{Dose Interval} \]

- Volume of distribution at steady state is termed \( V_{Dss} \) and is the apparent volume into which a drug will disperse during a prolonged infusion, and is the sum of all compartment volumes in the model.

Continuous Rate Infusions with Bolus Dosing

As seen, above starting an infusion at the rate required to maintain steady state is inefficient:

- For any desired plasma concentration, it will take three time constants (4-5 half-lives) for a continuous infusion to reach this concentration
  - If the half-life is long, then achieving a therapeutic level will take some time
- A bolus dose aimed to fill the \( V_D \) will allow steady-state to be reached immediately:

\[ \text{Loading dose} = V_D \cdot C_{\text{target}} \]
Stopping an Infusion

For a bi-exponential model (i.e. only one peripheral compartment), decline in plasma concentration can be modeled by the equation \( C' = Ae^{-\alpha t} + Be^{-\beta t} \). In this model:

- \( \alpha \) is the time-constant for redistribution
- \( \beta \) is the time-constant for terminal elimination
  (Provided the infusion has reached steady-state).
- Neither \( \alpha \) or \( \beta \) correspond to any individual rate constant

Factors affecting rate of offset of an infusion can be classified into pharmacokinetic, pharmacodynamic, and other drug factors:

- **Pharmacokinetic factors**
  - Distribution
    - \( V_D \)
      - High \( V_D \) will decrease clearance from central compartment. Factors affecting \( V_D \) include:
        - Ionisation
          - Ion trapping can cause drug to be sequestered.
        - Protein binding
        - Lipid solubility
          - Affected by body fat.
        - Speed of distribution
          - CO
            - Affects organ blood flow.
  - Redistribution
    - During an infusion, peripheral compartments become saturated with drug. When an infusion ceases, drug is redistributed central compartment.
      - This is related to **context-sensitive half time** (see below)
  - Metabolism
    - Route of clearance
      - Organ-dependent
        - Organ failures
        - Extraction ratio
        - Organ blood flow
    - Organ-independent
    - Saturatable kinetics
      - Zero-order kinetics.
  - Presence of active metabolites
  - Elimination
    - Route of excretion of active drug or active metabolites.
- Organ failures

- **Pharmacodynamic Factors**
  - Age
    - Sensitivity
      - Dose required for effect and dose required for recovery.
  - Organ failures
  - Pregnancy

- **Other drug factors**
  - Pharmacokinetic interactions
    - Enzyme inhibition/induction
  - Pharmacodynamic interaction
    - Drug tolerances
      - Tachyphylaxis
  - Drug action
    - Drugs which alter gene or receptor expression, or bind irreversibly (e.g. clopidogrel) may show ongoing effects even after the drug has left the system.

**Context-Sensitive Half-Time**

*Context-sensitive half time* is:

- **Defined** as the time for plasma concentration to fall to half of its value at the time of stopping an infusion
- **A method to describe the variability in plasma concentrations after ceasing an infusion**
  - The *"context"* is the duration of infusion.
- **Used** because terminal elimination half-life has little clinical utility for predicting drug offset
  - Half-lives are often misleading when discussing drug infusions.
- **Dependent on:**
  - **Duration of infusion**
    - During an infusion, drugs distribute out of plasma into tissues. When the infusion ceases, drug is cleared from plasma and tissue drug redistributes back into plasma.
      - The longer an infusion, the more drug has distributed out of tissues, and the longer the redistribution phase
      - The longest context-sensitive half time occurs when an infusion is at steady-state
  - **Redistribution**
    - The maximal CSHT reached depends on the:
      - **V<sub>D</sub>ss**
        - Drugs with a larger V<sub>D</sub>ss have a longer CSHT, as only a small proportion of the drug in the body will be in plasma and able to be cleared.
      - **Rate constant for elimination**
        - Drugs with a smaller rate constant for elimination have a longer CSHT.

Drugs with longer context-sensitive half-times will wear off less predictably.
• Remifentanil has little redistribution and a small Vd, and so has a very short context-insensitive half time. It wears off reliably and quickly following cessation of infusion.

**Context-Sensitive Decrement Time**

• Describe the time it takes for a drug level to fall to a particular percentage of its starting value following cessation of an infusion.

• They are used because the half-times do not describe mono-exponential decay.

  i.e. The time taken for drug concentration to reach 25% of its starting value is not twice the context sensitive half-time.

• The context-sensitive half-time could also be described as the 50% context-sensitive decrement time.

**References**


Last updated 2019-07-18
Drug Monitoring

Explain clinical drug monitoring with regard to peak and trough concentrations, minimum therapeutic concentration and toxicity

Drug monitoring:

- Describes the individualisation of dosing by maintaining plasma drug levels within a target range
- Is important in adjusting dose to account for inter-patient variability in response

Variability can be:
- Pharmacokinetic
  - Adjusting drug dose by monitoring plasma levels reduces pharmacokinetic variability.
- Pharmacodynamic
  - Drug dose is adjusted by evaluating the clinical effect.

Drug levels are measured to ensure the concentration is above the minimum therapeutic concentration but below toxic levels:

- **Minimum therapeutic concentration**
  - The $ED_{50}$, i.e. the dose required to have an effect in 50% of the population.
  - Determines desired trough levels

- **Minimum toxic concentration**
  - The $LD_{50}$, or the dose which is lethal in 50% of the population.
  - Determines the acceptable peak levels

From these levels two related terms are derived:

- Therapeutic range (also known as the therapeutic window)
  - Difference between these levels.
- Therapeutic index
  - Ratio between these levels, i.e.

$$Therapeutic\ Index = \frac{LD_{50}}{ED_{50}}$$

- A higher therapeutic index gives a greater margin for safety

**Indications**

Drugs are monitored in order to:

- Avoid toxicity
- Adjust dosing for efficacy
- Monitor compliance or determine failure of therapy
Drugs that typically require monitoring have a:

- Narrow target range
- Significant pharmacokinetic variability
- Relationship between the concentration in plasma and clinical effects
- Determined concentration range
- Validated monitoring assay

Drugs where the effect can be measured clinically (e.g. antihypertensives) tend to be adjusted based on observed effects. This is not possible when:

- The clinical response is the absence of a condition, e.g. antiepileptics
- The drug has a narrow therapeutic range

Drugs commonly monitored in the ICU setting include:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digoxin</td>
<td>0.8-2 microgram/L</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>10-20 mg/L*</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>5-20 microgram/L</td>
</tr>
<tr>
<td>Serolimus</td>
<td>5-15 microgram/L</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>10-20 mg/L</td>
</tr>
</tbody>
</table>

*Trough

**Timing of samples**

- Sampling for **toxicity** should occur at times of **peak concentration**
  - This requires accounting for absorption and distribution
    - e.g. Digoxin levels should be performed >6 hours following a dose to allow time for distribution to occur
    - If symptomatic, samples taken at this time may demonstrate toxic concentrations
  - Sampling for **monitoring** should ideally occur at **steady state**
    - i.e. after 4-5 elimination half-lives
    - For drugs with very long half-lives (such as amiodarone), sampling tends to occur earlier to ensure toxic levels have not been reached, as steady state may take months to achieve

- For drugs with short half-lives, **trough levels** (i.e. pre-dose levels) should be taken
  - This is the least variable point in the dosing interval.
- For drugs with long half lives, timing of sampling is less important

**Interpretation**

Interpretation of drug levels is dependent on:

- **Timing** of sample
- Duration of treatment at the current dose and **dosing** schedule
- Individual characteristics that may affect the **pharmacokinetics**
  - Age
  - Physiology
  - Comorbidities (hepatic, renal, cardiac)
Drug interactions
- Genetics
- Environmental

- **Protein binding**
  - Assays measure bound and unbound drug
    - Only unbound drug is pharmacologically active.
  - If binding is changed by disease or displacement by other drug, the proportion of unbound drug may change and targeted levels may need to be adjusted accordingly

- **Active metabolites**
  - Active metabolites are not measured but will contribute to the response.

---

**References**


Last updated 2018-09-21
Epidural and Intrathecal

Describe the pharmacokinetics of drugs in the epidural and subarachnoid space

In both spaces, speed of onset is determined by Fick’s Law.

Epidural Space

Factors important to epidural administration:

- Dose given
- Volume given
  - Increased volume increases area of subarachnoid that the drug is in contact with, increasing rate of diffusion.
- Solubility
  - Affected by:
    - pKa and pH
      - Determines unionised portion available to cross into CSF.
    - Protein binding
      - Determines free drug portion able to cross into CSF.
    - Lipid solubility
- CSF flow
  - Alters concentration gradient between epidural and subarachnoid space.

Intrathecal

Factors important to intrathecal administration:

- Dose
  - Much smaller doses required.
- Volume
  - Affects extent of spread.
- Baricity
  - Affects direction of spread:
    - Hyperbaric solutions will sink with gravity
      - e.g. Heavy bupivacaine (0.5% bupivacaine with 8% dextrose)
    - Hypobaric solutions will rise against gravity

References

2. ANZCA February/April 2007
3. Factors influencing distribution of bupivacaine after epidural injection - Diaz Notes.

Last updated 2017-09-17
Total Intravenous Anaesthesia and Target-Controlled Infusion

Describe the pharmacological principles of and sources of error with target controlled infusion

Total intravenous anaesthesia involves using IV agents alone to achieve hypnosis, analgesia, and muscle relaxation. TIVA:

- Advantages
  - Avoids adverse effects of anaesthetic agents
    - Nausea/vomiting
    - Pollution
    - Increased cerebral blood flow
- Disadvantages
  - Drug must be metabolised
  - Potential increased likelihood of awareness
    - Likely related to poor application of technique rather than the technique itself
    - Mostly related to disconnection of infusion without EEG monitoring
  - Variable plasma concentration

Target Controlled Infusion

TCI is the use of pharmacokinetic models (typically combined with microprocessor-controlled infusion pumps) to achieve a target concentration of drug in a particular body compartment.

TCI-systems:

- Are open-loop
  Effects of drug are not measured (unlike with end-tidal gas monitoring), which introduces a vulnerability that can lead to awareness.
  - e.g. Compared to inhalational anaesthetics, where the loop is closed by using end-tidal drug monitoring
- Follows the BET (Bolus, Elimination, Transfer) principle:
  A loading dose is given to saturate the volume of distribution to achieve target concentration

- Infusion rate is then set to maintain a target plasma concentration:
  \[ \text{Maintenance Infusion Rate (MIR)} = Ci \times C_p \]

- Rate compensates for:
  - Drug elimination
  - Drug distribution (transfer)
- Target \( C_p \) can be adjusted:
  - For a higher concentration:
    - A small bolus is given
    - Infusion rate is increased
  - For a lower concentration:
    - Infusion is paused until desired level is reached
    - Infusion rate restarts at a lower rate

Models can target either:

- Plasma concentration, \( C_p \)
Will not approximate $C_E$ until stead state is reached. Therefore:

- Increase $C_P$ during induction, so that $C_E$ will rise more quickly
- should be adjusted to the level of the surgical stimulus

**Effect-site concentration, $C_E$**
Over-pressure occurs automatically, so there is no requirement to increase target during induction.

**TCI Models for Propofol**

**The Bristol Model:**

- First pharmacokinetic model
- Based on three-compartment model of health patients
- Assumes:
  - Premedication with temazepam
  - Fentanyl $3\mu g.kg^{-1}$ on induction
  - Inhaled N₂O
  - A target plasma concentration ($C_P$) of $3\mu g.ml^{-1}$
- The model:
  - $1\text{mg.kg}^{-1}$ induction bolus
  - 10-8-6 maintenance:
    - $10\text{mg.kg}^{-1}.\text{hr}^{-1}$ for 10 minutes
    - $8\text{mg.kg}^{-1}.\text{hr}^{-1}$ for 10 minutes
    - $6\text{mg.kg}^{-1}.\text{hr}^{-1}$ thereafter

**Marsh and Schnider Models:**

- These are computer controlled models
- Both were derived on very small groups of patients (18 and 24 respectively)
- The models differ mostly in the first 10 minutes after induction, and progressively converge
The initial behaviour of the model is key in deciding which model to apply to any particular patient.

<table>
<thead>
<tr>
<th>Property</th>
<th>Marsh</th>
<th>Schnider</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targets</td>
<td>Typically target plasma concentration, but can target effect site.</td>
<td>Typically effect site, but can target plasma concentration.</td>
</tr>
<tr>
<td></td>
<td>Effect site targeting is usually done with the modified Marsh model, due to the large bolus dosing given by the standard Marsh model.</td>
<td>Plasma targeting gives inconsistent results, as the fixed size of V₁ means any increase in desired plasma concentration results in the same size bolus being given, irrespective of patient parameters.</td>
</tr>
<tr>
<td>Required variables</td>
<td>TBW (overestimates induction (but not maintenance) in obese patients, consider using IBW), Age (but not used in calculation)</td>
<td>Age, height (to calculate lean body mass), TBW</td>
</tr>
<tr>
<td>Values</td>
<td>Variable compartment sizes but bigger V₁</td>
<td>Fixed V₁ (4.27L) and V₃, variable V₂ and Ke₀</td>
</tr>
<tr>
<td>Other</td>
<td>The 'modified Marsh' model uses a kₑ₀ of 1.2L.min⁻¹ instead of 0.26L.min⁻¹, which decreases the adverse events. The modified Marsh is therefore preferable in patients at higher risk of overdose.</td>
<td>Limits BMI to &lt; 42 for males and &lt; 35 for females, to prevent absurd compartment sizes being calculated from the method used to calculate lean body mass</td>
</tr>
<tr>
<td>Overall</td>
<td>Faster induction due to larger V₁, which results in a larger loading dose</td>
<td>Reduced rate of adverse events. Overall less propofol used.</td>
</tr>
</tbody>
</table>

References

4. FRCA - Target Controlled Infusions in Anaesthetic Practice

Last updated 2019-07-20
Receptor theory

To explain the concept of drug action with respect to: receptor theory

To define and explain dose-effect relationships of drugs, including dose-response curves with reference to: therapeutic index, potency and efficacy, competitive and non-competitive antagonists, partial agonists, mixed agonist-antagonists and inverse agonists

To explain the Law of Mass Action and describe affinity and dissociation constants

A receptor is a component of a cell which interacts with a drug and **initiates a sequence of events leading to an observed change in function**.

- Existence of receptors is inferred from the response of tissues to drugs, genome sequencing, and molecular biology.
- A drug binds to a receptor forming a **receptor-drug complex**, which initiates a cascade of events to exert a pharmacological effect.

Dissociation Constants

Interaction between a receptor and a drug is based upon the **law of mass action**, which states the rate of a chemical reaction is proportional to the masses of reacting substances. This can be expressed as:

\[ [\text{Drug}] + [\text{Receptor}] \leftrightarrow [\text{Drug} - \text{Receptor}] \]

The ratio of the rate constant for the forwards reaction \( (K_{\text{association}}) \) and the backwards reaction \( (K_{\text{dissociation}}) \) is the **dissociation constant**. This is the concentration of drug when 50% of receptors are occupied:

\[ K_D = \frac{[\text{D}][\text{R}]}{[\text{D} - \text{R}]} \]

A **low** \( K_D \) value indicates that a lower concentration of drug is required to occupy 50% of the receptor, indicating that the drug has a **high affinity** for the receptor.

Physiological factors which affect the dissociation constant are determined by the **Arrhenius equation**:

\[ k = Ae^{-\frac{E_A}{RT}} \]

where:

- \( A \) is a constant
- \( T \) is temperature in Kelvin
- \( E_A \) is the activation energy required, which may be lowered by a **catalyst**
- \( R \) is the gas constant

Properties of Drugs

Key properties of drugs include:

- **Potency**
  - The **amount** of drug required to have an effect.
  - Given by the (typically the E\( _{50} \))
  - This relates to **Bowman's principle**, which states that the **least potent** anaesthetic agents have the **quickest onset**
  - This is because they are administered in higher doses (as they are less potent, more is required to get an effect), which
results in a high concentration gradient and a rapid distribution into tissues.

- **Efficacy**
  The **maximal** effect that a drug can generate.

- **Intrinsic activity**
  The size of effect a drug has when bound, which is graded from 0 to 1.
  - This is also known as **activity**

### Drug-Receptor Interactions

Drugs can be classified by the way they interact with receptors into:

- **Agonists**
  - Partial agonists
  - Inverse agonists

- **Antagonists**
  - Indirect antagonists

- **Allosteric Modulators**

- **Mixed Agonist-Antagonists**

### Agonists

An agonist will generate a **maximal** response at the receptor site. An agonist has **high affinity** and an **activity of 1**. Agonists can be compared by:

- **Relative potency** implies that if two agonists are equally efficacious, a smaller dose of one is required to get an effect
- **Relative efficacy** implies that the maximal effect of one agonist is greater than the other

![Agonist Graph](image)

#### Partial agonist

A partial agonist generates a **submaximal** response at the receptor. A partial agonist has a **high affinity** and an **activity between 0 and 1**. A partial agonist can act as an effective antagonist in the presence of a full agonist, as it will prevent maximal binding at a receptor, even with a high agonist concentration.

#### Inverse agonist

A drug which has a **negative activity** (between 0 and -1) producing the **opposite** response (compared to the endogenous agonist) at receptor.

- Occurs due to loss of **constitutive activity** at that receptor
Antagonist

An antagonist produces no response at the receptor site, and prevents other ligands binding. Antagonists have high affinity and an activity of 0.

Antagonists with these properties are also known as direct antagonists, which can be either:

- **Competitive antagonists**
  Displace other ligands from a binding site. Competitive antagonists can be:
  - Reversible
    The effect can be overridden by increasing the dose of agonist.
  - Irreversible
    Drug cannot be overridden by increasing dose of agonist. Dose-response curve appears similar to that of the non-competitive antagonist.

- **Non-competitive antagonists**
  Create a conformational change in the receptor. They cannot be overridden by increasing the dose of agonist.

![Dose-Response Graph](image)

Indirect Antagonist

Indirect antagonists reduce the clinical effect of a drug, but do so via means other than receptor interaction. They include:

- **Chemical antagonists**
  Where the drug binds directly to another. Examples include protamine and heparin, and sugammadex and rocuronium.

- **Physiologic antagonists**
  A countering effect is produced by agonism of other pathways.

Allosteric Modulator

A drug which binds to an allosteric site on the receptor and produces conformational change that alters the affinity of the receptor for the endogenous agonist.

Allosteric modulators can be:

- **Positive**
  Increases affinity for endogenous agonist.
  - e.g. Benzodiazepines are positive allosteric modulators at the GABA<sub>A</sub> receptor

- **Negative**
  Decreases affinity for endogenous agonist.
Mixed Agonist-Antagonist

A drug which has different effects on different receptors.

References

2. Encyclopaedia Britannica. Available at: https://www.britannica.com/science/law-of-mass-action

Last updated 2019-07-20
Receptor Types

A receptor is a protein, usually in the cellular membrane, to which a ligand may bind to generate a response.

- **Intracellular** receptors
  - May be either **cytoplasmic** or **intra-nuclear**.
    - Intracellular receptors are activated by lipid soluble molecules (such as steroids and thyroxine) to alter DNA and RNA expression
    - This results in an alteration of production of cellular proteins, so the effects tend to be slow acting.

- **Enzyme-linked** receptors
  - Are activated by a ligand and cause enzymatic activity on the intracellular side. They can be either:
    - **Monomers**
    - **Dimers**
      - Where two proteins join, or diamerise, on binding of a ligand.

- **Ion-channel** receptors (inotopic)
  - Create a channel through the membrane that allows electrolytes to flow down their electrical and concentration gradients.
  - They can be either:
    - **Ligand-gated channels**
      - Undergo conformational change when a ligand is bound. There are three important families of ligand channels:
        - Pentameric family
          - Consist of five membrane spanning subunits. Include:
            - Nicotinic ACh receptor
            - GABA_A receptor
            - 5-HT_3 receptor
          - Inotropic glutamate receptors Bind glutamate, a CNS excitatory neurotransmitter. Include:
            - NMDA receptor
High Ca$^{2+}$ permeability
- Inotropic purinergic receptors
  Form cationic channels that are permeable to Ca$^{2+}$, Na$^{+}$, and K$^{+}$
  Activated by ATP

- **Voltage-gated** channels
  - Open when the **threshold voltage** is reached, facilitating electrical conduction in excitable tissues.
  - In their normal physiological state, voltage-gated channels do not generally behave as receptors for a ligand, however some drugs (e.g., local anaesthetics) will bind to voltage-gated channels to exert their effect.
  - Have a common 4-subunit structure (each with 6 transmembrane segments) surrounding a central pore.
  - This pore is selective for the particular ion, which include:
    - Na$^+$
      - Located in myocytes and neurons.
      - Important in generating and transmitting an action potential by permitting sodium influx into cells
      - Inhibited by local anaesthetics, anti-epileptics, and some anti-arrhythmics.
    - Ca$^{2+}$
      - Divided into subtypes, including:
        - L
          Muscular contraction.
        - T
          Cardiac pacemaker.
        - N/P/Q
          Neurotransmitter release.
        - K$^+$
          Located in myocytes and important in repolarisation following an action potential.
  - Undergo a conformational change when the threshold potential is reached.
  - This is sensed by the S4 helix, which acts to open and close the channel.
  - Exist in one of three functional states:
    - Resting
      Pore is closed.
    - Active
      Pore is open, and ions can pass.
    - Inactive
      Transient refractory period where the pore is open, but ions cannot pass. This creates the **absolute refractory period** of a cell.

- **G-protein** coupled (metabotropic) receptors:
  - G-proteins are a group of heterotrimeric (containing three units; α, β, γ) proteins which bind GDP. When stimulated, the GDP is replaced by GTP and the α-GTP subunit dissociates to activate or inhibit an effector protein. The effect depends on the type of α-subunit:
    - **Gα** proteins
      Are **stimulatory**. These
      - Increase cAMP, leading to a biochemical effect
    - **Gβγ** proteins
      Are **inhibitory**. These:
      - Inhibit adenylyl cyclase, reducing cAMP
    - **Gq/11** proteins
      Have a variable effect, depending on the cell. These:
      - Activate phospholipase C
      - This affects the production of:
        - Inositol triphosphate (IP$_3$)
Stimulates Ca$^{2+}$ from the SR, affecting enzymatic function or causing membrane depolarisation.

- Diacylglycerol (DAG)
  Activates protein kinase C, which has cell-specific effects.
- Activate intracellular second messenger proteins when stimulated
  Second messenger systems:
  - Result in both transmission and amplification of a stimulus, as a single activated receptor can activate multiple proteins and each activated protein may activate several other intermediate proteins
  - This is known as a G-protein cascade

### Enzyme interaction

Drugs can interact with enzymes by antagonism or by being a false substrate.

### Enzyme antagonism

Most drugs which interact with enzymes inhibit their activity. This results in:

- Increased concentration of enzymatic substrate
- Decreased concentration of the product of the reaction

Drugs can be competitive, non-competitive, or irreversible inhibitors of enzymatic activity. Examples include:

- Ramipril is a competitive inhibitor of angiotensin-converting enzyme.
- Aspirin is an irreversible inhibitor of cyclo-oxygenase.

### False substrates

False substrates compete with the enzymatic binding site, and produce a product. Examples include:

- Methyldopa is a false substrate of the enzyme dopamine decarboxylase.

### Physicochemical

Drugs whose mechanism of action is due to their physicochemical properties. Examples include:

- Mannitol reduces ICP because it increases tonicity of the extracellular compartment (and is unable to cross the BBB), drawing free water from the intracellular compartment as a consequence.
- Aluminium hydroxide reacts with stomach acid to form aluminium chloride and water, reducing stomach pH.

### References

3. ANZCA August/September 2001

Last updated 2019-07-18
Receptor Types
Dose-Response Curves

To define and explain dose-effect relationships of drugs, including dose-response curves with reference to: graded and quantal response.

Standard Dose-Response Curves

A dose-response curve is a graph of concentration against the fraction of receptors occupied by a drug.

Log-Dose Response Curves

It is difficult to compare drugs using standard dose-response curves. Therefore, dose is commonly log-transformed to produce a log-dose response curve.

This curve:

- Compares log-dose versus clinical effect
- Demonstrates that the blue drug has greater potency than the red drug, though both are full agonists

Responses can be either graded or quantal:

- Graded responses demonstrate a continuous increase in effect with dose
  - E.g. Blood pressure and noradrenaline dose
- Quantal responses demonstrate a response once a certain proportion of receptors are occupied
  Examples include:
  - ED95
    Median dose of neuromuscular blocker required to produce a 95% loss of twitch height.
  - MAC
    Mean alveolar concentration of agent required to prevent movement in response to a surgical stimulus.
References

1. Anderson C. Pharmacodynamics 1, ICU Primary Prep. Available at:
   https://icuprimaryprep.files.wordpress.com/2012/05/pharmacodynamics-1.pdf

Last updated 2017-10-04
**Mechanisms of Action**

Drugs can act in four ways:

- **Receptors**
  - GPCR
  - Intracellular
    - Cytoplasmic
    - Intranuclear
      - e.g. Steroids, which alter RNA expression.

- **Ion Channels**
  - Blockade
  - Allosteric modulation

- **Enzyme interaction**
  An enzyme is a biological catalyst, increasing the speed of reaction. Enzyme interaction can be:
  - Irreversible inhibition
    - e.g. Aspirin, which irreversibly inhibits platelet thromboxane production.
  - Reversible inhibition
  - Competitive antagonism
    - e.g. ACE-I.
  - Non-competitive antagonism

- **Physicochemical**
  - Osmotic
    - e.g. mannitol.
  - Acid-base
    - e.g. antacids.
  - Chelation
  - Redox reactions

**References**


Last updated 2019-07-18
Adverse effects

Classify and describe adverse drug effects.

An adverse effect is:

- A noxious or unintended effect associated with administration of a drug at the normal dose
  - i.e., not an overdose
  - Occur:
    - Mainly in young and middle-aged individuals
    - Twice as common in women
    - May be exacerbated by asthma and pregnancy.
- Distinct from an adverse event, which is an untoward occurrence during treatment that does not necessarily have a causal relationship to drug administration

Adverse effects can be classified by mechanism as follows:

**Type A Adverse Reactions**

These are related to the pharmacological action of the drug. They are:

- Common
- Related to dose (dose-response relationship)
- Temporally associated with drug administration
- Reproducible
- Pharmacologically predictable based on understanding of the drug in question
  - e.g. hypokalaemia secondary to diuretic use

They typically result in:

- Organ-selective injury
- More pronounced with long-term use and in risk groups:
  - Extremes of age
  - Pregnancy
  - Renal failure
- High morbidity but low mortality
  Treatment is to decrease dose.

**Type B Adverse Reactions**

These are patient-specific or idiosyncratic reactions. They are:

- Rare
  - Potentially genetic, but poorly understood.
- Independent of dose
  - Occur with low doses
  - Do not have a dose-response relationship
- Not pharmacologically predictable
  Important causes include:
  - Acetylator status
  - CYP450 variants
Receptor abnormalities
Enzyme alterations/deficiencies
  e.g. Suxamethonium apnoea
Not necessarily reproducible

They typically result in:

- Immuno-allergic reactions
- Pseudo-allergy
- Idiosyncratic reaction
- Low morbidity but high mortality
  e.g. Stevens-Johnson Syndrome or anaphylaxis following penicillin administration

Treatment is to cease the medication.

**Type C Adverse Reactions**

These are 'statistical effects' associated with monitoring. They are:

- Typically an increased frequency of background disease that is detected due to increased screening
- Atypical for a drug reaction and not pharmacological predictable
- No identifiable temporal relationship
- Not reproducible

**References**


Last updated 2019-07-18
Drug Interactions

Classify and describe mechanisms of drug interaction.

Drug interactions occur "when the action of one drug modifies that of another".

Mechanisms of Drug Interaction

Drug interactions are best classified into three categories:

- Physicochemical
- Pharmacokinetic
- Pharmacodynamic

Physicochemical

Physicochemical interactions occur because of an incompatibility between chemical structures.

- e.g. Thiopentone and suxamethonium precipitate out of solution if prepared together or delivered together in the same line

Pharmacokinetic

Pharmacokinetic interactions can be sub-classified into those affecting absorption, distribution, metabolism, or elimination.

Absorption

For oral medications, absorption may be affected by drugs which alter:

- Gastric pH
- Gastric emptying time

Metoclopramide resolves gastric stasis and improves absorption of orally administered drugs

Distribution

Distribution may be affected by:

- Competition for plasma protein binding
  Loss of albumin and α1-acid glycoprotein
- Medications which alter cardiac output
- Displacement from tissue binding sites This typically occurs due to alteration of metabolic capacity of one drug by the other.
- Chelation of drug from tissues
  Chelating agents bind toxic elements and prevent tissue damage

Phenytoin is usually highly (90%) protein bound. A reduction in protein binding to 80% will double the free phenytoin level. For drugs with first-order kinetics, metabolism will increase proportionally however phenytoin rapidly saturates the enzyme system, leading to zero-order kinetics and a high plasma level.

β-blockers reduce cardiac output and will prolong the time to fasciculation of suxamethonium.

Metabolism

Metabolism may be affected by changes to the CYP450 enzymes:
**Enzyme induction**
- Barbiturates
- Phenytoin
- Carbamazepine

**Enzyme inhibition**
- Amiodarone
  
  Amiodarone inhibits metabolism of S-warfarin by CYP2C9, enhancing its effect.
- Diltiazem
- Verapamil
- Ciprofloxacin
- Macrolides
- Metronidazole
- Grapefruit juice

**Elimination**

Renal elimination can be affected by:

- Changes in urinary pH
- Competition for active tubular transport mechanisms

| Sodium bicarbonate increases urinary pH and enhances excretion of weak acids such as aspirin. |

**Pharmacodynamic**

Pharmacodynamic interactions can be **direct**, due to interaction on the same receptor system; or a **indirect**, when they act on different receptor system. These interactions can be classified as either:

- **Additive**
  
  When the effects summate.
  
  - e.g. Administering midazolam with propofol reduces the amount of propofol required to generate an effect.

- **Antagonistic**
  
  When the effects oppose each other.
  
  - e.g. Neostigmine indirectly antagonises the effect of NDMRs by increasing the level of ACh at the NMJ.

- **Synergistic**
  
  When the combined effect is greater than would be expected from summation alone.
  
  - e.g. Co-administration of remifentanil and propofol has a synergistic effect in maintenance of anaesthesia.

These three interactions can be graphically demonstrated using an **isobologram**, which draws a **line of equal activity** versus **concentration** of two drugs.
References


Last updated 2019-07-18
Alterations to Drug Response

Define tachyphylaxis, tolerance, addiction, dependence and idiosyncrasy

There are four mechanisms which result in variable response to drug:

- Alteration in drug that reaches the receptor
  This is typically due to pharmacokinetic factors.
- Relative difference in presence of exogenous and endogenous ligands
  Antagonists will have a greater effect in the presence of high endogenous ligand concentration.
- Variation in receptor function and number
  Up-regulation and down-regulation of receptors may occur as a consequence of prolonged stimulus.
- Alteration in function distal to the receptor

Key Terms

- **Tachyphylaxis** is the rapid decrease in response to repeated dosing over a short time period, usually due to depletion of transmitter
- **Desensitisation** is the loss in response over a long time period, usually due to change in receptor morphology or loss in receptor numbers
- **Withdrawal** is a pathological response when a drug is ceased
  - During administration receptors may be:
    - **Up-regulated** in the continued presence of an antagonist
    - **Down-regulated** in the continued presence of an agonist
  - Loss of receptor numbers may precipitate withdrawal when the agonist or antagonist is ceased
- **Addiction** is a behavioural pattern characterised by compulsive use and fixation on acquiring and using a drug
- **Idiosyncrasy** is an individual patient response to a drug
  Typically mediated by a reactive metabolite rather than the drug itself.

Tolerance

**Tolerance** is the requirement for a larger dose to achieve the same effect, due to altered sensitivity of the receptors to the stimulant. Mechanisms can be classified into:

- **Pharmacokinetic**
  - **Altered drug metabolism**
    Metabolism may be increased or decreased:
    - Enzymatic induction and increased drug metabolism
      Increased hepatic enzyme pathway capacity increases metabolism and lowers plasma concentration.
    - Decreased metabolism
      Decreased metabolism of a prodrug can result in a reduced effect.
- **Pharmacodynamic**
  - **Change in receptor morphology**
    Can occur with ion-channel receptors and GPCRs:
    - Ion-channel receptors bind the ligand but do not open the channel
    - GPCR become 'uncoupled' - phosphorylation of the receptor makes it unable to activate second messenger cascade, though it can still bind the ligand.
Receptor down-regulation
Prolonged exposure to agonists causes transmembrane (typically hormone) receptors to become internalised. This occurs more slowly than uncoupling.

Receptor up-regulation
Prolonged exposure to antagonists causes an up-regulation of receptor.
- Can lead to rebound effects when a drug is ceased (e.g. hypertension with cessation of clonidine)

Exhaustion of mediators
Similar to tachyphylaxis - depletion of a mediating substance decreases the effect.

Physiological adaptation
Actions of a drug may be countered by a compensatory homeostatic response.
- Active removal of the drug from the cell

Alterations in Drug Response: Patient Factors
Pharmacokinetics and pharmacodynamics are affected in pregnancy and at extremes of age.

Pregnancy
- Absorption
  - Decreased gastric emptying
  - Nausea and vomiting
  - Increased cardiac output
    - Increases IM and SC absorption
  - Volatiles:
    - Increased onset due to increased MV and reduced FRC
    - Decreased onset due to increased CO

- Distribution
  - Increased Vd due to:
    - Increased TBW
    - Increased plasma volume
    - Increased fat mass
  - Decreased albumin and α1-glycoprotein

- Metabolism
  - No change to HBF
  - Progesterone induces enzymes
  - Oestrogen competes for enzymes
  - Decreased plasma cholinesterase activity

- Elimination
  - Increased RBF
  - Increased GFR

- Pharmacodynamic
  - Decreased MAC
  - Increased LA sensitivity due to decreased α1-glycoprotein

Foetus
Drugs that cross the placenta can be teratogenic to the foetus, besides exerting their usual pharmacological effects.

Pharmacokinetic factors predominantly affect placental transfer, and include:

- **Lipid solubility**
  Lipid soluble drugs diffuse more rapidly.

- **Molecular size**
  Drugs with a molecular weight >1000 dalton cross the placenta slowly.

- **Protein binding**

- **Placental transporters**
  Some medications are actively removed from foetal circulation.

- **Placental metabolism**
  The placenta can metabolise some medications, although in some cases results in toxic metabolites.

Maternal pharmacodynamic factors predominantly affect the uterus and breast, but major organ systems are not significantly affected.

Drugs that cross the placenta can have dramatic effects in the foetus. These include:

- **Teratogenesis**
  A drug which adversely affects foetal development causing a permanent abnormality. Multifactorial mechanisms that are not well understood.

**Neonates**

At < 1 year of age, pharmacokinetics are significantly altered:

- **Absorption**
  - Delayed gastric emptying, increasing absorption of drugs metabolised in the stomach
  - Decreased secretion of pancreatic enzymes and bile salts impairs absorption of lipid soluble medications
  - Smaller muscle mass and higher relative muscle blood flow increases IM onset
  - Increased $V_A^{\text{FRC}}$ ratio increases onset of volatiles

- **Distribution**
  - $\text{TBW}$ is 70-75% (compared to 50-60% for an adult), and extracellular water is 40% (compared to 20%), which typically increases $V_d$
  - Preterm infants have reduced body fat
  - Greater proportion of cardiac output goes to head, increasing onset of centrally acting (e.g. anaesthetic) drugs
  - Decreased albumin and $\alpha_1$-glycoprotein
  - Immature BBB increases uptake of partially ionised drugs

- **Metabolism**
  - Enzymatic capacity of all pathways is reduced, which prolongs elimination half-lives and reduces clearance.
    - Hepatically metabolised drugs must be dose adjusted accordingly
      - The glucuronide pathway may not mature until age 4

- **Excretion**
  - $\text{GFR}$ is proportionally lower and dose not reach adult equivalence until 6-12 months
    - $\text{GFR}$ is further reduced in pre-term infants
    - $\text{GFR}$ is increased in 1-3 year olds

- **Pharmacodynamic**
  - Smaller $\text{ACH}$ reserves increase sensitivity to NMBs
  - Increased $\text{MAC}$ but more rapid onset
  - NSAIDs cause closures of ductus arteriosus

**Geriatric**
Though there is a linear decrease in functional capacity of major systems beginning at 45, alterations are predominantly a consequence of polypharmacy and drug interactions.

- **Absorption**
  - Laxatives and prokinetic increase gastric emptying and reduce absorption of oral agents

- **Distribution**
  - There is a proportional increase in fat
  - There is a proportional decrease in:
    - Lean body mass
    - Total body water
    - Albumin

- **Metabolism**
  - ↓ Hepatic blood flow
  - ↓ Enzymatic activity
    - Phase I > Phase II.

- **Elimination**
  - Loss of nephron number with age reduces renal clearance

- **Pharmacodynamic**
  - Increased sensitivity to sedatives, opioids, and hypnotics
  - Decreased sensitivity to β-agonists and antagonists
  - Decreased MAC
  - Polypharmacy increases potential for drug interactions

### Alterations in Drug Response: Disease Factors

#### Cardiac Disease

- **Absorption**
  - Decreased cardiac output decreases PO absorption due to decreased gradient

- **Distribution**
  - Decreased CO prolongs arm-brain circulation time
  - Increased α₁-glycoprotein increasing binding of basic drugs
  - Decreased $V_D$

- **Metabolism**
  - **Low-cardiac** output states reduce hepatic flow and will reduce metabolism of drugs with a high extraction ratio
  - **High-output** states have the opposite effect

- **Elimination**
  - Decreased renal blood flow

#### Hepatic Disease

- **Absorption**
  - Porto-caval shunting
    - Decreased first pass metabolism.

- **Distribution**
  - Impaired synthetic function reduces plasma proteins and increases unbound fraction
  - Increased $V_D$ due to fluid retention
Metabolic acidosis changes the ionised fraction of a drug.

**Metabolism**
- Impaired phase I and II reactions
- Reduced plasma esterase levels

**Elimination**
- Reduced biliary excretion

**Pharmacodynamics**
- Hepatic encephalopathy increases sensitivity to sedatives and hypnotics

### Renal Disease

**Absorption**
- Uraemia prolongs gastric emptying

**Distribution**
- Increased Vd due to fluid retention
- Metabolic acidosis adjusts the ionised fraction

**Metabolism**
- Buildup of toxic metabolites may inhibit drug transporters
- Uraemic toxins inhibit enzymes and drug transporters

**Elimination**
- Reduced clearance of active metabolites/active drug cleared renally

### Obesity

**Absorption:**
- Delayed gastric emptying
- Decreased subcutaneous blood flow
- Practical difficulty with IM administration

**Distribution:**
- Increased Vd of lipid soluble drugs
  - Dosing of lipid-soluble drugs by actual body weight
  - Dosing of water-soluble drugs by lean body weight
- Increased CO
- Increased α1-glycoprotein
- Increased blood volume
- Greater lipid binding to plasma proteins, increasing free drug fractions

**Metabolism:**
- Increased plasma and tissue esterase levels
- Normal or increased hepatic enzymes

**Elimination**
- Increased renal clearance due to increased CO

### Non-Specific Alterations to Drug Response

**Absorption:**
- Site of administration
Drugs given centrally will act faster than those given into peripheral veins.

- **Rate of administration**
  Faster rate of administration will increase rate of onset.

- **Pharmacodynamic**
  - Drug tolerance Increase requirement of drug.
    - e.g. induction anaesthetic agents in patients tolerant to CNS depressants.
      - Drug interaction
        - May be:
          - Synergistic
          - Additive
          - Antagonistic

---

**References**

5. Alfred Anaesthetic Department Primary Exam Tutorial Series

Last updated 2019-07-18
Pharmacogenetics

Outline genetic variability.

Explain the mechanisms and significance of pharmacogenetic disorders (e.g., malignant hyperpyrexia, porphyria, atypical cholinesterase and disturbance of cytochrome function).

**Genetic polymorphism** occurs when several functionally distinct genes exist within a population. Genetic polymorphism is:

- Common
- Important in determining an individual's susceptibility to adverse drug reactions
- A goal of **personalised medicine**
  
  Aims to adjust drug therapies for interpatient variability.

Pharmacogenetic disorders

Pseudocholinesterase

A condition where plasma cholinesterase is unable to breakdown suxamethonium, prolonging its duration of action. This disease:

- May be congenital or acquired
  - Congenital is autosomal recessive
    - Has four alleles
      - Usual
      - Atypical (dibucaine-resistant)
      - Silent (absent)
      - Fluoride-resistance
  - Acquired is due to a loss of plasma cholinesterase
    - Pregnancy
    - Organ failure
      - Hepatic
      - Renal
      - Cardiac
    - Malnutrition
    - Hyperthyroidism
    - Burns
    - Malignancy
    - Drugs
      - OCP
      - Ketamine
      - Lignocaine and ester local anaesthetics
      - Metoclopramide
      - Lithium
- Has been traditionally measured using the **dibucaine number**

  Dibucaine is:
  
  - An amide local anaesthetic which **inhibits plasma cholinesterase**
    
    Different forms are inhibited to different extents, with greater inhibition indicating a less severe mutation.
    
    - Percentage inhibition correlates with different genotypes, e.g.:
      - Normal (Eu:Eu) has a dibucaine number of 80 (80% inhibited)
- Dibucaine resistant (Ea:Ea) has a dibucaine number of 20 (20% inhibited)
- Note that acquired disease will have a normal dibucaine number, as the enzyme itself is working correctly, however does not exist in a large enough quantity to metabolise suxamethonium rapidly

**G6PD**

A common x-linked recessive condition that may cause haemolysis following administration of oxidative drugs. These include:

- Aspirin
- Sulfonamides
- Some antibiotics

**Malignant Hyperthermia**

Autosomal dominant deficiency in the skeletal muscle ryanodine receptor gene resulting in a defect of intracellular calcium regulation. This mutation:

- Causes massive calcium release from sarcoplasmic reticulum in the presence of volatile anaesthetic agents (and potentially suxamethonium)

  Leads to:
  - Increased muscle activity
  - Rapid increase in body temperature and lactic acidosis
  - High mortality from hyperthermia, hyperkalaemia/rhabdomyolysis, leading to ventricular arrhythmia and cardiac arrest

- Mutation present in 1:5,000 - 1:50,000

- Presents with:
  - Initially:
    - Tachycardia
    - Masseter spasm
    - Hypercapnea
    - Arrhythmia
  - Intermediate:
    - Hyperthermia
    - Sweating
    - Combined metabolic and respiratory acidosis
    - Hyperkalaemia
    - Muscle rigidity
  - Late:
    - Rhabdomyolysis
      - Myoglobinuria
      - Elevated CK
    - Coagulopathy
    - Cardiac arrest

- Management consists of:
  - Cease administration of volatile
    - Start TIVA
  - Give dantrolene
    - 2.5mg.kg\(^{-1}\) increments up to 10mg.kg\(^{-1}\)
    - 20mg vials reconstituted with 60ml sterile water
      - 3g mannitol as additive
      - Highly alkaline
Damaging if extravasation occurs.

- Treat complications:
  - Hyperkalaemia
  - Hyperthermia
  - Acidosis
  - Arrhythmias
  - Renal failure

**Porphyria**

Autosomal dominant deficiency in the first step of haeme synthesis. These mutations:

- Result in a partial deficiency of enzymes
- Lead to accumulation of porphyrin precursors
- May be precipitated by many drugs:
  - Ketamine
  - Clonidine
  - Ketorolac
  - Diclofenac
  - Phenytoin
  - Erythromycin
  - Barbiturates

**References**


Last updated 2019-07-18
Drugs in Pregnancy

The Therapeutic Goods Administration classifies drugs for suitability in pregnancy based on the potential of a drug to cause:

- Birth defects
- Detrimental effects at birth
- Problems in later life

The classification system is:

- Valid only for the dose and route of administration listed
  - Does not apply in overdose
- Not hierarchical
  - 'B' drugs are not safer than 'C' drugs

Categories

- **Category A**
  Taken by large number of women without detrimental effects.

- **Category B**
  Subclassified into:
  - Category B1
    Taken by a limited number of women without detrimental effect
    - Animal studies show no evidence of detrimental effect to the foetus
  - Category B2
    Taken by a limited number of women without detrimental effect
    - Animal studies are inadequate or lacking, but available data shows no evidence of detrimental effect to the foetus
  - Category B3
    Taken by a limited number of women without detrimental effect
    - Animal studies show evidence of foetal damage, but the significance of this in humans is unknown

- **Category C**
  - Drugs which have caused (or a suspected to cause) detrimental foetal effects, but without malformations
  - These effects may be reversible

- **Category D**
  - Drugs which have caused (or are suspected to cause) an increased incidence of foetal malformations or damage
  - May also have detrimental effects

- **Category X**
  - Drugs which have a high risk of causing permanent damage
  - Should not be used in pregnancy, or when pregnancy is possible

References


Last updated 2017-09-23
General Management of Poisoning

Understanding of the general principles of poisoning and its management.

Principles of management of poisoning:

"Recognition-Resus-RSI-DEAD"¹

- **Recognition**
  - Degree of emergency
  - Getting senior help
  - Application of 100% oxygen early

- **Resuscitation**
  - A: Control in any patient with significantly impaired conscious state
  - B: Oxygen if not previously applied. Mechanical ventilation if required.
  - C: Intravenous access is always required. Central venous access may be required.
  - D: Glucose level. Control seizures.
  - E: Control hypothermia

- **Risk assessment**
  - History including timing, amount, co-administered drugs, current patient status.

- **Supportive care**

- **Investigations**
  - ECG
  - Invasive monitoring may be required if haemodynamics are unstable.
  - Drug levels

- **Decontamination**
  - Activated charcoal may be appropriate if recent ingestion (<1 hour) and the airway is secured

- **Enhanced Elimination**
  - Used in severe poisoning when supportive care is likely to be inadequate. Includes:
    - Urinary alkalisation
    - Filtration

- **Antidotes**
  - E.g. naloxone for opiates

- **Disposition**

Footnotes

LITFL has a fantastic section on the approach to the poisoned patient if you want more information.

References

1. Nickson, C. Approach to the Acute Poisoning. LITFL.
2. Leslie RA, Johnson EK, Goodwin APL. Dr Podcast Scripts for the Primary FRCA. Cambridge University Press. 2011.
Tricyclic Antidepressant Overdose

Tricyclic antidepressants are weak bases typically used for depression and as an adjunct for analgesia. They have a complex mechanism of action, competitively inhibiting noradrenaline and serotonin reuptake, and also blocking muscarinic receptors, histaminergic receptors, α-adrenoreceptors, GABA-a receptors, and fast sodium channels.

Toxicity

In overdose, toxicity is predominantly due to cardiac and central effects, though there are effects on most of the major organ systems.

Cardiac toxicity

Cardiac toxicity is due to antagonism of α-adrenoreceptors use-dependent blockade of fast sodium channels.

α-antagonism results in vasodilatation and subsequent hypotension. Hypotension may also be due to myocardial depression from sodium channel blockade.

Blockade of fast sodium channels occurs in the His-Purkinje system, as well as the atrial and ventricular myocardium. This results in decreased myocardial impulse conduction. They block channels in the inactivated state, resulting in a use-dependent blockade such that the effect is greater at faster heart rates. This results in an increased depolarisation and repolarisation time.

ECG findings are consistent with this and are essentially pathognomonic:

- Widened QRS
- Right axis deviation of the terminal QRS
  >3mm terminal R wave in aVR.

Additional ECG findings include:

- Tachycardia
- Any degree of heart block
- Ventricular arrhythmias

Central toxicity

Central toxicity is predominantly due to anticholinergic effects, though antihistaminic effects contribute.

Anti-cholinergic effects tend to occur prior to cardiac effects, and include:

- Confusion
- Agitation
- Seizures
- Pupillary dilatation and blurred vision

Antihistaminic effects include obtundation.

Management

Standard management of poisoning applies. TCAs are not dialysable and as they are weak bases are not amenable to urinary alkalisation.
Cardiac toxicity

NaHCO₃ and hyperventilation to a pH >7.5 is used to manage cardiac toxicity. There are a number of proposed mechanisms of action for the benefit of alkalisation:

- Plasma alkalosis results in less ionised drug and increases distribution into tissues
- Plasma alkalosis increases protein binding of drug
- Intracellular alkalosis results in less bound intracellular drug, favouring its movement out of cells
- Extracellular alkalosis results in reduced H⁺/K⁺ exchange, increasing intracellular potassium and hypopolarising the cell.

In addition to the alkalising effects, sodium load from the NaHCO₃ improves the sodium concentration gradient into cells α-adrenoreceptor antagonism can be countered with use of an α-agonist such as noradrenaline.

Arrhythmias should be managed with drugs that do not prolong the action potential - so amiodarone and beta-blockers are contraindicated. Initial management should be using NaHCO₃, though MgSO₄ and lignocaine can be considered in refractory cases.

Central toxicity

Seizures should be managed with benzodiazepines, phenytoin, propofol, and phenobarbital. Avoid agents which result in QRS prolongation.

References

3. CICM July/September 2007
5. Nickson, C. Toxicology Conundrum 22. LITFL.
6. Nickson, C. Tricyclic Antidepressant Toxicity. LITFL.
7. UpToDate. Tricyclic antidepressant poisoning

Last updated 2019-07-20
Organophosphate Poisoning

Organophosphates are substances bind irreversibly to acetylcholinesterase, causing cholinergic excess. Examples include fertilisers and sarin gas.

Toxicity

Effects (as expected) are signs of muscarinic and nicotinic over-activation. This can be remembered by 'BLUDGES' for the muscarinic effects:

- Bradycardia (and subsequent hypotension)
- Lacrimation
- Urination
- Defecation
- GIT upset
- Emesis
- Sweating and Salivation

and 'M' for the nicotinic effects:

- Muscular spasm

Management

Management is aimed at reducing ACh burden:

- **Atropine**
  
  Competitive antagonises ACh at the muscarinic receptor.
  
  - Atropine is preferred over glycopyrrolate as it will cross the blood brain barrier and treat central ACh toxicity

- **Pralidoxime**
  
  Reactivates acetylcholinesterase by luring the organophosphate away from the enzyme with a tantalising oxime group.
  
  - Pralidoxime must be used within the first few hours of poisoning
  
  - After which the organophosphate-enzyme group 'ages' and is no longer susceptible.
  
  - Does not cross the blood-brain barrier and so cannot treat central effects

References

1. CICM March/May 2009

Last updated 2019-07-18
The Cell Membrane

Describe the cell membrane and cellular organelles and their properties.

Cell membranes are:

- Formed by a **phospholipid bilayer**
  Separates the intracellular and extracellular fluid.
- **Semi-permeable**
  Leads to different ionic concentrations (and therefore electrical charge) on either side of the membrane.
  - Alteration in charge means the membrane acts as a capacitor, with most cells having a **resting potential 70-80mV** lower than extracellular fluid.

### Ion Permeability

At rest, the cell is:

- Permeable to **potassium**
  - Potassium flows out down its concentration gradient
    This makes the resting potential becomes more negative.
    - This negative charge opposes the further movement of potassium and so an equilibrium is established between opposing electrical and chemical gradients
- Impermeable to other cations
  - The membrane is not perfectly impermeable to sodium, and Na\(^+\) will leak in down its concentration gradient.
    - The 3Na\(^+\)-2K\(^+\) ATPase pumps **three sodium ions** outside in exchange for **two potassium ions** in order to maintain these gradients.
    - As there is an unequal exchange of charge, this pump is **electrogenic**.

<table>
<thead>
<tr>
<th>Ion</th>
<th>Intracellular</th>
<th>Extracellular</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na(^+)</td>
<td>15</td>
<td>140</td>
</tr>
<tr>
<td>K(^+)</td>
<td>150</td>
<td>4.5</td>
</tr>
<tr>
<td>Cl(^-)</td>
<td>10</td>
<td>100</td>
</tr>
</tbody>
</table>

### References


Last updated 2018-06-25
Organelles

Describe the cell membrane and cellular organelles and their properties

Organelles are specialised functional subunits within a cell, typically contained within their own lipid bilayer.

Key organelles include:

- Mitochondria
- Endoplasmic reticulum
- Golgi apparatus

Mitochondria

Mitochondria:

- Produce ATP via aerobic metabolism
  - Only method of aerobic metabolism in the body.
    - Mitochondria exist in greater numbers in more metabolically active cells
- Consist of two membranes (outer and inner), which create three spaces,
  - Cytoplasm
    - Outside the outer membrane.
  - Intermembrane space
    - Between the membranes.
      - Outer membrane separates mitochondria from cytoplasm, but contains pores allowing some substances (pyruvate, amino acids, fatty acids) to pass
      - Inner membrane:
        - Isolates the electron transport chain from the intermembrane (space between inner and outer membranes) space.
        - Proteins on the inner membrane conduct the redox reactions important for ATP production
        - Electron transport chain pumps hydrogen ions into the intermembrane space
  - Inner mitochondrial matrix
    - Contents important in many metabolic processes:
      - Citric acid cycle
      - Fatty acid metabolism
      - Urea cycle
      - Haeme synthesis

References


Last updated 2019-07-18
Excitable Cells

Membrane Potential

At rest, membranes are:

- Permeable to potassium
- Impermeable to other cations

Generation of membrane potential:

- Intracellular potassium concentration is much higher than extracellular potassium concentration
  
  Due to the action of the Na\(^+\)-K\(^+\) pump.
- As the membrane is permeable to potassium, potassium will attempt to diffuse down this gradient, generating a negative intracellular charge which opposes further diffusion
- At some point, an electrochemical equilibrium is reached between:
  
  - The concentration gradient dragging potassium out of the cell
  - Negative electrical charge pulling it in
- This equilibrium is the **resting membrane potential**

  - RMP is determined by:
    
    - Permeability of the membrane to different ions
    - Relative ionic concentrations on either side of the membrane
    - Impermeable ions do not contribute to the resting membrane potential

  Altering membrane permeability causes a flow of ions and a change in voltage.

Nernst Equation

The potential difference generated by a permeable ion in electrochemical equilibrium when there are different concentrations on either side of the cell can be calculated via the **Nernst Equation**:

\[
E = \frac{R.T}{z.F} \ln \left( \frac{[\text{ion}]_{\text{outside}}}{[\text{ion}]_{\text{inside}}} \right),
\]

- \(E\) is the equilibrium potential for the ion
- \(R\) is the gas constant (8.314 J.deg\(^{-1}\).mol\(^{-1}\))
- \(T\) is the temperature in Kelvin
- \(F\) is Faraday’s Constant
- \(z\) is the ionic valency (e.g. +2 for Mg\(^{2+}\), -1 for Cl\(^-\))

Goldman-Hodgkin-Katz Equation

The Nernst equation describes the equilibrium potential for a single ion, and assumes that the membrane is completely permeable to that ion.

However, calculation of membrane potential requires examining the effects of many different ions with different permeability. This can be performed with the **Goldman-Hodgkin-Katz equation**: 

---

125
\[ E (mV) = \frac{R \cdot T}{F \cdot \ln} \frac{P_K [K^+]_o + P_{Na} [Na^+]_o + P_{Cl} [Cl^-]_o}{P_K [K^+]_i + P_{Na} [Na^+]_i - P_{Cl} [Cl^-]_i} \]

- \( P_x \) is the permeability constant for the ion, \( x \).
  - If the membrane is impermeable to \( x \), then \( P_x = 0 \).

**Note that:**
- This model does not consider valency.
- The concentrations of negative ions are reversed relative to positive ions.

### Excitable Cells

Excitable cells can respond to a stimulus by changing their membrane potential. This may be mediated:

- **Chemically**
  - e.g. ACh receptors causing Na\(^+\) channels to open.
- **Physically**
  - Pressure receptors physically deforming and opening Na\(^+\) channels.
- Stimulating an excitable cell increases Na\(^+\) permeability.
  - This increases (i.e. makes less negative) membrane potential.
- If several stimuli, or a large enough stimuli raises the membrane potential above the **threshold potential**, then an action potential will be generated.
- This is due to fast Na\(^+\) channels.
  - Also known as **voltage-gated** Na\(^+\) channels.
  - Open when **membrane potential** exceeds **threshold potential**.
    - Threshold potential is typically -55mV.
  - Fast sodium channels generate the **all-or-nothing** response:
    - Stimuli below the threshold potential do not generate an action potential.
    - Stimuli above threshold potential generate an action potential.
    - The size of the stimulus does not affect the magnitude of the action potential, as this is determined by the fast sodium channels.

### Key Players in the Action Potential

Fast Na\(^+\) channels are responsible for depolarisation. They exist in three states:

- **Closed**
  - Impermeable to Na\(^+\).
- **Open**
  - Permeable to Na\(^+\). Occurs when the membrane potential reaches threshold potential.
    - Different voltage-gated channels may have slightly different opening (threshold) potentials.
- **Inactivated**
  - Impermeable to Na\(^+\). Occurs shortly after the open state, and lasts until the membrane potential falls below -50mV.

**Voltage-gated K\(^+\) channels:**

- Are vital for repolarisation.
- **Open slowly** with depolarisation.
  - This increases potassium permeability and reduces membrane potential.

### Phases of the Action Potential
This describes the peripheral nerve action potential. The heart is covered under the cardiac action potential.

1. Rising Phase
   A stimulus which rises above the threshold potential opens fast Na\(^+\) channels, increasing Na\(^+\) influx.
   - Additional Na\(^+\) has a positive feedback effect, causing additional Na\(^+\) channels to open and further depolarisation
   - This drives the membrane potential towards the Nerst equilibrium for Na\(^+\)

2. Peak Phase
   Inactivation of fast-channels and delayed activation of K\(^+\) channels slows depolarisation.
   - Membrane potential peaks at 30mV

3. Falling Phase
   As potassium exits the cell, membrane potential continues to fall.
   - Voltage-gated K\(^+\) channels start to close at -50mV
   - Inactivation of fast sodium channels defines the absolute refractory period
     - The absolute refractory period lasts ~1ms

4. Hyperpolarisation
   As potassium channels close slowly, the membrane potential slightly undershoots resting potential, causing slight hyperpolarisation of the cell.
   - This is the relative refractory period
     - A large enough stimulus may overcome the additional hyperpolarisation and generate a second action potential.
       - The relative refractory period lasts 10-15ms

5. Resting
   Cell is stable at resting membrane potential.

**Propagation of the Action Potential**

- An increase in Na\(^+\) in one region will diffuse down the cell, raising the membrane potential above the resting potential in the adjacent membrane
- This causes local fast Na\(^+\) channels to open, and the cell depolarises
- This results in a propagating wave of depolarisation and repolarisation
- Regions of a nerve cell covered by a myelin sheath do not have ion channels
- In these cells, propagation is saltatory
  - This describes the “jumping” of the action potential between gaps in the myelin sheath.
    - These gaps are known as nodes of Ranvier
      - Ion channels generate an action potential at the nodes in the usual manner.
    - Between nodes, conduction is via local electrical currents
  - Myelination:
    - Increases conducting velocity
    - Reduces energy expenditure
      - Via reduction in total ion flux.

**Classification of Nerve Fibres**

Classified on their diameter and conduction velocity:

- **Type A**
  - Myelinated, 12-20μm in diameter, conduct at 70-120m.s\(^{-1}\). Subdivided into:
    - Aα
      - Motor fibres.
    - Aβ
      - Touch fibres.
Aγ
Intrafusal (proprioceptive) muscle fibre.

Aδ
Pain fibres.

Type B
Myelinated, < 3µm, conduct at 4-30m.s⁻¹. Innervate pre-ganglionic neurons.

Type C
Unmyelinated, 1µm, conduct at 0.5-2m.s⁻¹. Pain fibres.

References


Last updated 2019-07-18
Transport Across Cell Membranes

Explain mechanisms of transport of substances across cell membranes, including an understanding of the Gibbs-Donnan effect.

Substances can cross cell membranes by diffusion, active transport, and exo- or endocytosis.

**Diffusion**

There are several types of diffusion:

- **Simple diffusion**
  Molecules pass through the cell membrane or via a channel. This process is passive, and occurs down a concentration gradient.
  - Only lipid soluble molecules (gases, steroids) can pass directly through the lipid bilayer without a specialised channel
  - Voltage-gated and ligand-gated channels facilitate simple diffusion

- **Facilitated diffusion** (uniporters)
  Molecules bind to a carrier protein, and move together through the lipid bilayer, before separating on the other side.
  Facilitated diffusion is concentration gradient-dependent, and limited by the amount of carrier protein available.

The rate and extent of diffusion is affected by:

- Hydrostatic pressure gradients
- Concentration gradients
- Electrical gradients

**Active Transport**

Substances that are moved against a concentration gradient require active transport, and requires energy in the form of ATP.

Active transport mechanisms may be:

- **Primary** active transport
  The substance itself is moved.

- **Secondary** active transport
  The substance moves against a concentration gradient with another molecule that had a gradient established by active transport.
  - This molecule is typically sodium

- **Co-transporters** (symporters)
  Uses carrier proteins and moves two substances (e.g. sodium and an amino acid) across a membrane.
  - This process will be passive if the energy gained moving one substance down its concentration gradient is greater than the energy required to move the other substance up its concentration gradient

- **Counter-transporters** (antiporters)
  Use carrier proteins and moves two substances in opposite directions across the membrane.
  - May be active or passive

Key transporters include:

- **The Na⁺ -K⁺ ATP-ase pump**
  This moves three sodium ions out of a cell and two potassium ions in, cleaving one ATP in the process. This pump has many functions:
- Maintenance of cellular volume (which would otherwise burst from the influx of water with changing ECF tonicities) by net loss of osmoles
- Maintenance of the potential difference across the membrane
- Establishment of chemical gradients to be used in secondary active transport mechanism
  - e.g. Reabsorption of glucose in the kidney via the S-GLUT transporter

## Exo- and Endocytosis

These processes describe the formation of a vesicle (typically from membrane phospholipid) to transport substances:

- **Exocytosis**
  Vesicle containing a substance to be secreted fuses with the cell membrane when activated by calcium, depositing the substance outside the cell.

- **Endocytosis**
  The cell membrane invaginates around the substance, absorbing the substance into the cell. A vesicle (or vacuole) may or may not be created. Endocytosis may be subdivided into:
  - Phagocytosis, where leukocytes engulf bacteria into a vacuole
  - Pinocytosis, where substances are endocytosed but not into a vacuole

## Gibbs-Donnan Effect

Describes the tendency of diffusible ions to distribute themselves such that the ratios of the concentrations are equal when they are in the presence of non-diffusible ions.

The Gibbs-Donnan Effect:

- Occurs when:
  - A semi-permeable membrane separates two solutions
  - At least one of those solutions contains a non-diffusible ion
- The distribution of permeable charged ions will be influenced by both their valence and the distribution of non-diffusible ions, such that at equilibrium the products of the concentrations of paired ions on each side of the membrane will be equal:
  $$[Na^+]_A \times [Cl^-]_A = [Na^+]_B \times [Cl^-]_B$$
- Alters tonicity on either side of the cell membrane, causing movement of water which then upsets the Gibbs-Donnan effect. This results in no 'steady' stable state.

The two main contributors to the Gibbs-Donnan effect in the body are sodium and protein. This occurs because cell membranes:

- Are impermeable to protein
  Intracellular protein concentration is high.
- Effectively impermeable to sodium
  Due to the Na⁺-K⁺ ATP-ase pump.

Changing Gibbs-Donnan equilibriums also change the tonicity on each side of the cell membrane, causing movement of water which then upsets the Gibbs-Donnan effect - therefore there is no stable state.

The Gibbs-Donnan Effect is important for:

- Maintenance of cell volume
  Na⁺ acts as an effective osmole, reducing cellular swelling.
- Plasma oncotic pressure
  Increased plasma ion concentration increases oncotic pressure.
Resting Membrane Potential

References


Last updated 2018-09-21
Fluid Compartments

To describe the composition and control of intracellular fluid—and the mechanisms by which cells maintain their homeostasis and integrity—

On average, the human body is ~60% water. Distribution of water content can be divided conceptually into:

- **Intracellular fluid**: Composes 2/3 of total body water. ICF is:
  - Not a contiguous fluid space
  - Useful as the composition of cellular contents is relatively uniform:
    - Potassium is the dominant intracellular cation
    - Sodium concentrations are low.
    - The dominant anion is protein
    - Chloride concentration is relatively low.
    - Low in magnesium

- **Extracellular fluid**: Composes the remaining 1/3 of total body water, and is further divided into:
  - **Intravascular fluid**: Composes ~20% of ECF. This refers solely to plasma volume (as the volume of blood from cellular components is ICF). The ICF is:
    - Vital for transporting nutrients, waste, and chemical messengers between the plasma and cells
  - **Transcellular fluid**: Composes ~7% of ECF, and describes the volume of CSF, urine, synovial fluid, gastric secretions, and aqueous humor.
  - **Interstitial fluid**: Composes the bulk of ECF volume, and describes the fluid that occupies the volume between cells.

Variations

Actual total body water content varies predominantly with fat content. This leads to differences concentrations in:

- **Neonates**: ~75-80%.
- **Elderly**: ~50% by the age of 60, due to increased adiposity.
- **Women**: Typically ~55%.

Measuring Volumes of Fluid Compartments

All methods rely on the indicator-dilution method:

- A known amount (i.e. known volume of a known concentration) of indicator with affinity to a particular compartment is given and allowed to equilibrate
- The concentration of the indicator is then measured
- The difference between the measured concentration and the initial concentration is proportional to the volume of the compartment

Indicators used for calculation of:
- Plasma volume
  A colloid that will be retained in the vascular compartment; e.g. radio-labeled albumin.
- **ECF** volume
  A substance which can enter the interstitium but not cells; e.g. thiosulfate.
- Total body water
  A substance which can enter all compartments freely; e.g. heavy water $^{2}H_{2}O$.
- **ICF** volume
  Can be measured by the difference between calculated ECF volume and TVW.

## References

1. Brandis, K. Fluid Compartments. Anaesthesia MCQ.

Last updated 2019-07-18
Cell Homeostasis

To describe the composition and control of intracellular fluid and the mechanisms by which cells maintain their homeostasis and integrity.

Cellular respiration describes the production of ATP through a series of redox reactions. Oxygen is used as the oxidising agent, whilst the catabolic fuel may be glucose, fat, or protein.

Cellular respiration can be broken down into:

- Glycolysis/Lipolysis/Proteolysis
- Citric Acid Cycle
- Electron Transport Chain

Glycolysis

Glycolysis, or the Embden-Meyerhof pathway, describes the production of pyruvate from glucose. Glycolysis:

- Occurs in the cytoplasm
- Begins with the phosphorylation of glucose to glucose-6-phosphate
- Produces:
  - 2 ATP
  - 2 Pyruvate
  - 2 NADH
- Note that oxygen is not consumed and carbon dioxide is not produced
- In aerobic conditions:
  NADH exchanges electrons across the mitochondrial wall, regenerating NAD⁺ and allowing glycolysis to continue
- In anaerobic conditions:
  - NAD⁺ is regenerated through the production of lactate
  - When aerobic conditions are restored, lactate can be oxidised back to pyruvate and enter the CAC
  - Transported to the liver and converted back to pyruvate (and enter the CAC), or produce glucose (Cori cycle)

Citric Acid Cycle/Kreb's Cycle

- Takes place in the mitochondria
- Complicated
- Can take many various substrates:
  - Acetyl CoA
    - Produced by β-oxidation of fatty acids and pyruvate.
  - Pyruvate
  - Ketoacids
- Does not consume oxygen but also doesn’t function under anaerobic conditions, due to its requirement on fresh NAD⁺ from the ETC
- Produces:
  - NADH
  - FADH₂
  - CO₂
Electron Transport Chain

- Final stage of carbohydrate, fat, and protein catabolism
- ETC consists of five protein complexes
- Electrons are passed along the chain and combine with oxygen, releasing energy which stimulates the movement of hydrogen ions
- Each time a hydrogen ion crosses the mitochondrial matrix, an ATP is produced
  - This is called coupled phosphorylation
  - Uncoupled phosphorylation allows hydrogen ions to travel down their gradient without generating ATP, which produces excess heat instead
- 36-38 ATP are produced by aerobic glycolysis
  - Sources disagree on exactly how much ATP is produced.
  - 2 from the Embden-Meyerhof pathway
  - 34-36 from the CAC and ETC

References


Last updated 2019-07-18
Airway and Alveolar Anatomy

Describe the function and structure of the upper, lower airway and alveolus.

Upper Airway

The upper airway consists of the:

- **Mouth**
- **Nasal cavity**
  - Hairs filter large particles
  - Olfactory receptors detect harmful gases prior to inhalation
- **Pharynx**
- **Larynx**

Breathing can be oral or nasal. Nasal breathing offers:

- Good **humidification** and **filtration** of inhaled particles because the septum and turbinates have:
  - High mucosal surface area
  - High mucosal blood flow
  - Generate turbulent flow
- High resistance to flow
  
  At a **high minute ventilation**, oral breathing is favoured.

Structures

- **Pharyngeal dilator muscles**
  Including genioglossus and levator palati. Prevent pharyngeal collapse during negative-pressure ventilation and during sleep.

- **Larynx**
  Important for **airway protection**, **speech**, and **effort closure**.
  - Prevents aspiration during swallowing by elevating the epiglottis and occluding the aryepiglottic folds
  - **Phonation** is achieved by adjusting tension (and therefore resonance) of the vocal cords by action of the cricothyroid
  - During **inspiration**, **cricoarytenoid** muscles rotate the arytenoid cartilage and abduct the vocal cords to reduce resistance to airflow
  - During **expiration**, the **thyroarytenoid** muscles adduct the cords and increase resistance, providing **intrinsic PEEP**
    - 3-4 cmH₂O of **PEEP** is generated
    - Maintains patency of small airways
      
      Prevents alveolar collapse and therefore maintains **FRC**.
  - **Effort closure** is tighter occlusion of the laryngeal inlet, in which the aryepiglottic muscles contract strongly to act as a sphincter, allowing the airway to withstand up to 120cmH₂O of pressure.

Lower Airway

The lower airway consists of the **tracheobronchial tree**:

- From trachea to alveolus, the airways of the lungs **divide 23 times**
  
  The tracheobronchial tree is divided into two zones, based on whether they contain alveoli and therefore are able to participate in gas exchange:
  - The **conducting zone** is the first **16 divisions**
The respiratory zone is the last 7 divisions

Conducting Zone

The first 16 divisions constitute the conducting zone:

- Anatomically, the conducting zone consists of:
  - **Trachea**
    - Mean diameter of 1.8 cm and a length of 11cm
    - D-shaped cross section
      Curved cartilages anteriorly and longitudinal muscle (trachealis) posteriorly. External pressure of 40cmH\(_2\)O is sufficient to occlude the extrathoracic trachea.
    - Flow is typically turbulent in the trachea and large airways
  - **Bronchi**
    - Comprise the first four divisions of the trachea
    - Right main bronchus is wider and deviates less from the axis of the trachea (the left main bronchus has a tighter turn over the heart), which is why foreign bodies will tend to the right side
    - The two main bronchi divide into a total of 5 lobar bronchi, which in turn divide into a total of 18 segmental bronchi
      - Cross-sectional area of the respiratory tract is lowest at the third division
      - These bronchi will collapse when intrathoracic pressure exceeds intraluminal pressure by ~5cmH\(_2\)O.
      - Segmental bronchi travel with branches of the pulmonary artery and lymphatics
        These are the bronchi that demonstrate peribronchial cuffing and perihilar haze in early pulmonary oedema.
    - Flow is typically transitional in the smaller bronchi and bronchioles
  - **Bronchioles**
    - Embedded in the lung parenchyma
    - Do not have cartilage in their walls to maintain patency - are held open by lung volume
    - Resistance to flow tends to be negligible due to large cross sectional area, unless there is spasm of helical muscle bands in bronchial wall
  - **Terminal bronchioles**
    - Flow may become laminar in the smallest bronchioles as flow decreases

- Flow in the conducting zone during inspiration is fast and turbulent
- No gas exchange occurs in the conducting zone
  The volume of the conducting zone therefore contributes to **anatomic dead space**.
- Blood supply to the conducting zone is via the **bronchial circulation**

- **Mucous** is secreted by goblet cells in the bronchial walls to trap inhaled particles
- **Cilia** in the bronchial walls move rhythmically to drive the mucociliary elevator, driving mucous up to the epiglottis, where it is then swallowed or expectorated

Respiratory Zone

The remaining 7 divisions make up the respiratory zone. This region:

- Makes up the majority of lung volume
  All non-anatomical dead space volume is in the respiratory zone, and is \(\sim 30 \text{ml.kg}^{-1}\) (FRC) at rest
- Blood supply is via the pulmonary circulation
● Gas flow in the terminal respiratory zone is slow due to the exponential increase in cross-sectional area with each airway division
  ○ Diffusion is the predominant mechanism of gas movement

**Alveolus**

The alveolus is optimised for gas exchange:

- Spherical shape maximises surface area to volume ratio
- Total surface area of lung alveoli is 50-100m²
- Alveolar walls are extremely thin (0.2-0.3μm)
  Consequently, they are fragile and can be damaged by increases in capillary pressure
- Alveolar walls contain a dense mesh of capillaries 7 to 10μm thick, which is just large enough for an erythrocyte to pass through

The alveolar-capillary barrier consists of three layers:
- Type I pneumocytes
- Extracellular matrix
- Pulmonary capillary endothelium

Alveoli are composed of three types of cells:

- **Type I pneumocytes**
  Thin-walled epithelial cells optimised for gas exchange.
  ○ Form ~90% of the alveolar surface area

- **Type II pneumocytes**
  Specialised secretory cells.
  ○ Secrete surfactant
    Alveoli are inherently unstable, and surface tension of alveolar fluid favours collapse of the alveoli. **Surfactant** reduces surface tension, allowing the alveoli to expand.
  ○ Form ~10% of alveolar surface area

- **Alveolar macrophages**
  Alveoli have no cilia - inhaled particles are phagocytosed by alveolar macrophages in alveolar septa and lung interstitium.

---

**References**


Last updated 2019-07-18
Chest Wall and Diaphragm

Describe the structure of the chest wall and diaphragm and to relate these to respiratory mechanics.

The chest wall is formed by the ribs and intercostal muscles:

- **Ribs**
  - Slope antero-inferiorly, and are connected by the external, internal, and innermost intercostal muscles.

- **Intercostal muscles**
  - External intercostals slope antero-inferiorly
  - Internal and innermost intercostals slope infero-posteriorly

- **Diaphragm**
  - Complex dome-shaped membranous structure, consisting of a central tendon and peripheral muscles
  - Performs the majority of inspiratory work of breathing
  - Able to dramatically increase intraabdominal pressure, so is essential in:
    - Coughing
    - Vomiting
    - Sneezing
  - Role in maintaining lower oesophageal sphincter tone
  - It has three perforations:
    - T8 for the vena cava (eight letters)
    - T10 for the oesophagus (ten letters)
    - T12 for the aorta, thoracic duct, and azygos vein

![Graph showing inspiratory curves]

**Inspiration**

- During inspiration, the **diaphragm** and **external intercostal** muscles **contract**
  - Diaphragm pushes the intraabdominal contents down, increasing thoracic volume and generating a negative intrathoracic pressure
    - Diaphragm is supplied by the phrenic nerves from C3/4/5.
  - External intercostals pull the ribs antero-superiorly, which increases the cross-sectional area of the chest, further increasing thoracic volume (and negative pressure)
    - Intercostal muscles are supplied by intercostal nerves from the same spinal level
    - Paralysis of the external intercostals does not have a dramatic effect on inspiratory function provided the diaphragm is intact

- **Accessory muscles** include sternocleidomastoid and the scalene, which elevate the sternum and first two ribs respectively.
  - They are active in hyperventilation.
Expiration

- Expiration is passive during quiet breathing as elastic recoil of the lung will return them to FRC.
- When minute ventilation is high, expiration becomes an active process:
  - Abdominal wall muscles (rectus abdominis, internal oblique, external oblique, transversus abdominis) contract, raising intraabdominal pressure and forcing the diaphragm up.
  - Internal and innermost intercostals contract, pulling the ribs downwards and inwards, further decreasing thoracic volume.

Respiratory Mechanics in Spinal Injury

- Paralysis of the abdominal wall muscles (e.g. spinal injury) has significant affect on respiratory mechanics:
  - In the initial phases of injury, spinal shock results in a flaccid paralysis of the abdominal wall.
    - Intraabdominal pressure is low, and so the diaphragm moves inferiorly.
      - This results in a higher FRC but limits tidal volumes, as contraction of the diaphragm only increase thoracic volume by a small fraction.
  - Nursing in a supine position causes the abdominal contents to push the diaphragm superiorly, causing:
    - Lower FRC.
    - Greater proportional expansion with respiration, improving tidal volumes.
  - Once spastic paralysis ensues, the abdominal wall is rigid and the patient can be sat up.

References

Variations in Upper Airway Anatomy

Understand the differences encountered in the upper airway for neonates, children and adults.

**Neonates and Children**

Changes are most obvious below 1 year of age. They typically resolve by ~8 years of age.

- **Head and neck changes**
  - Obligate nose breathers
    - Nasal obstruction may significantly impair respiration.
  - Proportionally enlarged head and occiput
    - Optimal intubating position is neutral rather than ramped.
  - Proportionally short neck
    - Favours airway obstruction when flexed.
- **Laryngeal changes**
  - Disproportionately large tongue that complicates laryngoscopy
  - Epiglottis is u-shaped, longer, and stiffer
  - Larynx lies at C4 (rather than C6 in adults)
  - Narrowest part of the upper airway is the transverse diameter of the vocal cords
    - Not at the cricoid.
- **Intrathoracic changes**
  - Intrathoracic trachea is also shorter
    - May be only 4cm long, so there is little margin for error in tube placement.
  - Left and right bronchi arise at similar angles, so endobronchial intubation may occur on either side
  - Airways themselves are narrower, and have a higher resistance to flow.

**References**

1. Nickson, C. *Paediatric Airway*. LITFL.

Last updated 2019-11-02
Control of Breathing

Describe the control of breathing

Ventilation is controlled by a feedback loop involving:

- Inputs
- Integration and control centres
- Effectors

Inputs

Inputs to the respiratory centre comes from a number of sensors:

- Chemoreceptors
  Chemoreceptors act synergistically. Chemoreceptors are divided into:
  - Peripheral
  - Central
- Mechanoreceptors
- Other effects

Peripheral Chemoreceptors

Peripheral chemoreceptors are divided into:

- The carotid body
  Located at the bifurcation of the common carotid artery, and are innervated by the glossopharyngeal nerve (CN IX).
- The aortic body
  Located in the aortic arch, and innervated by the vagus (CN X).

Peripheral chemoreceptors are stimulated by:

- Low PaO₂
- High PaCO₂
  Peripheral receptors have a rapid (~1-3s) but weaker (~20% of response) to changes in CO₂, compared to central chemoreceptors
Central Chemoreceptors

- Central chemoreceptors are located on the ventral medulla, and are stimulated by a fall in CSF pH
  - $H^+$ and $HCO_3^-$ are ionised, and cannot cross the BBB by diffusion
  - Because of this, central chemoreceptors respond indirectly to changes in arterial $PaCO_2$
    - Carbon dioxide is lipid soluble and freely diffuses into CSF
    - In CSF, carbon dioxide combines with water (catalysed by carbonic anhydrase) to form $H^+$ and $HCO_3^-$
- This gives the central chemoreceptors a number of special properties:
  - **Increased sensitivity**
    - Increased relative to plasma due to minimal buffering (as there is less protein in CSF)
  - **Respond to respiratory acidosis**
    - Fixed acid does not cross the blood brain barrier and so have a minimal response on CSF pH. Cerebral hypoxia increases CSF lactate, which will stimulate respiration.

Mechanism of CO₂ Retention

- Prolonged respiratory acidosis (i.e. prolonged CSF acidosis) stimulates active secretion of bicarbonate into the CSF
- When pH normalises, the stimulation of central chemoreceptors ceases
- Similarly, renal absorption of bicarbonate increases, which normalises arterial pH and reduces peripheral chemoreceptor stimulation

Mechanoreceptors

Stretch receptors in bronchial muscle are stimulated by overinflation, and stimulate the **apneustic centre** to reduce inspiratory volumes. This is the Hering-Breuer reflex.

Other Stimulants

Other inputs which stimulate respiration include:

- Juxtacapillary receptors (J-receptors)
  - Receptors in alveolar walls, potentially stimulated by oedema and emboli.
- Irritant receptors
  - Inhalation of noxious gases stimulates respiration.
- Pain receptors
- Thalamus
Increased core temperature stimulates respiration.

- Limbic system
  Emotional responses.
- Cerebral cortex
  Conscious control of breathing.
- Muscle spindles
  Ventilatory response to exercise.

**Integration and Control**

The respiratory centre is located in the medulla and the pons. It consists of four groups:

- **Dorsal Respiratory Group (DRG)**
  Controls the diaphragm, and is so only involved with inspiration.
- **Ventral Respiratory Group (VRG)**
  Controls the intercostal muscles, and so is involved in inspiration and expiration.
- **Apneustic Centre**
  Modulates DRG function to prevent over-expansion. Loss of this area causes apneusis - long, deep breaths.
- **Pneumotaxic Centre**
  Also modulates the DRG, increasing RR and decreasing VT to maintain MV.

**References**

1. CICM February/April 2015
2. CICM March/May 2009

Last updated 2019-07-18
Respiration

Describe the inspiratory and expiratory process involving the chest wall, diaphragm, pleura and lung parenchyma

Explain the significance of the vertical gradient of pleural pressure and the effect of positioning

Change in lung volume occurs due to change in intrapleural pressures. Therefore, respiration relies on the thoracic cavity being airtight, with the trachea being the only method gas can enter or exit the chest.

Intrapleural pressure (Ppl)

Intrapleural pressure is the pressure in the space between the visceral and parietal pleura, or (physiologically) between the lungs and the chest wall.

- Usually negative, typically \(-5\text{cmH}_2\text{O}\) at rest
  
  Balance between the:
  - Outwards recoil of the chest wall
  - Inwards recoil of the lungs (Pl)

- Varies with vertical distance in the lung
  - Gravity pulls the lung parenchyma inferiorly
  - Intrapleural pressure is therefore:
    - More negative in the apex
      Typically \(-10\text{cmH}_2\text{O}\) at FRC
    - Less negative in the base
      Typically \(-3\text{cmH}_2\text{O}\) at FRC

- This changes the degree of inflation at FRC
  - Apical alveoli are maximally inflated
  - Basal alveoli are relatively deflated

- During inspiration, the pleural pressure changes evenly throughout the lung, however the basal alveoli are better ventilated because their compliance is increased (due to lower resting volume)

Inspiration

- Diaphragmatic and external intercostal/accessory muscle contraction causes an increase in the volume of the thorax
- Intrapleural pressure becomes more negative, typically to \(-8\text{cmH}_2\text{O}\)
- When \(P_{pl} > P_{el}\), the lungs expands
- Alveolar pressure (\(P_A\)) becomes sub-atmospheric, and inspiration occurs
- At end inspiration:
  - \(P_{pl} = P_{el}\)
  - \(P_A = P_{atmospheric}\)

Expiration

- Muscular relaxation causes the chest wall to passively return to their resting position
- Thoracic volume falls
- \(P_{pl}\) falls to \(-5\text{cmH}_2\text{O}\)
- The elastic recoil of the lung causes it to collapse until \(P_A = P_{atmospheric}\)
References


Last updated 2019-07-18
Compliance

Define compliance (static, dynamic and specific), its measurement, and relate this to the elastic properties of the respiratory system.

- Compliance is the change in volume for a given a change in pressure.
  Compliance is measured in ml.cmH₂O⁻¹.
- It occurs due to the tendency of a tissue to resume its original position after removal of an applied force.
- It is the inverse of elastance, which is the force at which the lung recoils for a given distension.
- A decreased compliance means the transpulmonary pressure must change by a greater amount for a given volume, which increases elastic work of breathing.

Compliance of the Respiratory System

- Compliance of the respiratory system is a function of both lung and chest wall compliance:
  \[ \frac{1}{C_T} = \frac{1}{C_L} + \frac{1}{C_W}. \]
- The curve is not linear as compliance varies with lung volume. In the normal range however, (-5 to -10cmH₂O) compliance of the lung and chest wall independently is typically stated as ~200ml.cmH₂O⁻¹.
  - Compliance of the respiratory system as a whole is therefore ~100ml.cmH₂O⁻¹

Measurement of Lung and Chest Wall Compliance

- Lung compliance is calculated from the alveolar-intrapleural pressure gradient.
- Chest-wall compliance is calculated from the intrapleural-ambient pressure gradient.
- Total compliance is calculated from the alveolar-ambient gradient.
- Measuring ambient and alveolar pressure is straightforward, as is calculating compliance of the respiratory system.
- Alveolar pressure is measured by taking a plateau pressure.
- Separating lung and chest wall compliance requires measurement of intrapleural pressure.
  - This is performed by measuring oesophageal pressure (using a balloon) with an open glottis, as oesophageal pressure approximates intrapleural pressure.
- Measurement of compliance of each system individually determines what proportion of plateau pressure is distributed to each.
  - If the lung is significantly less compliant than the chest wall, a greater pressure is required to distend the lung.
  - Therefore, the alveolar-intrapleural gradient will be much greater than the intrapleural-ambient gradient.
- This can be expressed by the equation:
  \[ \Delta P_{Pt.} = P_{Pt.} \times \frac{C_L}{C_L + C_W} \]

Static Compliance

- Static compliance is the compliance of the system at a given volume when there is no flow.
- Therefore there is no pressure component due to resistance.
- A static compliance curve is made by measuring the pressure across a range of lung volumes, with patient taking incremental breaths.
- Static compliance is a function of:
Elastic recoil of the lung
Surface tension of alveoli

Dynamic Compliance

- **Dynamic compliance** is the compliance measured during respiration, using continuous pressure and volume measurements.
- Therefore, dynamic compliance includes the pressure required to generate flow by overcoming resistance forces.
  - This means it is also a bit of a misnomer.
- Dynamic compliance is always less than static compliance, as there will always be a degree of airway resistance.
- Dynamic compliance is a function of respiratory rate.
  - In normal lungs at normal respiratory rates it approximates static compliance.
  - Reduced in in lung units with unequal time constants at high respiratory rates.
    - Due to incomplete filling of alveoli - the portion of pressure that is used to overcome airways resistance is therefore proportionally greater.

Specific Compliance

**Specific compliance** is the compliance per unit volume of lung, expressed as:

\[
C_s = \frac{C_T}{FRC}
\]

- Specific compliance is used to compare different lungs.

Hysteresis

- In general, hysteresis refers to any process where the future state of a system is dependent on its current and previous state.
- Specific to the lung, it means the compliance of the lung is different in inspiration and expiration.
There is hysteresis in both static and dynamic curves:
- In dynamic compliance curves:
  Airways resistance is a function of flow rate. Flow rate (therefore resistance) is maximal at the beginning of inspiration and end-expiration.
- In static compliance curves:
  There is no resistive component. Hysteresis is due to viscous resistance of surfactant and the lung.

Changes in Compliance

Respiratory system compliance can be affected by changes to either lung or chest wall compliance, and can be increased or decreased.

Increased Lung Compliance

- Normal ageing
- Asthma attack
- Emphysema

Decreased Lung Compliance

- Alterations in lung volume and consolidation
  Compliance is reduced at extremes of lung volume. It is highest at FRC.
  - Children
  - Pneumonecctomy/lobectomy
  - Atelectasis/collapse
  - Pneumonia
  - ARDS
- Increased pulmonary blood volume/venous congestion
  - APO
- Increased surface tension
  - Reduced surfactant
  - Hyaline Membrane Disease
- Impaired parenchymal compliance
  - Pulmonary fibrosis

Increased Chest Wall Compliance

- Collagen disorders

Decreased Chest Wall Compliance

- Chest wall restriction/structural abnormalities
  - Obesity
  - Spastic paralysis of chest wall musculature
  - Ossification of costal cartilages
  - Kyphosis/scoliosis
  - Scarring/constriction (e.g. circumferential burns)
- Position
  - Prone (60% reduced compliance)/supine
    This is due to the effect of position on lung volume.
References


Last updated 2019-07-20
**Time-Constants**

**Explain the concepts of time constants**

**A Refresher on Time Constants**

The time-constant is:

- The **time** that a **process would take to complete** if its **initial rate of change** remained constant
- Relevant when modeling a process using exponential functions
  - Remember an **exponential function** is a curve where the **rate of change is proportional to the current value**

For a quantity that decreases over time, the general case is:

\[ y = y_0 e^{-kt} \]

where:

- \( y_0 \) is the value of \( y \) at \( t = 0 \)
- \( -k \) is the rate constant (\( k \) plots a curve that grows)
- \( t \) is time

Importantly:

- \( k \) is the **reciprocal of the time constant**, \( \tau \)
- In a negative exponential, **time-constant** is the time it would take for \( y \) to reach 0 if the original rate of change was maintained.
- Other fun facts about the time constant (for an exponential decay) include:
  - After 1 \( \tau \), \( y \) will be 37\% (\( e^{-1} \)) of its initial value
  - After 2 \( \tau \), \( y \) will be 13.5\% (\( e^{-2} \)) of its initial value
  - After 3 \( \tau \), \( y \) will be 5\% (\( e^{-3} \)) of its initial value
  - After 5 \( \tau \), \( y \) will be 1\% (\( e^{-5} \)) of its initial value

**Physiological Significance**

The time-constant is used in respiratory physiology in:

- Timing inspiration and expiration
- Elimination of inhalational anaesthetics
- The change in PaO\(_2\) and PaCO\(_2\) after changes in ventilation

In ventilation:

- The time constant is affected by:
  - Compliance
  - Resistance
  - Inflation pressure

  At a **constant inflation pressure**, the **time constant is equal to the product of resistance and compliance**, i.e.
\[ \tau = C \times R. \]

- For two lung units of **equal compliance and resistance**
  - Inflation will occur as per the exponential growth function
  - Time-constants of each lung unit will be equal
  - No redistribution of gas will occur at end-inspiration as the pressure and volume of each unit is the same
- For two lung units, where one has **half the compliance but twice the resistance**
  - The time constants are equal, therefore both reach peak filling at the same time
    - However, the poorly compliant unit will only reach half the volume
  - No redistribution of gas will occur at end-inspiration as the pressure and volume of each unit is the same
- For two lung units, where one has **twice the resistance** of the other
  - The time-constants are unequal
  - The resistant unit will fill at half the rate of the other
    - If inspiration is prolonged both will reach the same volume
    - If inspiration is halted early, and expiration prevented, there will be a pressure gradient between the units (as compliance is the same), and gas will redistribute from the low-resistant unit to the high-resistant unit
- For two lung units where one has **half the compliance**
  - The time constants are unequal
  - The poorly compliant unit will fill at half the rate of the other
    - If inspiration is prolonged they will both reach the same pressure
      - The volume in the poorly compliant unit will be half that of the more compliant unit.
  - During inspiration, the pressure rises more rapidly in the poorly compliant unit, and if inspiration is stopped and expiration prevented, this will result in redistribution into the more compliant unit until pressures are equal

**In general:**

- **Rate of filling is determined by time constants**
  - High-resistance lung units have longer time constants and take longer to fill
- **Final volume** (assuming an indefinite inspiration) is a function of compliance
  - Poorly compliant units with empty and fill rapidly
    - This creates the concept of fast and slow alveoli, depending on their time constants.
- At a sustained inflation pressure:
  - A low-resistance unit shows initial greater volume change but rapidly approaches equilibrium volume
  - A high-compliance unit takes a greater overall volume over a longer period
- At end-inspiration:
  - Pressure in units with a shorter time-constant rises more rapidly and if a breath is held will result in redistribution to those units with a longer time-constant.

**Clinical Significance**

If time-constants are equal:

- The pressure in each unit is identical throughout inspiration and distribution
  - Therefore, dynamic compliance will be independent of respiratory rate.

If time-constants are unequal:

- Long-time constant units may still be inhaling whilst the rest of the lung has stopped, or begun exhalation
  - This is called pendelluft.
- In pendelluft, distribution of inspired gas is dependent on respiratory rate
  - As respiratory rate increases, the proportion of the tidal volume that is delivered to the region with a long time-constant decreases
    - Fast alveoli are preferentially inflated, causing V/Q scatter or shunt in the unventilated slow alveoli.
Dynamic compliance will decrease as respiratory rate rises and be markedly different from static compliance.

Footnotes

1. For a curve that grows overtime, the time constant is the time it would take for \( y \) to reach 63\% of its final value, i.e. 
\[
1 - \frac{1}{e}. 
\]

References


Last updated 2019-07-18
Resistance

Explain the relationship between resistance and respiratory gas flow

Describe the factors affecting airway resistance, and its measurement

Resistance (measured in cmH₂O.L⁻¹.sec⁻¹) comprises the energy lost as frictional and inertial impedance to gas flow, where energy is lost as heat. Flow is a function of pressure gradient, resistance, and type of flow.

Types of Flow

Flow can be either laminar or turbulent. In laminar conditions flow is proportional to driving pressure, whilst in turbulent conditions flow is proportional to the square root of driving pressure.

Reynolds’ Number

Type of flow can be predicted by Reynolds’s Number, a dimensionless index where:

\[ \text{Reynolds’ Number} = \frac{2 \pi d v}{\eta}, \]

where:

- \( r \) = Radius
- \( d \) = Gas density
- \( v \) = Velocity
- \( \eta \) = Gas viscosity

A Reynolds’ Number of < 2000 is predominantly laminar flow, whilst >4000 is predominantly turbulent.

Laminar Flow

In laminar flow:

- Gas moves in a series of concentric cylinders which slide over one another
  - Gas in the centre moves twice as fast compared to the outside, where it is almost stationary
- Gas appears in cross-section as an advancing cone
  - Gas may reach the end of the tube when the volume of flow is less than the volume of the tube.
  - This is the mechanism of alveolar ventilation when tidal volumes are less than anatomical dead space volume

In a straight unbranched tube, flow can be quantified by the Hagen-Poiseuille Equation:

\[ F = \frac{\Delta P \pi r^4}{8 \eta l}, \]

where:

- \( F \) = Flow
- \( \Delta P \) = Driving pressure
- \( r \) = Radius
- \( l \) = Length
- \( \eta \) = Viscosity

However, as in laminar conditions flow is proportional to the driving pressure and inversely proportional to resistance, flow can be substituted and the equation solved for resistance:
\[ R_{\text{esistance}} = \frac{8 \eta L}{\pi r^4} \]

This can be used to describe the factors affecting resistance:

- **Length**
  - Fixed constant.
- **Viscosity**
  - Varies with the particular gas mixture being used.
- **Radius**
  - Main determinant. May be divided into:
    - **Extraluminal factors**
      - Compression:
        - Haemorrhage, tumour, dynamic hyperinflation, atelectasis compressing airways, etc.
      - Lung volume:
        - Airway radius increases when lung volume expands due to radial traction on airways (until dynamic hyperinflation occurs, at which point airways are compressed again)
    - **Luminal constriction**
      - Bronchospasm, bronchoconstriction.
    - **Intraluminal obstruction**
      - Sputum plugging, aspiration.

Note that airway resistance:

- **Peaks** at the 5th generation
- **Rapidly decreases** with each airway division thereafter
  - This is due to the total cross-sectional area increasing dramatically.

**Turbulent Flow**
High flow rates and branching of airways disrupt disciplined laminar flow. Turbulent flow is:

- Dominant in the upper airway (where velocity is high)
- Dominant in early-generation airways due to regular branching, changes in diameter, and sharp angles
- Reduces after the 11th generation bronchioles
- Proportional to the square root of the driving pressure

Therefore, resistance is higher in turbulent flow than in laminar flow.

- Driving pressure is proportional to gas density, and independent of viscosity

Resistance in turbulent flow is managed by making flow less turbulent:

- Achieved by reducing Reynolds number
  - Helium mixtures reduce gas density
    - Of greater benefit in upper airway than lower airway disease.

**Transitional Flow**

Transitional flow occurs at branches and angles in the airways, as occur in most of the bronchial tree.

**References**


Last updated 2018-04-24
Surfactant

Describe the properties, production and regulation of surfactant and relate these to its role in influencing respiratory mechanics

Surface Tension

- Surface tension describes the tendency of a fluid to minimise its surface area
- It is related to the attraction between particles in the fluid relative to particles outside the fluid
- Surface tension is why:
  - Water scattered on a surface forms rounded droplets
  - Why multiple droplets will tend to coalesce into a single larger droplet

- This relationship is described by La Place's Law
  \[ P = \frac{2\gamma}{r} \] , where:
  - \( P \) is pressure
  - \( \gamma \) is surface tension
  - \( r \) is radius

- Alveoli obey Laplace’s Law
- High surface tension causes three problems with alveoli
  - Compliance falls when the alveolus is empty
    As the radius falls, the pressure required to open it (at a given surface tension) will be increased. This increases work of breathing.
  - Smaller alveoli will preferentially empty into bigger alveoli
    Smaller alveoli require greater transmural pressures to remain inflated. This causes smaller alveoli to empty into larger ones.
  - Fluid transudation
    Surface tension draws fluid from interstitial spaces and contributes to pulmonary oedema.

- Overall, high surface tension is detrimental to the lungs

Surfactant

- Surfactant is a substance which substantially reduces work of breathing by reducing alveolar surface tension
- Surfactant is produced by type II alveolar cells in response to lung inflation and respiration
- It is composed of:
  - 85% phospholipid
  - 5% neutral lipid
  - 10% protein
- Surfactant is amphipathic
  Each component has a hydrophobic and hydrophilic end.
  - This causes the molecules to orient themselves along the air-liquid interface, disrupting the attractive bonds between water molecules
  - Surface tension is reduced in proportion to the concentration of molecules
- The concentration of surfactant changes throughout the respiratory cycle
  - During expiration alveoli collapse
    The decrease in alveolar radius is offset by the increase in surfactant concentration, so the fall in radius is mitigated by
the drop in surface tension.

References

1. CICM September/November 2012

Last updated 2019-07-18
Volumes and Capacities

Explain the measurement of lung volumes and capacities, and factors that influence them
State the normal values of lung volumes and capacities
Define closing capacity and its clinical significance and measurement

The lung has four volumes and four (main) capacities:

- **A volume** is measured directly
- **A capacity** is a sum of volumes

Volumes

- **Tidal volume** \( (V_T) \)
  Volume of air during normal, quiet breathing.
  - Normal is \( 7 \text{ml.kg}^{-1} \), or 500ml

- **Inspiratory reserve volume** \( (IRV) \)
  Volume of air that can be inspired *above tidal volume*.
  - Normal is \( 45 \text{ml.kg}^{-1} \), or 2500ml

- **Expiratory reserve volume** \( (ERV) \)
  Volume of air that can be expired following tidal expiration.
  - Normal is \( 15 \text{ml.kg}^{-1} \), or 1500ml

- **Residual volume** \( (RV) \)
  Volume of air in the lungs following a maximal expiration.
  - Normal is 15-20ml.kg\(^{-1}\), or 1500ml

Capacities

- **Functional Residual Capacity** \( (FRC) \)
  \[ FRC = RV + ERV. \]
  - Normal is \( 30 \text{ml.kg}^{-1} \) or 3000ml
  - \( FRC \) decreases 20% when supine, and a further 20% under general anaesthesia

- **Vital Capacity** \( (VC) \)
  \[ VC = ERV + V_T + IRV. \]
  - Normal is 4500ml
• **Inspiratory Capacity (IC)**
  
  \[ IC = V_T + IRV. \]

  - Normal is 3000ml

• **Total Lung Capacity (TLC)**

  \[ TLC = RV + ERV + V_T + IRV. \]

  - Normal is 6000ml

### Functional Residual Capacity

The **FRC** has many important physiological functions:

• **Gas exchange**

  The **FRC** allows blood in the pulmonary circulation to become oxygenated throughout the respiratory cycle (if there was no **FRC**, then at expiration the lungs would be empty and no oxygenation would occur).

• **Oxygen Reserve**

  **FRC** is the only clinically modifiable oxygen store in the body, and allows continual oxygenation of blood during apneic periods.

• **Minimise Work of Breathing**

  Work of breathing is a function of lung resistance and compliance.

  - The lung sits on the **steepest** part of the compliance occurs at **FRC**

    Compliance is optimised as:

    - Alveoli are open and minimally distended
      - Below **FRC**, some alveoli collapse and the volume of lung available to receive the tidal volume decreases
        - Re-expansion of collapsed alveoli requires more work than expanding open alveoli.
      - Above **FRC**, some alveoli will become overdistended and their compliance will fall

    - **Airway resistance decreases** as airway radius increases as lung volume increases

• **Minimise RV Afterload**

  PVR is minimal at **FRC**.

  - Above **FRC**, compression of intra-alveolar vessels occurs and PVR increases
  - Below **FRC**, extra-alveolar vessels collapse and PVR increases

• **Maintain lung volume above closing capacity**

  If closing capacity (see below) exceeds **FRC**, then shunt will occur.

Factors affecting **FRC**:

• **FRC** is reduced by:

  - Supine positioning
    - Falls by ~20%.
  - Anaesthesia
    - Falls by ~20%.
  - Raised intra-abdominal pressure
  - Impaired lung and chest wall compliance

• **FRC** is increased by:

  - **PEEP**
    - Extrinsic
    - Intrinsic (gas trapping)
      - **PEEP**
  - Emphysema
  - Acute asthma
  - Age
May increase slightly.

**Measurement of Lung Volumes and Capacities**

- ERV, V_T, and IRV can all be measured directly using spirometry
  - A spirometer is a flow meter
    - The patient exhales as fast as possible through the flow meter
    - A flow-time curve is produced
    - This curve can be integrated to find volume
  - Any capacity which is a sum of these (IC, VC) can therefore be calculated
- RV cannot be measured by spirometry, as it can’t be exhaled
  - Therefore FRC and TLC cannot be calculated
- RV can be measured using:
  - Gas dilution
  - Body plethysmography

**Gas Dilution**

- Gas dilution relies on two principles:
  - Conservation of Mass
  - Helium has poor solubility and will not diffuse into circulation
- **Limitations** of gas dilution:
  - Only gas communicating gas can be measured - will underestimate FRC in gas-trapping
- **Method:**
  - Patient takes several breaths from a gas mixture containing a known concentration of helium (giving time for equilibration)
  - The concentration of expired helium is then measured
  - From the law of conservation of mass:
    \[ C_1 V_1 = C_2 V_2 \]
    - \( V_2 \) is equal to the volume of the gas mixture the patient was breathing from \( V_1 \) and the patients FRC
    - Therefore:
      \[ C_1 V_1 = C_2 (V_1 + FRC) \]
      \[ FRC = V_1 \frac{C_1 - C_2}{C_2} \]

**Body Plethysmography**

- Body plethysmography relies on:
  - Boyle’s law
    - Pressure and volume are inversely proportional at a constant temperature, i.e. \( P \times V = k \).
- **Method:**
  - Patient is placed in a closed box, with a mouthpiece that exits the box
  - The patient inhales against a closed mouthpiece:
    - When the patient inhales, the volume of gas in the box decreases (the patient takes up more space) and therefore the pressure increases
    - The change in volume of the box is given by:
\[ P_1 V_1 = P_2 V_2, \text{ where:} \]
- \( V_2 \) is the change in box volume, or \( V_1 - \Delta V \)
- Therefore:
  \[ P_1 V_1 = P_2 (V_1 - \Delta V) \]
  As \( \Delta V \) is the only unknown value, it can be calculated.
- The change in volume of the lung must be the same as the volume of the box \( \Delta V \)
- In the case of the lung, the initial volume \( V_1 \) is \( \text{FRC} \)
- Therefore:
  \[ \frac{P_1 \times \text{FRC}}{P_3 - P_1} = \frac{P_2 \Delta V}{P_3 - P_1} \]

Closing Capacity

- Closing capacity is \textit{volume at which small airways begin to close}.
  Closing capacity is the sum of residual volume and closing volume.
  - Because dependent lung is compressed by gravity, dependent (typically basal) airways are of smaller calibre than non-dependent (typically apical) airways.
  - During expiration, these airways are compressed first.
    Alveoli connected to these airways are isolated, and V/Q scatter or shunt occurs.
- If \textit{closing capacity exceeds FRC}, then airway closure occurs during normal tidal breathing.
  This occurs when:
  - \text{FRC} is decreased
  - \text{CC} is increased
    - Increases with age
      - \text{CC} exceeds \text{FRC} in the supine patient at 44
      - \text{CC} exceeds \text{FRC} in the erect patient at 66
  - This is clinically relevant during \textit{preoxygenation}, as it will limit the denitrogenation that can occur.

![Graph of Closing Capacity]

### Measurement of Closing Capacity

Closing capacity is measured using Fowler's Method, and is covered under \textit{Dead Space}.

### References

Last updated 2019-07-18
Spirometry

Describe the pressure and flow-volume relationships of the lung, chest wall and the total respiratory system.

Describe the measurement and interpretation of pulmonary function tests, including diffusion capacity.

Pulmonary function tests are performed with a spirometer, which measures either volume or flow (integrated for time) to quantify lung function.

Basic spirometry can be used to quantify:

- Lung volumes and capacities
  All except residual volume (and therefore FRC and TLC).
- Dynamic measurements
  - FEV₁
    Volume of air forcibly exhaled in one second.
  - FVC
    Forced vital capacity.
  - PEFR
    Peak expiratory flow rate.
  - Flow-volume loop

Additional testing can be performed to measure:

- Residual volume
  FRC and TLC can therefore be calculated.
- Diffusion capacity

Basic Spirometry

Basic spirometry includes:

- Forced spirometry
  Patient forcibly exhales a vital capacity breath, producing an exponential (wash-in) curve. This calculates:
    - PEFR from the gradient at time 0 (assuming maximal effort)
    - FEV₁ is the volume expired in 1s
      Normal is > 80% of predicted.
    - FVC is the total volume exhaled.
    - The FEV₁/FVC ratio
      Normal is > 0.7.
  - These values also quantify disease severity:
    - In obstructive airways disease:
      - FEV₁ <80% predicted
      - FEV₁/FVC ratio
    - Restrictive disease:
      - FEV₁ <80% predicted
      - FVC
      - FEV/FVC ratio >0.7
      The ratio is normal as the FEV₁ and FVC fall proportionally.
• Volume-Time Graph (also known as a spirograph or spirogram)
  Quantifies static lung volumes by having a patient perform:
  - Normal tidal breathing
  - Vital capacity breath
  - Vital capacity exhalation

Flow-Volume Loops

• Normal
  - Peak expiratory flow of \(~8\text{L.s}^{-1}\)
    Initial flow is highest as the increased lung volume increases the calibre of lung airways, reducing airways resistance.
    - This is called the effort dependent part of the curve
  - Flow tails off later in expiration
    - Lungs collapse, and airway calibre falls
    - Small airways are compressed
      - Any increase in expiratory pressure will increase airway resistance proportionally.
        - This is called dynamic airways compression, and results in a uniform flow rate that is independent of expiratory effort*
        This is therefore labeled the effort independent** part of the curve.
- **Obstructive lung disease**
  - RV and TLC are increased due to gas trapping
  - Peak flow is limited
  - Effort-independent portion becomes concave

- **Restrictive lung disease**
  - TLC is reduced, but residual volume is unchanged
  - Peak flow may be reduced (as seen here)
    
    However, this reduction is proportional to the decrease in volume, such that the FEV₁:FVC ratio is normal. If peak flow is preserved, the FEV₁:FVC ratio will be increased.
  - Effort independent part is linear

- **Fixed upper airway obstruction**
  - Describes an upper airway obstruction that does not change calibre during the respiratory cycle.
  - Peak inspiratory and expiratory flow rates are limited by the stenosis

- **Variable extrathoracic obstruction**
  - Variable as the obstruction changes during the respiratory cycle:
    - During (negative pressure) inspiration the lesion is pulled into trachea, reducing inspiratory flow
    - During expiration the lesion is pushed out of the trachea

    The way to remember this is an extrathoracic obstruction impedes inspiration
  - The reverse effect occurs in positive pressure ventilation
• **Variable intrathoracic obstruction**
  The opposite to extrathoracic obstruction.
  - During inspiration the airway calibre increases and inspiratory flow is unimpeded
  - During expiration the airway calibre falls and expiratory flow is reduced

**References**


Last updated 2019-07-18
Work of Breathing

Describe the work of breathing and its components

Work of breathing is the energy used by the muscles for respiration. It is defined as:

\[ Work = Pressure \times Volume, \text{ measured in Joules.} \]

- This gives the work for a single respiratory cycle
- Energy expenditure over time is better described as the "power of breathing".
- It does not take into account respiratory rate or flow rate

These factors have a significant effect on energy requirement.

- This would be given by the rate of work, or power, where:

\[ Power = \frac{Work}{Time}, \text{ measured in Watts.} \]

- Tidal breathing is efficient and uses < 2\% of BMR
- The oxygen requirement of breathing at rest is ~2-5\% of VO\textsubscript{2}, or ~3ml.min\textsuperscript{-1}

Determinants of Work of Breathing

Work of breathing is divided into:

- Elastic work
  - About 65\% of total work, and is stored as elastic potential energy. Energy required to overcome elastic forces:
    - Lung elastic recoil
    - Surface tension of alveoli

- Resistive work
  - About 35\% of total work, and is lost as heat. This is due to the energy required to overcome frictional forces:
    - Between tissues
      - Increased with increased interstitial lung tissue
    - Between gas molecules
      - Increased at high flow rates
      - Increased with turbulent flow
        - High respiratory rates
        - Upper airway obstruction
        - Increased airway density
          - Hyperbaric
          - Diving
      - Increased with decreased airway radius
        - Low lung volume
          - Inadequate PEEP
          - Decreased respiratory muscle tone
    - Bronchoconstriction
    - Dynamic airway compression
      - Effort-independent expiration.
    - Apparatus
      - Endotracheal Tube
      - HME filters
    - Airway resistance varies depending on airway division:
      - Resistance peaks at the 3rd airway division (lobar bronchi)
Falls with increasing airway divisions due to increased cross-sectional area

Graphing Work of Breathing

Work of breathing can be evaluated with a dynamic lung compliance curve:

- If there were no resistive forces, then this curve would be a straight line
- The triangular area is the elastic work done
- The resistive work of breathing causes the deviation of the inspiratory and expiratory lines:
  - The area between the compliance line and the inspiratory line is additional resistive inspiratory work done
  - The area between the compliance line and expiratory line is additional resistive expiratory work done
    - This work is typically done by elastic recoil of the lungs
    - If this area falls within the area of elastic work of breathing, it is a purely passive process, using the stored elastic potential energy of inspiration
    - If part of this area falls outside the area of elastic work of breathing, it demonstrates additional active work of expiration which may occur in obstructive lung disease or when minute ventilation is high

Active expiratory work:

Minimising Work of Breathing
Work of breathing can be minimised by optimising the determinants:

- Elastic work
  - PEEP
    - Keep lung volume at FRC and maximise number of ventilated alveoli.
  - Positioning
    - Optimise lung volume.
  - Surfactant
    - Minimising surface tension.
  - Optimise respiratory rate
    - Elastic work of breathing typically decreases with increased respiratory rate.

- Resitive work
  - Decrease respiratory rate
    - Respiratory rate is directly proportional to resistive work.
  - Increase laminar flow
    - Laminar flow is more efficient than turbulent flow. Laminar flow can be increased by:
      - Reducing gas density
        - Heliox.
      - Increase Radius
        - Increase lung volume
        - Bronchodilators

**Derivation**

Work is defined as:

\[ W = FD, \]

- \( W \) = Work in Joules
- \( F \) = Force in Newtons
- \( D \) = Distance in Metres

Additionally, pressure is defined as:

\[ P = \frac{F}{A}, \]

- \( P \) = Pressure in Pascal
- \( A \) = Area in Meters squared

Therefore:\n
\[ F = PA \]

Substituting:\n
\[ W = PAD \]
\[ W = PV, \]

- \( V \) = Volume

Therefore:

\[ Work = Pressure \times Volume \]
References


Last updated 2019-07-18
Oxygen Cascade

Describe and explain the oxygen cascade

The oxygen cascade describes the transfer of oxygen from air to mitochondria.

- In each step of the cascade the PaO₂ falls
  It demonstrates that oxygen delivery to tissues relies on the passive transfer of gas down partial pressure gradients.
- The steps of the cascade are:
  - Dry atmospheric gas
  - Humidified tracheal gas
  - Alveolar gas
  - Arterial blood
  - Mitochondria
  - Venous blood

Remember:

- Partial pressure determines rate and extent of gas transfer
- Oxygen content is what is important for cellular function

Atmospheric Gas

Atmospheric partial pressure of oxygen is a function of barometric pressure and the FiO₂:

- \( PO₂ = P_B \times F_iO₂ \), where:
  - \( P_B \) is 760mmHg
  - \( F_iO₂ \) is 0.21
- Therefore, \( PO₂ = 160\text{mmHg} \)
Humidified Tracheal Gas

- Gas is humidified during inspiration
- Gas in the proximal trachea is heated to 37°C and has 100% relative humidity
- The saturated vapour pressure of water at 37°C is 47mmHg
- Therefore:

\[ P_{O_2} = (P_i - P_{VP \ of \ Water}) \times F_iO_2, \text{ where:} \]

- and \( F_iO_2 \) are as above
- is 149mmHg

Alveolar Gas

Ideal alveolar \( P_{O_2} \) is calculated using the alveolar gas equation:

\[ P_{A\ O_2} = P_iO_2 - \frac{P_aCO_2}{R} + F \text{, where:} \]

- \( P_iO_2 \) is the alveolar partial pressure of oxygen
- \( P_iO_2 \) is the inspired partial pressure of oxygen
- \( P_aCO_2 \) is the arterial partial pressure of carbon dioxide
- \( R \) is the respiratory quotient, where

\[ R = \frac{\text{Volume of CO}_2 \text{ produced}}{\text{Volume of O}_2 \text{ consumed}} \]

- \( R \) is used in the alveolar gas equation to correct for the change in inspired relative to expired volume
- As generally less \( CO_2 \) is produced than \( O_2 \) consumed, expired volumes are typically less than inspired volumes
- \( R \) is dependent on the metabolic substrates used for metabolism:
  - Pure fat \( \approx 0.7 \)
  - Pure protein \( \approx 0.9 \)
  - Pure carbohydrate \( \approx 1 \)
  - The normal value for a Western diet is quoted as 0.8

\[ F \] is a correction factor, usually equal to ~2mmHg, and is given by

\[ F = P_aCO_2 \times F_iO_2 \times \frac{1 - R}{R} \]

Alveolar oxygen is therefore dependent on:

- \( P_iO_2 \), which is a function of:
  - \( F_iO_2 \)
  - Air pressure
- Alveolar ventilation

\[ P_aO_2 \propto \frac{1}{V_A} \]

Arterial Blood

The difference in partial pressure of oxygen between alveolar and arterial blood is called the A-a gradient:

\[ A \text{- a gradient} = PAO_2 - PaO_2 = PiO_2 - \frac{P_aCO_2}{R} - PaO_2 \]

- A normal A-a gradient is \( \frac{A_{pc}}{4} + 4 \)
Normal arterial PO$_2$ is 100mmHg

It occurs due to:
- Shunt/VQ scatter
  A small shunt is normal due to blood from the bronchial circulation and thebesian veins.
- Diffusion abnormality

Mitochondria

- PO$_2$ varies with metabolic activity, but typically quoted as 5mmHg
- The Pasteur point is the partial pressure of oxygen at which oxidative phosphorylation ceases, and is ~1mmHg

Venous Blood

- PO$_2$ is greater than mitochondrial PO$_2$
  Mixed venous blood typically quoted as 40mmHg.
- Higher than mitochondria as not all arterial blood travels through capillary beds

References


Last updated 2019-07-18
Diffusing Capacity and Limitation

- Explain perfusion-limited and diffusion-limited transfer of gases
- Define diffusing capacity and its measurement
- Describe the physiological factors that alter diffusing capacity

Rate of diffusion of gases is given by Fick’s Law:

\[
\text{Rate of Diffusion} = \frac{\Delta P \times A \times s}{T \times \sqrt{MW}},
\]

where:
- \(\Delta P\) is the pressure gradient across the membrane
- \(A\) is the area of the membrane
- \(s\) is the solubility of the substance
- \(T\) is the thickness of the membrane
- \(MW\) is the molecular weight of the substance

These can be divided into pressure, lung factors, and substance factors:

- **Pressure gradient**
  - In the lung, this is a function of:
    - Partial pressure of the gas in the alveolus
      This is affected by:
        - Atmospheric pressure
        - Ventilation
        - Alveolar hypoventilation will:
          - Increase PACO\(_2\)
          - Decrease PAO\(_2\)
    - Partial pressure of the gas in blood
      This is affected by:
        - Solubility of the gas in blood
          CO\(_2\) is \(~20\) times as soluble as O\(_2\) in blood.
        - Binding of gas to protein:
          - Particularly haemoglobin
            Affects the rate of uptake of O\(_2\) and CO, and is why calculated DL\(_{CO}\) is corrected for haemoglobin.
            - The shape of the oxy-haemoglobin dissociation curve allows a large volume of oxygen to be bound before PaO\(_2\) begins to rise substantially.
          - Formation of carbamino compounds
          - Anaesthetic agents to plasma contents
            e.g. albumin, cholesterol.

- **Lung factors**
  - Surface Area
    Affected by:
      - Parenchyma volume
      - Body size
      - Pathology
      - Many lung diseases will reduce surface area for gas exchange.
    - V/Q mismatch
      Both shunt and dead space reduce the surface area available for gas exchange.
- Pulmonary blood volume
  Vascular distension and recruitment also affects surface area. Factors affecting pulmonary blood volume include:
  - Cardiac output
    - Increased recruitment of vasculature in high output states
    - Decreased recruitment and increased V/Q mismatch in shock states.
  - Posture
    Increased surface area when supine relative to sitting or standing.
- Thickness
  Increasing alveolar-capillary membrane thickness impedes gas exchange. Causes of this include:
  - Pathology
    e.g. Pulmonary oedema and cardiac failure.

- Substance factors
  - Solubility
    More soluble substances will diffuse more quickly.
  - Molecular weight
    Smallal substances will diffuse more quickly.

**Diffusion and Perfusion Limitation**

Limitation refers to what process limits gas uptake into blood:

- Gases which are **diffusion limited** fail to equilibrate, i.e. the partial pressure of a substance in the alveolus does not equal that in the pulmonary capillary
  - e.g. Carbon Monoxide
- Gases which are **perfusion limited** have equal alveolar and pulmonary capillary partial pressures, so the amount of gas content transferred is dependent on blood flow
  - e.g. Oxygen

![Diffusion and Perfusion Limitation Graph](image)

**Oxygen**

- Oxygen diffusion takes \(~0.25\)s
- Pulmonary capillary transit time is 0.75s
- Therefore, under normal conditions oxygen is a **perfusion limited** gas
- However, **oxygen may become diffusion limited** in certain circumstances:
  - **Alveolar-capillary barrier** disease
    Decreases the rate of diffusion.
    - Decreased surface area
    - Increased thickness
  - **High cardiac output**
Decreases pulmonary transit time.
- **Altitude**
  Decreases PAO$_2$.

**Carbon Dioxide**
- Carbon dioxide is ventilation limited, rather than diffusion or perfusion limited
- This is because it is:
  - 20x more soluble in blood than oxygen
  - Rapidly produced from bicarbonate and carbamino compounds
  - Present in far greater amounts than oxygen
    - $1.8\text{L.kg}^{-1}$ exist in the body (though $1.6\text{L.kg}^{-1}$ of this are in bone and other relatively inaccessible compartments).
- Impairment of diffusion capacity causes type 1 respiratory failure as oxygen is affected to a much greater extent than carbon dioxide

**Other Gases**
- **Carbon monoxide**
  Diffusion limited due to:
  - High affinity for haemoglobin
    - Continual uptake into Hb results in a low partial pressures in blood.
- **Nitrous oxide** Perfusion limited as equilibrium between alveolus and blood is rapidly reached as it is:
  - Not bound to haemoglobin
  - Relatively insoluble

**Diffusion Capacity**
- Measurement of the ability of the lung to transfer gases
- Measured as DL$_{CO}$ or diffusing capacity of the lung for carbon monoxide
  Carbon monoxide is used as it is a diffusion limited gas.
- Process:
  - Vital capacity breath of 0.3% CO
  - Held for 10s and exhaled
  - Inspired and expired CO are measured
  - Difference is the amount of CO which is now bound to Hb
  - DL$_{CO}$ is corrected for:
    - Age
    - Sex
    - Hb
- DL$_{CO}$ is decreased in:
  - Thickened alveolar-capillary barrier
    - Interstitial lung disease
  - Reduced surface area
    - Emphysema
    - PE
    - Lobectomy/pneumonectomy
- DL$_{CO}$ is increased in:
  - Exercise
    - Recruitment and capillary distension.
  - Alveolar haemorrhage
Hb present within the lung binds CO.

- Asthma (may be normal)
  Potentially due to increased apical blood flow.
- Obesity (may be normal)
  Potentially due to increased cardiac output.

References

3. ANZCA March/April 1999
4. Deranged Physiology - Carbon Dioxide Storage and Transport

Last updated 2017-10-04
West's Zones

Describe West's zones of the lung and explain the mechanisms responsible for them

West's Zones take into account the effect of alveolar pressure on pulmonary blood flow. The lung is divided into four zones:

- **West Zone 1**: \( P_A > P_a > P_v \)
  - Alveolar pressure exceeds arterial pressure.
  - The alveolus compresses the capillary, and no blood flow occurs
  - As there is ventilation but no perfusion, this can also be thought of as dead space
  - This occurs when:
    - Alveolar pressure is high
      - PEEP
    - Arterial pressure is low
      - Shock
    - Hypovolaemia

- **West Zone 2**: \( P_a > P_A > P_v \)
  - Arterial pressure exceeds alveolar pressure, which exceeds venous pressure.
  - Blood flow occurs intermittently during the cardiac cycle
  - Alveolar pressure acts as a Starling resistor
  - Flow is proportional to the \( P_A - P_a \) gradient.
  - When \( P_a \) falls below \( P_A \) (e.g. in diastole), then no blood flow will occur

- **West Zone 3**: \( P_a > P_v > P_A \)
  - Arterial pressure exceeds venous pressure which exceeds alveolar pressure.
  - Blood flow occurs throughout the cardiac cycle
  - Flow is proportional to the \( P_a - P_v \) gradient.
  - For an accurate measure of PCWP, a PAC must be placed in West Zone 3 (so there is a continual column of blood)
  - This tends to happen naturally as the majority of pulmonary flow is to this region

- **West Zone 4**: \( P_a > P_i > P_v > P_A \)
  - Interstitial pressure acts as a Starling resistor for pulmonary blood flow.
  - It is seen when interstitial pressure is high (e.g. due to pulmonary oedema).

References


Last updated 2018-07-09
Basics of V/Q Matching

Optimal gas exchange occurs when regions of lung are ventilated in proportion to their perfusion, i.e. V/Q = 1

- Uneven distribution of ventilation and perfusion causes inefficient gas exchange:
  - Excessive ventilation causes excessive work
  - Inadequate ventilation causes inadequate gas exchange

Distribution of Ventilation

- The right lung is slightly better ventilated than the left
- In an erect patient the bases of the lung are better ventilated
  - The weight of lung above compresses the lung below, improving the compliance of dependent lung whilst stretching the non-dependent lung.
    - This is only significant at low inspiratory flow rates
    - The V/Q ratio in the bases is ~0.6
    - The V/Q ratio in the apices is >3
  - In a lateral position:
    - The dependent lung is better ventilated in a spontaneously breathing patient
    - The non-dependent lung is better ventilated in a ventilated patient

Distribution of Perfusion

- The pulmonary circulation is a low pressure circulation
- Gravity therefore has a substantial effect on fluid pressure
- Consequently, the distribution of blood throughout the lungs is uneven:
  - The bases perfused better than the apices
    - This is affected by lung volume, with the effect:
      - Becoming more pronounced at TLC (with apical perfusion falling precipitously)
      - Reversing slightly at RV

V/Q Ratios

- The global V/Q ratio for normal resting lung is 0.9
- The global V/Q ratio improves to 1.0 during exercise
V/Q Mismatch and Etymology

- V/Q mismatch occurs when V/Q ≠ 1:
  - **V/Q > 1** (Dead Space)
    - Ventilation in excess of perfusion.
    - However, pulmonary blood is passing ventilated alveoli and PaO₂ is normal
  - **V/Q 0 to 1** (V/Q scatter)
    - Perfusion in excess of ventilation.
    - Increasing in PAO₂ will increase PaO₂
    - This is commonly referred to by the general term of V/Q mismatch
  - **V/Q = 0** (Shunt)
    - Mixed venous blood entering the systemic circulation without being oxygenated via passage through the lungs. PaO₂ falls.

References


Last updated 2017-10-04
Dead Space

Dead space is the proportion of minute ventilation which does not participate in gas exchange.

Types of Dead Space

Dead space can be divided into:

- **Apparatus dead space**
  Dead space from equipment, such as tubes ventilator circuitry. Some apparatus dead space may actually reduce total dead space, as an ETT bypasses the majority of anatomical dead space of the patient (nasopharynx).

- **Physiological dead space**
  Dead space from the patient. Physiological dead space is divided into:
  
  - **Anatomical dead space**
    The volume of the conducting zone of the lung. Anatomical dead space is affected by:
    - **Size and Age**
      - 3.3ml.kg⁻¹ in the infant, falls to 2.2ml.kg⁻¹ in the adult
    - **Posture**
      - Decreases when supine.
    - **Position of the neck and jaw**
      - Increased with neck extension.
    - **Lung volumes**
      - Increases by ~20ml per litre of additional lung volume.
    - **Airway calibre**
      - Bronchodilation increases airway diameter and therefore V₅.
  
  - **Pathological/Alveolar Dead Space**
    Dead space caused by disease. Causes of pathological dead space include:
    - **Erect posture**
    - **Decreased pulmonary artery pressure/impaired pulmonary blood flow**
      - **Hypovolaemia**
      - **RV failure/Increased RV afterload:**
        - **HPV**
        - **MI**
        - **PE**
    - **Increased alveolar pressure**
      - Increases West Zone 1 physiology.
      - **PEEP**
    - **COAD**

Calculation of Dead Space

Two methods exist to allow dead space volumes to be calculated:

- **Physiological dead space** may be measured with **Bohr's method**
- **Anatomical dead space** may be measured by **Fowler's method**
- **Pathological dead space** may be calculated by subtracting anatomical dead space (Fowler's method) from physiological dead space (Bohr's Method)
Fowler’s Method

Fowler’s Method is a single-breath nitrogen washout test, used to calculate anatomical dead space and closing capacity.

Method:

- At the end of a normal tidal breath (at FRC) a vital-capacity breath of 100% oxygen is taken
- The patient then exhales to RV

Expired nitrogen concentration and volume is measured.

- A plot of expired nitrogen concentration by volume is generated, producing a graph with four phases:
  - Phase 1 (Pure Dead Space)
    Gas from the anatomical dead space is expired. This contains 100% oxygen - no nitrogen is present.
  - Phase 2
    A mix of anatomical dead space and alveolar (lung units with short time constants) is expired. The midpoint of phase 2 (when area A = area B) is the volume of the anatomical dead space.
  - Phase 3
    Expired nitrogen reaches a plateau as just alveolar gas is exhaled (lung units with variable time constants).
  - Phase 4
    Sudden increase in nitrogen concentration, which indicates closing capacity. This increase occurs because:
    - Basal alveoli are more compliant than apical alveoli
    - Therefore, during inspiration basal alveoli inflate more than apical alveoli
      The single 100% oxygen breath therefore preferentially inflates the basal alveoli. At the end of the vital capacity breath, the oxygen concentration in basal alveoli is greater than that of apical alveoli.
    - In expiration, the process is reversed:
      - Basal alveoli preferentially exhale
      - At closing capacity, small basal airways close and now only apical alveoli (with a higher concentration of nitrogen) can exhale
      - Measured expired nitrogen concentration increases

Bohr’s Method

Physiological dead space is measured using the Bohr equation. This calculates dead space as a ratio, or proportion of tidal volume:

\[
\frac{V_D}{V_T} = \frac{V_T - V_A}{V_T}
\]

The Bohr equation is based on the principle that all CO₂ exhaled must come from ventilated alveoli.

\[
\frac{V_D}{V_T} = \frac{P_{A_{CO_2}} - P_{E_{CO_2}}}{P_{A_{CO_2}}}
\]

Note that:
- $P\bar{E}CO_2$ is the mixed-expired carbon dioxide
  Partial pressure of CO$_2$ in an expired tidal breath.
- The Bohr equation requires alveolar PCO$_2$ to be measured
  As this is impractical, the **Enghoff modification** is typically used, which assumes that PACO$_2$ $\approx$ PaCO$_2$. The equation then becomes:
  $$\frac{V_D}{V_T} = \frac{P_vCO_2 - P\bar{E}CO_2}{P_aCO_2}$$
- A normal value for physiological dead space during normal tidal breathing is 0.2-0.35

**Physiological Consequences of Increased Dead Space**

In dead space:
- The V/Q ratio approaches infinity as alveolar perfusion falls
- This results in a rise in PaCO$_2$
- In a spontaneously-ventilating individual, this stimulates the respiratory centre to increase minute ventilation to return alveolar ventilation (and therefore CO$_2$) to normal
- There is minimal effect on PaO$_2$, as in pure dead space all blood is passing through ventilated alveoli and therefore undergoes gas exchange

**Relationship between Alveolar Ventilation and PaCO$_2$**

Atmospheric air contains negligible CO$_2$. As MV increases, PaCO$_2$ will fall, as will the gradient for further CO$_2$ diffusion. This can be expressed by the equation:

$$PaCO_2 \propto \frac{1}{V_A}$$

Note that this graph:
- Describes the change in PaCO$_2$ for a change in alveolar ventilation
  A doubling of alveolar ventilation will halve PaCO$_2$.
- Does not describe the change in ventilatory drive for a given change in PaCO$_2$
  This is covered under removal of CO$_2$.

**Footnotes**

Note that West Zone 1 (where PA > Pa > Pv) physiology is increased dead space.
The $\text{PaCO}_2$-$\text{ETCO}_2$ difference is a consequence of dead space, as dead space gas dilutes alveolar gas.

References


Last updated 2019-07-18
Shunt

Explain the concept of shunt and its measurement

Shunt is blood reaching the systemic circulation without being oxygenated via passage through the lungs.

Factors Contributing to Shunt

- Normal shunt
  - Anatomical shunt
    - Thebesian veins, which drain directly into the left cardiac chambers
    - Bronchial circulations, which drain into the pulmonary veins
  - Functional shunt
    - Blood draining through alveoli with a V/Q between 0 and 1.
    - This may not be true shunt, as blood may have some oxygen content but not be maximally oxygenated
- Pathological shunt
  Pathological shunting can be anatomical (e.g. congenital cardiac malformations), or physiological (e.g. pneumonia causing alveolar consolidation).
  - Intra-cardiac e.g. VSD
  - Extra-cardiac
    - e.g. Pulmonary AVM, PDA

Calculation of Shunt

- Shunt cannot be directly measured
- This is because we cannot separate true shunt (V = 0) from V/Q scatter (V/Q < 1) when sampling blood entering the left heart
- Venous admixture is used instead
  Venous admixture is the amount of mixed venous blood that must be added to pulmonary end-capillary blood to give the observed arterial oxygen content. Venous admixture:
  - Is a calculated, theoretical value
  - Assumes that alveoli have either complete shunt (no ventilation at all, i.e. V/Q = 0) or no shunt (V/Q = 1)
  - Is expressed as a ratio, or shunt fraction:
    \[
    \frac{\dot{Q}_S}{\dot{Q}_T} = \frac{C_vO_2 - C_aO_2}{C_eO_2 - C_vO_2},
    \]
    where:
    - \( \dot{Q}_S \) = Shunt blood flow
    - \( \dot{Q}_T \) = Cardiac output
    - \( C_eO_2 \) = Pulmonary end-capillary oxygen content, assumed to have an oxygen tension equal to PAO_2 (with the corresponding oxygen saturation)
    - \( C_aO_2 \) = Arterial oxygen content
    - \( C_vO_2 \) = Mixed venous oxygen content

Physiological Consequences of Shunt

Effect on Carbon Dioxide
No CO₂ can diffuse from shunted blood
Therefore PaCO₂ might be expected to rise, however:
- In a spontaneously breathing patient the increased PaCO₂ increases respiratory drive, and alveolar ventilation increases
  - Therefore, shunt does not tend to increase PaCO₂ unless:
    - The shunt fraction is large and
    - The patient is unable to increase their alveolar ventilation to compensate
- Additionally, the steepness of the CO₂ dissociation curve at the arterial point means that although CO₂ content increases, the increase in PaCO₂ is small

**Effect on Oxygen**
- PaO₂ falls proportionally to shunt fraction
- As shunted alveoli are perfused but not ventilated, true shunt is said to be unresponsive to an increase in FiO₂
  This is where technical definitions become important to avoid confusion.
  - For an alveoli with a V/Q between 0-1 (V/Q mismatch or V/Q scatter, but not true shunt):
    - There is perfusion, but relatively less ventilation
    - Therefore blood passing through this alveoli will be partially oxygenated
    - Increasing PAO₂ will improve oxygenation (assuming no diffusion limitation):
      - Administration of supplemental oxygen
      - Hyperventilation
      - As per the alveolar gas equation
  - For an alveoli with a V/Q of 0 (true shunt)
    There is no ventilation. Regardless of the increase in PAO₂, PaO₂ will not improve.

**The Isoshunt Diagram**
- Isoshunt diagram plots the relationship between FiO₂ and PaO₂ against a set of 'virtual shunt lines'
- These 'shunt fractions' are calculated from the above equation and so are actually V/Q admixture fractions


Last updated 2019-07-18
Oxygen Storage

Describe the oxygen and carbon dioxide stores in the body

The standard textbook 70kg male contains ~1.5L of oxygen, split between:

- ~850ml in blood
  - There is 20.4ml of oxygen per 100ml of blood, divided up as:
    - 20.1ml bound to haemoglobin
    - 0.3ml dissolved
- ~250ml bound to myoglobin
- ~450ml contained in FRC (21% of 2.4L)

This is why preoxygenation increases safe apnoea times, as the nitrogen washout increases the volume of oxygen stored.

Oxygen-Haemoglobin Dissociation Curve

The sigmoid shape of the oxygen-haemoglobin dissociation curve offers many physiological advantages:

- Buffering in case of low PaO₂
  - The plateau allows oxygen content to remain high, even if the PaO₂ falls
- Maintenance of diffusion gradient to tissues
  - The steep section allows a large amount of oxygen to be delivered with only a small drop in PaO₂, which allows the rate of oxygen delivery to be maintained (as the blood-tissue partial pressure gradient is steep) with an increase in oxygen demand.

- The sigmoid shape exists due to cooperative binding
  - Each oxygen which binds to Hb causes conformational changes which allow it bind additional oxygen molecules more easily.
    - When the fourth oxygen molecule has bound, Hb is said to be in the relaxed conformation (R state)
    - When no oxygen is bound, Hb is said to be in the tense state (T state)
- The curve can be right or left-shifted by changes in temperature, pH, CO₂, and 2-3 DPG
Note that the mixed venous point is not on the arterial curve (unlike how it is displayed above), as the venous dissociation curve is right-shifted relative to the arterial curve.

**Haemoglobin Species**

Haemoglobin is a four-tetramer molecule, and its species can be physiological or pathological:

- **Physiological**
  - **HbA**
    - Most common
    - 2 alpha and 2 beta subunits (α₂β₂)
  - **HbA₂**
    - Less common
    - 2 alpha and 2 delta subunits (α₂δ₂)
  - **HbF**
    - Foetal Hb
    - Higher affinity for oxygen due to lack of 2,3-DPG
    - 2 alpha and 2 gamma subunits (α₂γ₂)

- **Pathological**
  - **HbS**
    - Sickle-cell disease.
      - Abnormal beta subunit
      - Unable to deform as they pass through capillaries
        - Increases blood viscosity, thrombus, and ischaemia through capillary occlusion
          - Often causes splenic infarction
          - Reduced red cell lifespan to 10-20 days
  - **MetHb**
    - Methaemoglobinemia.
      - Ferrous iron (Fe²⁺) is oxidised to ferric iron (Fe³⁺)
      - Cannot bind oxygen, and left-shifts the oxyHb curve for normal Hb which reduces oxygen offloading at tissues
      - Normally prevented by:
        - Glutathione in red cell reduces oxidising agents
        - Methaemoglobin reductase enzyme uses NADH to reduce MetHb
      - Occurs due to:
        - Oxidising agents overwhelm capacity of glutathione system, e.g.:
          - SNP
          - NO
          - Amide local anaesthetics
Gas Transport

- Sulfonamides
- Failure of the methaemoglobin reductase enzyme
- G6PD

- COHb
  - Carboxyhaemoglobin.
  - Haemoglobin binds carbon monoxide with greater affinity than oxygen

- CyanoHb
  - Haemoglobin irreversibly binds cyanide molecules, causing a functional anaemia
  - Cyanide inhibits cytochrome oxidase in the electron transport chain, preventing oxidative phosphorylation occurring

Oxygen Saturation

Oxygen Saturation can be defined in two ways:

- **Functional Saturation**
  
  $$S_pO_2 (%) = \frac{[HbO_2]}{[HbO_2] + [CytCOHb] + [D.oxHb] + [MetHb]} \times 100$$

  However, additional haemoglobin species exist in varying amounts, and this definition may deceptively imply good oxygen delivery when this is not the case.

- **Fractional Saturation**
  
  $$S_pO_2 (%) = \frac{[HbO_2]}{[HbO_2] + [CytCOHb] + [D.oxHb] + [MetHb] + [COHb]} \times 100$$

  Fractional saturation includes carboxy- and met-haemoglobin, and so is a more accurate estimator of oxygen saturation.

Note that pulse oximetry doesn’t measure either of these and is dependent on the calibration, but will typically measure functional saturation.

Myoglobin

Muscle is highly metabolically active and has a large O₂ demand. Myoglobin serves as an O₂ store for muscle. It is similar to Hb in that it is a large O₂-binding iron-containing protein myoglobin, and is different because it:

- Contains one globin chain and one haeme group (binding one O₂ molecule), and so does not exhibit cooperative binding
  - The myoglobin dissociation curve therefore has a rapid upstroke and an early plateau.
- Has a P₅₀ of 2.7mmHg
  - This allows it to take up oxygen from haemoglobin (as the partial pressure gradient favours diffusion into the cell), and unload it into the cell (so it can actually be used).
- Is found in skeletal and cardiac muscle

References


Last updated 2019-07-18
## Carbon Dioxide

Describe the oxygen and carbon dioxide stores in the body

Describe the carbon dioxide carriage in blood including the Haldane effect and the chloride shift

Explain the carbon dioxide dissociation curve

Describe the movement of carbon dioxide from blood to the atmosphere

CO₂ is produced in the mitochondria during the citric-acid cycle as a product of metabolism.

- There is ~120L of carbon dioxide in the body
  - A total of 1.8L.kg⁻¹, 1.6L.kg⁻¹ of which is in relatively inaccessible compartments.
- Normal elimination (and, at steady state, production) of carbon dioxide is 200ml.min⁻¹

### Carbon Dioxide in Blood

In blood, CO₂ is stored as:

- Bicarbonate (90%)
- Dissolved gas
- Carbamino compounds

<table>
<thead>
<tr>
<th>Form</th>
<th>Arterial Blood</th>
<th>Additional CO₂ in venous blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bicarbonate</td>
<td>90%</td>
<td>60%</td>
</tr>
<tr>
<td>Dissolved</td>
<td>5%</td>
<td>10%</td>
</tr>
<tr>
<td>Carbamino compounds</td>
<td>5%</td>
<td>30%</td>
</tr>
</tbody>
</table>

#### Bicarbonate

- CO₂ diffuses freely into erythrocytes, where it can be catalysed by carbonic anhydrase to produce bicarbonate:
  \[ CO_2 + H_2O \leftrightarrow H_2CO_3 \leftrightarrow H^+ + HCO_3^- \]
- To maintain bicarbonate production, the products (H⁺ and HCO₃⁻) are then removed:
  - H⁺ ions are buffered to haemoglobin
    \[ HbO_2 + H^+ \leftrightarrow HHb + O_2 \]
  - Intracellular HCO₃⁻ is then exchanged with extracellular Cl⁻ via the BAND3 membrane protein
    - This is called the Hamburger, or Chloride Shift
    - Chloride entering the cell draws water in along its osmotic gradient, increasing the haematocrit of venous blood relative to arterial blood

#### Dissolved Gas

- As per Henry’s Law, the amount of carbon dioxide dissolved in blood is proportional to the PaCO₂
- As carbon dioxide is 20x as soluble as oxygen in water, dissolved carbon dioxide contributes much greater proportion of carbon dioxide content than dissolved oxygen does to oxygen content

#### Carbamino Compounds
- CO₂ can bind directly to proteins (predominantly haemoglobin), which displaces a H⁺ ion:
  \[ Hb + CO_2 \leftrightarrow HbCOO^- + H^+ \]
  - The H⁺ ion is then buffered by another plasma protein (also predominantly haemoglobin)
  \[ Hb + H^+ \leftrightarrow HHb \]
- Bound CO₂ does not contribute to the partial pressure gradient
- Carbamino compounds are only a small contributor to overall CO₂ carriage, but contribute about one third of the arterio-venous CO₂ difference due to the **Haldane effect**

  The Haldane effect states that deoxyHb binds CO₂ more effectively than oxyHb. This is because:
  - DeoxyHb is a better buffer of H⁺
    - pKa of deoxyHb is 8.2, compared to that of oxyHb which is 6.6.
    - Enhanced buffering contributes ~30% of the Haldane effect
  - DeoxyHb forms carbamino compounds more easily
    - Deoxy-Hb has 3.5x the affinity for CO₂ than Oxy-Hb.
    - This forms ~70% of the Haldane effect

### CO₂ Dissociation Curve

This curve plots PCO₂ against blood CO₂ content in ml.100ml⁻¹.

![CO₂ Dissociation Curve](image)

**Key points:**
- Mixed venous CO₂ content is 52ml.100ml⁻¹, at a PCO₂ of 46mmHg
- Arterial CO₂ content is 48ml.100ml⁻¹, at a PCO₂ of 40mmHg
- Approximately 50% of the arterial-mixed venous difference occurs due to the upwards shift of the curve, which is due to the Haldane effect
  - This is the mechanism for changes in PO₂ affecting the CO₂ dissociation curve.

### Removal of CO₂

CO₂ dissolves from pulmonary arterial blood into the alveolus down a concentration gradient. As inspired CO₂ is negligible, PACO₂ is a function of alveolar ventilation and CO₂ output, given by the equation:

\[
PACO_2 = \frac{CO_2 \text{ output}}{V_A}
\]

Simplified, PaCO₂ is inversely proportional to alveolar ventilation:

\[
PACO_2 \propto \frac{1}{V_A}
\]
Distribution of Carbon Dioxide

CO₂ in the body can be considered as a three-compartment model:

- Well-perfused (blood, brain, kidneys)
- Moderately-perfused (resting muscle)
- Poorly-perfused (bone, fat)

Each of these tissues has a different time-constant, such that a mismatch of ventilation with metabolic activity may take 20-30 minutes to equilibrate across compartments.

Therefore hyperventilation and hyperventilation have different effects on PCO₂:
- **Hyperventilation** causes a rapid decrease in PCO₂ in blood, subsequent (slower) redistribution from peripheral compartments
- **Hypoventilation** causes a rise in PaCO₂, the rate of which is determined both by production and distribution into plasma
  - With no ventilation, PCO₂ rises at 3-6mmHg.min⁻¹
  - Due to the Haldane effect the PaCO₂ will rapidly increase during passage through the pulmonary capillary (despite the fact that carbon dioxide content is unchanged) as the proportion of OxyHb increases
  - Therefore:
    - PaO₂ is more sensitive at detecting early hypoventilation provided PAO₂ is normal
    - Steady-state PCO₂ gives the best indication of adequacy of ventilation
      - In acute hypoventilation, produced CO₂ is preferentially stored in tissues, decreasing CO₂ elimination
      - In acute hyperventilation, CO₂ is mobilised from tissues resulting in increased CO₂ elimination

**CO₂ Cascade**

<table>
<thead>
<tr>
<th>Region</th>
<th>Value (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixed Venous</td>
<td>46</td>
</tr>
<tr>
<td>Alveolar</td>
<td>40</td>
</tr>
<tr>
<td>(Arterial)</td>
<td>40</td>
</tr>
<tr>
<td>Mixed-expired</td>
<td>27</td>
</tr>
</tbody>
</table>

- Venous CO₂ diffuses into the alveolus, reaching equilibrium with arterial PCO₂
- Alveolar CO₂ is then diluted by dead space gas, resulting in a lower ME’CO₂

**References**
2. FRCA: Anaesthesia Tutorial of the Week - Respiratory Physiology

Last updated 2018-04-24
Positive Pressure Ventilation

Describe the physiological consequences of intermittent positive pressure ventilation and positive end-expiratory pressure.

Physiological effects of positive pressure ventilation are mostly related to the increased mean airway pressure. This is a function of:

- Ventilation mode
- Tidal volume and peak (and plateau) airway pressure
- Respiratory rate
- I:E ratio
- PEEP

PEEP has a much larger effect than the other factors.

- PEEP is defined as a positive airway pressure at the end of expiration
- PEEP is distinct from positive airway pressure (which is not confined to a phase of the respiratory cycle) and CPAP (which is a mode of ventilation)
- iPEEP refers to intrinsic PEEP, auto PEEP or dynamic hyperinflation

iPEEP is PEEP generated by the patient, and occurs when expiration stops before the lung volume reaches FRC.

- Application of external PEEP may limit the generation of iPEEP by maintaining airway patency in late expiration

Respiratory Effects

- Decreased work of breathing
  - Decreased VO₂
    - More important when work of breathing is high.
- Alteration in anatomical/apparatus dead space
  - Intubation typically reduces dead space, as the additional apparatus dead space is of smaller volume than the anatomical dead space it replaces
  - Non-invasive ventilation masks cause a large increase in dead space
- Increases lung volume (and FRC, for PEEP) by an amount proportional to the compliance of the system
  - Improves oxygenation via alveolar recruitment
  - Improves lung compliance via alveolar recruitment, reducing work of breathing
  - Elevated airway pressures may increase the proportion of West Zone 1 physiology and alveolar dead space

\[ \frac{VT}{V_D} \]

In healthy lungs an increase in the \( \frac{VT}{V_D} \) ratio is seen when PEEP exceeds 10-15cmH₂O.

- Reduces airway resistance
  - Airway resistance decreases as lung volume increases.

Cardiovascular Effects

- Alteration in cardiac output
  - PEEP and IPPV generally decrease CO via decreasing VR due to the increase in intrathoracic pressure.
    - Leads to reduction in RV filling pressure, LV filling, and CO.
    - This is the predominant reason why CO falls with the application of PEEP
    - In a well patient, CO falls by:
      - 10% with IPPV and ZEEP
      - 18% with IPPV and 9cmH₂O of PEEP
      - 36% with IPPV and 16cmH₂O of PEEP
These changes are:
- More marked in hypovolaemia
  Changes are reversed with volume expansion.
- Less severe with poor lung compliance
  Reduced compliance greatly reduces the effect of PEEP and IPPV on the vasculature, as the change in intrapleural pressure is reduced.

- LV preload may also be reduced due to increased RV afterload
  - Increased RV afterload may increase RV EDV, displacing the interventricular septum into the LV
  - The bulging septum decreases LVEDV, causing LV diastolic function and reduced LV filling
  - This is an example of ventricular interdependence.
- Reduced LV afterload due to reduced LV transmural pressure
  In some cases, IPPV augments circulatory function by reducing LV afterload to a greater extent than preload.
  - Effects in a well patient are minimal, as PEEP is relatively small in magnitude compared to systemic arterial pressures
  - In patients generating highly negative intrathoracic pressures, the LV transmural pressure can increase markedly, increasing LV afterload and reducing cardiac output

- Reduction in MAP
  MAP decreases as PEEP increases.

- Changes to oxygen flux
  PEEP will tend to improve PO₂ whilst reducing CO.

- Changes to pulmonary vascular resistance and RV afterload
  - If lung volume is lower than FRC, then PVR will reduce as PEEP stretches open extra-alveolar vessels
  - Alveolar recruitment will reduce hypoxic-pulmonary vasoconstriction, further reducing PVR
  - If lung volume is higher than FRC, then PVR will increase as PEEP compresses alveolar vessels
  - Therefore, PEEP has variable effects on RV afterload depending on how it changes lung volume with respect to FRC

### End-Organ Effects

- Reduced urine output due to:
  - Reduced CO and renal blood flow
  - ADH release as a consequence of reduced atrial stretch and ANP release
    May worsen oedema in patients with prolonged periods of ventilation.

- Reduced hepatic blood flow due to:
  - Increased CVP and decreased CO lowering the pressure gradient for hepatic flow
    May result in circulation only intermittently throughout the cardiac cycle

### References

5. Yartsev, A. Indications and Contraindications for PEEP. Deranged Physiology.
7. Yartsev, A. [PEEP and Intrinsic PEEP](http://www.derangedphysiology.com/main/core-topics-intensive-care/mechanical-
Hypoxia

Explain the physiological effects of hyperoxia, hypoxaemia, hypercapnia, hypocapnia, and carbon monoxide poisoning.

- **Hypoxaemia** is a low partial pressure of oxygen in blood
- **Hypoxia** is an oxygen deficiency at the tissues, due to:
  - Impaired oxygen delivery
  - Impaired oxygen extraction

Oxygen delivery is given by the equation:

\[
DO_2 = HR \times SV \times (1.34 \times [Hb] \times S\text{p}O_2 + P\text{a}O_2 \times 0.003),
\]

where:

- 1.34 is Hüfner's constant
  - This is the oxygen carrying capacity of haemoglobin, in ml.g⁻¹ (of Hb).
  - The theoretical maximum is 1.39
  - In vivo it is 1.34 due to the effect of carboxyhaemoglobin and methaemoglobin compounds, which limit O₂ binding
- 0.03 is the solubility coefficient of O₂ in water at 37°C, in ml.s.mmHg⁻¹
  - Can also be expressed as 0.003 ml.s.dm⁻¹.mmHg⁻¹ (mls per deciliter per mmHg). Different texts use different values, depending on whether haemoglobin is reported in g.L⁻¹ or g.100ml⁻¹.

Classifications and Causes of Hypoxia

Hypoxia can be categorised into four types:

- Hypoxic hypoxia
- Anaemic hypoxia
- Ischaemic hypoxia
- Histotoxic hypoxia

Hypoxic Hypoxia

Hypoxic hypoxia, or hypoxaemia, is hypoxia due to low PaO₂ (and therefore low SpO₂), typically defined as a PaO₂<60.

Causes of hypoxaemia can be further classified based on their A-a gradient:

- Causes of hypoxaemia with a normal A-a gradient:
  - Low PiO₂
  - Decreased alveolar ventilation
- Causes of hypoxaemia with a raised A-a gradient:
  - Diffusion limitation
  - Shunt
  - (Increased oxygen extraction)

Low FiO₂

Hypoxaemia occurs at high altitudes when the PO₂ is decreased.

Decreased alveolar ventilation
A fall in alveolar ventilation \( \dot{V}_A = \text{Respiratory Rate} \times (V_{T'} - V_D) \) causes a rise in PACO₂, and therefore decreases PAO₂. Decreased \( V_A \) can occur with:

- Respiratory centre depression:
  - Drugs
  - Head injury (Raised ICP, closed head injury)
  - Encephalopathy
  - Fatigue
- Nerve dysfunction:
  - Spinal cord injury
  - GBS
  - MND
- NMJ dysfunction:
  - Paralysis
  - MG
- Muscular dysfunction:
  - Myopathy
  - Fatigue
  - Malnutrition
  - Dystrophy
- Chest wall abnormalities:
  - Kyphoscoliosis
  - Ankylosing Spondylitis
  - Pleural fibrosis

**Diffusion Limitation**

Impaired diffusion of O₂ across the membrane results in a lowered PaO₂. Diffusion limitation occurs due to:

- Decreased alveolar surface area
- Increased alveolar capillary barrier thickness
  - Pulmonary fibrosis
  - ARDS

**Shunt**

Shunt occurs when blood reaches the systemic circulation without being oxygenated via passage through the lung. As the alveolus is perfused but not ventilated, thus the V/Q ratio is **0**.

- Administration of 100% O₂ has less effect on PaO₂ as shunt fraction increases
  - Oxygen content of shunted alveoli is identical to mixed venous content
  - Oxygen content of non-shunted alveoli does not increase appreciably at high partial pressures as haemoglobin is already fully saturated

Shunt physiology is explored in more detail under **shunt**.

**Increased Oxygen Extraction**

- Increased oxygen extraction (VO₂) will not typically cause hypoxia

  This is because:
  - Normal VO₂ is 250mL.min⁻¹
  - Normal DO₂ is 1L.min⁻¹
Maximal oxygen extraction ratio is ~70% (though it varies between organs)
Therefore VO₂ can increase until it reaches 70% of the DO₂, a point called critical DO₂.
However, it may worsen hypoxia in the presence of a supply-side (DO₂) pathology

Anaemic Hypoxia

- Impaired oxygen delivery due to low Hb
- Typically asymptomatic at rest but limits exercise tolerance
- Compensation occurs by increasing levels of 2,3-DPG, causing a right-shift in the Hb-O₂ dissociation curve to favour oxygen off-loading at tissues

Carbon Monoxide Poisoning

- CO poisoning is classified as a subset of anaemic hypoxia as carboxyhaemoglobin reduces the effective amount of haemoglobin in solution
- CO has 210 times the affinity for Hb than O₂
  - CO rapidly displaces O₂ from Hb and is liberated slowly
- CO poisoning causes headache and nausea, but no increased respiratory drive since the PaO₂ is unchanged

Ischaemic Hypoxia

- Ischaemic hypoxia is due to impaired cardiac output resulting in impaired oxygen delivery

Histotoxic Hypoxia

- Histotoxic hypoxia is due to impaired tissue oxidative processes, preventing utilisation of delivered oxygen
- Most common cause of histotoxic hypoxia is cyanide poisoning, which inhibits cytochrome oxidase and prevents oxidative phosphorylation
- Managed by using methylene blue or nitrites, which form methaemoglobin, in turn reacting with cyanide to form the non-toxic cyanmethaemoglobin

Effects of Hypoxia

- With a normal PaCO₂, PaO₂ must fall to 50mmHg before an increase in ventilation occurs
- With a rising PaCO₂, a fall in PaO₂ below 100mmHg will stimulate ventilation via action on carotid and aortic body chemoreceptors
  - The effects of each stimuli are synergistic, and greater than what is seen with either effect alone
- Prolonged hypoxaemia will also lead to cerebral acidosis (via anaerobic metabolism), which will stimulate central pH receptors and stimulate ventilation

Acid-Base Changes

- Hypoxia results in both fixed and volatile acid-base disturbances
- Anaerobic metabolism results in lactate production
- Production of fixed acid results in a base deficit, and a low bicarbonate
- Hypoxia and metabolic acidosis stimulate ventilation and hypocarbia

CO₂ retention

- In chronic hypercarbia the CSF pH normalises (as bicarbonate is secreted into CSF), with a raised CO₂
Fall in PaO₂ becomes the predominant stimulus for ventilation

References

3. CICM July/September 2007
4. ICU Basic Book.

Last updated 2019-07-18
Hypo and Hypercapnea

Explain the physiological effects of hyperoxia, hypoxaemia, hypercapnia, hypocapnia, and carbon monoxide poisoning.

Carbon dioxide is lipid soluble and can rapidly cross membranes, allowing it affect acid-base status in any compartment.

Hypercapnea

- **Respiratory Effects**
  - Increased respiratory drive via chemoreceptor stimulation
- **CVS effects**
  - Peripheral vasodilation
    - May cause tachycardia from sympathetic stimulation
  - Pulmonary vasoconstriction
  - Myocardial depression
    Intracellular acidosis.
  - Arrhythmogenic
- **CNS effects**
  - Increased CBF
  - Increased ICP secondary to increased CBF
  - SNS activation
  - CNS depression
    When PaCO₂ > 100mmHg

Hypocapnea

- **Respiratory Effects**
  - Left-shift of oxyhaemoglobin dissociation curve
  - Respiratory depression
- **CVS effects**
  - Myocardial depression
    Intracellular alkalosis.
- **CNS effects**
  - Decreased cerebral blood flow
- **Electrolyte effects**
  - Decreased serum K⁺
  - Decreased serum Ca²⁺
    Leads to paresthesias and twitches.
    - Ca²⁺ binds to H⁺ binding site on albumin

References

Last updated 2019-07-18
Position and ventilation

Explain the effect of changes in posture on ventilatory function

Altered patient position can cause significant changes to V/Q matching.

Lateral Decubitus

In the lateral position in a spontaneously ventilating patient:

- Dependent lung ventilation improves by ~10%
  - Due to impaired compliance of the non-dependent lung (it hyperinflates) and improved compliance of the dependent lung (it is less expanded).
  - Dependent lung corresponds more to West Zone 3
  - Non-dependent lung corresponds more to West Zone 2
- Dependent lung perfusion improves by ~10%
  - Due to the effect of gravity.

In the lateral position in a positive-pressure ventilated patient:

- The majority (~55%) of the tidal volume is delivered to the non-dependent lung
- The majority of pulmonary blood flow is delivered to the dependent lung
- The compliance of the dependent lung falls due to compression from the:
  - Mediastinum
  - Abdominal organs
  - These move cephalad in a paralysed patient.
- The dependent lung typically receives greater blood flow due to the effect of gravity
  - This may worsen V/Q matching
- Blood flow is also affected by:
  - HPV
  - Anatomical factors
    - Blood flow is greater in central than peripheral portions.
  - Lung volume
    - Alterations in extra-alveolar and intra-alveolar pressures at FRC may alter regional blood flow.
- When both lungs are being ventilated, V/Q matching can be improved with selective application of PEEP to the dependent lung, which improves compliance

Thoracotomy

Opening of a non-dependent hemithorax causes:

- Increased compliance and FRC of the non-dependent lung
- Reduced compliance and FRC of the dependent lung

References

3. ANZCA August/September 2015

Last updated 2017-09-20
Humidification

Define humidity and give an outline of the importance of humidification

Humidification describes the amount of water vapour present in air:

- **Absolute Humidity** is the amount of water vapour in a given volume of air (g.m\(^{-3}\))
- **Relative Humidity** is the ratio between the amount of water vapour in a sample of air (absolute humidity) and the amount of water required to fully saturate that sample at its current pressure and temperature
- **Moisture** is the water produced by condensation when relative humidity exceeds 100%.
- Humidification of inspired air is important to avoid drying out mucosa and sputum, which leads to tissue damage and failure of the mucociliary elevator
- Optimal function requires a relative humidity of **greater than 75%**

Mechanism

The nose is:

- Optimised for humidification
  - The septum and turbinates increase contact of air with mucosal surfaces by:
    - Increasing **surface area**
    - Generating **turbulent flow**
  - The preferred orifice for breathing unless airways resistance becomes a significantly limiting factor
    - Airway obstruction (e.g. polyps)
    - At high minute ventilations (> 35L.min\(^{-1}\))

- Humidifies inspired gas to 90%, compared to **60%** for the mouth

Method of humidification:

- Fluid lining the airway acts as a heat and moisture exchanger
- In inspiration:
  - Relatively dry air is evaporates water from the airway lining
  - Relative humidity is increased to 90% in the nasopharynx and 100% BTPS by the second generation of bronchi
  - This gives a water vapour pressure of 47mmHg at BTPS, with an absolute humidity of 44g.m\(^{-3}\).
- In expiration:
  - Air cools in the upper airway
    - As cooler air has a lower saturated vapour pressure, moisture condenses on the airway.
  - Moisture is reabsorbed
    - This reduces potential water losses from the airway from 300ml.day\(^{-1}\) to 150ml.day\(^{-1}\).

References

3. CICM September/November 2012

Last updated 2018-09-21
Cough Reflex

Explain the pathways and importance of the cough reflex

Coughing:

- Is an airway protection reflex
- Involves deep inspiration followed by **forced expiration against a closed glottis**
  The sudden opening of the cords causes a violent rush of air at $>900 \text{km.h}^{-1}$, removing irritants and secretions from the airways.

Sensation

Vagus afferents have exquisitely sensitive light touch and corrosive chemical receptors in the larynx, carina, terminal bronchioles, and alveoli.

Integration

Vagal afferents synapse in the medulla, which coordinates the effector response.

Effector

A series of processes occur in three phases:

- Inspiratory phase
  A close to vital capacity breath is taken.
- Compressive phase
  Effort closure of the epiglottis to seal the larynx, followed by a violent contraction of abdominal musculature and internal intercostals, causing a rapid rise in intrapleural pressure to $>100 \text{mmHg}$.
- Expulsive phase
  Wide-opening of the cords and epiglottis, causing a violent expiration.
  - Compression of the lungs causes narrowing of the noncartilaginous airways and increases turbulent flow, removing adherent material from the tracheobronchial tree

References


Last updated 2019-07-18
Non-Respiratory Functions

Outline the non-ventilatory functions of the lungs

The lungs are a unique organ as:

- The entire cardiac output passes though the pulmonary circulation
- They have a huge capillary bed which blood is in contact with
- They have a large interface with the external environment

Consequently they are adapted to a number of non-respiratory functions, which include:

- Filtration
- Immune defence
- Blood reservoir
- Metabolism
- Drug Delivery
  - (Taking up drugs)
  - Inhalational Anaesthetics
- Synthetic
  - Endocrine

Filtration

The entire cardiac output passes through the 7μm pulmonary capillaries, which act as an effective sieve for particulate matter. This function may be impaired by intra-cardiac shunting (e.g. PFO) or pre-capillary anastomoses.

Complementing this role, the lungs are able to clear thrombi more rapidly than other organs as pulmonary endothelium has a high concentration of plasmin activator and heparin.

Metabolism

The pulmonary endothelium has a variety of effects on drugs and endogenous hormones:

<table>
<thead>
<tr>
<th>Class</th>
<th>Activated</th>
<th>Inactivated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amines</td>
<td></td>
<td>5-HT, Noradrenaline</td>
</tr>
<tr>
<td>Peptides</td>
<td>Angiotensin I (via ACE)</td>
<td>Bradykinin, ANP</td>
</tr>
<tr>
<td>Arachidonic acid derivatives</td>
<td>Arachidonic acid</td>
<td>Many prostaglandins</td>
</tr>
<tr>
<td>Other Drugs</td>
<td></td>
<td>Lignocaine, fentanyl</td>
</tr>
</tbody>
</table>

Blood Reservoir

The highly compliant pulmonary circulation contains a reservoir of ~500ml of blood which acts as a volume reserve for the LV.

Defence
The large surface area required for gas exchange leaves the lung vulnerable to invasion by airborn substances. This is attenuated by:

- **Mucous**
  A mucous layer protects large airways, as large (>8μm) particles impact into the mucous.
  - Mucous is exocytosed by goblet cells in response to noxious stimuli including chemical irritation as well as inflammatory and neuronal stimulation
  - The efficacy of the mucous-cilia system is enhanced by bronchoconstriction, which reduces flow velocity and causes particulate matter to settle

- **Cilia**
  Cilia are projections from epithelium which beat rhythmically at ~12Hz to propel mucous out of the airway at a rate of ~4mm.min\(^{-1}\).
  - Ciliary function can be impeded by pollutants, smoke, and infection
  - Ciliary function is stimulated by anaesthetic agents

- Inhaled particles which reach the respiratory zone are not trapped by mucous, but instead phagocytosed by alveolar macrophages
- Bronchoconstriction reduces flow velocity and causes particulate particles to settle in the mucous

**Drug Delivery**

The same properties that optimise the lung for gas exchange optimise it for delivery of inhaled agents. Drugs absorbed in the pulmonary circulation are:

- Lipophilic
- Alkaline (pKa >8)

**Endocrine**

Important endocrine functions of the lung include:

- Release of inflammatory mediators such as histamine, endothelin, and eicosanoids
- Release of nitric oxide to regulate smooth muscle
- ACE metabolises angiotensin I to angiotensin II

**References**


Last updated 2019-07-18
Altitude Physiology

Altitude causes a number of physiological effects, related to:

- Reduce atmospheric pressure
- Reduced temperature
- Reduced relative humidity
- Increased solar radiation

Pressure Effects

Reduced air pressure results in a proportional decrease in PO$_2$:

- At 3,000m, alveolar PO$_2$ is 60mmHg
- At 5,400m, consciousness is lost in unacclimatised individuals
- At 10,400m, air pressure is 187mmHg
  
  With 47mmHg of water vapour and an alveolar PCO$_2$ of 40, breathing 100% O$_2$ gives an alveolar PO$_2$ of 100mmHg.
- At 14,000m, consciousness is lost despite 100% O$_2$
- At 19,200m, the ambient pressure is so low that the boiling point of water is 37°C
  
  This is the Armstrong limit.

Respiratory

- Fall in PaO$_2$ is compensated by increasing minute ventilation, which decreases PACO$_2$ and therefore increases PAO$_2$
  
  Limits of compensation are reached on 100% oxygen at 13,700m
- Effective compensation is limited by the respiratory alkalosis, this is known as the braking effect:
  
  - Peripheral chemoreceptors detect hypocapnea
  - Central chemoreceptors detect alkalosis
- The subsequent respiratory alkalosis generates a compensatory metabolic acidosis
  
  This acidosis relaxes the braking effect and allows further hyperventilation, and is therefore an important part of acclimatisation.

- There is an initial left-shift of the oxygen-haemoglobin dissociation curve due to alkalosis
- This stimulates a compensatory increase in 2,3-DPG to right-shift the curve and improve oxygen offloading at the tissues

Cardiovascular

- PVR increases due to HPV
- Heart rate increases due to increased SNS outflow
Stroke volume falls (cardiac output remains the same) due to decreased preload:
- Plasma volume falls due to:
  - Pressure diuresis
  - Insensible losses from hyperventilation and reduce relative humidity
- Myocardial work increases
  - Increased HR
  - Increased viscosity of blood due to high haematocrit
  - Increased RV afterload from high PVR
  - Increased pulmonary capillary hydrostatic pressures lead to fluid transudation and pulmonary oedema

**Haematological**

- Increased risk of thrombotic events due increased haematocrit
- Increased red cell mass due to EPO secretion

**References**


Last updated 2019-07-18
Respiratory Changes with Obesity

Discuss the effect of morbid obesity on ventilation

Obesity is a multisystem disorder defined by an elevated body mass index (BMI):

- Normal: BMI < 25
- Overweight: BMI 25 - 30
- Obese: BMI > 30
- Morbidly Obese:
  - Obesity related disease and a BMI > 35
  - BMI > 40

Characteristics of obesity include:

- Complex genetic and environmental causes
- Increased caloric intake
- Increased metabolic rate (normal for BSA)

Morbid obesity causes several changes to the respiratory system:

- Airway
  - Increased risk of OSA
  - Increased risk of GORD and aspiration
  - Increased risk of difficult bag-mask ventilation
  - Increased risk of difficulty laryngoscopy

- Changes to respiratory pattern
  - Increased minute ventilation
    - Secondary to increased VO$_2$ and VCO$_2$
      Due to the increase in LBW and adiposity.
    - Increased airway reactivity
      Central adiposity increases circulating cytokines, including TNF-α, IL-6, leptin.

- Changes to volumes and capacities
  - Reduced respiratory system compliance
    - Decreased chest wall compliance
      Due to abdominal and chest wall fat.
      - Fat distribution may be more important than absolute BMI
    - Decreased lung compliance
      Basal atelectasis due to abdominal compression and reduced respiratory compliance.

  - Decreased ERV and FRC
    - Note that RV is generally relatively unchanged

- Increased airway resistance
  Due to decreased airway radius at lower lung volumes.

- Increased work of breathing
  Due to reduced respiratory compliance and increased airway resistance.

- Closing capacity encroaches on FRC
  As FRC falls, closing capacity becomes closer to FRC.
  - If closing volume exceeds expiratory reserve volume, then small airways will collapse during normal tidal breathing, causing shunt

- Changes to blood gases
• Increased A-a gradient
  Occurs when closing capacity exceeds FRC.

• Changes to respiratory circulation
  • PVR increases due to reduced FRC causing increased HPV
    May lead to secondary PHTN and right heart dysfunction.

## References


Last updated 2017-09-21
Respiratory Changes in Neonates and Children

Transition at Birth

Transition from placental gas exchange to pulmonary gas exchange occurs within 20s after birth:

- Compression of the thorax through the vaginal canal expels foetal lung water
- Elastic recoil, combined with cooling of the skin and mechanical stimulation (which stimulate the respiratory centre), facilitate first breath
- The rapid drop in pulmonary vascular resistance with spontaneous breathing drives the changes in the cardiac circulation
- The first three breaths establish functional residual capacity
  - Large changes in intrathoracic pressure in the first three breaths pressure drive alveolar amniotic fluid into the circulation, and establish FRC.

Neonates and Children

- Compliance
  - Neonatal chest walls are highly compliant relative to their lungs (due to both a reduced lung compliance and increased chest wall compliance), as compared to adults where lung and chest compliance is equal. Therefore elastic work of breathing is largely determined by the lungs.

- Oxygenation
  - O₂ consumption is ~10ml.kg⁻¹.min⁻¹ in neonates, and 6ml.kg⁻¹.min⁻¹ in children
  - There is a ~10% shunt after birth which contributes to a greater A-a gradient

- Ventilation
  - Obligate nose breathers
  - Increased CO₂ production due to higher metabolic rate
  - Increased minute ventilation, which is due to increased respiratory rate (25-40 breaths per minute)

- Neurological control of breathing
  - Respiratory patterns change following birth, and complete change to adult respiratory patterns may take some weeks.
  - Patterns include:
    - Periodic breathing is a slowly oscillating respiratory rate and VT
    - Periodic apnoea is intermittent apnoea interspersed with normal breathing.

- Volumes and capacities
Closing capacity is increased relative to adults, causing shunt
Functional residual capacity is unchanged
Tidal volume and dead space are unchanged

**Laryngeal anatomy**
- Large head
- Large tongue
- Large, stiff, U-shaped epiglottis
- Elevated larynx
  - Glottis is at C-3C4 (C6 in adults).
- Upper airway is narrowest at the cricoid ring (rather than the glottis).
- Trachea is shorter and narrower
  - 4-5cm long, 6mm diameter in the neonate.

**Small airways**
- Reduced bronchial smooth muscle so bronchospasm is uncommon
- Bronchioles contribute 50% of airways resistance
  - Bronchiolitis much more distressing in neonates and children.

---

**References**

2. CICM March/May 2013

Last updated 2018-07-14
Anti-Asthma Drugs

Describe the pharmacology of anti-asthma drugs.

- **Oxygen**
  Increases $\text{FiO}_2$ and improves saturation.

- **Heliox**
  Reduces specific gravity of inhaled gas mixtures, improving laminar flow.

- **$\beta_2$-agonists**
  Acts on a G-protein coupled receptor to ↑ cellular levels of adenylyl cyclase, ↑ cAMP, which results in smooth muscle relaxation and bronchodilatation.

- **Corticosteroids**
  Glucocorticoids are steroid hormones that bind to specific intracellular receptors and translocate into the nucleus, where they regulate gene expression in a tissue-specific manner. They are used in asthma as they cause:
  - Bronchodilatation by increasing bronchial smooth muscle response to circulating catecholamines
  - Decreased airway oedema by decreasing inflammatory responses and transudate production

- **Muscarinic antagonists**
  Anti-muscarinics are synthetic quaternary ammonium compounds which competitively inhibit M3 muscarinic receptors on bronchial smooth muscle, antagonising the bronchoconstrictor action of vagal impulses.

- **Methylxanthines**
  Methylxanthines are phosphodiesterase inhibitors, reducing levels of cAMP hydrolysis and increased intracellular levels of cAMP (via a different mechanism, so they are synergistic with $\beta_2$ agonists) and causing smooth muscle relaxation.

- **Ketamine**
  Increases sympathetic outflow and relaxes bronchial smooth muscle.

- **Volatile Anaesthetic Agents**
  Volatile anaesthetic agents reduces bronchial smooth muscle constriction where this is preexisting (such as asthma).

- **Leukotriene Antagonists**
  Selectively inhibits the cysteinyl leukotriene receptor, increased activity of which is involved in airway oedema and bronchial smooth muscle constriction.

References


Last updated 2019-07-18
Cardiac Anatomy

Describe the anatomy of the heart, the pericardium and coronary circulation

Echocardiographic Anatomy

The left ventricle is:

- Divided into four parts
  - From base to apex, in equal thirds along the long axis of the ventricle:
    - Basal
    - Mid-cavity
      - Identified by presence of the papillary muscles.
    - Apical
    - Apex
      - Tip of the ventricle, beyond where the cavity ends.
- Each part is divided into segments
  - Total of seventeen segments between:
    - 6 basal and mid-cavity segments
      - Inferior
        - Mid-cavity contains the postero-medial papillary muscle.
      - Infero-septal
      - Infero-lateral
      - Anterior
      - Antero-septal
      - Antero-lateral
        - Mid-cavity contains the anterolateral papillary muscle.
    - 4 apical segments
      - Inferior
      - Anterior
      - Lateral
      - Septal
    - Apical cap

Coronary Supply

The segments of the basal and mid-cavity parts are supplied by all three vessels:
In the apical part, the:

- **LAD**
  Supplies:
  - Anterior
  - Septal
- **LCx**
  Supplies:
  - Lateral
- **RCA**
  Supplies:
  - Inferior

The apical cap is supplied by the **LAD**.

---

**References**

1. Alfred Anaesthetic Department Primary Exam Tutorial Series
2. AHA 17 Segment Model. PMOD.

Last updated 2018-08-01
Coronary Circulation

Describe the anatomy of the heart, the pericardium and coronary circulation

Vascular Anatomy

Coronary Artery Anatomy

The **left main** coronary artery:

- Arises from the posterior aortic sinus superior to the left coronary cusp of the aortic valve
  - Eddy currents produced in the *sinuses of Valsalva* (outpouchings of the aortic wall) prevent the valves occluding the os of the LM and RCA during systole, so they remain patent throughout the cardiac cycle.
- The **left main** is 5-10mm long, and bifurcates to form the LAD and LCx

The **LAD**:

- Courses along the *anterior interventricular groove* to the apex of the heart
  - Here, it anastomoses with the posterior descending artery from the RCA.
- Supplies the *anterolateral myocardium* and anterior 2/3 of the interventricular septum
- Branches of the **LAD** include:
  - **Diagonal vessels**
    - Branches are named successively from proximal to distal, i.e. LADD1, LADD2, etc.
- Septal perforators

The LCx:

- Courses along the left atrioventricular groove between the LA and LV in the epicardial fat pad
- Supplies the inferolateral wall of the LV
- Gives off three obtuse marginal branches (OM₁, OM₂) which follow the left margin of the heart
- Runs in close approximation with the coronary sinus for much of its course

The RCA:

- Arises from the anterior aortic sinus, superior to the right coronary cusp of the aortic valve
- Courses vertically downwards in the right atrioventricular groove
- Supplies the RA and RV

The posterior descending artery:

- Arises from either the LCx or RCA
  - These vessels travel in opposite directions around the atrioventricular groove.
- Descends in the posterior interventricular groove before coursing along the base to anastomose with the LAD at the apex of the heart
- Is also known as the posterior interventricular artery

Coronary Dominance

Coronary dominance refers to which vessel gives rise to the PDA:

- In a right-dominant circulation the PDA is supplied by the RCA
- In a left-dominant circulation the PDA is supplied by the LCx

Additionally:

- The SA node is supplied by the RCA in 60% of individuals
- The AV node is supplied by the RCA in 90% of individuals

Venous Anatomy

- 85% of venous drainage occurs via the coronary sinus, which is formed from the cardiac veins:
  - The great cardiac vein runs with the LAD
  - The middle cardiac vein follows the PDA
  - The small cardiac vein runs with the RCA
  - The oblique vein follows the posterior part of the LA
- Most of the remainder is via anterior cardiac veins which drain directly into the RA
- A small proportion of blood from the heart is drained via the thebesian veins directly into four the cardiac chambers
  - Most into the right atrium, and least into the left ventricle. The portion of blood draining into the left side of the circulation contributes to physiological shunt.

Coronary Blood Flow

Coronary Blood Flow:

- Normal is ~250ml.min⁻¹ (~5% of resting CO)
- May increase 4x during strenuous exercise
  - Myocardial work may increase up to 9x, though as myocardial oxygen extraction is unchanged efficiency is actually improved during exercise.
CBF is dependent on:

- Coronary vascular resistance
- Coronary perfusion pressure
  The difference between aortic root pressure and the greater of RAP or intracavity pressure: i.e.
  \[
  CBF = \frac{P_{\text{Aorta}} - P_{\text{Cavity}}}{\text{CVR}} \cdot \frac{R \text{AP}}{R \text{AP}}
  \]
  - Note that the pressure gradient is usually Aorta-Cavity rather than Aorta-RA
    This is because the pressure in the ventricle acts as a Starling resistor - coronary flow is independent of RAP whilst
    \[ R \text{AP} < P_{\text{Cavity}} \]
- Heart rate
  LV CBF is affected in systole due to the changes in perfusion pressure, and compression of intramuscular vessels (causing an increase in CVR).
    - RV CBF is less affected, as the force of contraction is significantly smaller and a pressure gradient is maintained
    - Tachycardia reduces diastolic time and subsequently LV CBF

![Graph showing coronary blood flow over time]

**Control of Coronary Blood Flow**

CBF is autoregulated:

- **Myogenic autoregulation**
  This is common to many organ systems, and occurs within the coronaries.
    - Increasing transmural pressure increases the leakiness of smooth muscle membranes, depolarising them
    - Resistance increases proportionally to pressure, such that flow remains constant
- **Metabolic autoregulation**
  Anaerobic metabolism results in production of vasoactive mediates such as lactate and adenosine, which stimulate vasodilation and therefore increase flow (and oxygen delivery).
    - This is the predominant means for autoregulation in the heart
    - Typical myocardial oxygen extraction is 70% and raising this further is difficult
    Therefore, increasing oxygen supply requires an increase in blood flow.
Autonomic mechanisms also control some aspects of coronary blood flow:

- **Direct effects** include:
  - Parasympathetic and sympathetic innervation of coronary vessels, with release of ACh or NA and a decreasing or increasing coronary blood flow.
- **Indirect effects**
  - Are more important than direct effects.
  - Are related to autoregulation occurring with changing levels of myocardial work in response to parasympathetic or sympathetic stimuli.

**References**

2. CICM July/September 2007
4. Coronary Artery Graph based on Coronary Arterial Circulation - es. 2/3/2013. (Image). By Addicted04 (Own work) CC BY 3.0, via Wikimedia Commons.

Last updated 2019-07-18
Cardiac Cycle

Describe the normal pressure and flow patterns (including velocity profiles) of the cardiac cycle

The cardiac cycle:

- Describes sequence of events that occur in the heart over one beat
- Consists of two phases divided into six stages
- Typically is described as beginning in late diastole when the myocardium is relaxed and the ventricles are passively filling

Phases of the cardiac cycle:

- Diastole
  - Isovolumetric Ventricular Relaxation
  - Rapid Ventricular Filling
  - Slow Ventricular Filling
    (The cycle begins here).
  - Atrial Contraction
- Systole
  - Isovolumetric Ventricular Contraction
  - Ejection

Phases of the Cardiac Cycle

Events during each phase of the cardiac cycle are represented on Wigger’s Diagram:
Slow Ventricular Filling (Diastasis)

In slow ventricular filling:

- The AV valves are open and the semi-lunar valves are closed
- The ventricle is relaxed completely and fills slowly
  - The ventricles have been mostly filled during rapid ventricular filling and so the pressure gradient is reducing.
    - The pressure in each ventricle is almost zero
- **Arterial pressure is falling**, as it is end-diastole
- **CVP is slowly rising** as the ventricle and atria fill
  - This period occurs after the y descent.
- The ECG will show the beginnings of a P-wave at the end of this phase

Atrial Contraction

The atria contract, and remaining blood in the atria is ejected into the ventricle. This supplies 10% of the ventricular filling at rest, but up to 40% in tachycardia.

In atrial contraction:

- **Arterial pressure** is still falling
- The CVP waveform demonstrates the a wave as atrial contraction also causes blood to reflux into the SVC
- The ECG will show the PR interval

Isovolumetric Ventricular Contraction
Once the action potential passes through the AV node and bundle of His, ventricular contraction begins.

In isovolumetric contraction:

- Ventricular pressure rises, and the AV valves close
  This gives rise to the first heart sound, S1.
  - As ventricular pressure is still less than systemic vascular pressure, the semilunar valves remain closed
- Arterial pressure is still falling
  - The CVP waveform shows the C (closure) wave, as the tricuspid valve herniates back into the RA during ventricular contraction
  There is a similar spike in LA pressure as the mitral valve also bulges back into the LA.
- The ECG will show the remainder of the QRS or the start of the QT interval
  - Atrial repolarisation occurs at this stage, but is typically masked by ventricular depolarisation

Ejection

When ventricular pressure exceeds arterial pressure, the semilunar valves open and ejection occurs. Initial ejection is rapid, but as ventricular pressure falls and systemic pressure rises the gradient falls ejection becomes slower.

During ejection:

- Arterial pressure rises rapidly, and is slightly less than ventricular pressure during this stage
- The CVP waveform shows the x descent, as the shortening RV pulls the RA down, rapidly lowering CVP
- The ST segment shows on the ECG as the ventricles are fully depolarised, though the T wave may appear in late ejection

Isovolumetric Relaxation

When contraction is complete, the ventricles begin to relax. Inertia means that ejection continues for a short time.

During isovolumetric relaxation:

- The semilunar valves close
  This gives rise to the second heart sound, S2, and marks the beginning of isovolumetric relaxation.
  - This occurs when ventricular pressure falls below vascular pressure
- Arterial pressure begins to fall, interrupted by the dicrotic notch which is a brief increase in arterial pressure as the semilunar valves close
  - The v wave is visible on the CVP waveform
  Due to atria filling against closed AV valves.
  - The end of the T wave is visible on the ECG as ventricular repolarisation occurs

Rapid Ventricular Filling

Most of ventricular filling occurs in this phase. This is because in early ventricular diastole the ventricle is still relaxing and so a pressure gradient is maintained between the atria and ventricle.

During rapid ventricular filling:

- The AV valves open and ventricular filling occurs
  This occurs when atrial pressure exceeds ventricular pressure.
- Arterial pressure is falling
  - The y descent occurs when the AV valves open, causing a rapid drop in CVP as the ventricles fill
  - No electrical activity is produced - the ECG shows the TP interval
References

3. Wigger’s Diagram (with some modifications) from Wigger's Diagram. 21/3/2012. (Image). By DanielChangMD (revised original work of DestinyQx); Redrawn as SVG by xavax. CC BY 3.0, via Wikimedia Commons.

Last updated 2019-07-18
Cardiac Action Potential

Explain the ionic basis of spontaneous electrical activity of cardiac muscle cells

Describe the normal and abnormal processes of cardiac excitation and electrical activity

An action potential is a propagating change in the membrane potential of an excitable cell, used in cellular communication and to initiate intracellular processes. It is caused by altering the permeability of a membrane to different ions.

Pacemaker Potential

This pattern of electrical activity is seen in the SA and AV nodes. It has no resting state, and is continually depolarising.

![Graph of Pacemaker Potential](image)

Phases of the Pacemaker Potential

- **Phase 0**
  Begins at the threshold potential of -40mV, with a peak membrane potential of 20mV. Driven predominantly by the voltage-gated L-type (long-lasting) Ca²⁺ channels causing an influx of calcium ions.

- **Phase 3**
  Repolarisation phase, which occurs as K⁺ channels open and Ca²⁺ channels close. The nadir is called the maximum diastolic potential and is -65mV.

- **Phase 4**
  Phase 4 consists of:
  - The funny current
    A steady influx of Na⁺/K⁺ which gradually depolarises the cell.
    - Sympathetic stimulation increases the funny current, increasing the rate of depolarisation.
    - Parasympathetic stimulation increases K⁺ permeability, hyperpolarising the cell and flattens the gradient of phase 4.
Calcium current

In phase 4, this is the transient calcium current, driven by T-type calcium channels. They open when the membrane potential reaches ~50mV, also causing depolarisation.

Ventricular Action Potential

To prevent tetanic contraction (which would be bad) ventricular muscle has a long plateau prior to repolarisation, which lengthens the absolute refractory period to 250ms. The relative refractory period is 50ms.

Phases of the Ventricular Action Potential

- **Phase 0**: Depolarisation
  At the threshold potential, voltage-gated fast-\(Na^+\) channels open briefly, causing depolarisation. The membrane potential peaks at 30mV.

- **Phase 1**: Partial Repolarisation
  The closure of \(Na^+\) channels results in \(K^+\) fleeing the cell down its electrochemical gradient, causing a slight drop in voltage called partial repolarisation.

- **Phase 2**: Plateau
  L-type \(Ca^{2+}\) channels open, causing a slow inward \(Ca^{2+}\) current which maintains depolarisation and facilitates muscle contraction.

- **Phase 3**: Repolarisation
  Membrane permeability normalises, and outward potassium current returns the membrane potential to normal.

- **Phase 4**: Resting Potential
  Membrane potential returns to its resting -85mV.

Propagation of the Cardiac Action Potential

Pacemaker cells:
Are responsible for automaticity and rhythmicity of the heart
The fastest pacemaker is the focus for myocardial conduction
This is typically the SA node.
  - Should the SA node fail, the next fastest pacemaker will take over
  - This provides an element of redundancy

Conduction pathway:

- **Atrial Conduction**
  From the SA node, the impulse travels at ~1m.s⁻¹, depolarising the atria.
  - Current travels down Bachmann's Bundle, which connects the right atrium to the left atrium

- **AV node**
The AV node is the only (normal) site of connection between the atria and ventricles. AV nodal cells:
  - Transmits with a delay of 0.1s
    This allows time for atrial contraction to finish before ventricular contraction begins.
  - Have a prolonged refractory period and cannot conduct more than 220 impulses per minute
    - This period is prolonged by vagal stimulation, which increases potassium permeability and hyperpolarises the cell
    - Conversely, sympathetic stimulation increases calcium permeability and allows more rapid transmission
  - Conducts via three pathways:
    - Bachmann Pathway
      Also conducts to the LA.
    - Wenckebach pathway
    - Thorel pathway

- **Ventricular Conduction**
  From the AV node, the signal propagates:
  - Initially via the Bundle of His to the right and left bundles
  - Secondly via the Purkinje fibres which conduct at 1-4m.s⁻¹
    Purkinje fibres have a long refractory period, and spontaneously depolarise with an intrinsic rate of 30-40 bpm.
  - Lastly, ventricular muscle is depolarised
    Endocardium, papillary muscle and septum contract first, followed by apex, followed by the chambers.

**Autonomic Control**

- **Parasympathetic Innervation**
  - SA node by the right vagus
    There is continual PNS input ("Vagal tone") via inhibitory ACh GPCR, reducing the SA node from its intrinsic rate of 90-120bpm to a more sedate 60-100bpm.
  - AV node by the left vagus
  - The atria are innervated by parasympathetic neurons, whilst the ventricles are only minimally innervated
    PNS stimulation therefore has little effect on inotropy, but does affect chronotropy.
    - PNS stimulation may have no direct effect on inotropy, instead acting indirectly via changes in chronotropy

- **Sympathetic Innervation**
  - SNS activity causes release of noradrenaline (at post-ganglionic synapse) and adrenaline from adrenal medulla which stimulate cardiac β₁ receptors causing:
    - Positive chronotropy at the SA node
    - Positive inotropy at ventricular muscle
    - Positive lusitropy
    - Shorter action potential duration (due to opening of rectifying K⁺ channels
    - Increased AV conduction
Cardiac Transplant

The transplanted heart has no vagal/parasympathetic innervation but still expresses $\beta_1$ receptors, so it:

- Defaults to a resting heart rate of ~100bpm
- Becomes highly preload dependent as it cannot respond quickly to changes in SVR
- Not responsive to parasympatholytics (atropine, glycopyrrolate) or ephedrine (as this is indirectly-acting) to increase chronotropy - isoprenaline may be used
- Gradual response to demands in exercise (lacks local SNS innervation, but will still respond to circulating catecholamines)
- Increased sensitivity to catecholamines due to increased expression of $\beta_1$ receptors

References


Last updated 2019-07-18
Determinants of Cardiac Output

Define the components and determinants of cardiac output

Cardiac output a function of Heart Rate (HR) and Stroke Volume (SV):
\[ CO = HR \times SV. \]

- **Heart rate** is fairly intuitive
- **Stroke volume** is defined as the difference between ESV and EDV, i.e. \( SV = EDV - ESV \)

Stroke volume is a function of three factors:
- Preload
- Afterload
- Contractility

- Preload and afterload have *almost as many definitions as there are textbooks*
- For the purpose of the exam, it's good to have both a laboratory and a clinical definition
- These definitions are those which have appeared in old examiner reports, or given to me by cardiac anaesthetists

**Preload**

*Preload is defined as the myocardial sarcomere length just prior to contraction.*

- As this is not measurable without removing the heart and cutting it into tiny pieces, clinically it is usually **approximated by**
  - **EDV** or, less appropriately, by **EDP**
    - **EDV** is typically calculated on echocardiography
    - **EDP** is typically measured using a CVC or PAC
      - CVP \( \approx \) RVEDP
      - PCWP \( \approx \) LVEDP

**Determinants of Preload**

Preload is a function of:

- **Venous Return**
  - Intrathoracic Pressure
  - MSFP
    - Venous compliance
      - A decrease in venous compliance will increase LVEDP.
    - Volume state
- **Ventricular compliance**
  - Reduced in diastolic dysfunction.
- **Pericardial compliance**
- **Valvular disease**
  - AV valve disease will *impair* preload
  - Semilunar valve disease will *increase* preload
- **Atrial kick**
- **Wall thickness**
  - Increased ventricular wall thickness decreases preload.
    - HOCM/Hypertrophy
Preload and the Respiratory Cycle

- Negative intrathoracic pressure causes **RAP** and **PCWP** to fall
- This increases RA filling, so and **RVEDP** and **RVEDV** increase relative to the pleural pressure (though absolute pressure is still low)
- LV effects are more variable
  - Negative intrapleural pressures:
    - Increase LV transmural pressure
      - This impairs ejection.
    - Cause bowing of the interventricular septum into the LV
      - This reduces **LVEDV**.

Frank-Starling Mechanism

- The **Frank-Starling Law of the Heart** states that the **strength of cardiac contraction is dependent on initial fibre length**
- At a cellular level, additional stretch increases:
  - The number of myofilament crossbridges that can interact
  - Myofilament **Ca**\(^{2+}\) sensitivity
- This law is represented by the **ventricular function curve**
  - Plot of preload against stroke volume (or cardiac output, assuming a constant heart rate).
  - Right shift of the curve demonstrates negative inotropy
  - Left shift of the curve demonstrates positive inotropy

![Ventricular Function Curve](image)

- The failing ventricle:
  - In cardiac failure, the ventricle becomes overstretched
    - This reduces the number of overlapping crossbridges, reducing contractility.
  - This is limited in the acute setting by constriction of the pericardium, which prevents excessive ventricular dilation

Afterload
Afterload is the sum of forces, both elastic and kinetic, opposing ventricular ejection

- This definition is a bit wordy but avoids using the words “resistance” and “impedance”, which are strictly defined in physics (and crudely applied in medicine), and may be leapt on by the cruel examiner

Determinants of Afterload

Afterload is equal to **ventricular wall stress**, which is given by the equation:

$$\theta \propto \frac{P \cdot r}{T}$$

where:

- $\theta$ is ventricular wall stress
- $P$ is ventricular transmural pressure
- $r$ is ventricular chamber radius
- $T$ is ventricular wall thickness

Each of these factors are in turn influenced by:

- **Ventricular transmural systolic pressure**
  Transmural pressure is the difference between intrathoracic pressure and the ventricular cavity pressure during ejection.
  - Intrathoracic Pressure
    Negative intrathoracic pressure will increase afterload, as the ventricle has to generate a greater change in pressure to achieve ejection.
    - **PEEP** reduces LV afterload
    - Negative-pressure ventilation with a high work of breathing increases afterload
      This is why APO deteriorates - increased work of breathing increases LV afterload and worsens LV failure, increased pulmonary oedema, causing increased work of breathing...

- **Ventricular cavity pressure**
  To facilitate ejection, the ventricle must overcome:
  - **Outflow tract impedance**
    - Valvular disease
      - e.g. aortic stenosis
    - HOCM
  - **Systemic arterial impedance**
    Determined by resistance (SVR), inertia, and compliance:
    - Determinants of resistance are stated in the Poiseuille Equation:
      $$R = \frac{8 \cdot \eta \cdot l}{\pi \cdot r^4}$$
      where:
      - $\eta$ = Viscosity
        Affected by haematocrit (e.g. increased in polycythaemia)
      - $l$ = Vessel length
        Essentially fixed.
      - $r$ = Vessel radius
        - Greatest determinant
        - Function of degree of vasoconstriction of resistance vessels
  - **Inertia**
    - Given by the mass of blood in the column
    - Affected by heart rate
  - **Arterial compliance**
    Decreased arterial compliance increases afterload.
    - During ejection, the aorta and large arteries distend, reducing peak systolic pressure (impedance to
further ejection)
  - Decreased arterial compliance increases the change in pressure for any given volume, increasing afterload during ejection
  - Decreased arterial compliance increases the speed of propagation of reflected pressures waves returning to the aortic root
    - Wave arrival in diastole augments coronary blood flow
    - Wave arrival during systole further increases afterload
  - In diastole the arteries recoil and blood pressure and flow are maintained - the Windkessel effect.

- Ventricular chamber radius
  - End-Diastolic Volume
    Increased EDV increases ventricular radius and therefore wall tension.

- Myocardial wall thickness
  Increasing wall thickness (seen clinically as ventricular hypertrophy) decreases afterload by sharing wall tension (the product of pressure and radius) between a larger number of sarcomeres.

**Contractility**

Contractility describes the factors other than heart rate, preload, and afterload that are responsible for for changes in myocardial performance.

**Determinants of Contractility**

Contractility is primarily dependent on intracellular Ca\(^{2+}\). Determinants include:

- Drugs
- Disease
  - Ischaemia
    Reduced ATP production secondary to hypoxia, which impairs sarcoplasmic reticulum Ca\(^{2+}\) function. Further exacerbated by intracellular acidosis from anaerobic metabolism.
  - Heart Failure
    Impaired contractility reserve, i.e. minimal increase in contractility with sympathetic stimulation.
      - Reduced peak Ca\(^{2+}\) and sarcoplasmic reticulum uptake of Ca\(^{2+}\)
- Autonomic Tone
- Bowditch Effect
  Contractility improves at faster heart rates. This is because the myocardium does not have time to remove calcium, so it accumulates intracellularly.
- Anrep Effect
  Contractility increases as afterload increases.

**Measuring Contractility**

- As with the other determinants of cardiac output, there has been some difficulty in developing measurable indices for contractility
- All measures of contractility are affected by preload or afterload to some extent

\[
\frac{\Delta P}{\Delta t_{\text{max}}}
\]

The rate of rise of LVP, assuming a constant preload and afterload
- This index is preload dependent but afterload independent
- Typically, the \(\frac{\Delta P}{\Delta t_{\text{max}}\text{ max}}\) in isovolumetric ventricular contraction is used
A greater rate of rise indicates a more forceful contraction
Measurement requires LV catheterisation

- **End-Systolic Pressure-Volume Relationship**
  - Uses the ventricular Pressure-Volume Relationship
  - Line plotted at the tangent to the curve from the end-systolic point (when isovolumetric ventricular relaxation begins)
    - The steeper the gradient the greater the contractility

- **Ejection Fraction**
  Most common method used clinically is *ejection fraction*:

  \[
  EF \% = \frac{SV}{EDV} \times 100 = \frac{EDV - ESV}{EDV} \times 100
  \]

---

**Footnotes**

- The use of wall stress for preload and afterload comes from the Cardiovascular Haemodynamics text, but is not used in the CICM texts
- [This site](#) has a nice overview of wall tension, and the relationship of pressure to radius
- [This article](#) discusses the wall stress definition for preload and afterload
- Changes with ventilation are described with pretty graphs [here](#)

---

**References**

2. Deranged Physiology - Haemodynamic changes during mechanical ventilation
5. ANZCA July/September 2006

Last updated 2019-07-18
Venous Return

Define the components and determinants of cardiac output

The venous system has two key cardiovascular functions:

- Blood reservoir
  - Contains 65% of blood volume.
- Conduit for return of blood to the heart

Venous return is the rate at which blood is returned to the heart (in \( \text{L.min}^{-1} \)). At steady state, venous return is equal to cardiac output, and can be expressed as:

\[
VR = \frac{MSFP - RAP}{RVR},
\]

where:

- \( VR \) is venous return
- \( MSFP \) is the mean systemic filling pressure
  - This is the mean pressure of the circulation when there is no flow. It is an indicator of circulatory filling, and is a function of circulating volume and vascular compliance.
  - Normal mean systemic filling pressure is \(~7\text{mmHg}~\)
- \( RAP \) is the right atrial pressure
  - An elevated \( RAP \) reduces venous return.
- \( RVR \) is the resistance to venous return

This relationship can be expressed graphically:

- When venous return is 0, the measured right atrial pressure is an indication of mean systemic filling pressure
- Alterations to circulating volume and compliance affect both venous return and mean systemic filling pressure
Factors Affecting Venous Return

Venous return will be altered by any of the variables in the above equation:

- **MSFP**
  - Volume
    - e.g. Haemorrhage, resuscitation.
  - Compliance
- **RAP**
  - Respiratory pump
    - Negative intrathoracic pressure reduces RAP, improving venous return.
  - Positive pressure ventilation
  - Pericardial compliance
    - Constriction
    - Tamponade
- **Resistance to Venous Return**
  - Posture
  - Vascular compression
    - Obesity
    - Pregnancy
    - Laparoscopy
- **Other factors affecting venous return**
  - Skeletal muscle pump
    - Contraction of leg muscles in combination with an intact venous system propels blood back towards the heart.

Interaction between Venous Return and Cardiac Function Curves

Guyton's curve can be superimposed on Starling's curve to examine the interaction between venous and cardiac function over a range of conditions:
References


Last updated 2019-07-18
Myocardial Oxygen Supply and Demand

Describe myocardial oxygen demand and supply, and the conditions that may alter each

- Myocardial oxygen supply is a function of coronary blood flow
- Myocardial oxygen demand is determined by myocardial work
- Myocardial ischaemia occurs when demand exceeds supply

Myocardial Oxygen Supply

- Myocardial oxygen supply is dependent on:
  - Coronary artery flow
  - Oxygen content of blood
  - Oxygen extraction

- Functionally, coronary artery flow is the determinant. This is because:
  - Oxygen content in individuals without pulmonary disease is maximal
  - Resting myocardial oxygen extraction is near-maximal (~70%)
    - This high ER makes the heart less tolerant of anaemia than organs with a low ER.

- Therefore coronary blood flow is the limiting factor
- Coronary blood flow is given by the equation:

\[
CBF = \frac{P_{\text{Aortic Root}} - P_{\text{Cavity}}}{\text{Coronary Vascular Resistance}}
\]

  - Aortic root pressure is the driving pressure for coronary flow
  - Cavity (ventricular) pressure acts as a Starling resistor for coronary flow
    - Note that if RAP exceeds cavity pressure, RAP will be the pressure opposing coronary flow (due to downstream pressure at the coronary sinus)
    - Note that cavity and aortic root pressure change throughout the cardiac cycle, therefore:
      - The flow to each ventricle is different during the cardiac cycle
      - The left ventricle is best perfused in diastole
      - Therefore heart rate is an important determinant of coronary blood flow, as tachycardia will decrease coronary blood flow

- Flow to each ventricle is a function of how relationships change over the cardiac cycle

Left Ventricular Coronary Blood Flow:

Right Ventricular Coronary Blood Flow:
Myocardial Oxygen Demand

Normal myocardial oxygen consumption (MVO₂) is 21-27 ml.min⁻¹. The three major determinants are:

- **Heart rate**
  A change in heart rate will change the number of tension-generating cycles, causing a proportional change in MVO₂.

- **Contractility**
  Refers to the rate of tension development as well as its magnitude. Changing \( \frac{\Delta P}{\Delta t} \) will change MVO₂.

- **Ventricular wall tension**
  Ventricular wall tension is pressure work, or the work done by the ventricle to generate pressure but not to eject volume.
  - Wall tension is given by the Law of Laplace
    \[
    \text{Wall Tension} = \frac{P'r}{2}, \text{ where:}
    \]
    - \( P \) = Pressure during contraction
    - \( r \) = Radius
  - Wall tension is therefore a function of:
    - **Afterload**
      Increasing afterload will increase the pressure during contraction.
    - **Preload**
      Increasing preload will increase radius, but to a lesser extent than increasing afterload.
      This is because volume and radius are not directly proportional

Minor determinants of myocardial work are:

- **External work**
  External work can also be thought of as volume work, or the energy expended to eject blood from the ventricle.
  - This is encompassed by the area enclosed by the pressure-volume loop
    - Conversely, internal work is defined as the work required to change the shape of the ventricle and prepare it for ejection
      - On the pressure-volume loop internal work is represented by a triangle between the point of 0 pressure and volume, the end systolic point, and the beginning of rapid ventricular filling.
    - This is a minor determinant because the majority of ventricular work is generating the pressure required to eject blood, not actually move volume
    - External work is of greater importance at high CO
    - External work is used to calculate cardiac efficiency, given by the equation:
      \[
      \text{Cardiac Efficiency} = \frac{\text{External Work}}{\text{Myocardial O}_2 \text{ Consumption}}
      \]

- **Basal oxygen consumption**

\[
\text{Basal oxygen consumption} = \frac{1}{2} - 1
\]
Basal oxygen consumption (~8ml.min\(^{-1}\).100g\(^{-1}\)) comprises ~25% of MVO\(_2\).

References

2. Leslie RA, Johnson EK, Goodwin APL. Dr Podcast Scripts for the Primary FRCA. Cambridge University Press. 2011.

Last updated 2017-10-04
Pressure-Volume Relationships

Describe the pressure-volume relationships of the ventricles and their clinical applications.

Left Ventricular P-V Loop:

- Plot of left ventricular volume versus pressure.
- Time is not directly demonstrated on this graph, but the stages of the cardiac cycle can be inferred:
  - A-B is isovolumetric relaxation
    Ventricular pressure is less than aortic pressure but greater than atrial pressure, so both mitral and aortic valves are closed.
  - B-C is rapid and slow ventricular filling, followed by atrial systole
    Atrial systole is sometimes demonstrated by a sharp ‘bump’ towards C, as ventricular pressure will briefly rise out of proportion to ventricular volume.
  - C-D is isovolumetric contraction
    The ventricle contracts. As ventricular pressure is greater than atrial pressure but less than aortic pressure, the mitral valve closes (point C) and the aortic valve remains closed. Pressure increases without a change in volume.
    - This slope of this line is known as the \( \frac{\Delta P}{\Delta V} \), and is an index of contractility.
  - D-A is ventricular ejection
    When ventricular pressure exceeds aortic pressure, blood is ejected into the aorta and ventricular volume decreases.
  - The slope of the line B-C gives the elastance of the ventricle.

This is also known as the End-Diastolic Pressure Volume Relationship (EDPVR), and is often (erroneously) referred to as ventricular compliance.

- Elastance of the ventricle increases as it is filled
  This is demonstrated by the dashed line.
  - The ventricle only overfills at high filling pressures.
  - Increased elastance (such as in diastolic dysfunction) is demonstrated by an increased slope of this line, such that ventricular pressure will be higher at any given volume.
    Both ventricular and arterial elastance are low in normal circumstances (a state known as ventricular-arterial coupling), as this allows the ventricle to achieve a wide range of volume transfers in ejection with minimal change in filling pressure.
    - The horizontal distance between point B (ESV) and C (EDV) give the stroke volume.
  - Ejection fraction can then be calculated.
  - Preload is given by the EDV.
  - Afterload is:
    - Technically given by the pressure-volume relationship throughout the entirety of ejection.
      i.e. the slope D-A.
This comes from La Place’s law:

$$Afterload = \frac{P_{ejection} \times Radius_{ejection}}{2 \times Wall \, Thickness}$$

- Usually assumed to be given by the slope of a line drawn from the EDV (on the x-axis) to the end-systolic point (point A). This is also known as the arterial elastance line.
- The gradient of the arterial elastance line can be worked out from the loops.
- This is different from the above formula because it only considers the pressure-volume relationship at end-systole, not throughout the entirety of ejection.
- $E_A$ is a good substitute for afterload because it is relatively independent of preload and contractility, and will vary with changes in afterload.
  - i.e. For a given stroke volume, an increase in $E_A$ leads to an increase in SBP. Similarly, if the ventricle is unable to maintain a given stroke volume as $E_A$ increases, then SBP will fall.

- Contractility is given by the slope of the end-systolic pressure-volume relationship.
  - Also known as elastance at end-systole, or $E_{es}$, and is given by the tangent to the curve at end-systole.
  - This measurement is not entirely independent of other factors, as it is influenced by afterload.

### Basic Pressure-Volume Loops

These loops:
- Show isolated changes to one factor only
- Are not accurate of real-world physiology

In reality:
- Changing one factor will influence other factors
- These values change beat-to-beat

#### Left Ventricular P-V Loop - Increased Preload:

- EDV is increased, by definition
- The slope of the ESPVR remains unchanged (as contractility is unchanged)
- The slope of the afterload line ($E_{oa}$) is unchanged (as afterload is unchanged), but it is right-shifted due to the increased end-diastolic volume
- ESV is increased, though less than EDV, such that stroke volume increases

#### Left Ventricular P-V Loop - Increased Afterload:
EDV is unchanged (as preload is unchanged)
The slope of the ESPVR remains unchanged (as contractility is unchanged)
The slope of the afterload line \(E_{iva}\) has increased, but its x-intercept is unchanged
Note that the pressure-volume relationship throughout ejection is also steeper, and diastolic pressure has increased.
ESV is increased, causing a reduction in stroke volume

**Left Ventricular P-V Loop - Increased Contractility:**

EDV is unchanged (as preload is unchanged)
The slope and x-intercept of the afterload line \(E_{iva}\) is unchanged (as afterload is unchanged)
The slope of the ESPVR has increased, though its x-intercept is the same
ESV is decreased, causing an increase in stroke volume

**Advanced Pressure Volume Loops**

The easiest way to approach more complicated pressure-volume loops is to address each of the basic factors before trying to draw the curve:

- How is preload changed?
- How is afterload changed?
- How is contractility changed?
- How are isovolumetric contraction and isovolumetric relaxation changed?

These show the loop for the primary physiological change, without compensatory responses:

**Left Ventricular P-V Loop - Aortic Stenosis:**
Preload is increased due to the higher ESV, as the ventricle starts filling from a higher point.

Outflow tract impedance increases ventricular wall stress and therefore afterload.

This leads to the decrease in stroke volume.

Contractility is unchanged.

Left Ventricular P-V Loop - Aortic Regurgitation:

Preload is dramatically increased as the ventricle fills from both the aorta and atria during diastole.

Afterload is increased due to the greater wall stress during ejection.

Contractility is unchanged.

There is no true isovolumetric relaxation, as the ventricle will begin to fill from the aorta at the completion of ejection.

Diastolic pressure is decreased and so the period of isovolumetric contraction is brief.

Left Ventricular P-V Loop - Mitral Stenosis:

Preload is reduced due to the increased gradient across the mitral valve.

The effect of this is heart rate dependent, and will worsen as heart rate increases.

Afterload is unchanged.

Afterload may fall due to the reduction in ventricular wall stress.
• Contractility is unchanged
• ESV decreases (due to the reduced preload), though less than EDV, such that stroke volume is reduced

Left Ventricular P-V Loop - Mitral Regurgitation:

- Preload is increased as the regurgitant volume increases left atrial pressure and therefore ventricular filling pressure
- Afterload is reduced as blood is ejected into the low-pressure atrial system
- Contractility is unchanged
- There is no true isovolumetric contraction phase as blood is ejected into the atria while ventricular pressure exceeds atrial pressure
- There is no true isovolumetric relaxation phase, as once atrial pressure exceeds ventricular pressure the ventricle will begin to fill
- Apparent stroke volume is increased due to the large difference between EDV and ESV, however effective stroke volume is reduced as only a portion of this is forward flow

Right Ventricular P-V Loop:

- The right ventricular curve is very different to the left ventricular curve
- RV preload is increased relative to LV preload
  Note that stroke volume is the same (as both sides should have the same cardiac output).
- RV afterload is dramatically reduced due to the low-resistance pulmonary circulation
  • Much of the RV ejection occurs after systolic pressure is reached
  • The right ventricle is very sensitive to changes in afterload
- Contractility is reduced
  Right heart contractility is partially dependent on coordinated contraction with the LV (particularly the septum), and therefore is decreased with LV systolic failure or conducting system disease (such as bundle branch block).

Footnotes
The Khan Academy series Changing the Pressure-Volume Loop is a fantastic introduction to the topic.

References

3. Desai, R. Arterial elastance (Ea) and afterload. Khan Academy.
4. Redington, AN. Cardiopulmonary and Right–Left Heart Interactions. Thoracic Key.

Last updated 2019-07-18
Cardiac Reflexes

Describe the cardiac reflexes

Cardiac reflexes are fast-acting reflex loops between the CVS and CNS which contribute to the maintenance of cardiovascular haemostasis.

They include:

- **Baroreceptor reflex**
  Aortic arch and carotid sinus reflexes.

- **Bainbridge reflex**
  Atrial stretch receptor reflexes.

- **Chemoreceptor reflex**
  Decreased PaO$_2$ < 50mmHg or decreased pH sensed by peripheral chemoreceptors causes subsequent tachycardia and hypertension.

- **Cushing reflex**
  Brainstem compression causes ischaemia of the vasomotor centre leading to Cushings' Triad:
  - Hypertension
    May have a wide pulse pressure.
  - Bradycardia
    Due to baroreceptor response from hypertension.
  - Irregular respirations

- **Bezold-Jarisch reflex**
  Stimulation of C fibres of the vagus nerve in the cardiopulmonary region.
  - This causes:
    - Significant bradycardia
    - Hypotension
    - Apnoea, followed by rapid shallow breathing. These fibres can be stimulated by a number of substances, including:
      - Capsaicin
      - Serotonin
      - Those produced in myocardial ischaemia

- **Oculocardiac reflex**
  Pressure on the globe or traction on ocular muscles causes a decrease in heart rate. This is mediated by the:
  - Trigeminal nerve (afferent limb)
  - Vagus nerve (efferent limb)
  Increased vagal tone reduces SA nodal activity.

References

1. CICM September/November 2013
3. Open Anaesthesia - Oculocardiac reflex: afferent path

Last updated 2019-07-18
Starling Forces

Describe the essential features of the micro-circulation including fluid exchange (Starling forces) and control mechanisms present in the pre- and post-capillary sphincters.

Interstitial fluid is an ultrafiltrate of plasma, with the net filtration pressure determined by the net effect of opposing hydrostatic and oncotic pressures:

\[ NFP = P_{\text{Capillary Hydrostatic}} - P_{\text{Interstitial Hydrostatic}} - (P_{\text{Capillary Oncotic}} - P_{\text{Interstitial Oncotic}}) \]

These four variables are known as Starling’s forces.

Actual fluid movement is (of course) more complicated. Hydrostatic pressure falls along the capillary, and movement of solute and water are affected by other factors. Some of these are described by the:

- **Reflection coefficient** ($\sigma$)
  This describes the fact that a small amount of protein leaks from the capillary, slightly increasing interstitial oncotic pressure and slightly decreasing capillary oncotic pressure. It is dependent on the interstitial protein content, and has a value between 0 and 1.

- **Filtration coefficient** ($K_f$)
  Encompasses membrane permeability (to water) and membrane surface area. Varies between tissues:

The Starling Equation becomes:

\[ \text{Net Fluid Movement} = K_f(P_{CH} - P_{IH} - \theta (P_{CO} - P_{IO})) \]

**Typical Values for Pressures (mmHg)**

<table>
<thead>
<tr>
<th></th>
<th>Arteriolar end</th>
<th>Venous end</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capillary hydrostatic pressure</td>
<td>25</td>
<td>10</td>
</tr>
<tr>
<td>Interstitial hydrostatic pressure</td>
<td>-6</td>
<td>-6</td>
</tr>
<tr>
<td>Capillary oncotic pressure</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Interstitial oncotic pressure</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

**Organ-Specific Values**

In the glomerulus:

- Reflection coefficient is close to 1 due to the impermeability of the glomerulus to protein
- $K_f$ is high due to both high permeability and a large surface area.
- Hydrostatic pressure is high
- Glomerular oncotic pressure is essentially 0

In the liver:

- Reflection coefficient is close to 0 in hepatic sinusoids as they are very permeable to protein

In the lungs:

- Reflection coefficient of ~0.5 in the lungs due to significant leak of protein
  - Protein leak decreases as interstitial oncotic pressure rises, limiting further oedema formation
- The oncotic pressure gradient is small, and favours reabsorption
- Hydrostatic pressure gradient is small, but favours extravasation of fluid
  - Interstitial hydrostatic pressure becomes more negative closer to the hilum, drawing fluid into the pulmonary lymphatics

**Causes of Oedema**

Oedema can be localised or generalised, and in both cases caused by:

- **Increased Filtration Pressure**
  Occurs when capillary hydrostatic pressure exceeds interstitial hydrostatic pressure. Causes:
  - Increased Venous pressure
    This includes an increase in CVP:
    - CCF
    - TR
    - Increased venoconstriction
    - Increased MSFP
  - Impaired venous return
    - Obstruction
    - Respiratory muscle pump
    - Skeletal muscle pump
  - Positioning

- **Decreased Oncotic Pressure Gradient**
  - Decreased plasma protein
    - Hepatic failure
    - Critical Illness
  - Increased interstitial oncotic pressure
    - Mannitol/starch extravasation

- **Increased capillary permeability**
  - Inflammatory proteins
    - Substance P
    - Histamine
    - Kinins

- **Inadequate Lymph Flow**

**References**

2. Brandis, K. Starling's Hypothesis. Anaesthesia MCQ.
3. ANZCA August/September 2001

Last updated 2017-09-22
Variations in Blood Pressure

Describe the physiological factors that may contribute to pulse variations in blood pressure

Blood pressure is not uniform throughout the circulation. Ventricular ejection generates two waves:

- **A blood flow wave**
  - Travels at ~20cm.s\(^{-1}\)
- **An arterial pressure wave**
  - Distends the elastic walls of the large arteries during systole, which then recoil during diastole to facilitate continual blood flow. This is the Windkessel effect.
  - This wave travels at 4m.s\(^{-1}\)
  - This is what is felt when pulses are palpated, and what is seen on the arterial line waveform

Key pressures measured are:

- **Systolic blood pressure**
  - Maximal pressure generated during ejection.
  - Determined by:
    - Stroke volume
    - Systolic time
    - Arterial compliance
    - Reflected pressure wave
  - Relevant for:
    - Bleeding
      - Clot disruption
    - Aneurysmal wall pressure

- **Diastolic pressure**
  - Pressure exerted by the circulation upon the aortic valve.
  - Determined by:
    - Circulatory compliance
    - Circulating volume
    - Aortic valve (in)competence
  - Relevant for:
    - Coronary perfusion

- **Mean arterial pressure**
  - Average pressure in the circulation throughout the cardiac cycle, as measured by the area under the curve of the arterial line waveform.
  - Determined by:
    - Systolic blood pressure
    - Diastolic blood pressure
    - **Heart rate**
      - Increasing HR will tend to increase MAP, as overall systolic time (and therefore time spent at higher pressure) is increased.
      - Shape of the arterial waveform/diastolic runoff
      - The slow decrease in pressure after peak systolic pressure represent elastic recoil of large arteries, increasing the pressure driving blood into the peripheral circulation. A longer diastolic runoff period leads to a larger area under the curve, and a higher MAP.
  - Relevant for:
    - Organ perfusion
Changes by Site of Measurement

Measured pressure changes predictably at more distal sites:

- All gradients are increased
  Arterial upstroke and falloff are both steeper.
- The SBP increases
- DBP decreases
- MAP is constant
- The dicrotic notch occurs later and becomes less sharp
  This occurs due to reflections in arterial pressure waves.

Respiratory Variation

Ventilation causes variation in peak systolic pressure due to dynamic changes in cardiac loading conditions:

- **Negative pressure respiration** (i.e. regular breathing) generates a negative intrathoracic pressure during inspiration
  Leads to increased VR, but also pooling of blood in the pulmonary circulation and relative underfilling of the LV, leading to a decrease in SV and peak systolic blood pressure.
- **Positive pressure ventilation** causes the reverse
  Increased intrathoracic pressure during inspiration results in a decreased venous return but increases LV filling via compression of the pulmonary circulation.
- When this change is >10mmHg, it is known as **pulsus paradoxus**
- The magnitude of this effect varies with:
  - Magnitude of intrathoracic pressure change
  - Large changes in intrathoracic pressure cause correspondingly larger changes in ventricular filling.
  - Other factors affecting cardiovascular function
    - Preload
      - Volume state
    - Compliance
      - Pericardial compliance
        - Constriction
        - Tamponade
      - Cardiac compliance
        - Diastolic dysfunction
    - Afterload
      - PE
      - Raised intrathoracic pressure
        - PEEP
        - Tension PTHx
  - These differences can be measured:
    - Qualitatively
      - By looking at respiratory swing on an arterial line or plethysmograph; or by palpation.
    - Quantitatively
      - Using pulse pressure or stroke volume variation.

Pulse Pressure Variation

Describes the variation in pulse pressure over the course of a respiratory cycle. Pulse pressure variation is:

- Mathematically defined as:
Therefore, it is calculated as a percent

- Used as an indicator of fluid responsiveness
  - Patients higher on the Frank-Starling curve will have less change in stroke volume with an increase in preload, and therefore:
    - Reduced PPV
    - Be less fluid responsive
  - A PPV of >12% suggests volume responsiveness.
  - Note that this does not necessarily mean a fluid responsive patient needs fluid.

- Reliant on several assumptions:
  - Regular sinus rhythm
    - Irregular heart rates (particularly AF) lead to significant alterations in ventricular filling and therefore pulse pressure, independent of the respiratory cycle.
  - Controlled mechanical ventilation
    - No spontaneous efforts.
  - Adequate tidal volumes
    - Must be >8ml.kg\(^{-1}\).
  - Normal chest wall compliance
    - Requires a closed chest.

### Stroke Volume Variation

**SVV** is:

- Alternately defined as:
  - The percent change in stroke volume during inspiration and expiration over the previous 20 seconds
  - Variation of beat-to-beat SV from the mean value over the previous 20 seconds

\[
SVV = \frac{SV_{\text{max}} - SV_{\text{min}}}{SV_{\text{mean}}} \times 100
\]

- Calculated by specialised devices from an invasive arterial waveform Calculation incorporates:
  - Pulse pressure
  - Vascular compliance
    - Estimated from nomograms based on patient age, gender, height, and weight.
  - Vascular resistance
    - Estimated from arterial waveform shape.
- An alternative to PPV in measuring fluid responsiveness
  - Relies on similar principles.
- Probably less specific but more sensitive than PPV for identifying fluid responders

### Circulatory Factors

Changes in circulatory function:

- **Inotropy**
  - The rate of systolic upstroke is related to \( \frac{\Delta P}{\Delta t} \), and therefore contractility.

- **SVR**
  - The gradient between the peak systolic pressure and the dicrotic notch gives an indication of SVR. E.g., a steep downstroke suggests a low SVR, as the pressure in the circulation rapidly falls when ejection ceases.

- **Preload**
A beat-to-beat variation is seen with the respiratory cycle, due to the change in preload occurring with changes in intrathoracic pressure.

Pathological Changes

Some pathological causes include:

- **Aortic Stenosis**
  
  Causes a reduction in:
  
  - Pulse pressure
    
    Due to reduced stroke volume.
  
  - Gradient of upstroke
    
    Due to reduced stroke volume.

- **Aortic Regurgitation**
  
  - Wide pulse pressure
    
    Combination of:
    
    - Increased SBP due to the increased force of ejection due to increased preload (Starlings Law), which occurs due to high ESV
    
    - Decreased DBP due to part of the stroke volume flowing back into the ventricle through the incompetent valve

References


Last updated 2019-07-18
Pulmonary Circulation

Outline the anatomy of the pulmonary and bronchial circulations
Describe the physiological features of the pulmonary circulation and its resistance
Understand the differences between the pulmonary and systemic circulation

The pulmonary circulation is:

- A low-pressure, high-flow, high-pulsatility circulation
- Supplied by the pulmonary trunk (pressure 25/8 mmHg), driven by the RV (pressure 25/0 mmHg)
  - Arteries and veins run with the bronchi as far as the terminal bronchioles, dividing at the same points
  - Beyond this, they form a capillary bed so thin it is essentially sheet of flowing blood punctuated by alveoli

The bronchial circulation:

- Arises from the systemic circulation, and supplies blood to the conducting zone of the lung
- A third drains back to the systemic circulation
- The remainder drains into the pulmonary vessels - this is a physiologic shunt
  - Supply to tumours is predominantly from the bronchial circulation (rather than the pulmonary circulation) as these vessels respond to angiogenic factors.

Differences between Pulmonary and Systemic Circulations

Blood Pressure

Pulmonary arterial pressure is 25/8 mmHg (MAP 15 mmHg) compared to 120/80 mmHg (MAP 100 mmHg) in the systemic circulation. This is because the systemic circulation must:

- Regulate flow to different organs at different times
  - It therefore contains resistance vessels which allow it to allocate cardiac output accordingly.
- Maintain flow to organs far above the heart

Conversely, the pulmonary circulation must:

- Accept the entirety of cardiac output, with little capacity to regulate flow (hypoxic vasoconstriction being the exception)
- Minimise extravasation of fluid
  - As per Starlings Law, fluid movement out of the capillary is given by the difference in hydrostatic gradients and oncotic gradients
  - The net oncotic gradient is small (but favours reabsorption), however the pulmonary interstitium has no hydrostatic pressure
  - Increased pulmonary capillary pressure therefore causes extravasation of large volumes of fluid
- Consequently, pulmonary vessels are thin walled and contain minimal smooth muscle
- This makes the pulmonary circulation highly compliant - the volume of blood is able to change substantially with minimal change in pressure

Pulmonary Vascular Resistance

Vascular resistance follows Ohms law, i.e.:

\[ Vascular\ Resistance = \frac{P_{In} - P_{Out}}{Flow} \]
Pulmonary vascular resistance is \( \approx 1/10^{th} \) that of the systemic circulation.

- This is because the pressure drop across the pulmonary circulation is 10mmHg (MPAP - LAP), \( \approx 1/10^{th} \) that of the systemic circulation, and flow is the same.

Determinants of pulmonary vascular resistance are:

- **Pulmonary Artery Pressure**
  Increased PAP causes a decrease in PVR. This occurs because:
  - Previously closed pulmonary capillaries are recruited when their critical opening pressure is reached. This is more important when MPAP is low.
  - Vessels distend at higher pressures. This is more important when MPAP is high.

- **Lung volume** Lung volume has a variable effect on PVR.
  - At large lung volumes:
    - Resistance in large extra-alveolar vessels decreases as the vessels are pulled opening by distension of elastic tissues.
    - Resistance in small intra-alveolar vessels increases as they are compressed by the high lung volumes.
  - At small lung volumes, the reverse occurs.

- **Hypoxic Pulmonary Vasoconstriction**
  Low \( \text{PAO}_2 \) causes a vasoconstriction in the vessels supplying that alveolus, increasing PVR and directing blood to better ventilated alveoli.
  - Low alveolar \( \text{PO}_2 \) is the primary determinant.
  - Low mixed venous \( \text{PO}_2 \) also contributes.
  - Constriction begins when \( \text{PAO}_2 \) falls below 100mmHg, and becomes dramatic below 70mmHg.
  - This is important in:
    - Foetal circulation.
    - Alveolar consolidation.
      - Pneumonia.
      - Cardiogenic pulmonary oedema.
Raised LVEDP increases pulmonary venous pressures. Basal alveoli are more affected. HPV causes constriction of basal vessels, increasing blood flow to apical alveoli and resulting in upper lobe diversion seen on chest x-ray.

- High altitude
- HPV is attenuated by:
  - Elevated LAP
    Greater than 25mmHg.
  - High CO

- **Minor factors** which affect PVR:
  - **Increase** PVR:
    - Hypercarbia
    - Hypothermia
    - Acidaemia
    - Pain
  - **Decrease** PVR:
    - Bronchodilators
    - Volatiles

**Response to Substances**

**Oxygen:**

- The pulmonary circulation constricts when PO₂ falls, whilst the systemic circulation dilates

**Carbon Dioxide:**

- The pulmonary circulation constricts when PCO₂ rises, whilst the systemic circulation dilates

**Distribution of Pulmonary Flow**

Gravity has a significant effect on pulmonary blood flow:

- In the upright lung, flow decreases almost linearly with height
- In the supine lung, flow to posterior regions exceeds that of anterior regions
  
  This occurs due to the low driving pressure of the pulmonary circulation, which means gravity has a much more significant affect on pulmonary blood flow than systemic blood flow.

**West’s Zones**

The lung is divided into four zones, based on the relationship between alveolar and vascular pressures:

- **West’s Zone 1**
  In West’s Zone 1, PA > Pa > Pv.
  
  - This should not occur in normal conditions, because a normal pulmonary artery pressure is normally (just) sufficient
  
  This is because in the upright lung, the hydrostatic pressure difference will be about 30cmH₂O.
  
  - However, if alveolar pressure is raised (e.g. IPPV), or arterial pressure falls (shock), there may be a region where alveolar pressure exceeds arterial pressure

- **West’s Zone 2**
  In West’s Zone 2, Pa > PA > Pv.
  
  - Here, flow is determined by the arterial-alveolar pressure gradient rather than the arterial-venous gradient
    
    Alveolar pressure acts as a Starling Resistor, where flow is independent of downstream pressure.
West’s Zone 3

Occurs when alveolar pressure falls below venous pressure, i.e. \( \text{Pa} > \text{Pv} > \text{PA} \). Flow is dependent on the arterial-venous pressure gradient. Capillary pressure increases along their length, increasing transmural pressure and mean width.

West’s Zone 4

Occurs at low lung volumes, as extra-alveolar vessels collapse and shunt occurs. The interstitium is acting as a Starling resistor, which can be expressed as: \( \text{Pa} > \text{Pint} > \text{Pv} > \text{PA} \).

Hypoxic Pulmonary Vasoconstriction

As discussed above, HPV allows redirection of blood flow from poorly ventilated regions of the lung, and so improve V/Q matching. HPV is relevant in disease states, as well as specific physiologic circumstances:

- At high altitude, the \( \text{PAO}_2 \) is globally reduced, leading to high pulmonary artery pressures
- In utero, \( \text{PAO}_2 \) is negligible, and PVR is therefore very high
  
  This diverts blood from the pulmonary circulation into the left side of the heart via the foramen ovale. When the first breath is taken, pulmonary vessels dilate and the right-to-left shunt is reversed.

References


Last updated 2019-07-18
Cerebral Blood Flow

Describe the distribution of blood volume and flow in the various regional circulations and explain the factors that influence them, including autoregulation. These include, but not limited to, the cerebral and spinal cord, hepatic and splanchnic, coronary, renal and utero-placental circulations.

With respect to cerebral blood flow:

- Normal is ~750ml.min⁻¹ or ~15% of resting cardiac output
  - Note that the brain makes up only ~2% of body weight.
  - A relatively high blood flow is required due to the high cerebral metabolic rate for oxygen (CMRO₂) of 50ml.min⁻¹
- The brain is sensitive to interruptions in flow as it has:
  - A high metabolic rate
  - No capacity to store energy substrates

The factors affecting cerebral blood flow can be classified by the factors in the Hagan-Poiseuille Equation:

\[
CBF \approx \frac{\Delta P R^4}{8 \pi L}, \quad \text{where:}
\]

- \( \Delta P \) is the pressure difference driving flow, i.e. CPP
- \( R \) is the radius of the blood vessels
- \( \eta \) is the blood viscosity
  - These are also called rheologic factors.
- \( L \) is the length of the tube, a fixed quantity

Factors Affecting Perfusion Pressure (CPP)

- Cerebral Perfusion Pressure is the difference between mean arterial pressure and intracranial pressure:
  \[
  CPP = MAP - ICP
  \]
- A normal CPP is ~80mmHg
- In normal individuals, CBF is classically thought to be autoregulated over a CPP range of 60-160mmHg
  - This occurs by myogenic means, similar to the kidney
  - In normal circumstances, this is dependent on MAP (i.e., with a normal ICP < 10mmHg, CBF is regulated over a MAP range of 50-150mmHg).
- Note that more recent evidence would suggest that CBF is autoregulated over a much narrower range of perfusion pressures, and has a greater capacity to buffer an increased rather than decreased perfusion pressure

- At the lower limit, the reduced perfusion pressure means flow cannot be maintained even with maximal vasodilation
At the upper limit, the high perfusion pressure overcomes maximal vasoconstriction
  - Additionally, the increased CBF may result in damage to the blood-brain barrier
- The curve is left-shifted in neonates and children (due to lower normal MAP)
- The curve is right-shifted in chronic hypertension
- The curve is probably inaccurate in the pathological conditions where it would otherwise be useful, such as malignancy, subarachnoid haemorrhage, CVA, or TBI
  - This may be due to damage to either the feedback mechanisms, or the effectors (vasculature)
  - Flow may become pressure-dependent, and small changes in MAP can have large changes in CBF

Factors Affecting Vessel Radius

Vasodilation and constriction affect both cerebral blood flow and ICP, as vasodilatation increases cerebral blood volume and therefore may increase ICP through the Monroe-Kellie doctrine.

Vessel calibre is affected primarily by four factors:

- Cerebral metabolism
- \( \text{PaCO}_2 \)
- \( \text{PaO}_2 \)
- Neurohormonal factors
- Temperature

Cerebral Metabolism

Cerebral metabolism (typically given by the cerebral metabolic requirement for oxygen, \( \text{CMRO}_2 \)) has a linear association with cerebral blood flow - this is known as flow-metabolism coupling. This is controlled locally through the release of vasoactive mediators, such as \( \text{H}^+ \), adenosine, and NO. Determinants of cerebral metabolism include:

- Drugs
  Cerebral metabolism may be decreased by use of drugs such as benzodiazepines, barbiturates, and propofol.
- Temperature
  \( \text{CMRO}_2 \) decreases linearly by \( \sim 7\% \) per degree centigrade, allowing prolonged periods of reduced \( \text{CBF} \) without ischaemic complications.

\[ \text{CBF} \text{ almost linear between 20mmHg and 80mmHg} \]
- Above 80mmHg, the circulation is maximally dilated
- Below 20mmHg, the circulation is maximally constricted
  - Additionally, the alkalosis causes a left-shift of the oxyhaemoglobin curve. This reduces offloading of oxygen, causing

\( \text{PaCO}_2 \)

Carbon dioxide acts as a cerebral vasodilator.

- \( \text{CBF} \) is almost linear between 20mmHg and 80mmHg
  - Above 80mmHg, the circulation is maximally dilated
  - Below 20mmHg, the circulation is maximally constricted
    - Additionally, the alkalosis causes a left-shift of the oxyhaemoglobin curve. This reduces offloading of oxygen, causing
hypoxia and subsequent vasodilation.

- There is a right-shift in chronic hypercapnea
  The mechanism of action is complex, but involves local increase in $H^+$ ions.
- Changes to CBF with CO$_2$ are dependent on current arteriolar tone - vasodilatory effects of CO$_2$ are significantly reduced when the perfusing pressure is low.

PaO$_2$

- CBF increases rapidly when PaO$_2$ falls below 60mmHg so that cerebral oxygen delivery is maintained
  Hypoxia causes a release of adenosine and reduced calcium uptake, with subsequent vasodilation

Neurohormonal

- Autonomic control of cerebrovascular tone is limited, though is responsible for the right-shift in the autoregulation curve with sustained hypertension

Factors Affecting Blood Viscosity

- Blood viscosity is dependent on haematocrit
- Reduced haematocrit is associated with increased CBF, but reduced O$_2$-carrying capacity
  The optimal haematocrit is ~0.3-0.35, which provides the best balance between reduction of viscosity to improve cerebral blood flow, without reducing DO$_2$.

References


Last updated 2019-07-18
Hepatic Blood Flow

Describe the distribution of blood volume and flow in the various regional circulations and explain the factors that influence them, including autoregulation. These include, but not limited to, the cerebral and spinal cord, hepatic and splanchnic, coronary, renal and utero-placental circulations.

The liver serves as a blood reservoir (30ml per 100g, half of which may be mobilised in hypovolaemia), and receives 25% of cardiac output from a unique dual blood supply:

- Hepatic arterial system, which supplies about one-third of blood, but 40-50% of O₂. Hepatic arterial blood has an SpO₂ of ~98%, as would be expected. It is a high-pressure, high-resistance, high-flow system (average velocity 18cm.s⁻¹), with the capacity to autoregulate.

- Portal venous system, which supplies the remaining two-thirds of blood. It is a low-resistance, low-pressure, low-velocity system (average flow 9cm.s⁻¹), with no capacity to autoregulate.

The SpO₂ of portal venous blood varies depending on gut activity:
- In the resting gut, SpO₂ is ~85%
- In the active gut, SpO₂ is ~75%

Regulation of Flow

As with other organs, blood flow is autoregulated via intrinsic and extrinsic mechanisms, and may be affected by external factors.

Intrinsic Autoregulation

- Myogenic autoregulation
- Hepatic arterial buffer response
  - This is also known as the "hepatic artery-portal venous semi-reciprocal interrelationship".
    - Hepatic arterial resistance is proportional to portal venous blood flow, such that a reduction in portal venous flow causes a decrease in hepatic arterial resistance and increases hepatic arterial flow
      - This is probably mediated by adenosine.

Extrinsic Autoregulation

- Autonomic Nervous System
  - Both the hepatic and portal vasculature have sympathetic innervation:
    - The hepatic artery has dopamine receptors, as well as β- and α-adrenoreceptors
    - The portal vein has only α-adrenoreceptors
      - Activation of these receptors causes vasoconstriction, reducing the compliance of the hepatic vasculature and mobilising up to 250ml of blood in times of sympathetic stress.

- Endocrine and hormonal effects
  - A number of substances affect portal flow:

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Portal Vein Effect</th>
<th>Hepatic Artery Effect</th>
<th>Overall Effect on Flow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenaline</td>
<td>Constriction</td>
<td>Constriction (α), then dilation (β)</td>
<td>Reduced</td>
</tr>
<tr>
<td>Glucagon</td>
<td>Dilation</td>
<td>-</td>
<td>Increased</td>
</tr>
<tr>
<td>Secretin</td>
<td>-</td>
<td>Dilation</td>
<td>Increased</td>
</tr>
<tr>
<td>Angiotensin II</td>
<td>Constriction</td>
<td>Constriction</td>
<td>Reduced</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>Constriction</td>
<td>Constriction</td>
<td>Reduced</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>PCO₂</td>
<td>Constriction</td>
<td>-</td>
<td>Reduced</td>
</tr>
</tbody>
</table>

**External Factors**

Flow in the hepatic vein is dependent on venous return:

- Increased venous return (e.g. negative-intrathoracic pressure) increases hepatic flow
- Decreased venous return (e.g. positive-pressure ventilation, tamponade, haemorrhage), reduces hepatic flow, and in extreme cases flow may only occur intermittently throughout the cardiac cycle
- **Exercise** reduces both portal vein and hepatic arterial flow

**Microvasculature**

Hepatic arterioles and portal venules form the **hepatic triad** with a bile canaliculi. Hepatic arterioles and venules anastomose to form **sinusoids**, which create a specialised low-pressure (~2mmHg) capillary system which drains into the central veins of the hepatic acinus.

This arrangement:

- **Optimises hepatic O₂ extraction**
  - Increased hepatic O₂ demand is met by increasing O₂ extraction, rather than by increasing flow (as occurs in the heart).
- **Prevents shunting and retrograde flow**

**References**

1. CICM March/May 2013
2. Leslie RA, Johnson EK, Goodwin APL. Dr Podcast Scripts for the Primary FRCA. Cambridge University Press. 2011.

Last updated 2019-07-18
Baroreceptors

Describe the function of baroreceptors and to relate this knowledge to common clinical situations.

Baroreceptors are stretch receptors which monitor changes in arterial pressure. Arterial pressure is monitored by receptors in the:

- **Aortic arch**
  - Innervated by CNX
- **Carotid sinus**
  - Small dilation of the ICA at the level of the bifurcation.
  - Innervated by CNIX
  - Remember the carotid sinus is a baroreceptor, the carotid body is a chemoreceptor

**Low-pressure** stretch receptors:

- Respond to increased venous return
- Are inhibited by positive pressure ventilation
- Act by stretch and typically described as volume receptors
- Are located in the:
  - Atrial walls
  - SVC and IVC
  - Pulmonary circulation

**Baroreceptor Control**

Afferent fibres from CNIX and CNX travel to the NTS in the medulla. Effector neurons from the RVLM are GABAergic and therefore inhibitory, i.e. increased baroreceptor discharge reduces tonic sympathetic tone and increases vagal tone.

**Increased baroreceptor activity** therefore results in:

- Arterial and venous vasodilation
- Hypotension
- Bradycardia
- Decreased cardiac output
- Decreased respiratory rate

Conversely, increased activity of low-pressure stretch receptors results in an increase rather than a decrease in heart rate.

**Baroreceptor Activity**

Baroreceptors are:

- More sensitive to pulsatile pressure than constant pressure
  - A decrease in pulse pressure without a change in MAP will decrease baroreceptor firing.
- Active throughout the cardiac cycle
  - Rapid compensatory responses are vital in the short-term control of blood pressure, e.g. with posture.
- Active over the range from 50mmHg to 200mmHg
This curve is left-shifted in children and neonates, and right-shifted in chronic hypertension, though this is reversible

### Hormonal control

Activation of atrial/ventricular stretch receptors stimulates ANP/BNP release respectively, which act to reduce blood pressure in the following ways:

- **Increased GFR**
  - Act to constrict the efferent arteriole and dilates of the afferent arteriole. This subsequently inhibits renin secretion through increased hydrostatic pressure at the JGA and increased Na⁺ and Cl⁻ delivery to the macula densa.
- **Decreased aldosterone**
  - Via inhibition of aldosterone secretion.
- **Vasodilation**
  - Causes vasodilation of peripheral smooth muscle.

### References

2. CICM September/November 2014
3. ANZCA July/August 2000

Last updated 2018-06-25
Valsalva Manoeuvre

Explain the response of the circulation to situations such as changes in posture, haemorrhage, hypovolaemia, anaemia, intermittent positive pressure ventilation, positive end-expiratory pressure, and the Valsalva manoeuvre.

A Valsalva is forced expiration against a closed glottis. This can be achieved by increasing $P_{AW}$ to 40mmHg for 15 seconds. This increase in intrathoracic pressure alters many haemodynamic parameters.

Phases

A Valsalva manoeuvre consists of four phases:

Phase I

- $P_{AW}$ is increased to 40cmH$_2$O, with a corresponding increase in $P_{Thoracic}$
- $SBP$ and $DBP$ increase due to:
  - Compression of the aorta
  - Increased LV preload due to ejection of blood in the pulmonary vasculature

Phase II

- $VR$ falls due to increased $P_{Thoracic}$
- $CO$ falls due to decreased $VR$
- $SBP$ and $DBP$ fall due to decreased $CO$
- Baroreceptors are activated by the fall in BP, and SNS outflow increases, causing:
  - Increased $HR$
  - Increased $SVR$
    - BP therefore starts to recover late in Phase II

Phase III

- The Valsalva ceases, and $P_{AW}$ returns to 0cmH$_2$O
- $PVR$ rapidly drops as alveolar vessels re-expand
- $SBP$ and $DBP$ rapidly fall due to:
  - Decreased $PVR$ causing decreased LV preload
  - Loss of high intrathoracic pressure compressing the aorta

Phase IV

- $VR$ normalises
- $CO$ normalises due to normal $VR$ and $PVR$
- $SBP$ and $DBP$ transiently increase due to a normal CO entering a baroreceptor-driven high-$SVR$ vascular bed
- Baroreceptors respond to high $SBP$ an $DBP$ by increasing vagal tone:
  - $HR$ falls (reflex bradycardia)
  - BP falls
Abnormal Responses

Abnormal responses occur in cardiac failure and autonomic neuropathy.

CCF

In CCF a square-wave pattern is produced:

- Increasing P\textsubscript{AW} resulting in a sustained increase in SBP and DBP
- There is a slight decrease in SBP and DBP for the few seconds in phase III when airway pressure is released

Appears to be due to the increased circulating volume, as this difference resolves in venesected cardiac patients, and is demonstrated in normal individuals who are transfused to a high circulating volume.

Autonomic Neuropathy

Baroreceptor response to the Valsalva is minimal in both phase II and IV:

- In phase II, there is no compensatory increase in sympathetic outflow, so BP continues to fall until P\textsubscript{AW} returns to 0mmHg
- In phase IV, there is no compensatory increase in vagal tone and so BP returns to normal without overshooting

References

CVS Changes with Obesity

Describe the cardiovascular changes that occur with morbid obesity

Obesity is a multisystem disorder defined by an elevated body mass index (BMI):

- Normal: BMI < 25
- Overweight: BMI 25 - 30
- Obese: BMI > 30
- Morbidly Obese:
  - Obesity related disease and a BMI > 35
  - BMI > 40

Characteristics of obesity include:

- Complex genetic and environmental causes
- Increased caloric intake
- Increased metabolic rate (normal for BSA)

The effect of obesity on the cardiovascular system is complex, and can be classified into:

- Hormonal changes
  Abdominal visceral fat is responsible for secreting a large number of hormones which affect cardiovascular parameters:
  - Increased leptin
    Contributes to cardiac remodelling and LVH.
  - Angiotensinogen
    Leads to systemic hypertension and LV remodelling.
    - Small amounts are produced in adipocytes, which increases as fat volume increases
  - Plasminogen activator inhibitor-1
    Reduces fibrinolysis and predisposes to VTE.
  - Inflammatory adipokines
    Impair endothelial function, leading to increased SVR.
  - Catecholamines
    Increased contractility, SVR, and worsen endothelial function.
    - Released with:
      - Hypoxia
      - Hypercapnea
      - Negative intrathoracic pressure
      - Fragmented sleep
        Due to OSA.

- Changes in key cardiovascular parameters
  - Increased VO₂
    Due to increased LBM and fat mass.
  - Increased Blood Volume
    Due to increased angiotensin II and aldosterone.
  - Increased Stroke Volume
    Due to:
    - Increased preload (major factor)
    - Increased contractility (minor factor)
      Due to increased circulating adrenal hormones.
  - Increased Cardiac Output
To maintain DO$_2$.
   - Initially with preserved ejection fraction

- Cardiac changes
  - Diastolic dysfunction
    - Due to myocardial fibrosis impairing relaxation.
  - Fatty infiltration of myocardium and conducting system
    - Predisposes to arrhythmias
    - Risk is worsened by change in myocardial architecture, hypoxia, and increased circulating catecholamines.
  - Biventricular hypertrophy as a response to increased afterload
    - LV afterload increased due to systemic hypertension
      - LVH is much more common than RVH.
        - Eccentric hypertrophy due to volume overload
        - Concentric hypertrophy due to pressure overload or hormonal changes
    - RV hypertrophy due to:
      - LV diastolic failure
      - Increased PVR
        - Hypoxia
          - Due to:
            - Effects of OSA
            - Increased shunt through collapsed lung bases
            - Acidosis

References


Last updated 2019-07-18
Cardiovascular Effects of Ageing

Describe the cardiovascular changes that occur with ageing.

CVS effects of ageing can be divided into cardiac, vascular, and autonomic changes:

- **Cardiac changes**
  - Decreased receptor density and number
  - Decreased maximum heart rate
    Due to fibrosis of the SA node causing reduced pacemaker cell number and function, and reduction in catecholamine receptor density.
    - \[ \text{Maximum heart rate} \approx 220 - \text{Age} \]
  - Decreased inotropy
    Minor.
  - Increased reliance on atrial kick
    Reduced ventricular compliance increases the reliance on atrial kick to achieve adequate preload.
  - Decreased diastolic compliance
    - Due to hypertrophy from increased afterload

- **Vascular changes**
  - Reduced compliance
    Due to loss of elastic tissue in the large arteries.
  - Increased SVR
    Reduced compliance results in increased vascular resistance.
  - Reduced endothelial cell function (decreased NO)
    Impairs the ability of the vascular tree to adapt to changes in pressure/volume leading to:
    - Elevated SBP
    - Reduced DBP
    Reduced elastic recoil causes diastolic run off and a fall in diastolic blood pressure.
  - Reduced catecholamine receptor density
    Reduced responsiveness to (and increased number of) circulating catecholamines.

- **Autonomic**
  - Impaired autonomic function
    Due to decreased catecholamine responsiveness.
  - Impaired baroreceptor response
  - Decreased exercise tolerance
    Reliance on preload to maintain cardiac output.

References

1. ANZCA February/April 2016

Last updated 2019-07-20
Inotropes

Understand the detailed pharmacology of inotropes and vasopressors.

Inotropes are agents which alter myocardial contractility.

- Positive inotropes increase contractility
- Negative inotropes decrease contractility

Classes of Positive Inotrope

<table>
<thead>
<tr>
<th>Classes</th>
<th>Class I: Increase Intracellular Calcium</th>
<th>Class II: Calcium Sensitisers</th>
<th>Class III: Metabolic/Endocrine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examples</td>
<td>Adrenaline, milrinone, glucagon, digoxin</td>
<td>Levosimendan</td>
<td>T3, Insulin</td>
</tr>
<tr>
<td>General Mechanism of Action</td>
<td>Increase intracellular $\text{Ca}^{2+}$ by a variety of different pathways</td>
<td>Increase sensitivity of actomyosin to $\text{Ca}^{2+}$</td>
<td>Variable. T3 potentiates the effect (or increases expression of) cardiac $\beta_1$ receptors</td>
</tr>
</tbody>
</table>

References

1. Leslie RA, Johnson EK, Goodwin APL. Dr Podcast Scripts for the Primary FRCA. Cambridge University Press. 2011.

Last updated 2017-09-18
Adrenoreceptors

Understand the pharmacology of adrenoreceptor blocking drugs.

This covers the pharmacology of adrenoreceptors. The production and metabolism of endogenous catecholamines is covered under adrenal hormones. Detailed information on specific sympathomimetic agents, including structure-activity relationships, is in the pharmacopeia.

Adrenoreceptors are classified by their varying sensitivity to different catecholamines. Additionally:

- All adrenoreceptors are G protein-coupled receptors
  - Each receptor contains seven transmembrane α-helical subunits, three extracellular loops, and three intracellular loops
- Alpha receptors have different subunits and mechanisms of action
  - All beta receptors are:
    - G coupled
    - Activate adenylate cyclase increasing cAMP, leading to increased Na/K\textsuperscript{+} ATPase activity and hyperpolarisation

Adrenoreceptor Subtypes

\(\alpha_1\)-receptors:

- Are present in smooth muscle
  - Agonism causes vasoconstriction, relaxation of GIT muscle (via presynaptic receptors), and contraction of GU muscle.
- They are:
  - G\(_{Q}\) coupled
  - Phospholipase C activated increases IP\(_3\), increase calcium

\(\alpha_2\)-receptors:

- Are present in the CNS, arterioles, pancreas
  - Agonism causes sedation, analgesia, vasodilatation, and inhibition of insulin release.
- They are:
  - G\(_{Q}\) coupled
  - Inhibits adenylate cyclase, decreasing cAMP

\(\beta_1\)-receptors:

- Are present in cardiac muscle and the JGA
  - Cardiac agonism increases inotropy, chronotropy, and dromotropy
  - JGA agonism increases renin release
- Increase in cAMP increases intracellular calcium

\(\beta_2\)-receptors:

- Are present in skeletal vascular and bronchial smooth muscle, the liver, and on cell membranes
- Agonism causes:
  - Vasodilation and bronchodilation
  - Hepatic glycogenolysis
  - Increases activity of the Na\textsuperscript{+}/K\textsuperscript{+} ATPase pump, increasing intracellular potassium
  - Increase in cAMP increases Na\textsuperscript{+}/K\textsuperscript{+} ATPase activity and hyperpolarisation

\(\beta_3\)-receptors:

- Are present in fat
Agonism causes lipolysis and thermogenesis.

References


Last updated 2018-05-27
Antiarrhythmics

Understand the pharmacology of antiarrhythmic drugs

Antiarrhythmic drugs are typically classified using the Vaughan Williams classification system, which divides drugs into four classes based on their effect on the cardiac action potential. Many drugs will act via multiple mechanisms.

- **Class I:** Block voltage-gated Na channels
  - Class Ia: Intermediate dissociation
  - Class Ib: Fast dissociation
  - Class Ic: Slow dissociation
- **Class II:** β-Blockers
- **Class III:** Prolong the action potential (Usually via K⁺ channel blockade)
- **Class IV:** Ca²⁺ antagonists

This classification is notably incomplete, as some drugs (such as amiodarone) fit into multiple categories, and others (such as digoxin, adenosine, and magnesium) fit into none.

**Class I**

- Na⁺-channel blockade inhibits action potential prolongation by blocking active and refractory sodium channels in a use-dependent fashion
- This inhibits tachyarrhythmias whilst allowing normal conduction
- Extent of block depends on the heart rate, membrane potential, and the subclass of drug
- Sodium channel blockade increases pacing threshold and defibrillation energy requirement

**Class Ia**

- Class Ia drugs have mixed properties of Ib and Ic, and also have Class III effects
- As they prolong the AV conduction and prolong the action potential they increase both QRS duration and the QT interval
- Examples include procainamide

Pro-arrhythmic effects may result because AV nodal conduction may be increased, so despite decreased atrial activity increased ventricular conductance results in a potentially fatal shortening of diastolic time
Class Ib

- Class Ib drugs bind to open sodium channel, and will **associate and dissociate** from a sodium channel in the course of a **normal beat**
- Tachyarrhythmias are prevented because dissociation occurs too slowly for a further action potential to be generated
- Class Ib drugs will bind selectively to refractory channels, such as occurs in ischaemia
- As they have **little effect on normal cardiac tissue** they have **little effect on the ECG**
- Examples of class Ib agents include **phenytoin** and **lignocaine**

Class Ic

- Class Ic drugs **associate and dissociate slowly creating a steady-state level of block**
- This causes indiscriminate blockade and general reduction in excitability
- Class Ic agents are used to suppress unidirectional or intermittent conduction pathways
- As they markedly slow conduction velocity they **increase QRS duration**
- Examples of Class Ic agents include **flecainide**
**Class II**

Normal β-adrenergic stimulation has a number of pro-arrhythmic effects:

- Increased pacemaker potential current
- Increased slow-inward Ca\(^{2+}\) current
- Increased repolarising K\(^{+}\) and Cl\(^{-}\) currents
- Increased Ca\(^{2+}\) stored in the sarcoplasmic reticulum, which may be spontaneously released causing a delayed-afterdepolarisations
- Reduced serum [K\(^{+}\)]

β-blockers have an antiarrhythmic effect by antagonising these mechanisms. They are useful for treatment of arrhythmias occurring with sympathetic over-activation, such as post MI.

**Class III**

Blocking of outward K\(^{+}\) channels slows cardiac repolarisation, which increases the cardiac refractory period. This has a number of beneficial effects:

- Decreased automaticity
- Decreased ectopy
- Reduced defibrillation energy requirement
- Increased inotropy

Due to the prolonged repolarisation, they will also cause a long QT (though in the case of amiodarone this is not associated with an increased risk of TPD).

**Class IV**
Class IV drugs inhibit L-type Ca\(^{2+}\) channels, inhibiting the slow inward calcium current, which:

- Slows SA and AV nodal conduction
  AV blockade slows transmission of supra-ventricular arrhythmias.
- Reduces inotropy
- Prevents after-depolarisations
  This suppresses ectopy by reducing calcium leak from sarcoplasmic reticulum.

**Alternatives to Vaughan Williams**

As the Vaughan Williams classification system does not neatly divide agents, and some agents do not fit into any category, they may also be classified by their uses:

<table>
<thead>
<tr>
<th>Indication</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>SVT</td>
<td>Digoxin, adenosine, verapamil, β-blockers</td>
</tr>
<tr>
<td>VT</td>
<td>Lignocaine, mexiletine</td>
</tr>
<tr>
<td>SVT/VT</td>
<td>Amiodarone, flecainide procainamide, sotalol</td>
</tr>
<tr>
<td>Digoxin toxicity</td>
<td>Phenytoin</td>
</tr>
</tbody>
</table>

**References**


Last updated 2019-07-18
Functional Anatomy and Control of Renal Blood Flow

Describe the functional anatomy of the kidneys and renal blood flow.

Functional Anatomy

The functional unit of the kidney is the nephron. Nephrons:

- Are composed of the glomerulus, proximal tubule, loop of Henle, distal tubule, and collecting duct
- Are divided by their location into:
  - Superficial cortical nephrons
    - Have short loops of Henle.
  - Juxtamedullary nephrons
    - Have long loops of Henle, and the efferent arteriole forms the vasa recta for the kidney.
  - Mid-cortical nephrons
    - May have either long or short loops.

Control of Renal Blood flow

The kidneys:

- Receive 22% of cardiac output at rest
- Extract only 10% of delivered O₂
- Have a high renal blood flow exceeds that required for metabolism
  - High flow is instead needed to produce the large volume of glomerular filtrate (125ml.min⁻¹) required for excretion of waste.

Autoregulation

Renal blood flow is autoregulated over a wide range of mean arterial pressures (60-160mmHg) via:

- Myogenic autoregulation
- Tubuloglomerular feedback

Myogenic autoregulation:

- Describes the intrinsic constriction of the afferent arteriole in response to an increased transmural pressure
- This increases vascular resistance in proportion to the increase in pressure, keeping flow constant

![Graph showing glomerular filtration rate vs. perfusion pressure for normal and chronic hypertension conditions.](image-url)
**Tubuloglomerular feedback** is more complicated, and describes the constriction or dilation of the afferent arteriole in response to adenosine or NO (respectively) release from the macula densa:

- The macula densa lies in the wall of the ascending limb of the loop of Henle
- It detects change in tubular flow rate (probably via changing Na$^+$ flux across its membrane)
  - Increased flow in the loop indicates an increased perfusion pressure, prompting release of adenosine and constriction of the afferent arteriole
  - Decreased flow indicates a decreased perfusion pressure, reducing adenosine release and prompting the release of NO and renin, which causes the afferent arteriole to dilate

Notably, flow to juxtamedullary nephrons is not autoregulated. High blood pressure increases juxtamedullary flow, increasing GFR and impairing renal concentration, resulting in a pressure diuresis.

**Neuronal Control**

The kidneys are innervated by noradrenergic sympathetic nerves, which causes:

- Afferent and efferent arteriolar constriction
  - This increases capillary hydrostatic pressure (increasing filtration) and also increases capillary oncotic pressure (decreasing filtration).
    - This leads to an overall slight reduction in GFR

**Hormonal Control**

**Renin:**

- Is released from the juxtaglomerular apparatus by $\beta_1$ stimulation
- Catalyses the production of angiotensin I from circulating angiotensinogen
  - Angiotensin I is then converted into Angiotensin II by circulating ACE.
  - *The actions of the RAAS are described in more detail in the endocrine functions of the kidney.*

**References**


Last updated 2018-06-25
Glomerular Filtration and Tubular Function

Describe glomerular filtration and tubular function.

Glomerulus

- The glomerulus is a set of capillaries which invaginate Bowman’s capsule
- Fluid filters out of the capillary bed into Bowman’s space based on Starling forces:
  - Membrane permeability
  - Hydrostatic pressure gradients
  - Oncotic pressure gradient
  - Reflection coefficient

Glomerular Filtration Rate

Glomerular Filtration Rate is:

- The volume of plasma filtered by the glomerulus each minute
  Normal renal blood flow is 1.1 L.min⁻¹, however renal plasma flow is less (600 ml.min⁻¹ for a normal haematocrit).
  Therefore, the normal filtration fraction (proportion of renal blood flow which is filtered) is ~20%.
- Typically 125 ml.min⁻¹
  - Decreases with age (partially due to loss of nephron number)

GFR can be expressed as the product of Net Filtration Pressure and the combination of membrane permeability and membrane surface area, designated $K_f$ (the filtration coefficient):

$$GFR = NFP \times K_f$$

- Net Filtration Pressure is given by opposing Starling Forces across the glomerular membrane:
  $$NFP = P_{Glomerular\ Hydrostatic} - P_{Bowman’s\ Hydrostatic} - P_{Glomerular\ Oncotic}$$

As protein is not filtered in normal states, the oncotic pressure in Bowman’s Space is usually assumed to be 0 mmHg.
- The average capillary NFP is ~17 mmHg
- Hydrostatic pressure
  - Determined by renal blood flow and the relative constriction of the afferent and efferent arterioles. Hydrostatic pressure decreases along the capillary. Affected by:
    - MAP
    - Catecholamines
    - Local autoregulation
    - Myogenic
    - Tubuloglomerular Feedback
    - Hormones
      - Angiotensin II constricts the efferent arteriole more than the afferent arteriole, causing an increase in renal resistance with only a small decrease in GFR.
      - Prostaglandin E2 dilates the afferent arteriole, increasing GFR

- Osmotic pressure
  - Increases along the capillary, as protein free-fluid is filtered leaving a higher concentration of protein within the capillary. This change in capillary oncotic pressure is proportional to the filtration fraction - a greater filtration fraction will cause a higher oncotic pressure of fluid in the capillary.
Membrane permeability
Overall permeability is:
  A function of:
    Membrane permeability, in turn affected by:
      Capillary endothelium
      Basement membrane
        Negatively charged molecules have reduced filtration as the basement membrane is also negatively charged which opposes movement out of the capillary.
      Foot processes of podocytes
        Molecules less than 7000 Dalton are freely filtered, whilst larger molecules are filtered less.
    Membrane Surface Area
      Typically very high for water and solutes.
    Affected by:
      Glomerulonephritis
        Change in basement membrane or podocyte foot processes
      Angiotensin II causing contraction of mesangial cells

Tubular Function

Proximal Tubule
The proximal tubule reabsorbs 60% of glomerular filtrate. It reabsorbs basically everything, including protein, and secretes H⁺, organic ions (such as uric acid and salicylates), ammonium, and up to 60% of filtered urea load.

Loop of Henle
The loop of Henle consists of a thin descending limb and a thick ascending limb:
  The descending limb reabsorbs water only
  The thick ascending limb:
    Reabsorbs common ions (Na⁺, K⁺, Cl⁻) and HCO₃⁻
    Excretes H⁺
  The function of the loop is to concentrate urine in states of water deprivation
    This is done via the countercurrent mechanism.

Countercurrent Multiplier
The countercurrent concentrating system is:
  Formed from the loop of Henle and collecting ducts
  Driven entirely by the removal of NaCl from the ascending limb
  Most easily understood in stages:
    NaCl is actively transported out of the thick ascending limb, increasing interstitial osmolarity at that level
    Increased interstitial osmolarity results in water reabsorption from the descending limb, increasing tubular osmolarity at that level
    This more concentrated tubular fluid then flows to a deeper, more concentrated level, and more water is reabsorbed
    The effect is progressive concentration of tubular and interstitial fluid, but with a low and stable energy cost as the relative gradients that each transport pump works against is small
  The end result is a dilute urine leaving the ascending limb, but a highly concentrated medullary interstitium

Countercurrent Exchange
The **vasa recta** are peritubular capillaries that:

- Surround the loop of Henle of juxtamedullary nephrons
- Follow the loop into the medulla
- Have typically low blood flow
  
  This prevents "washout" of the countercurrent multiplier, as the slow blood flow allows solute concentrations to equalise at each level of the loop.
  - In hypovolaemic situations, renal blood flow falls and vasa recta flow decreases, further reducing washout
  - When renal blood flow is high, vasa recta flow increases
  
  This washes out part of the medullary concentration gradient and reduces the concentrating ability of the kidney.

**Distal tubules**

Fluid entering the distal tubule has about **one-third** the **osmolarity** of plasma. The distal tubule:

- Reabsorbs: \( \text{Na}^+, \text{Cl}^-, \text{HCO}_3^-, \text{Ca}^{2+} \)
- Secretes: \( \text{K}^+, \text{H}^+ \)

**Collecting Ducts**

- The collecting ducts lie in the interstitium (concentrated by the loop of Henle)
- In the absence of aquaporins, the collecting ducts are **impermeable to water**
  - Osmolality can fall as low as **50 mmol.L\(^{-1}\)** due to continued reabsorption of solute
  - In the presence of aquaporins, water flows down the osmotic gradient into the concentrated interstitium, resulting in a highly concentrated urine
  - **ADH** also **increases** collecting duct permeability of **urea**
    - Urea moves via solvent drag with water

**References**

3. CICM March/May 2010

Last updated 2019-07-18
Handling of Organic Substances

Describe the role of the kidney in the handling of glucose, nitrogenous products and drugs

Broadly speaking, the kidney:

- Reabsorbs important substances
- Filters and secretes waste products

Methods of Reabsorption

Reabsorption from tubule to blood can occur via two mechanisms:

- **Transcellular reabsorption**
  Substance is absorbed into tubular epithelium and then secreted into blood. This is typically achieved by symporters, which rely on the low intracellular sodium concentration to move substances out of the tubule against their concentration gradient.

- **Paracellular reabsorption**
  Substance passes through the matrix of tight junctions between epithelial cells.

Rate Limitation

There are functional upper limits on the rate of reabsorption of substances from the tubule. There are two limits:

- **Tubular Maximum (T_{max}) Limited**
  Saturation of transporters occur, so a further increase in solute concentration does not increase the rate of substance reabsorption.

  The maximum solute concentration for a T_{max} system is a function of the transporter.

- **Gradient Limited**
  Leaks in the tight junctions will result in solute moving from the interstitium back into the tubule if the tubular concentration falls too low.

  The maximum solute concentration for a gradient limited system is related to the permeability of the tight junctions.

Glucose

Glucose is:

- Freely filtered at the glomerulus
- Completely reabsorbed via the **transcellular route** in the proximal convoluted tubule under normal circumstances
- Actively transported via the SGLUT (Sodium-dependent Glucose symporter) transmembrane protein
  - Secondary active transport (down the established Sodium gradient)
  - There are two subtypes of the SGLUT protein:
    - **Low-affinity, high-capacity**
      Rapidly reabsorbs glucose, but is ineffective when glucose concentration is low. It is located early in the PCT, and reabsorbs ~90% of filtered glucose.
    - **High-affinity, low-capacity**
      Slowly reabsorbs glucose, but remains effective even when glucose concentration is low. It is located late in the PCT, where glucose concentration is lower (having already been reabsorbed by the high-capacity transporter), and reabsorbs ~10% of filtered glucose.
As GFR increases, glucose filtration and therefore glucose absorption increase. As glucose is co-transported with Na\(^+\), absorption of Na\(^+\) and H\(_2\)O also increase. This phenomenon is known as **glomerulo-tubular balance**.

Glucose reabsorption is a \(T_{\text{max}}\) system, and is overwhelmed when filtered glucose exceeds 300mg.min\(^{-1}\) or 16mmol.min\(^{-1}\). This typically occurs when plasma (and therefore filtered) glucose concentrations exceed 12mmol.L\(^{-1}\).

**Consequences of Glycosuria**

Glycosuria occurs when filtered glucose exceeds the capacity of the PCT to reabsorb it, and causes:

- Increased urine volume
  - Glucose acts as an osmotic diuretic by:
    - Reducing Na\(^+\) reabsorption in the PCT
      - As some glucose is not absorbed, the sodium that would normally be reabsorbed with (tubuloglomerular balance) is remaining in the tubule.
    - Reducing water and salt reabsorption in the Loop of Henle
      - Due to high tubular flow rates.
    - Impairs the formation of the medullary concentration gradient, limiting concentrating capacity
  - Stimulates ADH release
- Electrolyte derangements
  - Hypokalaemia due to:
    - Reduced K\(^+\) reabsorption due to high tubular flow rates
    - Aldosterone release due to hypovolaemia, increasing Na\(^+\) reabsorption and K\(^+\) secretion
    - ADH release in response to hypovolaemia
- Loss of substrate for ATP generation
- Increase risk of urinary infections

**Nitrogenous Products**

- Amino acids are reabsorbed by amino-acid transporters
  - These are not (entirely) selective, and reabsorb several structurally similar amino acids.
    - These shared pathways create competition for binding sites between amino acids
    - Excess of one substance will lead to both excretion of this substance in urine, as well as inappropriate excretion of related substances
- Larger proteins (such as albumin) are in fact filtered at the glomerulus (though in very small amounts)
  - Reuptake occurs in several stages:
    - Endocytosis at the luminal membrane
      - This is an energy-dependent process, requiring protein to bind to membrane receptors.
    - Degradation of protein into individual amino acids
• Reuptake across the basolateral membrane
• Smaller proteins and peptides (e.g. insulin, angiotensin II) are completely filtered
  • Catabolism occurs in the tubular lumen by membrane-surface peptidases
  • Amino acids are reabsorbed by standard amino-acid transporters

Urea

Urea is a small, water soluble molecule produced in the liver from ammonia as a method for eliminating nitrogenous waste.

Urea excretion is complex, as it has an important role in the counter current multiplier. This means that in the short term (hours to days) elimination may not match production, although over weeks they will be equal. Urea is:

• Freely filtered
• ~50% of filtered load is reabsorbed in the PCT by solvent drag (with water reabsorption)
  • Urea concentration is slightly increased as more water is reabsorbed than urea.
• The urea reabsorbed in the PCT is then secreted into the Loop of Henle via UT uniporters
  • Luminal concentration of urea is much higher in the ascending limb due to the absorption of water
  • ~50% is reabsorbed (again) in the medullary collecting ducts
  • Here, urine becomes so concentrated that luminal concentration of urea exceeds medullary concentration.
  • Overall, 50% of filtered load is excreted

pH Dependent Drug Reabsorption

• Many substances, such as drugs, are weak acids or bases
• Reabsorption of these substances is pH dependent
  • Weak acids are proportionally more ionised at a pH above their pKa
  • Weak bases are proportionally more ionised at a pH below their pKa
  • Unionised substances are lipid soluble, and able to diffuse into tubular cells down concentration gradients
  • Ionised substances are trapped within the lumen

References


Last updated 2019-07-18
Measurement of GFR

Describe the principles of measurement of glomerular filtration rate and renal blood flow

Renal clearance of a substance quantifies the effectiveness of kidneys in excreting substances. The definition of clearance is the volume (typically of plasma) cleared of a drug per unit time. Renal clearance can therefore be expressed as:

\[ Cl = \frac{U_C \cdot U_Q}{P_C}, \text{ where:} \]

- \( Cl \) = Clearance
- \( U_C \) = Urine concentration
- \( U_Q \) = Urine flow rate
- \( P_C \) = Plasma concentration

Clearance and GFR

As the elimination of most substances is dependent on glomerular filtration, clearance of a substance can be used to estimate GFR. Methods include:

- **Inulin**
  - Inulin is a naturally occurring polysaccharide.
    - Inulin clearance accurately measures GFR as it is:
      - Freely filtered by the glomerulus
      - Not secreted at the tubules
      - Not reabsorbed
    - However, inulin is not produced by the body and so must be given by IV infusion
      - This limits its clinical utility.

- **Creatinine**
  - Creatinine is a byproduct of muscle catabolism.
    - Creatinine is used clinically to measure renal function because it is:
      - Produced at a relatively constant rate
        - Factors affecting creatinine production include:
          - Race
          - Muscle mass
            - Age
            - Sex
          - Diet
        - Not metabolised
        - Freely filtered by the glomerulus
        - Minimally secreted
          - As GFR falls the proportion of creatinine secreted by renal tubules increases, so plasma creatinine will overestimate GFR when GFR is low.
        - Not reabsorbed
    - GFR can be approximated by creatinine clearance
      - \[ GFR \approx Cl_{Cr} = \frac{U_{(Cr)} \cdot U_Q}{P_{(Cr)}} \]
      - This is given by the equation:
Serum Creatinine

This formula demonstrates that GFR is inversely proportional to serum creatinine concentration.

- This is only true when both creatinine production and glomerular filtration are at steady-state
  - A sudden drop in glomerular filtration (e.g. aortic cross-clamp) will not result in an immediate rise in creatinine.
  - During acute changes in GFR, serum creatinine will underestimate GFR until a new steady state is reached

Creatinine must be produced and not eliminated for it to rise.

![Graph showing GFR and serum creatinine over time]

Estimating Creatinine Clearance

Using the above formula requires measurement of urine volume. This is:

- Typically performed by taking a 24 hour urine collection
- Tedious, and so creatinine clearance is often estimated
- A common method is the Cockcroft-Gault formula, which has a correlation of ~0.83 with creatinine clearance:

\[
CI = \frac{140 - A \times W \times S}{72 \times Cr},
\]

where:

- \( CI \) = Clearance
- \( A \) = Age
- \( W \) = Sex coefficient (Male = 1, Female = 0.85)
- \( Cr \) = Creatinine in \( \text{µmol.L}^{-1} \)

Alternative formulas are MDRD and CKD-EPI. These equations have two advantages of Cockcroft-Gault:

- They are better predictors of GFR
- They do not require weight, and so can be calculated by the laboratory automatically Other required data (e.g. age) can be taken from hospital records.

These estimates have similar weaknesses to the above:

- Dependent on serum creatinine, which can be highly variable. Formulas are derived from average values of dependent variables, and so will be unreliable at extremes of:
  - Age
  - Muscle mass
  - Critically ill
  - Malignancy
  - Diet

References


4. MD Calc - Cockcroft-Gault Equation.

5. NIDDK. Estimating Glomerular Filtration Rate (GFR)

Last updated 2019-07-18
Endocrine Functions of the Kidney

Outline the endocrine functions of the kidney

The kidney is involved in a number of endocrine processes and produces or metabolises a number of hormones:

- RAAS
- Vitamin D
- EPO
- Prostaglandins

Renin-Angiotensin-Aldosterone System

The RAAS is a signaling pathway involved in blood pressure control. It involves a number of hormones:

- **Angiotensinogen** is produced by the liver in response to:
  - Glucocorticoids
  - Thyroid hormones
  - Oestrogens
  - Angiotensin II
  - Various inflammatory proteins

- **Renin** is a protease produced by the kidneys in response to β₁ stimulation or hypotension, and exists to cleave angiotensinogen to angiotensin I

- **ACE** cleaves angiotensin I to angiotensin II, and also cleaves bradykinin into inactive metabolites

- **Angiotensin II** increases blood pressure via a number of mechanisms:
  - Simulates aldosterone release from the adrenal cortex, increasing sodium and water retention
  - Vasoconstriction of efferent greater than the afferent arterioles
    - Results in slight decrease in GFR at a lower perfusion pressure, but increases filtration fraction.
    - NB: Different sources quote different changes (increase or decrease) in GFR
    - The final effect may vary depending on the contribution of other autoregulatory processes.
  - Reduces $K_f$ through constriction of glomerular mesangial cells
  - Increased SNS activity and central and peripheral vasoconstriction
  - Increases thirst via hypothalamic stimulation
  - Stimulates ADH release, reducing renal water excretion
  - Stimulates release of angiotensinogen

- **Aldosterone** acts on the distal convoluted tubule to:
  - Increase reabsorption of $Na^+$ and water
  - Increase elimination of $K^+$ and $H^+$

Vitamin D

Vitamin D has a complex metabolic pathway which meanders through a number of organ systems:

- Vitamin D₃ may be absorbed in diet or produced in skin by the action of UV light on 7-dehydrocholesterol
- Vitamin D₃ is then hydrolysed in the liver by CYP450 enzymes to form 25-hydroxycholecalciferol (25-OHD₃)
- 25-OHD₃ is then converted in the proximal tubule to calcitriol - the active form
Erythropoietin

Erythropoiesis is stimulated by EPO release:

- In adults, EPO is released from the:
  - Peritubular capillary fibroblasts (85%)
  - Liver (15%)
- EPO is released in response to:
  - Hypoxia
  - Hypotension
  - Low Hct
- Erythropoiesis is inhibited by:
  - High red cell volume
  - Renal failure

Production of EPO is decreased in renal failure, which is why patients with end-stage renal disease require exogenous EPO.

References


Last updated 2018-09-21
Acid-Base Balance

Describe the role of the kidneys in the maintenance of acid/base balance

Acids produced by the body can be:

- **Volatile** (CO₂)
  - Body produces and eliminates ~13-20mol.day⁻¹
  - Removed by the lungs

- **Fixed** (everything else)
  - Include lactate, sulphate, phosphate, and ketones
  - Body produces and eliminates 10mmol.kg⁻¹.day⁻¹
  - Eliminated by the kidney

Mechanisms for elimination of acid include:

- Reabsorption of HCO₃⁻
  - This is equivalent to the removal of the same amount of H⁺.
  - As there is usually a net production of acid, under normal circumstances **all filtered HCO₃⁻ is reabsorbed**
  - Note that removal of an acid load is associated with greater HCO₃⁻ generation and reabsorption, not increased H⁺ secretion

- Bound to filtered buffers
  - As ammonium

- The rate and extent of these reactions is dependent on ECF pH and ion concentrations, which gives the kidney control over ion concentrations

- Urinary pH can fall as low as ~4.4, before the active transport of H⁺ is inhibited

Bicarbonate and the Kidney

Buffer systems minimise changes in pH until the kidney can eliminate excess hydrogen.

Bicarbonate is the predominant ECF buffer system (see Acid-Base physiology for more on buffers). By adjusting the level of HCO₃⁻ the kidney is able to adjust pH, as per the Henderson-Hasselbalch equation:

\[
pH = pK_a + \log \frac{[HCO_3^-]}{[CO_2]} = 6.1 + \log \frac{24}{1.2} = 7.4
\]

Where:

- \( pK_a = 6.1 \), the pKa of HCO₃⁻
- \([HCO_3^-] = 24\), the normal [HCO₃⁻] in mmol.L⁻¹
- \([CO_2] = 1.2\), the normal [CO₂] in mmol.L⁻¹

Bicarbonate is:

- Freely filtered
  - 4320 mmol.day⁻¹ of HCO₃⁻ is filtered (24mmol.L⁻¹ x 180 L.day⁻¹, normal range is 4-5mol.day⁻¹)
- Reabsorbed in the PCT (90%), thick ascending limb, DCT, and CT
Adjusting rate of absorption allows correction of an acidosis or alkalosis. All $\text{HCO}_3^-$ reabsorption is equivalent to a loss of $\text{H}^+$. 

**Reabsorption of Bicarbonate**

Reabsorption of bicarbonate involves several steps:

- $\text{H}^+$ is secreted into the lumen in one of three ways:
  - Primary $\text{H}^+$ ATPase in the PCT and DCT
  - $\text{H}^+\text{-Na}^+$ antiporter in the PCT and ascending limb
  - $\text{H}^+\text{-K}^+$ ATPase in the CT
- Secreted $\text{H}^+$ combines with filtered $\text{HCO}_3^-$ to form $\text{CO}_2$ and $\text{H}_2\text{O}$
- $\text{CO}_2$ and $\text{H}_2\text{O}$ diffuse into the tubular cell
- $\text{CO}_2$ and $\text{H}_2\text{O}$ are converted back into $\text{HCO}_3^-$ and $\text{H}^+$ in the tubular cell
- $\text{HCO}_3^-$ is reabsorbed into the capillary via the $\text{HCO}_3^-$-$\text{Cl}^-$ antiporter, and the $\text{H}^+$ ion is available to be secreted into the tubule (in exchange for $\text{K}^+$ in the collecting ducts and $\text{Na}^+$ in the proximal tubule)

This complicated process allows $\text{HCO}_3^-$ to be moved from the tubule to the tubular cell and then to the capillary. **There is no elimination of $\text{H}^+$** by this method - the purpose of $\text{H}^+$ secretion is to facilitate the reabsorption of $\text{HCO}_3^-$ into the tubular cell.

**Ammonia**

Glutamine provides a mechanism for elimination of a large number of $\text{H}^+$ ions:

- This is important in:
  - Elimination of excess metabolic acid
  - Renal compensation for acidosis
- This occurs via:
  - Filtered glutamine is absorbed into proximal tubular cells and metabolised to $\text{NH}_4^+$ (ammonium) and $\text{HCO}_3^-$
  - $\text{HCO}_3^-$ diffuses into blood, and the $\text{NH}_4^+$ is secreted into the tubule via the $\text{NH}_4^+$-$\text{Na}^+$ antiporter and eliminated in urine
  - The $\text{NH}_4^+ + \text{H}^+ \rightleftharpoons \text{NH}_3 \cdot \text{H}_2\text{O}$ reaction has a pKa of 9.2 meaning:
    - Ammonia cannot act as an effective urinary buffer
    - Ammonia is not a titratable acid, as it will not release H⁺ ions as urinary pH increases

This means filtered ammonia does not contribute to the lower limit of urinary pH (4.4), which is why it is so important in the renal correction of severe metabolic acidosis.

**Bound to Filtered Buffers**

Secreted $\text{H}^+$ may also combine with a filtered buffer (e.g. $\text{PO}_4^{3-}$). **These H⁺ ions are not reabsorbed.** About 36mmol of $\text{H}^+$ is eliminated with filtered $\text{PO}_4^{3-}$ each day, with each $\text{PO}_4^{3-}$ binding two $\text{H}^+$ ions.

**References**

1. CICM Sep/Nov 2014
2. ANZCA Feb/April 2012
4. Acid-Base Online Tutorial, University of Connecticu
5. Brandis, K. Renal Regulation of Acid-Base Balance, in 'Acid-base Physiology'.

299
Last updated 2019-07-18
Dialysis

Dialysis is the separation of particles in a liquid based on their ability to pass through a membrane.

Indications

Failure of normal renal functions, i.e.:

- Acid
- Electrolyte derangement
  - Particularly hyperkalaemia.
- Intoxications
- Overload
- Uremia

Physical Mechanisms

Fluid and electrolytes can be removed by four different mechanisms:

- **Diffusion**
  Diffusion is the spontaneous movement of substances from a higher concentration to a lower concentration, where rate of movement is proportional to the concentration gradient (as per Fick’s Law).

- **Ultrafiltration**
  Movement of water, as determined by Starling’s Forces.
  - When a solvent passes through a membrane, the process is called osmosis. The frictional forces between solutes and water molecules will pull dissolved substances along, a process known as bulk flow or solvent drag.

Implementation

- **Haemodialysis**
  Uses diffusion.
  - Blood is pumped through an extracorporeal circuit that contains a dialyser.
  - Dialysate flow is countercurrent, which maximises the gradient for diffusion.
  - Solutes move across a membrane between blood and dialysate, as per Fick’s Law:
    - Concentration gradient between blood and dialysate
    - Flow rate of blood and dialysate
    - Solubility of the solute
      - Mass
      - Charge
      - Protein binding
    - Dialysis membrane permeability
      - Thickness
      - Porosity
      - Surface area

- **Haemofiltration**
  Uses ultrafiltration.
  - Both a positive hydrostatic pressure in blood and a negative hydrostatic pressure in dialysate is generated, causing
ultrafiltration and removal of solutes via solvent drag.

- Elimination via bulk flow is **independent of solute concentration gradients across the membrane.**
- Transport is dependent on Starling Forces:
  - The transmembrane pressure generated
    - This is a function of:
      - Blood flow to the membrane
      -Determines hydrostatic pressure.
      - Oncotic pressure gradient
    - Porosity of the membrane
- Additionally, a high filtration fraction will cause excessive haemoconcentration, and clotting of the filter
- The filtered fluid (ultrafiltrate) is discarded, and replaced with another fluid depending on the desired fluid balance.

**Differences**

- Renal Replacement Therapy (RTT) can be via:
  - Peritoneal dialysis (PD)
  - Intermittent haemodialysis (IHD)
  - Continuous Renal Replacement Therapy (CRRT)
    - Continuous Veno-Venous Haemofiltration (CVVH)
    - Continuous Veno-Venous Haemodiafiltration (CVVHDF)

Method chosen depends desired effect:

- Small molecules (<500 Da) and electrolytes can be removed by filtration or dialysis
- Medium-sized molecules (500-5000 Da) are best removed by filtration
- Low molecular weight proteins (5000-50000 Da) are removed by filtration
  - This includes removal of inflammatory proteins, which may be beneficial in sepsis.
- Water is best removed by filtration

**Pharmacokinetics of RRT**

Pharmacokinetics are unpredictable, but are broadly affected by:

- **Drug factors**
  - **Free drug in plasma**
    - Drugs with a small proportion of free drug in plasma are (unsurprisingly) poorly removed by RRT (but **may be removed via plasmapheresis**). These include:
      - Highly (> 80%) protein bound substances
        - Examples included phenytoin, warfarin, and many antibiotics.
        - Not that this **may not apply in overdose**
          - Once protein binding sites are saturated, both free drug fraction and efficacy of dialysis is increased.
    - Drugs with a \( V_D \) greater than 1L.kg\(^{-1}\)
  - **Size/Molecular Weight**
    - Small molecules (< 500 Da) are more easily cleared by diffusive methods of RTT
    - Molecules > 15kDa are poorly dialysed
      - This includes proteins, heparins, and monoclonal antibodies.
  - **Volume of distribution**
    - Drugs with high volumes of distribution are poorly dialysed, as removal of drug from plasma only removes a small proportion of total-body drug content.

  **Dialysis factors**
Dose/Flow rates
Reduced flow rates will reduce clearance.
- Conventional high-flux haemodialysis has more rapid clearance compared to lower-flux haemoperfusion or CRRT

Membrane permeability

Timing
Drugs given between IHD or SLED sessions will not be cleared until the next sessions.

Patient factors
- Residual renal function
  Patients residual GFR will also affect pharmacokinetics.

An Incomplete List of Drugs

<table>
<thead>
<tr>
<th>Drugs Removed on RRT</th>
<th>Drugs not removed on RRT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbiturates</td>
<td>Digoxin</td>
</tr>
<tr>
<td>Lithium</td>
<td>TCAs</td>
</tr>
<tr>
<td>Aspirin</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Sotalol/Atenolol</td>
<td>Other beta-blockers</td>
</tr>
<tr>
<td>Theophylline</td>
<td>Gliclazide</td>
</tr>
<tr>
<td>Ethylene Glycol</td>
<td>Benzodiazepines</td>
</tr>
<tr>
<td>Methanol</td>
<td>Warfarin</td>
</tr>
<tr>
<td>Aminoglycosides, metronidazole, carbapenems, cephalosporins, penicillins</td>
<td>Macrolides, quinolones</td>
</tr>
</tbody>
</table>

References


Last updated 2019-07-18
Sodium and Water

Describe the function, distribution, regulation and physiological importance of sodium, chloride, potassium, magnesium, calcium and phosphate ions.

Normal total body Na⁺ is 60mmol.kg⁻¹, 70% of which is exchangeable. Total body Na⁺ is distributed as:

- 50% in ECF
  - Sodium is the dominant extracellular cation.
  - Typical ECF [Na⁺] of 140mmol.L⁻¹.
- 45% in bone
- 5% in ICF
  - A minor intracellular cation.
  - ICF [Na⁺] varies with cell type, but is typically 12-20mmol.L⁻¹.
  - Concentration is kept low by the action of the 2Na⁺⁻3K⁺ ATPase exchange pump and the low permeability of the cellular membrane to Na⁺.

Function of Sodium

- **Regulation of ECF volume**
  - Principal ECF cation. Changes in sodium levels cause compensatory fluid shifts. Loss of sodium content will result in hypotension/hypovolaemia, with consequent baroreceptor stimulation and activation of the RAAS. Baroreceptors will activate with a 7-10% change in volume.
- **Osmolarity**
  - Changes in sodium concentration affect osmoreceptors and will affect ADH and thirst mechanisms. Osmoreceptors will activate with a 1-2% change in osmolality.
- **Acid-Base balance**
  - Na⁺⁻H⁺ exchange pumps in the kidney are stimulated in acidosis.
- **Resting Membrane Potential**
  - Alterations in sodium concentration will affect intracellular potassium to a similar degree, which will alter the RMP.

Regulation of Sodium and Water

Regulation of any system is typically a balance between **input** and **output**:

- Sodium intake is essentially unregulated.
- Therefore, sodium concentration is a function of:
  - Sodium elimination
  - Sodium reabsorption
- **Water homeostasis**
  - Control of total body water is a major mechanism to regulate sodium concentration.

Sodium Elimination

Sodium is eliminated in:

- Sweat and GIT
  - Obligatory and not amenable to regulation.
Acclimatisation to hot environments improves the efficiency of sweating by reducing its tonicity, reducing sodium loss.

- GIT
- Urine

Adjust renal elimination is the main mechanism to regulate sodium concentration.

Can be performed in two ways:

- **Changes in GFR**
  Changes in GFR due to hyper or hypovolaemia will (indirectly) adjust sodium elimination. Increased plasma volume increases GFR, and vice versa.

- **Changes in sodium reabsorption**
  This is the main mechanism for controlling sodium in euvolaemia, and is mediated primarily by aldosterone.

### Sodium Reabsorption

Given that:

- Normal glomerular filtrate is \( \sim 180 \text{L.day}^{-1} \)
- The dominant osmole in glomerular filtrate is sodium
- Normal urine output is \( \sim 1.5 \text{L}^{-1} \)

The majority of filtered sodium must be reabsorbed. This is called **bulk reabsorption** and occurs in the PCT and LOH:

- 60% of total reabsorption is by the \( \text{Na}^{+}-\text{K}^{+} \) ATPase pump in the PCT
- 30% of total reabsorption is by the \( \text{Na}^{+}-\text{K}^{+}-2\text{Cl}^{-} \) co-transporter in the LOH

The remaining 10% of sodium reabsorption occurs in the DCT and CT. As it is under the influence of aldosterone, it is the component which is important in regulation. Aldosterone increases \( \text{Na}^{+} \) reabsorption by increasing the number or activity of these pumps:

- \( \text{Na}^{+}-\text{Cl}^{-} \) pumps in the DCT
- \( \text{Na}^{+}-\text{K}^{+} \) ATPase pumps in principal cells of the DCT
- \( \text{Na}^{+}-\text{H}^{+} \) pumps in intercalated cells of the CT

### Water Homeostasis

Body water homeostasis involves:

- Sensors
  - Osmoreceptors present in:
    - Macula densa
    - Circumventricular organs
      - Subfornical organ and the vascular organ of the lamina terminalis
- Effectors
  - Predominantly hormonal:
    - ADH
    - RAAS
    - Natriuretic peptides

### References

2. CICM September/November 2014

Last updated 2019-07-18
Potassium

Potassium is the major intracellular cation, with 90% of total body potassium present in the ICF. A further 8% is sequestered in bone, with 2% present in the ECF.

- Normal ECF concentration is 3.5-5mmol.L\(^{-1}\)
- Normal ICF concentration is ~150mmol.L\(^{-1}\)

**Function and Dysfunction**

Potassium is important for:

- Regulation of intracellular pH
- Control of intracellular volume
- DNA and protein synthesis
- Enzymatic function
- Resting membrane potential

The resting membrane potential is determined by the ratio of intracellular:extracellular potassium, as per the Nernst equation:

- Small changes in extracellular ion concentration produce large changes in voltage
  - This has significant effect on excitable tissues.
- Rapid changes in potassium concentration cause symptoms at lower levels than chronic changes
  - Symptoms are related to the change in action potential generation.

Ventricular Action Potential in Hyperkalaemia:

**Hyperkalaemia**

Hyperkalaemia causes:

- The resting membrane potential to become less negative
  - As per the Nernst equation.
  - This results in the resting membrane potential being closer to the threshold potential, increasing irritability
  - Several symptoms, including:
    - Weakness
    - Paralysis
    - Parasthesias
  - ECG findings are those of prolonged depolarisation and rapid repolarisation:
### Serum [K⁺] (mmol/L) vs ECG Findings

<table>
<thead>
<tr>
<th>Serum [K⁺] (mmol/L)</th>
<th>ECG Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5-6.5</td>
<td>Tall tented T waves</td>
</tr>
<tr>
<td>6.5-7.5</td>
<td>Loss of P wave, lengthening PR interval</td>
</tr>
<tr>
<td>7.5-8.5</td>
<td>Widening QRS</td>
</tr>
<tr>
<td>&gt;8.5</td>
<td>Sine-wave QRS</td>
</tr>
</tbody>
</table>

### Hypokalaemia

Hypokalaemia:
- Causes the resting membrane potential to become more-negative
  - This makes it more difficult for a stimulus to reach the threshold potential, and therefore it is harder to generate and propagate action potential.
- ECG findings are those of rapid depolarisation and prolonged repolarisation, and include:
  - Prolonged PR
  - Long QT
  - Flat T waves or TWI
  - U waves
  - ST depression
  - Severe hypokalaemia may result in:
    - Frequent supraventricular and ventricular ectopics
    - Supraventricular arrhythmias
    - Ventricular arrhythmias

### Regulation

Serum potassium is dependent on intake, sequestration, and elimination.

### Intake

Dietary intake may be highly variable. Potassium is completely absorbed from the upper GI tract.

### Sequestration

Several factors affect potassium sequestration:
- **Insulin** and β2-agonism results in increase activity of the Na⁺-K⁺ ATPase pump, shifting potassium into cells following a meal and during exercise
- **Acidosis** causes an extracellular shift of potassium, as hydrogen ions are exchanged for potassium ions
  - The reverse occurs in alkalosis.
- **Cell lysis** may release a large amount of potassium into circulation and cause significant hyperkalaemia if a large number of cells are destroyed
- **Aldosterone** increases uptake of potassium into cells

### Elimination

Elimination of potassium occurs via the kidneys, and is dependent on production of large volumes of glomerular filtrate and secretion by the distal convoluted tubule and collecting duct.

In normal conditions:
Potassium

- The PCT and ascending limb reabsorb the majority of absorbed potassium. This is essentially fixed.
  - PCT absorbs ~55%
  - Ascending limb absorbs ~30%
- The principal cells of the DCT and collecting duct secrete potassium.
- Altering potassium secretion is the main method by which the kidney regulates serum potassium.
  - The collecting duct has a much greater role than the DCT.
  - With normal dietary intake, more potassium is secreted than reabsorbed.
- This changes in conditions of potassium depletion.

Control of Tubular Secretion

Tubular potassium secretion is mainly a function of:

- **Plasma \([K^+]\)**
  - Increased plasma \([K^+]\) stimulates the \(Na^+-K^+\) ATPase pump in the principal cells, and also stimulates aldosterone release from the adrenal cortex.
- **Tubular flow rate**
  - Movement of potassium out of principal cells occurs down a passive concentration gradient. Increasing tubular flow rate increases the concentration gradient for potassium.
- **Aldosterone**
  - Aldosterone increases production of the \(Na^+-K^+\) ATPase pump, which increases potassium secretion and uptake into cells.

Minor contributors include:

- **Sodium and water content**
  - High sodium content inhibits aldosterone release, reducing potassium elimination.
  - High water content inhibits ADH excretion and reduces secretion of potassium, however high water content also increases flow through the renal tubule, which indirectly increases tubular secretion of potassium.
- **Alkalosis**
  - Alkalosis increases elimination of potassium as the \(Na^+-K^+\) ATPase pump is stimulated by low \(H^+\) ion concentration.

References


Last updated 2017-10-04
Principles of Acid-Base Physiology

Explain the principles underlying acid-base chemistry

There have been several different theories of acid-base chemistry. The one most relevant for the primary exam is the Brønsted–Lowry definition, which defines:

- An acid as a proton donor
- A base as a proton acceptor

pH

- Stands for the power of hydrogen
- Is a measure of hydrogen ion activity in a solution
  - Activity can be approximated by concentration
  - Therefore, pH can be expressed as a function of hydrogen ion concentration: $pH = -\log_{10}[H^+]$

Using pH rather than concentration makes it easier to compare different solutions.

pKa

- Strong acids (and bases) dissociate completely in solution
- Weak acids (and bases) only partially dissociate
  - They have a dissociated state (A-) and an undissociated state (HA)
- The ratio of concentrations on each side can be used to calculate the acid dissociation constant, $Ka$

$$Ka = \frac{[A^-][H^+]}{[HA]}$$

This equation describes the strength of an acid by indicating how readily the acid gives up its hydrogen.

- Similar to pH, this value is often log transformed to pKa to produce an index, which allows easy comparison of different substances:

$$pKa = -\log_{10}Ka$$

- pKa has several useful properties:
  - An acid of base will be 50% ionised when the pH of its solution equals its pKa
  - Acids are more ionised above their pKa
  - Bases are more ionised below their pKa
  - An increase in pH of 1 above the pKa will result in that substance being either 90% (for an acid) or 10% (for a base) ionised
Systemic Effects of Acid-Base Disorders

pH disturbance affects many organ systems:

- **Respiratory**
  - Increased $\dot{V}_A$
    - Peripheral and central chemoreceptors increase ventilation in response to a fall in pH.
  - Oxyhaemoglobin-Dissociation Curve
Right-shifted by a fall in pH.

- Bronchoconstriction
  Hypercapnea causes parasympathetically-mediated bronchoconstriction.

- Cardiovascular
  - Inotropy
    Inotropy falls in acidosis due to a direct myocardial depressant effect. May be offset by increased SNS tone in low-grade acidosis. Alkalosis may increase inotropy by increasing responsiveness to circulating catecholamines.
  - Decreased response to catecholamines
    When pH < 7.2.
  - Arrhythmias
    Secondary to altered SNS tone and electrolytes.
  - Vasodilation
    Directly due to hypercapnea.

- CNS
  H+ ions cannot cross the BBB, however CO2 can.

- Fluid and Electrolyte
  - Plasma K+ increases by 0.6mmol.L−1 for every 0.1 unit fall in pH
    This is due to impairment of the Na+/K+-ATPase
  - H+ ions bind to the same site on albumin as calcium, so ionised calcium will increase

- MSK
  - Bones
    Chronic metabolic acidosis consumes bone phosphate to buffer H+ ions, causing osteoporosis.

- Cellular
  - Enzyme function
    Denaturation and functional impairment.
  - Molecular ionisation
    Change in ionisation may change a molecules ability to cross cell membranes (e.g. reducing dose of thiopentone in acidosis), or affect their function
  - Resting membrane potential
    Change in ion permeability will alter RMP, and therefore how easy it is to generate an action potential.

### Change with Temperature

pH is temperature dependent:

- **pH increases** by 0.015 for every 1°C fall in temperature
  Due to decreased ionic dissociation of water.

- **Gas solubility** almost always increases when temperature falls
  Dissolving is typically (not always) an exothermic reaction. As the kinetic energy content of a molecule falls, its ability to dissociate from solution decreases.
  - As CO2 dissolves, PaCO2 falls
  - As blood gas machines operate at 37°C, a measurement error will occur if a patient is not close to 37°C
  - A hypothermic patient will have a higher pH and CO2 than measured

There are two common methods for managing pH of significantly hypothermic patients (e.g., those on CPB): **pH-stat** and alpha-stat.

**pH-stat**

- CO2 is added to the circuit so that pH and PaCO2 are normal when corrected for temperature
- This theoretically improves oxygen delivery by preventing the left-shift in the oxyhaemoglobin dissociation curve
- The increased CO2 also causes cerebral vasodilation, which:
- Increases speed and uniformity of cerebral cooling
- Increases risk of cerebral embolic events

**alpha-stat**

- pH and CO₂ values are maintained at ‘normal for 37°C’
  - Measured values will be different, as:
    - pH will be increased
    - CO₂ will be decreased
- Cellular autoregulation is preserved
- Unlike pH-stat, this does not cause cerebral vasodilation

**References**

2. ANZCA July/August 1999

Last updated 2019-07-18
Compensation

Explain the principles underlying acid-base chemistry

Metabolic Acidosis

Compensation to metabolic acidosis includes:

- Buffering
  Occurs over minutes to hours. Includes:
  - **ECF** buffers
    - Bicarbonate
    - Plasma proteins
    - Albumin
  - **ICF** buffers
    - Include phosphate, proteins
    - Leads to hyperkalaemia due to $\text{H}^+ / \text{K}^+$ exchange
      $\text{K}^+$ increases by 0.6mmol.L$^{-1}$ per 0.1 unit fall in pH.
    - Bone
      Exchange of $\text{Na}^+$ and $\text{Ca}^{2+}$ in bone.
      - Leads to demineralisation and release of alkaline compounds
  
- Respiratory compensation
  Occurs in minutes.
  - Rapid response
  - Cannot compensate completely

- Renal compensation
  Occurs over days to weeks. Includes:
  - Elimination of $\text{H}^+$ bound to filtered buffers
    - Include ammonium, phosphate
  - Reabsorption of bicarbonate
  - Active secretion of $\text{H}^+$ in the DCT/CT
    Under control of aldosterone.

References

1. Diaz, A. *Describe how the body handles metabolic acidosis*. Primary SAQs.

Last updated 2017-09-20
Buffers

Describe the chemistry of buffer mechanisms and explain their relevant roles in the body.

A buffer is a solution which consists of a weak acid and its conjugate base, that can resist a change in pH when a stronger acid or base is added.

\[ Buffer + H^+ \leftrightarrow H\cdot Buffer \]

Buffering:
- Is a key part of acid-base homeostasis
- Allows compensation for large changes in acid or alkali load with minimal change in hydrogen ion concentration
  - In one experiment, dogs were infused with 14,000,000 nmol.L\(^{-1}\) of H\(^+\), with a corresponding rise in H\(^+\) of only 36 nmol.L\(^{-1}\)

Efficacy of a buffer system is determined by:
- \( pK_a \) of the buffer
- 80% of buffering occurs within 1 pH unit of the \( pK_a \) of the system.
- pH of the solution
- Amount of buffer
- Whether it is an open or closed system
  - An open buffer system can have the amount of chemical at one (or both) ends adjusted by physiological means.
    - This alters the concentration of reactants at either end of the equation, thus altering the speed of the reaction via the Law of Mass Action

Buffer Systems

Important buffer systems include:
- Bicarbonate buffer system
- Protein buffer system
  - Haemoglobin buffer system
- Phosphate buffer system

All buffer systems are in equilibrium with the same amount of H\(^+\). This is known as the isohydric principle.

Bicarbonate Buffer System

The bicarbonate buffer system is:
- The most important ECF buffer system
- Bicarbonate is formed in the erythrocyte and then secreted into plasma
- Bicarbonate diffuses into the interstitium and is also the dominant fluid buffer in interstitial space
- Formed in the erythrocyte
- A buffer pair consisting of bicarbonate and carbonic acid
  - Carbonic acid is exceedingly short lived in any environment even remotely compatible with life and it rapidly dissociates to HCO\(_3^-\) and H\(^+\).

Hydrogen ions are consumed or released by the following reaction:

\[ H_2CO_3 \leftrightarrow HCO_3^- + H^+ \leftrightarrow CO_3^{2-} + 2H^+ \]
Carbonic anhydrase (present in erythrocytes) is an enzyme which allows rapid conversion of H₂O and CO₂ to H₂CO₃ (and back again).

Each stage of the reaction has an individual pKa:

- As the pKa of the \( H₂CO₃ ⇔ HC\bar{O}_₃^- + H^+ \) system is 6.1, these substances predominate at physiological pH.
- The pKa for the second stage of the reaction is 9.3 and so essentially no CO₃²⁻ exists in blood. Clinically this reaction can be ignored.

In clinical conditions, the reaction becomes:

\[
H₂O + CO₂ ⇔ H₂CO₃ ⇔ HC\bar{O}_₃^- + H^+
\]

- Addition of a strong acid drives the above reaction to the left, forming (briefly) H₂CO₃ before it dissociates to CO₂ and H₂O.
- CO₂ is then able to be exhaled, which prevents equilibration and allows the system to buffer more acid.

Bicarbonate is an effective buffer because it is:

- Present in large amounts.
- Open at both ends.
  - CO₂ can be adjusted by changing ventilation.
  - Bicarbonate can be adjusted by changing renal elimination.
  - This prevents the bicarbonate buffer system from equilibrating and allows it to resist large changes in pH despite its low pKa. However, because it relies heavily on changes in pulmonary ventilation it is unable to effectively buffer respiratory acid-base disturbances.

Protein Buffer System

- All proteins contain potential buffer groups.
  - However, the useful one at physiological pH is the **imidazole groups** of the histidine residues.
- Extracellularly, proteins have a small contribution which is entirely due to their low pKa.
- Intracellularly proteins have a much greater contribution because:
  - Intracellular protein concentration is much greater than extracellular concentration.
  - Intracellular pH is much lower (~6.8) and closer to their pKa.

Haemoglobin Buffer System

Haemoglobin is:

- A protein buffer system.
- Quantitatively the most important non-bicarbonate buffer system of blood.

This is because haemoglobin:

- Exists in greater amounts than plasma proteins (150g.L⁻¹ compared to 70g.L⁻¹).
- Each molecule contains 38 histidine residues.

This results in 1g of Hb ~3x the buffering capacity of 1g of plasma protein.

In the cell:

- Haemoglobin exists as a weak acid (\( HHb \)) as well as its potassium salt (\( KHb \)).
- In acidosis:
  - Additional H⁺ ions are bound to Hb molecules.
  - HCO₃⁻ diffuses down its concentration gradient into plasma.
  - Electroneutrality is maintained through the inwards movement of Cl⁻.
  - Dissolved CO₂ will also form carbamino compounds by binding to the terminal amino groups.
The pKa of Hb is variable depending on whether it has bound oxygen:

- **Deoxyhaemoglobin** has a pKa of 8.2
  - Because of its higher pKa, deoxyhaemoglobin will more readily accept H\(^+\) ions which makes it a better buffer of acidic solutions.
- **Oxyhaemoglobin** has a pKa of 6.6
  - Both are essentially equidistant from normal pH, and are equally effective buffers
  - Quantitatively, per mmol of oxyhaemoglobin reduced, ~0.7 mmol of H\(^+\) can be buffered
    - Therefore 0.7 mmol of CO\(_2\) can enter blood without a change in pH.

  - This is the mechanism behind the **Haldane effect**, and why venous blood is only slightly more acidic than arterial blood

**Phosphate Buffer System**

Phosphoric acid is:

- Tribasic and can therefore potentially donate three hydrogen ions
- However, only one of these reactions is relevant at physiological pH, with a pKa of 6.8:
  
  \[
  H_2PO_4^- \rightleftharpoons H^+ + HPO_4^{2-}
  \]

  - The quantitative effect is low despite the optimal pKa due to the low plasma concentration of phosphate
  - At higher concentrations, such as intracellularly and in urine, it is a significant contributor
  - In prolonged acidosis, CaPO\(_4\) can be mobilised from bones and can be considered as an alkali reserve

---

**Footnotes**

1. Alex Yartsev offers an excellent discussion on **buffering** in his excellent trademark prose at [Deranged Physiology](https://derangedphysiology.com/)
2. Brandis's **anaesthesia MCQ** is required reading

---

**References**


Last updated 2019-07-18
Cerebrospinal Fluid

Describe the physiology of cerebrospinal fluid

CSF is a transcellular fluid in the ventricles and subarachnoid space. ~150ml (2ml/kg) of CSF exist in a normal individual, divided evenly between the head and spinal column.

Functions

- **Mechanical Protection**
  Due to its low specific gravity, CSF reduces the effective weight of the brain (by a factor of 30) and therefore reduces trauma caused by the acceleration and deceleration of the brain.
- **Buffering of ICP**
  CSF can be displaced to the spinal subarachnoid and have its rate of reabsorption increased in order to offset an increase in ICP by another space-occupying lesion.
- **Stable Extracellular Environment**
  Neurons are sensitive to ionic changes in the extracellular environment. Ionic concentrations in CSF are tightly controlled, which ensures stable neuronal activity. Additionally, toxins are actively removed from CSF.
- **pH Regulation**
  pH of extracellular fluid is important in the control of respiration, and is also tightly regulated.
- **Nutrition**
  Supply of O₂ and simple sugars and amino acids, and removal of CO₂ occurs occurs in CSF.

Formation

CSF is produced in the choroid plexus (70%) and brain capillary endothelial cells (30%) at a rate of 0.4 ml.min⁻¹ (500ml.day⁻¹). It is produced by a combination of ultrafiltration and secretion from plasma:

- Na⁺ is actively transported
  Drives flow of Cl⁻ ions and water.
- Glucose is transported via facilitated diffusion down its concentration gradient

Factors Affecting Formation

Formation is relatively constant within normal parameters (altering the rate of absorption is the predominant means to control pressure), though it is reduced by:

- **Decreased Choroidal Blood Flow**
  CPP <70mmhg reduces=“” CSF formation.

Contents

<table>
<thead>
<tr>
<th>Content</th>
<th>Relative Change</th>
<th>[CSF]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na⁺</td>
<td>-</td>
<td>140 mmol.L⁻¹</td>
</tr>
<tr>
<td>Cl⁻</td>
<td>↑</td>
<td>124 mmol.L⁻¹</td>
</tr>
<tr>
<td>K⁺</td>
<td>↓</td>
<td>2.9 mmol.L⁻¹</td>
</tr>
<tr>
<td>Gluc</td>
<td>↓</td>
<td>3.7 mmol.L⁻¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>---</td>
<td>----------</td>
</tr>
<tr>
<td>pH</td>
<td>↓</td>
<td>7.33</td>
</tr>
<tr>
<td>PCO$_2$</td>
<td>↑</td>
<td>50mmHg</td>
</tr>
</tbody>
</table>
| Protein  |   | Variable*
| Ca$^{2+}$| ↓ | 1.12 mmol.L$^{-1}$
| Mg$^{2+}$| ↑ | 1.2 mmol.L$^{-1}$

* CSF [protein] is variable:

- Highest in the lumbar sac
- Lowest in the ventricles
- Always lower than plasma [protein]

This means CSF is a **poor buffer solution**, which increases its sensitivity to derangements in respiratory acid-base status.

In summary:

- [$\text{Na}^+$] is unchanged
- [$\text{Mg}^{2+}$] and [$\text{Cl}^-$] are increased
- Concentrations of everything else is less

**Circulation**

CSF flow is driven by respiratory oscillations, arterial pulsations, and ongoing production in the choroidal plexus.

- **Production** in the *choroidal plexus* in the *lateral ventricles*
- To the *third ventricle* via the *Foramen of Monro*
- To the *fourth ventricle* via the *Aqueduct of Sylvius*
- To the *cisterna magna* via the two lateral *Foramina of Luschka* and the midline *Foramen of Magendie*
- It may now pass either:
  - Cranially, to the *basilar cisterns* and via the *Sylvian fissure* to the *cortical regions*
  - Caudally, to the *spinal subarachnoid space* via the *central canal*

**Reabsorption**

Reabsorption of **CSF**:

- Occurs in the *arachnoid villi*, which are located in the *dural walls* of the *sagittal and sigmoid sinuses*
  - 85% of reabsorption occurs in intracranial arachnoid villi
  - Remainder by spinal arachnoid villi
- Is predominantly via pinocytosis and opening of extracellular fluid spaces
- Is *pressure-dependent*
  - Reabsorption occurs when the **CSF** pressure is 1.5mmHg greater than venous pressure

Typically an *ICP* < 7mmHg results in minimal **CSF** reabsorption. Above this, **CSF** absorption increases in a linear fashion up to 22.5mmHg.

**References**

Last updated 2019-07-18
Blood-Brain Barrier

The blood-brain barrier is a physiological barrier which prevents substances in the ECF of the body moving freely into the ECF of the brain. The functions of the BBB are:

- Maintain a stable extracellular milieu
  - Optimises neuronal function by preventing fluctuations in plasma $K^+$, $Na^+$, and $H^+$ affecting cerebral cells.
- Protection of the brain
  - Isolates the brain from toxins.
- Protection of the body
  - Isolates the rest of the body from CNS neurotransmitters.

Anatomy

The BBB occurs in three layers:

- Capillary endothelial cells
  - Joined with tight junctions, preventing free movement of solvent and solute.
    - Capillary endothelial cells contain high numbers of mitochondria, due to the higher energy cost of the active transport mechanisms.
- Basement membrane
- Astrocytes
  - Glial cell which extends foot processes around the basement membrane, and reduce permeability of endothelial cells.

Due to their function, several important CNS structures must exist outside of the BBB. These are known as the circumventricular organs, and include:

- Sensing structures
  - Chemoreceptor trigger zone (Area Postrema)
    - Identifies toxins in the systemic circulation, triggering vomiting.
  - Hypothalamus
    - Osmoreceptors detect systemic osmolarity.
  - Subfornical organ
    - Role in CVS and fluid balance.
  - Organum vasculosum

- Secreting structures
  - Pituitary
    - Secretes hormones.
  - Pineal gland
    - Secretes melatonin.
  - Choroid plexus
    - Produces CSF via secretion and ultrafiltration of plasma.

Movement of Substances

Substances can move via:

- Diffusion
  - For lipid soluble molecules only; e.g:
- CO₂
- O₂

**Facilitated diffusion**
For movement of larger/less soluble molecules down their concentration gradient, e.g:
- Glucose
- Water

**Active transport**
Responsible for movement of most small ions; e.g:
- Na⁺
- Cl⁻
- K⁺
- Mg²⁺
- Ca²⁺

Other substances are specifically excluded:

- **Catecholamines**
  Metabolised by MAO in capillary endothelium, preventing their action as CNS neurotransmitters.

- **Amino acids**
  Prevent action as neurotransmitters.

- **Ammonia**
  Metabolised in astrocytes to glutamine, limiting its neurotoxic effects.

---

**References**


Last updated 2019-07-18
Spinal Cord Anatomy

Describe the major sensory and motor pathways (including anatomy)

Spinal Cord Anatomy

The spinal cord in transverse section consists of a central section of grey matter containing neuronal cell bodies and synapses, and a peripheral section of white matter containing myelinated ascending and descending pathways. Important pathways are:

- **Corticospinal tract**
  Motor function. Crosses at the brain stem.
- **Dorsal column**
  Light touch and proprioception. Crosses at the brain stem.
- **Spinothalamic tract**
  Pain and temperature. Crosses within two vertebral segments.
- **Spinocerebellar tract**
  Unconscious proprioception. Does not cross.

Spinal Cord Syndromes

Lesions to certain anatomical regions of the spinal cord produce a particular constellation of findings.

**Complete Transection**

A complete transection results in loss of movement and sensation below the level of the lesion. Initially, paralysis is flaccid (and other signs, such as priapism, may be absent in this ‘spinal shock’ phase) becomes spastic after a few weeks. Bowel and bladder function is lost.

Lesions above T10 will result in impaired cough in the initial stage as the abdominal wall is unable to contract (intercostal muscle function may be impaired as well, but this is of less importance clinically).

**Central Cord Syndrome**

Central cord syndrome results in a flacid paralysis and loss of sensation of the upper limbs greater than the lower limbs.

**Anterior Cord Syndrome**

Anterior cord syndrome spares the dorsal columns only, therefore motor function and pain and temperature sensation are affected below the level of the lesion.

**Brown-Sequard Syndrome**

Hemisection of the cord results in:

- **Ipsilateral** loss of motor function below the level of the lesion
- **Ipsilateral** loss of light touch and proprioception below the level of the lesion
- **Contralateral** loss of pain and temperature sensation below the level of the lesion
- **Ipsilateral** loss of pain and temperature sensation at the level of the lesion
Cauda Equina

Cauda Equina syndrome results from compression of lumbosacral nerve roots below the level of the conus medullaris. It may produce a combination of UMN and LMN signs:

- Radiculopathy
- Sacral sensory loss
- Asymmetric LMN weakness and atrophy
- Erectile dysfunction and inability to ejaculate
- Urinary retention and overflow incontinence
- Constipation and overflow incontinence

References

Intracranial Pressure

Explain the control of intra-cranial pressure

Normal ICP is

- P1 is the first peak, and represents arterial pulsation
- P2 is the second peak, and represents intracranial compliance
  - If P2>P1, this is suggestive of poor intracranial compliance
- P3 is the third peak, and is a dicrotic wave representing valve closure

In addition, a second set of Lundberg waves are described:

- A waves are pathological, and consist of square-wave plateaus up to 50mmHg lasting 5-20 minutes. They are suggestive of herniation, and are always pathological.
- B waves are variable spikes in ICP at 30-120 second intervals, suggestive of cerebral vasospasm
- C waves are oscillations that occur 4-8 times per minute, and are a benign phenomena occurring with respiratory and blood pressure variations

Raised intracranial pressure may cause focal ischaemia when ICP >20mmHg, and global ischaemia when the ICP >50mmHg:

Monroe Kellie Doctrine

This states that:

- The skull is a rigid container of a fixed volume, containing approximately 8 parts brain, 1 part blood, and 1 part CSF
- As it has negligible elastance, any increase in volume of one substance must be met with a decrease in volume of another or a rise in ICP
  - Elastance is technically correct as we are discussing a change in pressure for a given change in volume
  - Compliance is a change in volume for a given change in pressure.

Physiological Responses to an Increase in ICP

- Displacement of CSF into the spinal subarachnoid space
- Compression of vascular bed
- Increased CSF reabsorption
- The Cushing reflex may occur in brainstem herniation
  - This is a triad of hypertension, bradycardia, and irregular respiration secondary to SNS activation, and is a reflexive response to medullary ischaemia.
    - Hypertension
To improve CPP.

- Bradycardia
  Due to a baroreceptor response.
- Irregular respiration
  Due to respiratory centre dysfunction.

**Physiological Basis of Treatment**

Treatment can be classified as per the Monroe Kellie doctrine:

**Brain**

- Osmotic agents such as mannitol and hypertonic saline
  Increase plasma osmolality and expand blood volume, creating an osmotic gradient between brain parenchyma and blood with a resulting reduction in brain oedema and ICP.
- Timely evacuation of mass lesions and intracranial haemorrhage

**CSF**

- External Ventricular Drain
  Facilitates removal of CSF.

**Blood**

- Reducing cerebral metabolic rate
  Results in reduced blood flow due to flow-metabolism coupling. May be achieved with:
    - CNS depressants such as propofol, benzodiazepines, or barbiturates
      Have several beneficial effects:
    - Depress cerebral metabolism which reduces oxygen requirements
    - Reduce seizure risk, which is detrimental because it greatly increases cerebral O₂ demand and impairs venous return
    - Improves ventilator dyssynchrony, limiting coughing and bearing down, and subsequent rises in ICP
    - Hypothermia
      Causes a reduction in cerebral metabolism and risk of seizures.
    - Prevention of hypoxia or hypercapnea
      Hypoxia and hypercapnea both cause vasodilatation, with a subsequent increase in cerebral blood volume, blood flow, and ICP.
    - Induced hypocarbia
      Causes vasoconstriction and a subsequent reduction in cerebral blood flow and blood volume. This leads to:
        - Reduction in ICP
        - Reduction in cerebral oxygen delivery
          Consequently, a low-normal ETCO₂ target is used to avoid tissue hypoxia.

**References**


Last updated 2019-07-18
Intraocular Pressure

Normal intraocular pressure is ~15mmHg, with a range of 12-20mmHg. Regulation of intraocular pressure is important for:

- Vision
  Sustained high (>25mmHg) can lead to blindness due to compression of axons of the optic nerve and the optic artery at the optic disc.

Determinants of Intraocular Pressure

As the globe has typically poor compliance, a small increase in volume can cause a large increase in intraocular pressure. Factors affecting volume include:

- Volume of aqueous humor
  Aqueous humor is a clear fluid that fills the anterior and posterior chambers of the eye, and provides avascular tissues with nutrients and oxygen whilst still allowing light to pass freely between the lens and retina. Volume of aqueous humor is a function of:
    - Production
      Aqueous humor is produced by secretion and filtration from capillaries in the ciliary body in the posterior chamber, and circulates through into the anterior chamber.
      - Production is accelerated by β2 agonism
      - Production is inhibited by α2 agonism
      - Carbonic anhydrase inhibitors decrease aqueous humor production probably by decreasing sodium secretion into the eye
    - Reabsorption
      Aqueous humor is reabsorbed into venous blood in the canal of Schlemm.
      - The trabeculae meshwork is the main source of resistance to reabsorption
        If this is blocked, a significant reduction in reabsorption can occur and IOP will increase.
      - Reabsorption is affected by:
        - Haemorrhage
          Blocks trabecular meshwork.
        - Muscarinic antagonism
          Dilates pupil, which brings the iris closer to canal and decreases absorption.
        - α1 agonism
          Dilates the pupil, decreasing absorption.
        - PGF2α
          Relaxes ciliary muscle, increasing absorption.

- Volume of blood within the globe
  Affected by:
  - MAP
  - Venous obstruction

- External factors
  Other factors affecting volume or compliance of the globe:
  - Extraocular muscle tension
  - Extraocular compression
References

1. ANZCA July/August 2000

Last updated 2019-07-18
Describe the physiology of sleep

Sleep is a naturally occurring state of unconsciousness from which one can be aroused by an external stimuli.

Sleep is important in:

- Homeostasis of many organ systems
- Memory formation
- Preservation of cognitive function

Stages of Sleep

Stages of sleep are classified based on EEG changes:

- **REM sleep**
  Characterised by EEG activity resembling that of awake individuals. REM sleep:
  - Lasts for 5-30 minutes
  - Event frequency decreases with age.
  - In REM sleep:
    - Irregular eye movements
    - Dreaming occurs
    - Irregular HR and RR
    - Muscle contraction occurs (but muscle tone is decreased)

- **Non-REM sleep**
  Deep sleep, characterised by depression of HR, SVR, BP, RR, and metabolic rate (~0.9 METs) It is divided into four stages on EEG:
  - Stage 1: 4-6Hz θ waves replace α-waves
    - Dosing, easily roused.
  - Stage 2: Similar to stage 1 with occasional high frequency 50μV bursts (sleep spindles)
  - Stage 3: 1-2Hz high-voltage δ waves appear
  - Stage 4: Large δ waves become synchronised
    - Deep sleep.

Periods of REM sleep alternate with non-REM sleep during the night, with an average of 4-5 cycles of REM sleep per night.

Respiratory Effects

GABAergic neurons depress the respiratory centre, leading to respiratory depression:

- Decreased MV
  - Decreased VT
    - Greatest decrease occurs during REM sleep, where it falls by ~25%.
  - Unchanged RR
- Increased PaCO₂
- Decreased PO₂
  - More pronounced in elderly.

- Collapse of airway soft tissue
Due to reduced tonic activity of pharyngeal muscles.

References

2. Leslie RA, Johnson EK, Goodwin APL. Dr Podcast Scripts for the Primary FRCA. Cambridge University Press. 2011.

Last updated 2019-07-18
Pain

Describe the physiology of pain, including the pathways and mediators

Key definitions:

- **Pain**
  Pain is an “unpleasant sensory or emotional experience associated with actual or potential tissue damage, or described in such terms.” Pain can be broadly classified by:
  - **Aetiology**
    - **Nociceptive pain**
      Stimulation of nociceptors by noxious stimuli.
    - **Visceral pain**
    - **Neuropathic pain**
      Nervous system dysfunction.
  - **Duration**
    - **Acute pain**
      Pain due to symptoms of current pathology.
    - **Chronic pain**
      Pain occurring after the pathological process has resolved.

- **Hyperalgesia**
  Increased response to a normally painful stimulus.
  - **Primary hyperalgesia**
    Local reduction in pain threshold.
  - **Secondary hyperalgesia**
    Hyperalgesia away from the site of injury due to alteration in spinal cord signaling.

- **Allodynia**
  Painful response to a normally painless stimuli. Occurs due to pathological synapse between second-order neurones in the spinal cord.

- **Anaesthesia dolorosa**
  Pain in an area which is anaesthetised.

Peripheral Nociception

Nociceptors are receptors which respond to a noxious stimulus. Nociceptors:

- Can be **stimulated** or **sensitised** by:
  - Chemical signals
    See table.
  - Mechanical signals
    - **Shear stress**
  - Thermal signals
    - Hot nociceptors activate above 43°C
    - Cold nociceptors activate below 26°C
  - Stimulation initiates a nervous impulse
  - Sensitisation increases a receptors sensitivity to a stimulating mediator

Key chemical stimulating and sensitising mediators include:
<table>
<thead>
<tr>
<th>Stimulating Mediators</th>
<th>Sensitising Mediators</th>
</tr>
</thead>
<tbody>
<tr>
<td>H⁺</td>
<td>Prostaglandins</td>
</tr>
<tr>
<td>K⁺</td>
<td>Leukotrienes</td>
</tr>
<tr>
<td>ACh</td>
<td>Substance P</td>
</tr>
<tr>
<td>Histamine</td>
<td>Neurokinin A</td>
</tr>
<tr>
<td>5-HT</td>
<td>Calcitonin GRP</td>
</tr>
<tr>
<td>Bradykinin</td>
<td></td>
</tr>
</tbody>
</table>

**Nociceptors**

Impulses are conducted by two types of **primary afferent fibres**:

- **Aδ fibres**:
  - Small (~2-5μm diameter)
  - **Myelinated**
  - Conduct sharp pain at up to 40m.s⁻¹
  - Mediate initial reflex responses to acute pain
  - Synapse in laminae I in the dorsal horn
  
  Substance P is the neurotransmitter at the NK1 receptor.

- **C fibres**:
  - <2μm diameter
  - **Unmyelinated**
  - Conduct dull pain at 2m.s⁻¹
  - Synapse in laminae II in the dorsal horn
  
  Substance P is the neurotransmitter at the NK1 receptor.

**Pain Pathway and Site of Action of Analgesics**

The response to a painful stimulus requires a cascade of processes:

- **Activation of nociceptors**
  Membrane depolarisation in response to stimulus. If the stimulus is great enough to reach the threshold potential, an action potential is generated.
  - **NSAIDS** reduce nociceptor mediated inflammation
  - **Opiates** act on peripheral **MOP** receptors
  - **Local anaesthetics** prevent signal propagation

- **Synapse in the dorsal horn**
  Input from both Aδ and C fibres, and descending interneurons.
  - Descending inhibitory input reduces nociceptive transmission
  
  Basis of "gate control" theory. Descending input increased with:
  
  - **Touch**
    - Aβ 'touch' fibres stimulate inhibitory interneurons in the dorsal horn, 'closing the gate' by increasing **descending inhibition** and prevent signals from peripheral C fibres from rising to the thalamus.
  - **Arousal**
  - **Opioid receptors**
    - Particularly **MOP** (pre- and post-synaptically).
      - **Opioids** act pre-synaptically to reduce Substance P and glutamine release.
  - α₂ receptors
**Neuropathic Pain**

Pain due to a lesion of the somatosensory system, rather than a stimulus itself. Neuropathic pain is divided into:

- **Central neuropathic pain**
  From CNS injury, e.g. spinal cord injury, CVA, multiple sclerosis.

- **Peripheral neuropathic pain**
  Damage from:
  - Diabetes
    Ischaemia of Schwann cells causes demyelination, causing the exposed axon to generate action potentials inappropriately.
  - Trauma
    Transected axons may regrow with endings that spontaneously fire or that have altered threshold potentials.

**Mechanisms of Neuropathic Pain**

- **Neuroma**
  Healing of damaged nerves leads to neuroma formation. Neuromas:
  - Are more sensitive to painful stimuli
  - Cause spontaneous pain
  - May sprout and innervate local tissues
    Movement of these tissues may lead to pain.

- **Windup**

- **Phantom limb pain**
  Neurons damaged in removal of a limb develop additional synapses, leading to phantom sensations.

**Features of Neuropathic Pain**

Neuropathic pain is associated with:

- Clonidine, tricyclic antidepressants, noradrenaline-reuptake inhibitors, and endogenous catecholamines.
  - Gabapentin and pregabalin inhibit presynaptic neurotransmitter release

- **Wide dynamic range** neurones
  Receive afferent input from chemical, thermal, and mechanoreceptors.
  - Typically more difficult to stimulate
  - Important in wind-up
    Mediated by NMDA agonism.
  - Ketamine reduces windup and central sensitisation
  - Lead to secondary hyperalgesia
  - Lead to allodynia
    Via additional synapses to sensory neurones in lamina III and IV.
  - Interneuron synapses with a second-order neurones fibre
    These secondary afferents:
    - Cross within 1-2 vertebral segments and ascends in the spinothalamic tract
    - Receives input from descending fibres
    - **Opioids** act post-synaptically to hyperpolarise second-order neurones

- **Reflex arc**

- **Higher centres**
  Pain perception occurs in the somatosensory cortex.
Injury or disease that causes nerve injury
- Burning or electrical quality
- Reduced or absent sensation
- Poor response to typical analgesia

**Chronic Regional Pain Syndrome**

Damage to the SNS can lead to abnormalities in autonomic function:
- Change in temperature due to vasomotor dysfunction
- Altered sweating
- Reduced hair growth
- Osteoporosis
- Hyperalgesia and allodynia

**Pain in the Elderly**

Nervous System Changes:

- **Peripheral Nervous System**
  - Nerve deterioration
  - Decreased myelination
  - Decreased conduction velocity
  - Reduced range and speed of ANS responses
  - Increased resting sympathetic tone
- **Central Nervous System**
  - Decreased pain perception
  - Increased sensitivity to anaesthetic and analgesics
    - Reach ceiling effects more rapidly.
  - Degeneration of myelin
    - Subsequent cognitive dysfunction due to neuronal circuit dysfunction.
  - Generalised atrophy
  - Decreased neurotransmitter production

**References**

8. Gibson S. Pathophysiology of Pain.

Last updated 2019-07-18
Autonomic Nervous System

Describe the autonomic nervous system, including anatomy, receptors, subtypes and transmitters (including their synthesis, release and fate)

The ANS is the section of the nervous system which regulates involuntary and visceral functions. These include:

- Haemodynamics
- Digestion
- Urination and defecation
- Thermoregulation
- Sexual function

The autonomic nervous system can be divided into

- **Central ANS**
  - Control occurs in the hypothalamus, brainstem, and spinal cord.

- **Peripheral ANS**
  - Divided anatomically and functionally into the:
    - Sympathetic nervous system
    - Parasympathetic nervous system

GRAPH FROM PAGE 258 of GANONG

Central Control

The hypothalamus controls autonomic functions by neural and endocrine mechanisms. It is subdivided anatomically into four regions:

- **Anterior hypothalamus**
  - Controls the PNS and thermoregulation. It also releases ADH in response to increased plasma osmolality, and oxytocin.

- **Medial hypothalamus**
  - Inhibits appetite in response to increase in blood glucose.

- **Lateral hypothalamus**
  - Contains the thirst centre and drive to seek food.

- **Posterior hypothalamus**
  - Controls vasomotor centres, modulating sympathetic vasoconstriction, as well as positive and negative inotropy and chronotropy. Also modulates wakefulness in response to sympathetic stimuli.

Signals from the hypothalamus have a tonic output to:

- All smooth muscle
- Heart
- Exocrine organs
- Endocrine organs
- GIT
- GU

Central Anatomy
In the grey matter of the spinal cord, efferent nerves synapse with two other nerves connected in series. This maintains tonic autonomic outflow.

FIGURE FROM PAGE 67 - POWER AND KAM

Efferent nerves exit the spinal root anteriorly, and form the ventral root.

Conversely, afferent nerves exit posteriorly, forming the dorsal root and then dorsal root ganglion, before synapsing in the spinal cord.

**Sympathetic Nervous System**

The sympathetic nervous system optimises the body for short-term survival.

Sympathetic innervation is from the sympathetic trunks. These:

- Are a paired bundle of sympathetic neurons which run lateral to the vertebral bodies from T1 to L2
- The trunk is subdivided into four parts:
  - The **cervical part** innervates the head, neck, and part of the thorax
  - The **thoracic part** is further subdivided into:
    - Upper thoracic from T1-T5, which innervates the aorta, heart, and lungs
    - Lower thoracic from T6-T12, which innervates the foregut and midgut
  - The **lumbar part** forms the coeliac plexus
  - The **pelvic part** innervates the pelvic visceral and lower limb vasculature
- Contain the sympathetic ganglion, which is a synapse between the:
  - **Short pre-ganglionic fibre**
    - Cell body is located in the lateral horn of the spinal cord, and connects to the sympathetic ganglion.
    - Releases ACh to stimulate the post-ganglionic fibre.
  - **Long post-ganglionic fibre**
    - Cell body is located in the sympathetic ganglion, and stimulates the effect site.
    - Has a nicotinic ACh receptor
    - Releases NA at the effect site
    - Sensitivity (for ACh) and activity (for NA release) is modulated by a number of other substances:
      - Enkephalin
      - Neuropeptide Y
      - Dopamine
      - Adrenaline
      - Prostaglandin
      - GABA
      - Neureotensin

There are three exceptions to the above structure:

- The **adrenal gland** is a modified sympathetic ganglion. It is:
  - Directly innervated by preganglionic neurons releasing ACh
  - Sweat glands have muscarinic receptors, and are stimulated by ACh rather than noradrenaline
  - Skeletal muscle arterioles also have muscarinic ACh receptors, and are stimulated by ACh

**Effect**

Sympathetic stimulation has a number of effects by either direct neural innervation or adrenaline release. They are consistent with a 'fight or flight' response, and optimise the body for short-term stress conditions.
Parasympathetic Nervous System

Parasympathetic innervation arises from the:

- **Cranial nerves**
  - From CN III, VII, IX, and (mostly) X.
    - The vagus is the major cranial parasympathetic, innervating the:
      - Heart via the cardiac plexus
        - The SA node is innervated by the right vagus
        - The AV node is innervated by the left vagus
        - The ventricles are also sparsely innervated from the left vagus.
      - Lungs via the pulmonary plexus
      - Stomach, liver, spleen, and pancreas, and gut proximal to the splenic flexure via the gastric plexus.

- **Hypogastric plexus**
  - Arises from S2-S4, and innervates the bladder, uterus, and gut distal to the splenic flexure.

The parasympathetic nervous system ganglia site close to the target organ. This means that the:

- **Pre-ganglionic fibre is long**
  - Preganglionic cell body sits within the brainstem (cranial nerves) or sacral grey matter (hypogastric plexus)
  - Releases ACh to stimulate the post-ganglionic neurone at a **nicotinic ACh** receptor
- **Post-ganglionic fibre is short**
  - Releases ACh to stimulate the target organ at a **muscarinic ACh** receptor

**Effect**

<table>
<thead>
<tr>
<th>Effector Organ</th>
<th>Parasympathetic Innervation</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CNS</strong></td>
<td>CN III via the Edinger-Westphal nucleus, CN VII</td>
<td>Pupillary constriction (CN III), lacrimation (CN VII)</td>
</tr>
<tr>
<td><strong>Lungs</strong></td>
<td>CN X</td>
<td>Bronchoconstriction, increased mucous production</td>
</tr>
<tr>
<td><strong>Heart</strong></td>
<td>CN X</td>
<td>↑↑↑ Chronotropy, ↑↑ dromotropy, ↑ inotropy, ↑ lusitropy (↑ in inotropy and lusitropy is greater in the atria than the ventricles)</td>
</tr>
<tr>
<td></td>
<td>CN VII (submaxillary and mandibular salivary glands), CN IX</td>
<td></td>
</tr>
<tr>
<td>GIT</td>
<td>(parotid gland), CNX (stomach to proximal two-thirds of the transverse colon), hypogastric plexus (distal one-third of the transverse colon to rectum)</td>
<td>Salivation, decreased sphincter tone, increased motility</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>GU</td>
<td>Hypogastric plexus</td>
<td>Detrusor contraction, erection</td>
</tr>
</tbody>
</table>

**Ganglion Blockade**

Blockade of the ganglion (at the nicotinic ACh receptor) blocks transmission and reduces sympathetic and parasympathetic impulse transmission. Clinical effect of ganglion blockade depends on which part of the ANS is dominant in that organ system:

- **SNS dominant organ systems**
  - Effective sympatholysis:
    - Vasculature
      - Vasodilation, hypotension.
    - Sweat glands
      - Anhydrosis.
- **PNS dominant organ systems**
  - Effective parasympatholysis:
    - Heart
      - Tachycardia.
    - Iris
      - Mydriasis.
    - GIT
      - Decreased ton.
    - Bladder
      - Urinary retention.
    - Salivary
      - Reduced secretions.

**Enteric Plexus**

The enteric plexus is a system of autonomic nerves in the GIT which is free of CNS control. It consists of sensory and integrative neurons as well as excitatory and inhibitory motor neurons which generate coordinated muscular activity.

**References**

Anticonvulsants

An understanding of the pharmacology of anti-depressant, anti-psychotic, anti-convulsant, and anti-Parkinsonian medication

Anticonvulsants work via a number of different mechanisms:

**Sodium Channel Blockers**

Sodium channel blockers:

- Stabilise the inactive state of the channel, preventing return to the active state and prevent generation of further action potentials
  - This halts post-tetanic potentiation and limits the development of seizure activity.
- May also have Class I antiarrhythmic properties
  - Due to Na⁺ blocking effects.
- Include:
  - Phenytoin
  - Carbamazepine
  - Lamotrigine

**GABA Mediators**

GABA is the key inhibitory neurotransmitter in the CNS. GABA mediators:

- Enhance the effect of GABA
  - Multiple potential mechanisms:
    - Direct GABA-receptor agonists
      - e.g. Benzodiazepines and phenobarbital.
    - Positive allosteric modulation
      - e.g. Propofol and thiopentone.
    - GABA reuptake inhibition
      - e.g. Tiagabine.
    - GABA transaminase inhibition
      - e.g. Vigabatrin.
    - Increase GABA synthesis
      - e.g. Sodium Valproate.

**Glutamate Blockers**

Glutamate is an important CNS excitatory neurotransmitter. Glutamate antagonists:

- Are generally avoided due to their side effect profile, which includes psychosis and hallucinations
- Include topiramate

**Other Agents**

Gabapentin and pregabalin:
Do not appear to mediate GABA
Inhibit of excitatory \( \alpha_\delta \) voltage-gated calcium channels in the CNS
This gives them anticonvulsant properties.

References


Last updated 2017-08-11
Neurotransmitters

Describe the major neurotransmitters and their physiological role, with particular reference to GABA, excitatory and inhibitory amino acids, acetylcholine, noradrenaline, dopamine and serotonin and NMDA receptor.

GABA

Gamma aminobutyric acid is the major inhibitory CNS neurotransmitter. GABA receptors have three subtypes:

- **GABA**\(_A\)**
  - Inotropic receptor important for the action of many drugs.
    - Pentameric structure
      - 2 α
        - Bind GABA.
      - 2 β
      - 1 γ
    - Affected by many different drugs:
      - Benzodiazepines
        - Positive allosteric modulation at the α/γ interface.
      - General anaesthetic agents
        - Including propofol, barbiturates, halogenated volatiles, and etomidate.
          - Act at the β subunit
            - Cause a conformational change which increases Cl\(^{-}\) opening time, hyperpolarising the cell.

- **GABA**\(_B\)**
  - Metabotropic receptor.

- **GABA**\(_C\)**
  - Inotropic receptor located only in the retina.

NMDA

N-methyl D-aspartate receptor is an inotropic receptor that is:

- Agonised by glutamate
  - Glycine is co-agonist
- Voltage dependent
  - Central pore usually blocked by an Mg\(^{2+}\) ion
  - Becomes unblocked when partially depolarised
- Important in the action of drugs which do not act at the GABA\(_A\) receptor
  - Antagonised by:
    - Ketamine
    - Xenon
    - N\(_2\)O

References

Local Anaesthetics

Understanding of the pharmacology of local anaesthetic drugs, including their toxicity

Local anaesthetic drugs create a use-dependent temporary blockade of neuronal transmission by blocking the voltage-gated sodium channel in the cell membrane, preventing depolarisation.

Mechanism of Action

Action is dependent on blockade of the sodium channel. Two theories exist:

- **Unionised** drug passes through the cell membrane, and then becomes ionised intracellularly
- The ionised drug is then able to bind to the open sodium channel, and prevent conduction of sodium and therefore generation of an action potential
  - Local anaesthetics also display reduced affinity for K⁺ and L-type Ca²⁺ channels
  - This theory explains use-dependent blockade, as sodium channels can only be blocked in their open state
- An alternative suggested mechanism of action is the drug enters the cell membrane and mechanically distorts the channel, rendering it ineffective
- Onset is inversely proportional to the size of the fibre
  - From fastest to slowest:
    - Pain
    - Temperature
    - Touch
    - Deep pressure
    - Motor

Chemical Structure of Local Anaesthetics

All local anaesthetics are weak bases consisting of:

- A hydrophilic component
- A lipophilic aromatic ring
- An amide or ester link connecting the two

Chemical structure influences pharmacological behaviour:

- **Hydrophilic portion**
  - Typically the tertiary amine.
  - Determines ionisation
    - 3 bonds: Lipid soluble
    - 4 bonds: Water soluble
- **Lipophilic portion**
  - Typically aromatic ring.
  - Determines lipid solubility, and therefore potency, toxicity, and duration of action
- **Ester vs. amide**
  - Amides
    - Hepatically metabolised (hydroxylation and N-de-alkylation)
      - This is slower, therefore there is a greater risk of systemic toxicity.
    - Stable in solution
● **Esters**
  - Heat-sensitive
    - Cannot be autoclaved.
  - Rapidly hydrolysed in plasma
    - Organ independent elimination.
  - Have a greater incidence of allergy
    - Due to the inactive metabolite PABA.
● **Amine group length**
  - Potency and toxicity increase as carbon-chain increases
  - Toxicity (but not potency) continues to increase beyond 10 carbons
● **Isomerism**
  - Alters behaviour:
    - Levobupivacaine is less toxic
    - R-ropivacaine is less potent and more toxic

### Key Characteristics of Local Anaesthetics

Characteristics are related to chemical structure. These include:

- **Potency**
  - Potency is expressed with the minimum effective concentration of local anaesthetic ($C_m$)
    - This is the concentration of LA that results in complete block of a nerve fibre in 50% of subjects in standard conditions.
    - More potent agents have a lower $C_m$.
  - Potency is a function of:
    - Lipid solubility
      - Potency (and also toxicity) increases with greater lipid solubility.
    - Vasodilator properties
      - In general, local anaesthetics cause vasodilation in low concentrations, and vasoconstriction at high concentrations (except cocaine, which causes vasoconstriction at all concentrations).

- **Duration of action**
  - Duration of action is a function of:
    - Drug factors
      - Vasodilator properties
        - Vasoconstriction increases the duration of block.
      - Use of additives
        - Addition of adrenaline to lignocaine increases duration of block.
      - Lipid solubility
        - Increased lipid solubility increases duration of action, as agent remains in the nerve for longer.
          - Potency therefore has a positive correlation with duration of action
          - Duration of action is increased when pH increases, as the ionised portion falls
    - Protein binding
      - Highly protein bound agents have an increased duration of action due to increased tissue binding.
      - Protein binding decreases with decreasing pH, increasing the fraction of unbound drug
        - This is why agents such as bupivacaine are more cardiotoxic in acidotic patients.
      - Local anaesthetics are predominantly bound to α-1-acid glycoprotein (AAG)
      - AAG is reduced in pregnancy, increasing the free drug fraction and therefore reducing the toxic dose of LA in pregnant patients.
    - Patient factors
      - Tissue pH
        - Decreased duration of block when tissue pH is low.
- Metabolic impairment
  - Hepatic failure increases duration of action of aminosteroids
  - Butylcholinesterase deficiency increases duration of ester local anaesthetics
  - Site of administration: Well vascularised tissue (e.g., intercostal area) will have greater systemic uptake of drug than vessel poor tissue.

- **Onset**
  Speed of onset is related to:
  - Drug factors
    - Dose
      Increasing the dose increases the speed of onset, as per Fick's Law.
      - Increased concentration will increase speed of onset and block density
      - Increased volume (without increasing dose, resulting in decreased concentration) will decrease speed of onset
    - Lipid solubility
      An increased lipid solubility increases the speed at which the local anaesthetic enters the nerve. **However:**
      - Lipid solubility also correlates with potency
      - Therefore, in practice, more lipid soluble agents are administered in lower doses, and so have a **reduced speed of onset**
        This is known as Bowman's Principle.
  - Ionised portion
    Only unionised drug can cross cell membranes. Ionisation is a function of:
    - pKa
    - Tissue pH
      - This is also why anaesthetics are ineffective in anaesthetising infected tissue, as the low pH makes the majority of the LA ionised and unable to cross the cell membrane.
  - Patient factors
    - Nerve activity
      Local anaesthetics produce a **frequency dependent blockade**, meaning nerves firing frequently will be blocked more rapidly than quiescent nerves
    - Nerve fibre size
      Larger nerves require an increased concentration of local anaesthetic to achieve blockade than smaller nerves.
    - Nerve type
      Different nerve fibres are affected at different speeds, which is mostly (though not entirely) a function of critical length.
      - Aγ (proprioceptive) are affected first
      - Small myelinated Aδ (sharp pain, cold) fibres are affected second
      - Large myelinated nerves are affected third These include Aα (motor) and Aβ (touch) fibres.
      - Unmyelinated nerves are affected last
        These include C (dull pain, heat) fibres.
    - Hyperkalaemia
      Reduces onset of action.

**Toxicity**

Local anaesthetics are:
- Toxic to both the **CNS** and **CVS**
- Toxicity occurs when there is an excess plasma concentration
  This occurs when the rate of drug entering the systemic circulation is greater than the drug leaving the systemic circulation due to redistribution and metabolism.

Toxicity is related to the:
Drug factors

Drug used
Agents are compared using the **CC/CNS ratio**, which is the ratio of the dose of drug required to cause cardiovascular collapse (CC) compared to the dose required to cause seizure. It is a crude alternative to the therapeutic index.

Dose used
Continuous infusions are more likely to cause a delayed onset of local anaesthetic toxicity.

Block factors

Site of administration
This affects the rate of uptake into the systemic circulation, and the likelihood of inadvertent intravascular injection. Ranked (from highest to lowest):
- Intravascular (obviously)
  This is the most common cause of LA toxicity.
  Site is also relevant here: an injection into the carotid artery will cause toxicity at a lower dose than if injected into a peripheral vein.
- Intercostal
- Caudal
- Epidural
- Brachial plexus
- Subcutaneous

Use of adjuncts
- Adrenaline
  Vasoconstrictor properties reduce systemic absorption of LA.

Technique
- Frequent aspiration
- Test dose
- Use of ultrasound

Patient factors
Anything that increases peak [plasma] can lead to an increased risk of LA toxicity.
- Blood flow to affected area
- $\alpha_1$-acid glycoprotein
  Low levels of this protein increase free drug fraction.
  Neonates and infants have half the level of AAG than adults.
- Hepatic disease
  Reduces clearance of amides, which may cause toxicity with repeated doses or use of infusions.
- Age
  Organ blood flow (and therefore clearance), as well as pharmacokinetic interactions may affect clearance of LA. Both children and the elderly have reduced clearance of LA.
- Acidosis
  Increases unionised portion.
- Hypercarbia
  Increases cerebral blood flow.

Cardiac Toxicity

Cardiac toxicity occurs due to:
- Blocking of the cardiac Na$^+$ channel ($K^+$ and Ca$^{2+}$ channels may also be involved)
  Severity of toxicity will vary depending on how long the agent binds to the channel, with less toxicity caused by agents spending less time bound:
  - Lignocaine
Spends the shortest time bound to the channel, so causes the least amount of toxicity. This is also why lignocaine can be used as an antiarrhythmic, but other agents can not.

- **Bupivacaine**
  Takes 10x as long to dissociate as lignocaine. This can lead to re-entrant arrhythmias, and then VF. The risk of this is increased in tachycardia due to use-dependent blockade.
- **Ropivacaine**
  Dissociates more rapidly from cardiac channels than bupivacaine.

- Direct myocardial depressant effects
  Reduces cAMP levels by disrupting metabotropic receptors.

**Cardiac toxicity is triphasic:**

- **Initial phase**
  - Hypertension
  - Tachycardia

- **Intermediate phase:**
  - Hypotension
  - Myocardial depression

- **Terminal phase:**
  - Severe hypotension
  - Vasodilation
  - Various arrhythmias
    - Sinus bradycardia
    - Variable degree heart block
    - VT
    - VF
    - Asystole

**CNS Toxicity**

Local anaesthetics in their unionised state can cross the BBB and interfere with CNS conduction. **CNS toxicity is biphasic:**

- Initially, inhibitory interneurons are blocked
  This causes excitatory effects:
    - Perioral tingling
    - Slurred speech
    - Visual disturbances
    - Tremulousness
    - Dizziness
    - Confusion
    - Convulsions
  Typically signifies the end of the excitatory phase.

- Secondly, there is a general depression of all CNS neurons
  This causes inhibitory effects:
    - Coma
    - Apnoea

**Treatment**

Toxicity is managed with an ABC approach, though definitive management uses Intralipid emulsion:

- Intralipid is an emulsion of soya oil, glycerol, and egg phospholipids.
  Mechanism of action in uncertain, but theories include:
- Lipid sink
  ILE binds unionised LA, causing it to distribute off receptor sites.
- Fatty acid metabolism
  Cardiac fatty acid metabolism is interrupted by LA. ILE provides a source of fatty acids to allow metabolism to continue.
- Competitive antagonism
  ILE may directly inhibit LA binding.

- Dosing of Intralipid 20%:
  - Bolus of 1.5ml.kg\(^{-1}\) over 1 minute
  - Infusion at 15ml.kg\(^{-1}.hr\)^{-1}

- Complications include **pancreatitis**
  Note that ILE interferes with amylase and lipase assays, and so these will be unreliable.

- Note that whilst propofol can be used to treat seizures, the amount of lipid contained in propofol is inadequate to bind LA

## References


Last updated 2019-07-18
Neuraxial Blockade

Describe the physiological consequences of a central neuraxial block

Central neuraxial blockade refers to blockade of fibres in the spinal cord by administration of intrathecal or epidural local anaesthetic.

Respiratory Responses

An increasing level of block will lead to greater effects:

- Thoracic
  - Impediment to active expiration and expectoration due to blockade of intercostals and abdominal wall musculature
  - Loss of vital capacity
  - Loss of some accessory muscle use
- Cervical
  - Impediment due to diaphragmatic blockade.

Cardiovascular Responses

Occur due to blockade of sympathetic chain fibres in the thoracolumbar region.

An increasing level of block will lead to greater effects:

- Sacral
  - Parasympathetic blockade only. Minimal CVS effects.
- Lower thoracic/lumbar
  - Arteriolar and venous vasodilation in lower abdomen and lower limbs, causing a fall in SVR, BP, and GFR.
- Upper thoracic
  - Loss of cardioaccelerator fibres above T5, causing a reduction in heart rate and contractility, compounding hypotension due to fall in SVR.
- Cranial Nerves
  - Vagal blockade will reduce PNS tone and attenuate some of the loss of SNS tone.
- Brainstem
  - Inhibition of vasomotor centre with profound fall in CVS parameters.

CNS Responses

An increasing level of block will lead to greater effects:

- Cervical
  - Horner’s syndrome (miosis, anhydrosis, ptosis) due to loss of sympathetic trunks.
- Cranial nerve Pupillary dilation due to CN III blockade.
- Brainstem and Cerebral Cortex Anaesthesia due to blockade of the reticular activating system and thalamus.

References
1. Diaz, A. *Cardiovascular Response to Central Neuraxial Blockade*. Primary SAQs.
2. ANZCA July/August 2007

Last updated 2019-07-20
Acetylcholine Receptors

Understanding of the pharmacology of anticholinesterase drugs.

Describe the adverse effects of anticholinesterase agents.

This covers the pharmacology of acetylcholine receptors and the production and metabolism of Ach. Detailed information on specific agents is in the pharmacopeia.

Acetylcholine is a neurotransmitter vital for normal function of:

- CNS
- ANS
- Muscle contraction

Synthesis, Release, and Metabolism

ACh is produced in the nerve cytoplasm by acetyltransferase from:

- Choline
  From diet and recycled Ach.
- Acetyl-coenzyme A
  Produced in the inner mitochondrial matrix.

Once synthesised, ACh is then packaged into vesicles (each containing ~10,000 ACh molecules), which are released in response to calcium influx occurring at the culmination of an action potential.

Acetylcholine is metabolised by acetylcholinesterase on the post-junctional membrane. AChE:

- Has two binding sites:
  - Anionic binding site
    Binds the positively charged quaternary ammonium moiety.
  - Esteratic binding site
    Binds the ester group of ACh.
- Once bound, ACh is acetylated
- Acetylated-ACh is then hydrolysed to produce acetic acid

ACh Receptor Subtypes

There are two types of ACh receptor:

- **Nicotinic ACh receptors**
  - Inotropic
    Linked to an ion channel.
    - Non-specific - may allow Na⁺, K⁺, or Ca²⁺ to cross
  - Consists of five subunits:
    - Two α
      - Bind ACh,
    - One β
    - One δ
    - One γ
  - Located in:
- Post-synaptic NMJ
- Preganglionic autonomic nervous system
  Antagonism causes ganglion blockade.
- Brain
- Known as nicotinic because nicotine agonises this receptor
- Activation:
  - 2 ACh molecules must bind to activate the receptor
  - Once bound, receptor undergoes a conformational change which opens the central ion pore
    Permeability to Na⁺ (and to a lesser extent, K⁺ and Ca²⁺) increases, leading to depolarisation
- **Muscarinic ACh receptors**
  - Metabotropic
    G-protein coupled.
  - Known as muscarinic because muscarine also agonises this receptor
  - Subdivided into:
    - M₁ (Gq)
      Secretory glands and CNS.
    - M₂ (Gi)
      Heart.
    - M₃ Gq
      Bronchial and arteriolar smooth muscle.
    - M₄ (Gi) and M₅ (Gq)
      CNS.

## References


Last updated 2019-07-18
Opioids

Key definitions:

- **Opiates** are all naturally-occurring substances with morphine-like properties
- **Opioids** is a general term for substances with an affinity for opioid receptors
- **Opium** is a mixture of alkaloids from the poppy plant

Classification of Opioids

- **Naturally occurring**
  - Endogenous opioids
    - Endorphins
    - Enkephalins
    - Dynorphins
  - Opium derivatives
    - Phenanthrenes
      - Morphine
      - Codeine
  - **Semisynthetic**
    Simple modifications to morphine.
    - Diacetylmorphine
    - Buprenorphine
    - Oxycodone
  - **Synthetic**
    - Phenylpiperidines
      - Fentanyl
      - Alfentanil
      - Remifentanil
      - Pethidine
    - Diphenylpropylamines
      - Methadone

Opioid Receptor Classification

All opioid receptors are Gi receptors. Activation:

- Inhibits adenyl cyclase, reducing cAMP
  - Pre-synaptically inhibits voltage-gated Ca\(^{2+}\) channels
    - Decreases Ca\(^{2+}\) influx
    - Reduces neurotransmitter release
  - Post-synaptically stimulates activates K\(^+\) channels
    - Causes K\(^+\) efflux
    - Leads to membrane hyperpolarisation

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Actions</th>
<th>Notable Properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOP</td>
<td>Analgesia (spinal and brain), euphoria, meiosis (via stimulation of the Edinger-Westphal nucleus), nausea and vomiting (via CTZ), sedation, bradycardia, inhibition</td>
<td>Only opioid receptor to cause</td>
</tr>
</tbody>
</table>
of gut motility, urinary retention, physical dependence | nausea/vomiting
---|---
KOP | Analgesia (predominantly spinal), sedation, meiosis, dysphoria | Less respiratory depression
DOP | Analgesia, respiratory depression, urinary retention, physical dependence | Minimal constipation
NOP | Anxiety, depression, change in appetite | Hyperalgesia at low doses, analgesic at high doses

Mechanism of effects:

- **Respiratory depression**
  Decreases central chemoreceptor sensitivity to CO₂.
- **Constipation**
  Stimulation of opioid receptors in the gut.
  - Normally activated by local endogenous opioids (used as neurotransmitters)
  - Agonism of these receptors (μ, k, and to a smaller extent, δ) reduces GIT secretions and peristalsis

References


Last updated 2019-07-18
Inhalational Anaesthetics

Structure-activity relationships of inhalational agents

Describe the uptake, distribution and elimination of inhalational anaesthetic agents and the factors which influence induction and recovery from inhalational anaesthesia including the:
- Concepts of partition coefficients, concentration effect and second gas effect
- Relationships between inhaled and alveolar concentration
- Significance of the distribution of cardiac output and tissue partition coefficients on uptake and distribution of volatile agents

Describe the concept and clinical application of MAC in relation to inhaled anaesthetic agents

Describe how the pharmacokinetics of drugs commonly used in anaesthesia in neonates and children differ from adults and the implications for anaesthesia

Properties of an ideal inhalational anaesthetic agent

Inhaled anaesthetics are chemicals with general anaesthetic properties that can be delivered by inhalation. They can be divided into:

- **Volatile** anaesthetic agents
  - Volatility refers to the tendency of a liquid to vapourise. Volatile agents include:
    - Sevoflurane
    - Isoflurane
    - Desflurane
    - Methoxyflurane
    - Enflurane
    - Halothane
    - Ether
- **Anaesthetic gases**
  - Nitrous oxide
  - Xenon

Key Principles of Inhalational Agents

Key principles:

- The **clinical effect** of an inhalational agent is dependent on its **partial pressure** within the CNS
- At equilibrium, the partial pressure in the CNS (\(P_g\)) equals the partial pressure in blood (\(P_a\)), and in the alveoli (\(P_A\))
  - Reaching equilibrium is rarely achieved in practice as it takes many hours.
- Rate of onset and offset of an inhalational agent are dependent on both physiological and pharmacological factors affecting the transfer of agent:
  - Into the alveoli
  - From the alveoli into blood
  - From blood into the CNS

Minimum Alveolar Concentration (MAC)

MAC is defined as the minimum alveolar concentration at steady state which prevents a movement response to a standard surgical stimulus (1cm forearm incision) in 50% of a population.
Note that this definition:

- Does not reflect lack of awareness
- Does reflect the action of an agent on spinal cord reflexes
  
  This is why 1 **MAC** is adequate for the majority of patients, as awareness and recall are suppressed at lower MAC values than are required for immobility.
- Consciousness is better estimated by MAC-aware

End-tidal concentration of agent that prevents appropriate responses to a verbal command in 50% of a population.

- Note that this technically measures awareness rather than memory.
- **MAC-aware** is typically **one-third** of MAC for commonly-used agents
- Is only valid at sea-level

The **clinical effect** of an agent is **dependent** on its **partial pressure not concentration**.

- At 1atm, these are almost the same
  
  1atm \(\approx\) 100kPa; therefore 2% sevoflurane is \(\approx\) 2kPa
- As altitude increases, the actual partial pressure will fall for any given concentration i.e. 2% sevoflurane at 0.5atm is \(\approx\) 1kPa of sevoflurane.

**MAC** is:

- A measure of potency (i.e. the EC\(_{50}\) of the agent, where the outcome is movement)

  The MAC of an agent is inversely proportional to potency; i.e. more potent agents require smaller alveolar concentrations to produce anaesthesia.
  
  - This gives rise to the **Meyer-Overton hypothesis**, which suggests that anaesthesia requires a sufficient number of molecules to dissolve into the neuronal cell membrane.
    
    - If this was true, the product of the oil:gas partition coefficient and MAC would be constant, which is not the case.

- Additive

  The MACs of different agents used simultaneously are additive.

- Normally-distributed

  Not all patients will be unresponsive at 1 MAC.

  - The standard deviation is 0.1, so 95% of patients will not move in response to a stimulus at 1.2 MAC

- Estimated clinically using **end-tidal** gas measurement

  **MAC** is not based on arterial partial pressure (\(F_A\)) of agent.

  - This is an important difference, because **even at steady-state, \(F_A \neq F_A\)**
  
  - This occurs due to:
    
    - V/Q mismatch
      
      Shunted alveoli will not absorb anaesthetic agent, and unperfused alveoli will contain agent that is not being absorbed.
      
      - This is worsened by the effects of anaesthesia
    
    - Volatile agents are heavy and have finite diffusibility

    However, the difference between \(F_A\) and \(F_A\) for any agent is the same at steady state (and in absence of nitrous oxide)

    This means that, at steady-state, MAC will be proportional to, and an accurate measure of, \(P_A\.

- One of several related terms:

  - **MAC awake**

    Concentration required to prevent response to a verbal stimuli in **absence of noxious stimuli**.

    - Typically \(~1/3\text{rd}\) of MAC for most agents (sevoflurane, isoflurane, desflurane)
    
    - Notably higher for nitrous oxide (MAC-aware \(\approx\) 2/3\text{rd}s of MAC)

    **MAC-aware** is typically less than MAC-asleep as:

    - Hysteresis between alveolar and effect site concentrations
      
      During induction, alveolar concentration is higher than effect site concentration, and so overestimates effect.
      
      During wash out, alveolar concentration is less than effect site concentration, and the reverse effect occurs.

    - "Neural inertia"
      
      Intrinsic resistance of nerve cells to a change in their state.
MAC-BAR
Minimum alveolar concentration required to block adrenergic response, i.e. to prevent a rise in HR or BP following skin incision.

MAC<sub>50</sub>
The MAC required to prevent a movement response to a standard surgical stimulus in 95% of the population.

MAC<sub>hr<sup>-1</sup></sub>
The amount of time a patient is exposed to 1 MAC of an agent. Used to compare different agents.

**Factors Affecting MAC**

<table>
<thead>
<tr>
<th>Decreases MAC</th>
<th>Increases MAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (~6%/10 years ↑) and neonates</td>
<td>Youth</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Hyperthermia</td>
</tr>
<tr>
<td>Hypocapnea</td>
<td>Hypercapnea</td>
</tr>
<tr>
<td>Hyponatraemia</td>
<td>Hypermotaemia</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>Acute alcohol and other CNS depressant intoxication</td>
<td>Chronic ETOH and CNS depressant abuse</td>
</tr>
<tr>
<td>Chronic amphetamine intake</td>
<td>Acute amphetamine intake</td>
</tr>
<tr>
<td>Hypovolaemia/Hypotension</td>
<td></td>
</tr>
<tr>
<td>Lithium</td>
<td></td>
</tr>
<tr>
<td>Hypoxia</td>
<td></td>
</tr>
<tr>
<td>Anaemia</td>
<td></td>
</tr>
<tr>
<td>Pregnancy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SNS activation and anxiety</td>
</tr>
<tr>
<td></td>
<td>Increased P&lt;sub&gt;atm&lt;/sub&gt;</td>
</tr>
</tbody>
</table>

Note that addition of other agents (e.g. opioids) will affect different MAC subtypes (e.g. MAC<sub>50</sub> vs MAC<sub>BAR</sub>) differently.

**Partition Coefficients**

A partition coefficient describes the relative affinity of an agent for two phases, and is defined as the ratio of the concentration of agent in each phase, when both phases are of equal volume and the partial pressures are in equilibrium at STP.

- The blood:gas partition coefficient describes the solubility of the agent in blood relative to air, when the two phases are of equal volume and in equilibrium at STP. A low blood:gas partition coefficient indicates a rapid onset and offset. This is because:
  - Poorly soluble agents generate a high P<sub>A</sub>, which creates a steep gradient between P<sub>A</sub> and P<sub>B</sub>, giving a rapid onset of action
  - Conversely, soluble agents dissolve easily into pulmonary blood without substantially increasing P<sub>A</sub>
    This causes leads to a slow onset due to:
    - A large fall in P<sub>A</sub> as the agent leaves the alveolus, decreasing the gradient for further diffusion
    - A small gradient between P<sub>A</sub> and P<sub>B</sub>

- The oil:gas partition coefficient describes the solubility of the agent in fat relative to air, when both phases are of equal volume and in equilibrium at STP. A high oil:gas partition coefficient indicates a greater potency, and therefore a low MAC.
**Pharmacokinetics of Inhalational Agents**

Achieving the required $P_B$ requires maintaining $P_A$ at a high enough level. By increasing $P_A$, the pressure gradient for diffusion into blood, and therefore CNS, is increased.

As discussed above, rate of onset of an inhalational agent is dependent on rate of uptake:

- Into the alveoli
- From the alveoli into blood
- From blood into the CNS

Factors affecting *alveolar concentration of agent*:

- **Inspired concentration**
  A high inspired concentration ($F_i$) will increase the rate of increase of alveolar concentration ($F_A$). Inspired concentration is dependent on:
  - Delivered concentration in fresh gas
  - Fresh gas flow
    - Increasing FGF (and the concentration of agent in the added gas) increases $F_i$.
  - Volume of the breathing system
    - A lower circuit volume will increase the rate at which the patient reaches equilibrium with the circuit, and therefore increase $F_i$.
  - Circuit absorption
    - Absorption of agent by the circuit will decrease $F_i$.

- **$V_A$**
  Increased alveolar ventilation increases $F_i$, as it replenishes agent that has been taken up into the vasculature.
  - Similarly, increased dead space will prolong induction, as anaesthetic gas will be delivered to non-perfused alveoli

- **FRC**
  A large FRC will dilute the amount of agent inspired with each breath, and so reduce $F_i$.
  - This is measured with the $V_A/FRC$ ratio
    - Increased ratio increases speed of onset.
      - Normal in adults: 1.5:1
      - Normal in neonates: 5:1

- **Second gas effect**
  Use of $N_2O$ with another agent will increase the $P_A$ of that agent. This is because:
  - $N_2O$ is 20x as soluble in blood as either blood or nitrogen, and is administered in high concentrations, so it is rapidly absorbed from alveoli
  - If nitrous oxide is delivered at high concentrations, it's rapid absorption means that alveoli will shrink, causing:
    - An increase in the fractional concentration of all other gases
      - This is known as the concentration effect, and increases the pressure gradient driving diffusion into blood, increasing speed of onset.
        - The concentration effect is the cause of the second gas effect
        - The concentration effect is more pronounced as Fi$N_2O$ increases
        - The concentration effect is more profound in lung units with moderately low V/Q ratios, causing in a large increase in $F_A$
          - This results in a larger value of $F_A$ for any given $F_A$, even at steady state.
          - Augmented ventilation as more inhalational agent is drawn in the alveoli from dead space gas
    - The second gas effect also causes diffusion hypoxia
      - When inspired $N_2O$ is reduced, $N_2O$ will leave blood and enter the alveolus, displacing other gases in the alveolus.
        - This can cause a reduction in PAO$_2$, and therefore hypoxaemia
        - Diffusion hypoxia is avoided by delivering 100% oxygen, which maintains an adequate PAO$_2$ as $N_2O$ is removed
Note that \( \text{N}_2\text{O} \) reaches a higher ratio faster than desflurane, despite its lower blood:gas partition coefficient, due to the concentration effect.

Factors affecting drug uptake from the lungs:

- **Blood:gas partition coefficient**

  Agents with a low blood:gas partition coefficient reach equilibrium more rapidly. The blood:gas coefficient is affected by:
  - Temperature
    Blood:gas partition coefficients decrease as temperature increases.
  - Haematocrit
    Variable effect, which depends on the particular agents affinity for red cells or plasma (and serum constituents, e.g. albumin).
    - An agent that is less soluble in red cells (e.g. isoflurane) will have a decreased blood-gas partition coefficient in anaemia.
  - Fat
    Blood:gas partition coefficient increases following fat ingestion.

- **Alveolar blood flow**

  Increased alveolar blood flow increases uptake and delivery to tissues, including the CNS.

  - However, the increased uptake causes a reduction in \( P_A \).
  - Therefore, rate of onset is reduced when alveolar blood flow is high.
    - This effect is more pronounced with agents with a high blood:gas partition coefficient.
    - Alveolar blood flow is a function of:
      - Cardiac output
      - Shunt

- **Alveolar-Venous partial pressure gradient**

  The difference in partial pressure of agent in the alveolus and venous blood is due to the uptake of drug in tissues. Tissue uptake is dependent on:

  - Tissue blood flow
    - As the CNS has a high blood flow, it will equilibrate more quickly.

  - Blood:tissue solubility coefficients
    - Muscle has similar affinity to blood, but equilibrates more slowly than the CNS due to lower blood flow.
    - Fat has a much higher affinity for anaesthetic than muscle, but equilibrates very slowly due to the very low blood flow.
    - This is of greater importance in the obese, especially during prolonged anaesthesia, as they have a longer equilibration time and therefore prolonged emergence.

**Wash-out of Inhalational Agents**
Recovery is dependent on how quickly an inhalational agent can be eliminated from the effect site, and can be graphed by the $F_A/F_{A0}$ ratio over time:

Washout can be divided into:

- **Rapid washout**
  - Of agent in circuit and FRC.
  - The time constant for removal of agent from the circuit is a function of circuit volume and fresh gas flow, i.e.
    \[ \tau = \frac{CA}{FGF} \]

- **Slow washout**
  - Of agent in patient.
  - The time constant for removal of agent from the patient is a function of FRC and minute ventilation, i.e.
    \[ \tau = \frac{FRC}{MV} \]

Factors affecting volatile washout:

- **Brain-Blood and Tissue-Blood**
  - Tissue:Blood coefficient of agent
  - Duration and depth of anaesthesia
    - Important for highly soluble agents used in long cases.

- **Blood-Alveolus**
  - Blood:gas coefficient of agent
    - Highly soluble agents will have an increased amount of drug dissolved in tissue, so a large reservoir of drug exists that will have to be removed.
  - Alveolar Cardiac output
    - **Decreased** cardiac output increases elimination.
      - Shunt
        - Decreases elimination.

- **Alveolus-Air**
  - $\frac{MV_A}{FRC}$
    - Increased alveolar ventilation increases elimination.

- **Other factors**
  - Metabolism of agent
    - Agents undergoing metabolism are eliminated more rapidly.
  - Absorption of agent into circuit
  - Percutaneous loss
Loss of agent by diffusion from tissues into external environment.

**Alteration to Pharmacokinetics**

Increased rate of induction in *children* due to:

- Increased $\frac{V_A}{FRC}$ ratio
  - Increases $P_A$.
- Lower albumin and cholesterol
  - Reduced blood-gas solubility coefficients for some agents.

Increased rate of induction in *elderly* due to:

- Lower MAC requirement
- Lower albumin
  - Reduces blood-gas solubility coefficients for some agents.
- Lower cardiac output
  - $P_A$ and therefore $P_B$ is established more rapidly.

Altered rate of induction in *pregnancy* due to:

- Increased $\frac{V_A}{FRC}$ ratio
  - Increased minute ventilation
    - This is of greater importance in spontaneous ventilation, as this is controlled by the anaesthetist during controlled ventilation.
  - Decreased FRC
    - Increases $P_A$, increasing $P_B$ and speed of onset.
- Lower albumin
  - Reduces blood-gas solubility coefficients for some agents.
- Increased CO
  - Reduces rate of rise of $P_A$, reducing $P_B$ and therefore speed of onset.
- Reduced MAC requirement
  - Progesterone has some sedative properties.

**Alteration to Pharmacokinetics with Special Methods of Administration**

In *target-controlled anaesthesia*, FGF and agent $F_1$ are controlled by the machine to reach the target $F_A$ rapidly at low concentrations. This causes:

- An initial over-pressure of $F_1$, in order to fill the FRC and reach the desired $F_A$
- A more rapid induction, as the target $F_A$ is reached more rapidly

In *liquid injection*, anaesthetic agent is injected into the breathing system. This causes:

- A very large degree of overpressure
  - In this circumstance, the rate of rise of end-expired agent concentration is identical for different agents.
    - i.e. Onset is independent of the blood:gas coefficient

**Mechanism of Action of Inhaled Anaesthetic Agents**

Mechanisms of action can be divided into:

- **Macroscopic**
  - At the level of the brain and spinal cord.
    - In the spine by:
Decreasing transmission of noxious afferent signals at the thalamus
- Inhibition of spinal efferents, decreasing motor responses
  - In the brain by:
    - Global depression of CBF and glucose metabolism

**Microscopic**

Synapses and axons by:
- Inhibiting pre-synaptic excitatory activity:
  - ACh
  - 5-HT
  - Glutamine
- Augmenting post-synaptic inhibitory activity:
  - GABA

**Molecular**

Anaesthetic agents may alter the function of molecules within the CNS. These include:
- Alteration of α-subunits of the GABA<sub>A</sub> receptor
  - This prolongs the time it spends open once activated, prolonging the inhibitory Cl⁻ current and increasing the degree of hyperpolarisation.
- Enhance the activity of two-pore K<sup>+</sup> channels
  - Increases the resting membrane potential of both pre-synaptic and post-synaptic CNS neurons.

**Incomplete Theories of the Mechanism of Action of General Anaesthetic Agents**

**Meyer-Overton Hypothesis:**
- Potency of anaesthetics relates to their lipid solubility
- Anaesthetic molecules dissolve into CNS membranes, disrupting their effect
  - Flaws:
    - Not all lipid soluble drugs have general anaesthetic affects
    - Other factors disrupt cell membranes without causing anaesthesia

**Volume Expansion, Pressure Reversal** (Mullin's Critical Volume Hypothesis):
- CNS cell membranes expand with general anaesthetic agents
  - This distorts channels responsible for maintaining membrane potential and generating action potentials.
- Increased ambient pressure reverses general anaesthesia
  - Flaws:
    - Does not account for stero-selectivity of drug-receptor interactions
      - I.e. receptors select for one stereoisomer over others.

**Structure-Activity Relationships of Inhaled Anaesthetics**

- Chemical structures of different volatile anaesthetics are covered in the pharmacopeia.

Different chemical and physical properties alter the effect of inhalational agents:
- **Physical**
  - Molecular weight
    - A decrease in molecular weight decreases boiling point and therefore increases SVP.
- **Chemical**
  - H<sup>+</sup> content
    - Greater hydrogen content:
      - Increases flammability
      - Increases potency
• F⁻ content
  Greater fluoride content:
  ■ Decreases flammability
  ■ Decreases oxidative metabolism
    This decreases toxicity.
  ■ Decreases potency
• Cl⁻ content
  Increased chloride increases potency.
• -CHF₂ (Di-fluor-methyl group)
  ■ Produces CO in the presence of dry soda lime

The Ideal Inhaled Anaesthetic Agent

From the properties discussed above, we can construct the following ideal agent:

• Physicochemical
  • Liquid at room temperature
  • High SVP
  • Low specific heat capacity
  • Long shelf-life
  • Light stable
  • Heat stable
  • Does not react with the components in the breathing circuit
    ■ Rubber
    ■ Metal
    ■ Plastic
    ■ Soda lime
  • Not flammable/explosive
  • Smells nice
  • Preservative free
  • Environmentally friendly
  • Cheap
• Pharmacokinetic
  • High oil:gas partition coefficient
  • Low MAC.
  • Low blood:gas partition coefficient
    Rapid onset and offset.
  • Not metabolised
  • Non-toxic
• Pharmacodynamic
  • Does not cause laryngospasm or airway hyperreactivity
  • No effect on HDx parameters
  • Analgesic
  • Hypnotic
  • Amnestic
  • Anti-epileptic
  • No increase in ICP
  • Skeletal muscle relaxation
  • Anti-emetic
  • No tocolytic effects
- Not teratogenic or otherwise toxic
- No drug interactions

References


Last updated 2019-11-08
Hormones

A hormone is a chemical messenger produced by a ductless gland which has its action at a distant target cell via a specific receptor.

- **Lipid hormones**, divided into:
  - **Steroids**
    Steroids are synthesised from cholesterol, and are released as they are produced (they are not stored). They are highly lipid soluble and act on cytoplasmic and intra-nucleic receptors.
    - Aldosterone
    - Testosterone
    - Oestrogen
    - Cortisol
  - **Eicosanoids**
    Eicosanoids are formed from cell membrane phospholipid.
    - Prostaglandins
    - Thromboxanes
    - Leukotrienes

- **Peptide hormones**
  Peptide hormones are store in granules and released by exocytosis. They are divided into:
  - **Short-chain**
    - Insulin
    - ADH
    - Oxytocin
    - ACTH
  - **Long-chain**
    - GH
    - Prolactin
  - **Glycopeptides**
    Proteins with carbohydrate groups.
    - LH
    - FSH
    - TSH

- **Monoamine derivatives**
  Derived from a single amino acid.
  - Catecholamines
    Stored in granules and act at membrane receptors.
    - Adrenaline
    - Noradrenaline
  - Serotonin
  - Thyroxine

References

Insulin, Glucagon, and Somatostatin

Describe the physiology of insulin, glucagon and somatostatin.

Insulin

Insulin is a polypeptide hormone, and is:

- Synthesised from proinsulin in the rough endoplasmic reticulum of B cells in the Islets of Langerhans
- Excreted via exocytosis in response to an increase in intracellular Ca^{2+}
- Minimally protein bound with a tiny volume of distribution $V_D$ 0.075 L.kg^{-1}, increased to 0.146 L.kg^{-1} in diabetics.
- Metabolised in liver, muscle, and kidney by glutathione insulin transhydrogenase, with renal elimination of inactive metabolites
- Circulatory half-life of ~5min.

Actions of Insulin

Insulin binds to a specific insulin receptor (a membrane-spanning protein composed of $\alpha$ and $\beta$ subunits) on the cell membrane. The complex is internalised, and its effects are mediated by tyrosine kinase.

<table>
<thead>
<tr>
<th>System</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle</td>
<td>Increased glucose, amino acid, ketone, and K^+ uptake</td>
</tr>
<tr>
<td>Fat</td>
<td>Increased glucose (via GLUT4), amino acid, and K^+ uptake</td>
</tr>
<tr>
<td>Liver</td>
<td>Decreased: gluconeogenesis, ketogenesis. Increased: glycogen synthesis, glycolysis, protein synthesis, lipid synthesis</td>
</tr>
<tr>
<td>General</td>
<td>Increased cell growth</td>
</tr>
</tbody>
</table>

Glucose Tolerance

Hyperglycaemia occurs in diabetes due to decreased peripheral utilisation as glucose uptake is reduced due to absence of or resistance to insulin. In addition, the suppressive effect of insulin on hepatic gluconeogenesis is absent or reduced.

Glucagon

Glucagon is a polypeptide hormone, and is:

- Synthesised in the A cells of the pancreas
- Has a circulating half-life of ~5min
- Metabolised predominantly in the liver
  Secreted directly into the portal vein, and undergoes first-pass metabolism resulting in low circulating levels.
Liver | Glycogenolysis, gluconeogenesis, glucose release, ketone formation
---|---
CVS | Inotropy
Fat | Lipolysis
Metabolic | Increased metabolic rate, GH release, somatostatin release, insulin release

Secretion of glucagon is influenced by a number of factors:

<table>
<thead>
<tr>
<th>Stimulate Release</th>
<th>Inhibit Release</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoglycaemia and starvation</td>
<td>Somatostatin</td>
</tr>
<tr>
<td>Amino acids</td>
<td>Secretin</td>
</tr>
<tr>
<td>Physiological stress: Exercise, infection</td>
<td>Free Fatty Acids</td>
</tr>
<tr>
<td>β-agonists</td>
<td>α-agonists</td>
</tr>
<tr>
<td>Cortisol</td>
<td>Insulin</td>
</tr>
<tr>
<td>ACh</td>
<td>Ketones</td>
</tr>
<tr>
<td>Theophylline</td>
<td>GABA</td>
</tr>
</tbody>
</table>

**Somatostatin**

Somatostatin is a **polypeptide** hormone that:

- Inhibits secretion of other hormones including:
  - Glucagon
  - Insulin
  - Other pancreatic peptides
- May function as a neurotransmitter in the **CNS**

**References**


Last updated 2019-07-18
Control of Blood Glucose

Explain the control of blood glucose

Normal blood glucose in the non-diabetic is 4-6 mmol.L⁻¹, though will rise after consumption of carbohydrate. Glucose regulation can be divided into:

- **Short-term**
  - Regulation via secretion or inhibition of insulin and glucagon from the pancreatic islets.
- **Long-term**
  - Regulation via both neuronal (SNS activation) and hormonal (cortisol, GH) mechanisms.

Hormonal Mechanisms

**Short Term**

Glucose levels are sensed directly in the pancreas and will result in insulin release when the BGL is >5.6 mmol.L⁻¹. Pancreatic B cells respond directly to glucose by secreting insulin in a biphasic fashion:

- An initial, rapid increase in release
  - Glucose enters via the GLUT-2 transporter, and is converted to pyruvate which enters the citric acid cycle and produces ATP
  - ATP inhibits ATP-sensitive K⁺ channels, reducing K⁺ efflux and causing depolarisation
  - Depolarisation causes Ca²⁺ release, resulting in exocytosis of insulin granules
- A prolonged, slow increase in release
  - Glutamate is produced as a by-product of the citric acid cycle
  - Glutamate stimulates maturation of other insulin granules
  - Release of these granules causes the second phase of insulin release

Conversely, a low glucose level stimulates secretion of glucagon. This is typically less important than the effect of insulin unless in situations of starvation or severe physiological stress.

**Long Term**

Sustained hypoglycaemia increases fat utilisation and decreases glucose utilisation (limiting further drops in blood glucose), via stimulating release of:

- GH
- Cortisol

Neuronal Mechanisms

Hypoglycaemia directly stimulates the hypothalamus, causing:

- Increased SNS tone
  - Adrenaline release in turn stimulates hepatic glucose release.

Organ Effects

Glucose levels are influenced by the:
Liver

Insulin and glucagon act on the liver to continually adjust the relative rates of glycogenolysis and glycogenesis, allowing it to function as an effective buffer of blood glucose.

- Hepatic disease significantly limits the efficacy of this system, and results in a widely-fluctuating blood glucose level
- Kidney
  - A transient glycosuria may be seen as hyperglycaemia decreases renal absorption of glucose

Physiological Responses to Hypoglycaemia

<table>
<thead>
<tr>
<th>BSL (mmol.L⁻¹)</th>
<th>Symptoms</th>
<th>Endocrine Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.6</td>
<td></td>
<td>Insulin secretion inhibited</td>
</tr>
<tr>
<td>3.8</td>
<td>Autonomic dysfunction</td>
<td>Glucagon, adrenaline, and GH secretion</td>
</tr>
<tr>
<td>2.8</td>
<td>CNS dysfunction</td>
<td></td>
</tr>
<tr>
<td>2.2</td>
<td>Lethargy, Coma</td>
<td></td>
</tr>
<tr>
<td>1.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.6</td>
<td>Permanent brain damage, Death</td>
<td></td>
</tr>
</tbody>
</table>

References


Last updated 2019-07-18
Hypothalamus and Pituitary

Describe the control, secretions and functions of the pituitary and the hypothalamus

Hypothalamus

The hypothalamus is a circumventricular organ that regulates a large number of autonomic processes:

- **Thermoregulatory**
  Integrates thermoreceptor input and controls activity of heat loss and heat gain mechanisms.

- **Satiety**
  Feelings of hunger are modulated by glucose, CCK, glucagon, and leptin.

- **Water balance**
  Contains osmoreceptors which control ADH release from the posterior pituitary
  - Angiotensin II stimulates thirst and ADH release via the subfornical organ and organum vasculosum

- **Circadian rhythms**
  Balance between anterior and posterior hypothalamic stimulation controls sleep-wake cycle.

- **Pituitary control**
  - Anterior pituitary by hormone secretion into the long portal vein. Secreted hormones include:
    - GnRH, stimulates FSH and LH release
    - CRH, stimulates ACTH release
    - GHRH, stimulates GH release
    - TRH, stimulates TSH release
    - Somatostatin, inhibits GH and TSH release
    - Dopamine, inhibits prolactin release
  - Posterior pituitary by neuronal innervation

- **Behaviour**
  Punishment and reward centres.

- **Sexual function**

Pituitary

The hypothalamic-pituitary axis describes the complex feedback loops between these endocrine organs:

- **Short-loop feedback** describes negative feedback from the pituitary on the hypothalamus, e.g. GH inhibiting GHRH release
- **Long-loop feedback** describes negative feedback from a pituitary target gland (i.e. thyroid, adrenal, gonads) on the hypothalamus, e.g. cortisol inhibiting CRH (as well as ACTH) release.
  - These axes are also named with target gland, e.g. hypothalamic-pituitary-adrenal axis

Pituitary Hormones

The pituitary gland secretes eight hormones from two lobes:

- **Anterior Pituitary**
  Secretes six hormones in response to hypothalamic endocrine stimulus. These are classified as:
  - **Stimulating** hormones, which act at another gland:
    - **ACTH**
      Short-chain peptide that stimulates cortisol release from the zona fasciculata. Release is stimulated by CRH, and inhibited by cortisol.
- **TSH**
  Glycoprotein that stimulates synthesis and release of T₃ and T₄. Release is stimulated by TRH, and inhibited by T₃.

- **FSH**
  Glycoprotein gonadotropin. Release is stimulated by GnRH, and inhibited by circulating sex steroids. Has different effects depending on sex:
  - Females: Stimulates oestrogen synthesis and ovarian follicle development.
  - Males: Stimulates sperm maturation.

- **LH**
  Glycoprotein gonadotropin with different effects depending on sex:
  - Females: Rapid increase stimulates ovulation and corpus luteum development.
  - Males: Stimulates testosterone synthesis.

- **Direct acting** hormones:

  - **GH**
    Long-chain peptide released in a pulsatile fashion. Release is stimulated by GHRH and is typically high with exercise, hypoglycaemia, and stress. Release is inhibited by somatostatin and IGF-1. GH has generally anabolic effects:
      - Directly stimulates lipolysis, increasing circulating FFA
      - Indirectly stimulates IGF-1 release, promoting cell growth and development

  - **Prolactin**
    Long-chain peptide which promotes breast development during gestation, and lactation after delivery.

- **Posterior pituitary**

  Secretes two hormones:

  - **ADH**
    Short-chain peptide which is:
    - Released in response to osmoreceptors in the circumventricular organs detecting a change in osmolality
    - Reduced when osmolality is <275 mosm.L⁻¹
    - Increased when osmolality is >290 mOsm.L⁻¹
    - Effective at:
      - V₁ receptors in vascular smooth muscle, causing vasoconstriction
      - V₂ receptors in kidney collecting ducts to increase water reabsorption, and on endothelium to increase vWF and factor VIII release
      - V₃ receptors in the pituitary to stimulate ACTH release

  - **Oxytocin**
    Short-chain peptide, structurally similar to ADH, which causes:
    - Uterine contraction
    - Let-down reflex
      Stimulates milk release on suckling.
    - Psychological
      Pair bonding.

---

**References**

2. Nickson, C. Vasopressin. LITFL.

Last updated 2019-07-18
Hypothalamus and Pituitary
Thyroid

Describe the control, secretions and functions of the thyroid.

The thyroid gland:

- Produces and secretes two hormones in response to TSH:
  - T₄ (thyroxine, 93%)
  - T₃ (tri-iodothyronine, 7%)
- Secretions are controlled via a negative-feedback loop on the hypothalamic-pituitary-thyroid axis
  - Increased TSH results in:
    - Increased iodine uptake
    - Increased iodination to form T₄ and T₃
    - Increased proteolysis of thyroglobulin, which releases T₄ and T₃
- Secretions are decreased with decreased iodine uptake
  - Perchlorate
    - Blocks Na⁺/I⁻ symporter.
  - Wolff-Chaikoff effect
    - A reduction in thyroid hormone production due to a high circulating [iodide].

Synthesis

Thyroid hormones are:

- **Synthesised in follicles**
  - A follicle is formed of a single layer of cuboidal epithelium around a central lumen (follicular cavity) containing thyroglobulin.
    - Iodide is transported into follicular cells via a secondary active transport mechanism
      - Na⁺/I⁻ co-transporter.
    - Iodide is then oxidised to iodine
    - Thyroglobulin is synthesised in the endoplasmic reticulum of the follicular cell and excreted into the follicular cavity
    - Iodine is excreted into the follicular cavity using a chloride exchange pump
    - In the follicular cavity:
      - Thyroid peroxidase catalyses the iodination of thyroglobulin, forming mono-iodotyrosine and di-iodotyrosine
      - These are subsequently oxidised, forming T₃ and T₄ respectively

In summary:

- Iodide is taken into the thyroid follicles by secondary active transport, and oxidised to iodine
- Thyroglobulin is synthesised in the follicle, and excreted into the follicular cavity
- Iodine is secreted into the follicular cavity, where it combines with thyroglobulin to produce T₄ and T₃

Secretion and Metabolism

Thyroid hormones are:

- Secreted in vesicles via endocytosis into the surrounding capillaries
  - Colloid enters thyroid cell via pinocytosis at the apical membrane
  - Vesicles then fuse with lysosomes
- Thyroid hormone cleaved from thyroglobulin by proteases
- Free T₃ and T₄ diffuse through the base of the thyroid cell into surrounding capillaries
- Highly protein bound to albumin and thyroxine-binding globulin
  - T₄ has a t½ of 7 days
  - T₃ has a t½ of 24 hours
  - Both are deiodinated in the liver, kidney, and muscle
    - 55% of T₄ will be first deiodinated to T₃

### Physiological Effects

**Thyroid hormones:**

- Act on thyroid receptors in the **cell nucleus**
  - Increasing gene transcription, protein synthesis, and mitochondria size and number.
- **T₃** is 3-5x more active than **T₄**

**Effects of thyroid hormone are predominantly metabolic:**

<table>
<thead>
<tr>
<th>System</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Resp</strong></td>
<td>↑ MV due to ↑ CO₂ production</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>↑ HR, ↑ inotropy, ↑ CO, ↓ SVR, ↓ DBP</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>↑ Excitability: Seizures, tremor</td>
</tr>
<tr>
<td><strong>MSK</strong></td>
<td>↑ Osteoblastic activity</td>
</tr>
<tr>
<td><strong>GU</strong></td>
<td>Impotence (men), oligomenorrhea (women)</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>↑ GIT motility</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td>↑ BMR up to 100%, ↑ carbohydrate metabolism (↑ glucose uptake, ↑ glycolysis, ↑ gluconeogenesis), ↑ fat metabolism (↑ lipolysis, ↑ non-shivering thermogenesis, ↓ plasma cholesterol, ↓ plasma phospholipids, ↓ triglycerides), ↑ protein metabolism (↑ anabolism at physiological levels, ↑ catabolism at high levels)</td>
</tr>
</tbody>
</table>

### References

2. CICM September/November 2008

Last updated 2019-07-18
Adrenal Hormones

Describe the control, secretions and functions of renal and adrenal hormones.

This covers the production of adrenal hormones. Information specific to catecholamines receptor function can be found under adrenoreceptors, whilst detailed information on specific agents, including structure-activity relationships, is in the pharmacopeia.

The adrenal glands are paired triangular glands at the superior pole of the kidney. The gland can be divided into:

- Adrenal cortex
  - Consists of three layers which produce **steroid hormones** (A good mnemonic is GFR for the layers, and ACT(H) for hormones)
    - Zona Glomerulosa
      - Predominantly produces mineralocorticoids (aldosterone).
    - Zona Fasciculata
      - Predominantly produces glucocorticoids (cortisol).
    - Zona Reticularis
      - Predominantly produces sex steroids (testosterone).

- Adrenal medulla
  - Produces catecholamines.

Steroid Hormones

Mineralocorticoids

Aldosterone is the key mineralocorticoid hormone, accounting for 95% of mineralocorticoid activity:

- Release is stimulated by:
  - Increased serum $K^+$
  - Increased Angiotensin II
    - Hypovolaemia
    - Decreased osmolarity
  - Increased ACTH
  - Decreased serum pH
- Acts to increase sodium and water retention (and removal of potassium), via:
  - Increased expression and activation of $\text{Na}^+$/K$^+$ pumps on the basolateral membrane of DCT and CT cells, causing increased Na$^+$ (and water) reabsorption and K$^+$ elimination
  - Stimulation of the Na$^+$/H$^+$ pump in intercalated cells on the DCT

Glucocorticoids

Cortisol (hydrocortisone) is the primary glucocorticoid in the body, accounting for 95% of endogenous glucocorticoid effect.

Cortisol is:

- Produced at $\sim$15-30mg.day$^{-1}$
- Released in response to ACTH

**ACTH** is released in response to CRH, which is:

- Released in response to stress
- Modulated by circadian rhythms, and demonstrates diurnal variation:
  - CRH peaks just before waking
  - CRH troughs during sleep
Cortisol has effects on many organ systems, and in physiological amounts cause:

- CVS
  - Increased sensitivity to catecholamines
  - Increases fluid retention
- Metabolic
  (Essentially anti-insulin effects):
  - Gluconeogenesis
    - To provide substrates, it also stimulates:
      - Proteolysis
      - Lipolysis
  - Decreased glucose uptake

### Catecholamines

Naturally occurring catecholamines include:

- Adrenaline
- Noradrenaline
- Dopamine

Synthesis of catecholamines occurs in the adrenal medulla, which is a modified sympathetic ganglion composed of chromaffin cells.

- Synthesis and release is dependent on ACh release by the presynaptic neuron
  Unlike many other hormones, catecholamine secretion is not a negative-feedback loop.

Process of catecholamine synthesis:

- Tyrosine is concentrated in the adrenal medulla
- Tyrosine is hydroxylated to DOPA by tyrosine hydroxylase
  - This is the rate-limiting step, and is probably the best enzyme to remember.
- DOPA is decarboxylated to dopamine
- Dopamine is converted to noradrenaline
- Noradrenaline is converted to adrenaline by PNMT (Phenylethanolamine N-methyltransferase)
  - This may only occur in the adrenal medulla.

Plasma half-lives of noradrenaline and adrenaline are small as a consequence of their metabolism and elimination.

- Extraneuronal uptake in the lungs, liver, kidney, and GIT
- Neuronal uptake by sympathetic nerve endings
- Inactivation by MAO in nerve cytoplasm
- Inactivation by COMT in the liver and kidney

### References


Last updated 2018-06-25
Calcium Homeostasis

Describe the function, distribution, regulation and physiological importance of sodium, chloride, potassium, magnesium, calcium and phosphate ions.

Describe the control of plasma calcium.

Calcium is a bivalent cation. Almost all (99%) of calcium is located in bone, with the remainder in plasma and soft tissues. Normal plasma levels are 2.2-2.55 mmol.L\(^{-1}\), which (in plasma) may be:

- Ionised (free) calcium (50%)
  - Normal range 1.1 to 1.3mmol\(^{-1}\).
- Bound to albumin (40%)
- As calcium compounds (10%)

Functions of Calcium

- **Cell Signaling**
  - Calcium has a number of roles in cell signaling:
    - Affects cell sodium permeability and therefore the RMP of excitable cells
    - Calcium triggers exocytosis of neurotransmitter vesicles
    - Calcium is an important second messenger for some G proteins

- **Bone**
  - Calcium has two functions in bone:
    - Physical structure
    - Alkali reserve
      - Calcium phosphate can be mobilised to buffer acidosis.

- **Enzymatic cofactor**
  - Calcium is an important cofactor in enzymatic pathways, including the coagulation cascade. Clinical hypocalcaemia does not cause coagulopathy however, as calcium levels low enough to prevent coagulation are not compatible with life.

Regulation of Calcium

Calcium is regulated to maintain a stable ionised calcium level. Three hormones are involved in the regulation of calcium:

- **Parathyroid Hormone**
  - Protein hormone secreted by the four parathyroid glands, located on the posterior surface of the thyroid, in response to a fall in iCa\(^{2+}\) levels, and acts to increase plasma calcium:
    - Increase calcium reabsorption in the PCT and late DCT
    - Increase osteoclastic activity in bone
    - Increase vitamin D activation in the intestine, which in turn increases intestinal absorption of dietary calcium

- **Vitamin D/Calcitriol**
  - Once converted to calcitriol in the kidney (via stimulation from PTH), vitamin D acts to:
    - Increase calcium reabsorption from kidney and gut
    - Increase bone calcification

- **Calcitonin**
  - Peptide hormone secreted by the C cells of the thyroid gland, in response to a rise in iCa\(^{2+}\) greater than 2.4mmol.L\(^{-1}\).
Calcitonin acts to:
- Decrease absorption of calcium from gut and kidney
- Decrease osteoclastic activity of bone

References


Last updated 2017-09-08
Histamine

Describe the physiology of histamine and serotonin

Histamine is an endogenous amine produced by decarboxylation of histidine. Histamine is:

- Present in all tissues
  - Particularly abundant in those exposed to the outside environment:
    - Lungs
    - Gut
    - Skin (lungs, gut, skin)
- Produced in and released by:
  - Mast cells
    - Released by exocytosis during inflammatory and allergic reactions.
  - Basophils
  - Histaminocytes in the stomach
  - Histaminergic neurons in the CNS
- Metabolised by:
  - Histaminase
  - Imidazole N-methyltransferase

Histamine Receptors and Effects

Histamine acts on:

- $H_1$ receptors
  - $G_q$ receptor involved broadly in inflammation and vasodilation.
- $H_2$ receptors
  - $G_s$ receptor involved in gastric acid secretion.
- $H_3$ receptors
  - $G_i$ presynaptic receptor in the CNS.
- $H_4$ receptors
  - $G_i$ receptor located in bone marrow and other solid haematological organs (spleen, liver, thymus).

<table>
<thead>
<tr>
<th>System</th>
<th>$H_1$</th>
<th>$H_2$</th>
<th>$H_3$</th>
<th>$H_4$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resp</td>
<td>Bronchoconstriction</td>
<td>Bronchodilation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVS</td>
<td>↑ Vasodilation (endothelial effect), coronary vasoconstriction, ↓ AV nodal conduction</td>
<td>↑ HR, ↑ inotropy, coronary vasodilation, ↑ capillary permeability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td></td>
<td></td>
<td></td>
<td>Presynaptic inhibition of neurotransmission</td>
</tr>
<tr>
<td>MSK</td>
<td>Weal due to local vasodilation, itch, ↑ nociception</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GIT</td>
<td>↑ Peristalsis</td>
<td>↑ Gastric acid secretion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haeme</td>
<td></td>
<td></td>
<td></td>
<td>Alter IL-16 release</td>
</tr>
</tbody>
</table>
References


Last updated 2017-09-17
Prostanoids

Prostanoids are a diverse family of eicosanoids (20-carbon molecules), produced from arachidonic acid, and include:

- Thromboxane
- Prostacyclin
- Prostaglandins

Synthesis

Arachidonic acid is converted into:

- Leukotrienes by LOX
- Cyclic endoperoxidases by COX enzymes

These undergo further metabolism to produce:

- Thromboxanes
  - Thromboxane A₂
- Prostacyclins
  - PGI₂
- Prostaglandins
  - PGE₂
    - EP₁
    - EP₂
    - EP₃
  - PGF₂α
  - PGD₂

![Diagram of Prostanoid Synthesis]

Effects

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Receptor</th>
<th>Respiratory</th>
<th>Vascular</th>
<th>GIT</th>
<th>GU</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thromboxane A₂</td>
<td>Gq</td>
<td></td>
<td>Vasoconstriction</td>
<td></td>
<td></td>
<td>Platelet aggregation</td>
</tr>
<tr>
<td>PGI₂</td>
<td>Gs</td>
<td>Bronchodilation</td>
<td>Vasodilation (renal and pulmonary)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGE₂ EP₁</td>
<td>Gq</td>
<td>Bronchoconstriction</td>
<td>Increased contraction</td>
<td></td>
<td></td>
<td>Renal vasodilation</td>
</tr>
<tr>
<td>PGE₂ EP₂</td>
<td>Gs</td>
<td>Bronchodilation</td>
<td>Closure of ductus arteriosus</td>
<td>Decreased contraction</td>
<td></td>
<td>Renal vasodilation</td>
</tr>
<tr>
<td>Prostanoids</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>--------</td>
<td>--------</td>
<td>----------------</td>
<td>----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGE₂ EP₃</td>
<td>Gi</td>
<td></td>
<td>Gastric mucous production, GIT contraction</td>
<td>Uterine contraction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGF₂α</td>
<td>Gq</td>
<td>Bronchoconstriction</td>
<td>Vasoconstriction</td>
<td>Uterine contraction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGD₂</td>
<td>Gs</td>
<td></td>
<td>Renal vasodilation</td>
<td>Promote sleep</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**References**


Last updated 2019-07-18
Skeletal Muscle

- Describe the anatomy and physiology of skeletal, smooth, and cardiac muscle
- Describe the mechanism of excitation-contraction coupling

Skeletal muscle has a number of functions:

- Facilitate movement
- Posture
  - Via tonic contraction of antagonistic muscle groups.
- Soft tissue support
  - Abdominal wall and pelvic floor support viscera.
- Voluntary sphincter control
- Heat production

Structure and Contents

Skeletal muscle consists of long tubular cells, known as muscle fibres, which run the length of the muscle. Skeletal muscle cells:

- Are under voluntary control from the somatic nervous system via α-motor fibres
  - α-motor fibres may control multiple myofibres, forming a motor unit.
- Are 10-100μm in diameter
- Contain several hundred peripheral nuclei
- Contain multiple mitochondria
  - Slow oxidative fibres (red fibres)
    - Contain multiple mitochondria, produce sustained contraction, and are resistant to fatigue.
  - Fast glycolytic fibres (white fibres)
    - Contain low numbers of mitochondria and large amounts of glycogen, and produce strong contractions but are more easily fatigued.
- Contain sarcoplasmic reticulum
- Contain large amounts of glycogen
  - ~200g total.
- Contain myoglobin
- Appear striated microscopically due to the arrangement of myofibrils
  - Myofibrils are multiple myofilaments arranged in parallel
  - Myofilaments are formed from multiple sarcomeres arranged in series
  - A sarcomere is the functional unit of muscle

Muscle fibres are surrounded by layers of connective tissue:

- Endomysium
  - Thin layer which surrounds each muscle fibre.
- Perimysium
  - Surrounds bundles of muscle fibres.
- Epimysium
  - Thick layer which surrounds an entire muscle.

These layers of connective tissue join at the end of a muscle to form a tendon or aponeurosis.

Sarcomere
The sarcomere is the functional contractile unit of muscle. Average sarcomere length is 2.5μm.

The sarcomere contains two main proteins:

- **Myosin** (thick) filaments
  - Myosin is a large protein with two heads, which bind actin and ATP. The myosin head flexes on its neck during contraction.

- **Actin** (thin) filaments
  - Actin is a smaller protein than myosin, and potentiates the ATPase of myosin. Actin filaments have a groove which contains another protein called tropomyosin, to which troponin attaches to.
    - Troponin has three subunits:
      - Troponin T - binds troponin to tropomyosin
      - Troponin I - prevents myosin binding to actin by physically obstructing the binding site
      - Troponin C - Binds Ca\(^{2+}\) which initiates contraction

These proteins are arranged to form three bands and two lines:

- **A-band**
  - The myosin filaments.

- **H-band**
  - The section of myosin filaments not overlapping with actin filaments.

- **I-band**
  - The section of actin filaments not overlapping with myosin filaments.

- **Z-line**
  - Each end of the sarcomere. Actin from adjacent sarcomeres are connected at the Z line.

- **M-line**
  - Band of connections between myosin filaments.

---

**Excitation-Contraction Coupling**

Muscle contraction normally requires the coordination of electrical (signaling) events with mechanical events.

- In response to ACh stimulating nicotinic receptors, the Na\(^+\) and K\(^+\) conductance of the end-plate increases and an **end-plate potential** is generated.
- Muscle fibres undergo successive depolarisation and an action potential is generated along T tubules.
  - These deliver the AP deep into the cell, and close to the sarcoplasmic reticulum.
- Ca\(^{2+}\) is released from sarcoplasmic reticulum.
  - This process involves:
    - Dihydropyridine Receptor
      - Specialised voltage-gated L-type Ca\(^{2+}\) channel, activated by T-tubular depolarisation. Responsible for a small amount of Ca\(^{2+}\) transport.
    - Ryanodine Receptor
A second \( \text{Ca}^{2+} \) channel which is attached to, and activated by, the dihydropyridine receptor, causing a much larger release of \( \text{Ca}^{2+} \).

- \( \text{Ca}^{2+} \) is released from the SR (increasing intracellular \( \text{Ca}^{2+} \) 2000x) and binds to \text{troponin C}, weakening the troponin I - actin link and uncovering myosin-binding sites on actin.
- Cross-linkages form between actin and myosin, which releases \text{ADP}
- The release of \text{ADP} triggers a \text{power stroke}, which is a process of attachment, pulling, and detachment
  Each cycle shortens the sarcomere by \( \sim \text{10nm} \):
  - The myosin head rotates on its 'neck', moving to a new actin binding site
  - \text{ATP} binds to the (now free) binding site on the myosin
  - \text{ATP} is hydrolysed to \text{ADP}, in the process "re-cocking" the myosin head
    This process causes the thick and thin filaments to slide on each other, with the myosin heads pulling the actin filaments to the centre of the sarcomere. Therefore, over the course of a power stroke:
    - The A-band is unchanged
    - The H-band shortens
    - The I-band shortens
- Power strokes continue as long as there is \text{ATP} and \( \text{Ca}^{2+} \) available

- In relaxation:
  - \( \text{Ca}^{2+} \) is pumped back into the sarcoplasmic reticulum
    This is an \text{ATP}-dependent process, and is why muscle relaxation is active.
  - Troponin releases \( \text{Ca}^{2+} \)
  - Binding sites are occluded by troponin, and no further contraction occurs

References

3. Slomianka, L. Muscle. University of Western Australia - School of Anatomy and Human Biology.

Last updated 2019-07-18
Skeletal Muscle Innervation

Motor Units

- A motor unit consists of an α-motor neuron and the group of muscle cells that it innervates
  - An action potential in this neuron will cause contraction of all the myocytes in the unit
  - Large muscles have many myocytes per unit
  - Small, precise muscles (e.g. extraocular) have few myocytes per unit

Force of Contraction

Muscle tension is dependent on three factors:

- **Initial myocyte fibre length**
  Optimal stretch maximises the number of overlapping actin and myosin filaments.
- **Number of contracting myocytes**
  Recruitment of additional motor units increases the force of contraction.
- **Frequency of Action Potentials**
  High frequency action potentials cause accumulation of calcium in the cytoplasm (the Bowditch or Treppe effect), increasing force of contraction.
  - As the absolute refractory period of skeletal muscle is shorter than cardiac muscle, **tetany**, or sustained muscle contraction, can occur

Proprioception

Proprioception is the ability of the body to determine its position in space. There are two key proprioceptive sensors:

- Muscle spindles
- Golgi tendon organs

Muscle Spindles

Muscle spindles sense changes in muscle length. They:

- Are a specialised muscle fibre, known as **intrafusal fibres**
- Run parallel to myocytes (also known as **extrafusal fibres**)
- Consist of two elements:
  - Central, non-contractile portion which senses tension
  - Contractile ends
  - This allows the muscle spindle to adjust its length with its muscle, so that a constant tension in the non-contractile portion can be maintained over a range of muscle lengths.

Muscle spindles have both afferent and efferent innervation:
● Afferent type Ia fibres adjust their electrical output to signal both current fibre length and rate of change
● Afferent type II fibres only signal fibre length
● Efferent γ neurons innervate the contractile elements

Voluntary muscle contraction results in contraction of both motor units (α1 neurons) and intrafusal fibres (γ-motor neurons).

Tonic innervation of γ-motor neurons increases muscle tone by stretching the non-contractile portions, increasing Ia firing and subsequent α-motor unit firing.

**Golgi Tendon Organs**

Golgi tendon organs are stretch receptors located between muscle and tendon. They:

● Run in series to myocytes
● Sense stretch
● Cause reflexive muscle relaxation, intended to prevent muscle damage

**Reflexes**

A reflex is an involuntary, predictable movement in response to a stimulus. There are two types:

● **Monosynaptic**: Motor neuron synapses directly with the sensory neuron
  
  Monosynaptic reflexes are rapid, but only generate simple responses. There are five components to a monosynaptic reflex:
  
  ○ Sensory receptor
    
    Typically muscle spindles.
  
  ○ Afferent neuron
    
    Type Ia afferents relay signal from muscle spindle to ventral horn via the dorsal root.
  
  ○ Synapse between afferent and efferent neuron
    
    In the ventral horn
  
  ○ Efferent neuron
    
    α-motor neuron travels from the ventral horn and innervates the motor unit.
  
  ○ Effector muscle Innervated motor unit contracts in response.

● **Polysynaptic**: Motor neuron is separated from the sensory neuron by one or more interneurons in the dorsal horn
  
  This allows modulation of signal. Responses are slower but more complex, e.g. withdrawal of a limb from a hot object.

**Twitch and Tetany**

● A **twitch** is the response of a muscle to a single stimulus (action potential)

● A **tetanic** contraction describes the sustained contraction produced by repetitive stimulation before relaxation can occur
  
  ○ This stimulation must be causing above a **critical frequency**, which is dependent on the action potential duration for a cell
  
  ○ Repetitive stimulation causes repeated SR depolarisation, leading to sustained high intracellular $Ca^{2+}$ levels as $Ca^{2+}$ entry exceeds $Ca^{2+}$ exit
  
  ○ Force from tetanic contraction is up to 4x greater than that of a twitch

**References**

2. ANZCA March/April 2000
Last updated 2019-07-18
Neuromuscular Blockers

Understanding of the pharmacology of neuromuscular blocking drugs

The neuromuscular junction is a chemical communication between the motor neuron and the muscle cell. Vesicles containing ACh are released when activated by Ca$^{2+}$, and influx of which occurs when the action potential reaches the nerve terminal.

Nicotinic ACh receptors sit on the shoulders of junctional folds of muscle cells, whilst acetylcholinesterase is buried in the clefts.

Factors Affecting Neuromuscular Blockade

### Patient Factors

<table>
<thead>
<tr>
<th>Factor</th>
<th>Effect</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic Disease</td>
<td>Prolonged duration of aminosteroids and suxamethonium</td>
<td>Decreased metabolism, decreased production of pseudocholinesterase in severe disease</td>
</tr>
<tr>
<td>Pseudocholinesterase deficiency</td>
<td>Prolonged duration of suxamethonium</td>
<td>Decreased metabolism</td>
</tr>
<tr>
<td>Age</td>
<td>Increased sensitivity in neonates, particularly premature infants</td>
<td>Incomplete maturation of NMJ</td>
</tr>
<tr>
<td>Hypokalaemia</td>
<td>Potentiates non-depolarising blockade, reduces depolarising blockade</td>
<td>Increases magnitude of stimulus required to depolarise cell</td>
</tr>
<tr>
<td>Hyperkalaemia</td>
<td>Potentiates depolarising blockade, reduce non-depolarising blockade</td>
<td>Decreases magnitude of stimulus required to depolarise cell</td>
</tr>
<tr>
<td>Hypermagnesaemia</td>
<td>Potentiates blockade</td>
<td>Decreases ACh release, decreases sensitivity of post-synaptic membrane</td>
</tr>
<tr>
<td>Hypocalcaemia</td>
<td>Potentiates blockade</td>
<td>Decreases presynaptic ACh release, decreases sensitivity of post-synaptic membrane</td>
</tr>
<tr>
<td>Respiratory acidosis</td>
<td>Potentiates blockade</td>
<td>Enhances effect of NMB agents</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Potentiates blockade</td>
<td>Reduces hepatic metabolism, renal elimination, Hoffman degradation</td>
</tr>
<tr>
<td>Hypovolaemia</td>
<td>Slows rate of onset and enhances duration</td>
<td>Prolonged circulation time</td>
</tr>
<tr>
<td>Myasthenia Gravis</td>
<td>Increased sensitivity to non-depolarising agents</td>
<td>Autoimmune blockade of receptors gives pre-existing level of block</td>
</tr>
<tr>
<td>Eaton-Lambert Syndrome</td>
<td>Increased sensitivity to all NMBs</td>
<td>Autoimmune destruction of voltage-gated Ca$^{2+}$ channels prevent ACh vesicle exocytosis</td>
</tr>
</tbody>
</table>

### Drug Factors

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Effect</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frusemide</td>
<td>Potentiates blockade at low dose, reduces blockade at high dose</td>
<td>Inhibits protein kinases (reducing AMP/ATP synthesis) at low dose, inhibits PDE at high doses which increases ACh release</td>
</tr>
<tr>
<td>Inhalational anaesthetics</td>
<td>Potentiates blockade</td>
<td>Stabilise post-junctional membrane, blockade of presynaptic ACh receptors</td>
</tr>
</tbody>
</table>
Antibiotics

Local anaesthetics

Anticholinesterases

OCP

Ca\(^{2+}\)-channel blockers

Lithium

Potentiate blockade

Variable. Aminoglycosides and tetracyclines prolong blockade

Potentiate blockade

Reduce ACh release and stabilise post-junctional membrane

Reduces blockade

Increase ACH levels at the NMJ by decreasing breakdown

Potentiates depolarising blockade

Competes for binding sites on plasma cholinesterases

Potentiates blockade

Inhibit Ca\(^{2+}\) dependent ACh release

Potentiates blockade

Augments action of NMBs

Additional Factors Affecting Onset of Neuromuscular Blockade

Most of these can be related to Fick’s Law:

<table>
<thead>
<tr>
<th>Factor</th>
<th>Effect</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potency</td>
<td>Low potency decreases time to onset</td>
<td>Bowman's principle: Less potent drugs must be administered in higher doses, and so have a greater concentration gradient driving diffusion to the effect site</td>
</tr>
<tr>
<td>Dose</td>
<td>Increased dose decreases time to onset</td>
<td>Greater concentration gradient</td>
</tr>
<tr>
<td>Cardiac Output</td>
<td>High output decreases time to onset</td>
<td>Increased drug delivery</td>
</tr>
<tr>
<td>Muscle group flow</td>
<td>High muscular flow decreases time to onset</td>
<td>Increased drug delivery</td>
</tr>
<tr>
<td>Priming Principle</td>
<td>(May) decrease time to onset</td>
<td>A 'priming' dose of non-depolarising blocker is to an awake patient given prior to induction. This occupies less than 70% of receptors, so does not cause significant neuromuscular blockade. After induction, a second dose is given to occupy the remaining receptors and complete blockade.</td>
</tr>
</tbody>
</table>

References

2. ICU Adelaide. Neuromuscular Blockers.
4. ANZCA February/April 2011

Last updated 2019-07-18
Basal Metabolic Rate

Basal Metabolic Rate is the energy output required to sustain life at rest.

- 'Resting' is defined as an individual who is:
  - Fasted for 12 hours
  - In a comfortable external environment
  - At mental and physical rest
- Normal values are:
  - 100W.day$^{-1}$
  - 70kcal.hr$^{-1}$

Metabolic rate is the actual energy consumption of an individual, and is greater than BMR due to a number of factors.

Factors Affecting Metabolic Rate

Metabolic Rate is affected by:

- **Age**
  - BMR decreases as age increases.
    - Neonates have a BMR twice that of an adult
    - Children have an increased BMR relative to that of an adult
    - BMR declines by 2% for each decade of life
- **Body Composition**
  - Lean muscle has a greater energy requirement than fat.
    - Higher body fat percentage results in a lower BMR
      - Females have a lower BMR for this reason - when adjusted for lean mass there is no difference
- **Diet**
  - Digestion increases BMR by ~10% due to the energy required to assimilate nutrients
    - This is known as the specific dynamic action of food.
      - Protein > carbohydrate > fat
    - Note that the Specific Dynamic Action for each macromolecule is not related to the respiratory quotient for that food type.
  - Starvation decreases the BMR
- **Exercise**
  - Skeletal muscle is the largest and most variable source of energy consumption
- **Environment**
  - Cooler environments increase BMR
  - Temperate environments decrease BMR up to 10%
- **Physiological states**
  - Pregnancy increases BMR up to 20% in 2nd and 3rd trimester
  - Lactation increases BMR
  - Catecholamines increase BMR
  - Corticosteroids increase BMR
- **Disease states**
  - Malignancy increases BMR
Sepsis increases BMR
Hyperthyroidism increases BMR

Measurement of BMR using Indirect Calorimetry

BMR is measured using indirect calorimetry, which calculates heat production via measurement of VO₂ and VCO₂. A number of methods exists depending on whether the patient is intubated or not, or whether they are requiring supplementary oxygen.

In general:
- Patients should be relaxed and fasted
- FiO₂ needs to be calculated (or taken from the ventilator settings), and E₁CO₂ and E₁O₂ must be measured
- Steady-state should be achieved across a five minute period
  - The average MVO₂ and MVCO₂ changes by <10%
  - The respiratory quotient (\( RQ = \frac{VCO₂}{VO₂} \)) change by <5%
    - This ratio will vary depending on the substances metabolised:
      - Carbohydrates ≈ 1
      - Protein ≈ 0.8
      - Fat ≈ 0.7

Resting Energy Expenditure is given by the abbreviated Weir equation:

\[ REE = 3.94 \times (F_iO₂ - E₁O₂) + (1.1 \times VCO₂) \text{ in Watts per unit time of measurement.} \]

Errors in Indirect Calorimetry
- Air leaks and measurement errors
- Measures consumption (rather than requirements)
- Point estimate of a dynamic process

Footnotes

The respiratory quotient is the value of \( \frac{VCO₂}{VO₂} \) at steady-state, whilst the respiratory exchange ratio is affected by metabolic rate.

References
2. ANZCA Feb/April 2006
3. LITFL - Indirect Calorimetry

Last updated 2019-07-18
Fat Metabolism

Digestion

Triglycerides are the main constituent of body fat in animals and vegetables, and therefore in dietary fat. They consist of three fatty acid molecules joined by a glycerol molecule.

As fats are not water soluble, they tend to clump together in chyme and are hard to digest due to the low surface area:volume ratio. Emulsification speeds up the digestive process, and occurs via the action of:

- Bile salts
  Many bile salts have a hydrophobic and a hydrophilic end, which give a detergent action. Bile salts bound to fatty acids form a **mixed micelle** which can be further digested by enzymes or directly absorbed.
- Partially digested fats
- Mechanical action of the stomach

Once emulsified, triglycerides can be hydrolysed by lipase into fatty acids and monoacylglycerol.

Absorption

Absorption occurs in a number of stages:

- Mixed micelles, free fatty acids, monoacylglycerol, and cholesterols are absorbed via facilitated diffusion into the enterocyte
- From the enterocyte:
  - Short-chain fatty acids (those with < 12 carbon atoms) enter the portal vein and travel directly to the liver
  - Long-chain fatty acids are re-esterified and packaged with a layer of protein and cholesterol to form a **chylomicron**
    Re-esterification maintains the concentration gradient for diffusion of fatty acids, allowing further uptake to occur.
      - Chylomicrons are ejected from the cell into the lymphatics and travel to the systemic circulation
      - Chylomicrons are removed from circulation by lipoprotein lipase
        Lipoprotein lipase is found on capillary endothelium and bound to albumin.
        - Lipoprotein lipase breaks down triglyceride in chylomicrons and VLDL to free fatty acids and glycerol
          This reaction uses heparin as a cofactor.
        - Free fatty acids and glycerol are then free to enter adipose tissue

Storage

Fat is stored as **triglycerides**, and forms the bulk of energy storage of the body.

Triglycerides are synthesised by the liver:

- Occurs when insulin levels are high and glycogen stores are full
- From excess carbohydrate and amino acids
  These are converted to fatty acids and glycerol, and then esterified to form triglyceride. This is known as lipogenesis.

Metabolism
Free fatty acids can be absorbed by adipocytes for storage, or be β-oxidised to acetyl CoA in the liver, which can enter the citric acid cycle to produce ATP.

References

Carbohydrate Metabolism

Describe the physiology and biochemistry of fat, carbohydrate and protein metabolism

Storage

Carbohydrates are stored in liver and muscle as glucose polymers known as glycogen.

- The liver contains ~100g of glycogen
  This can maintain plasma glucose for ~24 hours.
- Skeletal muscle contains ~200g of glycogen
  This cannot be released into circulation, and is for use only by the muscle.

Production of glycogen is stimulated by insulin, which is released as plasma glucose levels rise following carbohydrate ingestion. When plasma glucose levels fall, the release of glucagon and adrenaline stimulates glycogenolysis.

Glycolysis

Glycolysis:

- Describes the process of converting glucose into pyruvate
  This is known as the Embden-Meyerhof pathway.
- Occurs in the cytoplasm
- Does not consume oxygen or produce carbon dioxide
- Produces 2 ATP
  Glycolysis allows production of ATP in anaerobic conditions.

Gluconeogenesis

Gluconeogenesis is the production of glucose from other molecules. Gluconeogenesis:

- Requires ATP to perform
  Some organs (heart, brain) rely on glucose for ATP
- Has many potential substrates:
  - Lactate
  - Pyruvate
  - Glycerol
  - Amino acids
  - CAC-intermediates
- Is stimulated by glucagon
- Is inhibited by biguanides (metformin)

References


Last updated 2019-07-18
Protein Metabolism

Describe the physiology and biochemistry of fat, carbohydrate and protein metabolism

Essential amino acids cannot be produced by transamination - they must be supplied in the diet.

Metabolism

Protein catabolism involves the deamination of amino acids. Deamination can occur in one of two ways:

- **Oxidative deamination**
  Hepatic deamination, removing the amino group to create a ketoacid and ammonia. Ammonia produced in the liver enters the urea cycle and becomes urea, which requires 3 ATP.

- **Transamination**
  Amino group is transferred by aminotransferases to another amino acid or a ketoacid to produce:
  - Keto acids, which:
    - Enter the citric acid cycle and produce ATP
    - Get converted to glucose or fatty acids
  - Amino groups
    - Enter the urea cycle and become urea

Footnotes

Ammonia can also be produced in the kidney by the deamination of glutamate in the kidney. In this instance:

- It is eliminated directly in urine as ammonium
- Does not enter the urea cycle

References


Last updated 2019-07-18
Requirements and Starvation

Fasting

Fasting is the metabolic state achieved after complete digestion and absorption of a meal.

Fasting can be divided into:

- **Early fasting**
  - Less than 24 hours.
    - Plasma glucose falls due to consumption
    - Leads to hormonal changes:
      - Insulin release decreases, causing:
        - Liver
          - Decreased glycogenesis
          - Increased gluconeogenesis
        - Muscle
          - Decreased glucose utilisation
          - Decreased glycogenesis
          - Decreased protein synthesis
        - Fat
          - Decreased lipogenesis
          - Due to:
            - Decreased glucose uptake
            - Decreased TG uptake
        - Increased lipolysis
      - Adrenaline release increases, causing:
        - Decreased insulin release
        - Increased lipolysis
        - Increased muscle FFA use
        - Increased hepatic glycogenolysis and gluconeogenesis
      - Glucagon release increases
  - Cellular metabolism alters:
    - Decreased glucose uptake by non-obligate glucose consumers e.g. Muscle.
    - Increased FFA and ketone body use
      - β-oxidation of FFAs to meet ATP requirements, leading to formation of ketone body.

- **Sustained fasting**
  - Greater than 24 hours. See starvation below.

Starvation

Starvation is the failure to absorb sufficient calories to sustain normal body function, requiring the body to survive on endogenous stores.

- **Days:**
Energy is conserved through reduction in movement

Hormonal changes
- Increased gluconeogenesis, using glycerol, lactate, and amino acids
- Insulin concentrations fall further
- Cortisol levels increase
- Glucagon levels peak at 4 days

Metabolic changes
- Glucose use continues to fall, and FFA use increases
- Further fall in muscle protein synthesis

Weeks:
- Tissues adapt to metabolise ketones (with plasma levels rising up to 7 mmol.L\(^{-1}\), and gluconeogenesis falls
  - The brain still requires 100g of glucose per day
- BMR falls
- All but life-saving movement ceases
- Death typically occurs after 30-60 days, when muscle catabolism weakens the respiratory muscles such that secretions can no longer be cleared, and pneumonia occurs

Refeeding Syndrome

Refeeding syndrome is a deranged metabolic state that occurs with feeding after a period of prolonged fasting, typically >5 days.

There are three pathogenic mechanisms:

- A large spike in insulin causes increased cellular uptake (and low plasma levels) of:
  - Glucose
  - Magnesium
  - Phosphate
  - Potassium
- Sodium and water retention occurs, which may precipitate cardiac failure
- Increased carbon dioxide production increases minute ventilation and work of exhausted respiratory muscles

Management is by slow institution of feeding and aggressive electrolyte management.

References

2. ANZCA August/September 2001

Last updated 2019-07-18
Anaerobic Metabolism

Describe the consequences of anaerobic metabolism and ketone production

Lactate

The Embden-Meyerhof pathway:

- Describes the conversion of glucose to pyruvate (and two ATP)
- Does not consume O₂ or produce CO₂
- Therefore it occurs in both anaerobic and aerobic conditions.
- Consumes two NAD⁺ and produces two NADH

In anaerobic conditions (in the erythrocyte, and in the setting of cellular hypoxia):

- There is no oxygen available to allow further ATP production via the electron transport chain
- There is also no regeneration of NAD⁺ in the ETC.
- In order for glycolysis to continue, NAD⁺ is regenerated via production of lactate

\[ \text{P}r\text{yruvate} + \text{NAD}^{+} \rightarrow \text{Lactate} + \text{NAD}^{+} \]

About 1400mmol of lactate is produced per day. Lactate is either:

- Oxidised in the cell
  This requires restoration of NAD⁺, e.g. resolution of cellular hypoxia.
- Circulated to the liver
  Lactate is then:
  - Oxidised to pyruvate
  - Converted to glucose
  This process is known as the Cori cycle.

Ketones

Ketones:

- β-oxidation of fatty acids in the liver produces acetyl-CoA
- Acetyl-CoA usually enters the citric acid cycle to produce ATP
- When large amounts of acetyl CoA are produced, they may instead condense to form acetoacetate, which can then be reduced to β-hydroxybutyrate
  These substances are known as ketones
- Ketones can only be produced by the liver, and only used as a substrate by the kidney, as well as skeletal and cardiac muscle
- Production of ketones is accelerated by glucagon and adrenaline

References

2. ANZCA August/September 2011
Regulation of Body Temperature

Outline the mechanisms for heat transfer between the body and its environment.

Define the thermoneutral zone, and describe the mechanisms by which normal body temperature is maintained.

- Regulation of body temperature is done by balancing heat loss and heat production, predominantly through behavioural mechanisms and skin.
- The body is able to maintain a relatively constant core temperature under a wide range of environmental conditions.
  - The thermoneutral zone is the range across which the basal rate heat production (and oxygen consumption) is balanced by the rate of heat loss.
    - For an adult it is typically 27-31°C.
    - In neonates it is higher, typically 32-34°C.

Principles

Net flux of heat is determined by the balance of metabolic heat production and the contribution of four mechanisms of heat loss:

- Radiation
- Conduction
- Convection
- Evaporation

Radiative

Radiative heat exchange:

- Describes the loss of heat through EMR by all objects above 0°K.
  - Radiative heat loss is proportional to temperature.
  - Radiative heat loss does not require a transfer medium.
  - Makes up ~45% of heat loss under thermoneutral conditions.
  - Depends on the temperature differential between an individual and their environment.
    - A cold environment (e.g., operating theatre) causes a large radiant heat loss.
      - The heat loss from the patient is greater than the heat gain from the surrounding environment.

Conduction

Conduction is the transfer of heat (as kinetic energy) by direct contact from a higher temperature object to the lower temperature one. Conduction:

- Requires physical contact between bodies to conduct heat.
  - Solids conduct heat better than gases.
  - There is no conduction in a vacuum.
- Heat loss via conduction is minimal in air but is a major cause of heat loss in immersion.
  - As arteries and veins typically run next to each other, arterial heat tends to be transferred to the (cooler) veins, limiting further heat loss.
    - This is similar to counter-current exchange in the kidney.
  - As fat is a poorer conductor of heat than muscle, increased body fat will slow heat loss by conduction.

Convection
**Convection** is loss of heat by conduction by a moving object. Convection is:

- The predominant mechanism of heat loss in the naked human
  Effects are greater effects at higher wind speeds.

**Evaporation**

Evaporative losses describe the loss of heat energy due to the latent heat of vapourisation of water. Evaporation of 100ml of water will reduce body temperature by ~1°C.

**Temperature Sensation and Regulation**

Temperature sensors are **central** and **peripheral**, whilst regulation occurs centrally.

**Central Sensation**

Central temperature sensors exist in the:

- Abdominal viscera
- Spinal cord
- Hypothalamus
  - Anterior hypothalamus is the most important central thermoreceptor, and responds to both increased and decreased temperatures by **altering their rate of depolarisation**, eliciting an array of neuronal and hormonal responses.
- Brainstem
  
  The **inter-threshold range** is the range of core temperatures not triggering a response.

- Normal is 0.2 to 0.4°C.
- Widens under anaesthesia to ~4°C

**Peripheral Sensation**

Peripheral temperature sensors are:

- **Free nerve endings**
  - Extremely sensitive
  - Alter their rates of firing by orders of magnitude in response to temperature change.
- Divided into:
  - **Cold receptors**
    - Lie beneath the epidermis, and are excited by cooling (inhibited by warming), active from 10-40°C, with a static maxima at 25°C.
  - **Warm receptors**
    - Lie deep to the dermis, are excited by warming (and inhibited by cooling), active from 30-50°C, with a static maxima at 44°C.

**Regulation**

Temperature sensation runs from cutaneous receptors via the spinothalamic tracts and medulla to the hypothalamus. Cortical input is received via the thalamocortical relay, whilst primitive responses are effected via the midbrain.

**Effector Responses**
<table>
<thead>
<tr>
<th></th>
<th>Increase heat loss</th>
<th>Reduce heat loss/Increase heat gain</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS</td>
<td>Remove clothing, sprawl, reduce activity.</td>
<td>Huddle, seek shelter, add clothing</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Increase peripheral vasodilation and AV shunting, and cardiac output to improve flow to cutaneous tissues</td>
<td>Vasoconstriction, peripheral circulatory shut down</td>
</tr>
<tr>
<td>Musculocutaneous</td>
<td>Sweating</td>
<td>Piloerection, Shivering</td>
</tr>
<tr>
<td>Metabolic</td>
<td></td>
<td>Increased BMR, non-shivering thermogenesis</td>
</tr>
</tbody>
</table>

- **Vascular changes** are the least metabolically costly and can result in dramatic increases (up to 60% of cardiac output) in skin blood flow.
- When environmental temperature exceeds body temperature, conduction and convection result in heat gain - evaporative cooling via sweating is the only way to reduce body temperature.
- Efficacy of sweating is related to relative humidity.
- Piloerection (hair standing on end) traps a layer of warm air close to the body to act as an insulator. This is of more importance in other primates than in man, as they have enough body hair to make it effective.
- Increasing basal metabolic rate and 'waste' heat production is essential to maintain temperature in cold environments. This can be through:
  - Shivering
    The simultaneous contraction of agonistic and antagonistic muscles.
  - Non-shivering thermogenesis:
    - **Hormonal**
      Levels of thyroid hormone and adrenaline increase, raising metabolic rate in all cells.
    - **Brown fat**
      Brown fat produces heat through uncoupled oxidative phosphorylation, which uses the electron transport chain to produce heat rather than ATP. Brown fat is:
      - A vital mechanism for heat production in the neonate (they have an immature shivering response), and forms ~5% of neonatal mass.
      - Located in:
        - Neck
        - Supraclavicular
        - Interscapular
        - Suprarenal
      - Sympathetically innervated
        Contains large numbers of β3 receptors.

**Effect of Anaesthesia**

General anaesthesia causes a 1-3°C drop in core body temperature, which occurs in three phases:

- **Rapid reduction**
  Core temperature falls by 1-1.5°C in the first 30 minutes.
  - Predominantly due to vasodilation, which is due to:
    - Reduction in SVR, with generalised vasodilation and increased skin blood flow.
      Heat redistribution is the major initial factor (rather than heat loss), as vasodilation leads to increased heat content of peripheries.
    - Impairs thermoregulatory vasoconstrictive responses.
      Inter-threshold range is widened to 4°C (up from 0.4°C).
- Gradual reduction
  Further drop in core temperature of 1°C over following 2-3 hours.
  - Due to heat loss exceeding heat production
    Non-shivering thermogenesis is the only response available to paralysed, anaesthetised patient.
- Plateau
  Once core body temperature falls far enough, thermoregulatory responses are activated and further heat loss is attenuated by increased metabolic heat production.

Neuraxial anaesthesia:
- Hypothermia is less extreme as thermoregulation is only affected in areas covered by the blockade
- Plateau does not occur as vasoconstrictive responses are inhibited by the blockade

**References**

3. Diaz A. Define "thermoneutral zone". Briefly explain how the body regulates temperature when the ambient temperature exceeds the thermoneutral zone. Primary SAQs.

Last updated 2019-07-18
**Inflammation**

Describe the factors involved in the process of inflammation and the immune response, including innate and acquired immunity.

Inflammation is a non-specific response triggered by a pathogen or tissue injury, which aims to limit further tissue damage.

Inflammation is classically characterised by:

- Pain
- Heat
- Redness
- Swelling
- Loss of function

This is a consequence of:

- Vasodilation
  - Increases blood flow to area, which increases supply of immune cells and resources for cellular repair.
- Increased vascular permeability
  - Increases extravasation of protein and immune cells.
- Migration of phagocytes
  - Remove pathogens and cellular debris.

**Process of Inflammation**

- Tissue damage
  - Trauma causes mechanical disruption of vasculature and mast cell degranulation, causing local inflammation and activation of haemostatic mechanisms
  - Infection stimulates degranulation of local macrophages, releasing inflammatory cytokines and triggering mast cell degranulation
- Local inflammatory response
  - Histamine causes arteriolar and post-capillary venule dilatation and subsequent extravasation
  - Release of chemotactic molecules attracts circulating inflammatory cells
- Systemic inflammatory response
  - Severe inflammation may lead to cytokines in the systemic circulation, causing:
    - Fever
    - Neutrophil recruitment from bone marrow
    - Release of acute-phase proteins from liver

**References**


Last updated 2018-09-21
Innate Immunity

Describe the factors involved in the process of inflammation and the immune response, including innate and acquired immunity.

The innate immune system consists of protective mechanisms which are present life-long, and typically forms the first line of defence against pathogens.

Key features of innate immunity include:

- Immediacy
- Non-specific response
- Not modified by repeat exposures

The innate immune system consists of three components:

- Physicochemical barriers
- Humoral mechanisms
- Cellular Mechanisms

Physicochemical Barriers

These include:

- Skin
- Mucous membranes
  - Mucous
  - Mucociliary elevator
- Gastric acid
- Urination

Optimised by high flow rates and low residual bladder volumes.

Innate Humoral Mechanisms

Humoral mechanisms describes the role of inflammatory proteins in innate immunity:

- Complement

  The complement system is a complex group of about 25 plasma proteins important in both innate and adaptive immunity.

  The complement system is activated by:

  - Antigen-antibody complexes
    - The 'classical pathway,'
  - Substances in the bacteria cell wall
    - The 'alternative pathway,'

  Complement has a number of inflammatory functions:

  - Destruction of bacteria
    - Several complement proteins come together to form a membrane attack complex, which creates large pores in cell membranes, causing water to diffuse in and bacteria to burst.
  - Opsonisation of bacteria
    - Bound complement acts as a binding site for phagocytes.
  - Activation of monocytes and phagocytes
  - Chemotaxis
Attracts leucocytes.
- Mast cell degranulation
  Augments inflammation.

- **Acute-Phase Proteins**
  Inflammatory proteins with a number of effects:
  - Opsonisation
  - Inflammatory mediators
    - Increase blood flow and delivery of inflammatory cells via three mechanisms:
      - Dilatation and increased capillary permeability
      - Endothelial activation increasing leukocyte adhesion
      - Attraction of neutrophils and monocytes

- **Proteolytic enzymes**
  Bactericidal enzymes located in saliva, tears, respiratory mucous, and neutrophils.

### Innate Cellular Mechanisms

Cellular components of the innate immune system include:

- **Mast cells**
  Exist in loose connective tissue and mucosa, and contain many intracellular granules of heparin and histamine.

- **Leukocytes**
  - Neutrophils (60% of all leukocytes)
    Phagocytose bacteria and fungi (15-20 per neutrophil). This process consists of a number of steps:
      - Exit circulation by **marginating** along capillary border when activated
      - Migrate via **chemotaxis** towards the tissue insult
      - **Phagocytose opsonised** bacteria and fungi
      - Kill organisms with a **respiratory burst**:
        A granule containing hydrogen peroxide, hydroxyl and oxygen radicals fuses with the target cell membrane, destroying both the target and the neutrophil.
  - Monocytes
    Become **macrophages** when they leave circulation and enter tissue. Macrophages have a lifespan of 2-4 months, and can phagocytose up to 100 bacteria before it dies. Functions include:
      - Phagocytosis and destruction of pathogen
      - Especially intracellular pathogens (*listeria, mycobacteria*), parasites, and fungi.
      - Breakdown of damaged body cells
      - Present antigen to T-helper cells
      - Secretion of inflammatory mediators
  - Eosinophils
    Kill multicellular parasites.
  - Basophils
    Contain heparin and histamine.
  - Lymphocyte
    Subtype of leukocyte important in adaptive immunity. Include:
      - **Natural Killer cells**
        Active against viral and tumour cells.
      - **B cells**
      - **T cells**
Innate Immunity

References


Last updated 2019-07-18
Adaptive Immunity

Describe the factors involved in the process of inflammation and the immune response, including innate and acquired immunity.

The adaptive immune system responds to an exposure, demonstrating specificity and memory, with improved efficacy on repeat exposure.

Adaptive immunity may be:

- **Active**
  - Primary immune response generated by exposure to antigen.
    - Infection
    - Vaccination
      - An inactive (but still foreign and therefore antigenic) protein component of a pathogen is given to the patient, resulting in an immune response. Subsequent exposure to the whole pathogen triggers a secondary immune response.

- **Passive**
  - Preformed antibody is given to the patient. This will provide treatment/coverage for the life of the antibody, but immunity will be lost when the antibody breaks down or supplies are exhausted.
    - Transplacental
    - Colostrum
    - Administration of serum

Components of the active immune system include:

- **Cellular**
  - Predominantly T lymphocytes

- **Humoral**
  - Including complement and antibody.

Adaptive Cellular Immunity

Lymphocytes are divided into two types:

- **B lymphocytes**
  - Are produced in the bone marrow, and migrate to lymphoid (nodes, spleen, MALT) where they are renamed plasma cells and produce antibody. Functions include:
    - Production of antibody against specific antigens
    - Presentation of antigen to T-cells to active them
    - Proliferation to form memory cells

- **T lymphocytes**
  - Are produced in the bone marrow and migrate to the thymus where they mature. T cells which express antibody to host protein apoptose, resulting in only 2% of immature T cells surviving. Mature T cells then spread to lymphoid tissue. There are five types of T cells, of which two are most important:
    - **Helper T-cells**
      - 2/3d of T-cells are helper cells, are identified by their CD4 membrane protein. Functions include:
        - Cytokine production
        - B lymphocyte stimulation
        - Macrophage activation
    - **Cytotoxic T-cells**
Are identified by their CD8 membrane protein. Functions include:
- Destruction of virally infected and tumour cells
  All cells express proteins that they are producing on membrane MHC I molecules, for inspection by immune cells. Infected or tumour cells will express foreign proteins, and cause activation of cytotoxic T cells:
  - Induce apoptosis in the target cell
  - Rapid division of cytotoxic T cell, which then inspects other cells for infection
  - Transformation to memory cells

Adaptive Humoral Immunity

Antibodies Y-shaped immunoglobulins which:
- Are produced in response to a pathogen
- Are specific to that pathogen

Antibody functions include:
- Opsonisation
- Agglutination
  Each antibody can bind multiple pathogens, increasing target size for leukocytes.
- Inactivation of pathogen
  Antibody binding may disable the pathogen.
- Activation of complement
  Antibody-antigen complexes cause complement activation.

Primary Immune Response

The process of invasion of a new pathogen to antibody production takes ~5 days, and occurs in a number of steps:
- APC phagocyte a pathogen
  APCs include macrophages and dendritic cells.
- APC express antigen (bits of pathogen) on cell surface
- APC travel to lymphoid tissue and present it to B and T cells
- When an APC finds a B and T cell with a reciprocal antibody:
  - T helper cell becomes activated by APC
  - T helper cell rapidly proliferates ('clonal expansion')
    - Proportion become memory cells
  - B cells are activated by both the APC and a T-helper cell (requires both)
  - B cells rapidly proliferate
    - Proportion become memory cells
    - Proportion become plasma cells
      - Plasma cells produce antibody at a rate of 2000 molecules per second, which overrides normal cellular homeostasis, causing death within a week.
      - Antibody produced in a primary immune response is IgM, with some IgG produced later on.

Secondary Immune Response

Repeat invasion by the same pathogen is met with a much more rapid and aggressive immune response:
- APCs phagocyte a pathogen
- APCs express and present antigen
- Memory T and Memory B cells formed during the primary response are activated, and begin rapidly dividing and producing antibody
References


Last updated 2019-07-18
Hypersensitivity

Explain the immunological basis and pathophysiological effects of hypersensitivity, including anaphylaxis.

Understand the pharmacology of the drugs used in the treatment of anaphylaxis.

Hypersensitivity reactions are exaggerated immune responses that cause host injury.

Classification of Hypersensitivity Reactions

The Gel and Coombs system classifies hypersensitivity reactions by the mechanism. It is commonly used but fails to classify more complex diseases.

<table>
<thead>
<tr>
<th>Type I - Immediate hypersensitivity</th>
<th>Type II - Cellular hypersensitivity</th>
<th>Type III - Immune-complex deposition</th>
<th>Type IV - Delayed hypersensitivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timing: Seconds to minutes</td>
<td>Timing: 5-8 hours</td>
<td>Timing: 2-8 hours</td>
<td>Timing: 24-72 hours</td>
</tr>
<tr>
<td>Mediator: IgE</td>
<td>Mediator: IgM, IgG</td>
<td>Mediator: IgM, IgG, IgA</td>
<td>Mediator: T-cell</td>
</tr>
<tr>
<td>Pathophysiology: Basophil and mast cell degranulation</td>
<td>Pathophysiology: Antibody binding to cell surface antigen, resulting in cell death via complement membrane attack complexes, or phagocytosis by macrophages</td>
<td>Pathophysiology: Tissue deposition of Ab-Ag complexes. Accumulation of PMNs, macrophages, and complement.</td>
<td>Pathophysiology: T-cell induced mononuclear cell accumulation. Release of monokines and lymphokines.</td>
</tr>
<tr>
<td>Disease example(s): Anaphylaxis (systemic), Atopy (local)</td>
<td>Disease example(s): Transfusion reactions, hyperacute allograft rejection</td>
<td>Disease example(s): SLE, necrotising vasculitis, post-Strep GN</td>
<td>Disease example(s): TB, Wegener's Granulomatosis, Granulomatous vasculitis</td>
</tr>
</tbody>
</table>

Type I Hypersensitivity

- Antigen simulates a B lymphocyte to produce a specific IgE against it
- This IgE then binds to Fc receptors on mast cells, sensitising them to this exposure
- On re-exposure the antigen binds (cross-links) IgE on mast cells, causing degranulation:
  - Histamine, leukotrienes, and prostaglandins are released
  - This may cause local or systemic effects, depending on method of exposure:
    - A systemic reaction is called anaphylaxis, and manifests as a combination of:
      - Hypotension
      - Bronchospasm
      - Laryngeal oedema
      - Rashes
    - Local reactions depend on the route of exposure, and include
      - Asthma
      - Inhaled.
      - Allergic rhinitis
      - Nasopharyngeal mucosa.
- Non-immune anaphylaxis (also known as anaphylactoid) reactions are characterised by a immediate generalised reaction clinically indistinguishable from true anaphylaxis, but the immune nature is unknown, or not due to a type I hypersensitivity
Management of Anaphylaxis

- **Adrenaline** is the drug of choice, as it treats cardiovascular collapse, bronchospasm, and decreases oedema formation.
  - In adults, 0.3-0.5mg IM Q5-15min
  - In children, 0.01mg/kg IM Q5-15min
- **Glucagon** may be used in β-blocked patients resistant to adrenaline.
  - In adults, 1-5mg IV over 5 minutes, followed by infusion at 5-15microg/min
  - In children, 20-30mcg/kg up to 1mg over 5 minutes
- Non-pharmacological management includes early intubation to protect against airway obstruction due to angioedema.
- Adjuncts include antihistamines and steroids. They are second line as they do not attenuate cardiovascular collapse, resolve airway obstruction, or have strong evidence behind their use. They include:
  - Diphenhydramine 25-50mg IV (Children: 1mg/kg up to 40mg) up to 200mg in 24/24
  - Salbutamol, for bronchodilation
  - Methylprednisolone 1-2mg/kg, ostensibly to protect against rebound anaphylaxis (though there is minimal evidence)

Type II Hypersensitivity

- Antibodies bind to cell surface antigen
- Antibody-Antigen complex **activates complement**
- Complement generates an inflammatory response
- Cell death occurs via:
  - Complement membrane attack complex
  - Phagocytosis

Clinical picture depends on affected organs. Examples include:

- Hyperacute allograft rejection
- Transfusion reactions and haemolytic disease of the newborn
- Goodpasture's syndrome
- Autoimmune cytopaenias
- Myasthenia Gravis

Type III Hypersensitivity

- Immune-complex reaction where Ab-Ag complexes are formed and deposited in tissues
- Subsequent complement activation causes inflammation and neutrophils activation, leading to tissue damage
- There are two subtypes of type III reactions:
  - Formation of complexes in circulation and subsequent deposition in tissues
    - e.g. Serum sickness
  - Formation of complexes in tissues
    - Small amounts are typically removed by the reticuloendothelial system, but in this case there are too many, or they are too small, to be cleared effectively.
    - e.g. The Arthus reaction (a localised vasculitis, which may be necrotising)

Type IV Hypersensitivity

- Antigen is presented to T lymphocytes which proliferate and become sensitised
- T-cells then release cytokines, attracting macrophages and leading to local inflammation
- During prolonged exposure, macrophages may fuse to form giant cells and form a granuloma. Examples include:
  - TB
- Granulomatous vasculitis

## References

1. CICM July/September 2007

Last updated 2019-07-18
Classification of Microorganisms

Describe the classification of micro-organisms, including viruses, bacteria, protozoa and fungi.

Microorganisms can be classified as prokaryotes (bacteria), viruses, or eukaryotes (which include fungi, helminths, and protozoa).

Bacteria

- Bacteria are prokaryotic organisms
- Most clinically relevant bacteria can be classified by Gram stain and shape
  - Gram stain separates bacteria according to their cell wall composition
    - It cannot be used on organisms that lack a cell wall, such as mycoplasma.
      - A crystal violet followed by an iodine solution is applied to the slide, which is then washed with a solvent
      - Gram +ve organisms will retain the stain due to their thick peptidoglycan cell wall, whilst gram negative organisms become colourless
    - A safranin pink stain is then applied, which stains the gram -ve bacteria pink
  - Bacteria can also be classified by shape into:
    - Cocci
      - Appear round on microscopy.
    - Rods

Combining of these two systems classifies a large proportion of microbes:

<table>
<thead>
<tr>
<th>Examples</th>
<th>Gram Positive</th>
<th>Gram Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cocci</td>
<td>Staphylococcus Aureus, Streptococcus Pneumoniae</td>
<td>N. Meningitidis, N. Gonorrhoea</td>
</tr>
<tr>
<td>Rods</td>
<td>Listeria, Clostridium difficile</td>
<td>Escherichia Coli, Pseudomonas aeruginosa</td>
</tr>
</tbody>
</table>

Bacterial Subclassification

Additional testing can be done to further classify bacteria:

- Catalase testing is performed on Gram positive cocci
  - Hydrogen peroxide is added to a bacterial sample, and in the presence of catalase will produce oxygen.
    - Catalase positive indicates Staphylococci
    - Catalase negative indicates Streptococci (and enterococci)

- Coagulase testing is performed on Staphylococcal species
  - Coagulase is an enzyme which cleaves fibrinogen to fibrin. The staphylococcal colony is added to rabbit plasma and incubated. In the presence of coagulase, fibrin is formed.
    - Coagulase positive strongly suggests S. Aureus
    - Coagulase negative examples include S. epidermidis or S. saprophyticus

- Haemolytic testing is performed on Streptococcal species
  - Bacterial colonies are added to blood agar, and the colour change (due to haemolysis) is noted.
    - α haemolytic organisms produce dark green agar, as methaemoglobin is produced by hydrogen peroxide produced by these organisms. Examples include:
      - Strep. pneumoniae
      - Strep. viridans
    - β-haemolytic organisms produce yellow agar from complete haemolysis. Examples include:
Strep. pyogenes
Strep. agalactiae
- γ-haemolytic organisms leave the agar unchanged. Examples include:
  - E. faecalis
  - E. faecium
- Additionally, gram negative rods should be further classified into pseudomonal and non-pseudomonal organisms

Viruses

Viruses consist of molecules of either DNA or RNA shielded in a protein coat. They require the use of host cell structures for reproduction and are therefore obligate intracellular parasites. They can be classified by five properties:

1. **DNA/RNA**
   - DNA viruses replicate in the cell nucleus using a host polymerase.
2. **Double-stranded** or single-stranded
   - i. Most DNA viruses are double-stranded (dsDNA)
   - ii. Most RNA viruses are single-stranded (ssRNA)
3. **Negative-sense** or positive-sense (RNA viruses only)
   - i. Positive-sense genomes may be translated directly into mRNA
   - ii. Negative-sense genomes require an RNA-dependent RNA polymerase to translate them to a positive-sense strand prior to translation.
4. **Capsid Symmetry**
   - The protein coat may be either icosahedral or helical
5. **Enveloped** or non-enveloped
   - In addition to a protein coat, viruses may have a lipid membrane (acquired from the host cell) around their protein coat.

Eukaryotic Organisms

Eukaryotic organisms include fungi, protozoa, and helminths, as well as plants and animals. They differ from prokaryotic organisms in a number of ways:

<table>
<thead>
<tr>
<th>Property</th>
<th>Prokaryotes</th>
<th>Eukaryotes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chromosomes</td>
<td>Single, circular</td>
<td>Multiple</td>
</tr>
<tr>
<td>Nucleus and Organelles</td>
<td>None</td>
<td>Membrane bound nucleus and organelles</td>
</tr>
<tr>
<td>Cell wall</td>
<td>Usually</td>
<td>In plants</td>
</tr>
<tr>
<td>Ribosome</td>
<td>70S</td>
<td>80S in cell, 70S in organelles</td>
</tr>
<tr>
<td>Size</td>
<td>0.2-2mm</td>
<td>10-100mm</td>
</tr>
</tbody>
</table>

- **Fungi** typically feed on dead/decomposing/the immunocompromised and produce spores. They are subclassified into:
  - **Yeast**
    - Yeasts are unicellular. They are divided into:
      - Candida
        - Albicans
        - Non-albicans More difficult to treat.
      - Cryptococcus
  - **Moulds**
    - Moulds are are filamentous.
      - Aspergillus
- *Penicillium*
  - *Dimorphous* Have characteristics of both yeasts and moulds.
- *Histoplasma*
- *Protozoa* are parasitic single-celled eukaryotes. They can be intracellular or extracellular.
- *Helminths* are parasitic multi-celled eukaryotes. They can be intracellular or extracellular. They are subdivided into tapeworms (cestodes), flukes (trematodes), and roundworms (nematodes).

### Footnotes

1. This classification does not capture spirochetes, mycoplasmas, chlamydias, and other less commonly encountered organisms. A more complete classification uses six properties:

1. Cell Wall Structure
   - i. Flexible (e.g. Spirochetes)
   - ii. Rigid
   - iii. Non-existent (e.g. *Mycoplasma spp.*)
2. Morphology
   - i. Unicellular
   - ii. Filamentous
3. Growth Location
   - i. Extracellular
   - ii. Obligate intracellular parasites (e.g. *Chlamydia spp.*)
4. Gram Stain
   - i. Gram positive
   - ii. Gram negative
5. Shape
   - i. Cocci
   - ii. Rods
6. O₂ tolerance
   - i. Aerobes
   - ii. Anaerobes (e.g. *Clostridium spp.*)

### References

1. Harvey RA, Cornelissen CN, Fisher BD. Lippincott Illustrated Reviews: Microbiology (Lippincott Illustrated Reviews Series), 3rd Ed. LWW.
2. CICM September/November 2008

Last updated 2019-07-20
Antimicrobial Resistance

Describe the principles of antimicrobial resistance

Resistance occurs when the maximal level of the agent tolerated is insufficient to inhibit growth.

Resistance can occur broadly via two mechanisms:

- Genetic Alteration
  - Spontaneously, through mutation and subsequent natural selection of resistant organisms
  - Transference of resistance genes from organism to organism via plasmids

- Protein Expression
  Increasing or decreasing expression of proteins with subsequent change in efficacy of antimicrobials.

Mechanisms

Specific mechanisms of resistance (which may be genetic alterations or changes in protein expression) include:

- Prevent access to target
  - Decrease permeability
    - Narrowing of porin channels
      e.g. Streptococcal resistance to penicillins typically occurs by reducing access to PBPs.
    - Loss of non-essential transporter channels
      e.g. Anaerobes have no oxygen-transport channel which prevents penetration by aminoglycosides.
  - Active efflux of agent
    Increased efficiency or expression of efflux pumps. Can be:
    - Removed from cell
    - Trapped between cell wall layers
      e.g. Glycopeptide resistance in VRSA.

- Alter antibiotic target site
  - Changes in binding site protein will increase resistance to agents with low affinity
  - Over-expression of target protein
  - Synthesis of target-protecting proteins

- Modification or Inactivation of Drug
  - Metabolism of drug
    e.g. β-lactamases hydrolyse β-lactam rings

- Modification of Metabolic Pathways
  - Development of metabolic pathways to bypass site of action of antibiotic
    e.g. Resistance to Trimethoprim-Sulfamethoxazole by allowing bacteria to synthesis or absorb folic acid.

References

1. Harvey RA, Cornelissen CN, Fisher BD. Lippincott Illustrated Reviews: Microbiology (Lippincott Illustrated Reviews Series). 3rd Ed. LWW.
2. CICM September/November 2008

Last updated 2019-07-18
Antiseptics

Outline the pharmacology of antiseptics and disinfectants

Key Definitions

Relevant definitions for antiseptics include:

- **Cleaning**
  Physical removal of foreign material.
  - Used for *non-critical items*, which come into contact with healthy skin but not mucous membranes (e.g. blood pressure cuff)

- **Decontamination**
  Destruction of contaminants such that they cannot reach a susceptible site in sufficient number to cause harm.

- **Disinfection**
  Elimination of all pathological organisms, excluding spores.
  - Used for *semi-critical items*, which are those that contact mucous membranes but do not break the blood barrier (e.g. endoscopes, laryngoscopes)

- **Sterilisation**
  Elimination of all forms of microbial life, including spores.
  - Used for *critical items*, which are those that enter sterile or vascular tissue and pose a high risk of infection (e.g. surgical instruments, vascular and urinary catheters)

Antiseptic Agents

<table>
<thead>
<tr>
<th>Drug</th>
<th>Isopropyl Alcohol</th>
<th>Chlorhexidine</th>
<th>Povidone Iodine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmaceutics</strong></td>
<td>Typically 60-90% - requires some water to denature protein. Flammable.</td>
<td>May be aqueous or combined with isopropyl alcohol.</td>
<td>Iodine combined with a polymer (povidone) to enhance water solubility</td>
</tr>
<tr>
<td><strong>Antiviral Properties</strong></td>
<td>Poor antiviral</td>
<td>Poor antiviral</td>
<td>Good antiviral</td>
</tr>
<tr>
<td><strong>Antibacterial Properties</strong></td>
<td>Broad spectrum antibacterial</td>
<td>Broad spectrum antibacterial and antifungal</td>
<td>Broad spectrum including fungi, spores (unlike iodine), and tuberculosis</td>
</tr>
<tr>
<td><strong>Toxic</strong></td>
<td>Irritant on mucous membranes and open wounds</td>
<td>Hypersensitivity</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Persistent antiseptic effect</td>
<td></td>
<td>Requires continual release of iodine to achieve effect. Inactivated by organic substances. Stains.</td>
</tr>
</tbody>
</table>

References

Respiratory Changes of Pregnancy

Explain the physiological changes during pregnancy, and parturition

Respiratory changes in pregnancy are a function of two things:

- Anatomical compression of the chest
- Increased VO₂ and VCO₂

Anatomical Changes

- Diaphragm pushed upwards by ~4cm
- Increased AP and transverse diameter of the chest wall (~2-3cm)
- Large airway dilation, reducing airway resistance by ~35%

Volumes and Capacities

From conception until term:

- VT increases by 40%
- Inspiratory capacity increases by 10%
- Expiratory capacity decreases by 30%
- Total lung capacity decreases by 5%
- Vital capacity is unchanged

From ~20 weeks until term:

- ERV decreases
- RV decreases
- FRC decreases
  - By 20% erect
  - By 30% supine

Ventilation

Progesterone stimulates respiratory centres, shifting the O₂ and CO₂ response curves to the left which causes hyperventilation and a respiratory alkalosis. From conception until term:

- MV increases by 50%
  - 10% increase in RR
  - 40% increase in VT
- PCO₂ falls to ~26-32mmHg, with a compensatory drop in plasma [HCO₃⁻] to 18-21mmol.L⁻¹

Labour and Postpartum

During labour:

- MV increases 70% due to pain and increased oxygen demand
- This causes hypocapnea, so cessation of uterine contractions (and the associated pain and oxygen demand) are followed by a
hypoventilatory period producing desaturation

FRC and RV return to normal within 48 hours of delivery.

References


Last updated 2019-07-18
Cardiovascular Changes of Pregnancy

- Explain the physiological changes during pregnancy, and parturition
- Physiological consequences of changes in posture during pregnancy

Pregnancy is a time of increased metabolic demand, which cardiovascular changes reflect. These changes include:

- Increased intravascular volume Occurs via two mechanisms:
  - Increased oestrogen causes an increased plasma volume
    - This decreases capillary oncotic pressure, predisposing to oedema
    - This may be exacerbated by the gravid uterus compressing the IVC, especially near-term
  - Increased EPO causes an increased red cell volume
- Increased venous return Due to increased intravascular volume and MSFP.
  - The gravid uterus may compress the IVC and impair VR, hence pregnant women are positioned with a left lateral tilt to displace the uterus off the IVC
- Increased VR causes an increase in CO (with both an increase in HR and SV, as well as a decrease in SVR)
- Decreased SVR results in SBP, DBP and MAP dropping (despite the increase in CO)

Magnitude of Changes by Trimester

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Direction</th>
<th>First Trimester</th>
<th>Second Trimester</th>
<th>Third Trimester</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma volume</td>
<td>↑</td>
<td>35%</td>
<td>45%</td>
<td>50%</td>
<td>Peaks between 32-36th week, decreases slightly thereafter</td>
</tr>
<tr>
<td>Blood volume</td>
<td>↑</td>
<td>5%</td>
<td>15%</td>
<td>20%</td>
<td>Increases less than plasma volume, resulting in the fall in haematocrit to 33%</td>
</tr>
<tr>
<td>HR</td>
<td>↑</td>
<td>15%</td>
<td>18%</td>
<td>25%</td>
<td>Increases progressively throughout</td>
</tr>
<tr>
<td>SV</td>
<td>↑</td>
<td>20%</td>
<td>25%</td>
<td>30%</td>
<td>Increases progressively throughout</td>
</tr>
<tr>
<td>CO</td>
<td>↑</td>
<td>20%</td>
<td>40%</td>
<td>45%</td>
<td>Increases throughout and dramatically in labour</td>
</tr>
</tbody>
</table>

Changes During Labour

- Uterine contraction boluses ~300ml of blood into the maternal circulation
  - Causes an increase in CO by up to 30% during the active phase and 45% during ejection.
  - Associated with corresponding increase in SBP and DBP by 10-20mmHg
- Post-partum CO is up to 80% of pre-labour values due to autotransfusion, and returns to normal within 2 weeks of delivery

References

Foetal Circulation

Explain the physiological changes during pregnancy, and parturition

In Utero

The foetal circulation has a number of structural differences:

- **Two umbilical arteries**
  The umbilical artery returns deoxygenated blood to the placenta.
  - PO2 of 18mmHg (SpO2 45%)
  - Over 50% of the combined output of both foetal ventricles enters the placenta

- **One umbilical vein**
  The umbilical vein supplies oxygenated blood to the foetus.
  - Has a PaO2 of 28mmHg (SpO2 70%)
  - 60% of blood from the umbilical vein enters the IVC
  - 40% of blood enters the liver

- **Two ducts:**
  - **Ductus venosus**
    Shunts blood from the umbilical vein to the IVC.
  - **Ductus arteriosus**
    Shunts blood from the pulmonary trunk to the descending aorta.

- **A foramen ovale**
  Shunts blood from the right atrium to the left atrium.

- **Immature myocardium**
  Foetal myocardium does not obey Starlings Law, and does not adjust contractility for any given preload. Therefore:
  - SV is fixed
  - CO is HR dependent
  - Normal HR at term is 110-160 bpm.

These structural differences alter the pathway of blood circulation:

- **Oxygenated blood returns via the umbilical vein**
  - 40% flows to the liver
  - 60% is returned to the IVC

- **Oxygenated blood in the IVC is directed via the Eustachian valve through the foramen ovale**

- Blood returning from the SVC is directed into the RV, and then into the descending aorta by the ductus arteriosus
  - ~10% of RV output flows through the pulmonary circulation

This arrangement has several features:

- Blood with the most oxygen is delivered to the arch vessels to supply the brain
- Blood with the least oxygen is delivered to the umbilical arteries for gas exchange
- Both the RV and the LV eject into systemic circulations, and are of similar size and wall thickness

Changes at Birth

Several changes happen at birth:

- Placental circulation is lost
There is a transition from circulation in parallel to circulation in series.

- **An FRC is established**
  Reversal of hypoxic pulmonary vasoconstriction results in a rapid drop in PVR.
- **The cord is clamped**
  The systemic vascular bed volume falls, and SVR increases due to the loss of the low-resistance placental circulation.

- **The fall in PVR lowers RV afterload**
  RAP falls due to the loss of hypoxic pulmonary vasoconstriction.

- **The rise in SVR increases LV afterload**
  LAP rises as the LV moves up the Starling curve.

- **When LAP exceeds RAP, the foramen ovale closes**
  A degree (~10%) of residual shunt remains. Shunt is:
    - Bidirectional
      - Left-to-right shunt is un concerning
      - Right-to-left shunt has usually only minor effects on systemic SpO2
        Will be increased with ↑ PaCO2, excessive PEEP, ↓ pH.
        - Beware embolic material
          Don't forget the bubbles.
    - Increased left sided afterload causes flow reversal in the ductus arteriosus
      There is progressive closure of the ductus over hours to days, under the influence of prostaglandins and oxygenated blood flowing through the duct.

- **The ductus venosus progressively fibroses over a period of days to weeks**

## References


Last updated 2019-06-14
The Placenta

Outline the functions of the placenta, and determinants of placental blood flow.

The placenta is an organ of maternal and foetal origin which supports the developing foetus.

Physiological Properties

The placenta has three broad functions:

- Interface between foetus and mother for nutrient exchange
- Immunological barrier
- Endocrine

Nutrient and Waste Exchange Functions

The primary purpose of the placenta is diffusion of nutrients and oxygen, and removal of waste.

As with the lung, diffusion is dependent on Fick’s Principle, i.e.:

\[ \dot{V} = \frac{A \times D \times \Delta P}{T} \]

where:

- \( \dot{V} \) = Flow of substance across the membrane
- \( A \) = Area of the membrane
- \( D \) = Diffusion constant for the substance, where
- Molecules < 600 Da in size more readily diffuse down concentration gradients
- \( \Delta P \) = Concentration difference across the membrane
- Maternal placental flow is ~600mL.min\(^{-1}\) at term - double that of foetal flow - which improves diffusion by increasing the concentration gradient for solutes
- \( T \) = Thickness of the membrane

O₂ Diffusion

At the end of pregnancy, PO₂ for foetal blood:

- Entering the placenta via the umbilical artery is 18mmHg (SpO₂ 45%)
- Leaving the placenta via umbilical vein is 28mmHg (SpO₂ 70%)

The foetus is able to have adequate delivery of O₂ despite the low PO₂ for four reasons:

- **High Cardiac Index**
  Increased cardiac output increases DO₂.

- **Foetal Hb**
  Contains two gamma subunits instead of beta subunits. These prevent the binding of 2,3-DPG, which result in a left-shifted Oxy-Haemoglobin dissociation curve, favouring oxygen loading at a low PaO₂.

- Foetal [Hb] is 50% greater than maternal [Hb]

- The Double Bohr effect:
The Bohr effect states that an increase in PaCO₂ right-shifts the oxyhaemoglobin dissociation curve. Conversely, the affinity of Hb for O₂ increases in alkalaeemia. The double Bohr effect describes this happening in opposite directions in the foetal and maternal circulations, favouring transfer of O₂ to the foetus:

- In the placenta, foetal CO₂ diffuses into maternal blood down its concentration gradient.
  This makes foetal blood relatively alkaline, and maternal blood relatively acidic. Therefore:
  - O₂ unloading of maternal blood is favoured.
  - O₂ loading of foetal blood is favoured.

**CO₂ Diffusion**

CO₂ is extremely lipid soluble, and so passes easily across membranes. Foetal PaCO₂ is ~50mmHg, and intervillous PCO₂ is ~37mmHg. CO₂ offloading is favoured in the foetus by:

- A high Foetal [Hb] increases the amount of CO₂ that can be carried as carbaminohaemoglobin.
- The Double Haldane effect:
  The Haldane effect states that deoxygenated Hb binds CO₂ with more affinity than oxygenated Hb. The double Haldane effect describes this happening in opposite directions in the maternal and foetal circulations, favouring CO₂ transfer to the mother:
  - As maternal blood releases O₂, this favours maternal loading of CO₂ without an increase in maternal PCO₂ (Haldane effect).
  - The release of CO₂ from the foetal Hb favours O₂ loading, which in turn favours further maternal O₂ release.

**Nutrient Diffusion**

In late pregnancy, foetal caloric requirements are high (approximately the same as the mother). Facilitated diffusion of glucose via carrier molecules occurs in trophoblasts.

Active transport occurs for amino acids, Ca²⁺, Fe, folate, and vitamins A and C. Other transporters actively remove substances from foetal circulation.

**Immunological Function**

The placenta is selectively permeable to IgG via pinocytosis, which allows maternal antibodies to provide passive immunity to the foetus.

**Endocrine Function**

Synthesises:

- βHCG
- hPL
- Oestriol
• Progesterone

Development

The placenta develops simultaneously from foetus and mother:

• From the uterine wall, the mother produces blood sinuses around the trophoblastic cords
  • These in turn send out placental villi
• This creates a sinus of maternal blood invaginated by multiple foetal villi
• Foetal villi are supplied by two umbilical arteries and a single umbilical vein
• Maternal sinuses are filled from the uterine arteries
• The maternal sinuses are supplied by spiral arteries

Properties of the Developing Placenta

• Thick(er) membrane impairs permeability
  Placental membrane permeability is small in early-to-mid pregnancy, reaching maximum at ~34 weeks
• Smaller surface area

Properties of the Mature Placenta

• Thick membrane - improved permeability
• Surface area of 14m²
• Weight of ~500g
• Blood flow of 600mL.min⁻¹ at term
  Flow is reduced during contractions due to increased uterine pressure and also with α-adrenergic stimulation.

References


Last updated 2019-07-18
Gastric Secretions

The GIT produces a number of substances which can be classified by region and function:

- **Saliva**
  - H₂O (98%)
  - Digestive proteins
    - Amylase
    - Lipase
    - Mucin
    - Haptocorrin (Binds Vitamin B12)
  - Immunological proteins
    - Lysozyme
    - Lactoferrin
    - IgA

- **Gastric**
  - Digestive
    - HCl
    - Gastrin
    - Pepsin
    - Intrinsic Factor
  - Mucosal Protection
    - Mucous
    - HCO₃⁻

- **Small Bowel**
  - Digestive
    - Pancreatic
      - Lipase
      - Amylase
      - Trypsinogen
    - Endocrine
      - Secretin
      - Somatostatin

Control of Secretions

Secretion occurs in three phases:

- **Cephalic**
  Thought/sight/taste/smell of food, resulting in vagal-mediated stimulus to release gastrin. Accounts for ~30% of production.

- **Gastric**
  Stretch of the stomach stimulates HCl secretion and gastrin release. Accounts for ~50% of production.

- **Intestinal**
  A drop in pH of the proximal duodenum releases secretin to stimulate the exocrine pancreas.
**Salivary Secretions**

Approximately 1L of saliva is produced by the parotid, submandibular, and sublingual glands each day.

Saliva has four main functions:

- **Lubrication**
  - Mucin
- **Digestion**
  - Amylase
  - Lipase
    Particularly important in neonates who produce little pancreatic lipase.
- **Neutralisation of acid**
  - For protection prior to vomiting.
- **Antibacterial**

**Gastric Secretions**

The stomach produces ~2L of secretions per day:

- **Acid secretion**
  - **Parietal cells** contain an H⁺-K⁺ exchange pump.
    - H⁺ is produced by carbonic anhydrase on CO₂ and water, with 'waste' HCO₃⁻ removed from the cell in exchange for Cl⁻.
      - High levels of acid production result in large amounts of bicarbonate being secreted into blood
        - This creates an **alkaline tide** as portal venous pH increases dramatically
        - Respiratory quotient of the stomach may become negative due to consumption of CO₂
    - This pump is activated in response to increased levels of intracellular Ca²⁺ from stimulation by:
      - ACCh
      - Histamine (H₂)
      - Gastrin
  - Inhibited by:
    - Low gastric pH
    - Somatostatin

- **Gastric**
  - Gastrin is a peptide family secreted from antral G cells.
    - Secretion is stimulated by:
      - Neural (vagal) stimulation in the cephalic phase of digestion
        - Main mechanism.
      - Protein and amino acids in the stomach
      - Drugs
        - Alcohol
        - Caffeine
    - Secretion is inhibited by:
      - Low pH
      - Secretin
      - Glucagon
  - Gastrin has a number of pro-digestive effects:
    - Stimulates gastric acid secretion
    - Stimulates pancreatic secretion
Stimulates biliary secretion
Increases gastric and intestinal motility

- **Pepsinogens**
  - Chief cells secrete pepsinogen I and is released by ACh or β stimulation. Pepsinogen is cleaved to pepsin in the gastric lumen, and breaks down protein.

- **Intrinsic Factor**
  - Parietal cells produce intrinsic factor, which forms a complex with B12 which facilitates its later absorption in the terminal ileum.

- **Mucous**
  - Neck cells produce mucopolysaccharide, glycoprotein, and HCO3⁻ in response to stimulus by prostaglandins, which protects mucosa and lubricates food.

- **Pancreatic Secretions**
  - Exocrine pancreatic secretions are produced by the acinar and ductal cells, at the rate of 1.5L per day.
    - Release is stimulated by:
      - CCK
      - Secretin
      - ACh
      - Via vagal stimulation.
    - Consist of:
      - HCO3⁻
        - To alkalise gastric contents.
      - Pancreatic bicarbonate production lowers venous pH, and neutralises the alkaline tide of the stomach.
      - Water
      - Enzymes
        - Trypsinogen
          Proteolysis.
        - Amylase
          Hydrolysis of glycogen, starch, and complex carbohydrate.
        - Lipase
          Hydrolysis of dietary triglycerides.

**Endocrine Function**

- Cholecystokinin (CCK) is a peptide family secreted by intestinal enteroendocrine cells (I cells) in the mucosa of the duodenum and jejunum. Cholecystokinin:
  - Regulates satiety
  - Regulates leptin release from fat
  - Stimulates secretions from the gallbladder and duodenum
- Secretin stimulates pancreatic release. Secretin is:
  - Released by the proximal duodenum in response to low pH
- Motilin stimulates the migrating motor complex. Motilin is:
  - Released cyclically from M cells in the small bowel

**References**

Last updated 2019-07-18
**Oesophagus**

Describe the control of gastrointestinal motility, including sphincter function.

The oesophagus is a muscular tube connecting the pharynx to the stomach. The oesophagus has:

- **Skeletal muscle** in its **upper third**
- **Smooth muscle** in its **lower third**

**Lower Oesophageal Sphincter**

The LoS is:

- The most distal 2-4cm of the oesophagus
- Macroscopically indistinguishable from the rest of the oesophagus
  - However it has a higher concentration of nerve cells and is able to constrict at a higher pressure
- Tonically innervated by the vagus
- Important in the prevention of reflux

Competency of the LoS is required to prevent reflux

- **Barrier pressure** is the pressure difference between the pressure at the lower oesophageal sphincter and the pressure in the stomach, and is typically ~15-25mmHg

Barrier pressure is affected by:

- Changes in lower oesophageal sphincter pressure
  - Swallowing
    Barrier pressure decreases during swallowing, and transiently increases immediately afterwards.
  - Anatomical
    - **Age**
      Sphincter tone is decreased in neonates and the elderly.
    - **Diaphragm**
      An external sphincter is formed by the diaphragmatic crura, and exerts a *pinch-cock* action on the oesophagus.
    - **Stomach**
      A fold in the stomach wall just distal to the GOJ creates a *flap valve*, which occludes the GOJ when gastric pressure rises.
  - **Oesophagus**
    The oesophagus enters the stomach at an oblique angle, limiting retrograde flow.

- **Hormonal**
  - Gastrin, motilin, α-agonism **increase** LoS tone
  - Progesterone, glucagon, vasoactive intestinal peptide (VIP) **decrease** LoS tone

- **Drugs**
  - ETOH, IV and volatile anaesthetic agents, and anticholinergics **decrease** LoS tone
  - Suxamethonium, metoclopramide, and anticholinesterases **increase** LoS tone

- **Changes in gastric pressure**
  - Raised intraabdominal pressure
  - **Obesity**
  - **Pregnancy**

- **Disease**
  - **Hiatus hernia**
    GOJ moves into the thorax, causing:
Loss of pinch-cock action
Negative intrathoracic pressure reduces LoS pressure and therefore barrier pressure

References

2. ANZCA July/August 1999
4. ANZCA August/September 2015

Last updated 2019-07-18
Control of Gastric Emptying

Gastric emptying is a neurally and hormonally mediated process which aims to present food to the small bowel in a controlled manner. Different drugs, hormones, and physiological states can either encourage or inhibit gastric emptying.

Determinants of Gastric Emptying

Rate of gastric emptying is a function of:

- **Antral pressure**
  Main determinant as pyloric resistance tends to be low, and is affected by:
  - Stomach
  - Duodenum
  - Systemic factors
  - Drugs
- **Pyloric resistance**

Stomach

- **Gastric distension**
  Vagal excitation from gastric stretch causes release of gastrin, increasing peristaltic frequency.
- **Composition of chyme:**
  - Liquids empty faster than solids
    - Liquids have a half-time of ~20 minutes, and empty in an exponential fashion
    - Solids have a half-time of ~2 hours, with a dwell time of ~30 minutes, and empty in a linear fashion
  - Protein independently stimulates gastrin release

Duodenum

The duodenum has hormonal mechanisms which have a negative feedback on gastric emptying. These include:

- **Duodenal distension**
- **Hypoosmolar and hyperosmolar** chyme
- **Acidic chyme**
  In response to acid the duodenum releases secretin and somatostatin:
  - Secretin directly inhibits gastric smooth muscle
  - Somatostatin inhibits gastrin release
- **Fat and protein**
  Fat and protein breakdown products stimulate release of cholecystokinin, which inhibits gastrin.
  - Carbohydrate-rich meals empty faster than protein, which empty faster than fat.

Systemic

- **Motilin** released by the small bowel enhances the strength of the migrating motor complex, a peristaltic wave of contraction through the whole GIT which occurs every 60-90 minutes
- **Sympathetic** input from the coeliac plexus inhibits gastric emptying
- Pregnancy has a number of effects on gastric emptying:
  - Progesterone relaxes smooth muscle and inhibits gastric smooth muscle response to ACh and gastrin, as well as creating
incompetence of the LoS leading to GORD
- Gastrin production increases
  - Some gastrin is produced by the placenta.
- Gastric acid production is increased during the third trimester
- **Parasympathetic** input enhances gastric motility

**Effect of drugs**

Drugs which increase gastric emptying include:
- Metoclopramide
- Erythromycin

Drugs which inhibit gastric emptying include:
- Opioids
- Alcohol
- Anticholinergic agents

**References**

1. CICM July/September 2007

Last updated 2019-07-18
Swallowing

Describe the control of gastrointestinal motility, including sphincter function

Swallowing is divided into three phases:

- **Oral Phase**
  - Voluntary
  - Food is pushed against hard palate by tongue

- **Pharyngeal Phase**
  - Involuntary
  - Coordinated by medulla.
  - Closure of nasopharynx
  - Adduction of vocal cords
  - Hyoid elevation and deflection of epiglottis
  - Pharyngeal contraction
    - Props food bolus towards oesophagus

- **Oesophageal Phase**
  - Involuntary
  - Closure of UoS
    - Resting barrier pressure 100mmHg.
  - Relaxation of LoS
    - Resting barrier pressure 20mmHg, which is a balance between:
      - LoS pressure (30mmHg)
      - Antral pressure (10mmHg)
  - Oesophageal peristalsis

Impairment of any of these processes increases risk of aspiration:

- Obtundation
  - Reduced cough reflex.
- Muscular weakness
- Impaired medullary coordination

References


Last updated 2019-07-18
Physiology of Vomiting

Describe the control of gastrointestinal motility, including sphincter function

Vomiting is the active, forceful expulsion of gastric contents from the stomach. It is different from regurgitation which is a passive process.

It is a mechanism to expel toxic substances from the GIT.

Stimulation

Stimulants to vomiting can act centrally, or directly in the bowel:

- **Central stimulation**
  Central stimuli may act directly on the vomiting centre. Others act via the CTZ, which is part of the area postrema located outside of the blood-brain barrier, and so it can be stimulated by circulating substances. Central vomiting stimuli include:
    - Direct:
      - Emotion
      - Pain
      - Olfactory
      - Visual
    - Via the CTZ:
      - Vestibular acting on:
        - H₁
        - ACh
      - Drugs/Toxins acting on:
        - 5-HT₃
        - D₂
        - μ-opioid receptors

- **GIT stimulation**
  GIT stimuli travel SNS and PNS afferents to the vomiting centre. The CTZ is not involved and so anti-emetics which act here are not useful in this type of vomiting.

  GIT vomiting stimuli include distension and toxins. Neurotransmitters include:
    - 5-HT₃ in mucosal stretch receptors
    - ACh in NTS afferents
    - H₁ in NTS afferents

Postoperative Nausea and Vomiting

Central structures involved include:

- Chemoreceptor trigger zone
- NTS
- Multiple pathways exist (similar to those described above), and neurotransmitters involved include:
  - 5-HT₃
  - D₂
  - NK₁
  - H₁
  - mACh
Risk factors
  
  Patient factors
  - Female
  - Non-Smoker
  - Young age
  - History of PONV or motion sickness

  Anaesthetic factors
  - Volatile use
  - Nitrous oxide use
    - Relative risk of 1.4.
  - Opioid use
  - Anaesthesia duration

  Surgical factors
  - Gynaecological surgery
    - Likely not an independent risk factor, and simply confounded by female gender.
  - Strabismus surgery in children

Process of vomiting

Vomiting consists of a set of processes coordinated by the vomit centre in the medulla oblongata, and is divided into three phases:

  - **Pre-ejection phase**
    - Prodromal nausea
    - Salivation
    - Retrograde intestinal contraction which forces intestinal contents into the stomach

  - **Retching Phase**
    - Deep inspiration and breath-holding to splint the chest
    - Epiglottic closure
    - Elevation of the soft palate (prevents nasal soiling)

  - **Expulsive phase**
    - Relaxation of oesophageal sphincters
    - Pyloric contraction
    - Violent contraction of the diaphragm and abdominal muscles

References


Last updated 2019-07-18
Functions of the Liver

Describe the storage, synthetic, metabolic and excretory functions of the liver

Storage

The liver is important in storage and release of:

- Carbohydrates as glycogen
  The adult liver stores ~100g of glycogen.
- Fat as triglycerides
- All fat-soluble vitamins (A, D, E, K)
- Many water soluble vitamins including folic acid and B₁₂
- Iron
- Copper

Synthetic

Synthetic functions include:

- Bile production
- Plasma proteins including:
  - Clotting factors
  - Albumin production
    120-300mg.kg⁻¹ of albumin is produced per day, dependent on nutritional status, plasma oncotic pressure, and endocrine function.

Metabolic

Metabolic functions include:

- Carbohydrate
- Fat
- Protein
- Bilirubin metabolism
- Drugs and Toxins

Carbohydrates

- Monosaccharides and disaccharides passively diffuse into hepatocytes
  Gradient is maintained by converting glucose to glucose-6-phosphate which is used to produce glycogen. This maintains the gradient for diffusion.
- Glycogen is either synthesised (glycogenesis) or broken down (glycogenolysis) depending on plasma glucose and insulin:
  - Increased blood glucose stimulates insulin release, increasing the formation of glycogen through activation of glycogen synthetase
  - Decreased blood glucose stimulates glycogenolysis and gluconeogenesis from amino acids.

Lipids
• Fat can be:
  • Stored as triglycerides
  • Hydrolysed to glycerol and fatty acids, which is used for ATP production

**Proteins and Urea**

Amino acids are absorbed from blood to be used for gluconeogenesis and for protein synthesis. In order to produce substrates for the CAC, Amino acids may be:

• Transaminated
• Deaminated
• Decarboxylated

The nitrogenous scrap of these reactions is urea, which is produced in several stages:

• A variety of metabolic processes convert amino acids to glutamate
• Glutamate is converted to ammonia by glutamate dehydrogenase
• Ammonia then enters the urea cycle to produce (surprisingly) urea, at the cost of 3 ATP
  • A normal diet of 100g protein per day produces ~30g of urea, and 1000mmol of hydrogen ions

**Endocrine**

• Produces angiotensinogen
• Produces IGF-1
• Converts T4 to T3

**Immunoprotective**

• **Kupffer** cells
  Tissue macrophages of the hepatic reticuloendothelial system. They phagocytose harmful substances including:
  • Endotoxins
  • Bacteria
  • Viruses
  • Immune complexes
  • Thrombin
  • Fibrin complexes
  • Tumour cells

**Acid-Base Balance**

May produce or consume large numbers of hydrogen ions:

• Carbon dioxide production
• Metabolism of organic acid anions
  • Lactate
  • Ketones
  • Amino acids
• Ammonium
• Production of plasma proteins
  Notably albumin
References


Last updated 2019-07-18
Laboratory Assessment of Liver Function

Synthetic Function

Measures of synthetic function include:

- **Albumin**
  - Main plasma protein.
  - Normal range 28-58g.L⁻¹
  - Half-life ~20 days
  - Important in:
    - Maintenance of plasma oncotic pressure
    - Binding
      - Calcium
      - Drugs
    - Decreased in liver dysfunction and malnutrition

- **Coagulation Assays**
  - Clotting factors are produced by the liver. Hepatic impairment may result in reduced production and abnormality of clotting assays, although functional clotting function may be normal (as pro-coagulant proteins are affected to a similar extent).
  - INR
    - Test of the extrinsic pathway.
  - APTT
    - Test of intrinsic pathway.

Metabolic Function

Transaminases are released when liver parenchyma is damaged, and are used to evaluate metabolic function:

- **ALT**
  - Normal range < 54 U.L⁻¹.
- **AST**
  - Normal range < 35 U.L⁻¹.

Obstructive Tests

- **ALP (Alkaline Phosphatase)**
  - Enzyme involved in dephosphorylation of many compounds. ALP is found in all cells, but particularly in the liver, bile duct, bone, kidney, and placenta.
    - Normal range is 30-120 U.L⁻¹
- **GGT**
  - Enzyme found in biliary duct.
    - Normal range:
      - Males: 11-50 U.L⁻¹
      - Females: 7-30 U.L⁻¹
- **Bilirubin**
Byproduct of haemoglobin metabolism. May be measured as total, or as conjugated and unconjugated bilirubin.

References

1. Diaz, A. Outline the clinical laboratory assessment of liver function. Primary SAQs.
Describe the physiology of bile and its metabolism

Bile is a dark green solution produced by the liver to facilitate absorption of fat and fat-soluble vitamins (ADEK) through emulsification. Bile is:

- Produced by the liver at the rate of 1L per day
- Concentrated in the gallbladder
- Important in the absorbance of lipid and fat-soluble vitamins
- Formed from:
  - Water
  - Protein
  - Bilirubin
  - Bile salts

The sodium and potassium salts of bile acids. Bile acids:

- Are produced from cholesterol
- Are amphipathic, and act as emulsifiers of lipid
  Break up large fat globules into smaller micelles, which can then be absorbed.
- Major bile acids include:
  - Cholic acid
  - Chenodeoxycholic acid
- Are absorbed in the terminal ileum, and recycled by the portal circulation

Lipids
Electrolytes

References


Last updated 2019-07-18
Erythrocytes

Outline the physiological production of blood and its constituents

Erythrocytes:
- Are 7.5μm in diameter
- Are 2μm thick
- Have a lifespan of 120 days
- Have:
  - No nucleus
    - Maximises cell volume available for Hb.
  - No mitochondria
    - Cannot perform aerobic metabolism - all ATP is generated via glycolysis.
  - No ribosomes
    - Incapable of producing protein
- Have a biconcave disc shape
  - This maximises surface area (optimising gas transfer) and makes the cells flexible enough to pass through capillary beds (which are narrower than the cell).
- Are important in:
  - Delivering O₂ to the tissues and delivering CO₂ to the lungs
  - Acid-Base balance
  - Metabolism of some drugs
- Carry ~29pg of haemoglobin
- Comprise 40-50% of blood volume

Production

Erythrocytes have a myeloid progenitor which differentiates into the myeloid line. EPO (see endocrine functions of the kidney) stimulates myeloid progenitor cells to:
- Differentiate
- Proliferate
- Proerythroblasts begin synthesis of Hb, with ongoing production occurring until the cell is mature
- Further differentiation results in successive loss of organelles, increasing Hb content
- The loss of ribosomes and nucleus of the reticulocyte are the final stage of erythropoiesis
- The entire process takes ~7-10 days

Function

- Gas Carriage
- Acid-Base Buffering
  - Production of HCO₃⁻
  - Binding of H⁺ to Hb
- Metabolism
  - Esterases (and other -ases) in erythrocytes metabolise many drugs, including:
    - Remifentanil
    - SNP (reacts with Hb to form NO, CN, and Met-Hb)
    - Esmolol
Elimination

Old red cells are removed from circulation via:

- Phagocytosis by macrophages in:
  - Spleen
    - Major mechanism.
  - Liver
  - Bone marrow
- Haemolysis

~10% of red cell breakdown occurs in circulation, where the Hb dimers are then bound to haptoglobin by haemopexin.

This is important to prevent glomerular filtration of haeme, and loss of iron

Haemoglobin Metabolism

Haemoglobin is broken down into:

- Globin
  - Broken down into constituent amino acids.
- Iron
  - Re-enters haemoglobin synthetic pathway.
- Haeme

Complex metabolic pathway, notable as it is the only metabolic process that produces carbon monoxide:

- Metabolised to biliverdin by splenic macrophages in the reticuloendothelial system of the spleen
  - Circulating erythrocytes are phagocytosed by splenic macrophages
  - Haptoglobin binds circulating Hb, the Hb-Haptoglobin complex is then phagocytosed by splenic macrophages
- Biliverdin is reduced to unconjugated bilirubin
  - This is fat soluble, and binds to albumin.
- Unconjugated bilirubin is conjugated in the liver to conjugated bilirubin
- Conjugated bilirubin is secreted in bile by active transport
  - This is impaired during hepatic disease, leading to increased bilirubin levels in plasma.
- Secreted conjugated bilirubin is metabolised to urobilinogen by gut bacteria
- Urobilinogen may have a number of fates:
  - Enterohepatic recirculation and elimination in bile (again)
  - Further metabolism by gut bacteria to stercobilinogen and then to stercobilin
  - Enterohepatic recirculation and urinary excretion, where it is oxidised to urobilin

In Disease

<table>
<thead>
<tr>
<th></th>
<th>Blood</th>
<th>Urine</th>
<th>Faeces</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prehepatic disease</td>
<td>↑ Unconjugated bilirubin</td>
<td>↑ Urobilinogen, bilirubin not present</td>
<td>Normal</td>
</tr>
<tr>
<td>Intrahepatic disease</td>
<td>↑ Conjugated bilirubin, ↑ Unconjugated bilirubin</td>
<td>Bilirubin present</td>
<td>May be pale due to decreased urobilinogen excreted in bile</td>
</tr>
<tr>
<td>Posthepatic disease</td>
<td>↑ Conjugated bilirubin</td>
<td>↑ Urobilinogen, bilirubin present</td>
<td>Pale</td>
</tr>
</tbody>
</table>

References

Last updated 2019-07-18
Iron Homeostasis

Describe the normal nutritional requirements

Approximately 3-5g of iron is found in the body as:

- **Oxygen-carrying globin molecules**
  - Haemoglobin (~70%) and myoglobin (~5%).
- **Catalyst for biological reactions (~25%)**
  - Catalase, peroxidase, and cytochromes all require iron.

Absorption

Dietary iron comes in two forms:

- **Haeme groups**
  - Directly absorbed via specialised transport proteins.
- **Dietary iron salts**
  - Ferrous (Fe$^{2+}$) iron is soluble, and is absorbed via facilitated diffusion across the enterocyte membrane
    - Reduced acidity of the stomach will reduce the absorption of ferrous iron
  - Ferric (Fe$^{3+}$) iron precipitates when pH > 3, and so cannot be absorbed independently by the small bowel.
    - A pathway may exist for absorption of ferric iron from soluble chelates

- Once in the enterocyte, iron can be:
  - Stored, bound to **ferritin**
  - Transported via **ferroportin** out of the enterocyte, where it is then oxidised to ferrous iron and bound to **transferrin**

Regulation

- Excretion is uncontrolled
- Regulation of iron levels is only by absorption
  - **Hepcidin** is a liver protein which inhibits the action of ferroportin
    - High hepcidin prevents iron transport from the enterocyte
    - Hepcidin is deficient in haemochromatosis

References


Last updated 2017-09-23
Platelets

Outline the physiological production of blood and its constituents

Describe the process and regulation of haemostasis, coagulation and fibrinolysis

Platelets are small cell fragments which are vital in haemostasis via forming a platelet plug. They:

- Have a lifespan of 7-10 days
- Are removed by the reticuloendothelial system in the spleen and liver

Production

Platelets are:

- Anuclear circulating cell bodies, which bud from megakaryocytes
  - As the megakaryocyte cell volume increases, the cell membrane invaginates and small platelets bud off.
    - The time from stem cell to platelet is ~10 days, and is stimulated by thrombopoietin
- New platelets are held in the spleen for 36 hours until they mature

Contents

- \(\alpha\)-granules
  - Contain fibronectin, fibrinogen, vWF, PDGF, and Thrombospondin, platelet factor 4.

- \(\delta\)-granules
  - Contain 5-HT, ATP, ADP, and \(Ca^{2+}\).

- Contractile proteins
  - Facilitate platelet deformation when activated.

Activation

Platelets are activated by:

- Collagen
  - Exposed by damaged endothelium.
- Adrenaline
- ADP
  - Thrombin

Activation results in several events:

- Exocytosis of granules
- Activation of membrane phospholipase \(A_2\) to form thromboxane \(A_2\)
- Deformation from a disc to a sphere with long projections
- Promotion of the coagulation cascade
- Change in glycoprotein (GP) expression by the action of ADP:

  - ADP antagonists (e.g. clopidogrel) prevent expression of the GPIIb/IIIa complex.
    - GP IIb/IIIa facilitate platelet attachment to vWF
      - vWF also binds to sub-endothelial connective tissue.
    - GP IIb/IIIa are also receptors for fibrinogen, which encourages platelet aggregation
References


Last updated 2019-07-18
Transfusion

Understanding the adverse consequences of blood transfusion, including that of massive blood transfusion

Production and Storage of Blood Products

Red cells, platelets, and FFP have different storage requirements.

Red Blood Cells

- Stored blood decays over time - this is known as a storage lesion
  Preservatives are used to extend the time blood can be stored:
  - Kept at ~4°C (balance between freezing and being too warm)
    - Reduces cellular metabolic requirement
    - Inhibits bacterial growth
  - Collected in an aseptic fashion
  - Stored in special solutions:
    - SAGM is currently used by the Australian Red Cross:
      - Saline
      - Adenine
        Substrate for ATP synthesis
    - Glucose
      Substrate for RBC glycolysis
    - Mannitol
    - CPDA1 (citrate-phosphate-dextrose-adenine) was traditionally used
      - Citrate binds calcium, preventing clotting
      - Phosphate acts as a buffer and phosphate source for metabolism
      - Dextrose
      - Adenine

  - A storage lesion describes the changes that occur in stored blood:
    - Loss of 2,3 DPG
      Less of a factor in CPDA1 blood.
    - Haemolysis
    - Hyperkalaemia
      Typically not clinically relevant as potassium is taken up into red cells when metabolism resumes.
    - Acidaemia
    - Hyponatraemia
      Not clinically significant.

  - Blood can be stored for up to 35 days, which corresponds to 70% survival

Platelets

Platelets require particular storage conditions to remain functional:

- Temperature ~22°C
  Below this, platelets deform and become non-functional
- Gas exchange
  Platelets are stored in a bag which allows gas exchange to occur, minimising lactic acid and carbon dioxide production
Agitation
Platelets are stored on an agitator which prevents clotting and ensures the platelets are well mixed, which maximises the diffusion gradient for gas exchange.

pH control
pH is kept between 6.2 to 7.8 to prevent degranulation.

As platelets do not contain antigen, there is not a strict requirement for platelets to be type matched. However:

- Rh(+) platelets should be avoided in Rh(-) patients
- The small amount of contaminating red cells may precipitate rhesus disease.
- Plasma incompatibility should be avoided as this may lead to haemolysis of recipient red cells
  - Children are at greater risk due to their proportionally smaller blood volume

**Fresh Frozen Plasma**

Fresh Frozen Plasma is:

- Prepared either via:
  - Separation from whole blood
  - Apheresis
    - Removal of a large volume (typically 800ml) of plasma from a single patient, with return of red cells to the donor.
- Once collected, it is frozen and re-thawed in a water bath prior to use

**Cryoprecipitate**

Cryoprecipitate is prepared by removing the precipitate from FFP which forms at 1–6°C. Cryoprecipitate contains predominantly:

- Fibrinogen
- Fibronectin
- vWF
- Factor VIII
- Factor XIII

**Whole Blood**

Whole blood undergoes additional changes:

- White cells become non-functional within 4-6 hours of collection, though antigenic properties remain
- Platelets become non-functional within 48 hours of storage at 4°C
- Factor levels decrease significantly after 21 days

**Blood Groups**

Blood groups refer to the expression of surface antigens by red blood cells, as well as any antibody in plasma. Blood groups can be divided into three types:

- ABO
- Rhesus
- Other antibodies These are additional antibodies that a patient may express in plasma, and include Kell, Lewis, Duffy, etc.

**ABO**

The ABO blood group is:
• A complex carbohydrate-based antigens series
  These may be either A or B antigen, and patients may express one, both, or neither, giving four blood groups (A, B, AB, O).
• Expressed on the **H-antigen stem** of RBCs, and on the surface of tissue cells.
  - The **Bombay Blood Group** (or hh or Oh group) describes individuals who do not express the H antigen
    These individuals:
    - Don't express A- or B-antigen (as there is no H-antigen stem) and are 'universal donors'
    - Express H-antibody
      Can only receive blood from other individuals with the Bombay phenotype
• Individuals express IgM antibody to foreign blood groups
  This develops within 6 months of birth, likely due to environmental exposure to similar antigens.
• Associated with a severe hypersensitivity reaction if an ABO-mismatch occurs

<table>
<thead>
<tr>
<th>Group</th>
<th>RBC</th>
<th>Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>A-antigen</td>
<td>B-antibody</td>
</tr>
<tr>
<td>B</td>
<td>B-antigen</td>
<td>A-antibody</td>
</tr>
<tr>
<td>O</td>
<td>-</td>
<td>A-antibody</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B-antibody</td>
</tr>
<tr>
<td>AB</td>
<td>A-antigen</td>
<td>B-antibody</td>
</tr>
</tbody>
</table>

**Rhesus**

The Rhesus blood group is the next most important group after ABO. The Rhesus system:

- Consists of ~50 different antigens, the most important of which is **D**
  - Rhesus status is therefore expressed as positive (D - 85% of the population) or negative (anything-but-D).
- Rhesus antibody does not naturally occur in Rh(-) individuals
  - This is relevant in Rhesus disease
    - A Rh(-) mother exposed to Rh(+) blood will develop Anti-D antibody, which can cross placenta and induce abortion in a future Rh(+) foetus. This can occur with:
      - Incompatible transfusion
      - Foetal-maternal haemorrhage

**Compatibility Testing**

Donor blood must be tested with recipient blood to avoid a transfusion reaction. This involves three processes:

- **Blood Typing (ABO/Rh)**
  - Blood is typed by mixing it in vitro with plasma (and plasma with erythrocytes) of known groups (containing IgM antibody (Anti-A, Anti-B, Anti-AB)), and observing for agglutination.
- **Antibody Screen**
  - For other antibodies.
  - Testing is similar to ABO screening, except plasma is mixed with red cells containing known antigen (e.g. Kell, Duffy), and monitored for agglutination.
- **Cross-match**
  - Involves two processes:
    - **Saline test**
      - Erythrocytes are suspended in saline and mixed with antibodies at room temperature, monitoring for agglutination.
      - This confirms ABO type
    - **Indirect Coombs' test**
Identifies IgG antibody in host plasma which would cause haemolysis of transfused red cells. This is typically no longer done, as it offers negligible extra safety over the above processes. Doing it involves:

- Incubating
  - Binds IgG Ab to antigen on RBC membrane.
- Washing
  - Removes serum and unbound IgG.
- Testing with an antibody to IgG, known as antiglobulin serum.
  - A positive test will cause clumping of red cells, as each antiglobulin serum will bind two IgG molecules, which have in turn been bound to red cells
  - A negative test will cause no agglutination, as the IgG has not been bound to red cells
  - If negative, the antiglobulin serum is re-used on a control sample to ensure that it is not a false negative

## Transfusion Reactions

Transfusion reactions can be classified as either acute (<24 hours) or delayed (>24 hours), and as immunological or non-immunological.

### Immunological Acute Reactions

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Incidence</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABO Mismatch</td>
<td>1:40,000</td>
<td>ABO incompatibility causing rapid intravascular haemolysis, which may cause chest pain, jaundice, shock, and DIC. RhD-reactions tend to cause extravascular haemolysis.</td>
</tr>
<tr>
<td>Haemolytic (acute)</td>
<td>1:76,000</td>
<td>Immunological destruction of transfused cells (Type II hypersensitivity). Presents with fever, tachycardia, pain, progressing to distributive shock</td>
</tr>
<tr>
<td>Febrile, non-haemolytic</td>
<td>~1:100</td>
<td>Cytokine release from stored cells causing a mild inflammatory reaction, with temperature rising to ≥38°C or ≥1°C above baseline (if &gt;37°C). Benign - but requires exclusion of a haemolytic reaction.</td>
</tr>
<tr>
<td>Urticaria</td>
<td>1:100</td>
<td>Hypersensitivity to plasma proteins in the transfused unit</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>1:20,000</td>
<td>Type I hypersensitivity reaction to plasma protein in transfused unit</td>
</tr>
<tr>
<td>TRALI</td>
<td>Variable</td>
<td>Donor plasma HLA activates recipient pulmonary neutrophils, causing fever, shock, and non-cardiogenic pulmonary oedema</td>
</tr>
</tbody>
</table>

### Non-Immunological Acute Reactions

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Incidence</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Massive Transfusion Complications</td>
<td>Variable</td>
<td>See below</td>
</tr>
<tr>
<td>Non-immune mediated haemolysis</td>
<td>Rare</td>
<td>Due to physicochemical damage to RBCs (freezing, device malfunction). May lead to haemoglobinuria, haemoglobinaemia, tachycardia and fevers.</td>
</tr>
<tr>
<td>Sepsis</td>
<td>1:75,000 (platelets), 1:550,000 (RBC)</td>
<td>Contamination during collection or processing. Most common organisms are those which use iron as a nutrient and reproduce at low temperatures, e.g. <em>Yersinia Pesti</em>.</td>
</tr>
<tr>
<td>Transfusion Related Circulatory Overload (TACO)</td>
<td>&lt; 1:100</td>
<td>Rapid increase in intracellular volume in patients with poor circulatory compliance or chronic anaemia. May result in pulmonary oedema and be confused with TRALI.</td>
</tr>
</tbody>
</table>
Delayed Immunological Reaction

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Incidence</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delayed haemolytic transfusion reaction</td>
<td>1:2,500</td>
<td>Development of sensitisation with the reaction occurring 2-14 days after a single exposure. Typically Kidd, Duffy, Kell antibodies.</td>
</tr>
<tr>
<td>Post-transfusion Purpura</td>
<td>Rare</td>
<td>Alloimmunisation to Human Platelet Antigen causing sudden self-limiting thrombocytopenia</td>
</tr>
<tr>
<td>TA-GVHD</td>
<td>Rare</td>
<td>Transfused lymphocytes recognise host HLA as positive causing marrow aplasia, with mortality &gt;90%</td>
</tr>
<tr>
<td>Alloimmunisation</td>
<td>1:100 (RBC antigens), 1:10 (HLA antigens)</td>
<td>Previous sensitisation leading to antibody production on re-exposure.</td>
</tr>
<tr>
<td>Transfusion-related Immune Modulation</td>
<td>Not known</td>
<td>Transient immunosuppression following transfusion potentially due to cytokine release from leukocytes</td>
</tr>
</tbody>
</table>

Delayed Non-Immuneologica Reaction

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Incidence</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iron Overload</td>
<td>Chelation after 10-20 units, organ dysfunction 50-100 units</td>
<td>Each unit of PRBC contains ~250mg of iron, whilst average excretion is 1mg.day⁻¹.</td>
</tr>
</tbody>
</table>

Complications of Massive Transfusion

A massive transfusion is one where:
- Greater than one-half of circulating volume in 4 hours
- Whole circulating volume in 24 hours

Risk of complication from a massive transfusion is influenced by:
- Number of units
- Rate of transfusion
- Patient factors

<table>
<thead>
<tr>
<th>Complication</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Air embolism</td>
<td>Inadvertent infusion</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Cooled products</td>
</tr>
<tr>
<td>Hypocalcaemia</td>
<td>Consumption with coagulopathy and bound to citrate added to transfused units</td>
</tr>
<tr>
<td>Hypomagnesaemia</td>
<td>Bound to citrate in transfused units</td>
</tr>
<tr>
<td>Citrate toxicity</td>
<td>Citrate is added to stored units as an anticoagulant</td>
</tr>
<tr>
<td>Lactic acidosis</td>
<td>Hyperlactataemia due to anaerobic metabolism in stored units</td>
</tr>
<tr>
<td>Hyperkalaemia</td>
<td>Potassium migrates from stored erythrocytes into plasma whilst in storage</td>
</tr>
</tbody>
</table>

References

Last updated 2019-07-18
Haemostasis

Describe the process and regulation of haemostasis, coagulation and fibrinolysis.

Haemostasis describes the physiological processes that occur to stop bleeding. It involves three processes:

- **Vessel constriction**
  Decreases flow, which limits further haemorrhage and reduces the shear stresses which break up forming clot

- **Platelet plug formation** or Primary Haemostasis
  Platelets adhere to the damaged vessel wall and aggregate

- **Fibrin formation** or Secondary Haemostasis
  Fibrin is formed from fibrinogen (via the coagulation cascade), which stabilises the platelet plug

**Primary Haemostasis**

Following a vascular injury, the exposure of subendothelial proteins stimulates platelets to form an occlusive plug via several processes:

- **Adhesion**
  Exposed collagen binds to GPIa receptor on platelets.
  vWF also binds to platelets.

- **Activation**
  Metabolic activation, increasing Phospholipase A₂ and Phospholipase C, increasing platelet intracellular Ca^{2+} and initiating a transformation from a disc to a sphere with long projections.
  - Metabolic activation is stimulated by:
    - Collagen
    - Adrenaline
    - ADP
    - Thrombin
  - Additionally, platelets release ADP and thromboxane A₂ from their *alpha granules* and *dense bodies*, amplifying further platelet aggregation and adhesion

- **Aggregation**
  With other platelets - held together by fibrin - forming a plug.

- **Contraction**
  After some time platelets contract, retracting the clot and sealing the wall.

**Secondary Haemostasis**

The coagulation cascade is an amplification mechanism which activates clotting factors in order to produce fibrin.
Participating factors in the coagulation cascade can be either enzymes or cofactors:

- Enzymes circulate in their inactive form, and become active (e.g. VII $\Rightarrow$ VIIa) when hydrolysed by their precursor factor
- Cofactors amplify the cascade

### Pathways

The cascade is divided into the **intrinsic pathway** and **extrinsic pathway**, which join to form the **common pathway**. *In vitro*, the intrinsic and extrinsic pathways operate separately. This is an artifact of lab measurement - *in vivo* the pathways are co-dependent.

### Extrinsic Pathway

The extrinsic pathway contains two factors, and the process of activation **occurs in seconds**:

- Tissue Factor
  - Membrane protein on sub-endothelial cells, which is exposed when the vessel is damaged (it is found in a few other places as well). It binds to factor VII to form VIIa, and thus activates the extrinsic pathway.
- Factor VII

### Intrinsic Pathway

The intrinsic pathway is activated **over minutes**, and contains:

- Contact factors
  - Only important *in vitro* when conducting lab testing - deficiency of these factors does not cause a coagulopathy.
HMWK activates factor XII.

Factor XII
Factor XIIa activates factor IX, as does thrombin.

- Factor XI
- Factor IX
- Factor VIII

Factor VIII circulates in a complex with vWF, preventing it from degradation. When activated by thrombin, it acts as a cofactor for factor IXa to activate factor X.

The intrinsic pathway is activated by:

- Thrombin
  Main activator of the intrinsic pathway in vivo.
- Collagen
- Glass
  In vitro.

**Common Pathway**

The common pathway contains:

- Factor X
- Factor V
  Cofactor (similar to factor VIII), which when activated by thrombin allows factor Xa to convert prothrombin into thrombin.
- Factor II (prothrombin)
  Has several key roles:
  - Cleaves fibrinogen to fibrin
  - Activates factor XIII
    - Factor XIIIa stabilises clot by forming cross-bridges between fibrin in a platelet plug.
  - Amplification of the clotting cascade by activating factors V and VIII
  - Activates protein C
    - Thrombin binds with thrombomodulin to form a complex which inhibits coagulation.
- Factor I (fibrinogen)

**The Cell-Based Model of Coagulation**

- The cascade model (above) accurately describes the process of clotting in vitro, but not in vivo
- The cell-based model has several changes, noting the central role of the platelet:
  - **Initiation phase**
    Coagulation begins with tissue factor being exposed, which also activates platelets.
  - **Amplification phase**
    A positive feedback loop occurs:
    - Production of Xa causes production of thrombin (IIa), priming the system
    - Thrombin then activates factors V, VIII, and IX, accelerating Xa production and further thrombin generation
  - **Propagation phase**
    Platelets bind activated clotting factors, causing high rates of thrombin formation around them.

**References**

Last updated 2019-07-18
**Haemostatic Regulation**

Describe the mechanisms of preventing thrombosis including endothelial factors and natural anticoagulants.

Haemostasis must be controlled to prevent rampant clotting of the vascular tree. This involves both endothelial factors and proteins.

**Endothelial Regulation**

Intact endothelium and the glycocalyx prevent clotting in a number of ways:

- **Minimise stasis**
  - High blood flow
    - Especially where flow is turbulent (large arteries).
  - Maximise laminar flow
    - Glycocalyx smooths flow.

- **Inhibition of platelet adhesion and activation**
  - NO, prostacyclin, and ecutonucleotidases (which degrade ADP) inhibit platelet activation.

- **Membrane-bound anticoagulant proteins**
  - **Heparan** (not heparin)
    - Activates antithrombin III.
  - **Thrombomodulin**
    - Binds thrombin, preventing cleavage of fibrinogen to fibrin. The thrombin-thrombomodulin complex activates protein C (which in turn inactivates factors Va and VIIIa).

- **Prevent exposure of procoagulant protein**
  - Collagen
  - vWF
  - Tissue Factor

- **tPA secretion** (see ‘Clot Lysis’)

**Clot Regulation**

- **Effect of blood flow**
  - Dilutes clotting factors
    - Activated clotting factors are washed away and metabolised by the RES.
  - Laminar flow
    - Causes axial streaming of platelets, minimising endothelial contact and chance of activation.

- **Activation of anticoagulant factors**
  - **Tissue Factor Pathway Inhibitor**
    - Inhibits VIIa, antagonising the action of tissue factor
  - **Antithrombin III**
    - Inhibits the serine proteases, i.e. the non-cofactor factors in all three pathways - IIa, VIIa, IXa, Xa, XIa, XIIa.
  - **Protein C**
    - Inactivates protein Va and VIIIa, and is activated by thrombin.
  - **Protein S**
    - Cofactor which helps protein C.
Clot Lysis

Clot breakdown is performed by:

- **Tissue Plasminogen Activator (tPA)**
  Binds to fibrin, and then cleaves plasminogen to plasmin. This keeps the plasmin formation in the vicinity of the clot, limiting its systemic spread of.

- **Plasmin** cleaves fibrin into *fibrin degradation products*
  FDPs conveniently inhibit further thrombin and fibrin formation.

References


Last updated 2019-07-18
Coagulopathy Testing

Outline the methods for assessing coagulation, platelet function and fibrinolysis

Coagulation Factors

All these tests measure how long it takes to make fibrin. They evaluate different parts of the coagulation cascade, which help localise where a coagulopathy may be occurring.

In these tests:

- Citrate is added to blood
  Binds calcium and prevents clotting.
- Sample is centrifuged
- Plasma decanted
- Calcium (to replace the calcium lost by binding to citrate) and a reagent is added
- Time taken to clot measured

Prothrombin Time/INR

The prothrombin time measures the extrinsic pathway. Tissue factor has to be added to the sample in order start clotting - this is why it is known as the extrinsic pathway as a substance extrinsic to the sample must be added. As the PT varies significantly between different labs, the INR is used to allow values to be compared.

Any disorder of the extrinsic or common pathways will prolong the PT, i.e. deficiency or inhibition of:

- Factor VII
- Factor X
- Factor II (prothrombin)
- Factor V
- Factor I (fibrinogen)

Although warfarin affects factors in all three pathways, its clinical effects are measured using INR. This is because:

- Factor VII has the shortest half-life of the clotting factors affected by warfarin
  Therefore so its levels will fall the quickest.
- Therefore a fall in Factor VII levels is the earliest indication of changes in coagulation status due to warfarin
- As factor VII is only in the extrinsic pathway, the PT/INR are the only tests which can evaluate its function

(Activated) Partial Thromboplastin Time

The partial thromboplastin time measures the intrinsic pathway, which begins produce fibrin when activated by the addition of phospholipid to the sample (phospholipid is contained in platelets, and so is not technically "extrinsic"). The activated partial thromboplastin time is the same test, except an activating agent is added to speed up the reaction.

Any disorder of the intrinsic or common pathways will prolong the APTT, i.e. deficiency or inhibition of:

- Factor XI
- Factor IX
- Factor VIII
- Factor X
- Factor V
- Factor II (prothrombin)
- Factor I (fibrinogen)

Heparin affects both sides of the pathway (IIa, IXa, Xa, XIa) however typically affects intrinsic factors more than extrinsic.

In addition, **anti-phospholipid antibodies** will also prolong the APTT by binding the added phospholipid.

**Activated Clotting Time**

Activated Clotting Time is used to for the dosing and reversal of heparin in cardiopulmonary bypass and other extracorporeal circuits.

Fresh whole blood is added to a tube with an activator (e.g. glass beads) to stimulate the intrinsic pathway. The time until clot formation is measured in seconds. Different activators will have different normal ranges, and target ranges for the circuit in use.

**Platelet Function**

Evaluate how well platelets aggregate in response to factors like ADP, collagen, arachidonic acid, and adrenaline (i.e., endogenous stimulators of platelet aggregation).

In this test, the aggregating agent is added to a tube of platelets, and the change in turbidity measured. Different patterns of response (or non-response) can be diagnostic of different platelet function disorders.

**Point of Care Testing**

Point of care coagulation testing:

- **Involves testing of whole blood**
  
  Traditional testing uses plasma only.
  
  - Therefore includes the **cell-based model** of coagulation
  
  May **better represent actual clotting function** compared with traditional coagulation factor testing.

- **Provides information on all phases of clotting**

**Viscoelastic Methods**

Include:

- **Thromboelastography** (TEG)
  
  Continuous measurement and display of viscoelastic properties of a blood sample from initial fibrin formation to clot retraction, and ultimately fibrinolysis. Involves:
  
  - A known volume (typically 0.36ml) of whole blood added to activators in two disposable cuvettes (cups) heated to 37°C
    
    - Contact activators (such as kaolin) are added to the blood to accelerate clotting
    
    - A heparinase cuvette is also commonly used so clotting function can be measured during full anticoagulation (e.g. CPB)
  
  - Pin attached to torsion wire immersed into blood Torsion on the pin is converted (by a transducer) into a TEG tracing.
  
  - Cuvette rotates through 4°45’ in alternate directions
    
    Each rotation takes 10s.
  
  - Pin initially remains stationary as it rotates through the un-clotted blood
    
    This is represented by a straight line on the tracing.
  
  - **As blood clots, cup rotation exerts torque on the pin**
    
    The stronger the blood clot, the greater the torque exerted on the pin

- **Rotational Thromboelastometry** (ROTEM)
Modified version of TEG:
- A pin fixed to a steel axis is rotated in blood via movement of a spring
  The cuvette remains stationary.
- Two samples are used:
  - Tissue factor is added to measure the extrinsic pathway (known as the ENTEM cuvette)
  - Contact activator is added to measure the intrinsic pathway (INTEM cuvette)
- Impedance to rotation is detected by an optical system:
  - LED
  - Mirror on the steel axis
  - Electronic camera
- Uses different reference ranges and nomenclature to TEG

### Advantages and Disadvantages of TEG/ROTEM

<table>
<thead>
<tr>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid compared with traditional testing</td>
<td>Still measures coagulation in artificial conditions</td>
</tr>
<tr>
<td>Uses whole blood, providing a more complete picture of plasma-RBC-platelet interaction</td>
<td>Does not measure contribution of endothelium and therefore conditions affecting platelet adhesion (e.g. von Willebrand's disease)</td>
</tr>
<tr>
<td>Real-time display of clot evolution</td>
<td>Harder to institute QA outside of laboratory</td>
</tr>
<tr>
<td>Reduces non-evidence-based transfusion</td>
<td>Measurement methodology is not yet standardised between institutions</td>
</tr>
<tr>
<td>Predictive of post-operative hypercoagulable states</td>
<td>Baseline measurement does not predict post-operative bleeding</td>
</tr>
<tr>
<td>Very sensitive to heparin effect</td>
<td>Does not measure effect of hypothermia</td>
</tr>
<tr>
<td></td>
<td>Requires training and competency of non-lab staff</td>
</tr>
<tr>
<td></td>
<td>More expensive than traditional testing</td>
</tr>
</tbody>
</table>

### Interpreting TEG/ROTEM

Note that reference ranges are not included here, and will vary depending on the:
- Technique (TEG/ROTEM) used
- Activator used
- Adjuvants added
e.g. Citrated vs. recalcified samples.

<table>
<thead>
<tr>
<th>Parameter (TEG)</th>
<th>Parameter (ROTEM)</th>
<th>Definition</th>
<th>Relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R (reaction) time</td>
<td>CT (clotting time)</td>
<td>Time until 2mm amplitude</td>
<td>Time until initial fibrin formation, dependent on plasma concentration of clotting factors</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------</td>
<td>--------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>K time</td>
<td>CFT (clot formation time)</td>
<td>Time for amplitude to increase from 2-20mm</td>
<td>Measurement of clot kinetics (clot amplification), dependent on fibrinogen</td>
</tr>
<tr>
<td>α angle</td>
<td>α angle</td>
<td>Angle between the tangent to the tracing at 2mm and the midline</td>
<td>Rapidity of fibrin formation and cross-linking. Alternate measure of clot kinetics, dependent on fibrinogen</td>
</tr>
<tr>
<td>MA (maximum amplitude)</td>
<td>MCF (maximum clot thickness)</td>
<td>Greatest amplitude</td>
<td>Indicates point of maximal clot strength, dependent predominantly on platelets (80%) and fibrinogen (20%), binding via GPIIb/IIIa. Treatment with platelets or DDAVP.</td>
</tr>
<tr>
<td>CL 30 (clot lysis 30)</td>
<td>LY 30</td>
<td>Percent decrease in amplitude 30 minutes after MA</td>
<td>Clot stability, dependent on fibrinolysis. Reduced CL 30 can be treated with an antifibrinolytic, such as TXA</td>
</tr>
</tbody>
</table>

**References**

2. Activated Clotting Time - Practical Haemostasis.

Last updated 2019-07-18
SI Units

The International System of Units (SI, or Système International d'Unités), is a set of measurement standards which defines (almost) all standards in terms of uniform natural phenomena, and form the base of the metric system.

Base SI Units

There are seven base SI units, with many derived units made from combinations of these. Base SI units are mutually independent. They consist of:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Unit</th>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time (T)</td>
<td>Second</td>
<td>s</td>
<td>Duration of 9,192,631,770 periods of the radiation corresponding to the transition between two hyperfine levels of the ground state of an atom of Cs-133</td>
</tr>
<tr>
<td>Length (L)</td>
<td>Metre</td>
<td>m</td>
<td>Distance that light travels in a vacuum in 1/299,792,458th of a second</td>
</tr>
<tr>
<td>Current (I)</td>
<td>Ampere</td>
<td>A</td>
<td>The constant current that would produce a force of $2 \times 10^{-7}$ Newton between two conductors of infinite length and negligible cross section in a vacuum</td>
</tr>
<tr>
<td>Temperature (T)</td>
<td>Kelvin</td>
<td>°K</td>
<td>1/273.16th of the triple point of water. The triple point is the temperature at which a substance exists in equilibrium in all three phases (solid, liquid, gas).</td>
</tr>
<tr>
<td>Amount (n)</td>
<td>Mole</td>
<td>mol</td>
<td>The amount of substance which contains as many elementary entities as in 0.012kg of Carbon 12</td>
</tr>
<tr>
<td>Luminous Intensity (I)</td>
<td>Candella</td>
<td>cd</td>
<td>Luminous intensity of a source which emits monochromatic radiation at $540 \times 10^{-12}$ Hz at radiant intensity of 1/683 watts per steradian</td>
</tr>
<tr>
<td>Mass (M)</td>
<td>Kilogram</td>
<td>kg</td>
<td>Weight of the International Prototype Kilogram (IPK)</td>
</tr>
</tbody>
</table>

Derived Units

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Unit</th>
<th>Abbreviation</th>
<th>Conversion to Base SI Units</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Area (A)</td>
<td>Square metre</td>
<td>m²</td>
<td>$m^2$</td>
<td></td>
</tr>
<tr>
<td>Velocity (V)</td>
<td>Metre per Second</td>
<td>m.s⁻¹</td>
<td>$\frac{m}{s}$</td>
<td></td>
</tr>
<tr>
<td>Acceleration (A)</td>
<td>Metre per Second per Second</td>
<td>m.s⁻²</td>
<td>$\frac{m}{s^2}$</td>
<td></td>
</tr>
<tr>
<td>Force (F)</td>
<td>Newton</td>
<td>N</td>
<td>$N = \frac{kg \cdot m}{s^2}$</td>
<td>Force required to accelerate 1kg at 1m.s⁻²</td>
</tr>
<tr>
<td>Pressure (P)</td>
<td>Pascal</td>
<td>Pa</td>
<td>$P_{\text{a}} = \frac{N}{m^2}$</td>
<td>Force per area</td>
</tr>
<tr>
<td>Energy/Work/Quantity of Heat (E)</td>
<td>Joule</td>
<td>J</td>
<td>$J = N \cdot m = \frac{y \cdot m^2}{s^2}$</td>
<td>Energy converted when 1N is applied to 1kg over 1m</td>
</tr>
<tr>
<td>Dose Equivalence (D)</td>
<td>Sievert</td>
<td>Sv</td>
<td>$Sv = \frac{J}{kg} = \frac{m^2}{s^2}$</td>
<td>Radiation dose per mass</td>
</tr>
</tbody>
</table>
### References

   - And various subpages

Last updated 2017-09-22
Electrical Safety

Understand the concepts of patient safety as it applies to monitoring involving electrical devices

Electrical Principles

- **Charge** is the property of a subatomic particle which causes it to experience a force when close to other charged particles. Charge is measured in coulombs (C).
- **Current** is the flow of electrons through a conductor. Current is measured in amps (A).
- **Voltage** is the strength of the force that causes movement of electrons. By tradition, voltages are quoted relative to ground (or earth). If a potential difference exists, a current will flow from that object to the earth via the path of least resistance. If this path contains a person, an electrical injury may result.
- **Resistance** describes to what extent a substance reduces the flow of electrons through it. Resistance is measured in ohms (Ω).
  - Substances with **high resistance** are insulators.
  - Substances with **low resistance** are conductors.
- **Inductance** is the property of a conductor by which a change in current induces an electromotive force in the conductor, and any nearby conductors.
- **Capacitance** is the ability of an object to store electrical charge. Measured in Farads (F), where one farad is when one volt across the capacitor stores one coulomb of charge.
  - A capacitor is an electrical component consisting of two conductors separated by an insulator (called a dielectric).
  - When a **direct current** flows, electrons (a negative charge) build up on one of these conductors (called a plate), whilst an electron deficit (positive charge) occurs on the other plate.
    - Current will flow until the build up of charge is equal to the voltage of the power source.
    - Current can be **rapidly discharged** when the circuit is changed.
  - An **alternating current** can flow freely across a capacitor, and causes no buildup of charge.
- **Impedance** describes to what extent the flow of **alternating current** is reduced when passing through a substance. Impedance can be thought of as 'resistance for AC circuits', and is a combination of resistance and reactance.
  - Reactance is a function of two things:
    - Induction of voltage in conductors by the alternating magnetic field of AC flow.
    - Capacitance induced by voltages between these conductors.

Electrical Injury

Potential electrical injuries can be divided into:

- **Ventricular Fibrillation**
  - Likelihood is a function of:
    - Current density
    - Frequency
  - Lowest current density required is at **50Hz**.

- **Burns**
  - Function of current density. Burns typically occur at the entry and exit point as this is where current density is highest.
**Tetanic Contraction**

Flexors are stronger than extensors, which may maintain grip on live wire. Death may result from either VF or asphyxiation from sustained respiratory muscle contraction.

**Electrical Shock**

Electrical shocks are divided into two types, based on their ability to induce VF:

- **Microshock**
  
  Current required to induce VF when applied directly to myocardium.
  - Typical current is *0.05-0.1mA*
  - This requires **skin breach**
    - Potential causes:
      - Guidewire
      - Pacing lead
      - Column of conducting fluid
      - CVC
      - PICC

- **Macroshock**
  
  Current required to induce VF from surface contact.
  - Typical current is *100mA*
  - This is much higher because most of this current is not going to the ventricle, and so the total current must be greater to achieve sufficient **current density** in the myocardium to induce VF

Other detrimental effects seen at lower currents include:

<table>
<thead>
<tr>
<th>Current (mA)</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Tingling</td>
</tr>
<tr>
<td>5</td>
<td>Pain</td>
</tr>
<tr>
<td>8</td>
<td>Burns</td>
</tr>
<tr>
<td>15</td>
<td>Skeletal muscle tetany</td>
</tr>
<tr>
<td>50</td>
<td>Skeletal muscle paralysis &amp; respiratory arrest</td>
</tr>
</tbody>
</table>

**Principles of Electrical Safety**

Power points contain three wires:

- **Active**
  
  240V. Measuring voltage for AC current is not intuitive, as the voltage will be negative half the time. The root mean square (RMS) is used instead - each value for the voltage is squared (giving a positive number), and then divided by the number of samples to give an average.

- **Neutral**
  
  0V, relative to ground.

- **Earth**
  
  Direct pathway into ground.

An electrical circuit is completed between an appliance and the power station by returning current to the station via the earth. This is an **earth referenced power supply**.

**Electrical Dangers**
Methods of Electrical Safety

- **Insulation**
  Conductors are coated by a high-resistance substance, preventing current flowing where it shouldn't.

- **Fuses**
  Safety devices which cease all current flow when current exceeds a certain threshold (typically 20A). If there is a fault which greatly lowers resistance (i.e. insulation breaks, causing a device to become live and drain via the earth wire), a high current will flow and the fuse will be triggered.
  - A fault requires:
    - A fault that causes a high current flow
    - The fuse to work correctly

- **Residual Current Devices**
  An RCD measures the current difference between the active and neutral lines.
  - In an non-fault situation, these will be equal
  - In a fault situation, current will be being delivered by the active line but not returned via the neutral
    - Current will instead flow to ground via faulty equipment/through the patient.
    - The RCD will detect if there is a >10mA difference between the active and neutral lines, and disconnect power within 10ms if it does so
  - A fault requires:
    - Current to flow
    - A single fault will turn off the circuit
  - Pros: Safe
  - Cons: Will shut off power to the device, which is bad for ECMO/CPB/ventilators without battery backup

- **Line Isolation Supply**, with a line isolation monitor
  A line isolated supply is a 'transformer' with an equal number of windings, such that the voltage produced is the same on each side. However, the powerpoint is not physically connected to the supply, creating an earth-referenced floating supply.
  - A fault requires:
    - Two faults
      - This makes a failure with potential for shock much less likely.
      - Active wire must be connected to ground
      - Neutral wire must be connected to ground
      - A circuit then exists: active wire - ground - neutral wire, and a current could flow
  - A line isolated supply is paired with a line isolation monitor
    - This monitor states how much current could flow, if a second fault completed the circuit.
    - This is called a prospective hazard current
    - The line isolation monitor continuously checks the hazard current by evaluating the impedance between the active wire and ground, and the neutral wire and ground
      - In a no-fault situation, both impedances should be the same and close to infinite (Impedance won't be absolutely infinite as there will always be a small current leak from devices).
      - In a single-fault situation, the calculated impedance for the affected line will be significantly lower, and therefore the prospective hazard current will increase
      - An alarm will sound when the prospective hazard current exceeds 20mA
  - Pros: A single fault is not dangerous and will not result in a power loss (important for vital equipment)
Cons: Two or more faults are dangerous, and will still not result in a power loss

● Equipotential earthing
  This is the only method which prevents microshock.
  ● Ultra-low resistance earth cables are attached to electrical devices and the patients bed
  ● These cables are then attached to special wall earth connectors
  ● This ensures all equipment is referenced to a common ground, minimising the risk of leakage currents between devices and the patient

Classification of Electrically Safe Equipment

These classifications are designed to limit macroshock:

● Class I: Earthed
  Any part that can contact the user is earthed to ground.
  ● If a fault develops such that parts of the device that the user can touch are live, then there is a risk of shock
  ● If the case is earthed, the path of least resistance should be via the earth wire
    This will cause a large current to flow, and should blow a fuse, ceasing current flow.

● Class II: Double-insulated
  All parts of the device that the user can touch have two layers of insulation around them, reducing the chance of the device becoming live.

● Class III: Low-voltage
  Device operates at less than 40V DC/24V AC, limiting the severity of shock a device can deliver.

Classification of Electrically Safe Areas

● B areas: Protection against macroshock
  ○ Residual Current Devices
  ○ Line Isolation Supply

● BF areas: Cardiac (microshock) protection
  ○ Equipotential Earthing
    All devices, and the patient, are earthed to each other by thick copper (i.e. low-resistance), such that any potential difference between devices will be equalised via the path of least resistance (the wire, not the patient).

● Z areas: No particular protections

Electrical Devices which Attach to Patients

Devices such as ECG and BIS require an electrical connection to the patient. Risk of electrocution by these devices is reduced by:

● High resistance wires

References

1. Electricity and Electrical Hazards,
2. Alfred Anaesthesia Primary Exam Tutorial Program

Last updated 2019-07-18
Wheatstone Bridge

The Wheatstone bridge is an electrical device used to accurately measure very small changes in electrical resistance. The Wheatstone bridge is:

- Used in many other medical devices (e.g. invasive pressure monitoring)
- A device with infinite gain
- A null deflection galvanometer
- Not an amplifier
  As it does not increase current amplitude.

Mechanism

The Wheatstone bridge consists of:

- Battery
- Four resistors
  - and $R_3$ are known and fixed
  - is known and adjustable
  - is unknown
- Galvanometer

The Wheatstone bridge relies on the ratio of resistances between the known ($\frac{R_1}{R_2}$) and unknown ($\frac{R_4}{R_3}$) legs:

- When $\frac{R_2}{R_1} = \frac{R_4}{R_3}$ equal current flows down either limb and there is no current flow across the galvanometer
  At this point the bridge is said to be balanced.
  - The equation can then be re-arranged to solve for $R_4$:
    $$R_4 = \frac{R_2}{R_1} R_3$$
- Very small changes in $R_4$ lead to a current flow across the bridge
- $R_{2}$ can then be adjusted until the bridge is balanced, and the value of $R_4$ calculated

References
1. Alfred Anaesthetic Department Primary Exam Tutorial Series

Last updated 2017-10-02
Neuromuscular Monitoring

Describe the concept of depth of neuromuscular blockade and explain the use of neuromuscular monitoring

Describe the clinical features and management of inadequate reversal of neuromuscular blockade

The degree of neuromuscular blockade can be assessed:

- **Clinically**
  - Crude compared to electrical assessment. Tests include:
    - Sustained head lift > 5 seconds
      - Suggests < 30% blockade.
    - \( V_T > 10\text{ml.kg}^{-1} \)
    - Tongue protrusion
  - Electrically
    - Using a nerve stimulator. Can be:
      - Visual/tactile
        - Monitoring of twitch height by anaesthetist.
      - Electrical
        - Monitoring of twitch height by a device:
          - Accelerometer
            - Acceleration is proportional to force for any given mass \( F = ma \), therefore an accelerometer taped to the thumb can be used to assess force of contraction.
          - Mechanical force transducers
            - Muscle tension is measured using a strain gauge. Requires control prior to administration.
          - Electromyography
            - EMG response is measured using electrodes over the muscle. The AUC of the response curve can be used to calculate degree of blockade.

Nerve Stimulator

A nerve stimulator:

- Consists of two electrodes, a power supply, and some buttons for control
- Produces a monophasic, square wave at constant current, lasting no more than 0.3ms
- Generates a supra-maximal stimulus
  - Ensures every nerve fibre is depolarised, which means a consistently reproducible response will be generated. A supra-maximal stimulus is 25% greater than the maximum required to depolarise all nerve fibres.
- Allows assessment of different muscle groups
  - Not all muscle groups are affected equally by neuromuscular blockade.
    - Typically smaller muscle groups are more sensitive
    - The positive (red) lead is placed proximal
    - Ulnar nerve
      - Electrodes are placed along the ulnar border of the wrist at the flexor crease, and thumb adduction is assessed.
    - Facial nerve
      - The positive electrode is placed at the outer canthus, and the negative electrode is placed anterior to the tragus. Eyebrow twitching is assessed.
    - Posterior tibial nerve
      - Electrodes are placed posterior to the medial malleolus, and plantar flexion is assessed.
Stimulation Patterns

There are five common stimulation patterns:

- **Train of Four**
  Four single twitches (0.1ms) delivered at 2Hz (i.e. 1.5s for all 4).
  - Number of observed twitches gives an indication of receptor occupancy
    - With increasing blockade, the amplitude and number of observed twitches decreases.
      - **Fade** is the reduction of twitch height with repeated stimuli during a partial neuromuscular block
        Occurs due to the effect of non-depolarising agents on the presynaptic membrane, reducing ACh production.
      - Number of observed twitches depends on the degree of blockade:
        - No twitches ≈ 100% blockade
        - One twitch ≈ 90% blockade
        - Two twitches ≈ 80% blockade
        - Three twitches ≈ 75% blockade
        - Reversal agents should not be given with a ToF count < 3.
      - Four twitches ≈ < 75% blockade
  - The ratio of the amplitude of T₁ to T₄ (ToF ratio) can also be used as a measure of blockade:
    - ToF ratio > 90% is adequate for extubation
    - ToF ratio > 70% suggests adequate respiratory function
  - Should not be repeated faster than every 10s

- **Tetanic stimulation**
  High frequency (50-200Hz) supramaximal stimulus for 5 seconds.
  - Normal muscle will exhibit tetanic contraction
  - Partially paralysed muscle exhibits fade
    - Degree of fade is proportional to degree of blockade, and is very sensitive.

- **Post-tetanic count (PTC)**
  Used in deep blockade when there is no response to ToF. A tetanic stimulus is given, followed 3s later by single twitches at 1Hz.
  - No response may be seen in very deep blockade
  - However, twitches may be seen prior to the return of a ToF response.
    - This is called post-tetanic facilitation, and occurs due to the tetanic stimulus mobilising ACh vesicles into the pre-junctional area.
    - Typically, a ToF of 1 will occur when the PTC ≈ 9
  - Should not be repeated faster than every 6 minutes
    - Due to residual post-tetanic potentiation.

- **Double burst**
  Two 0.2ms 50Hz (tetanic) stimuli are applied 750ms apart.
  - Two identical contractions occur in normal muscle
  - Amplitude of the second burst is reduced in partially paralysed muscle
    - DB ratio is similar to the ToF ratio, but is easier to assess clinically.
  - A ratio > 0.9 is required for adequate reversal

- **Single twitch**
  A single stimulus lasting ~0.2ms is applied.
  - > 75% blockade causes a depressed response
  - A twitch must be assessed prior to blockade so a baseline can be established
References

1. Leslie RA, Johnson EK, Goodwin APL. Dr Podcast Scripts for the Primary FRCA. Cambridge University Press. 2011.

Last updated 2019-07-18
Pressure Transduction

A transducer converts one form of energy to another. Pressure transducers convert a pressure signal to an electrical signal, and require several components:

- Catheter
- Tubing
- Stopcock
- Flush
- Transducer

This system must be calibrated in two ways:

- **Static calibration**
  Calibrates to a known zero.
- **Dynamic calibration**
  Accurate representation of changes in the system.

Static Calibration

Static calibration involves:

- Leveling the transducer (typically to the level of the phlebostatic axis at the right atrium, or the external auditory meatus)
  A change in transducer level will change the blood pressure due to the change in hydrostatic pressure (in cmH₂O).
- **Zeroing**
  - Opening the transducer to air
  - Zeroing the transducer on the monitor
  A change in measured pressure when the transducer is open to air is due to drift, an artifactual measurement error due to damage to the cable, transducer, or monitor.

Dynamic Calibration

Dynamic calibration ensures the operating characteristics of the system (or dynamic response) are accurate. Dynamic response is a function of:

- **Damping**
  How rapidly an oscillating system will come to rest.
  - Damping is quantified by the damping coefficient or damping ratio
    - Describes to what extent the magnitude of an oscillation falls with each successive oscillation
    - Calculated from the ratio of the amplitudes of successive oscillations in a convoluted fashion:

\[
D = \sqrt{\frac{\left(\ln \frac{D_2}{D_1}\right)^2}{\pi^2 + \left(\ln \frac{D_2}{D_1}\right)^2}},
\]

where:

\[
D_2, D_1, \ldots
\]
- **Resonant Frequency**
  How rapidly a system will oscillate when disturbed and left alone.
  - When damping is low, it will be close to the **natural frequency** (or undamped resonant frequency)

- **Damping and natural frequency** are used (rather than the physical characteristics) as they are both **easily measured** and **accurate** in describing the dynamic response
- These properties are actually determined by the systems elasticity, mass, and friction, but it is conceptually and mathematically easier to use damping and resonance

### Pressure Waveforms and Dynamic Response

- The dynamic response required is dependent on the nature of the pressure wave to be measured
- Accurately reproducing an arterial waveform requires a system with a greater dynamic response compared to a venous waveform
- An arterial pressure waveform is a periodic (repeating) complex wave, that can be represented mathematically by **Fourier analysis**
  - Fourier analysis involves expressing a complex (arterial) wave as the sum of many simple sine waves of varying frequencies and amplitudes
    - The frequency of the arterial wave (i.e., the pulse rate) is known as the **fundamental frequency**
    - The sine waves used to reproduce it must have a frequency that is a **multiple** (or **harmonic**) of the fundamental frequency
      - Increasing the number of harmonics allows better reproduction of high-frequency components, such as a steep systolic upstroke
    - Accurate reproduction of an **arterial** waveform requires up to **10 harmonics** - or **10 times the pulse rate**
    - An arterial pressure transducer should therefore have a dynamic response of **30Hz**
      - This allows accurate reproduction of blood pressure in heart rates up to 180bpm (180 bpm = 3Hz, 3Hz x 10 = 30Hz)

### Resonance

- If high frequency components of the pressure waveform approach the natural frequency of the system, then the system will resonate
- This results in a distorted output signal and a small **overshoot in systolic pressure**.

### Damping

A pressure transduction system should be adequately damped:

![Damping Diagram](image)

- An **optimally** damped waveform has a damping of **0.64**. It demonstrates:
  - A rapid return to baseline following a **step-change**, with **one overshoot and one undershoot**
- A **critically damped** waveform has a damping coefficient of **1**. It demonstrates:
- The most rapid return to baseline possible following a step-change **without overshooting**
- An **over-damped** waveform has a damping coefficient of \( \geq 1 \). It demonstrates:
  - A slow return to baseline following a step-change with no oscillations
  - Slurred upstroke
  - Absent dicrotic notch
  - Loss of fine detail
- An **under-damped** waveform has a damping coefficient close to 0 (e.g. 0.03). It demonstrates:
  - A very rapid return to baseline following a step-change with several oscillations
  - Systolic pressure overshoot
  - Artifactual bumps

Optimally damped waveforms are accurate for the widest range of frequency responses:

![Dynamic Response Graph](attachment:image)

**Testing Dynamic Response**

Dynamic response can be tested by inducing a **step-change** in the system, which allows calculation of both the natural frequency and the damping coefficient. Clinically, this is performed by doing a **fast-flush test**.

- Fast flush valve is opened during diastolic runoff period (minimises systemic interference)
- The pressure wave produced indicates the natural frequency and damping coefficient of the system:
  - The **distance between** successive oscillations should be identical and equal to the natural frequency of the system
  - The **ratio of amplitudes** of successive oscillations gives the damping coefficient

**Optimising Dynamic Response**

The lower the natural frequency of a monitoring system, the smaller the range of damping coefficients which can accurately reproduce a measured pressure wave. Therefore, the optimal dynamic response is seen when the natural frequency is as **high as possible**. This is achieved when the tubing is:

- Short
- Wide
- Stiff
- Free of air

Introducing an air bubble will increase damping (generally good, since most systems are under-damped), however it will lower the natural frequency and is detrimental overall.

---

**Footnotes**

*Fundamentals of Pressure Measurement*
Pressure exerted by a static fluid is due to the weight of the fluid, and is a function of:

- Fluid density (in kg.L\(^{-1}\))
- Acceleration (effect of gravity, in m.s\(^{-2}\))
- Height of the fluid column

This can be derived as follows:

\[
\text{Pressure} = \frac{\text{Force}}{\text{Area}} = \frac{\text{Mass} \times \text{Acceleration}}{\text{Area}}
\]

\[
\text{Density} = \frac{\text{Mass}}{\text{Volume}}, \text{ therefore } \text{Mass} = \text{Volume} \times \text{Density}
\]

Combining the above equations:

\[
\text{Pressure} = \frac{\text{Density} \times \text{Volume} \times \text{Acceleration}}{\text{Area}} = \text{Density} \times \text{Length} \times \text{Acceleration}
\]

- This is usually expressed as: 
  \[
  \text{Pressure} = \rho \cdot h \cdot g
  \]

- Note that this expression does not require the mass or volume of the liquid to be known
- This is why pressure is often measured in height-substance units (e.g. mmHg, cmH\(_2\)O)

References

2. Alfred Anaesthetic Department Primary Exam Program

Last updated 2019-07-18
Pressure Waveform Analysis

Describe the invasive and non-invasive measurement of blood pressure and cardiac output including calibration, sources of errors and limitations

Analysis of arterial pulse contour is:

- **Real-time** and **continuous**
- Used to estimate cardiac output
  
  Less accurate but also less invasive (e.g. **thermodilution**) or technically demanding (e.g. **echocardiography**) than other methods.
  - Therefore also calculate (and often display) stroke volume variation and pulse pressure variation

Principles

All models recognise that the **amplitude of the systolic upstroke** is:

- Directly proportional to **stroke volume**
- Inversely proportional to **arterial compliance**

Other principles used by some (but not all) devices include:

- **Three-element Windkessel model**
  
  Characterises the arterial tree as having three major features:
  - Aortic Impedance
  - Arterial Compliance
    - Predicted using patient characteristics.
  - Systemic Vascular Resistance
- **Conservation of Mass**

Devices

**Devices** can be **classified based on** whether they are:

- **Calibrated/Uncalibrated**
  - **Calibrated**
    
    Initial estimation is refined using a dilution technique.
    - Dilutions may be by:
      - **Thermodilution**
        - Cold saline injected into **SVC**
          - Using an **IJV** or **SCV CVC**.
        - Temperature changed measured at the femoral artery
      - **Lithium dilution**
        - Small amounts of lithium chloride injected into a central vein
        - Change in lithium concentration measured in radial artery
        - **CO** by calculated **Stewart-Hamilton equation**
    - Periodically recalibrated to correct for drift
  - **Uncalibrated**
    
    Not corrected for a measured 'true' cardiac output.
    - Inaccurate for short term changes in arterial properties
Not validated in:
- Shock
- ARDS
- Hepatic surgery
  Due to changes in arterial tone.
- Cardiac surgery

- Invasive/Non-invasive
  - Invasive
    Rely on a (usually femoral) arterial catheter.
  - Non-invasive
    Rely on the volume clamp method:
    - Inflatable cuff wrapped around finger
    - Plethysmograph estimates blood volume in the digital arteries
    - Cuff inflates and deflates throughout the cardiac cycle, keeping the volume of the arteries constant
      Arterial pressure is proportional to cuff pressure.
    - Incorrect in:
      - Peripheral oedema
      - Vasoconstricted states

Common Devices in Use

- PiCCO/VolumeView/FloTrac
  - Calibrated
  - Invasive
  - 3-element Windkessel
  - Mechanism:
    - Calculates area under systolic part of the arterial curve
    - Divides calculated area by aortic compliance
      Compliance estimated by proprietary algorithm each time the device is calibrated.
  - SVR is continuously estimated from calculated CO and measured BP

- LiDCO
  - Calibrated
  - Invasive
  - Conservation of mass
  - Compliance inferred from biometric data

- ClearSight/CNAP
  - Uncalibrated
  - Non-invasive

- T-Line
  - Calibrated
    Proprietary, non-validated auto-calibrating algorithm.
  - Non-invasive
  - Uses radial applanation tonometry

References

Last updated 2019-07-18
Non-Invasive Blood Pressure

Describe the invasive and non-invasive measurement of blood pressure and cardiac output including calibration, sources of errors and limitations

Non-invasive blood pressure measurements is performed with either a:

- Device for Indirect Non-invasive Automatic Mean Arterial Pressure (DINAMAP)
  Automatic blood pressure cuff.
- Von Recklinghausen's oscillotonometer
  "Manual" blood pressure cuff.
  - Uses two cuffs, and therefore two tubes

DINAMAP

Components:

- One cuff
  Performs both arterial occlusion and measurement.
- Tubing
- Device for inflating the occlusive cuff and gradually deflating it
- Pressure transducer
- Display

Method:

- Cuff is inflated above SBP
- Cuff deflates at a rate of 2-3mmHg.s⁻¹
  When cuff pressure equals:
  - SBP
    Turbulent flow occurs past the cuff, creating pressure oscillations. The pressure at which these are first detected is the SBP.
  - MAP
    The pressure at which amplitude of oscillations is maximal.
- DBP is calculated from MAP and SBP

Cons

- Requires an appropriately sized cuff
  Cuff should be ~20% greater than arm diameter.
  - Cuffs that are too small will over-read
  - Cuffs that are too wide will under-read
- Requires a regular rhythm
- Inaccurate at extremes of blood pressure
- Inaccurate when used more frequently than once per minute
- Inaccurate when the vessel is incompressible
  - Heavily calcified vessels
  - When applied to forearm/foreleg
- May cause neuropraxia
Von Recklinghausen's Oscillotonometer

Components:
- Two cuffs
  - Occlusive cuff
  - Measurement cuff
- Tubing
- Device for inflating the occlusive cuff and gradually deflating it
- Aneroid barometer for transducing pressure
- Display

Process:
- Cuff is inflated until the radial pressure is no longer palpable
  This is approximates SBP.
- Cuff is deflated, and re-inflated to 20mmHg above the estimated SBP
- Cuff is deflated at a rate of 2-3mmHg.s\(^{-1}\) whilst auscultating the brachial artery
  When cuff pressure equals:
    - SBP
      Turbulent flow occurs past the cuff, turbulent flow causes the first of the Korotkoff sounds (clear tapping pulsations) to be heard.
    - DBP
      The cuff no longer compresses the vessel at all, so no turbulent flow occurs and nothing is auscultated.

References

1. ANZCA July/August 2000

Last updated 2019-07-18
Cardiac Output Measurement

Describe the invasive and non-invasive measurement of blood pressure and cardiac output including calibration, sources of errors and limitations

Explain the derived values from common methods of measurement of cardiac output (i.e. measures of vascular resistance)

Cardiac output measurement can be performed:

- **Invasively**
  - Pulmonary Artery Catheter
    - Thermodilution
    - Fick Principle
  - TOE
  - Arterial waveform analysis
    - PiCCO
    - Vigileo
- **Non-invasively**
  - TTE
  - MRI
  - Thoracic impedance

Thermodilution

Thermodilution remains the gold standard of cardiac output measurement.

This technique:

- Requires a pulmonary artery catheter
  
  Various different designs exist. For CO measurement, they require:
  - A proximal port at the RA/SVC
  - A temperature probe at the tip
    Typically a silicon oxide thermistor.
  - A balloon at the tip
    To float it into position.
  - A distal (PA) port is required for measuring PAP and the PCWP, but is not required for CO calculation

Method for Intermittent Cardiac Output Measurement by Thermodilution

- A known volume of (typically dextrose) at a known temperature (classically cooled, but this is not required) is injected into the proximal port
- The temperature of blood is measured at the tip
  
  This produces a temperature-time curve.
- The area under the curve can be used to calculate cardiac output, as per the modified Stewart-Hamilton Equation:

\[
Q = \frac{V(T_f - T_i)k_1k_2}{\int_{t_1}^{t_2} \Delta T \, dt},
\]

  where:

  - \( Q \) = Cardiac output
  - \( V \) = Volume of injectate
  - \( T \) = Temperature of blood
Temperature of injectate

Density constant
Relates to the specific heat and specific gravity of both injectate and blood.

Computation constant
Accounts for catheter dead space and heat exchange during injection.

Area under the change in temperature-time curve

**Errors in Thermodilution**

- **Natural variability**
  Cardiac output varies up to 10% with changes in intrathoracic pressure during respiration. Therefore:
  - A mean of 3-5 measurements should be taken
  - Measurements should be taken at end-expiration

- **Incorrect volume of injectate**
  - Too much underestimates CO
  - Too little overestimates CO

- **Warm fluid**
  The closer the temperature of injectate is to blood, the greater degree of error introduced to the measurement.
  - Colder injectate is more accurate, but carries the risk of inducing bradyarrhythmias

- **Poorly positioned PAC**
  The PAC must be positioned in West’s Zone 3 for blood flow to occur past the tip, and for the measured temperature to be accurate.
  - Tricuspid regurgitation
    Results in retrograde ejection of injectate back past the valve.
  - Arrhythmia

**Fick Principle**

Cardiac Output can also be measured using the Fick Principle. This technique:

- **Uses the Fick Principle**
  The flow of blood to an organ is equal to the uptake of a tracer substance divided by the arterio-venous concentration difference.
  - In this case, the tracer substance is oxygen
  - The ‘organ’ is the whole body
  - This produces the equation: \( CO = \frac{VO_2}{C_{av}-C_v} \), where:
    - \( CO \) is Cardiac Output
    - \( VO_2 \) is the patients oxygen consumption
      Typically estimated as 3.5ml.kg\(^{-1}\).min\(^{-1}\)
    - \( C_{av} \) is arterial oxygen content
    - \( C_v \) is mixed venous oxygen content

- Relies on mixed venous blood sampled from the pulmonary artery, and arterial blood sampled from a peripheral arterial line

**References**


Last updated 2019-07-18
Pulse Oximetry

Describe the principles of pulse and tissue oximetry, co-oximetry and capnography, including calibration, sources of errors and limitations

Pulse oximetry relies on several principles:

- Oxygenated and deoxygenated haemoglobin absorb light of different wavelengths to different extents. Light of 660nm and 940nm is used.
  - Deoxyhaemoglobin has a greater absorbance of red (660nm) light than oxyhaemoglobin
  - Oxyhaemoglobin has a greater absorbance of infrared (940nm) light than deoxyhaemoglobin
  - The relative absorbance of each allows determination of the proportions of oxygenated and deoxygenated haemoglobin

- The Beer-Lambert Law(s):
  Absorption of light passing through a substance is directly proportional to both the distance it travels through the substance and the concentration of attenuating species within the substance. It is a composite of:
    - Beer’s Law
      Absorption of light is proportional to the concentration of "attenuating species"
    - Lambert’s Law
      Absorption is proportional to the thickness of the solution, or more precisely, that each layer of equal thickness absorbs an equal proportion of radiation that passes through it

- Blood flow is pulsatile

Method

A pulse oximeter consists of:

- Two diodes of the desired wavelengths
- Photocell
- Microprocessor

- During pulsatile flow, the expansion and contraction of the blood vessels alters the distance and haemoglobin concentrations, changing the absorption spectra of blood (as per the Beer-Lambert Law).

- Non-pulsatile elements are due to tissues and venous blood

- These are subtracted from the total, leaving the pulsatile element which represents the arterial component

- The ratio of absorbance of the pulsatile elements and the non-pulsatile elements is called $R$, and is calculated as:
  $R = \frac{Pulsatile_{440}/Non - Pulsatile_{940}}{Pulsatile_{440}/Non - Pulsatile_{940}}$
  - R is compared with a set of standardised values to deliver a calculated SpO₂
    - An R of 1 gives an SpO₂ of 85%
    - An R of 0.4 gives an SpO₂ of 100%
    - An R of 2 gives an SpO₂ of 50%

The Isobestic Point

- The isobestic point is the wavelength at which light is absorbed equally by both haemoglobin species
- Light absorption is therefore independent of saturation, and is instead a function of haemoglobin concentration
- This can be used to correct for haemoglobin concentration
- There are two isobestic points for oxygenated and deoxygenated haemoglobin, at 590nm and 805nm

501
Limitations

- Requires detectable pulsatile flow
  - Limited by poor peripheral perfusion (shock, hypotension, hypothermia) and non-pulsatile flow (ECMO, CPB)
  - Body movements confound readings (shivering, seizing)
- Low saturations
  - Inaccurate below 70%, and completely unreliable below 50%.
- Venous pulsation
  - Detected as pulsatile flow, and erroneously interpreted by the microprocessor as arterial flow.
- Confounded by ambient light
  - The diodes are cycled at several hundred times per second which allows the detector to compensate for the effect of ambient light (the values when the diodes are off give the effect of ambient light).
- Absorption spectra confounded by:
  - Haemoglobinopathies
    - Carboxyhaemoglobin causes the pulse oximeter to read artificially high due to it also absorbs 660nm light
    - Methaemoglobinemia causes the SpO₂ to trend towards 85%, as though it absorbs 660nm light is also absorbs 940nm light to a greater degree
  - Dyes
    - Methylene blue will cause the SpO₂ to read < 65% for several minutes
    - Indocyanine green will also cause a decreased SpO₂

References

3. CICM March/May 2014

Last updated 2019-07-18
Oxygen Analysis

Describe the principles of measuring oxygen concentration

As oxygen is a molecule containing two similar atoms, its partial pressure cannot be determined using infrared techniques (unlike CO₂). Oxygen content of a gas is instead determined using:

- Paramagnetic analyses
- Fuel Cells

Paramagnetic Analysis

Principles of paramagnetic analysis:

- Oxygen is paramagnetic
  - This means it is attracted by magnetic fields, but does not propagate the field.
  - This is because its two unpaired valent electrons have the same spin.
- Many other gases weakly repelled by magnetic fields (diamagnetic)
- The attraction of a gas mixture to a magnetic field is therefore proportional to its oxygen content
- Many different methods exist which use this property to determine oxygen content

Pressure Method

- Gas tested flows into a tube
- A reference gas flows into a parallel tube
- Both gases then pass through:
  - Flow restrictors
  - Magnetic field
    - This is being turned on and off at ~100Hz.
- The gases combine in the magnetic field
- The greater the oxygen content of the gas, the more it will move into the magnetic field
  - This movement creates a negative pressure behind the gas.
- The pressure difference between the tested gas and the reference gas is proportional to the oxygen content of the test gas.

Temperature Method

Used in many modern devices.

- Gas flows through a magnetic field, causing the particles to align
  - This changes the thermal conductivity of the oxygen molecules.
- The change in thermal conductivity of the gas mixture is proportional to the oxygen content
- This is detected by measuring current passing through a heated wire

Pros

- Accurate
- Rapid response time
  - Modern analysers can identify breath-to-breath variation in FiO₂.
- Don't require regular calibration
Cons

- Water vapour reduces accuracy
- Interference from other paramagnetic gases
  - Nitric oxide
    Effect is minimal as nitric is delivered in far smaller volumes than oxygen, and is only weakly paramagnetic.

Fuel Cells

Fuel cells rely on reduction of oxygen to measure oxygen partial pressure. They consist of:

- Oxygen permeable membrane
- KOH solution
  This contains:
  - Lead anode
    Lead is consumed as the fuel cell operates.
  - Gold cathode

Method

- Oxygen diffuses across the membrane into the potassium hydroxide solution
- At the cathode:
  \[ O_2 + 4e^- + 2H_2O \rightarrow 4OH^- \]
- At the anode:
  \[ Pb + 2OH^- \rightarrow PbO + H_2O + 2e^- \]
- The oxygen consumption is proportional to the current generated, which is measured with an ammeter

Pros

- No power required
- Small
- Accurate

Cons

- Will accumulate nitrogen in the presence of N_2O
  Results in an under-reading of PO_2.
- Must be replaced after 6-12 months
- Requires regular two-point calibration
  21% and 100% oxygen are used.
- Relatively slow response time compared to paramagnetic analysers
  ~20s.

References

End-Tidal Gas Analysis

Describe the principles of pulse and tissue oximetry, co-oximetry and capnography, including calibration, sources of errors and limitations

Principles

Several mechanisms for ET\textsubscript{CO\textsubscript{2}} measurement exist:

- Infrared Spectroscopy
- Colourimetric Methods
- Rayman Scattering
- Gas Chromatography

Infrared Spectroscopy

Infrared spectroscopy relies on the fact that:

- Gases with two or more different atoms will absorb infrared radiation
- Different gases absorbing different wavelengths to different degrees
- Measuring the absorbed wavelengths and comparing with the likely composition of a mixture, a system can be designed using a specific wavelength to measure gas concentrations and avoid interference

End-tidal gas analysis using infrared light is used in the measurement of:

- CO\textsubscript{2}
  - Capnography is the continuous measurement and graphical display of the partial pressure of CO\textsubscript{2} in expired gas. This is the most common method to measure ET\textsubscript{CO\textsubscript{2}}.
- Anaesthetic agents

Measurement of CO\textsubscript{2}

Components:

- Sapphire sampling chamber containing gas sample
  - CO\textsubscript{2} absorbs infrared radiation at a peak wavelength of 4.28\textmu m
  - The sapphire lens only allows 4.28\textmu m light through
- Emitter
- Detector
- Microprocessor
- Display

Method:

- Light is emitted and passes through the sampling chamber
  - A lens is used to focus emitted light.
- Levels of radiation are measured on the other side of the chamber
- Levels correspond to the amount of gas present in the sample
- The less radiation that reaches the detector, the more gas there is in the sample absorbing it
Equipment Errors

Errors can be classified into:

- Specific to technique
  - The collision broadening effect
    Intermolecular forces vary depending on their proximity to other molecules in the gas mixture. A change in intermolecular forces may alter their bond-energy and the frequencies at which they absorb radiation. It can be overcome by:
    - Correcting for the presence of other gases
    - Manually adjusting the obtained values
  - Crossover with other gas mixtures
    CO₂ and N₂O have similar absorbance spectra, and may lead to error when a device is not designed to measure both wavelengths.

- Failure of equipment
  These can be overcome by use of double-beam capnometer. This uses a reference chamber which contains CO₂-free air, and the same emitter-detector system. All absorption from this system must occur due to artifact (as no CO₂ is present). The artifactual component is then subtracted from the value detected in the main chamber. This corrects for:
    - Variable amount of infrared radiation released
    - Variable sensitivity of the detector
    - Variable efficacy of the crystal window and lens system

- Relating to type of capnometer used
  E₇CO₂ may be either side-stream or in-line.
    - Side-stream CO₂ involves a length of narrow tubing drawing gas from the expiratory limb of the breathing circuit (typically from the HME filter) to the capnograph
      - Side-stream requires a flow of 150 ml.min⁻¹
      - Has a (pretty insignificant) delay (<1s) in measurement
      - May be blocked by water vapour, and require use of a water trap to remove condensation
    - In-line systems have a sampling chamber attached in-line with the ETT
      - The sampling chamber slightly increases the dead-space of the circuit
        May be relevant in children or very difficult to ventilate patients.
      - Adds weight to patient end of the breathing circuit
      - Require heating to 41°C to avoid condensation

Normal E₇CO₂ Waveform

The normal trace consists of four components:

1. The baseline
   This consists of:
   - Inspiratory time
- Early dead-space exhalation
  This is the period immediately before phase 2, where some gas with a PCO$_2$ of 0 is exhaled.
2. Alveolar exhalation, where PCO$_2$ rises rapidly
3. Alveolar plateau, where PCO$_2$ flattens
   The highest-point of this curve is labeled E$_T$CO$_2$.
4. Inspiration, where PCO$_2$ returns to 0

**E$_T$CO$_2$ Waveform Variations**

Airway obstruction:
- Occurs due to uneven emptying of alveoli with different time-constants

Hyperventilation:
- Lower E$_T$CO$_2$ with shorter baseline
- Plateau phase may not occur at very high respiratory rates

Rebreathing:
- Baseline increases as inspired CO$_2$ is measured from gas analyser

**Changes in E$_T$CO$_2$**

Normal E$_T$CO$_2$ is 32-42 mmHg, whilst normal PaCO$_2$ is 35-45 mmHg.
High \textit{E}_T\text{CO}_2

This may be from:

- Decreased ventilation
  - Decreased RR
  - Decreased V_T
  - Increased V_D and therefore a greater V_D:V_T ratio
- Increased production of CO_2
  - Increased metabolic rate
    - Sepsis
    - Tourniquet release
    - ROSC following arrest
- Increased inspired
  - Rebreathing (i.e. equipment/ventilator malfunction)
  - External source of added CO_2

Low \textit{E}_T\text{CO}_2

**Rapid Loss of \textit{E}_T\text{CO}_2**

- Failure of ventilation
  - Circuit disconnect
  - Airway obstruction
  - Bronchospasm
- Failure of circulation
  - Cardiac arrest
  - Shock

**Gradual Loss of \textit{E}_T\text{CO}_2**

- Increased \(V_A\) (i.e. increased MV)
- Decreased \textit{CO}_2 production
  - Hypometabolic state
    - Hypothermia
- Increased \(V_D\), i.e. V/Q mismatch
  - Increased West Zone I physiology:
    - Hypotension
    - Increased RV Afterload:
      - PE
      - High PEEP
- Sampling error
  - Air entrainment into the sample chamber
  - Inadequate V_T

**Discrepancy between \textit{E}_T\text{CO}_2, PACO}_2, and \textit{PaCO}_2**

The normal gradient between \textit{PaCO}_2 and \textit{E}_T\text{CO}_2 is 0-5 mmHg. Healthy and awake individuals should have essentially no (<1ml) alveolar dead space, and so essentially no gradient. This gradient is increased in patients with:

- V/Q mismatch
  - \textit{E}_T\text{CO}_2 will underestimate arterial \textit{CO}_2 as gas from un-perfused alveoli (with negligible \textit{CO}_2) will dilute \textit{CO}_2 expired gas
**Colourimetric Methods**

Litmus paper which changes colour when exposed to hydrogen ions (produced by CO$_2$) can be used to confirm endo-tracheal intubation, though they may generate false-positive results due to gastric pH.

**References**


Last updated 2019-07-18
Blood Gas Analysis

Describe the methods of measurement of oxygen and carbon dioxide tension in blood and blood pH

Blood gas machines directly measure three variables and calculate the remainder. Measured variables are:

- $\text{PO}_2$
- $\text{CO}_2$
- pH

Calculated variables include:

- Bicarbonate
  Using the pH, $\text{CO}_2$ and the Henderson-Hasselbalch equation.
- Base Excess
  Calculated using the Henderson-Hasselbalch and Siggaard-Anderson equation. Can be expressed in two ways:
  - Base Excess
    The amount of alkali that must be added to the sample to return it to a normal pH, at a temperature of 37°C and a PaCO$_2$ of 40mmHg.
  - Standardised Base Excess
    As base excess, but calculated for blood with a Hb concentration of 50g.L$^{-1}$. This is thought to better represent the ECF as a whole.

Oxygen Tension

Oxygen tension is measured with a Clarke electrode. This consists of:

- A chamber for the blood sample
- A chamber containing a potassium chloride solution, which:
  - Is separated from the blood chamber by an oxygen-permeable membrane This prevents blood being in direct contact with the cathode, which would lead to protein deposition on the cathode and incorrect measurement.
  - Contains a platinum cathode
  - Contains a silver/silver Chloride anode
- A battery applying 0.6V across the electrodes

![Diagram of Clarke electrode](Oxygen_Permeable_Membrane.png)

**Method**

- A voltage of 0.6V is applied across the electrodes, causing the silver to reactive with chloride in the solution to produce electrons:

$$\text{Ag} + \text{Cl}^- \rightarrow \text{AgCl} + e^-$$
This potential difference is required to start the reaction
- 0.6V is chosen because it is enough to start the reaction but will have minimal effect on measured current flow
- At the cathode, oxygen combines with electrons and water to produce hydroxyl ions:
  \[ O_2 + 4e^- + 2H_2O \rightarrow 4OH^- \]
- For each oxygen molecule present at the cathode, four electrons can be consumed
- Increasing the oxygen available at the cathode increases the number of electrons consumed, and therefore increases current flow
  - Oxygen will move from the sample chamber to the measuring chamber according to its partial pressure
  - Measured current flow is therefore proportional to oxygen tension in blood

**Calibration, Limitations, and Accuracy**

- Calibration is performed with standard gas mixtures
  Requires regular two-point calibration.
- Cathode must be kept clean from protein and not damaged
- Cathode must be kept at 37°C
- May read falsely high with halothane

**pH Measurement**

pH is a measure of the hydrogen ion concentration in solution, and is defined as the negative logarithm to the base 10 of the \([H^+]\):

\[ pH = -\log_{10}[H^+] \]
- A pH of 7.4 is a \([H^+]\) of 40nmol.L\(^{-1}\) at 37°C
  - A change in a pH unit of 1 is equivalent to a 10-fold change in the \([H^+]\)
  - A change in pH of 0.3 is equal to doubling or halving the \([H^+]\)

The pH electrode consists of:

- A chamber for the blood sample
- A measuring chamber, separated from the sample by H\(^+\)-permeable glass, which contains:
  - A buffer solution
  - A silver/silver chloride measuring electrode
- A reference chamber, also separated from the chamber by H\(^+\)-permeable glass, which contains:
  - A KCl solution
  Has no buffering properties.
A mercury/mercury chloride reference electrode

Method

- Relies on the principle that two solutions with different $H^+$ activities will develop a potential difference between them (proportional to the concentration gradient)
- $H^+$ passes through the glass along a concentration gradient:
  - A variable potential difference is generated in the measuring chamber, as $H^+$ ions are buffered and the concentration gradient is maintained
  - A constant potential difference is generated in the reference chamber, as there is no buffer of $H^+$ ions in the KCl solution
- Once $H^+$ has equilibrated between blood and the KCl solution, the potential difference between the measuring and reference electrodes is proportional to the $H^+$ concentration in blood

Calibration, Limitations, and Accuracy

- Calibration is performed with two phosphate buffer solutions containing two different (known) $[H^+]$
- Must be kept at 37°C
  - Hypothermia increases solubility of CO$_2$ and therefore lowers PaCO$_2$
    - A reduced partial pressure of CO$_2$ is required to keep the same number of molecules dissolved (as per Henry’s Law)
    - Therefore, as blood cools its pH will increase
- Electrodes must be kept clean from protein and not damaged

Carbon Dioxide Tension

Carbon dioxide tension is measured with a Severinghaus electrode, which is based on the pH electrode, as PaCO$_2$ is related to $[H^+]$. The Severinghaus electrode consists of:

- A chamber for the blood sample, separated from the bicarbonate chamber by a CO$_2$ permeable membrane
- A chamber containing bicarbonate solution in a nylon mesh, and separated from both the measuring and reference chambers by $H^+$-permeable glass
- A measuring chamber containing:
  - A buffer solution
  - A silver/silver chloride measuring electrode
- A reference chamber containing:
  - A KCl solution
  - A mercury/mercury chloride reference electrode
Method

- CO₂ diffuses from blood into the bicarbonate chamber
- CO₂ reacts with water in the bicarbonate chamber to produce H⁺ ions
- From here, the process is identical to the pH electrode, except bicarbonate takes the place of blood:
  - H⁺ ions diffuse into the reference chamber until the H⁺ ion concentration has equilibrated
  - H⁺ ions continually diffuse into the measuring chamber (as they are buffered)
    - This establishes a constant pH gradient
      This gradient is proportional the H⁺ ion concentration in the bicarbonate chamber, which is proportional to the CO₂ content of blood.

Calibration, Limitations, and Accuracy

- Calibration is performed with solutions of known CO₂ concentration
- Must be kept at 37°C
  Hypothermia decreases solubility of CO₂ and therefore decreases pH
- Electrodes must be kept clean from protein and not damaged
- Slow response time relative to pH electrode due to time taken for CO₂ to diffuse and react
  This can be accelerated with carbonic anhydrase

Footnotes

1. Technically pH is defined as the activity of H⁺ in a solution. Clinically, activity is identical to concentration, so in medicine these definitions are functionally the same.

References

1. Leslie RA, Johnson EK, Goodwin APL. Dr Podcast Scripts for the Primary FRCA. Cambridge University Press. 2011.


Last updated 2018-09-21
Gas Flow

Describe the measurement of flow, pressure and volume of gases

Types of Flow:

- Laminar flow
  Fluid moving in a steady manner without turbulence.
- Turbulent flow
  Irregular fluid movement in radial, axial, and circumferential axes.
  - Laminar flow is more efficient than turbulent flow, as it requires a smaller pressure gradient to generate the same flow
  - For two fluids moving at the same speed, the velocity of individual particles in laminar flow will be both higher and lower
- Transitional flow
  Mixture of laminar and turbulent flow. Flow is typically turbulent in the centre, and laminar at the edges.

Devices used to measure gas flow include:

- Variable-Orifice Flowmeters
- Fixed-Orifice Flowmeters
  Pneumotachograph.
- Hot wire flowmeter

Note orifice based flowmeters rely on the Hagan-Poiseuille Equation:

\[
Q = \frac{\Delta P r^4 \pi}{8 \mu l}
\]

- Viscosity (\(\mu\)) and length (\(l\)) are fixed by both devices
- Fixed orifice flowmeters also fix radius (\(r\)), such that the change in pressure must therefore be proportional to flow:
  \[
  Q = \Delta P \pi k', \text{ where } k' \text{ is a constant}
  \]
- Variable orifice flowmeters also fix pressure (\(\Delta P\)), such that flow can be calculated from the radius:
  \[
  Q = r^4 \pi k
  \]

Flowmeters

Constant pressure, variable orifice flowmeters are found on wall and cylinder gases. They consist of:

- An inverse conical tube (i.e. narrower at the bottom, and wider at the top)
- A needle valve
- A bobbin
  May have a groove which causes the bobbin to spin, confirming it is not stuck.

Method:

- Gas flows from the bottom to the top of the tube
- The bobbin obstructs flow
  Therefore there is a pressure difference across it.

  Remember: 
  \[
  \text{Pressure} = \frac{\text{Force}}{\text{Area}} = \frac{\text{Mass} \times \text{Acceleration}}{\text{Area}}
  \]

  - At equilibrium, the pressure exerted by the bobbin on the flow of gas (\(P = \frac{\text{Gravity} \times \text{Bobbin Mass}}{\text{Bobbin Cross-sectional Area}}\))
is equal to the pressure exerted by the gas on the bobbin

- As flow is increased, the bobbin is pushed further up the flowmeter due to the increased pressure
- The bobbin will reach a new equilibrium position when the orifice of the flowmeter has become wide enough for the pressure on the bobbin to equal the pressure of gravity

- Flowmeters are calibrated for individual gases as:
  - Laminar (typically low flows) flow is proportional to viscosity
  - Turbulent (typically high flows) flow is proportional to density

**Pros**

- Cheap
- No additional power supply required
- Accurate

  Readings may be altered by:
  - Change in temperature affects viscosity and density of gas
  - Change in pressure affects density of gas

**Cons**

- Must be vertical
- Bobbins can become stuck

**Pneumotachographs**

**Constant orifice, variable pressure** flowmeter. Several different designs exist, and include:

- Fleisch pneumotachograph
  - Consists of several fine bore parallel tubes placed in the gas circuit
  - Decreased radius and increased resistance reduces gas flow velocity, improving laminar flow.
  - A differential pressure transducer is placed at either end of the tubes
  - The pressure drop across the tubing is directly proportional to flow

- Pitot tubes
  - Consists of two tubes placed into the gas circuit:
    - One faces into the gas flow
    - The other faces away from the gas flow
  - The pressure difference between tubes is proportional to flow

**Pros**

- Accurate
- Continual measurement
- Allow calculation of volumes

\[ \text{Volume (L)} = \text{Flow (L s}^{-1}) \times \text{Time (s)} \]

**Cons**

- Increased resistance
- Increased dead space
- Require laminar flow
Inaccurate when:
- Flows are higher than what the system is designed for
- Alteration in gas density
  - Change in gas mixture
- Alteration in gas temperature

**Hot Wire Flowmeter**

Components:
- Two fine platinum wires in the gas circuit
  - One heated to 180°C at 0.1L.min⁻¹
  - One at 0°C
- Ammeter

Method:
- As gas flows, the wire cools
- Rate of heat dissipation is proportional to gas flow
- The amount of current required to return the wire to 180 is measured, and is proportional to flow

**Pros**
- Accurate
- Fast

**Cons**
- Fragile

**References**


Last updated 2019-07-18
Principles of Ultrasound

Describe the physical principles of ultrasound and the Doppler Effect.

Ultrasound is an imaging technique where high-frequency sound waves (2-15MHz) are used to generate an image. An ultrasound wave is produced by a probe using the **piezoelectric effect**:

- Certain crystalline structures will vibrate at a particular frequency when a certain voltage is applied across them
  - The conversion of electrical energy to kinetic energy is how the ultrasound probe creates an ultrasound wave.
- Similarly, they can generate a voltage when a vibration is induced in them
  - This is how the probe interprets reflected waves.

**Basic Principles**

- **Spatial resolution**
  - How close two separate objects can be to each other and still be distinguishable. It is divided into:
    - **Axial resolution**, how far apart two objects can be when one is above the other (in the direction of the beam)
    - **Lateral resolution**, how far apart two objects can be when side-by-side
- **Contrast resolution** is how similar two objects can appear (in echogenic appearance) and still be distinguishable
- **Higher frequency** settings offer greater spatial resolution but decreased penetration
- **Lower frequency** settings offer reduced spatial resolution but increased penetration
  - They are used for visualising deep structures.

**Affect of Tissues on Ultrasound**

At tissue interfaces, the wave may be:

- **Absorbed**
  - Sound is lost as heat, and increases with decreased water content of tissues.
- **Reflected**
  - Sound bounces back from the tissue interface, and returns to the probe.
    - Reflection is dependent on the:
      - **Difference in sound conduction** between the two tissues
      - **Angle of incidence** (close to 90° improves reflection)
      - **Smoothness** of the tissue plane
  - The amplitude of sound returning to the probe determines echogenicity, or how white the object will be displayed
  - The time taken for the sound to return determines depth
    - The time taken for a wave to return is proportional to twice the distance of the object from the probe
    - Depth can be calculated using $d = \frac{1}{2}vt$, where:
      - $d$ is Depth
      - $V$ is the speed of sound in tissue, and is assumed to be 1540 ms\(^{-1}\)
      - $t$ is Time
  - Sound passes through the tissue, and may be reflected or absorbed at deeper tissues.
  - **Transmitted**
  - Sound is reflected from tissue but is not received by the probe.
  - **Scattered**
  - Sound is reflected from tissue but is not received by the probe.

**Attenuated**
Attenuation describes the loss of sound wave with increasing depth, and is a function of the above factors.

- Attenuation is managed by increasing the **gain**
  Gain refers to amplification of returned signal.
- **Time-gain compensation** refers to amplification of signals which have taken longer to return, which amplifies signals returned from deep tissues

### Modes

Ultrasound modes include:

- **B-Mode** (brightness mode)
  The standard 2D ultrasound mode, and plots the measured amplitude of reflected ultrasound waves by the calculated depth from which they were reflected.
- **M-Mode** (movement mode)
  Selects a single vertical section of the image and displays changes over time (i.e. depth on the y-axis, and time on the x-axis).

### Doppler Effect

The doppler effect is the change in observed frequency when a wave is reflected off (or emitted from) a moving object, relative to the position of the receiver. In medical ultrasound, this is the change in frequency of sound reflected from a moving tissue (e.g. an erythrocyte). It is given by the equation:

\[
V = \frac{\Delta F \cdot s}{2F_0 \cos \theta}
\]

where:

- \(V\) = Velocity of object
- \(\Delta F\) = Frequency shift
- \(s\) = Speed of sound (in blood)
- \(F_0\) = Frequency of the emitted sound
- \(\theta\) = Angle between the sound wave and the object

Reflected frequencies are **higher towards the probe** and **lower away**.

### Calculation of Cardiac Output

Remember, \(C'O = HR \times SV\).

- Heart rate is measured
- Stroke volume is calculated by:
  - Measuring the **cross-sectional area** of the left ventricular outflow tract
    Obtained by measuring the diameter using ultrasound.
  - Measuring the **stroke distance**
    Obtained via integrating the velocity-time waveform for time across the left ventricular outflow tract (LVOT VTI).
      - The integral of flow (m/s \(\times\) time (s)) for time (s), produces a distance (m)
  - Multiplying the LVOT cross-sectional area (m\(^2\)) by the stroke distance (m), produces a volume (m\(^3\))

This is the stroke volume.

### References

Last updated 2019-07-18
Temperature and Humidity

Describe the measurement of temperature and humidity

**Temperature** is the tendency of a body to transfer heat energy to another body, and is measured in degrees. It is distinct from **heat**, which is the kinetic energy content of a body, and is measured in Joules. The two are related by the **specific heat capacity**, which describes how much energy (J) must be applied to a body to raise its temperature from 14°C to 15°C, without a change in state.

Humidity may be either **absolute** or **relative**:

- **Absolute Humidity** is the mass of water vapour in a volume of air
- **Relative Humidity** measures the percentage saturation of air at current temperature, or more formally:
\[
\text{Relative Humidity} = \frac{\text{mass of water vapour in volume of air}}{\text{mass of water vapour if air was fully saturated}} = \frac{\text{absolute humidity}}{\text{mass of water if air was fully saturated}}
\]

**Measurement of Temperature**

Temperature is measured by a number of methods:

**Liquid Expansion Thermometry**

This is used in mercury thermometers. These consist of:

- A graduated **evacuated capillary** of negligible volume, attached to
- A mercury reservoir, of much greater volume, separated by
- A constriction ring

  Prevents travel of mercury up the capillary by gravity.

**Mechanism:**

- When heated, the kinetic energy of the mercury increases and it expands, forcing it up the capillary

  As the thermal expansion coefficient for all liquids is very small, the capillary must be of a very small volume to create a usable device.

- The speed that this occurs is related to the **time-constant** of the system

  This is typically 30 seconds. Measurement therefore takes ~4 time-constants, or 2 minutes.

**Pros**

- Easy to use
- Accurate
- Reusable
- Sterilisable
- Cheap

**Cons**

- Slow response
  Only accurate once it has reached thermal equilibrium.
- Glass can break
  May cause release of mercury or alcohol.
- Inaccurate at:
- Low temperatures with mercury
  Freezes at -38.8°C.
- High temperatures with alcohol
  Boils at 78.5°C.

**Electrical**

Electrical methods include:

- **Resistance thermometer**
  Platinum wire increases electrical resistance with increasing temperature.
  - Therefore the voltage drop across the wire will correspond to the temperature of the wire
  - Change in resistance is linear across the temperature range
  - However, these are expensive.

- **Thermistor**
  Metal (e.g. SiO₂) semiconductor which changes its resistance in a predictably non-linear fashion (run-away exponent) with temperature.
  - Can be manufactured so that change is linear over the clinical range
  - Much cheaper than wire resistance methods
  - The degree of voltage drop is usually very small, however this can be amplified using a Wheatstone bridge

- **Thermocouple**
  At the junction of two dissimilar metals, a potential difference will be produced proportional to their temperature. This is known as the Seebeck effect.
  - Non-linear (wash in exponent)
  - Degrade over time

**Measurement of Humidity**

Humidity can be measured by a number of methods:

- **Hair Hygrometer**
  Hair (actual hair) changes elasticity depending on the humidity of air. Changes in elasticity can be related to changes in humidity.

- **Wet and Dry Bulb**
  This system measures both temperature and relative humidity.
  - Two thermometers are used
    - One is wrapped in a wick, which is attached to a water reservoir
      This is the wet thermometer.
    - The dry thermometer gives a measurement of surrounding air temperature
    - The wet thermometer is cooled due to evaporative cooling from the wick
      High energy water molecules become vapour, leaving only low energy molecules behind.
  - The **temperature difference** between the thermometers is a function of:
    - Latent heat of vapourisation of water
    - How much evaporative cooling is occurring
      This is function of humidity.
    - At 100% relative humidity, no evaporative cooling will take place and the temperatures will be equal
    - As humidity decreases, evaporative cooling will cool the wet thermometer, and the temperature difference allows humidity to be determined
References


2. Alfred Anaesthetic Department Primary Exam Tutorial Series

Last updated 2019-07-18
Electrocardiography

Describe the principles behind the ECG

The ECG is a graphical representation of the electrical activity of the heart, as measured by the sum of electrical vectors at the patients skin.

Components

An ECG consists of:

- Electrodes
  Disposable, sticky components which act as conductors due to a silver/silver chloride coating. To reduce electrode impedance, skin should be:
    - Hairless
    - Dry
    - Clean
- Cables
  Shielded to prevent currents being induced and electrocuting the patient.
- Processor
- Monitor

ECG Leads

ECG leads are created by taking the potential difference between two electrodes, which varies by 0.5-2mV through the cardiac cycle as myocardium depolarises. ECG leads are divided into:

- Limb leads
  Potential difference between limb electrodes:
    - I: RA to LA
    - II: RA to LL
    - III: LA to LL
- Augmented leads
  Potential difference between the average of the limb leads (called the indifferent electrode) and each individual limb lead.
    - Augmented leads are of much lower voltage and must be amplified
    - Three augmented leads exist (one for each limb electrode)
- Precordial leads
  Potential difference between the indifferent electrode and one of the six additional electrodes placed on the chest wall.

The relationship between electrodes and leads is described with Einthoven’s Triangle:
Method

- As the myocardial membrane potential changes across the cardiac cycle, a potential difference can be measured at the skin.
  - A depolarisation wave traveling towards the positive electrode (or a repolarisation wave traveling away) will cause an upward deflection in the ECG.
- These potential differences are very small, and therefore need to be:
  - Distinguished from background interference
  - Several techniques exist:
    - **Common mode rejection**
      Identical electrical activity occurring in multiple electrodes is likely due to interference rather than cardiac activity, and is removed from the measured signal.
      - A ground electrode is typically used for this purpose
    - **ECG modes**
      ECGs can be set to varying levels of sensitivity.
      - **Diagnostic mode**
        Responds to higher range of frequencies, but is at greater risk of interference.
      - **Monitor mode**
        ECG responds to a lower range of frequencies, reducing interference but also resolution. This is common on 3-lead ECG.
    - **High input impedance**
      Minimises signal loss.
      - Amplified
        Frequencies in the desired signal range are amplified.

Sources of Error

- Improve signal detection
  - Good adherence
  - Optimal skin contact
    Ensure dry and hairless.
- Minimise external electrostatic forces
  - Earthed
  - Diathermy
  - Shivering
Risks

- ECG electrodes can act as an exit electrode for surgical diathermy

References

2. CICM February/April 2016

Last updated 2019-07-18
Humidifiers

Humidifiers add water vapour to inspired gas, taking the place of normal body mechanisms which are bypassed or impeded by invasive and non-invasive ventilation. Maintaining adequate humidity of inspired gas is important in:

- Reducing metabolic load
  Humidification of inspired gas accounts for ~15% of basal heat expenditure.
- Maintaining function of the mucociliary elevator
  Inspiration of dry gas increases viscosity of mucous.
- Reducing water loss
  Water will be absorbed from mucosa to humidify gas.

Humidifiers can be classified into active or passive.

Passive Humidifiers

Passive humidifiers:

- Do not require power
- Do not require water

The Heat and Moisture Exchange (HME) filter is the classic passive humidifier:

- Placed between the patient and the patient Y-piece
- Consists of:
  - A moisture exchange layer
    - Pleated, hygroscopically coated foam or paper.
      - Expired gas cools as it passes, condensing onto the foam, with condensation promoted by hygroscopic coating (usually this is NaCl)
      - The latent heat of vapourisation results in a decreased temperature of expired gas
    - A filter layer
      - Typically a electrostatic or hydrophobic material.
  - Expired gas is cooled and dried
  - Inspired gas is then heated and humidified
  - An HME takes up to 20 minutes to be fully effective, and can achieve a relative humidity up to 70%
  - Efficacy depends upon the patient's core temperature and the condition of the airway

Pros

- Cheap
- Lightweight
- Straightforward
- May contain anti-bacterial filter

Cons

- May be blocked with vomit and secretions
- Increase airway resistance
- Increase dead space
- Not as effective as powered active systems
- Only last 24 hours
• Takes 15-20 minutes to become fully effective

**Active Humidifiers**

Active Humidifiers:

• Require either:
  • Power
    Unpowered humidifiers are typically less effective, and only operate well at lower flow rates.
  • Water
    (Or both)

• Consist of:
  • A water bath
    Typically sterile water.
  • A heating element
    To heat the water bath.
  • A gas pipe
    Inspired gases are bubbled through the water bath to humidify them.
  • A water trap
    To trap condensed water. Should be changed regularly to minimise infection risk.

**Pros**

• Greater humidification
• Appropriate for long-term ventilation

**Cons**

• Bulky
• Expensive
• Require power
• Infection risk from water bath

**References**


Last updated 2019-07-18
Supplemental Oxygen

Describe different systems to deliver supplemental oxygen and the advantages and disadvantages of these systems.

Devices for delivery of oxygen can be classified into:

- Variable performance devices
- Fixed performance devices

Variable Performance Devices

Variable performance devices:

- Do not deliver a fixed FiO$_2$
  - This is because respiratory flow is non-uniform
    - Although minute ventilation may be 5-6L.min$^{-1}$, peak inspiratory flows are substantially higher.
  - Delivered FiO$_2$ is dependent on oxygen flow and inspiratory flow
    - Increasing oxygen flow rate will increase FiO$_2$, but the effect will vary depending on the device (volume, seal) and the patient

- Include:
  - Nasal Cannulae
    - Prongs delivering gas at 1-4L.min$^{-1}$.
      - Higher flows may dry mucosa, and lead to epistaxis
      - Nasopharynx acts as an oxygen reservoir, somewhat increasing FiO$_2$
      - Well tolerated
        - Allow eating, drinking, and talking
  - Hudson Mask
    - Simple unsealed mask, allowing gas flow up to 15L.min$^{-1}$.
      - Cheap
      - Less well tolerated
      - Rebreathing may occur
  - Non-Rebreather Mask
    - Modified version of the Hudson mask, containing a reservoir bag.
      - Reservoir bag is filled during expiration
      - Gas is drawn from the reservoir bag during inspiration, increasing FiO$_2$
        - Some air is entrained from around the mask and so FiO$_2$ is < 1.

Fixed Performance Devices

Fixed performance devices:

- Theoretically deliver a fixed FiO$_2$
  - These are usually flow limited as well, and so FiO$_2$ may decrease at higher inspiratory flows.

- Include:
  - Venturi
    - Consists of a cone through which oxygen flows. Apertures on the side of the cone entrain room air.
      - Air is entrained via:
        - Frictional drag of molecules
        - The venturi effect (though this is controversial)
The widening of the cone leads to an increase in fluid velocity and therefore a decrease in pressure, as per the Bernoulli principle.

- Entrained air is proportional to flow rate, so the ratio of oxygen to air is constant for any given aperture size. This is known as the **entrainment ratio**.
- Will deliver the specified FiO₂ provided oxygen flow is above the minimum rate. Therefore become variable performance devices when inspiratory flow greatly exceeds oxygen flow.

## References


Last updated 2019-07-18
Bispectral Index

Describe the principles behind the BIS

Bispectral Index (BIS) is a proprietary signal-processed EMG and EEG monitor used to estimate depth of anaesthesia.

The BIS outputs four values:

- BIS
  Dimensionless index between 0 and 100 where:
  - 0 represents cortical electrical silence
  - 85-100 represents normal awake cortical activity
  - 40-60 is consistent with general anaesthesia
- Signal Quality Index (SQI)
  Dimensionless index between 0 and 100 which gives an indication of the accuracy of the BIS value.
- Electromyography
  Gives an indication of the influence of muscle activity on BIS values.
- Suppression Ratio (SR)
  Percentage of previous 63 seconds where EEG is isoelectric.

Method

Proprietary, but involves:

- Multivariate logistic regression of EEG features that correlate with clinical levels of sedation
- Initial validation on a cohort of healthy volunteers, not undergoing surgery
- Use of four frontotemporal EEG monitors

Analytic techniques:

- Compressed Spectral Array
  The signal over a short period (e.g. 5-10 seconds) of EEG recordings are analysed together
  Each period is known as an epoch.
  A Fourier transformation is performed
  This breaks the EEG signal down into the sine waves used to produce it.
  A histogram of each frequency is plotted
  As anaesthesia deepens, lower frequencies begin to dominate
  The spectral edge frequency is the frequency greater than 95% of the frequencies in the compressed spectral array
  It is an indicator of anaesthetic depth, but not of drug concentration.

- Coherence
  Under anaesthesia, the electrical activity in different sections of the brain falls out of phase.

Pros

- Reduced anaesthetic awareness in high risk patient groups
  Trauma, GA caesarian section, cardiac surgery.
- Non-invasive
- Use appears to result in reduced anaesthetic use and more rapid emergence
**Cons**

- Proprietary algorithm
- Expensive
- May be inaccurate with:
  - Hypothermia
  - Hypercarbia
  - Hypoxia
  - Muscle relaxants
    BIS may fall inappropriately.
  - Non-GABAergic agents (e.g. ketamine, nitrous oxide)
    May not fall appropriately.

**References**


Last updated 2019-07-18
Medical Gas Supply

Describe the supply of medical gases (bulk supply and cylinder) and features to ensure supply safety including pressure valves and regulators and connection systems

Production

Fractional Distillation

Oxygen is produced on the industrial scale by fractional distillation of atmospheric air. This process:

- Relies on the fact that different gases have different boiling points
  By liquefying air and then heating it gradually, each gas can be removed separately as it boils.
- Occurs in stages:
  - Atmospheric air is filtered
    Removes dust and other contaminants.
  - Air is compressed to 6 atm and then cooled to below ambient temperature
    Water vapour condenses and is removed.
  - Compressed air passed through a zeolite sieve which removes CO₂
  - Compressed air is allowed to re-expand
    As it does so it loses heat energy as per Gay-Lussac’s Law, and liquefies.
      - Air must be cooled below the boiling point of the desired gases
        This requires getting gases very cold, and so the process may be mechanically assisted using a turbine, and/or a heat exchanger. Key boiling points (at 1 atm):
          - Nitrogen: 77°K
          - Oxygen: 90°K
          - Helium: 4°K
        Helium can be produced by fractional distillation, but liquefying it is understandably difficult given the very, very low boiling point. Helium can also be mined, as helium produced by alpha decay of radioactive materials may be trapped in gas pockets under the earth.
  - Liquid air is then fractionally distilled
    Temperature of liquid air is raised slowly.
      - As the boiling point of each gas is reached (e.g. 77°K for nitrogen), that gas will begin to vapourise from the liquid, and can be collected
      - The remaining liquid can then be further heated, until the boiling point for the next gas is reached
      - This process can be repeated until all the desired gases have been separated

Oxygen Concentrator

Oxygen concentrators:

- Produce up to 95% oxygen from air by removing nitrogen
- Built using two zeolite lattices
  - Pressurised air is filtered through one lattice
    - Nitrogen and water vapour are retained in the lattice
    - Oxygen and argon are concentrated
      - Produces a 95% oxygen/5% argon mixture.
  - The unused column is heated to release the bound nitrogen and water
**Pros**
- Cheap
- Reliable
- Avoid need for oxygen delivery

**Cons**
- Result in an accumulation of argon when used at low flows on a circle system
- Require continuous power
- Fire and explosion risk

**Storage**

**Medical Gas Cylinders**

Gas cylinders are:
- Made from chromium molybdenum or aluminium
- Used as:
  - Backup for a piped supply
  - When a piped supply is not available (transports)
  - When the gas is uncommonly used (e.g. nitric oxide)
- The common cylinder used in hospital is CD
  - This contains 460 L of oxygen at 15°C and 137 bar.
- Cylinders are not completely filled, to reduce risk of overpressure and explosions if the temperature rises
  - The filling ratio is the weight of liquid in a full cylinder compared to the weight of water that would completely fill the cylinder
    - In cool climates, the filling ratio is ~0.75
    - In warmer climates, the filling ratio is reduced to ~0.67
- Cylinders are tested for safety every 5-10 years
  - Tests include:
    - Endoscopic examination
    - Tensile tests
    - 1% of cylinders are destroyed to perform testing on the metal.

**Pros**
- Portable
- Reusable

**Cons**
- Heavy
- Limited supply

**Cylinder Manifolds**

Cylinder manifolds are formed of sets of large gas cylinders used in parallel.
- All cylinders in a group are used together
When the pressure falls below a set level, a pressure valve will switch and gas will be drawn from another cylinder group. The first (now empty) cylinder group is exchanged for full cylinders.

**Pros**

- Cheap
- Useful as a backup supply

**Cons**

- Less capacity than a VIE
- Fire and explosion risk

**Vacuum Insulated Evaporator**

The VIE:

- Stores liquid oxygen
  - It is vacuum insulated as it must keep oxygen below its critical temperature (-119°C). The VIE typically stores oxygen between -160°C and -180°C, and at 700kPa.
  - The gas is stored below its critical temperature and above its boiling point
  - The amount of oxygen remaining is calculated from its mass
- Does not require active cooling
  - Instead it is cooled by:
    - Insulation
    - Evaporation
    - Heat entering the VIE causes liquid oxygen to evaporate. Oxygen vapour is drawn off the VIE to the pipeline supply, so the VIE remains cool and at a steady pressure provided oxygen is being drawn from it.
- Has a pressure relief valve to prevent explosions if oxygen is not being used
- Has an evaporator to evaporate large volumes of oxygen rapidly if demand is high
  - This is simply an uninsulated pipe exposed to the outside temperature

**Pros**

- Cheapest option for oxygen delivery and storage
  - Storing oxygen as a liquid is much more efficient than as a gas
  - Does not require power

**Cons**

- Set-up costs are expensive
- Requires a back-up setup
- Will waste large volumes of oxygen if not being used continuously
- Fire and explosion risk

**Safety in Medical Gas Supply**

Many systems exist to ensure safety:

- Colour coding of cylinders and hoses
  - Oxygen is white
  - Nitrogen is black
- Air is black with white shoulders
- Nitrous oxide is blue
- Helium is brown
  - Heliox is brown with white shoulders
- Carbon dioxide is grey-green
- Labeling of connections

**The pin index system**

Used to prevent the wrong gas yoke being connected to a cylinder.

- Pins protrude from the back of the yoke
- Holes exist on the valve block
- Pins and holes must line up for the cylinder to be connected
- There are six positions, divided into two groups of three

  Common combinations include:
  - Oxygen: 2-5
  - Air: 1-5
  - Nitrous oxide: 3-5

**Sleeve Index System**

Used in Australia when connecting pipeline gases.

- Wall block contains a sleeve when prevents fitting the incorrect gas hose to the wall
- Screw thread is identical in all cases

**Non-Interchangeable Screw Thread (NIST)**

Used (but not in Australia) when connecting pipeline gases.

- NIST connectors have a probe and a nut
- Probe diameter is gas-specific, preventing the wrong gas from being connected

**Testing**

- Must demonstrate
  - Correct oxygen concentrations
  - Absence of contamination
  - Delivery of adequate pressure when several other systems on the same pipeline are in use
- Testing must be performed twice on a new installation:
  - First by engineers
  - Second by a medical officer

  In theatres, this should be the director of the anaesthetic department or their delegate, who should hold fellowship of ANZCA.

---

**References**

2. ANZCA August/September 2016

Last updated 2019-07-18
Vapourisers

Describe the principles and safe operation of vapourisers

Delivery of gas that is fully saturated with anaesthetic agent would result in lethal doses being administered. The use of a vapouriser allows a safe dose of anaesthetic agent to be given. Vapourisers can be divided into:

- Variable bypass vapourisers
  Air that is fully saturated with gas is mixed with a 'bypass' stream of gas, diluting the delivered concentration. Further subdivided into:
  - Plenum
    Requires supra-atmospheric pressure to operate.
    - More accurate
  - Draw-over
    Driven by the patients inspiratory effort.
    - Portable

Variable Bypass Vapouriser

Variable bypass vapourisers aim to deliver the same concentration of anaesthetic agent over a range of flows. They achieve this by:

- Flow management
  - Baffles and wicks increase the surface area of the liquid/gas interface, increasing the rate of vapourisation.
    - Excessively high flow rates may result in gas not being fully saturated with agent when it exits the vapouriser stream
    - These are less effective in draw-over vapourisers, as resistance must be minimised

- Temperature management
  The SVP of volatile agents increases non-linearly as temperature increases. Temperature changes:
  - Occur through:
    - Changes in ambient temperature
    - Loss through latent heat of vapourisation
      Liquid agent from the vapouriser will cool over the course of an anaesthetic.
  - Are managed with:
    - Temperature stabilisation
      Use of materials with both a high thermal conductivity and specific heat capacity, allowing the vapourising chamber to buffer changes in surrounding temperature.
    - Temperature compensation
      Adjusts flow into either the vapourising chamber or bypass chamber to account for changes in environmental temperature. Methods include:
      - Bimetallic strip
        Metal strip which bends in response to environmental temperature, adjusting the amount of gas entering the vapourising chamber.
      - Aneroid bellows
        Connect to a cone in the opening of the bypass chamber. As temperature decreases, the bellows contract and the cone partially obstructs the bypass channel.

Difference Between Plenum and Draw-Over Vapourisers

Plenum vapourisers are:
- More accurate
  Designed to deliver accurate agent concentrations over a wide range (0.25-15L.min\(^{-1}\)) of flow rates
  - Below 250ml.min\(^{-1}\) the resistance of the flow splitting valve becomes more significant, causing the amount of gas in the bypass stream to be higher than intended
  - Above 15L.min\(^{-1}\) gas may not be fully saturated
- Heavier
  Typically built of metals such as copper to maximise thermal stability.
- High internal resistance
  - Must be used out-of-circle
  - Must be used with positive-pressure

Draw-Over Vapourisers are:

- Less accurate
  - Less use of baffles and wicks to minimise inspiratory resistance
- Less thermally stable
  - Oxford Minature Vapouriser does not have a bimetallic strip
  - Oxford Minature Vapouriser uses glycol as a thermal buffer

**Measured Flow Vapourisers**

Measured flow vapourisers have a separate stream of agent-saturated gas that is added to the gas flow. This requires the device to:

- Measure fresh gas flow rate
- Adjust vapour-gas flow rate so the desired concentration is delivered

This system is used for the delivery of desflurane, as desflurane:

- Has a very high SVP
  Requires high bypass flow rate to dilute to a clinically useful concentration.
- Has a low boiling point
  Intermittently boils at room temperature, which will cause large fluctuations in delivery:
  - Excessive agent delivery during boiling
    This will lead to cooling due to the latent heat of vapourisation.
  - Cooled desflurane will have a much lower saturated vapour pressure
    Significant under-delivery will then occur.

The Tec6 vapouriser:

- Heats desflurane to 39°C
  SVP of desflurane at this temperature is 1500mmHg.
- Gaseous desflurane is then added to the fresh gas flow
  The amount added depends on:
  - Desired concentration
  - Fresh gas flow rate
  As flow increases the resistance to flow of desflurane vapour decreases.

**General Safety Features of Vapourisers**

Agent specificity:

- Key indexed filling
- Pin indexed safety system connectors
Vapourisers

- Colour coding of unit and agent containers

Single agent administration:
- Interlock mechanism
  Prevents multiple vapourisers being turned on.
- Single cartridge slot (Aladdin system)

Tipping and overfilling:
- Long vapourisation chamber inflow
- Heavy construction
- Transport modes
- Side filling and overflow ports

Anti-pumping:
- Check valves and long vapourisation chamber inflow prevent entrainment of vapouriser gas in the inflow of the bypass channel

Agent depletion:
- Filling gauges
- Low pressure alarms (Tec 6)

Other Factors Affecting Vapourisers

Carrier Gas Composition:
- Nitrous oxide and air are more viscous than oxygen
  This leads to decreased flow through the vapourising chamber when FiO₂ is low
  This effect is not clinically significant.

Altitude:
- Clinical effect of volatile agent is a function of their partial pressure in tissues
- As SVP is independent of atmospheric pressure, this is unchanged at altitude
- A vapouriser set at 2% will deliver 4% gas at 0.5atm pressure, however as the atmospheric pressure is reduced the same partial pressure of vapour is delivered

- The delivered concentration of an agent at altitude is given by the equation:

\[
\text{Delivered Concentration \( \% \) = Intended Concentration} \times \frac{P_{\text{cal}}}{P_{\text{alt}}} , \text{where:}
\]

- \( \text{Actual Delivered Concentration} \) is the concentration of agent in the gas delivered to the patient
  This must be multiplied by the atmospheric pressure to find the partial pressure of agent delivered to the patient.
- \( \text{Intended Concentration} \) is the concentration dialed up on the vapouriser
- \( P_{\text{cal}} \) is the atmospheric pressure where the vapouriser was calibrated
- \( P_{\text{alt}} \) is the atmospheric pressure where the vapouriser is being used

References


Last updated 2019-07-18
Breathing Systems

This provides a general overview of anaesthetic breathing systems. The circle system in particular is covered elsewhere.

Classifications:

- **Open**
  - Anaesthetic gases not confined to the circuit.
  - Limited current practical application
  - Expensive, environmental contamination.
  - e.g. Ether masks

- **Non-rebreathing**
  - No expired gas is re-inspired; requires a one-way valve.
  - Limited practical application
  - Requires a low-resistance draw-over vapouriser
  - e.g. Tri-service apparatus
    - Robust
    - Inexpensive

- **Rebreathing systems**
  - Expired gas is re-inspired.
  - Absorption systems
    - Requires method for CO₂ absorption.
      - **Circle**
        - Common anaesthetic circuit, covered in detail under. Can be:
          - Vapouriser Out-of-Circuit
            - Common system, covered in detail under circle system.
          - Vapouriser in-circuit
            - Uncommon system.

- **Absorption**
  - Rebreathing expired gas is part of circuit design.
  - Mapleson Systems

Mapleson System

Properties:

- Rebreathing of expired gas **does not necessarily equate to CO₂ retention**, provided the FGF is above a certain multiple (circuit dependent) of the patients MV
  - PaCO₂ is a function of FGF and CO₂ production **only**
    - Increasing MV without increasing FGF will result in re-breathing of CO₂ and unchanged PaCO₂.
- In any spontaneous ventilation mode, patients will hyperventilate if FGF is inadequate

Types:
Mapleson A

Setup
- APL valve close to mask
- Tubing between bag and mask
- FGF close to mask

Flow requirements
- Spontaneous ventilation: \(0.7 \times MV\)
  - APL valve is set low. Initial exhalation (which is mostly dead space, and not containing CO\(_2\)) will fill bag until bag pressure exceeds APL valve opening pressure. Provided the APL valve is set low, the majority of CO\(_2\) will exit through the APL valve, and FGF required to clear CO\(_2\) from the circuit is low.
- Controlled ventilation: \(> 3 \times MV\)
  - APL valve is set high. More of the exhalation will fill the bag, and so a greater FGF is required to prevent re-breathing.

Mapleson B & C

Setup
- APL valve and FGF are situated close to the mask.
  - Mapleson B has long tubing between the mask and bag
  - Mapleson C has short tubing between the mask and bag

Flow requirements
- Spontaneous and controlled ventilation are similar, at \(3 \times MV\).

Mapleson D

Setup
- FGF is close to mask
- Valve is close to bag
- Tubing between FGF and APL valve
  - Co-axial versions exist, but are functionally similar.

Flow requirements
- Spontaneous ventilation: \(2 \times MV\)
- Controlled ventilation: \(0.8 - 1 \times MV\)
  - Best circuit for controlled ventilation.

Mapleson E/Ayre’s T-piece

Setup
- T-shaped circuit with no valve or bag

Mapleson F/Jackson-Rees modification to the Ayre’s T-piece

Setup
- Bag (with hole) added to the stem of the T of a Mapleson E
  - Allows monitoring of ventilation, and occluding the hole of the bag allows controlled ventilation.
  - Functionally identical to a Mapleson D, with an operator-controlled APL valve

Flow requirements
- As per Mapleson D.
  - Spontaneous ventilation: \(2 \times MV\)
  - Controlled ventilation: \(0.8 - 1 \times MV\)

References

Circle System

This covers the circle breathing system. A general overview of anaesthetic breathing systems is covered under anaesthetic circuits.

The circle breathing system is a highly efficient system which:

- Has several key advantages
  - Preserves anaesthetic gases making volatile anaesthesia cost-effective
  - Preserves medical gases (oxygen) which is useful in resource-limited settings (e.g. prehospital)
  - Preserves heat and moisture
  - Reduces fire risk
    Particularly with older agents.
- Requires re-breathing of expired gases
  CO₂ is actively removed.
- Is a closed-circuit system
  - The only gases which must be replaced are those:
    - Consumed by the patient
    - Oxygen
    - Absorbed and metabolised volatile agents
    - Lost via leak

Principles

A circle circuit consists of:

- A Y-piece, connecting the circuit to the patient
- Expiratory and inspiratory valves, ensuring unidirectional flow
- A means of generating pressure
In most systems this consists of both a ventilator and a reservoir bag with APL valve attached, with a bag/vent switch to swap between circuits.
  - These are typically placed on the expiratory limb so that gas can be removed via scavenging prior to passage through soda lime
    This reduces soda lime consumption, as some CO₂ will be scavenged.
- Soda lime
  To absorb CO₂.
- Fresh gas flow
  - Includes oxygen, air and nitrous oxide
  - Oxygen enters the back-bar last
  - When the vapouriser is out-of-circuit, all fresh gas flow will pass through the vapouriser prior to entering the circle
- A separate high-pressure high-flow oxygen flush, which bypasses the vapouriser

Soda Lime

Soda lime:

- Consists of granules of:
  - 81% Ca(OH)₂
  - 4% NaOH
  - 15% H₂O
  - Silicates
Hardens granules.
- pH indicator
  - Visual representation of uptake of CO$_2$ by soda-lime.
    - Phenolphthalein
      - Red to white.
    - Ethyl violet
      - White to purple.
- Granules are 4-8 mesh in size
  - Will pass through a mesh with 4 holes per square inch, but not 8
  - Balance between surface area (speed/efficacy of reaction) and resistance to flow
- Absorbs CO$_2$ by following reaction:

\[
\begin{align*}
CO_2 + H_2O & \rightarrow H_2CO_3 \\
H_2CO_3 + 2NaOH & \rightarrow Na_2CO_3 + 2H_2O + Heat \\
Na_2CO_3 + Ca(OH)_2 & \rightarrow CaCO_3 + 2NaOH + Heat
\end{align*}
\]
- This increases the pH of the soda lime, causing the pH indicator to change colour
- 100g of soda lime can absorb ~26L of CO$_2$

**Pros**
- Cheaper to operate
- Conserves gases, heat, and moisture
- Low dead space
- Reduced greenhouse effects

**Cons**
- Gas mixture settings are not delivered to the patient
  - Settings affect the fresh gas flow mixture, whilst the patient respires gas from the circuit. These are not identical, especially at low flows.
- Nitrogen may build up in the circuit during low-flow anaesthesia, and potentially lead to delivery of a hypoxic gas mixture
- Less portable than open-circuit systems
- Increased circuit resistance
- Requires soda lime, which can be toxic
  - Produces Compound A-E from sevoflurane
  - Produces carbon monoxide from desflurane, isoflurane, and enflurane
  - Dangerous if aspirated

**References**


Last updated 2019-07-18
Scavenging

Describe the hazards of anaesthetic gas pollution and the methods of scavenging anaesthetic gases

Scavenging is the removal and safe disposal of waste anaesthesia gases from the breathing circuit to avoid contamination of the theatre environment. This is important as continuous exposure of staff to anaesthetic gases has been implicated in:

- Cognitive impairment
- Spontaneous abortion
- Infertility
- Haematological malignancy

Methods of Scavenging

A scavenging system consists of:

- Gas collection assembly
  - Connects to the APL valve and ventilator relief valve
  - Collects gas vented from the circuit.
  - Uses a 30mm connector
    - Prevents accidental connection to the breathing system.
- Transfer tubing
- Scavenging interface
  The structure of the scavenging interface depends on the type of scavenging system.
  - Open interface
    - **Active** scavenging systems use a pump to generate a pressure gradient drawing gas to the disposal assembly. The scavenging interface is open to air to prevent the negative pressure being transmitted to the patient.
  - Closed interface
    - **Passive** scavenging systems use a series of positive and negative pressure relief valves.
      - When gas pressure in the collection assembly exceeds \(5\text{cmH}_2\text{O}\), the positive relief valve opens and gas enters a reservoir bag.
      - When gas pressure in the disposal assembly falls below \(0.5\text{cmH}_2\text{O}\), the negative relief valve opens and gas enters the disposal assembly.
- More transfer tubing
- Disposal assembly

References


Last updated 2019-07-18
Diathermy

Discuss the principles of surgical diathermy, its safe use and the potential hazards

Diathermy is the use of an electrical current to cut tissue and coagulate blood via localised heating. Diathermy:

- Uses **high frequency, alternating current** passing between two electrodes
  - Frequencies between 300kHz and 2MHz are used, which have a negligible risk of inducing arrhythmia.
- Heat energy produced is proportional to electrical power dissipated \( (I^2 R) \)
- Relies on the principle of current density
  \[
  \text{Current Density} = \frac{\text{Current}}{\text{Area}}
  \]
  - A high current density at the electrode causes tissue damage
  - A low current density (e.g. at the plate of a unipolar electrode) causes heating without damage

Diathermy Types

Diathermy can be either:

- **Unipolar**
  - Consists of a probe containing one electrode, and a large plate (placed elsewhere on the patient) containing the other probe.
- **Bipolar**
  - Consists of a pair of forceps with each point containing a separate electrode. Minimises the current passing between probes, and is used when using diathermy on electrically sensitive tissues (e.g. brain).

Diathermy Modes

Diathermy modes include:

- **Cutting**
  - Low-voltage mode producing a high current in the shape of a continuous sine wave.
- **Coagulate**
  - High-voltage mode producing a damped sine wave response.
- **Blended**
  - Mixture of cutting and coagulate on different tissues.

Risks

- **Burns**
  - From incorrectly applied unipolar plate.
- **Electrocution**
  - May injure patient, staff, or damage equipment and implants.
- **Electrical Interference**
  - May inhibit pacing in certain pacemakers, or trigger ICDs.
- **Smoke production**
  - Respiratory irritant, dissemination of viral particles, and may be carcinogenic.
- **Tissue dissemination**
  - Potential source of metastatic seeding.
References


Last updated 2017-09-16
Lasers

Describe the principles of surgical lasers, their safe use and the potential hazards

A laser is a device for light amplification by stimulated emission of radiation. Laser light is:

- Non-divergent
  All photons move in parallel.
- Coherent
  All photons are in phase.
- Monochromatic
  All photons have the same wavelength.

Lasers are used clinically for:

- Precise incisions
destruction of cells by localised vapourisation of water.
- Destruction of chemicals
tattoos, oncological drugs.
- Tissue destruction without heating
  opthalmology.

Principles

Method:

- An energy source is passed through a lasing medium, housed in a resonator made of mirrors
- As the lasing medium is excited, electrons enter a higher energy level
  When more than 50% of electrons are at a higher energy level, population inversion has occurred.
- As electrons fall back to their resting state, they release a photon
  A spontaneous emission occurs when an electron enters its resting state spontaneously
  A stimulated emission occurs when an electron enters its resting state after being struck by a photon released from a spontaneous emission
  Stimulated emissions result in amplification of light release
- The mirrors in the resonating chamber ensure most light is reflected back into the chamber, causing more stimulated emissions
- The exit from the chamber can be be adjusted so only certain polarities of light are emitted
- A lens may be used to focus the laser beam

- Lasers may be:
  Pulse wave
    Uses short bursts of laser light to minimise collateral damage.
  Continuous wave
    May lead to excessive heating.

Pros

- Precise surgery and haemostasis
Cons

- Require multiple safety precautions
  - Laser safety officer
  - Eye protection
  - Warning signs on doors
  - Cover theatre windows
  - Non-combustible drapes
  - Matte finish on equipment to minimise chance of reflection
- Additional risks in airway surgery
  - Use lowest FiO₂ possible
  - Avoid N₂O
  - Consider use of heliox
  - Use specialised laser tubes
    Normal PVC ETTs are combustible.

References


Last updated 2019-07-18
Subclavian Vein

Describe the anatomy relevant to central venous access (including femoral, internal jugular, external jugular, subclavian and peripheral veins)

The subclavian vein:

- Is a continuation of the axillary vein as it crosses the upper surface of the first rib
- Travels posterior to the clavicle, separated from the subclavian artery by the anterior scalene
- Joins with the internal jugular vein to form the brachiocephalic vein

Borders

- Anteriorly by the clavicle, subclavius muscle, and pectoralis major
- Posteriorly by anterior scalene muscle and subclavian artery
- Inferiorly by first rib and lung apex
- Superiorly by skin, subcutaneous tissue, and platysma
- Medially by the brachiocephalic vein
- Laterally by the axillary vein

Surface Anatomy

The needle is placed in the deltopectoral groove, inferior and lateral to the middle third of the clavicle. The needle is inserted at a shallow angle, passing under the middle third of the clavicle aiming at the sternal notch.

References


Last updated 2019-07-18
Internal Jugular Vein

Describe the anatomy relevant to central venous access (including femoral, internal jugular, external jugular, subclavian and peripheral veins)

The internal jugular vein:

- Originates at the jugular bulb
  This is a dilatation formed by the confluence of the inferior petrosal sinus and the sigmoid sinus.
- Exits the skull via the jugular foramen
- Descends laterally to the internal carotid (and later the common carotid) in the carotid sheath
- Terminates behind the sternal end of the clavicle, where it joins with the subclavian vein to form the brachiocephalic vein

Borders

- Anteriorly by SCM
- Posteriorly by the lateral mass of C1, scalene muscles, and lung pleura
- Medially by the internal carotid

Relationships

- Vagus nerve lies behind/between the carotid and IJV
- Cervical sympathetic plexus lies posterior to the carotid sheath
- Deep cervical lymph nodes lie close to the vein
- External jugular crosses the sternomastoid belly of SCM, running posteriorly and more superficial to the IJV, later perforating deep fascia to drain into the subclavian vein
- Pleura rises above the clavicle, and is close to the vein at its termination
- Thoracic duct passes lateral to the confluence of the left IJV and SCV, and may be injured during left IJV cannulation
  - The right lymphatic duct may be injured during right IJV cannulation, but due to its smaller size this is less common

Surface Anatomy

Identify the triangle formed by the two heads of SCM and the clavicle. Palpate the artery, and ensure the site of entry is lateral to the carotid. Aim:

- Caudally, at a 30 angle to the frontal plane
- Parallel to the sagittal plane
- Towards the ipsilateral nipple

Ultrasound Anatomy

Identify the vein deep to SCM, noting that it is (unlike the adjacent ICA):

- Non-pulsatile
- Thin walled
- Compressible
**Approaches**

- **Anterior**
  At the medial border of SCM, 3-4cm above the clavicle. Requires retraction of the carotid medially.
- **Central approach**
  At the apex of the triangle formed by each muscle belly of SCM and the clavicle.
- **Posterior approach**
  At the posterior edge of SCM, just superior to where the EJV crosses the sternomastoid.

**References**

1. Lasts
2. [http://radiopaedia.org/articles/internal-jugular-vein](http://radiopaedia.org/articles/internal-jugular-vein)
4. Internal jugular vein catheterisation: Posterior and Central Approach

Last updated 2019-07-18
Intercostal Catheter

Describe the anatomy relevant to the insertion of an intercostal catheter

An intercostal catheter drains the intrapleural space.

Surface Anatomy

An ICC should be placed in the safe triangle:

![Safe Triangle Diagram]

This is bordered:

- **Anteriorly** by pectoralis major
- **Posteriorly** by latissimus dorsi
  - Too far posterior will injure the long thoracic nerve.
- **Superiorly** by the base of the axilla
- **Inferiorly** by the 5th intercostal space
  - Too far inferiorly risks placement in the liver or spleen.

Layers of Dissection

- Skin
- Subcutaneous tissue
- External intercostal
- Internal and innermost intercostal muscles
  - Note the **neurovascular bundle** which sits on the inferior aspect of the ribs, therefore aim to place the ICC at the bottom of the intercostal space - "above the rib below".
- Parietal pleura

References

1. LITFL - Chest Drain

Last updated 2017-09-18
Antecubital Fossa

Describe the anatomy relevant to central venous access (including femoral, internal jugular, external jugular, subclavian and peripheral veins)

The antecubital fossa is a triangular space on the anterior aspect of the forearm.

Borders

The triangular borders are formed:

- Medially by pronator teres
- Laterally by brachioradialis
- Superiorly by an imaginary line between the medial and lateral epicondyles
- The roof of the fossa is formed by subcutaneous tissue
- The floor is formed by brachialis and supinator

Contents

From medial to lateral:

- Median nerve
- Brachial artery
- Biceps tendon and aponeurosis
- Radial and posterior interosseous nerves
- Veins
  - Basilic vein
  - Cephalic vein
  - Venous variations:
    - A median cubital vein connecting the basilic and cephalic veins
    - A median vein of the forearm, which divides into a median basilic and median cephalic vein which drain into the basilic and cubital veins

References

1. FRCA - The Cubital Fossa

Last updated 2019-07-18
Tracheostomy

Describe the anatomy relevant to the performance of naso, or endo, tracheal intubation, a cricothyroidotomy or tracheostomy.

Trachea

The trachea is fibrocartilagenous tube which:

- Extends from the larynx superiorly to the Plane of Louis inferiorly
- Terminates by division into the right and left mainstem bronchi
- Runs at 15 degrees parallel to the surface of the neck, such that the distal trachea is deeper than the proximal trachea
- Has a D-shaped cross section
  - Anterior wall is formed by 18-22 incomplete cartilaginous rings which maintain tracheal patency
  - Posterior wall of the trachea is spanned by longitudinal smooth muscle known as trachealis
- Is typically:
  - 10cm long
  - 2.3cm wide
  - 1.8cm in AP diameter

Relationships

- Lateral to the trachea are the:
  - Carotid sheaths
    - Contains the carotid artery, internal jugular vein, and vagal nerves.
  - Thyroid lobes (and inferior thyroid arteries)
  - Recurrent laryngeal nerves.
- Inferior to the thyroid isthmus lies the thyroid veins
- Posterior to the trachea are the:
  - Oesophagus
  - Vertebral column

Surface Anatomy

Midline neck structures are relevant surface anatomy:

- Laryngeal structures
  - Including: Hyoid, thyroid cartilage, cricothyroid membrane, cricoid cartilage.
- Sternal notch
- Thyroid lobes
  - Lie lateral to trachea.

Layers of Dissection

- Skin
- Subcutaneous fat
- Superficial and Deep Pretracheal fascia
- Tracheal wall
Ideally between 1st and 2nd rings

References


Last updated 2019-07-18
**Toxic Alcohols**

**Alcohols** include:
- Ethanol
- Methanol
- Ethylene Glycol

In toxicity:
- All present with symptoms of alcohol intoxication
- All contribute to the osmolar gap
- Different toxicities occur due to the different metabolites

**Ethanol**

Ethanol is a weak alcohol with a complicated mechanism of action similar to volatile anaesthetic agents:
- Enhanced GABA-mediated inhibition
  - This is reversible with flumazenil.
- Inhibition of Ca$^{2+}$ entry
- Inhibition of NMDA function
- Inhibition of adenosine transport

<table>
<thead>
<tr>
<th>Property</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosing</td>
<td>One unit is ~8g/10ml of pure ethanol</td>
</tr>
<tr>
<td>Absorption</td>
<td>Rapid PO absorption</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Saturatable kinetics at &gt;4mmol.L$^{-1}$ due to high doses requiring extensive NAD$^+$ for oxidation, limiting metabolism to ~1 unit per hour. Low (0.2) extraction ratio, so high portal vein concentrations from rapid absorption (e.g. shots) causes a greater pharmacological effect. Ethanol is metabolised by alcohol dehydrogenase to acetylaldehyde, which is metabolised by aldehyde dehydrogenase to acetyl CoA.</td>
</tr>
<tr>
<td>Elimination</td>
<td>10% eliminated unchanged in air and urine</td>
</tr>
<tr>
<td>Resp</td>
<td>Respiratory depression</td>
</tr>
<tr>
<td>CVS</td>
<td>Vasodilatation increasing heat loss, reduced cardiovascular disease mortality due to increased HDL and inhibition of platelets. Alcoholic cardiomyopathy in abuse.</td>
</tr>
<tr>
<td>CNS</td>
<td>Slurred speech, intellectual impediment, motor impediment, euphoria, dysphoria, increased confidence. Dementia, encephalopathy, peripheral neuropathy, and cerebellar atrophy with chronic use.</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Stimulates ACTH release and 'pseudo-Cushing's syndrome'. Inhibits testosterone release. May cause lactic acidosis and hypoglycaemia in toxicity.</td>
</tr>
<tr>
<td>Renal</td>
<td>Inhibition of ADH release, causing diuresis. Ethanol is osmotically active and contributes to the osmolar gap.</td>
</tr>
<tr>
<td>GIT</td>
<td>Gastritis. Fatty liver, progressing to hepatitis, necrosis, fibrosis and cirrhosis</td>
</tr>
<tr>
<td>GU</td>
<td>Tocolytic effect</td>
</tr>
<tr>
<td>Haeme</td>
<td>Inhibition of platelet aggregation</td>
</tr>
<tr>
<td>Metabolic</td>
<td>High energy content comparable with fat (29kJ.g$^{-1}$)</td>
</tr>
<tr>
<td>Other</td>
<td>Synergistic with other CNS depressants. Metabolic interactions with warfarin, phenobarbitone, and steroids</td>
</tr>
</tbody>
</table>
Methanol

- Metabolised by alcohol dehydrogenase to formaldehyde and then formic acid
- Formic acid is neurotoxic
  - Damages retina and the optic nerve.

Ethylene Glycol

- Metabolised by alcohol dehydrogenase to glycoaldehyde, and (via several intermediate steps) to oxalic acid
- Oxalic acid binds calcium, which causes:
  - Hypocalcaemia
    - Long QT
  - Acute renal failure

References

3. LITFL- Toxic Alcohol Ingestion

Last updated 2019-07-18
# Naloxone

Pure MOP antagonist used for:

- Treatment of opioid overdose
- Reducing constipation
  
  In combination with PO oxycodone.

## Property

<table>
<thead>
<tr>
<th>Property</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>μ-selective opioid receptor competitive antagonist</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Opioid overdose, neuraxial opioid side effects (e.g. pruritus), prevention of constipation in combination with oral opioids</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Clear, colourless solution at 400mcg.ml⁻¹</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>IV, IM, PO</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>0.1-0.4mg Q5min, 0.5mg.kg⁻¹.hr⁻¹ by infusion</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>Very high first pass metabolism leading to ~2% PO bioavailability</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>50% protein bound. Vd 2L.kg⁻¹, highly lipid soluble.</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Rapid hepatic glucuronidation</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal elimination</td>
</tr>
<tr>
<td><strong>Resp</strong></td>
<td>Reversal of opioid-induced respiratory depression (↑ RR, ↑ Vf)</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>↑ SVR &amp; ↑ BP, arrhythmia due ↑ in SNS tone</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>↓ Analgesia, ↓ sedation, ↓ miosis. Antanalgesic in opioid naive patients. Precipitation of opioid withdrawal.</td>
</tr>
<tr>
<td><strong>Other considerations</strong></td>
<td>Duration of action is ~30-40 minutes is shorter than some opioids, which may lead to re-narcosis if not given subsequent doses or by infusion</td>
</tr>
</tbody>
</table>

## References


Last updated 2019-07-18
Flumazenil

Competitive antagonist and inverse agonist of the benzodiazepine receptor.

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Imidazo-benzodiazepine</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Reversal of BZD</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>IV</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>0.1mg boluses up to 2mg</td>
</tr>
<tr>
<td><strong>Onset</strong></td>
<td>Within 2 minutes</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>Moderate lipid solubility, 50% protein bound. t1/2β &lt; 1 hour - may require infusion.</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Hepatic to inactive metabolites</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal of metabolites</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>May precipitate seizures or BDZ withdrawal due to inverse agonist effect</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>N/V</td>
</tr>
</tbody>
</table>

References


Last updated 2017-09-17
**Oxygen**

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Naturally occurring gas</td>
</tr>
<tr>
<td>Uses</td>
<td>Improve FiO₂, CO poisoning, hyperbaric O₂ therapy</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>Inhaled</td>
</tr>
<tr>
<td>Dosing</td>
<td>0.21-1.0 FiO₂</td>
</tr>
<tr>
<td>Absorption</td>
<td>Diffusion across the alveolar capillary membrane in proportion to membrane area and partial pressure gradient, and inversely proportional to membrane thickness</td>
</tr>
<tr>
<td>Distribution</td>
<td>Bound to plasma Hb, and dissolved in plasma</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Metabolised in mitochondria of cells during the citric acid cycle to produce ATP, creating CO₂</td>
</tr>
<tr>
<td>Elimination</td>
<td>Exhalation as CO₂, or combined with H₂O to produce HCO₃⁻ and eliminated in urine</td>
</tr>
<tr>
<td>Resp</td>
<td>Respiratory drive in all individuals. May result in a fatal ↓ in those dependent on hypoxic drive. <strong>Pulmonary toxicity</strong> due to free radial formation when PiO₂&gt;0.6bar - pneumonitis/ARDS due to lipid peroxidation of the alveolar-capillary membrane. Absorption atelectasis.</td>
</tr>
<tr>
<td>CVS</td>
<td>Improvement in all CVS parameters in the setting of hypoxia. However, hyperoxia ↓ CO, ↓PVR, ↓PAP, and causes coronary vasoconstriction with prolonged administration</td>
</tr>
<tr>
<td>CNS</td>
<td><strong>CNS</strong> O₂ toxicity, typically at pressures &gt;1.6 bar though this is variable. Presents with a variety of neurological symptoms, progressing to disorientation and seizure. Retrolental fibroplasia in neonates exposed to high FiO₂.</td>
</tr>
<tr>
<td>Other</td>
<td>Fire risk</td>
</tr>
</tbody>
</table>

**References**

2. RAH Advanced Diving Medicine Course Notes: Chapter 6 Oxygen and Carbon Dioxide Toxicity

Last updated 2019-07-18
Helium

Helium is an inert gas which is used to reduce the specific gravity of inhaled gas mixtures. It is typically provided as a 0.79/0.21 Helium-Oxygen (Heliox) mixture (though other dilutions exist).

<table>
<thead>
<tr>
<th>Specific Gravity (as compared to air)</th>
<th>Helium</th>
<th>Heliox (0.79/0.21)</th>
<th>Oxygen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.18</td>
<td>0.34</td>
<td>1.09</td>
</tr>
</tbody>
</table>

Reduced specific gravity results in a proportional reduction in Reynolds Number, improving laminar flow within the airways.

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Inert Gas</td>
</tr>
<tr>
<td>Uses</td>
<td>Obstructive lung disease, deep water diving</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear, colourless solution</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>Inhaled</td>
</tr>
<tr>
<td>Dosing</td>
<td>Typically as Heliox: 79% He/21% O₂</td>
</tr>
<tr>
<td>Absorption</td>
<td>Diffusion across the alveolar capillary membrane in proportion to membrane area and partial pressure gradient, and inversely proportional to membrane thickness</td>
</tr>
<tr>
<td>Distribution</td>
<td>Distributes proportionally to solubility and tissue partial pressures</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Not metabolised</td>
</tr>
<tr>
<td>Elimination</td>
<td>Respiratory exhalation along a pressure gradient</td>
</tr>
<tr>
<td>Resp</td>
<td>Significantly decreases the specific gravity of inhaled gas mixtures</td>
</tr>
<tr>
<td>Toxic Effects</td>
<td>High Pressure Neurologic Syndrome at &gt;16 atm</td>
</tr>
</tbody>
</table>

References

1. RAH Advanced Diving Medicine Course Notes: Chapter 6 Oxygen and Carbon Dioxide Toxicity

Last updated 2017-12-22
Beta Agonists

This covers the inhaled β-agonists used for bronchodilation. Information on catecholamines and sympathomimetics with activity on β-receptors is covered under adrenergic vasoactives.

Common Features

<table>
<thead>
<tr>
<th>Pharmacodynamic Effects</th>
<th>β-agonists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resp</td>
<td>Bronchodilatation, ↓ HPV causing ↑ shunt and potential ↓ PaO₂ if O₂ is not co-administered.</td>
</tr>
<tr>
<td>CVS</td>
<td>↑ HR (β₁ with higher doses), ↓ BP (β₂ with lower doses)</td>
</tr>
<tr>
<td>GU</td>
<td>Tocolytic.</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Hypokalaemia from β₂ stimulation of Na⁺/K⁺ ATPase, hyperglycaemia.</td>
</tr>
<tr>
<td>Other</td>
<td>Potentiates non-depolarising muscle relaxants</td>
</tr>
</tbody>
</table>

Differences

<table>
<thead>
<tr>
<th>Property</th>
<th>Salbutamol</th>
<th>Salmeterol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Synthetic sympathomimetic amine</td>
<td>Synthetic sympathomimetic amine</td>
</tr>
<tr>
<td>Uses</td>
<td>Acute asthma/bronchospasm, hyperkalaemia</td>
<td>Nocturnal and exercise-induced asthma</td>
</tr>
<tr>
<td>Presentation</td>
<td>MDI (100µg), solution at 2.5-5mg.ml⁻¹ for nebulisation</td>
<td>MDI</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>Inhaled, IV</td>
<td>Inhaled</td>
</tr>
<tr>
<td>Dosing</td>
<td>1-2 puffs via MDI, 5mg nebulised. 0.5mcg.kg⁻¹.min⁻¹ as IV infusion.</td>
<td></td>
</tr>
<tr>
<td>Onset</td>
<td>Rapid</td>
<td>Slow</td>
</tr>
<tr>
<td>Distribution</td>
<td>Low protein binding</td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>High first pass hepatic to inactive metabolites, t₁/₂β 6 hours.</td>
<td>Extensive hepatic via CYP3A4</td>
</tr>
<tr>
<td>Elimination</td>
<td>Urinary elimination of active (30%) drug and inactive metabolites</td>
<td>Renal of metabolites</td>
</tr>
</tbody>
</table>

References


Last updated 2017-09-07
Antimuscarinics (Respiratory)

Antimuscarinics with predominantly cardiac effects are covered at Antimuscarinics (Cardiac), whilst atropine is covered separately.

These agents competitively antagonise ACh at M₃ receptors in bronchial smooth muscle, preventing parasympathetic mediated bronchoconstriction.

<table>
<thead>
<tr>
<th>Property</th>
<th>Ipratropium</th>
<th>Tiotropium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Muscarinic antagonist</td>
<td>Muscarinic antagonist</td>
</tr>
<tr>
<td>Uses</td>
<td>Bronchodilatation</td>
<td>Bronchodilatation</td>
</tr>
<tr>
<td>Presentation</td>
<td>MDI or solution for nebulisation</td>
<td>MDI</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>Inhaled</td>
<td>Inhaled</td>
</tr>
<tr>
<td>Dosing</td>
<td>18mcg MDI, 500µg nebuliser</td>
<td></td>
</tr>
<tr>
<td>Absorption</td>
<td>5% bioavailability via inhaled route</td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic to inactive metabolites</td>
<td></td>
</tr>
<tr>
<td>Elimination</td>
<td>Equal renal and faecal elimination</td>
<td></td>
</tr>
<tr>
<td>Resp</td>
<td>Bronchodilation</td>
<td>Bronchodilation</td>
</tr>
<tr>
<td>GIT</td>
<td>Decreased GI secretions in large doses</td>
<td>Decreased GI secretions in large doses</td>
</tr>
<tr>
<td>CNS</td>
<td>Mydriasis if deposited in eye</td>
<td>Mydriasis if deposited in eye</td>
</tr>
</tbody>
</table>

References


Last updated 2017-08-02
Phosphodiesterase Inhibitors / Methylxanthines

Methylxanthines non-selectively inhibit phosphodiesterase, which results in reduced levels of cAMP hydrolysis and therefore increased intracellular cAMP, and subsequent smooth muscle relaxation. This effect is synergistic with β2 agonists, which also increase cAMP by increasing production.

<table>
<thead>
<tr>
<th>Property</th>
<th>Theophylline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Methylxanthine/Non-selective phosphodiesterase inhibitor</td>
</tr>
<tr>
<td>Uses</td>
<td>Asthma and COAD</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV or PO</td>
</tr>
<tr>
<td>Dosing</td>
<td>4-6mg.kg⁻¹ IV load, then at 0.4mg.kg⁻¹.hour⁻¹ targeting serum concentration of 10mcg.ml⁻¹</td>
</tr>
<tr>
<td>Absorption</td>
<td>High oral bioavailability</td>
</tr>
<tr>
<td>Distribution</td>
<td>Vd 0.5L.kg⁻¹, 40% protein binding.</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic via CYP450 to active metabolites (caffeine and 3-methylxanthine), low hepatic extraction ratio</td>
</tr>
<tr>
<td>Elimination</td>
<td>Highly variable elimination affected by age, renal disease, hepatic disease</td>
</tr>
<tr>
<td>Resp</td>
<td>Bronchodilation, ↑ Diaphragmatic contractility</td>
</tr>
<tr>
<td>CVS</td>
<td>↑ Inotropy, ↑ chronotropy. Narrow therapeutic range due to arrhythmogenic (VF) properties</td>
</tr>
<tr>
<td>CNS</td>
<td>↓ Seizure threshold</td>
</tr>
<tr>
<td>Renal</td>
<td>Natriuresis and hypokalaemia</td>
</tr>
<tr>
<td>Toxic Effects</td>
<td>Low therapeutic index, with toxicity manifested as tachyarrhythmias including VF, tremor, insomnia and seizures</td>
</tr>
</tbody>
</table>

References


Last updated 2019-07-18
Leukotriene Antagonists

Selectively inhibit the cysteinyl leukotriene receptor, increased activity of which is involved in airway oedema and bronchial smooth muscle constriction.

<table>
<thead>
<tr>
<th>Property</th>
<th>Montelukast</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Leukotriene Antagonist</td>
</tr>
<tr>
<td>Uses</td>
<td>Asthma, allergic rhinitis</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO</td>
</tr>
<tr>
<td>Dosing</td>
<td>10mg daily</td>
</tr>
<tr>
<td>Absorption</td>
<td>64% PO bioavailability</td>
</tr>
<tr>
<td>Distribution</td>
<td>t0.5 5 hours, &gt;99% protein bound</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic by CYP3A4</td>
</tr>
<tr>
<td>Elimination</td>
<td>Predominantly faecal</td>
</tr>
<tr>
<td>Resp</td>
<td>Bronchodilatation</td>
</tr>
</tbody>
</table>

References


Last updated 2017-09-20
Corticosteroids

Glucocorticoids are endogenous (hydrocortisone) and synthetic (prednisolone, methylprednisolone, dexamethasone) steroid hormones with **metabolic**, **anti-inflammatory**, and **immunosuppressive** effects. They bind to specific intracellular receptors and translocate into the nucleus, where they regulate gene expression in a tissue-specific manner.

Corticosteroids have multiple indications including:

- Replacement in adrenal suppression or other cortisol-deficient states
- Autoimmune disorders
- Anaphylaxis and atopic disorders, including asthma
- Hypercalcaemia
- Chemotherapy
- Immunosuppression following transplantation

### Common Features

<table>
<thead>
<tr>
<th>System</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Resp</strong></td>
<td>↑ Bronchial smooth muscle response to circulating catecholamines, ↓ airway edema</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>↑ Inotropy, ↑ vascular smooth muscle response to circulating catecholamines (↑ receptor expression), ↑ BP secondary to mineralocorticoid effects</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Mood changes, sleep disturbance, psychosis</td>
</tr>
<tr>
<td><strong>MSK</strong></td>
<td>Atrophy, thinning of skin</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>Glycosuria, Na⁺ and fluid retention (mineralocorticoid effect), hypokalaemia</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>Gastric ulceration</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td>↑ Gluconeogenesis, diabetes, ↑ protein catabolism, fat redistribution, adrenal suppression (negative feedback on ACTH), ↑ lipolytic response to circulating catecholamines</td>
</tr>
<tr>
<td><strong>Immune</strong></td>
<td>↓ Transudate production, ↓ production of inflammatory mediators, ↓ macrophage function, ↓ transport of lymphocytes, ↓ T-cell function, ↓ antibody production, ↑ susceptibility to infection,</td>
</tr>
<tr>
<td><strong>Toxic Effects</strong></td>
<td>Relative steroid deficiency in adrenal suppressed individuals with infection or surgery</td>
</tr>
</tbody>
</table>

### Comparison of Corticosteroids

<table>
<thead>
<tr>
<th>Property</th>
<th>Hydrocortisone</th>
<th>Prednisolone</th>
<th>Methylprednisolone</th>
<th>Dexamethasone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Route of Administration</strong></td>
<td>IV/PO</td>
<td>PO</td>
<td>PO/IV/IM</td>
<td>IV</td>
</tr>
<tr>
<td><strong>Relative Dose Equivalents</strong></td>
<td>100mg</td>
<td>25mg</td>
<td>20mg</td>
<td>4mg</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>50% PO bioavailability</td>
<td>100% PO bioavailability</td>
<td></td>
<td>60% PO bioavailability</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>Variable protein binding depending on concentration, V₅ 0.5 L.kg⁻¹</td>
<td>Variable protein binding depending on concentration, V₅ 0.5 L.kg⁻¹</td>
<td>V₅ 1 L.kg⁻¹</td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>Hepatic</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Elimination</td>
<td>Elimination t₀.₅ is 2 hours</td>
<td>Elimination t₀.₅ is 3 hours</td>
<td>Elimination t₀.₅ is 3 hours</td>
<td>Elimination t₀.₅ is 4 hours</td>
</tr>
<tr>
<td>Relative mineralocorticoid effect</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**References**


Last updated 2019-07-18
# Pulmonary Vasodilators

<table>
<thead>
<tr>
<th>Property</th>
<th>Nitric Oxide</th>
<th>Iloprost</th>
<th>Sildenafil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Inorganic gas</td>
<td>Synthetic eicosanoid with prostacyclin activity</td>
<td>PHTN, erectile dysfunction</td>
</tr>
<tr>
<td>Uses</td>
<td>ARDS, RVF, PHTN</td>
<td>PHTN</td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Aluminium cylinders with 100/800ppm NO/N2</td>
<td>Synthetic analog of epoprostenol</td>
<td></td>
</tr>
<tr>
<td>Route of Administration</td>
<td>Inhaled</td>
<td>Inhaled</td>
<td>PO</td>
</tr>
<tr>
<td>Dosing</td>
<td>1-40ppm, via inspiratory limb of ventilator</td>
<td></td>
<td>20mg TDS</td>
</tr>
<tr>
<td>Absorption</td>
<td></td>
<td>40% PO bioavailability</td>
<td></td>
</tr>
<tr>
<td>Distribution</td>
<td>Avidly bound to Hb</td>
<td></td>
<td>95% protein bound, $V_D$ of 100L</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Metabolised to methaemoglobin and nitrite prior to reaching systemic circulation - $t_{1/2}$ of &lt; 5s</td>
<td>Metabolised to methaemoglobin and nitrite prior to reaching systemic circulation - $t_{1/2}$ of &lt; 5s</td>
<td>Hepatic by CYP450</td>
</tr>
<tr>
<td>Elimination</td>
<td></td>
<td></td>
<td>Faecal</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>Stimulates cGMP which reduces intracellular Ca$^{2+}$</td>
<td>Stimulates cAMP which reduces intracellular Ca$^{2+}$ and smooth muscle growth</td>
<td>Inhibits cGMP</td>
</tr>
<tr>
<td>Resp</td>
<td>Inhibits HPV, improves V/Q matching</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVS</td>
<td>↓ vascular resistance, ↓ PVR in ventilated alveoli and improving V/Q matching. ↑ Capillary permeability.</td>
<td>↑ BP with compensatory ↑ HR</td>
<td>↓ PVR</td>
</tr>
<tr>
<td>CNS</td>
<td>↑ CBF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haeme</td>
<td>Inhibits platelet aggregation. MetHb</td>
<td>Inhibits platelet aggregation</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Rebound pulmonary HTN on abrupt cessation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## References


Last updated 2019-07-18
Adrenergic Vasoactives

This covers the pharmacology of specific catecholamines and sympathomimetics. The synthesis of endogenous catecholamines is covered under adrenal hormones, whilst specifics of catecholamine receptor function is covered under adrenoreceptors.

Adrenergic drugs:

- Act via:
  - Dopamine (D)
  - Adrenoreceptors (α and β)
- Can be:
  - Direct-acting
    Stimulate the receptor.
  - Indirect-acting
    Stimulate the release of noradrenaline to cause effects.
- Classified as either:
  - Naturally-occurring catecholamines
  - Synthetic catecholamines
  - Synthetic sympathomimetics
    Drugs which act on adrenoreceptors but are not classified as catecholamines due to their chemical structure.

Comparison of Commonly Used Adrenergic Agents

<table>
<thead>
<tr>
<th>Properties</th>
<th>Noradrenaline</th>
<th>Adrenaline</th>
<th>Phenylephrine</th>
<th>Metaraminol</th>
<th>Ephedrine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Natural Catecholamine</td>
<td>Natural Catecholamine</td>
<td>Sympathomimetic phenylethylamine derivative</td>
<td>Synthetic sympathomimetic</td>
<td>Synthetic sympathomimetic</td>
</tr>
<tr>
<td>Uses</td>
<td>↑ SVR</td>
<td>Cardiac arrest, anaphylaxis, inotropy, chronotropy, adjunct in local anaesthetics</td>
<td>↑ SVR</td>
<td>↑ SVR</td>
<td>↑ SVR without ↓ in HR</td>
</tr>
<tr>
<td>Dosing</td>
<td>Start at 0.05µg/kg/min</td>
<td>Infusion starts at 0.01µg/kg/min</td>
<td>Bolus start at 50-100mcg</td>
<td>Bolus 0.5-2mg</td>
<td>3-6mg bolus</td>
</tr>
<tr>
<td>Route</td>
<td>IV</td>
<td>IV/IM/ETT/SC</td>
<td>IV/IM/SC</td>
<td>IV</td>
<td>IV</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear, colourless, light-sensitive solution. Sodium metabisulfite as excipient.</td>
<td>A clear, colourless solution typically at 0.1-1mg/ml</td>
<td>Clear, colourless solution at 100mcg/ml</td>
<td>Clear, colourless solution in ampoule at 10mg/ml, typically reconstituted to 0.5mg/ml</td>
<td>Clear, colourless solution in 30mg/ml ampoule</td>
</tr>
<tr>
<td>Absorption</td>
<td>IV only</td>
<td>Variable ETT and SC absorption</td>
<td>IM onset 15 minutes, duration up to 1 hour</td>
<td>IV only</td>
<td>IV or IM</td>
</tr>
<tr>
<td>Absorption Time</td>
<td>1½ 2min. Metabolised by mitochondrial MAO and</td>
<td>1½ 2min. Metabolised by mitochondrial MAO and</td>
<td>Some uptake into</td>
<td></td>
<td>Hepatic (not metabolised by MAO and COMT), giving ↓</td>
</tr>
</tbody>
</table>
Metabolism
COMT in liver, kidney, and blood to VMA and metadrenaline.
COMT within liver, kidney, and blood to VMA and metadrenaline.
Hepatic by MAO
adrenergic nerve endings
longer (10-60 minute) duration of action and a \( t_{1/2\beta} \) of 3-6 hours

Elimination
Pulmonary uptake of up to 25%. Urinary excretion of metabolites
Urinary excretion of metabolites
Renal of metabolites, \( t_{1/2\beta} \) 2-3 hours
50% unchanged in urine

Mechanism of action
\( \alpha >> \beta \)
\( \beta > \alpha \) at lower doses. At high doses \( \alpha \) effects dominate.
Direct \( \alpha \)
Direct and indirect (via ↑ NA release) \( \alpha \) agonism
\( \uparrow \) NA release (indirect \( \alpha_1 \)) and direct \( \alpha \) and \( \beta \) agonism

Respiratory
\( \uparrow \) MV, bronchodilation
\( \uparrow \) MV, bronchodilation
Bronchodilation

CVS
\( \uparrow \) SVR, \( \uparrow \) HR, \( \uparrow \) SVR and PVR, \( \uparrow \) BP, \( \uparrow \) CO, \( \uparrow \) myocardial O_2 consumption. Coronary vasodilation. Arrhythmogenic.
\( \uparrow \) SVR and BP, potential reflex bradycardia. Not arrhythmogenic.
\( \uparrow \) SVR/PVR, reflex bradycardia. Indirect \( \uparrow \) in coronary flow.
Direct and indirect (via NA release) \( \uparrow \) in HR, BP, and CO. Arrhythmogenic.

CNS
\( \uparrow \) Pain threshold, \( \uparrow \) MAC
\( \uparrow \) MAC, mydriasis.

MSK
Necrosis with extravasation
Necrosis with extravasation

Renal
\( \downarrow \) RBF
\( \downarrow \) RBF and \( \uparrow \) in sphincter tone
\( \downarrow \) RBF
\( \downarrow \) RBF

Metabolic
\( \uparrow \) BMR, \( \uparrow \) lipolysis, \( \uparrow \) gluconeogenesis and BSL, \( \uparrow \) Lactate. Initially \( \uparrow \) insulin secretion (\( \beta \)), then \( \downarrow \) (\( \alpha \))

GU
\( \downarrow \) Uterine blood flow and foetal bradycardia
\( \downarrow \) Uterine blood flow
\( \downarrow \) Uterine blood flow

Comparison of Less Common Adrenergic Agents

<table>
<thead>
<tr>
<th>Properties</th>
<th>Dopamine</th>
<th>Isoprenaline</th>
<th>Dobutamine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Natural Catecholamine</td>
<td>Synthetic Catecholamine</td>
<td>Synthetic Catecholamine</td>
</tr>
<tr>
<td>Uses</td>
<td>Haemodynamic support</td>
<td>Severe bradycardia</td>
<td>Stress testing, increasing CO</td>
</tr>
<tr>
<td>Dosing</td>
<td>Start 1µg/kg/min</td>
<td>Infusion from 0.5-10µg/min</td>
<td>0.5-20µg/kg/min</td>
</tr>
<tr>
<td>Route</td>
<td>IV</td>
<td>IV</td>
<td>IV</td>
</tr>
</tbody>
</table>
**Presentation**
- Clear, colourless solution with 200mg or 800mg in water
- Clear solution at 1mg/ml
- 250mg dobutamine in 20ml water

**Metabolism**
- $t_{1/2}$ 3 min. 25% of dose converted to noradrenaline. Remainder is metabolised by MAO and COMT similar to noradrenaline.
- Hepatic by COMT
- $t_{1/2}$ 2 min. COMT to inactive metabolites.

**Elimination**
- Renal, $t_{1/2} \beta$ 3 minutes
- Urinary excretion of unchanged drug and metabolites

**Mechanism of action**
- $D_1$, $D_2$; $\beta > \alpha$ at lower dose
- $\beta_1 > \beta_2$
- $\beta_1 > > \beta_2$, $D_2$

**Respiratory**
- Potent bronchodilation
- Bronchodilation

**CVS**
- $^\dagger$ Inotropy, $^\dagger$ HR, $^\dagger$ CO, coronary vasodilation. At high doses, $^\dagger$ SVR and PVR, $^\dagger$ VR.
- $^\dagger$ SVR, potential reflex bradycardia. Not arrhythmogenic.
- $^\dagger$ HR, CO, contractility, and automaticity. $B_2$ effects may $\downarrow$ SVR and BP.

**CNS**
- Inhibits prolactin. Nausea.
- Stimulant
- Tremor

**MSK**
- Necrosis with extravasation

**Renal**
- $^\dagger$ RBF and $^\dagger$ urinary output with no improvement in renal function

**GIT**
- Mesenteric vasodilation

---

**Structure-Activity Relationships of Sympathomimetics**

![Beta Carbon Diagram]

Catecholamines consist of:
- A catechol ring
  - A benzene ring with two hydroxyl groups in the 3 and 4 position.
  - Losing one hydroxyl group
    - Increases lipid solubility and decreases the potency 10-fold
- Prevents metabolism by COMT, prolonging duration of action
- Losing both hydroxyl groups decreases the potency 100-fold
  - Changing the hydroxyl groups to the 3 and 5 position increases beta-2 selectivity when there is also a large substitution present on the amine group

- An ethylamine tail
  Consists of:
  - Beta carbon
    The first carbon.
    - Adding a hydroxyl group decreases lipid solubility and CNS penetration
    - Adding any group increases alpha and beta selectivity
  - Alpha carbon
    The second carbon.
    - Adding a group prevents metabolism by MAO, prolonging duration of action
    - Methylation increases indirect activity
  - Amine group
    The terminal nitrogen.
    - Addition of a methyl group generally increases beta selectivity
      As the chain length increases, so does the beta selectivity.

**Dopamine**

![Dopamine Diagram]

- Dopamine is the prototypical catecholamine, to which others are compared

**Noradrenaline**
Noradrenaline has a hydroxyl group added to the beta carbon, increasing its alpha selectivity

Adrenaline

Adrenaline is similar to noradrenaline with an additional hydroxyl group on the beta carbon
Adrenaline also has a methyl group added to the terminal amine, increasing beta selectivity

Metaraminol
Metaraminol has an additional hydroxyl group on the beta carbon. Metaraminol has only one hydroxyl group on the phenol ring, so:

- It is no longer classified as a catecholamine
- It is not metabolised by COMT, prolonging its duration of action
- It has reduced potency, requiring administration in higher doses

Metaraminol has an additional methyl group on the alpha carbon, preventing metabolism by MAO and further prolonging its duration of action.

**Ephedrine**

- Like metaraminol, ephedrine has a hydroxyl group on the beta carbon and a methyl group on the alpha carbon
- Ephedrine has no hydroxyl groups on the phenol ring, further reducing its potency and increasing its elimination half-life
- Ephedrine has a methyl group on the amine, increasing its beta selectivity

**References**

3. Yartsev A. Deranged Physiology - Structure of Synthetic Catecholamines

Last updated 2019-07-18
Non-Adrenergic Vasoactives

Key non-adrenergic cardiovascular drugs include vasopressin (and its analogues, terlipressin and ornipressin), phosphodiesterase III inhibitors such as milrinone, and calcium sensitiser such as levosimendan.

<table>
<thead>
<tr>
<th>Property</th>
<th>Vasopressin (ADH)</th>
<th>Milrinone</th>
<th>Levosimendan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Natural nonapeptide</td>
<td>Phosphodiesterase III inhibitor</td>
<td>Calcium sensitiser and phosphodiesterase inhibitor</td>
</tr>
<tr>
<td>Uses</td>
<td>Haemorrhage, DI, catecholamine-sparing vasopressor</td>
<td>Refractory CCF and low CO states</td>
<td>Severe acute heart failure</td>
</tr>
<tr>
<td>Dosing</td>
<td>5-10 units IV bolus, up to 4U/hr infusion</td>
<td>Load 12-24mcg/kg over 10min, then infusion at 0.05-2mcg/kg/min</td>
<td></td>
</tr>
<tr>
<td>Route</td>
<td>IV/SC/IM</td>
<td>IV</td>
<td>IV</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear solution</td>
<td>Yellow solution at 1mg/ml</td>
<td>2.5mg/mL in 5ml &amp; 10ml vials</td>
</tr>
<tr>
<td>Distribution</td>
<td>70% protein bound</td>
<td>Very high protein binding &gt;90%</td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>t1/2 10 minutes. Metabolised by tissue peptidases and renal elimination.</td>
<td>t1/2 1-2.5 hours</td>
<td>t1/2 1 hour. Hepatic to active metabolite with a t1/2 ~70 hours</td>
</tr>
<tr>
<td>Elimination</td>
<td>80% of drug is excreted unchanged</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanism of action</td>
<td>V₂ receptors (kidney, platelets) are adenylate cyclase mediated. V₁ (vascular smooth muscle) and V₃ receptors (pituitary) are phospholipase C/inositol triphosphate mediated</td>
<td>Inhibits phosphodiesterase breakdown of cAMP, increasing intracellular Ca²⁺ levels. Also increases speed of Ca²⁺ uptake into cardiac muscle, increasing lusitropy.</td>
<td>Binds to troponin C increasing myofilament Ca²⁺ sensitivity. Also opens K⁺ channels causing vasodilation. It may also have some PD III inhibition effect.</td>
</tr>
<tr>
<td>CVS</td>
<td>↑ SVR through vasoconstriction</td>
<td>Increased inotropy, increased lusitropy, decreased SVR and PVR (PVR decreases more than SVR). Increased dysrhythmias.</td>
<td>Increased CO without increased O₂ demand, vasodilation, prolonged QTc with risk of arrhythmia</td>
</tr>
<tr>
<td>GIT</td>
<td>GIT smooth muscle contraction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>↑ Aquaporin insertion into the apical membrane of collecting ducts which ↑ water reabsorption</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematological</td>
<td>↑ Coagulation factor mobilisation and ↑ platelet aggregation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic</td>
<td>Hyponatraemia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

References

Last updated 2019-07-18
Centrally Acting Anti-Hypertensives

<table>
<thead>
<tr>
<th>Property</th>
<th>Clonidine</th>
<th>Methyldopa</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Central α₂-agonist (200:1 α₂:α₁)</td>
<td>Phenylalanine derivative</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Analgesia, sedation, anti-hypertensive</td>
<td>Antihypertensive (especially in pregnancy)</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Clear colourless solution at 150μg.ml⁻¹</td>
<td>Tablets - not appropriate for urgent blood pressure reduction</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO/IV at 10-200mcg up to QID. Can be added to neuraxial blockade at 1-2mcg.kg⁻¹ to decrease opioid requirement.</td>
<td>PO/IV.</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>50-200μg QID.</td>
<td>250-500mg PO BD/TDS.</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>100% PO bioavailability with rapid absorption</td>
<td>Highly variable PO bioavailability</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>20% bound, V_D 2L.kg⁻¹</td>
<td>50% protein bound, V_D 0.3L.kg⁻¹</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>50% hepatic to inactive metabolites, t₁/₂β 9-18 hours</td>
<td>Intestinal and hepatic</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>50% renal elimination unchanged</td>
<td>40% renal elimination unchanged</td>
</tr>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Agonist of central α2 receptor, ↓ SNS tone via decreased NA release from peripheral nerve terminals.</td>
<td>Metabolised to α-methyl-noradrenaline in the CNS, which agonises central α2 receptors.</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>Initial ↑ in BP due to α₁ stimulation, evident with bolus dosing. Followed by prolonged ↓ in BP, ↑ PR, ↓ AV conduction, ↑ baroreceptor sensitisation (lower HR for a given increase in BP). Cessation may cause rebound HTN.</td>
<td>↓ SVR with unchanged HR or CO</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Sedation, analgesia due to ↓ NA release which ↓ opioid requirement. Adjunct in chronic pain and in opioid withdrawal. Anxiolysis at low doses. Central antiemetic effect.</td>
<td>May ↓ MAC</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td>Stress response to surgical stimulus is inhibited</td>
<td></td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>Diuresis secondary to inhibition of ADH</td>
<td></td>
</tr>
</tbody>
</table>

References


Last updated 2017-09-12
Calcium Channel Blockers

Ca\(^{2+}\)-channel blockers:

- Have affinity for L-type calcium channels
  - L-type channels exist in myocardium, nodal, and vascular smooth muscle.
  - Variable affinity for each causes a preference for either nodal and inotropic, or vascular effects
- Prevent Ca\(^{2+}\) entry into cells in a use-dependent fashion

<table>
<thead>
<tr>
<th>Class</th>
<th>Chemical Structure</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>Phenylalkylamines</td>
<td>Verapamil</td>
</tr>
<tr>
<td>Class II</td>
<td>Dihydropyridines</td>
<td>Nifedipine, amlodipine, nimodipine</td>
</tr>
<tr>
<td>Class III</td>
<td>Benzothiazepines</td>
<td>Diltiazem</td>
</tr>
</tbody>
</table>

Comparison of Calcium Channel Blockers

<table>
<thead>
<tr>
<th>Property</th>
<th>Verapamil</th>
<th>Amlodipine</th>
<th>Diltiazem</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Phenylalkylamine</td>
<td>Dihydropyridine</td>
<td>Benzothiazepine</td>
</tr>
<tr>
<td>Uses</td>
<td>SVT, excluding AF with WPW</td>
<td>HTN, Angina</td>
<td>Angina, HTN, SVT, Raynaud's, migraine, oesophageal dysmotility</td>
</tr>
<tr>
<td>Presentation</td>
<td>20-240mg tablet, PO solution, IV at 2.5mg.ml(^{-1})</td>
<td>Tablet</td>
<td>Tablet</td>
</tr>
<tr>
<td>Isomerism</td>
<td>Racemic preparation. The D-isomer also has some local anaesthetic activity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO/IV</td>
<td>PO</td>
<td>PO</td>
</tr>
<tr>
<td>Dosing</td>
<td>80-160mg BD/TDS</td>
<td>2.5-10mg daily</td>
<td>30-120mg TDS</td>
</tr>
<tr>
<td>Absorption</td>
<td>20% bioavailability</td>
<td>60% bioavailability</td>
<td>40% bioavailability</td>
</tr>
<tr>
<td>Distribution</td>
<td>90% protein bound</td>
<td>90% protein bound, lipid insoluble.</td>
<td>80% protein bound</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic to active norverapamil</td>
<td>Hepatic to inactive metabolites</td>
<td>Hepatic to active metabolites</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of active metabolites</td>
<td>Renal of inactive metabolites</td>
<td>Renal of active metabolites. t(_{1/2}) 2-7 hours</td>
</tr>
<tr>
<td>CVS</td>
<td>↓ HR via SA and ↓ AV nodal conduction, ↓ inotropy, ↓ SVR, ↓ BP, arrhythmia including HB</td>
<td>↓ SVR, ↓ BP, with reflexive ↑ HR, ↑ inotropy, ↑ CO</td>
<td>↓ AV nodal conduction but typically stable HR, ↓ SVR, ↓ CVS, ↓ MVO(_2), ↑ CO</td>
</tr>
<tr>
<td>CNS</td>
<td>↓ Cerebral vascular resistance</td>
<td>↓ Cerebral vascular resistance with nimodipine</td>
<td></td>
</tr>
<tr>
<td>GIT</td>
<td></td>
<td>↓ LOS tone</td>
<td></td>
</tr>
<tr>
<td>Interactions</td>
<td>Contraindicated with concurrent β-blocker use due to profound ↓ HR, ↓</td>
<td>Contraindicated with concurrent β-blocker use due to profound ↓</td>
<td></td>
</tr>
</tbody>
</table>
References


Last updated 2019-07-18
Direct Vasodilators

Direct vasodilators include:

- **Ca$^{2+}$ channel blockers** (see Calcium Channel Blockers)
- **Nitrates**
  
  Increase production of NO:
  - NO activates guanylate cyclase, increasing cGMP
  - cGMP inhibits Ca$^{2+}$ uptake into smooth muscle and enhances its sequestration into smooth endoplasmic reticulum
  
  The decrease in cytoplasmic [Ca$^{2+}$] causes smooth muscle relaxation and vasodilation

- **Hydralazine**
  
  Multimodal mechanism of action, including:
  - Opens K$^+$ channels, hyperpolarising vascular smooth muscle
  - Decreases intracellular Ca$^{2+}$ in vascular smooth muscle
  - Activation of guanylate cyclase

<table>
<thead>
<tr>
<th>Property</th>
<th>Sodium Nitroprusside</th>
<th>GTN</th>
<th>Hydralazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Inorganic Nitrate</td>
<td>Organic Nitrate</td>
<td>Direct vasodilator</td>
</tr>
<tr>
<td>Uses</td>
<td>Afterload (with some preload) reduction</td>
<td>Afterload &amp; preload reduction, angina</td>
<td>HTN</td>
</tr>
<tr>
<td>Presentation</td>
<td>Solution at 10mg.ml$^{-1}$, must be protected from light</td>
<td>Spray, tablets, patch, IV solution which is absorbed into PVC - requires a polyethylene administration set</td>
<td>20mg ampoule or powder. Should not be reconstituted with dextrose.</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV only</td>
<td>IV, topical, sublingual</td>
<td>PO, IV</td>
</tr>
<tr>
<td>Dosing</td>
<td>0.5-6µg.kg$^{-1}$.min$^{-1}$</td>
<td>10-200µg.min$^{-1}$</td>
<td>5-20mg IV</td>
</tr>
<tr>
<td>Absorption</td>
<td>&lt;5% PO bioavailability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>Prodrug. Reacts with Oxy-Hb in RBC to form 1x NO, 5x CN$^-$, and MetHb. MetHb reacts with CN to form cyanomethaemoglobin. CN is metabolised in the liver and kidney to form SCN, the majority of which is excreted in urine (though may be reconverted to CN). CN may also combine with hydroxocobalamin (vitamin B$_{12}$) to form cyanocobalamin, which is eliminated in urine.</td>
<td>Prodrug. Metabolised to NO and glycerol dinitrate (which is then also converted to NO) in the liver.</td>
<td>N-acetylated in gut and liver</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of SCN and cyanocobalamin. Impaired in renal failure which may worsen CN toxicity. $t_{1/2}$ for SCN is 2-7 days</td>
<td>$t_{1/2}$ 1-4mins. Urinary excretion</td>
<td>Dependent on acetylation rates</td>
</tr>
<tr>
<td>Resp</td>
<td>Inhibit hypoxic pulmonary vasoconstriction leading to ↑ shunt</td>
<td>Bronchodilation</td>
<td></td>
</tr>
</tbody>
</table>

588
CNS decreases cerebrovascular resistance, increases cerebral blood flow.

CNS: following cerebral vasodilatation

Haematological: Methaemoglobinemia, Methanoglobinemia

Toxic Effects: Three mechanisms: hypotension, thiocyanate toxicity, CN toxicity.

Cyanide toxicity occurs only with SNP, as CN\(^{-}\) is produced as a byproduct of metabolism.

<table>
<thead>
<tr>
<th>Nitrate Toxicity</th>
</tr>
</thead>
</table>

Nitrate toxicity can be related to:

- Cyanide
- Thiocyanate
- Methaemoglobinemia

Cyanide Toxicity

Cyanide toxicity occurs only with SNP, as CN\(^{-}\) is produced as a byproduct of metabolism.

- **Kinetics**
  - Rapid cellular uptake
  - Small V\(_D\)
  - Hepatically metabolised to thiocyanate, using thiosulfate as a substrate

- **Mechanism**
  CN\(^{-}\) binds to cytochrome oxidase, preventing oxidative phosphorylation. This causes histotoxic hypoxia, and is characterised by:
  - Rapid loss of consciousness and seizures
  - Metabolic acidosis
  - Lactataemia
  - Arrhythmia
  - Increased MVO\(_2\)
  - Hypertension
    - Due to tachyphylaxis to SNP

- **Risk of cyanide toxicity from SNP is related to:**
  - Infusion rate
  - Infusion duration

- **Management**
  - Supportive care, including inotropes
  - Cyanide chelators: Bind CN\(^{-}\), removing it from the circulation. Include:
    - Dicobalt edetate
    - Hydroxycobalamin (Vitamin B\(_{12}\))
    - Sulfur donors

Increased CBF

Methaemoglobinemia can occur with GTN.

GTN patches may **explode** if left on during DC cardioversion.
Provide additional sulphydryl groups, allowing further hepatic metabolism of CN\(^-\) to SCN. Include:
- **Thiosulfate**
- **Nitrites**
  Converts Oxy-\(\text{Hb}\) to Met-\(\text{Hb}\), which has a higher affinity for CN\(^-\) than cytochrome oxidase. Include:
  - Sodium nitrite
  - Amyl nitrite

### Thiocyanate Toxicity

Thiocyanate is produced with hepatic metabolism of CN\(^-\). Toxicity occurs when thiocyanate accumulates, which occurs in:

- Long duration SNP infusions
  7-14 days.
- Patients with renal failure
  Reduced clearance, may occur in 3-6 days.
- Patients given thiosulfate for management of CN\(^-\) toxicity.

- **Effects**
  Multisystemic, including:
  - Rash
  - Abdominal pain
  - Weakness
  - CNS disturbance

- **Treatment**
  - Dialysis

### Methaemoglobinemia

Methaemoglobinemia occurs when the \(\text{Fe}^{2+}\) (ferrous) ion in haemoglobin is oxidised to the \(\text{Fe}^{3+}\) (ferric) form, which is *unable* to bind oxygen.

- Due to the high concentration of oxygen in erythrocytes, methaemoglobin is continually being formed
- Several endogenous reduction systems exist to keep MetHb levels stable at \(~1\%\)
  - Predominantly cytochrome-b\(_5\) reductase
  - NADPH-MHb reductase
  - This reduces methaemoglobinemia in the presence of a reducing agent, classically *methylene blue*.
  - Reduced glutathione
    - More important in preventing oxidative stress in other cells than the RBC.
- Disease occurs due to the *loss* in oxygen-carrying capacity from the *loss* of effective haemoglobin
  - E.g. a 20% MetHb level gives a *theoretical* oxygen carrying capacity of 80% of the actual haemoglobin
  - There is in fact a slight left shift of the *oxyhaemoglobin dissociation curve*, as oxygen binds more tightly to the partially-oxidised haemoglobin.

### References

4. CICM September/November 2008
5. LITFL- Cyanide Poisoning


Last updated 2019-07-18
Angiotensin Converting Enzyme Inhibitors

ACE inhibitors prevent the conversion of angiotensin I to angiotensin II by angiotensin converting enzyme (ACE) in the lungs, in turn reducing effects of angiotensin II. These effects include:

- Vasoconstriction
- Noradrenaline reuptake inhibition
- Thirst
- ADH release
- ACTH release
- Aldosterone release
- Reduces Kf, reducing GFR

Indications

- **Hypertension**
  - Particularly in insulin dependent diabetes with diabetic nephropathy
  - Less effective for this indication in the black population
  - Contribute to post-operative hypertension and may be withheld perioperatively

- **Cardiac failure**
  - All grades.

- **MI with LV dysfunction**
  - Improved prognosis.

Classification

Can be divided into three groups based on pharmacokinetics:

- **Active drug with active metabolites**
  - Captopril.
- **Prodrug**
  - Ramipril.
- **Not metabolised and excreted unchanged in urine**
  - Lisinopril.

Common Features of ACE Inhibitors

<table>
<thead>
<tr>
<th>Property</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resp</td>
<td>Bradykinin cough</td>
</tr>
<tr>
<td>CVS</td>
<td>↓ SVR and BP. Unaffected HR and baroreceptor response.</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Hypoglycaemia in diabetics</td>
</tr>
<tr>
<td>Renal</td>
<td>With a normal renal perfusion pressure, natriuresis results. However, a fall in renal perfusion pressure may cause pre-renal failure (e.g. renal artery stenosis).</td>
</tr>
<tr>
<td>Haeme</td>
<td>Agranulocytosis, thrombocytopenia</td>
</tr>
<tr>
<td>Immune</td>
<td>Angioedema</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Metabolic</td>
<td>↑ Renin release.</td>
</tr>
<tr>
<td>Interactions</td>
<td>↓ Aldosterone release, which ↑ the efficacy of spironolactone and may precipitate hyperkalaemia. Pharmacodynamic interaction with NSAIDs to drop renal perfusion pressure.</td>
</tr>
</tbody>
</table>

**References**


Last updated 2019-11-02
Angiotensin Receptor Blockers

Angiotensin receptor antagonists are very similar to ACE inhibitors, except:

- Bradykinin does not accumulate as it is still broken down by ACE.
  Therefore there is no cough and patient compliance is improved.
- The $AT_1$ receptor in cardiac tissue is more comprehensively blocked which may improve cardiac outcomes
- The $AT_2$ receptor is not blocked, which may also improve cardiac outcomes

References


Last updated 2017-07-27
Potassium Channel Activators

Potassium channel activators stimulate ATP sensitive K⁺ channels, causing an increase in intracellular cGMP and subsequent relaxation of smooth muscle in the:

- Heart
- Venous capacitance vessels
- Arterioles

<table>
<thead>
<tr>
<th>Property</th>
<th>Nicorandil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uses</td>
<td>HTN, angina, CHF</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO</td>
</tr>
<tr>
<td>Dosing</td>
<td>10-30mg BD</td>
</tr>
<tr>
<td>Absorption</td>
<td>80% PO bioavailability</td>
</tr>
<tr>
<td>Distribution</td>
<td>Negligible protein binding</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic denitration</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of active drug and metabolites</td>
</tr>
<tr>
<td>CVS</td>
<td>↓ Preload, ↓ afterload, ↓ BP, ↑ coronary flow</td>
</tr>
<tr>
<td>CNS</td>
<td>Headache, improves with ongoing use</td>
</tr>
<tr>
<td>Haeme</td>
<td>Inhibition of platelet aggregation</td>
</tr>
</tbody>
</table>

References


Last updated 2017-09-22
# Sodium Channel Blockers

Sodium channel blockers include:

- **Class Ia:**
  - Procainamide
  - Quinidine
  - Disopyramide
- **Class Ib:**
  - Lignocaine
  - Mexiletine (lignocaine analogue)
- **Class Ic:**
  - Flecainide

In general:

- IV preparations are given for VT
- Good PO bioavailability and low protein binding
- Metabolites are renally cleared

<table>
<thead>
<tr>
<th>Property</th>
<th>Procainamide</th>
<th>Lignocaine</th>
<th>Flecainide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Class Ia amide</td>
<td>Class Ib amide local anaesthetic</td>
<td>Class Ic amide local anaesthetic</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>SVT/VT</td>
<td>VT</td>
<td>SVT/VT</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Clear solution at 10-20mg.ml⁻¹ (1-2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO/IV</td>
<td>IV</td>
<td>PO/IV</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>100mg IV load, followed by infusion at 2-6mg.ml⁻¹</td>
<td>Load at 1mg.kg⁻¹ followed by infusion at 1-3mg.min⁻¹</td>
<td>2mg.kg⁻¹ (up to 150mg) load over 10-30 minutes, followed by infusion at 1.5mg.kg⁻¹.hr⁻¹, aiming for levels of &lt;0.9mg/ml</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>75% bioavailability</td>
<td>IV only for arrhythmia</td>
<td>90% orally bioavailable</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>Hepatic to active metabolites via acetylation - slow acetylators at increased risk of side effects</td>
<td>Hepatic amidases to inactive metabolites</td>
<td>Hepatic to active metabolites</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Reduces the rate of rise of phase 0, raises the threshold potential, and prolongs the refractory period without prolonging the action potential</td>
<td>Reduces the rate of rise of phase 0 of the action potential. Repolarisation phase is shortened.</td>
<td>Reduces the rate of rise of phase 0 of the action potential. Repolarisation is unchanged.</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>↓ HR, ↓ SVR, ↓ BP, ↓ CO, heart block, may ↑ HR when used for SVT, ↑ QT with risk of TDP</td>
<td>AV block, myocardial depression causing unresponsive ↓ BP</td>
<td>Precipitate pre-existing conduction disorders, ↓ inotropy, ↑ pacing and defibrillation threshold</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Circumoral tingling, dizziness, paraesthesia, confusion, seizures, coma</td>
<td>Dizziness, paraesthesia, headache</td>
<td></td>
</tr>
<tr>
<td>Immune</td>
<td>Lupoid syndrome in 20-30%, reduces antimicrobial effect of sulfonamides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------------------------------</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Interactions</td>
<td></td>
<td>Pharmacokinetic interactions with digoxin, propranolol, amiodarone</td>
<td></td>
</tr>
</tbody>
</table>

**References**


Last updated 2019-07-18
Beta-Blockers

β-blockers are competitive (often highly selective) antagonists of β-adrenoceptors. They are sub-classified into selective and non-selective agents:

- Selective (β₁ antagonism) (BEAM)
  - Bisoprolol
  - Esmolol
  - Atenolol
  - Metoprolol
- Non-selective (β₁ and β₂ antagonism)
  - Propranolol
  - Sotalol
  - Timolol
- Non-selective (β & α antagonism)
  - Carvedilol
  - Labetalol

Indications

- Cardio
  - Angina
  - Arrhythmia
    - Rate-control in AF
    - Paroxysmal SVT
    - Sinus tachycardia from ↑ catecholamines
  - Cardiac Failure
  - Secondary prevention for MI
- Vascular
  - Hypertension (2nd line)
    - Also useful for aggressive control of BP.
  - Hypotensive anaesthesia
  - Attenuate hypertensive response to laryngoscopy
- Non-CVS
  - Thyrotoxicosis
  - Glaucoma (topically)
  - Anxiety
  - Migraine prophylaxis

Common Features

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kinetics</td>
<td>Variability primarily due to lipid solubility. Poor lipid solubility confers poor gut absorption and minimises need for hepatic metabolism. Lipid soluble agents will have CNS effects and be excreted in breast milk.</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Bronchospasm.</td>
</tr>
<tr>
<td>Property</td>
<td>Esmolol</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Class</td>
<td>Cardioselective</td>
</tr>
<tr>
<td>Uses</td>
<td>Short-term treatment of tachyarrhythmia and HTN</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear, colourless solution</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV</td>
</tr>
<tr>
<td>Dosing</td>
<td>50-200μg.kg⁻¹.min⁻¹</td>
</tr>
<tr>
<td>Absorption</td>
<td>IV only</td>
</tr>
<tr>
<td>Distribution</td>
<td>60% protein bound</td>
</tr>
<tr>
<td>Metabolism</td>
<td>RBC esterases to an inactive metabolite and methyl alcohol. t1/2 of 10 minutes</td>
</tr>
</tbody>
</table>

**Comparison of Beta Blockers**

**CVS**
- ↓ Inotropy, ↓ HR, ↓ MVO₂, ↓ BP, ↑ SVR (β₂ effect), worsen arrhythmia.

**CNS**
- Tiredness, nightmares, and sleep disturbance with lipid soluble agents. ↓ IOP.

**Metabolic**
- ↓ Insulin release and blunted hypoglycaemic response (β₂ effect).

**Interactions**
- Contraindicated with cardioselective Ca²⁺ channel blockers, due to extreme ↓ HR & ↓ inotropy.
<table>
<thead>
<tr>
<th>Elimination</th>
<th>Renal elimination of active drug</th>
<th>Renal elimination of metabolites</th>
<th>elimination inactive metabolit</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>Venous irritant</td>
<td></td>
<td>↓ SVR, ↓ HR, ↓ CO when given acutely</td>
</tr>
<tr>
<td>CNS</td>
<td></td>
<td></td>
<td>Orthostat dizziness</td>
</tr>
</tbody>
</table>

## References

1. Leslie RA, Johnson EK, Goodwin APL. Dr Podcast Scripts for the Primary FRCA. Cambridge University Press. 2011.

Last updated 2019-07-18
Amiodarone

Amiodarone is an antiarrhythmic agent with a complex mechanism of action and many effects.

- $K^+$ channel blockade in cardiac myocytes, inhibiting the slow outward current and slowing repolarisation (Class III)
- $\beta$-blocker-like activity on SA and AV nodes, decreasing automaticity and slowing nodal conduction (Class II)
- $Ca^{2+}$ channel blocker-like activity on L-type $Ca^{2+}$ channels, decreasing the slow inward $Ca^{2+}$ current, increasing depolarisation time and decreasing nodal conduction (Class IV)
- $\alpha$-blocker-like activity, decreasing SVR

<table>
<thead>
<tr>
<th>Property</th>
<th>Amiodarone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Class III antiarrhythmic, though exhibits action from all 4 classes.</td>
</tr>
<tr>
<td>Uses</td>
<td>VT/VE, resistant arrhythmia, ALS.</td>
</tr>
<tr>
<td>Presentation</td>
<td>100/200mg tablets, IV: 150mg ampoule to be reconstituted in D5W.</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV/PO.</td>
</tr>
<tr>
<td>Dosing</td>
<td>IV: Load with 5mg.kg$^{-1}$ over 1/24, with a further 15mg.kg$^{-1}$ over the following 24/24 PO: 200mg TDS for 1/52, 200mg BD for 1/52, 200mg OD thereafter.</td>
</tr>
<tr>
<td>Absorption</td>
<td>Poor PO absorption with bioavailability ~50%.</td>
</tr>
<tr>
<td>Distribution</td>
<td>Highly protein bound with very high $V_D$ of ~70L.kg$^{-1}$ due to accumulation in fat and muscle.</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic metabolism with inhibition of CYP3A4, to the active desmethylamiodarone.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Very long $t_{1/2}$ of up to ~55 days. Biliary, skin, and lacrimal elimination, with &lt; 5% of drug eliminated renally. Not removed by dialysis.</td>
</tr>
<tr>
<td>Resp</td>
<td>10% 3-year risk of pneumonitis, fibrosis, pleuritis.</td>
</tr>
<tr>
<td>CVS</td>
<td>↓ HR, ↓ BP, ↓ SVR, ↑ QT without risk of TDP. Irritant to peripheral veins.</td>
</tr>
<tr>
<td>CNS</td>
<td>Mild blurring of vision from corneal deposition, sleep disturbance, vivid dreams, peripheral neuropathy.</td>
</tr>
<tr>
<td>MSK</td>
<td>Photosensitivity, grey skin.</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Hyperthyroidism (1%) and hypothyroidism (6%).</td>
</tr>
<tr>
<td>GIT</td>
<td>Nausea, vomiting, cirrhosis, hepatitis, and jaundice.</td>
</tr>
<tr>
<td>Other</td>
<td>Amiodarone has potential to cause a number of drug interactions due to its inhibition of CYP3A4 and its high protein binding. A selection include: Digoxin, statins, warfarin, phenytoin, and other antiarrhythmics. Contraindicated in porphyria.</td>
</tr>
</tbody>
</table>

A mnemonic for some of the rarer effects is BITCH:  
- Blue skin  
- Interstitial lung disease  
- Thyroid  
- Corneal  
- Hepatic
References


Last updated 2019-07-18
Sotalol

The D-isomer of sotalol is a **class III antiarrhythmic**, whilst the L-isomer also has **class II activity**.

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Class III antiarrhythmic</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Tachyarrhythmia prophylaxis</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Solution at $10\text{mg}\cdot\text{ml}^{-1}$ and tablets</td>
</tr>
<tr>
<td><strong>Isomerism</strong></td>
<td>Racemic mixture</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO/IV</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>PO: 40-160mg BD IV: 50-100mg over 20 minutes</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>&gt;90% bioavailability</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>No protein binding</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Not metabolised</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Excreted unchanged in urine</td>
</tr>
<tr>
<td><strong>Resp</strong></td>
<td>Bronchospasm</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>Torsades (&lt;2%) - more common with high doses, long QT, and electrolyte imbalances</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Masking symptoms of hypoglycaemia</td>
</tr>
<tr>
<td><strong>GU</strong></td>
<td>Sexual dysfunction</td>
</tr>
</tbody>
</table>

**References**


Last updated 2019-07-18
Digoxin

Digoxin is a cardiac glycoside used in the treat of atrial arrhythmias and in cardiac failure as a positive inotrope.

Digoxin has both a direct and indirect mechanism of action:

- **Direct**
  - Inhibits cardiac Na\(^+\)/K\(^+\) ATPase, causing:
    - Increasing intracellular [Na\(^+\)], increasing activity of the Na\(^+\)/Ca\(^{2+}\) pump
    - Increased intracellular Ca\(^{2+}\) increases inotropy
    - Decreased K\(^+\) results prolongs refractory period of the AV node and bundle of His

- **Indirect**
  - Parasympathomimetic effects by increasing ACh release at cardiac muscarinic receptors.
    - Slows AV nodal conduction and ventricular response
    - This improves coronary blood flow, increasing time for ventricular filling, and improving cardiac output.

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Cardiac Glycoside</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Arrhythmia - particularly AF/Flutter, and CCF</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Tablets, elixir, clear colourless solution</td>
</tr>
<tr>
<td><strong>Route of</strong></td>
<td>PO/IV</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>PO: 62.5μg-250μg, IV: 250-500μg load</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>&gt;70% bioavailability though varies with formulation</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>25% protein bound. V(_D) 5-11L.kg(^{-1}), dependent on lean mass</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Minimal hepatic metabolism</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal elimination of active metabolites t(_{1/2}) 35 hours - increased in renal failure</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>↓ HR, ↑ inotropy, arrhythmias including; bigeminy, PVCs, 1(^{st}), 2(^{nd}), 3(^{rd}) degree AV block, SVT, VT</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Deranged red-green colour perception, visual disturbances, headache</td>
</tr>
<tr>
<td><strong>Immune</strong></td>
<td>Eosinophilia and rash</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td>Gynaeecomastia</td>
</tr>
<tr>
<td><strong>Toxic Effects</strong></td>
<td>Narrow TI. Severe arrhythmia with DC cardioversion</td>
</tr>
</tbody>
</table>

**Interactions**

<table>
<thead>
<tr>
<th>Interaction</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased level</td>
<td>Amiodarone, captopril, erythromycin, verapamil</td>
</tr>
<tr>
<td>Decreased level</td>
<td>Antacids, cholestyramine, phenytoin, metoclopramide</td>
</tr>
</tbody>
</table>

**References**

Last updated 2018-09-21
Adenosine

Adenosine acts via $A_1$ adenosine receptors in the SA and AV node, which when stimulated open $K^+$ channels causing hyperpolarisation and a reduction in $Ca^{2+}$ current, with subsequent blockade of AV nodal conduction.

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Naturally occurring purine nucleoside</td>
</tr>
<tr>
<td>Uses</td>
<td>SVT</td>
</tr>
<tr>
<td>Presentation</td>
<td>Colourless solution at $3mg.ml^{-1}$</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV</td>
</tr>
<tr>
<td>Dosing</td>
<td>$3mg/6mg/12mg$ in increasing doses</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Rapidly deaminated in plasma. $t_{1/2} &lt; 10s$</td>
</tr>
<tr>
<td>Resp</td>
<td>Bronchospasm, ↑ RR and $V_{T}$</td>
</tr>
<tr>
<td>CVS</td>
<td>↓ ↓ AV nodal conduction, may cause AF/lutter</td>
</tr>
<tr>
<td>Toxic Effects</td>
<td>Contraindicated in sick-sinus syndrome, $2^{nd}/3^{rd}$ degree AV block</td>
</tr>
</tbody>
</table>

**Interactions**

<table>
<thead>
<tr>
<th>Interaction</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased</td>
<td>Dipyridamole</td>
</tr>
<tr>
<td>Decreased</td>
<td>Methylxanthines, such as aminophylline and caffeine</td>
</tr>
</tbody>
</table>

**References**


Last updated 2017-07-27
Magnesium

Mg$^{2+}$ is a cation that is important for neurotransmission and neuromuscular excitability. Magnesium:

- Inhibits ACh release at the NMJ
- Acts a cofactor in multiple enzyme systems
- Is important in the production of:
  - ATP
  - DNA
  - RNA

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uses</td>
<td>HypoMg, arrhythmia, eclampsia, tocolysis, barium poisoning, asthma, tetanus, autonomic hyperreflexia</td>
</tr>
<tr>
<td>Presentation</td>
<td>2mmol.ml$^{-1}$, made up into 10mmol in 100ml for peripheral administration</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO/IV</td>
</tr>
<tr>
<td>Dosing</td>
<td>IV: 10-20 mmol</td>
</tr>
<tr>
<td>Distribution</td>
<td>30% protein bound</td>
</tr>
<tr>
<td>Elimination</td>
<td>Significant urinary excretion, even when deficient</td>
</tr>
<tr>
<td>Resp</td>
<td>Bronchodilation</td>
</tr>
<tr>
<td>CVS</td>
<td>↓ SVR, hypotension, ↓HR</td>
</tr>
<tr>
<td>CNS</td>
<td>CNS depression, anticonvulsant</td>
</tr>
<tr>
<td>GU</td>
<td>↓ Uterine tone and contractility</td>
</tr>
</tbody>
</table>

**Clinical Effects of Magnesium**

<table>
<thead>
<tr>
<th>[Plasma]</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 0.7 mmol.L$^{-1}$</td>
<td>Arrhythmia</td>
</tr>
<tr>
<td>4-6 mmol.L$^{-1}$</td>
<td>Nausea, hyporeflexia, speech impairment</td>
</tr>
<tr>
<td>6-10 mmol.L$^{-1}$</td>
<td>Weakness, respiratory depression, bradycardia</td>
</tr>
<tr>
<td>&gt; 10 mmol.L$^{-1}$</td>
<td>Cardiac arrest</td>
</tr>
</tbody>
</table>

**References**


Last updated 2017-09-20
Magnesium
Atropine

Naturally occurring tertiary amine which competitively antagonises ACh at the muscarinic receptor, causing parasympatholytic effects.

<table>
<thead>
<tr>
<th>Property</th>
<th>Atropine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Naturally occurring tertiary amine. Muscarinic antagonist.</td>
</tr>
<tr>
<td>Uses</td>
<td>Bradycardia, organophosphate poisoning, antischialogogue, treatment of PDPH</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear, colourless solution at 600μg.ml⁻¹. Racemic mixture, with only the L-isomer active</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV</td>
</tr>
<tr>
<td>Dosing</td>
<td>600μg-3mg</td>
</tr>
<tr>
<td>Distribution</td>
<td>50% protein bound, V₃ 3L.kg⁻¹. Crosses BBB.</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Extensive hepatic hydrolysis</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of metabolites and unchanged drug</td>
</tr>
<tr>
<td>Resp</td>
<td>Bronchodilation, ↓ secretions</td>
</tr>
<tr>
<td>CVS</td>
<td>↑ HR due to ↑ AV nodal conduction, peaks within 2-4 minutes and lasts 2-3 hours</td>
</tr>
<tr>
<td>CNS</td>
<td>Central anticholinergic syndrome, ↑ IOP, ↑ CSF secretion in choroid, cerebral vasoconstriction</td>
</tr>
<tr>
<td>MSK</td>
<td>Inhibits sweating</td>
</tr>
<tr>
<td>GIT</td>
<td>↓ LoS tone</td>
</tr>
</tbody>
</table>

References


Last updated 2019-07-18
Diuretics

An understanding of the pharmacology of diuretics.

Diuretics are drugs that act on the kidney to increase urine production. They can be classified by their mechanism of action into:

- Thiazides
- Loop diuretics
- Potassium sparing
- Aldosterone antagonists
- Osmotic
- Carbonic Anhydrase inhibitors

Common Features of Diuretics

<table>
<thead>
<tr>
<th>Property</th>
<th>Diuretics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption</td>
<td>Typically poor bioavailability (exception: acetazolamide)</td>
</tr>
<tr>
<td>Distribution</td>
<td>Variable protein binding</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Generally not metabolised. Key exceptions: Spironolactone is extensively metabolised with active metabolites, and a small amount of frusemide is metabolised to glucuronide.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of unchanged drug</td>
</tr>
<tr>
<td>CVS</td>
<td>Reduced intra and extravascular volume</td>
</tr>
<tr>
<td>Renal</td>
<td>Any diuretic which inhibits sodium reabsorption can precipitate hypokalaemia (as a greater intra-luminal concentration of sodium results in exchange of sodium for potassium ions), hyponatraemia (as there is still a net loss of sodium), and alkalosis (from loss of hydrogen ions exchanged for sodium, or the overall raised strong ion difference).</td>
</tr>
</tbody>
</table>

Comparison of Diuretics

<table>
<thead>
<tr>
<th>Thiazides</th>
<th>Loop Diuretics</th>
<th>Potassium Sparing</th>
<th>Aldosterone antagonists</th>
<th>Osmotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Example</td>
<td>Hydrochlorothiazide</td>
<td>Frusemide</td>
<td>Amiloride</td>
<td>Spironolactone</td>
</tr>
<tr>
<td>Site</td>
<td>Distal tubule</td>
<td>Loop of Henle</td>
<td>Distal tubule</td>
<td>Distal tubule</td>
</tr>
<tr>
<td>Mechanism of action</td>
<td>Inhibit Na⁺ and Cl⁻ reabsorption, and increase Ca²⁺ reabsorption in the DCT</td>
<td>Inhibit NKCC2, the Na⁺/K⁺/2.Cl⁻ transport protein in the thick ascending limb, impeding the counter-current multiplier. This reduces the hypertonicity of the medulla, and subsequent water reabsorption in the collecting system.</td>
<td>Inhibits Na⁺/K⁺ exchange pump. Weak effect.</td>
<td>Competitive aldosterone antagonist. Aldosterone stimulates Na⁺ reabsorption, which in turn stimulates K⁺ secretion.</td>
</tr>
</tbody>
</table>
### Resp

<table>
<thead>
<tr>
<th>Cardiac</th>
<th>Antihypertensive due to reduced plasma volume and SVR</th>
<th>Arteriolar vasodilation, reducing SVR and preload</th>
<th>Increases intravascular volume, increasing preload. May increase CO or result in cardiac failure.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td></td>
<td>1 ICP</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>Reduced renal blood flow and GFR</td>
<td>Increased renal blood flow and GFR</td>
<td>Increased renal blood flow</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Blood dyscrasias</td>
<td>Deafness, typically following large doses. More common in kidney impairment and with aminoglycoside use.</td>
<td>Gynaecomastia and menstrual irregularity due to anti-androgynism from aldosterone antagonism</td>
</tr>
</tbody>
</table>

Last updated 2019-07-18
Intravenous Fluids

Intravenous fluids can be classified into:

- **Crystalloids**
  
  Can pass freely through a semipermeable membrane. Can be further classified into:
  
  - **ECF replacement solutions**
    
    Have a \([Na^+]\) similar to ECF, such that they are confined mostly to the ECF.
  
  - **Maintenance solutions**
    
    Designed to distribute throughout TBW.
  
  - **Special solutions**
    
    These solutions don't fit into the above two categories, and include:
    
    - Hypertonic saline
    - Mannitol
    - 8.4% Sodium Bicarbonate

- **Colloids**
  
  Substance evenly dispersed throughout another solution in which it is insoluble. Can be classified into:
  
  - **Naturally occurring**
    
    - Albumin
      
      Heat-treated human albumin.
      
      - Produced at low pH but not technically sterile
      
      - Use within 3 hours of opening.
      
      - Contributes to plasma oncotic pressure
      
      - Contributes to drug and endogenous substance binding
  
  - **Synthetic**
    
    - Dextrans
      
      High molecular weight sugars synthesised from sucrose by bacteria.
      
      - Interfere with haemostasis due to vWF inhibition
      
      - Interfere with blood crossmatch
      
      - Risk of anaphylaxis
    
    - Gelatins
      
      High molecular weight proteins produced by collagen hydrolysis.
      
      - Greatest anaphylaxis risk
      
      - Do not interfere with clotting
    
    - Hydroxyethyl starches
      
      - Risk of anaphylaxis
      
      - Risk of renal impairment
      
      - Accumulate in the reticuloendothelial system

### Comparison of Crystalloids

<table>
<thead>
<tr>
<th>Contents (mmol.L(^{-1}))</th>
<th>0.9% NaCl</th>
<th>Hartmann's</th>
<th>Plasmalyte</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na(^+)</td>
<td>154</td>
<td>130</td>
<td>140</td>
</tr>
<tr>
<td>Cl(^-)</td>
<td>154</td>
<td>109</td>
<td>98</td>
</tr>
<tr>
<td>K(^+)</td>
<td></td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Ca(^{2+})</td>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Intravenous Fluids

<table>
<thead>
<tr>
<th></th>
<th>Mg^{2+}</th>
<th>Lactate</th>
<th>Acetate</th>
<th>Gluconate</th>
<th>pH</th>
<th>1.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mg^{2+}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Acetate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Gluconate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>5.0</td>
<td>6.5</td>
<td>5.5</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### References

http://www.anaesthesiamcq.com/FluidBook/fl7_2.php

Last updated 2019-07-18
Propofol

Propofol (2-6 di-isopropylphenol) is a phenolic derivative with effects on many receptors including:

- **GABA<sub>A</sub>**
  - Potentiates the effect of GABA, prolonging Cl<sup>-</sup> channel opening and hyperpolarising the cell.
- **Glycine**
- **Nicotinic ACh**
- **D<sub>2</sub> receptors**

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Phenolic derivative</td>
</tr>
<tr>
<td>Uses</td>
<td>Induction of anaesthesia, sedation, TIVA</td>
</tr>
<tr>
<td>Presentation</td>
<td>White oil-in-water emulsion at a pH of 7-8.5 containing:</td>
</tr>
<tr>
<td></td>
<td>- 10-20mg.ml&lt;sup&gt;-1&lt;/sup&gt; propofol</td>
</tr>
<tr>
<td></td>
<td>- 10% Soybean oil (solubilising agent)</td>
</tr>
<tr>
<td></td>
<td>- 1.2% Purified egg phosphatide (emulsifier)</td>
</tr>
<tr>
<td></td>
<td>- 2.25% Glycerol (for tonicity)</td>
</tr>
<tr>
<td></td>
<td>Bacteriostatic additives including:</td>
</tr>
<tr>
<td></td>
<td>- Generics: Sodium metabisulfite</td>
</tr>
<tr>
<td></td>
<td>- Diprivan: Disodium edetate (less allergenic)</td>
</tr>
<tr>
<td></td>
<td>Risk of bacterial contamination limits shelf life.</td>
</tr>
<tr>
<td></td>
<td>Energy content is 1.1kcal.ml&lt;sup&gt;-1&lt;/sup&gt;</td>
</tr>
<tr>
<td>pKa</td>
<td>11 - almost all is unionised (and active) at physiologic pH</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV only</td>
</tr>
<tr>
<td>Dosing</td>
<td>Induction: 1-2.5mg.kg&lt;sup&gt;-1&lt;/sup&gt; Maintenance: 4-12mg/kg/hr. Target plasma concentration of 4-8μg.ml&lt;sup&gt;-1&lt;/sup&gt; to maintain general anaesthesia</td>
</tr>
<tr>
<td>Distribution</td>
<td>98% protein bound. Very high V&lt;sub&gt;D&lt;/sub&gt; at 4L.kg&lt;sup&gt;-1&lt;/sup&gt;. Rapid initial distribution: t&lt;sub&gt;1/2α&lt;/sub&gt; (fast) 1-3 minutes, intermediate distribution t&lt;sub&gt;1/2β&lt;/sub&gt; (slow) 30-70 minutes. t&lt;sub&gt;1/2ke0&lt;/sub&gt; of 2.7 min.</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic and extra-hepatic metabolism to inactive glucuronides and sulphates; t&lt;sub&gt;1/2β&lt;/sub&gt; 2-12 hours. <strong>Clearance of 30-60ml.kg.min</strong>&lt;sup&gt;-1&lt;/sup&gt;, unaffected by renal and hepatic disease. Context sensitive half-time peaks at 50 minutes following a 9 hour infusion.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Tri-exponential. Renal elimination of inactive metabolites.</td>
</tr>
<tr>
<td>Resp</td>
<td>Respiratory depression, apnoea. Strong suppression of laryngeal reflexes.</td>
</tr>
<tr>
<td>CVS</td>
<td>i Arterial and venous vasodilation (via stimulating NO release) causing i SVR and i VR, with i BP. i Inotropy via i in SNS tone, i MVO&lt;sub&gt;2&lt;/sub&gt;. Depresses baroreceptor reflex. Pain on injection due to lipid emulsion.</td>
</tr>
<tr>
<td>CNS</td>
<td>Hypnosis. Rapid LoC (within 1 arm-brain circulation time). i CMRO&lt;sub&gt;2&lt;/sub&gt;, CBF, and ICP. Anticonvulsant. i IOP. Paradoxical excitatory effects seen in ~10% - dystonic movements of subcortical origin. EEG demonstrates non-specific seizure-like activity.</td>
</tr>
<tr>
<td>MSK</td>
<td>Pain on injection into small veins</td>
</tr>
<tr>
<td>Renal</td>
<td>Green urine</td>
</tr>
<tr>
<td>GIT</td>
<td>Anti-emetic. i Hepatic Blood Flow</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Fat overload syndrome, lipaemia following prolonged infusion. Inhibits mitochondrial function.</td>
</tr>
</tbody>
</table>

Propofol infusion syndrome: Acidosis, bradycardia, and MODS following prolonged infusion (>24 hours).
mitochondrial defects. Believed due to inhibition of mitochondrial function.

References

   http://www2.pedsanesthesia.org/meetings/2007winter/pdfs/Morgan-Friday1130-1150am.pdf

Last updated 2019-07-18
Barbiturates

Thiopentone is a positive allosteric modulator at GABA_A receptors (at a separate site to benzodiazepines) in the CNS. Barbiturates cause:

- Decreased rate of dissociation of GABA
  - Increases the duration of channel opening, causing effective hyperpolarisation due to increased Cl^- conductance.
  - Clinical effects differ from benzodiazepines as benzodiazepines increase frequency of opening, whilst barbiturates increase duration
- Direct activation of the channel at higher doses

<table>
<thead>
<tr>
<th>Property</th>
<th>Thiopentone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Barbiturate</td>
</tr>
<tr>
<td>Uses</td>
<td>Induction of anaesthesia, status epilepticus, control of ICP refractory to other measures</td>
</tr>
<tr>
<td>Presentation</td>
<td>500mg of yellow powder with NaCO_3 for reconstitution as a 2.5% solution. Container uses nitrogen as a filler gas (to prevent HCO_3^- formation when CO_2 combines with water during reconstitution, which ↓ pH and therefore water solubility). pH of 11 when reconstituted - bacteriostatic solution.</td>
</tr>
<tr>
<td>Isomerism</td>
<td>Tautomer. pKa of 7.6, such that 60% is unionised at pH 7.4 (i.e. water solubility decreases once injected).</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV</td>
</tr>
<tr>
<td>Dosing</td>
<td>3-7mg.kg^-1. Consider 75mg boluses, assessing haemodynamic and neuronal effects.</td>
</tr>
<tr>
<td>Distribution</td>
<td>65-85% protein bound. High lipid solubility and CBF gives a rapid, reliable onset. Rapid offset due to redistribution, with a fast 1/2alpha of 8 minutes. Prolonged elimination half life (11 hours) contributes to long CSHT. Increased unionised portion in acidosis. 11/2ke0 of 1.2 minutes.</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Capacity dependent CYP450 metabolism - saturates at high doses (long CSHT with infusion). Metabolised to (active) pentobarbital, which also increases the duration of its clinical effects.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal of metabolites, &lt; 1% excreted unchanged</td>
</tr>
<tr>
<td>Resp</td>
<td>Respiratory depression, bronchospasm, laryngospasm</td>
</tr>
<tr>
<td>CVS</td>
<td>Vasodilation and venodilation (↓ MSFP), ↓ inotropy, with compensatory tachycardia (baroreceptor response preserved)</td>
</tr>
<tr>
<td>CNS</td>
<td>Hypnosis and anaesthesia within 40 seconds of injection, with reliable loss of lash reflex. Anticonvulsant. Dose-dependent flattening of the EEG (β α θ δ burst suppression isoelectric), causing progressive ↓ CMRO_2 (55% of maximal during burst suppression), ↓ CBF, and ↓ ICP. Resolution of induction dose in 5-10 minutes due to redistribution.</td>
</tr>
<tr>
<td>Endocrine</td>
<td>↓ RBF causing ↓ UO</td>
</tr>
<tr>
<td>GIT</td>
<td>Hepatic enzyme induction</td>
</tr>
<tr>
<td>Immune</td>
<td>Anaphylaxis ~1;20,000</td>
</tr>
<tr>
<td>Metabolic</td>
<td>May precipitate acute porphyric crises and is contraindicadted in these patients</td>
</tr>
<tr>
<td>Other</td>
<td>Intraarterial injection causes precipitation as water solubility decreases at blood pH. Microembolisation and ischaemia result, which should be treated with intraarterial local anaesthesia, analgesia, anticoagulation, and sympathetic blockade of the limb. Tissue necrosis on extravasation.</td>
</tr>
</tbody>
</table>
References

2. LITFL - Thiopentone

Last updated 2019-07-18
Ketamine

Ketamine is a phencyclidine derivative used for induction, sedation, analgesia, and as a bronchodilator in severe asthma.

Ketamine acts via:

- **Non-competitive antagonist** of NMDA and glutamate receptors in the CNS
- Reduces presynaptic glutamate release
- Sodium channel inhibition
  - Local anaesthetic-like effect.
- Potential monoaminergic, muscarinic, and nicotinic antagonism

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Phencyclidine derivative</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Induction of anaesthesia, sedation, analgesia, asthma</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Clear, colourless solution forming an acidic solution (pH 3.5-5.5)</td>
</tr>
<tr>
<td><strong>Isomerism</strong></td>
<td>Racemic mixture or the single S(+) enantiomer, which is 2-3x as potent as the R(-) enantiomer but has less bronchodilatory properties</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>IV, IM, PO, PR, PN, via epidural (with preservative-free solution)</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>Induction: 1-2mg.kg(^{-1}) IV, 5-10mg.kg(^{-1}) IM, Sedation: 0.2-0.5mg.kg(^{-1}) IV</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>25% protein bound. (t_{1/2}\alpha) 10-15 minutes</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Hepatic metabolism to active norketamine by CYP450 and then to inactive metabolites, (t_{1/2}\beta) 2-4 hours</td>
</tr>
<tr>
<td><strong>Resp</strong></td>
<td>Bronchodilation, tachypnea, relative preservation of laryngeal reflexes. Apnoea with rapid injection. Preserved central response to CO(_2).</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>↑ Sympathetic outflow: ↑ HR, ↑ BP, ↑ SVR, ↑ MVO(_2). Acts directly as a myocardial depressant - beware maximally stimulated patient. Depresses baroreceptor reflex.</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Dissociation, analgesia, emergence phenomena (hallucinations, delirium) reduced by concurrent BDZ administration (increasing risk with higher doses and rapid administration). Produces dissociative anaesthesia within 90 seconds by dissociating thalamocortical and limbic systems on EEG. Purposeful movements unrelated to stimulus may occur even during surgical anaesthesia. ↑ IOP.</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>Cystitis with long-term, high-dose use</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>N/V</td>
</tr>
</tbody>
</table>

**References**

3. CICM July/Sept 2007
4. Lupton T, Pratt O. Intravenous drugs used for the induction of anaesthesia.

Last updated 2019-07-18
Dexmedetomidine

Dexmedetomidine is a central α₂-agonist (α₂:α₁ activity 1600:1) used for its sedation and analgesic properties.

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Imidazole derivative</td>
</tr>
<tr>
<td>Pharmaceutics</td>
<td>D-stereoisomer of medetomidine (the L-stereoisomer is inactive)</td>
</tr>
<tr>
<td>Uses</td>
<td>Sedation without respiratory depression</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear colourless solution at 10µg.ml⁻¹</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV only</td>
</tr>
<tr>
<td>Dosing</td>
<td>0.2-0.7µg.kg⁻¹.hr⁻¹</td>
</tr>
<tr>
<td>Distribution</td>
<td>95% protein bound</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic to inactive metabolites</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal of metabolites, t₁/₂β of 2 hours</td>
</tr>
<tr>
<td>CVS</td>
<td>Initial transient ↑ SVR and BP due to α₁ effects, followed by ↓ MAP, ↓ HR.</td>
</tr>
<tr>
<td></td>
<td>Rebound ↑ BP when abruptly ceased.</td>
</tr>
<tr>
<td>CNS</td>
<td>Sedation, anxiolysis at low dose (anxiogenic at high dose), amnesia. ↓ MAC.</td>
</tr>
<tr>
<td></td>
<td>↓ SNS outflow.</td>
</tr>
</tbody>
</table>

References


Last updated 2017-09-16
Local Anaesthetic Agents

- Local anaesthetic drugs deliver a use-dependent, temporary blockade of neuronal transmission
- Unionised drug passes through the cell membrane, and then becomes ionised intracellularly
- The ionised drug is then able to bind to the ion channel, and prevent conduction of sodium and therefore generation of an action potential
- All local anaesthetics consist of:
  - A hydrophilic component
  - A lipophilic aromatic ring
  - An amide or ester link connecting the two

Common Features of Local Anaesthetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Amide (-NHCO-) or Ester (-COOH-)</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>Amides are stable in solution, esters are unstable in solution. All are formulated as a hydrochloride salt to ensure water solubility.</td>
</tr>
<tr>
<td>pKa</td>
<td>All are weak bases, and have a pKa &gt; 7.4</td>
</tr>
<tr>
<td>Onset</td>
<td>Onset is related to dose (Fick's Law) and pKa, with a low pKa giving a faster onset as there is more unionised drug present and therefore more drug able to cross the cell membrane. This is why local anaesthetics are poor at anaesthetising infected tissues, as the tissue pH is low resulting in a greater proportion of ionised drug, and less drug reaching the effect site.</td>
</tr>
<tr>
<td>Duration of Action</td>
<td>Duration of action is related to protein binding, with greater protein binding giving a longer duration of action</td>
</tr>
<tr>
<td>Potency</td>
<td>Potency is related to lipid solubility (higher lipid solubility increases potency) and vasodilator properties (weaker vasodilators having greater potency)</td>
</tr>
<tr>
<td>Absorption</td>
<td>Systemic absorption varies with site of entry (from highest absorption to lowest: IV, intercostal, caudal epidural, lumbar epidural, brachial plexus, subcutaneous), dose, and presence of vasoconstrictors</td>
</tr>
<tr>
<td>Distribution</td>
<td>Amides are extensively protein bound, esters are minimally bound</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Amides are hepatically metabolised, esters are hydrolysed by plasma cholinesterases (giving a much shorter 1/2)</td>
</tr>
<tr>
<td>CVS</td>
<td>Vasodilatation at low concentrations, vasoconstriction at high concentrations. Inhibition of cardiac Na&lt;sup&gt;+&lt;/sup&gt; channels, inhibiting maximum rate of rise of phase 0 of the cardiac action potential. Negative inotropy proportional to potency.</td>
</tr>
<tr>
<td>CNS</td>
<td>Does-dependent CNS effects: circumoral tingling, visual disturbances, tinnitus, tremors, dizziness, slurred speech, convulsions, coma, apnoea. Potentiated by other CNS depressants and hypercarbia (due to ↑ CBF and ↓ seizure threshold).</td>
</tr>
<tr>
<td>Toxic Effects</td>
<td>Esters have a higher incidence of allergy due to their metabolite para-amino benzoic acid (PABA). Local anaesthetic toxicity is predominantly CNS and CVS.</td>
</tr>
</tbody>
</table>

Comparison of Local Anaesthetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Lignocaine</th>
<th>Bupivacaine</th>
<th>Ropivacaine</th>
<th>Cocaine</th>
</tr>
</thead>
</table>

622
<table>
<thead>
<tr>
<th>Class</th>
<th>Amide</th>
<th>Amide</th>
<th>Amide</th>
<th>Ester</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uses</td>
<td>Local/regional/epidural, ventricular dysrhythmia</td>
<td>Local/regional/epidural</td>
<td>Local/regional/epidural</td>
<td>Topical anaesthesia and vasoconstriction</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear, colourless solution at 0.5/1/2% with or without adrenaline. Spray. Ointment. 4% solution.</td>
<td>Clear, colourless solution at 0.25/0.5%</td>
<td>Clear, colourless solution</td>
<td>1-4% solution, Moffat's solution (8% cocaine, 1% NaCO₃, 1:2 000 adrenaline)</td>
</tr>
<tr>
<td>pKa</td>
<td>7.9</td>
<td>8.1</td>
<td>8.1</td>
<td>8.6</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>SC, epidural, IV</td>
<td>SC, epidural</td>
<td>SC, epidural</td>
<td>Topical</td>
</tr>
<tr>
<td>Onset/Duration</td>
<td>Rapid onset, short duration</td>
<td>Intermediate onset, long duration</td>
<td>Intermediate onset, long duration</td>
<td>20-30 minutes</td>
</tr>
<tr>
<td>Maximum Dose</td>
<td>Analgesia: 4mg.kg⁻¹ without adrenaline, 7mg.kg⁻¹ with adrenaline</td>
<td>2mg.kg⁻¹</td>
<td>3mg.kg⁻¹</td>
<td>3mg.kg⁻¹</td>
</tr>
<tr>
<td>Distribution</td>
<td>70% protein bound</td>
<td>Highly protein bound</td>
<td>Lower lipid solubility reduces motor block compared to bupivacaine</td>
<td>Highly protein bound</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic with some active metabolites</td>
<td>Hepatic to inactive metabolites</td>
<td>Hepatic to active metabolites</td>
<td>Plasma esterases, some hepatic metabolism (unlike other esters)</td>
</tr>
<tr>
<td>Elimination</td>
<td>Reduced in hepatic or cardiac failure</td>
<td></td>
<td></td>
<td>Elimination of active drug and inactive metabolites</td>
</tr>
<tr>
<td>CC/CNS ratio</td>
<td>7</td>
<td>3</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

## Other

- Most toxic of LA agents as it takes longer to dissociate from the myocardial Na⁺ channel. **Levobupivacaine** is less cardiotoxic the racemic mixture, possibly as it has more intrinsic vasoconstrictive properties.
- May cause ↑ BP, ↑ HR, coronary vasoconstriction, myocardial depression, VF, ↑ temperature due to ↑ serotonin, dopamine, and noradrenaline reuptake

### Lignocaine Toxicity

<table>
<thead>
<tr>
<th>Serum concentration (µg.ml⁻¹)</th>
<th>Phase</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Safe</td>
<td>Antiarrhythmic. May begin to have lightheadedness, circumoral tingling, numbness</td>
</tr>
<tr>
<td>5</td>
<td>Excitatory</td>
<td>Dysarthria</td>
</tr>
<tr>
<td>8</td>
<td>Excitatory</td>
<td>Visual changes</td>
</tr>
</tbody>
</table>
### Pharmaceutics of Topical Local Anaesthetics

Effect of topical local anaesthetics is governed by **Fick’s Law**.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmaceutic Factors</strong></td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Aerosol improves speed of onset by moisturising skin</td>
</tr>
<tr>
<td>Concentration of active component</td>
<td>Increase speed of onset</td>
</tr>
<tr>
<td>Stability</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>↑ pH ensures more local anaesthetic is in the unionised form, ↑ absorption.</td>
</tr>
<tr>
<td>Additives</td>
<td>Affect pH and vasoconstrictor activity</td>
</tr>
<tr>
<td><strong>Drug Factors</strong></td>
<td></td>
</tr>
<tr>
<td>Molecular weight</td>
<td>Small molecules will diffuse more easily</td>
</tr>
<tr>
<td>pKa</td>
<td>Affects ionisation and therefore lipid solubility</td>
</tr>
<tr>
<td>Lipid solubility</td>
<td>↑ lipid solubility improves speed of onset.</td>
</tr>
<tr>
<td>Potency</td>
<td>Determines amount of drug needed to produce an effect</td>
</tr>
<tr>
<td>Vasoconstrictor activity</td>
<td>Will affect both speed of onset and degree of systemic absorption</td>
</tr>
<tr>
<td><strong>Patient Factors</strong></td>
<td></td>
</tr>
<tr>
<td>Site</td>
<td>Degree of vascularity of site</td>
</tr>
<tr>
<td>Skin</td>
<td>Skin thickness and area will affect onset</td>
</tr>
</tbody>
</table>
Benzodiazepines

Benzodiazepines are double-ringed positive allosteric modulators of the GABA receptors in the CNS. They:

- Bind to the α/γ interface of the receptor, increasing affinity of the receptor for GABA
- This leads to hyperpolarisation of the cell membranes and decreased neuronal transmission

The mechanism varies between receptors:
- GABA_A is a ligand gated post-synaptic Cl⁻ ion channel
  Activation increases Cl⁻ conductance via increasing frequency of channel opening.
- GABA_B is a pre- and post-synaptic G-protein coupled receptor
  Activation increases K⁺ conductance.

Common Features of Benzodiazepines

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uses</td>
<td>Sedation, anxiolysis, hypnotic, anticonvulsants, amnestic, muscle relaxation</td>
</tr>
<tr>
<td>Absorption</td>
<td>Highly lipid soluble and protein bound, very low V_D</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Generally active metabolites.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of active and inactive metabolites.</td>
</tr>
<tr>
<td>Resp</td>
<td>↓ V_T, ↑ RR, apnoea.</td>
</tr>
<tr>
<td>CVS</td>
<td>↓ SVR, ↓SBP, ↑ DBP, ↑ HR. Typically stable CO.</td>
</tr>
<tr>
<td>CNS</td>
<td>Hypnosis, sedation, anterograde amnesia, anticonvulsant, ↓ CBF, ↓ MAC.</td>
</tr>
<tr>
<td>MSK</td>
<td>Skeletal muscle relaxation.</td>
</tr>
<tr>
<td>Metabolic</td>
<td>↓ Adrenergic stress response.</td>
</tr>
</tbody>
</table>

Comparison of Benzodiazepines

<table>
<thead>
<tr>
<th>Property</th>
<th>Midazolam</th>
<th>Diazepam</th>
<th>Clonazepam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicochemical</td>
<td>pKa 6.5. Structure is dependent on surrounding pH - at a pH &lt; 4 its ring structure opens and it becomes water soluble.</td>
<td>40% propylene glycol.</td>
<td></td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO/IV/IM.</td>
<td>PO/IV/IM.</td>
<td>PO.</td>
</tr>
<tr>
<td>Absorption</td>
<td>50% PO bioavailability.</td>
<td>Good PO bioavailability.</td>
<td></td>
</tr>
<tr>
<td>Distribution</td>
<td>V_D 1.5L.kg⁻¹, 95% protein bound.</td>
<td>95% protein bound.</td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>Partially metabolised to oxazepam and 1-α-hydroxy-midazolam. Clearance ~7ml.kg⁻¹.min⁻¹.</td>
<td>Hepatic to all active metabolites including oxazepam, temazepam, and des-methyl-diazepam (has t1/2β up to 100 hours).</td>
<td>Hepatic to inactive metabolites.</td>
</tr>
<tr>
<td>Elimination</td>
<td>t₁/₂β 2-4 hours, prolonged with cirrhosis, CHF, obesity and in the t₁/₂β 20-45 hours.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
References


Last updated 2019-07-18
Antidepressants

*Symptoms and management of TCA overdose is covered under* Tricyclic Antidepressant Overdose.

Antidepressant drugs include:

- **Tricyclic Antidepressants (TCAs)**
  - Mechanism of action by multiple effects, including:
    - Competitively inhibit reuptake of NA and 5-HT
    - Muscarinic antagonism
      - Leads to anticholinergic side effects (dry mouth, blurred vision, constipation, urinary retention).
    - H₁ and H₂ antagonism
    - α₁ antagonism
    - NMDA antagonism
  - Selective Serotonin Reuptake Inhibitors (SSRIs)
    - Inhibit neural reuptake of 5-HT
    - Preferred over TCAs as:
      - Similar effectiveness
      - Better side effect profile
  - Monoamine Oxidase Inhibitors (MAO-Is)
    - Inhibit monoamine oxidase on external mitochondrial membrane, increasing the level of amine neurotransmitters in the CNS and PNS
      - Two enzymes exist:
        - **MAO-A**
          - Dominant enzyme in CNS
          - Acts on serotonin, noradrenaline, adrenaline
        - **MAO-B**
          - Dominant in GIT and platelets
          - Responsible for 75% of MAO activity
          - Preferential metabolism of non-polar amines
  - MAO-Is classified by their mechanism and selectivity
    - Non-selective, irreversible
      - Bind covalently to the enzyme, permanently inactivating it.
        - May lead to hypertensive crisis when catecholamine levels increased
          - Tyramine in food
            - Metabolised by MAO-B.
          - Indirectly acting sympathomimetics
            - Absolutely contraindicated.
        - Risk of serotonin syndrome with serotonin reuptake inhibitors
          - Include:
            - Phenelzine
            - Isocarboxazid
            - Tranylcypromine
          - Enzyme levels will take 2-3 weeks to recover following cessation
    - **MAO-A selective, reversible**
      - Hypertensive crisis is less common
        - MAO-B unaffected - tyramine is metabolised
        - Short acting
        - Enzyme levels normalise after 24 hours of cessation.
Moclobemide
- MAO-B selective
- Much lower risk of hypertensive crisis
- Include:
  - Selegiline
- Discontinuation syndrome may occur if abruptly ceased

<table>
<thead>
<tr>
<th>Property</th>
<th>Tricyclic Antidepressants</th>
<th>Selective Serotonin Reuptake Inhibitors</th>
<th>Monoamine Oxidase Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Example</td>
<td>Amitriptyline</td>
<td>Fluoxetine</td>
<td>Treatment resistant depression. Now largely superseded due to side-effect profile</td>
</tr>
<tr>
<td>Uses</td>
<td>Depression, treatment of chronic pain and trigeminal neuralgia</td>
<td>Depression, anxiety</td>
<td></td>
</tr>
<tr>
<td>Absorption</td>
<td>High PO bioavailability</td>
<td>High PO bioavailability</td>
<td></td>
</tr>
<tr>
<td>Distribution</td>
<td>Highly lipid soluble with High V₃. Very highly protein bound - leads to interactions with warfarin, digoxin, and aspirin</td>
<td>Highly protein bound, high Vₑ</td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic with active metabolites. Large interpatient variability</td>
<td>Hepatic with non-linear kinetics</td>
<td>Venlafaxine does not affect CYP450 enzymes.</td>
</tr>
<tr>
<td>Elimination</td>
<td></td>
<td>Unaffected by renal impairment</td>
<td></td>
</tr>
<tr>
<td>Resp</td>
<td>Dry mouth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVS</td>
<td>Postural hypotension, ↑ HR. QT prolongation and widening QRS in overdose, with arrhythmia more likely when QRS exceeds 0.16s.</td>
<td>Less cardiotoxic than TCAs, may precipitate serotonin syndrome</td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>Sedation, blurred vision, lowered seizure threshold. Excitation, followed by seizures and depression in overdose.</td>
<td>Identical antidepressant effect to TCAs. Less sedation</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>Urinary retention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GU</td>
<td>Sexual dysfunction</td>
<td>Greater incidence of sexual dysfunction compared with TCAs</td>
<td></td>
</tr>
<tr>
<td>GIT</td>
<td>Constipation</td>
<td>Greater incidence of N/V compared with TCAs</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Multiple complex drug interactions, including arrhythmias and variable BP with sympathomimetics, central anticholinergic syndrome, serotonin syndrome, and seizures. ↑ Sensitivity to catecholamines - suggest avoiding: -Indirectly acting sympathomimetics -Ketamine -Surgical stress</td>
<td>Continue during perioperative period to avoid risk of discontinuation syndrome.</td>
<td></td>
</tr>
</tbody>
</table>
Serotonin Syndrome

Serotonin syndrome is excessive serotonin in the CNS, typically as a consequence of drug interactions. The syndrome may be mild, moderate, or severe, and presents with some or all of:

- Altered mental state
  - Confusion
- Motor changes
  - Myoclonus
  - Hyperreflexia
  - Tremor
- Autonomic instability
  - Diaphoresis
  - Shivering
  - Fever

Serotonin syndrome is typically self-limiting and resolves with cessation of the drug.

References


Last updated 2019-07-18
Antipsychotics

Antipsychotics are drugs used for the management of psychoses and thought disorders. They have a complicated mechanism of action with effects on multiple receptors:

- **Central dopamine (typically D2, but varies with agent) antagonism**
  - Responsible for the antipsychotic properties
- **5-HT2 antagonism**
- **Other receptors which are quantitatively less important:**
  - H1 antagonism
  - α1 antagonism
  - Muscarinic ACh antagonism

Based on their affinity to various receptors, they are (loosely) classified as either:

- **Typical** or 1st generation antipsychotics
  - Higher affinity for D2 receptors (subsequently less blockade of 5-HT2), causing a greater effect on 'positive' symptoms' and a greater incidence of extrapyramidal side effects
- **Atypical** or 2nd generation, which typically have fewer motor effects
  - Have greater effect on negative symptoms.

### Common Features of Antipsychotics

<table>
<thead>
<tr>
<th>Property</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uses</strong></td>
<td>Behavioural emergencies, schizophrenia/psychosis</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>QT prolongation</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Apathy, ↓ initiative, ↓ response to external stimuli, ↓ aggression. No loss of intellectual function.</td>
</tr>
<tr>
<td><strong>Endocrine</strong></td>
<td>↑ Prolactin (typical antipsychotics)</td>
</tr>
<tr>
<td><strong>Haeme</strong></td>
<td>Leukopenia and agranulocytosis (predominantly clozapine, but can be all)</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td>Weight gain, diabetes, hypercholesterolaemia (all atypical &gt; typical)</td>
</tr>
<tr>
<td><strong>Other Toxicities</strong></td>
<td>Neuroleptic malignant syndrome, EPSE</td>
</tr>
</tbody>
</table>

### Neuroleptic Malignant Syndrome

**Antipsychotic Malignant Syndrome** is rare and presents similarly to MH, with a rapid rise in body temperature and confusion. It has a high mortality (up to 20%).

### Extra-Pyramidal Side Effects

Motor disturbances from antipsychotic use are termed EPSEs, and are divided into two main types:

- **Acute Dystonic Reactions** are involuntary movements and parkinsonian symptoms. They are:
  - More common with typical agents
  - Decline with ongoing use
  - Reversible with cessation of the agent
- **Tardive dyskinesia** is similar to ADR, except:
Involuntary movements are more pronounced and disabling
- It occurs with long term use (10-20 years)
- They are irreversible, and worsen when therapy is stopped

## Comparison of Antipsychotics

<table>
<thead>
<tr>
<th>Property</th>
<th>Haloperidol</th>
<th>Olanzapine</th>
<th>Clozapine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Typical</td>
<td>Atypical</td>
<td>Atypical (&quot;3rd gen&quot;)</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Behavioural Emergencies</td>
<td>Behavioural Emergencies, Psychosis/Schizophrenia</td>
<td>Treatment resistant schizophrenia</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Tablets, syrup, clear solution for injection at 5mg.ml⁻¹</td>
<td>Tablets, solution for injection</td>
<td>Yellow tablet</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO/IM/IV</td>
<td>PO/IM</td>
<td>PO</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>1-5mg IV, 2-30mg IM, 1-15mg PO</td>
<td>IM 5-10mg, PO 5-20mg</td>
<td>Must be prescribed by a psychiatrist</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>50% PO bioavailability</td>
<td>60% PO bioavailability</td>
<td>Rapid absorption</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>92% protein bound</td>
<td>93% protein bound, V₅₀ ~14L.kg⁻¹</td>
<td>V₅₀ 2L.kg⁻¹</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Hepatic to largely inactive metabolites</td>
<td>Hepatic to inactive metabolites</td>
<td>May obey zero-order kinetics at the upper limit of the dose range</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal of metabolites</td>
<td>Renal of inactive metabolites</td>
<td>Renal of active drug (~25%) and inactive metabolites</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>Hypotension</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>Antiemetic</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Haeme</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CVS**
- Hypotension
- Myocarditis (potentially fatal)

**CNS**
- Seizures

**GIT**
- Antiemetic
- Hepatitis

**Haeme**
- Agranulocytosis, thromboembolic disease

## References


Last updated 2019-07-18
## Anticonvulsants

In general, anticonvulsants are:

- Well absorbed orally
- Highly protein bound
- Hepatically metabolised by CYP450 enzymes, and induce their own metabolism (as well as that of other drugs)
- Renally eliminated
- Interact with each other

<table>
<thead>
<tr>
<th>Property</th>
<th>Phenytoin</th>
<th>Sodium Valproate</th>
<th>Carbamazepine</th>
<th>Levetiracetam</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uses</strong></td>
<td>GTCS, partial seizures, trigeminal neuralgia, ventricular arrhythmias</td>
<td>Partial seizures</td>
<td>Antiepileptic, trigeminal neuralgia</td>
<td>GTCS, partial seizures, myoclonic seizures, seizure prophylaxis</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Capsules, syrup, solution. IV formulation incompatible with dextrose.</td>
<td>Tablets, syrup, solution</td>
<td>Tablets, suppositories, syrup</td>
<td>Tablets, oral liquid, IV liquid</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO, IV, IM</td>
<td>PO, IV</td>
<td>PO</td>
<td>PO, IV (over 15 minutes)</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>15-20mg.kg⁻¹ load, aiming plasma levels 10-20mcg.ml⁻¹</td>
<td>300-1250mg BD</td>
<td>50-800mg BD</td>
<td>Typically 1g loading, then 500mg BD increasing up to 1.5g BD. Dose adjusted in renal impairment.</td>
</tr>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Stabilises Na⁺ channels in their inactive state, inhibiting generation of further action potentials.</td>
<td>Stabilises Na⁺ channels in their inactive state and GABAergic inhibition</td>
<td>Stabilises Na⁺ channels in their inactive state and potentiates GABA</td>
<td>Unknown, but different to other antiepileptics and may be related to inhibition of N-type Ca²⁺ currents</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>Slow PO absorption. PO bioavailability 90%</td>
<td>PO bioavailability 100%</td>
<td>95% PO bioavailability</td>
<td>Near 100% PO bioavailability</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>Highly protein bound</td>
<td>Highly protein bound</td>
<td>Highly protein bound</td>
<td>Nil significant protein binding, V₆⁻0.5L.kg⁻¹</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Hepatic hydroxylation with highly individual variation in dosing. Obeys first-order kinetics in the therapeutic range, and zero-order kinetics just above the therapeutic range. Metabolised by CYP450. Induces warfarin, benzodiazepines, OCP metabolism. Inhibited by metronidazole, chloramphenicol, isoniazid. Genetic polymorphism results in Hepatic to inactive and active metabolites</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>Hepatic hydrolysis to inactive metabolites</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of inactive metabolites and active drug</td>
<td>Renal elimination of metabolites and active drug</td>
<td>Renal elimination of active drug (major route) and metabolite (minor route)</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>CVS</td>
<td>↓ BP, heart block, and asystole with rapid administration, antiarrhythmic properties</td>
<td>↓ Seizure threshold</td>
<td>↓ Seizure threshold, anxiolytic. Minimal ↓ in seizure threshold on cessation.</td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>↑ Seizure threshold, paraesthesia, ataxia, nystagmus, slurred speech, tremor, vertigo.</td>
<td>↑ Seizure threshold</td>
<td>↑ Seizure threshold, anxiolytic. Minimal ↓ in seizure threshold on cessation.</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>Water retention from ADH-like effects</td>
<td>Rarely precipitates AKI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haeme</td>
<td>Aplastic anaemia and other blood dyscrasias</td>
<td>Thrombocytopenia, leukopenia (requires regular testing)</td>
<td>Thrombocytopenia</td>
<td></td>
</tr>
<tr>
<td>Immune</td>
<td>Rash</td>
<td>SJS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic</td>
<td>Hyperammonaemia</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**References**

3. CICM March/May 2010

Last updated 2019-07-20
GABA Analogues

Gabapentin and pregabalin:

- Are both structural analogues of GABA
- Have no direct action on the GABA\(_A\) receptor
- Act on the \(\alpha_\delta\) subunit of voltage gated Ca\(^{2+}\) channels in the CNS, inhibiting neurotransmitter release
- May have some NMDA receptor activity

Comparison of GABA Analogues

<table>
<thead>
<tr>
<th>Property</th>
<th>Gabapentin</th>
<th>Pregabalin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uses</strong></td>
<td>Focal seizures, neuropathic pain</td>
<td>Focal seizures, neuropathic pain, anxiety</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO</td>
<td></td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>100mg TDS, increasing up to 1200mg TDS</td>
<td>50mg BD/TDS, up to 600mg in divided doses (BD or TDS)</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>PO bioavailability of 60%, decreases with increasing dose due to saturation of transporter</td>
<td>90% PO bioavailability, delayed by food but unaffected by dose</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>Minimally protein bound</td>
<td>Minimally protein bound</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Not metabolised</td>
<td>Not metabolised</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal elimination of active drug, (t_1/2) 6 hours</td>
<td>Renal elimination of active drug, (t_1/2) 6 hours</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Drowsiness, ataxia, psychiatric symptoms</td>
<td>Confusion, psychiatric symptoms, drowsiness</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>N/V</td>
<td></td>
</tr>
</tbody>
</table>

References


Last updated 2019-07-18
Inhalational Anaesthetic Agents

Describe the effects of inhalational agents on the cardiovascular, respiratory and central nervous systems

Describe the toxicity of inhalational agents

Describe the comparative pharmacology of nitrous oxide, halothane, enflurane, isoflurane, desflurane, sevoflurane, xenon and ether

This section covers features and structures of inhalational anaesthetics. Structure-activity relationships are covered under inhalational anaesthetics.

Common Features of Inhalational Agents

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolism</td>
<td>Hepatic CYP450 (CYP2E1) metabolises C-halogen bonds to release halogen ions (F−, Cl−, Br−), which can be nephrotoxic and hepatotoxic. The C-F bond is minimally metabolised compared to the C-Cl, C-Br, and C-I bonds. All agents undergo hepatic oxidation, except for halothane which is reduced.</td>
</tr>
<tr>
<td>Resp</td>
<td>All halogenated agents ↓ V̅̅̅̅̅̅̅ and ↑ RR, with an overall ↓ in MV and therefore cause PaCO₂ to ↑; and ↓ sensitivity of central respiratory centres to CO₂. Impairment of HPV may worsen V/Q matching and ↑ shunt.</td>
</tr>
<tr>
<td>CVS</td>
<td>↓ MAP (predominantly by ↓ in SVR due to NO release and Ca²⁺ channel blockade), ↓ inotropy due to Ca²⁺ channel blockade.</td>
</tr>
<tr>
<td>CNS</td>
<td>Hypnosis. ↓ CMRO₂. Above 1 MAC there is uncoupling of the CBF-CMRO₂ relationship, and CBF ↓ despite ↓ in CMRO₂ due to cerebral vasodilation. ICP may mirror CBF changes. All except halothane have some analgesic effect. ↓ EEG frequency such that θ- and δ-wave dominate the EEG as depth ↑. May cause burst suppression.</td>
</tr>
<tr>
<td>MSK</td>
<td>Muscle relaxation via blockade of Ca²⁺ channels. Additional augmentation of the effects of NMBD due to skeletal muscle vasodilation. May precipitate MH.</td>
</tr>
<tr>
<td>Renal</td>
<td>Dose dependent ↓ in RBF, GFR, and UO secondary to ↓ in MAP and CO. Fluorinated ethers produce F⁻ ions when hepatically metabolised, which may produce high-output renal failure at serum concentrations &gt;50μmol/L. This is probably only a concern with methoxyflurane (as it has significant (&gt;70%) hepatic metabolism) when used at anaesthetic doses.</td>
</tr>
<tr>
<td>GIT</td>
<td>↓ Hepatic blood flow.</td>
</tr>
<tr>
<td>GU</td>
<td>Tocolysis.</td>
</tr>
<tr>
<td>Toxic Effects</td>
<td>Decreased fertility and increased risk of spontaneous abortion in operating theatre personnel.</td>
</tr>
</tbody>
</table>

Comparison of Common Inhalational Agents

<table>
<thead>
<tr>
<th>Property</th>
<th>Sevoflurane</th>
<th>Isoflurane</th>
<th>Desflurane</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutics</td>
<td>Minimally soluble, light stable, not flammable. Formulated with 300ppm of H₂O to prevent formation of HF acid by Lewis acids in glass.</td>
<td>Soluble in rubber, light stable, not flammable.</td>
<td>Light sensitive, flammable at 17%.</td>
</tr>
</tbody>
</table>
### Structure

<table>
<thead>
<tr>
<th>Structure</th>
<th>Molecular Weight</th>
<th>Boiling point</th>
<th>SVP (mmHg) at 20°C</th>
<th>Blood:gas coefficient</th>
<th>Oil:gas coefficient</th>
<th>MAC</th>
<th>Metabolism</th>
<th>Resp</th>
<th>CVS</th>
<th>CNS</th>
<th>Toxic Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>200.1</td>
<td>58.5°C</td>
<td>158</td>
<td>0.7</td>
<td>50</td>
<td>2</td>
<td>3-5% CYP2E1 metabolism to hexafluorosopropanol and inorganic F⁻ (which may be nephrotoxic)</td>
<td>Bronchodilation, ↑ MV. Smallest ↑ in V₆ and therefore smallest ↑ in PaCO₂</td>
<td>↑ QT, ↓ SVR causing ↓ MAP without a reflex ↑ HR. Inotropy unchanged. Smallest ↓ in BP of any inhalational agent.</td>
<td>↑ Post-operative agitation in children compared to halothane. Smallest ↑ in CBF at &gt; 1.1 MAC, with no increase in ICP up to 1.5 MAC. Cerebral autoregulation intact up to 1.5 MAC.</td>
<td>Sevoflurane interacts with soda lime to produce Compound A (as well as B through E, which are unimportant), which is nephrotoxic in rats (but not, it seems, in humans).</td>
</tr>
<tr>
<td></td>
<td>184.5</td>
<td>48.5°C</td>
<td>239</td>
<td>1.4</td>
<td>98</td>
<td>1.15</td>
<td>0.2% hepatic to nontoxic metabolites</td>
<td>Bronchodilation, airway irritability. ↑ MV (greater than halothane) with ↑ in RR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>168.0</td>
<td>23.5°C</td>
<td>669</td>
<td>0.42</td>
<td>29</td>
<td>6.6</td>
<td>Airway irritability manifest as coughing and breath-holding, ↑ secretions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Toxic Effects

-CHF₂ group may react with dry soda lime to produce CO.
<table>
<thead>
<tr>
<th>Property</th>
<th>Enflurane</th>
<th>Halothane</th>
<th>Xenon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutics</td>
<td>Structural isomer of isoflurane with different physical properties</td>
<td>Light unstable. Corrodes some metals and dissolves into rubber.</td>
<td>Not flammable. Very expensive to produce.</td>
</tr>
<tr>
<td>Structure</td>
<td>![Structure Diagram]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>184.5</td>
<td>197</td>
<td>131</td>
</tr>
<tr>
<td>Boiling point</td>
<td>56.5°C</td>
<td>50.2°C</td>
<td>-108°C</td>
</tr>
<tr>
<td>SVP (mmHg)</td>
<td>175</td>
<td>243</td>
<td>-</td>
</tr>
<tr>
<td>Blood:gas coefficient</td>
<td>1.8</td>
<td>2.4</td>
<td>0.14</td>
</tr>
<tr>
<td>Oil:gas coefficient</td>
<td>98</td>
<td>224</td>
<td>1.9</td>
</tr>
<tr>
<td>MAC</td>
<td>1.7</td>
<td>0.75</td>
<td>71</td>
</tr>
<tr>
<td>Metabolism</td>
<td>~25% undergoes oxidative phosphorylation by CYP450 systems, producing trifluoroacetic acid, which binds to protein and can cause a T-cell mediated hepatitis, which can be fatal in ~1/10,000 anaesthetics.</td>
<td>Not metabolised.</td>
<td></td>
</tr>
<tr>
<td>Resp</td>
<td>Largest ↓ in V̇T, therefore largest ↑ in PaCO₂</td>
<td>↑ in RR, ↓ in V̇T with overall unchanged PaCO₂</td>
<td></td>
</tr>
<tr>
<td>CVS</td>
<td>Produces 3Hz &quot;spike and wave&quot; EEG pattern at high concentrations, resembling grand mal seizures</td>
<td>Greatest ↑ in inotropy, HR, SVR, and MAP. Significant ↑ in catecholamine sensitivity.</td>
<td>More stable MAP, ↑ HR</td>
</tr>
<tr>
<td>CNS</td>
<td>Produces 3Hz &quot;spike and wave&quot; EEG pattern at high concentrations, resembling grand mal seizures</td>
<td>Greatest ↑ in CNS blood flow at &gt; 1.1 MAC</td>
<td>Analgesic, ↑ PONV</td>
</tr>
<tr>
<td>MSK</td>
<td>Direct nephrotoxicity, potentially related to fluoride (though this association is not present with other anaesthetic agents)</td>
<td>Muscle relaxation when &gt;60%. Does not trigger MH.</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>Direct nephrotoxicity, potentially related to fluoride (though this association is not present with other anaesthetic agents)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GU</td>
<td>Least tocolytic effect</td>
<td>Hepatic damage may be: - Reversible transaminitis - Fulminant hepatic necrosis, with a</td>
<td></td>
</tr>
<tr>
<td>Toxic effects</td>
<td>Produces F⁻ ions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
References


Last updated 2017-10-07
## Nitrous Oxide

Describe the pharmacology of nitrous oxide

Describe the comparative pharmacology of nitrous oxide, halothane, enflurane, isoflurane, desflurane, sevoflurane, xenon and ether.

<table>
<thead>
<tr>
<th>Property</th>
<th>Nitrous Oxide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceuticals</td>
<td>Non-flammable but supports combustion. Produced by heating ammonium nitrate to 250°C. Potential contaminants include NH₃, N₂, NO₂, and HNO₃.oine as a liquid, such that the gauge pressure is only accurate when all remaining N₂O is in the gaseous phase. The filling ratio is the mass of N₂O in the cylinder compared to the mass of water it could hold, and is 0.75 in temperate regions, and 0.67 in warmer regions.</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>44</td>
</tr>
<tr>
<td>Boiling point</td>
<td>-88°C</td>
</tr>
<tr>
<td>Critical Temperature/pressure</td>
<td>36.5°C / 72 bar</td>
</tr>
<tr>
<td>SVP (at 20°C)</td>
<td>39,000 mmHg</td>
</tr>
<tr>
<td>Blood:gas coefficient</td>
<td>0.47</td>
</tr>
<tr>
<td>Oil:gas coefficient</td>
<td>1.4</td>
</tr>
<tr>
<td>MAC</td>
<td>105 (MAC awake 68)</td>
</tr>
</tbody>
</table>
| Mechanism of Action           | Several different mechanisms, including:
- Stimulates dynorphin release (acts at KOP receptor)
- Positive allosteric modulator at GABA_A receptor
- NMDA antagonist                                                                                           |
| Metabolism                    | < 0.01% hepatic reduction.                                                                                                                        |
| Resp                          | Diffusion hypoxia due to second gas effect. Small ↓ in VT, ↑ in RR such that MV is unchanged.                                                   |
| CVS                           | ↑ SNS tone, mild myocardial depression. ↑ PVR - beware in pulmonary hypertension.                                                             |
| CNS                           | Powerful analgesic when > 20%, via endorphin and enkephalin modulation, and on opioid receptors. ↑ CBF. Loss of consciousness common at 80%. 1.4x relative risk of PONV |
| GU                            | Not tocolytic - useful adjuvant in GA caesarian section to reduce volatile anaesthetic use                                                        |
| GIT                           | Expansion                                                                                                                                     |
| Metabolic                     | ↑ Homocysteine.                                                                                                                                |
| Toxic Effects                 | More soluble than N₂ means it will rapidly diffuse into air-filled cavities, increasing the volume of compliant cavities (PTHx, bowel), and increasing the pressure of non-compliant cavities (middle ear). Prolonged use (> 6 hours) oxidates cobalt ion in vitamin B₁₂, preventing its action as a cofactor for methionine synthetase, preventing DNA synthesis. This leads to:
- Megaloblastic changes in bone marrow
- Agranulocytosis
- Peripheral neuropathy
- Possible teratogenicity - avoid in early pregnancy
Greenhouse gas. |
**Entonox**

Entonox is a 50/50 mixture of nitrous oxide and oxygen, used as analgesia in labor and minor procedures.

<table>
<thead>
<tr>
<th>Property</th>
<th>Entonox (50% O₂, 50% N₂O)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmaceutics</strong></td>
<td>The gases dissolve each other and behave differently than would be expected from their individual properties. This is the Poynting effect.</td>
</tr>
<tr>
<td><strong>Critical Temperature/Pressure</strong></td>
<td>Pseudocritical temperature of -6°C, below which it will separate into liquid 50% N₂O (with some dissolved O₂), and gaseous O₂. This is most likely to occur at 117 bar, and can lead to delivery of a hypoxic mixture.</td>
</tr>
</tbody>
</table>

Delivery of a hypoxic mix is prevented by:
- Storing cylinders horizontally (↑ area for diffusion)
- Storing cylinders at temperatures > 5°C
- Using a dip tube so that liquid 50% N₂O is used before the gaseous mixture

**References**

3. ANZCA February/April 2006

Last updated 2019-07-18
Opioids

Common Features

<table>
<thead>
<tr>
<th>Property</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uses</td>
<td>Analgesia, sedation, elimination of sympathetic response to laryngoscopy/surgical stress response</td>
</tr>
<tr>
<td>Resp</td>
<td>↓ CNS sensitivity to CO₂ causing respiratory depression (↓ RR &gt; ↓ VT) - ↑ reliance on hypoxic drive (therefore respiratory depression may be potentiated by high FiO₂)</td>
</tr>
<tr>
<td>CVS</td>
<td>↓ HR. May ↓ BP due to histamine release (less with synthetic agents). ↑ PVR</td>
</tr>
<tr>
<td>CNS</td>
<td>Sedation, euphoria. Nausea and vomiting due to CTZ stimulation. Meiosis due to stimulation of the Edinger-Westphal nucleus. ↓ MAC up to 90%</td>
</tr>
<tr>
<td>Renal</td>
<td>↓ RPF, ↑ ADH, ↑ ureteric and sphincter tone</td>
</tr>
<tr>
<td>MSK</td>
<td>Muscle rigidity, pruritus (especially with intrathecal administration)</td>
</tr>
<tr>
<td>Metabolic</td>
<td>↓ ACTH, prolactin, gonadotrophic hormone secretion. ↑ ADH secretion</td>
</tr>
<tr>
<td>GIT</td>
<td>↓ Peristalsis and GIT secretions with subsequent constipation</td>
</tr>
<tr>
<td>Immunological</td>
<td>Impaired: chemotaxis, lymphocyte proliferation, and antibody production</td>
</tr>
</tbody>
</table>

Comparison of Naturally Occurring Opioids

<table>
<thead>
<tr>
<th>Property</th>
<th>Morphine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receptor</td>
<td>MOP, KOP</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>SC/IM/IV/Intrathecal</td>
</tr>
<tr>
<td>pKa</td>
<td>8.0, 23% unionised at physiologic pH.</td>
</tr>
<tr>
<td>Absorption</td>
<td>Low (relative) lipid solubility - slower onset and SC absorption. PO preparations absorbed in small bowel, bioavailability 30% - high first pass metabolism.</td>
</tr>
<tr>
<td>Distribution</td>
<td>~35% protein binding, V₃ 3.5L.kg⁻¹</td>
</tr>
<tr>
<td>Clearance (ml.kg⁻¹.min⁻¹)</td>
<td>15</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic glucuronidation to 70% inactive morphine-3-glucuronide and 10% active morphine-6-glucuronide, which is 13x as potent as morphine. t₁/₂ of 160 minutes.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of active metabolites - accumulation in renal failure</td>
</tr>
<tr>
<td>Time to Peak Effect (IV)</td>
<td>10-30 minutes</td>
</tr>
<tr>
<td>Duration (IV)</td>
<td>3-4 hours</td>
</tr>
<tr>
<td>Equianalgesic Dose (IV, to 10mg IV morphine)</td>
<td>10mg</td>
</tr>
</tbody>
</table>

Comparison of Semisynthetic Opioids
### Oxycodone vs Buprenorphine

<table>
<thead>
<tr>
<th>Property</th>
<th>Oxycodone</th>
<th>Buprenorphine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Receptor</strong></td>
<td>MOP, KOP, DOP</td>
<td>Partial MOP agonist, KOP antagonist (antanalgesic effect)</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO/IV</td>
<td>Topical</td>
</tr>
<tr>
<td><strong>pKa</strong></td>
<td>8.5, &lt; 10% is unionised at physiologic pH.</td>
<td></td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>PO bioavailability 60-80%</td>
<td>Significant 1st pass metabolism</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>As lipid soluble as morphine, 45% protein bound, $V_D \text{3L.kg}^{-1}$. More rapid onset than morphine despite higher pKa potentially due to active CNS uptake</td>
<td></td>
</tr>
<tr>
<td><strong>Clearance (ml.kg$^{-1}$.min$^{-1}$)</strong></td>
<td>13</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Hepatic demethylation to noroxycodone (80%, via CYP3A) and the more potent and active oxymorphone (20%, via CYP2D6). $t_{1/2}$ 200 minutes.</td>
<td>Hepatic to active norbuprenorphine</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal elimination of active drug and metabolites</td>
<td>70% biliary, 30% renal elimination, $t_{1/2}$ 40 hours</td>
</tr>
<tr>
<td><strong>Time to Peak Effect (IV)</strong></td>
<td>5 minutes</td>
<td></td>
</tr>
<tr>
<td><strong>Duration (IV)</strong></td>
<td>4 hours</td>
<td></td>
</tr>
<tr>
<td><strong>Equianalgesic Dose (IV, to 10mg IV morphine)</strong></td>
<td>10mg. Note 10mg PO oxycodone is ≈ 15mg PO morphine due to higher first pass metabolism of morphine</td>
<td></td>
</tr>
</tbody>
</table>

### Comparison of Synthetic Opioids

<table>
<thead>
<tr>
<th>Property</th>
<th>Fentanyl</th>
<th>Alfentanil</th>
<th>Remifentanil</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Receptor</strong></td>
<td>MOP</td>
<td>MOP</td>
<td>MOP</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>SC/IM/IV/Epidural/Intrathecal/Transdermal</td>
<td>IV</td>
<td>IV (contains glycine, so cannot be administered intrathecally)</td>
</tr>
<tr>
<td><strong>pKa</strong></td>
<td>8.4, &lt; 10% unionised at pH 7.4</td>
<td>6.5, 90% unionised at pH 7.4 conferring rapid onset</td>
<td>7.3 means 58% unionised at physiologic pH.</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>Rapid onset of action (&lt; 30s, peak at 5min) due to lipid solubility (600x that of morphine).</td>
<td>90x more lipid soluble than morphine, but more rapid onset than fentanyl. This is due to: 1. Low pKa means a greater proportion is unionised at physiological pH. 2. Lower potency of alfentanil compared to fentanyl means a greater dose is required (Bowman's Principle)</td>
<td>20x more lipid soluble than morphine.</td>
</tr>
</tbody>
</table>
### Distribution

- **600x as lipid soluble as morphine conferring a larger $V_D$ (4L.kg$^{-1}$). 85% protein bound.**

- **90x as lipid soluble as morphine, small $V_D$ of 0.6L.kg$^{-1}$. 90% protein bound.**

- **20x as lipid soluble as morphine, very small $V_D$ of 0.4L.kg$^{-1}$. 70% protein bound. CSHT is constant due to rapid metabolism.**

### Clearance (ml.kg$^{-1}$.min$^{-1}$)

- **13**
- **6**
- **40**

### Metabolism

- **Significant first pass pulmonary endothelial uptake. Hepatic demethylation to inactive norfentanyl. $t_{1/2}\beta$ of 190 minutes, longer than morphine due to higher lipid solubility and $V_D$.**

- **Shorter elimination $t_{1/2}\beta$ than fentanyl (100 minutes) despite lower clearance due to lower $V_D$. Prolonged with administration of midazolam due to CYP3A4-5 competition.**

- **Rapid metabolism by plasma and tissue esterases - $t_{1/2}\alpha$ 10 minutes**

### Elimination

- Renal elimination of inactive metabolites

- Renal elimination of metabolites

- Renal of inactive metabolites

### Time to Peak Effect (IV)

- **5 minutes**
- **90 seconds**
- **1-3 minutes**

### Duration (IV)

- **Variable depending on dose and distribution. With doses > 3μg.kg$^{-1}$ tissues become saturated and the duration of action is significantly prolonged**

- **5-10 minutes**

- **Offset 5-10 minutes from ceasing infusion**

### Equianalgesic Dose (IV, to 10mg IV morphine)

- **150mcg**
- **1mg**
- **50mcg**

---

**References**

4. ANZCA July/September 2010

Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine.

Last updated 2019-07-18
COX Inhibitors

Cyclo-oxygenase inhibitors are typically used to treat mild to moderate pain. Oral COX inhibitors typically have:

- Rapid absorption
- High protein binding
- Low VD

Mechanism of Action

There are two(ish) isoenzymes of COX:

- COX-1
  Important for homeostatic function.

- COX-2
  Induced with tissue damage and contributes to inflammation. COX-2:
  - Exists in the vascular endothelium where it synthesises prostacyclin (which opposes the action of thromboxanes)
  - Inhibition may result in a relative abundance of thromboxane, causing platelet aggregation and vasoconstriction

- COX-3
  Variant of COX-1 which exists centrally and mediates the analgesic and antipyretic effects of paracetamol.

Effects occur due to:

- Decrease in endoperoxidases
  Inhibited by COX.
- Increase in other arachidonic-acid derived factors
  Due to the diversion of arachidonic acid down other pathways.

COX inhibition has different effects in different tissues:

- Prevents subsequent conversion of prostaglandins to thromboxane A2 and PGI2
- Peripherally, inhibition of prostaglandin synthesis is anti-inflammatory
- Centrally, it is anti-pyretic
- In the stomach, it decreases mucous production and leads to mucosal ulceration

- Aspirin (a non-specific COX inhibitor), prevents production of both thromboxane A2 and PGI2
  - As platelets have no nucleus, the COX inhibition remains for the entirety of the platelet lifespan
  - Endothelial cells will produce new COX within hours, and so its anti-inflammatory effects are temporary

Adverse Effects

- Asthma/Bronchospasm
  Secondary to increased leukotriene synthesis due to increased arachidonic acid levels. Occurs in 20% of asthmatics with NSAID use.

- Platelet dysfunction
  A consequence of COX-1 inhibition only, and may result in increased perioperative bleeding risk (though decreased AMI and CVA risk).

- Thrombotic events, including MI and CVA
  Risk is greater with COX-2 inhibitors, due to selective inhibition of prostacyclin. with NNH for non-fatal MI being 500 patient-years, and NNH for fatal MI being 1000 patient-years.
- **Impaired GFR**
  Occurs as a consequence of uninhibited afferent arteriolar constriction. Worse with concurrent hypovolaemia, renal artery stenosis, or concurrent ACE-I use.

- **Gastric erosion**
  A consequence of impaired mucosal secretion through COX-1 inhibition. This can result in pain, anaemia, or fatal bleed. In general, risk of gastric erosion is (from highest to lowest risk):
  - Ketorolac
  - Diclofenac/naproxen
  - Ibuprofen (<1.2g/day)
  - COX-2 Inhibitors

- **Transaminitis** may occur following NSAID use

### Comparison of COX Inhibitors

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Aspirin</th>
<th>Diclofenac</th>
<th>Ketorolac</th>
<th>Ibuprofen</th>
<th>Celecoxib</th>
<th>I</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Irreversible inhibition of platelet thromboxane production. As platelets are anucleate, they are unable to regenerate thromboxane.</td>
<td>Non-selective COX inhibitor</td>
<td>Non-selective COX inhibition</td>
<td>Non-selective COX inhibition</td>
<td>COX-2 inhibitor (30:1 in favour of COX-2)</td>
<td>CC intl (6: fav CC)</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Prevention of arterial thromboembolism, MI, CVA, migraine, analgesia, others (e.g. Still's disease)</td>
<td>Mild-to-moderate pain</td>
<td>Potent anti-analgesic, minimal anti-inflammatory properties</td>
<td>Mild-to-moderate pain</td>
<td>Analgesia, particular chronic arthritic pain</td>
<td>Ac int pai</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>85% protein bound. Weak acid with a pKa of 3, unionised in the stomach and ionised at physiological pH</td>
<td></td>
<td></td>
<td></td>
<td>97% protein bound</td>
<td></td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>Gastric absorption (pKa 3) leads to rapid onset.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Hepatic metabolism to salicylic acid and glucuronides. May have zero-order elimination in overdose.</td>
<td></td>
<td></td>
<td></td>
<td>CYP to inactive metabolites</td>
<td>CYP2C9 to inactive metabolites</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal. Elimination may be increased with urinary alkalisation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Low-dose (100mg)</td>
</tr>
</tbody>
</table>
Dose

daily) selectively inhibits platelet COX, whilst preserving endothelial COX, resulting in decreased platelet aggregation whilst maintaining vasodilation. 300-900mg for analgesia/migraine.

| 50mg BD/TDS | 15-30mg IM/IV Q6H | 400-800mg TDS, or 10mg/kg BD | 100-200mg BD |

Route

PO | PO/PR/IM/IV | IM/IV (off-label in Australia) | PO/PR | PO | IV |

Respiratory

Aspirin uncouples oxidative phosphorylation, increasing O₂ consumption and CO₂ production. It also may stimulate, and (at higher doses) depress the respiratory centre. In overdose, these are significant, and may result in a mixed respiratory and metabolic acidosis.

CVS

MI and CVA risk reduction. Increased bleeding.

Risk of MI similar to COX-2 inhibitors. Local thrombus with IV injection.

Lower dose not associated with prothrombotic events.

Unclear effect on CVA and MI, but recommended to avoid use in IHD/CVD

Metabolic

Reye's syndrome is mitochondrial damage, hepatic failure, and cerebral oedema (and encephalopathy) in children <12. Mortality 40%.

Unclear effect on CVA and MI

References


Last updated 2019-07-18
Tramadol

Tramadol is an analgesic agent with a complicated mechanism of action:

- Action at all opioid receptors, but particularly MOP, causing analgesia as well as nausea and vomiting
- Inhibits 5-HT reuptake which provides descending inhibitory analgesia
- Inhibits NA reuptake descending inhibitory analgesia
- NMDA receptor antagonist

<table>
<thead>
<tr>
<th>Properties</th>
<th>Tramadol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Cyclohexanol derivative. Racemic mixture of (+)Tramadol which has greater MOP and 5HT reuptake effects, and (-)Tramadol, which mediates NA reuptake inhibition</td>
</tr>
<tr>
<td>Uses</td>
<td>Analgesia</td>
</tr>
<tr>
<td>Presentation</td>
<td>Racemic mixture - each isomer has complementary effects. IV solution is clear at 50mg.ml⁻¹</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO/IV/Topical</td>
</tr>
<tr>
<td>Dosing</td>
<td>50-100mg QID. Potency 1/5th that of morphine.</td>
</tr>
<tr>
<td>Absorption</td>
<td>Bioavailability 70%</td>
</tr>
<tr>
<td>Distribution</td>
<td>V_D 4L.kg⁻¹</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic to active and inactive metabolites</td>
</tr>
<tr>
<td>Excretion</td>
<td>Urinary of predominantly inactive metabolites, t_1/2β 300 minutes</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Minimal respiratory depression</td>
</tr>
<tr>
<td>CVS</td>
<td>Avoid concomitant MAO-I use given NA reuptake inhibition</td>
</tr>
<tr>
<td>CNS</td>
<td>Increased seizure risk in those with epilepsy or concurrent SSRI/SNRI/TCA use. Minimal addiction potential</td>
</tr>
<tr>
<td>GIT</td>
<td>N/V</td>
</tr>
</tbody>
</table>

References


Last updated 2019-07-18
Paracetamol

Paracetamol an analgesic and antipyretic which is typically classed as an NSAID, though it is unique and important enough to get its own page. It has a number of mechanisms of action:

- **Non-selective COX inhibition**, including COX-3
  This confers some of the analgesic properties
- **Inhibition of central prostaglandin synthesis**
  This confers the antipyretic effect by inhibiting prostaglandin E synthesis in the anterior hypothalamus in response to pyrogens
- **Serotonergic inhibition**
  Provides some additional analgesic action
- **Cannabinoid inhibition**
  Provides some additional analgesic action via endocannabinoid reuptake inhibition.

<table>
<thead>
<tr>
<th>Property</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>NSAID, acetanilide derivative</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Analgesia, antipyretic</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Tablets, capsules, syrup, clear colourless solution for IV administration</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO/PR/IV</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>10-15mg.kg⁻¹ Q4H up to 90mg.kg⁻¹.day⁻¹</td>
</tr>
<tr>
<td><strong>Onset</strong></td>
<td>IV: 5 mins, peak at 40 mins</td>
</tr>
<tr>
<td></td>
<td>PO/PR: 40 mins, peak at 1 hour</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>Rapid absorption (via small bowel, therefore proportional to gastric emptying), variable bioavailability (up to 90%) - greater by PR route</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>10% protein bound, small Vd: 0.5-1L.kg⁻¹ (though larger than other NSAIDs)</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Predominantly hepatic glucuronidation. However, 10% is metabolised to NAPQI by CYP2E1 which is hepatotoxic.</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Active secretion into renal tubules - consider dose reduction in renal impairment</td>
</tr>
<tr>
<td><strong>Resp</strong></td>
<td>May exacerbate analgesic asthma due to glutathione depletion</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Excellent analgesia. Synergistic with other analgesics, resulting in agent-sparing effect and reduced side effects</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td>Antipyretic</td>
</tr>
<tr>
<td><strong>Haeme</strong></td>
<td>Cytopaenias (rare)</td>
</tr>
</tbody>
</table>

**Toxicity**

- Paracetamol is partially metabolised to the toxic N-acetyl-p-amino-benzoquinone imine (NAPQI)
  - In normal circumstances this rapidly conjugated with glutathione
  - In toxicity, glutathione is exhausted
  - NAPQI then covalently binds to critical proteins in hepatocytes, causing centrilobular hepatic necrosis and cell death
Toxic doses:
- $>200\text{mg.kg}^{-1}$ in a single ingestion
- Repeated ingestion of $>150\text{mg.kg}^{-1}\text{day}^{-1}$ for two days
- $>100\text{mg.kg}^{-1}\text{day}^{-1}$ for three days

Risk factors for toxicity:
- Glutathione deficiency
  - Extremes of age
  - Malnutrition
  - Hepatic dysfunction
- Enzyme inducers:
  - Anti-epileptics
    - Carbamazepine
    - Phenytoin
    - Phenobarbitone
  - Rifampicin
  - ETOH
  - OCP

Features of Overdose

- Conscious
- Nausea, vomiting, and epigastric pain
- Haemolytic anaemia
- Distributive shock
- Hyperglycaemia
- Late ($>48$ hours) hepatic failure
- Later (3-5 days) coagulopathy
- Fulminant hepatic failure (3-7 days)

Treatment of Overdose

- Activated charcoal with tablet ingestion if seen within 1 hour of ingestion.
- Serum paracetamol level to determine requirement for NAC (N-acetylcysteine) based on the nomogram
  - IV NAC is used as it is a glutathione precursor, replenishing depleted glutathione and facilitating further conjugation of NAPQI

References

3. Paracetamol Poisoning. Royal Children's Hospital.

Last updated 2019-07-18
Antimuscarinics (Cardiac)

Antimuscarinics used for bronchodilation are covered under Antimuscarinics (Respiratory), whilst atropine is covered separately.

Antimuscarinics are as competitive, reversible antagonists of ACh at the muscarinic receptor. They are divided into:

- Naturally occurring tertiary amines
  These can cross the blood-brain barrier, and have central effects.
  - Atropine
  - Hyoscine

- Synthetic quaternary amines
  Do not cross the blood-brain barrier.
  - Glycopyrrolate

<table>
<thead>
<tr>
<th>Property</th>
<th>Glycopyrrolate</th>
<th>Hyoscine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Quaternary amine. Muscarinic antagonist</td>
<td>Tertiary amine</td>
</tr>
<tr>
<td>Uses</td>
<td>Bradycardia, antisialagogue</td>
<td>Antisialagogue, motion sickness</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear, colourless solution at 200μg.ml⁻¹. Incompatible with diazepam and thiopentone.</td>
<td>Racemic, only L-isomer active</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV/IM</td>
<td>PO, SC, IV/IM</td>
</tr>
<tr>
<td>Dosing</td>
<td>200-400μg</td>
<td>20-40mg IV slow push or IM</td>
</tr>
<tr>
<td>Absorption</td>
<td>Minimal PO absorption - not used via this route.</td>
<td>&lt; 50% PO bioavailability</td>
</tr>
<tr>
<td>Distribution</td>
<td>Crosses placenta but not BBB, Vₐ 0.5L.kg⁻¹</td>
<td>VD 2L.kg⁻¹</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Minimal hepatic hydrolysis</td>
<td>Extensive metabolism by hepatic esterases</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal of 85% unchanged drug</td>
<td>Renal of metabolites</td>
</tr>
<tr>
<td>Resp</td>
<td>Bronchodilation, antisialagogue</td>
<td>Bronchodilation, greatest antisialagogue effect</td>
</tr>
<tr>
<td>CVS</td>
<td>Initial bradycardia due to partial agonist effect. Reverses vagal causes of bradycardia, may cause tachycardia in doses &gt;200μg. HR peaks at 3-9 minutes following administration.</td>
<td>Least likely anticholinergic to cause tachycardia</td>
</tr>
<tr>
<td>CNS</td>
<td>Most likely anticholinergic to cause central anticholinergic syndrome</td>
<td></td>
</tr>
<tr>
<td>MSK</td>
<td>Anhydrosis</td>
<td></td>
</tr>
<tr>
<td>GIT</td>
<td>Reduced oral and gastric secretions, and gastric motility</td>
<td>Reduced oral and gastric secretions, and gastric motility. Increases biliary peristalsis</td>
</tr>
<tr>
<td>GU</td>
<td>Difficult micturition</td>
<td></td>
</tr>
</tbody>
</table>

References

Last updated 2018-07-29
## Anticholinesterases

Anticholinesterases antagonise AChE, decreasing the breakdown of ACh and therefore increasing its availability at the:

- **Nicotinic receptor**
  - Increases muscle strength.
  - Reversal of non-depolarising neuromuscular blockade
- **Muscarinic receptor**
  - Increases parasympathetic tone.

Anticholinesterases can be:

- Reversible
- Form a carbamylated enzyme complex
- Irreversible

<table>
<thead>
<tr>
<th>Property</th>
<th>Neostigmine</th>
<th>Organophosphates</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Quaternary amine, forms carbamylated enzyme complex</td>
<td>Irreversible anticholinesterase</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Reversal of non-depolarising NMB, myasthenia gravis, analgesia</td>
<td>Insecticides, pesticides, chemical weapons</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Clear, colourless, light stable solution at 2.5mg.ml⁻¹</td>
<td></td>
</tr>
<tr>
<td><strong>Route of</strong></td>
<td>PO, IV, intrathecal</td>
<td>Topical</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>0.05mg.kg⁻¹ for reversal, 15-30mg PO for MG</td>
<td></td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>Low PO bioavailability</td>
<td>Rapid topical absorption due to high lipid solubility</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>Does not cross BBB, Vd 0.7L.kg⁻¹</td>
<td>Crosses BBB</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Majority by plasma esterases to quaternary alcohol, with some hepatic metabolism</td>
<td>Not metabolised</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>55% unchanged in urine</td>
<td>t½/2a of weeks</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>50 minutes</td>
<td>Until new AChE is synthesised</td>
</tr>
<tr>
<td><strong>Resp</strong></td>
<td>Bronchospasm, ↑ secretion</td>
<td>Bronchospasm, ↑ secretion</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>↓ HR (may be profound), ↓ CO</td>
<td>↓ HR, ↓ CO</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>N/V and analgesic when administered intrathecally, cerebral vasoconstriction</td>
<td>Central cholinergic syndrome</td>
</tr>
<tr>
<td><strong>MSK</strong></td>
<td>Reversal of NMB, ↑ fasciculations, ↑ sweating, may cause paralysis</td>
<td>Paralysis</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>↑ Peristalsis, ↑ LoS tone, N/V</td>
<td>↑ Peristalsis, ↑ LoS tone, N/V</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Muscarinic receptors affected at low dose, nicotinic receptors at high dose</td>
<td>May be reversed in initial stages (before organophosphate-AChE complex has ‘aged’) with pralidoxime</td>
</tr>
</tbody>
</table>
References

2. ANZCA 2007 Feb/April

Last updated 2019-07-18
Depolarising NMBs

Succinylcholine binds to the nicotinic ACh receptor causing depolarisation. It cannot be hydrolysed by acetylcholinesterase in the NMJ, and so remains bound to the receptor. This:

- Produces a sustained depolarisation which keeps voltage-gated sodium channels in their inactive state
- Prevents the post-junctional membrane from responding to further ACh release

<table>
<thead>
<tr>
<th>Property</th>
<th>Succinylcholine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Depolarising muscle relaxant.</td>
</tr>
<tr>
<td>Uses</td>
<td>Facilitate tracheal intubation.</td>
</tr>
<tr>
<td>Presentation</td>
<td>Colourless solution of pH 3, at 50mg.ml⁻¹. Structurally, it is two ACh groups joined at the acetyl groups.</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV, IM.</td>
</tr>
<tr>
<td>Dosing</td>
<td>1-2mg.kg⁻¹ IV, 3-4mg.kg⁻¹ IM up to 150mg.</td>
</tr>
<tr>
<td>Onset and Duration</td>
<td>IV onset in 30s to 1 minute, lasting 2-3 minutes, with offset typically within 10 minutes. Offset occurs due to dissociation of drug out of NMJ into plasma, as a concentration gradient is established by drug breakdown in plasma. Prolonged duration in patients with pseudocholinesterase deficiency. IM onset in 2-3 minutes.</td>
</tr>
<tr>
<td>Distribution</td>
<td>30% protein bound. Nil distribution due to rapid metabolism - VD 0.25L.kg⁻¹. Crosses placenta in very small amounts.</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Rapid hydrolysis by plasma cholinesterases such that only 20% of administered dose reaches the NMJ.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Minimal renal elimination due to rapid metabolism.</td>
</tr>
<tr>
<td>Resp</td>
<td>Apnoea, and suxamethonium apnoea. May cause masseter spasm. † Salivation due to muscarinic effects.</td>
</tr>
<tr>
<td>CVS</td>
<td>Arrhythmia due to SA node stimulation, as well as secondary to hyperkalaemia. Bradycardia (due to muscarinic effects with second/large doses, or in children).</td>
</tr>
<tr>
<td>CNS</td>
<td>† ICP (due to contraction), † IOP (by 10mmHg - this is significant) such that it is contraindicated in globe perforation.</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Malignant Hyperthermia.</td>
</tr>
<tr>
<td>MSK</td>
<td>Myalgias post depolarisation, particularly in young females. Prolonged blockade with pseudocholinesterase deficiency.</td>
</tr>
<tr>
<td>Renal and Electrolyte</td>
<td>Hyperkalaemia (K⁺ † by ~0.5mmol.L⁻¹) due to depolarisation causing K⁺ efflux, † in burns (&gt;10%), paraplegia (first 6 months) and neuromuscular disorders including critical illness myopathy.</td>
</tr>
<tr>
<td>GIT</td>
<td>Intragastric pressure † by 10cmH₂O, matched by † in LoS pressure.</td>
</tr>
<tr>
<td>Immunological</td>
<td>Anaphylaxis - highest risk of all NMBs at ~11/100,000</td>
</tr>
</tbody>
</table>

Adverse Effects

The adverse effects of suxamethonium can be remembered as three major, three minor, and three pressures:

- Major
- Anaphylaxis
- Suxamethonium Apnoea
- Malignant hyperthermia
- Minor
  - Hyperkalaemia
  - Myalgias
  - Bradycardia
- Pressure
  - IOP
  - ICP
  - Intragastric pressure

## Phase I and Phase II Blockade

Initial blockade is termed **Phase I**, which is a partial depolarising block. Sustained use of suxamethonium may cause a Phase II block which:

- Appears similar to a non-depolarising block
- May be due to:
  - Presynaptic inhibition of ACh synthesis and release
  - Desensitisation of the post-junctional receptor

**Key differences include:**

<table>
<thead>
<tr>
<th>Property</th>
<th>Phase I Block</th>
<th>Phase II Block</th>
</tr>
</thead>
<tbody>
<tr>
<td>Block Amplitude</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>Train-of-four ratio</td>
<td>&gt;0.7</td>
<td>&lt; 0.7</td>
</tr>
<tr>
<td>Post-tetanic potentiation</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Effect of anticholinesterases</td>
<td>Block augmented</td>
<td>Block inhibited</td>
</tr>
</tbody>
</table>

## Malignant Hyperthermia

- Rare autosomal dominant genetic condition
- Triggered by suxamethonium and volatile anaesthetic agents
- Mutation of the ryanodine receptor causes excessive amounts of calcium to leave the sarcoplasmic reticulum, causing continual muscle contraction
  - Results in greatly increased carbon dioxide, lactate, and heat production
  - Cell lysis with myoglobinaemia and hyperkalaemia results

## Suxamethonium Apnoea

- A deficiency of butylcholinesterase causes suxamethonium to not be metabolised
- May be congenital (genetic) or acquired (hepatic failure)
- Can be treated with fresh frozen plasma

## References
2. Suxamethonium Chloride Injection BP PRODUCT INFORMATION

Last updated 2019-07-18
Non-Depolarising Neuromuscular Blockers

Non-depolarising NMBs are muscle relaxants used to:

- Facilitate laryngoscopy and tracheal intubation
- Control ICP
- Improve respiratory system compliance
- Improve patient safety on transportation

Mechanism of action is by competitive antagonism of ACh at the NMJ, preventing generation of end-plate potentials. Effective pharmacodynamic response requires >70% receptor occupation.

Common Features of Neuromuscular Blockers

<table>
<thead>
<tr>
<th>Property</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>IV/IM</td>
</tr>
<tr>
<td>Distribution</td>
<td>Small V&lt;sub&gt;D&lt;/sub&gt; as they are polar and unable to cross lipid membranes</td>
</tr>
<tr>
<td>Elimination</td>
<td>Reduced urinary clearance which prolongs the mechanism of action of aminosteroids in renal failure</td>
</tr>
<tr>
<td>Resp</td>
<td>Apnoea</td>
</tr>
<tr>
<td>MSK</td>
<td>↑ Duration in hypothermia</td>
</tr>
<tr>
<td>Renal</td>
<td>↑ Duration in acidosis, ↑ duration in hypokalaemia, ↓ duration in hyperkalaemia, ↑ duration in hypermagnesaemia</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Critical Illness Myopathy in patients with long-term relaxant use</td>
</tr>
</tbody>
</table>

The ED<sub>95</sub> is:

- The dose of a neuromuscular blocking drug required to produce a 95% reduction in twitch height in 50% of the population
- A commonly-used therapeutic end-point for neuromuscular blocking drugs
  Typically, induction doses used are 2-5x the ED<sub>95</sub>.

Comparison of Neuromuscular Blockers

<table>
<thead>
<tr>
<th>Property</th>
<th>Rocuronium</th>
<th>Vecuronium</th>
<th>Pancuronium</th>
<th>Atracurium</th>
<th>Cisatracurium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Aminosteroid</td>
<td>Aminosteroid</td>
<td>Bis-quaternary aminosteroid</td>
<td>Benzylisoquinolinium derivative</td>
<td>Benzylisoquinolinium derivative</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear, colourless solution at 10 mg.ml&lt;sup&gt;−1&lt;/sup&gt;</td>
<td>10mg powder for reconstitution in water. Contains mannitol and NaOH.</td>
<td>Colourless solution at 2 mg.ml&lt;sup&gt;−1&lt;/sup&gt;, which must be stored at 4°C</td>
<td>Colourless solution at 10mg.ml&lt;sup&gt;−1&lt;/sup&gt;, which should be stored at 4°C</td>
<td>R-Cis, R'-Cis isomer of atracurium, which is 15% of atracurium by weight but provides 50% of its NMBD action. Colourless solution a 2-5mg.ml&lt;sup&gt;−1&lt;/sup&gt;, which should be stored at 4°C</td>
</tr>
<tr>
<td>Intubating Dose</td>
<td>0.6-1.2 mg.kg⁻¹</td>
<td>0.1 mg.kg⁻¹</td>
<td>0.05-0.1 mg.kg⁻¹</td>
<td>0.5 mg.kg⁻¹</td>
<td>0.15-0.2 mg.kg⁻¹</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>ED₉₅</td>
<td>0.3 mg.kg⁻¹</td>
<td>0.05 mg.kg⁻¹</td>
<td>0.07 mg.kg⁻¹</td>
<td>0.25 mg.kg⁻¹</td>
<td>0.05 mg.kg⁻¹</td>
</tr>
<tr>
<td>Onset</td>
<td>45-90s</td>
<td>90-120s</td>
<td>90-150s</td>
<td>90-120s</td>
<td>60-180s</td>
</tr>
<tr>
<td>Duration</td>
<td>~30 minutes with normal renal function, repeat doses may be more unpredictable</td>
<td>45-65 minutes</td>
<td>60-100 minutes</td>
<td>15-35 minutes</td>
<td>25-30 minutes</td>
</tr>
<tr>
<td>Metabolism</td>
<td>&lt; 5% hepatic deacetylation to inactive metabolites</td>
<td>20% hepatic deacetylation with weakly active metabolites</td>
<td>20% hepatic deacetylation with weakly active metabolites</td>
<td>60% by ester hydrolysis, with remainder by Hofmann elimination. Metabolised to laudanosine, which causes seizures in high concentrations (relevant when administered by long infusion)</td>
<td>Hofmann elimination</td>
</tr>
<tr>
<td>Elimination</td>
<td>60% biliary, 40% urinary. Prolonged duration in hepatic and renal failure</td>
<td>70% biliary, 30% urinary</td>
<td>80% biliary, 20% urinary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resp</td>
<td>↑ HR at high doses</td>
<td>No ↑ HR</td>
<td>↑ HR and MAP due to muscarinic antagonism</td>
<td>Risk of ↓ BP with rapid injection</td>
<td>Slight risk of bronchospasm with rapid injection</td>
</tr>
<tr>
<td>CVS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune</td>
<td>Higher risk of anaphylaxis, ~6/100,000. Anaphylaxis risk associated with use of pholcodine in the previous 3 years.</td>
<td>Notably no anaphylaxis recorded in NAP 6</td>
<td></td>
<td>Anaphylaxis ~ 4/100,000.</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Reversible with sugammadex</td>
<td>Reversible with sugammadex</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**References**


Last updated 2019-07-20
**Dantrolene**

Dantrolene is a ryanodine (RYR1) receptor antagonist, which prevents release of Ca\(^{2+}\) from the sarcoplasmic reticulum, uncoupling the process of excitation-contraction.

<table>
<thead>
<tr>
<th>Property</th>
<th>Dantrolene</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uses</strong></td>
<td>MH, NMS, ecstasy intoxication, chronic muscle spasticity</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Vials of orange powder containing 20mg dantrolene and 3g mannitol, reconstituted with 60ml of H(_2)O to form an alkaline solution.</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>2.5mg.kg(^{-1}) IV every 10-15 minutes, up to 10mg.kg(^{-1}). Once resolved, continue giving 1mg.kg(^{-1}) every 4-6 hours for 24 hours.</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>IV only, may cause skin necrosis if extravasates.</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>85% protein bound</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Hepatic metabolism to active 5-hydroxy-dantrolene</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal of metabolites, t(_1/2) of 12 hours</td>
</tr>
<tr>
<td><strong>Resp</strong></td>
<td>Respiratory failure due to skeletal muscle weakness</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>Volume overload due to large volume given with administration</td>
</tr>
<tr>
<td><strong>MSK</strong></td>
<td>Skeletal muscle relaxation</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>Diuresis</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>Hepatic failure</td>
</tr>
</tbody>
</table>

**References**

3. ANZCA August/September 2011

Last updated 2017-09-16
Sugammadex

<table>
<thead>
<tr>
<th>Property</th>
<th>Sugammadex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Gamma cyclodextrin.</td>
</tr>
<tr>
<td>Uses</td>
<td>Reversal of neuromuscular block induced by rocuronium and vecuronium.</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear colourless solution at 100mg.mL(^{-1}).</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>Store below 30°C.</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV only.</td>
</tr>
<tr>
<td>Dosing</td>
<td>2mg.kg(^{-1}) if ToF &gt; 2.</td>
</tr>
<tr>
<td></td>
<td>4mg.kg(^{-1}) if PTC &gt; 2.</td>
</tr>
<tr>
<td></td>
<td>16mg.kg(^{-1}) for reversal following RSI dose.</td>
</tr>
<tr>
<td>Distribution</td>
<td>(V_D) of 11-14L.kg(^{-1}).</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Not metabolised.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of active drug and complex.</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>Forms a complex with rocuronium and vecuronium, causing reversal of neuromuscular blockade.</td>
</tr>
<tr>
<td>CVS</td>
<td>Rarely may precipitate bradycardia - can result in cardiac arrest.</td>
</tr>
<tr>
<td>Immune</td>
<td>Anaphylaxis.</td>
</tr>
<tr>
<td>Other</td>
<td>Interacts with OCP - treat as missed pill</td>
</tr>
<tr>
<td></td>
<td>Shortened duration of rocuronium and vecuronium when used within 24 hours of sugammadex administration. Onset is delayed up to 5 minutes, and duration shortened by 10-15 minutes. This period may be extended in renal failure.</td>
</tr>
</tbody>
</table>

References

1. Sugammadex Full Prescribing Information. FDA.

Last updated 2019-07-20
## Anticoagulants

<table>
<thead>
<tr>
<th>Property</th>
<th>Warfarin</th>
<th>Heparin</th>
<th>Enoxaparin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uses</strong></td>
<td>AF, DVT/PE, Prosthetic Valves</td>
<td>AF, DVT/PE, Extra-corporeal Circuit Anticoagulation</td>
<td>DVT Prophylaxis</td>
</tr>
<tr>
<td><strong>Pharmaceutics</strong></td>
<td>Marevan and coumadin may potentially have different bioavailabilities (it has not been assessed) and so should not be substituted</td>
<td>Mucopolysaccharide organic acid which occurs naturally in the liver and in mast cells, with a highly variable molecular weight (between 5,000 and 25,000 Da)</td>
<td>Smaller fragments of heparin (prepared from UFH), with a mean molecular weight of 5,000 Da</td>
</tr>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Prevents the return of vitamin K to its reduced form, and therefore the gamma-carboxylation of vitamin-K dependent clotting factors (II, VII, IX, X), as well as Protein C and Protein S)</td>
<td>Potentiates the effect of ATIII, rapidly increasing its anti-IIa and anti-Xa effect (1:1 effect). In higher concentrations also inhibits IXa, Xla, XIIa, and platelet aggregation.</td>
<td>Potentiates the action of ATIII, increasing inhibition of Xa and Ia, but (unlike UFH) in a 4:1 ratio. More predictable effect on Xa standardises dosing and justifies lack of monitoring requirement.</td>
</tr>
<tr>
<td><strong>Onset</strong></td>
<td>8-12 hours. Peak at 72 hours due to the half-life of existing clotting factors, and the total body stores of vitamin K</td>
<td>Immediate IV onset</td>
<td></td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>100% bioavailability</td>
<td>IV, SC</td>
<td>SC only</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>99% protein bound</td>
<td>Low lipid solubility, highly protein bound</td>
<td>Does not bind to heparin-binding proteins</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Complete hepatic metabolism. Significant pharmacokinetic interaction with enzyme inducers and inhibitors.</td>
<td>Hepatic interactions due to enzymatic induction (ETOH, amiodarone, salicylates, NSAIDs) and inhibition (OCP, barbiturates, carbamazepine)</td>
<td>Renal elimination of metabolites</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Faecal and renal elimination of metabolites, t1/2β of 40 hours</td>
<td>Renal of inactive metabolites</td>
<td>Renal of active drug and inactive metabolites</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>Microthrombi</td>
<td>Hypotension with rapid IV administration</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td>Less osteoporosis due to less protein (and therefore tissue) binding</td>
<td>Osteoporosis</td>
<td></td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>Inhibits aldosterone secretion</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>N/V</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Haeme</strong></td>
<td>Haemorrhage</td>
<td>Haemorrhage, HITTs</td>
<td>Haemorrhage, lower risk of HITTs than UFH. Less thrombocytopenia.</td>
</tr>
<tr>
<td><strong>Immune</strong></td>
<td>Hypersensitivity reactions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reversal</td>
<td>Waiting</td>
<td>Vitamin K</td>
<td>FFP</td>
</tr>
<tr>
<td>----------</td>
<td>---------</td>
<td>-----------</td>
<td>-----</td>
</tr>
<tr>
<td>Other</td>
<td>Teratogenic. Complicated pharmacokinetics requiring monitoring using INR.</td>
<td>Requires monitoring with APTT or ATIII levels. Large interpatient variability due to variable amounts of ATIII.</td>
<td>1 unit is the amount of heparin required to prevent 1ml of blood clotting for 24 hours at 0°C</td>
</tr>
</tbody>
</table>

**HITTs**

**Heparin-Induced Thrombotic Thrombocytopenia** comes in two flavours:

- **Type I:**
  - Is non-immune mediated
  - Occurs within 4 days of anticoagulant doses
  - Is an isolated thrombocytopenia without clinical significance

- **Type II:**
  - Is immune mediated
  - Occurs within 4-14 days
  - Is associated with serious thrombosis and high mortality (typically from PE) and morbidity (from CVA and limb ischaemia)

**Protamine**

Protamine is:

- A basic cationic protein derived from salmon sperm which combines with the acidic anionic heparin to form a stable, inactive salt in solution
- Cleared more rapidly than heparin
  Rebound anticoagulation may occur.

Adverse effects from protamine include:

- Histamine release
  - Bronchospasm
  - Hypotension
- Pulmonary hypertension
  This can be profound and result in a dramatic increase in RV afterload and EDV, with a corresponding fall in LV preload (interventricular interdependence), leading to dramatic hypotension and arrest.
  - Mediated by thromboxanes
  - Due to protamine-heparin complexes, rather than protamine alone
    Administration of protamine in absence of heparin does not lead to pulmonary hypertension.
- Anticoagulation
  When given in excess.

**References**
3. ANZCA August/September 2011

Last updated 2019-07-18
Direct Thrombin Inhibitors

Direct thrombin inhibitors prevent cleavage of fibrinogen to fibrin, and are therefore very effective anticoagulants.

<table>
<thead>
<tr>
<th>Property</th>
<th>Dabigatran</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>NOAC</td>
</tr>
<tr>
<td>Uses</td>
<td>VTE prophylaxis, AF</td>
</tr>
<tr>
<td>Presentation</td>
<td>75/110mg Capsules</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO</td>
</tr>
<tr>
<td>Dosing</td>
<td>VTE: 220mg daily, AF: 150mg BD</td>
</tr>
<tr>
<td>Absorption</td>
<td>6.5% bioavailability</td>
</tr>
<tr>
<td>Distribution</td>
<td>35% protein bound</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Prodrug - activated by plasma and hepatic esterases</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of active drug</td>
</tr>
<tr>
<td>Haeme</td>
<td>Haemorrhage</td>
</tr>
<tr>
<td>Immune</td>
<td>Allergy</td>
</tr>
<tr>
<td>Other</td>
<td>Significant interactions with amiodarone, quinidine, St. John's Wort, as well as other anticoagulant and antiplatelet agents. Dialysable. Potentially reversible with idarucizumab.</td>
</tr>
</tbody>
</table>

References


Last updated 2019-07-18
Antifibrinolytics

Antifibrinolytics include aprotinin, aminocaproic acid, and tranexamic acid. All prevent the breakdown of fibrin (I) by various mechanisms. TXA competitively inhibits plasminogen activator, reducing rate of fibrinolysis.

<table>
<thead>
<tr>
<th>Property</th>
<th>Tranexamic Acid (TXA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Antifibrinolytic</td>
</tr>
<tr>
<td>Uses</td>
<td>Trauma (within 3 hours), cardiac surgery, obstetric surgery, and menorrhagia</td>
</tr>
<tr>
<td>Presentation</td>
<td>Tablets, syrup, clear colourless solution for injection</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IV, PO</td>
</tr>
<tr>
<td>Dosing</td>
<td>1g slow IV, which may be followed by infusion of 1g over 8 hours</td>
</tr>
<tr>
<td>Absorption</td>
<td>50% bioavailability</td>
</tr>
<tr>
<td>Distribution</td>
<td>Low plasma protein binding, $V_D$ 9-12 litres</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Minimal hepatic metabolism</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal of active drug - dose reduce in renal impairment</td>
</tr>
<tr>
<td>GIT</td>
<td>Nausea, vomiting</td>
</tr>
<tr>
<td>Haematological</td>
<td>Reduces fibrinolysis, possible increase in DVT/PE</td>
</tr>
<tr>
<td>Immunological</td>
<td>Allergic dermatitis</td>
</tr>
</tbody>
</table>

References

2. LITFL - Tranexamic Acid

Last updated 2019-07-18
Antiplatelets

Note aspirin is included under COX inhibitors.

Classification of Antiplatelet Agents

Antiplatelet agents can be classified by which stage of platelet function they affect:

- **Adhesion**
  - vWF inhibitors
e.g. Dextran 70.
- **Activation**
  - Prostacyclins
e.g. Epoprostenol.
  - Phosphodiesterase inhibition
e.g. Dipyridamole.
  - COX inhibitors
    Prevent thromboxane A2 production, e.g. aspirin.
- **Aggregation**
  - ADP receptor antagonists
    Prevent activation of GP IIb/IIIa receptors, e.g. clopidogrel.
  - GP IIb/IIIa receptor antagonists
    Prevent platelet aggregation via fibrin linkages between GP IIb/IIIa receptors, e.g. tirofiban.

Comparison of Common Antiplatelet Agents

<table>
<thead>
<tr>
<th>Property</th>
<th>Clopidogrel</th>
<th>Dipyridamole</th>
<th>Tirofiban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>ADP antagonist</td>
<td>Phosphodiesterase inhibitor</td>
<td>GP IIb/IIa antagonists</td>
</tr>
<tr>
<td>Uses</td>
<td>PVD, STEMI, NSTEMI, stent prophylaxis</td>
<td>CVA</td>
<td>UA, NSTEMI</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO only</td>
<td>PO/IV</td>
<td>IV only</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>Irreversibly prevents ADP from binding to its receptor on the platelet, preventing activation of the IIb/IIIa receptor</td>
<td>Inhibits platelet adhesion to walls, potentiates prostacyclin activity and increases platelet cAMP, ( \text{Ca}^{2+} ) and inhibiting platelet aggregation and deformation. Also acts as a coronary vasodilator.</td>
<td>Reversible antagonism of IIb/IIa receptor, preventing platelet aggregation</td>
</tr>
<tr>
<td>Dosing</td>
<td>300mg load, 75mg daily thereafter</td>
<td>200mg BD for CVA</td>
<td>Load 25 mcg.kg(^{-1}), maintenance 15mcg.kg(^{-1})</td>
</tr>
<tr>
<td>Absorption</td>
<td>Rapid absorption and onset within 2 hours</td>
<td>Variable depending on oral intake</td>
<td>IV only. Onset within 10 minutes</td>
</tr>
<tr>
<td>Distribution</td>
<td>Highly protein-bound drug and metabolites</td>
<td>Highly protein bound</td>
<td>65% protein bound</td>
</tr>
</tbody>
</table>
### Metabolism

**Prodrug.** Majority hydrolysed by esterases to inactive drug, with a small proportion hepatically metabolised by CYP450 to active form. Prolonged duration of action due to irreversible ADP blockade rather than long elimination half-life.

Partial hepatic to inactive metabolites

Not metabolised.

<table>
<thead>
<tr>
<th>Elimination</th>
<th>Urinary and faecal</th>
<th>Renal and faecal</th>
<th>Urinary as unchanged drug. Platelet aggregation returns to baseline within 4-8 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>Vasodilatation may drop CPP in AS and recent MI</td>
<td>Coronary artery dissection</td>
<td></td>
</tr>
<tr>
<td>GIT</td>
<td>Mucosal irritation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haeme</td>
<td>Haemorrhage</td>
<td>Thrombocytopenia and haemorrhage</td>
<td>Haemorrhage</td>
</tr>
<tr>
<td>Other</td>
<td>Many pharmacokinetic interactions, including genetic variability. Previously thought to kinetically interact with omeprazole - more recently disproved.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### References


Last updated 2019-07-18
Penicillins

- Penicillins are bactericidal antibiotics that prevent cell-wall synthesis by preventing cross-linking of peptidoglycans by replacing the natural substrate with their β-lactam ring
- Penicillins bind to penicillin binding proteins (PBP s) in the bacterial wall
- Penicillins only rarely achieve complete eradication of sensitive organisms without addition of a synergistic antibiotic (such as gentamicin)

Common Features

<table>
<thead>
<tr>
<th>Property</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption</td>
<td>Typically well absorbed orally. IM dosing tend to cause localised pain and irritation.</td>
</tr>
<tr>
<td>Distribution</td>
<td>Typically have good tissue penetration. Only cross the blood-brain barrier and enter bone if it is inflamed. Typically low protein binding (exception is flucloxacillin, which is 95% protein bound).</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Typically small proportion is hepatically metabolised.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Majority (60-90%) is eliminated unchanged in urine predominantly by active tubular secretion, with renal clearance proportional to total renal plasma flow. A small quantity is secreted in bile.</td>
</tr>
</tbody>
</table>

Mechanisms of Resistance

- Alteration or protection of PBP s
  - Gram negative bacteria may have altered permeability of porins in their outer membrane, which protects the PDP
- Hydrolysis by β-lactamase-producing bacteria
  - Clavulanic acid and tazobactam inhibit β-lactamase, which can render otherwise resistant bacteria sensitive
  - Notably, flucloxacillin has a modified beta-lactam ring that is not sensitive to β-lactamases

Comparison of Penicillins

<table>
<thead>
<tr>
<th>Examples</th>
<th>Narrow spectrum, naturally occurring</th>
<th>Narrow spectrum, synthetic</th>
<th>Extended spectrum</th>
<th>Antipseudomonal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications</td>
<td>Gram positives and anaerobes, particularly streptococci and meningococci. Also listeria, Clostridia, and Treponema.</td>
<td>Gram positive cocci, particularly staphylococci but also streptococci.</td>
<td>Gram positive, particularly enterococci. Some gram negative.</td>
<td>Gram positive, gram negative including pseudomonas.</td>
</tr>
<tr>
<td>Other bits</td>
<td>Highly bactericidal</td>
<td>Less active than benzylpenicillin on organisms sensitive to both.</td>
<td>Can penetrate some gram-negatives.</td>
<td>Gram negative cover.</td>
</tr>
</tbody>
</table>

References
4. CICM July/September 2007

Last updated 2019-07-18
# Glycopeptides

Non-β-lactam agents that inhibit cell wall synthesis. They are:

- Active against gram-positive anaerobes and aerobes
- Bacteriostatic against enterococci and streptococci
- Bactericidal against staphylococci

<table>
<thead>
<tr>
<th>Property</th>
<th>Vancomycin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uses</strong></td>
<td>MRSA, C. difficile</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Powder for reconstitution</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO, IV, Intrathecal</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>Peak levels determined by dose, trough levels by dose and interval</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>No oral bioavailability. Poor CSF penetration</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>$V_D$ 0.4-1 L.kg$^{-1}$. Poor CSF penetration even with inflamed meninges - higher levels are required for CNS penetration. ~50% protein bound.</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Minimal hepatic metabolism</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>90% secreted unchanged in urine - significantly prolonged in renal impairment</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>Phlebitis, red man syndrome (profound non-anaphylactic histamine release with rapid injection)</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Ototoxicity</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>Nephrotoxicity, typically temporary and resolves on cessation</td>
</tr>
<tr>
<td><strong>Haematological</strong></td>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td><strong>Immunological</strong></td>
<td>'Red man syndrome' due to histamine release with rapid injection, with accompanying ↑ HR ↓ BP. Neutropenia.</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Synergistic action with cephalosporins, aminoglycosides, and rifampicin</td>
</tr>
</tbody>
</table>

## References

2. Wellington ICU Drug Manual

Last updated 2019-07-18
Aminoglycosides

Bactericidal antimicrobials that prevent protein synthesis by irreversible binding to the 30S ribosomal subunit, preventing mRNA transcription.

- As they are large, polar molecules, they must be actively transported into the cell
  - This occurs with an oxygen dependent transporter
  - Therefore they are not effective against anaerobes.
- Transport is inhibited by increased Ca$^{2+}$, Mg$^{2+}$, low pH, and low O$_2$
- Aminoglycoside killing is dependent on the peak concentration over MIC
  - Typically peak concentration must be 8-10x MIC.
  - Exposure to aminoglycosides causes bacteria to down-regulate aminoglycoside uptake, and therefore increases MIC
    - This effect disappears after ~24 hours, and is one justification for daily dosing of aminoglycosides. Additional justifications include:
      - Allows larger single doses to be used, increasing bactericidal effect
      - Aminoglycosides exhibit a post-antibiotic effect
    - Ongoing bactericidal activity even after concentration falls.

<table>
<thead>
<tr>
<th>Property</th>
<th>Gentamicin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uses/Spectrum</strong></td>
<td>Gram negative including pseudomonas, limited gram positive (staph, limited strep), synergistic effects with β-lactams and vancomycin.</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>IV only.</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>4-7mg.kg$^{-1}$.</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>70% protein bound. Very small V$_{D}$ of 0.2L.kg$^{-1}$, which may result in significant pharmacokinetic changes with oedema.</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Not metabolised.</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Eliminated unchanged, elimination t$_{1/2}$ prolonged up to 70 hours in renal impairment.</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Ototoxicity due to accumulation in perilymph, and is usually permanent. Increased risk with concomitant frusemide use.</td>
</tr>
<tr>
<td><strong>MSK</strong></td>
<td>Muscle weakness.</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>Nephrotoxicity due to accumulation in the renal cortex, typically reversible.</td>
</tr>
<tr>
<td><strong>Toxic Effects</strong></td>
<td>Narrow therapeutic index, requires monitoring and dose reduction in renal impairment.</td>
</tr>
</tbody>
</table>

References

3. Deranged Physiology - Kill Characteristics of Antibiotic Agents

Last updated 2017-08-12
**Lincosamides**

Inhibit protein synthesis by disrupting the 50S ribosomal subunit. May be bacteriostatic or bacteriocidal, depending on the concentration and the particular organism.

<table>
<thead>
<tr>
<th>Property</th>
<th>Clindamycin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Spectrum of Activity</strong></td>
<td>Gram positive cocci, anaerobes. Little action against gram negative aerobes. Also active against some protozoa, such as <em>P. falciparum</em>.</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>PO/IV</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>150-300mg Q6H</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>90% PO bioavailability</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>Excellent bony penetration</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Hepatic to active and inactive metabolites</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal elimination of all metabolites</td>
</tr>
<tr>
<td><strong>MSK</strong></td>
<td>May cause neuromuscular blockade in overdose</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>Reasonable incidence of GIT upset, with fatal pseudomembranous colitis reported. Deranged LFTs</td>
</tr>
<tr>
<td><strong>Immune</strong></td>
<td>Atopy, eosinophilia, DRESS</td>
</tr>
</tbody>
</table>

**References**


Last updated 2019-07-18
Metronidazole

Metronidazole interrupts cellular metabolism by preferential reduction, capturing electrons that would be usually transferred to other molecules. This leads to a build up of cytotoxic intermediate metabolic compounds and free radicals, that result in DNA breakage and subsequent cell death.

<table>
<thead>
<tr>
<th>Property</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Nitroimidazole</td>
</tr>
<tr>
<td>Uses</td>
<td>Anaerobes and protozoa</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO/IV</td>
</tr>
<tr>
<td>Dosing</td>
<td>500mg BD</td>
</tr>
<tr>
<td>Absorption</td>
<td>100% bioavailability</td>
</tr>
<tr>
<td>Distribution</td>
<td>Crosses BBB</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic to active metabolites</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal of active metabolites</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Significant rash, nausea, vomiting, headache, flushing</td>
</tr>
<tr>
<td>GIT</td>
<td>Nausea, vomiting, metallic taste</td>
</tr>
<tr>
<td>Immunological</td>
<td>Hypersensitivity reactions</td>
</tr>
<tr>
<td>Interactions</td>
<td>Disulfiram-like reaction with ETOH</td>
</tr>
</tbody>
</table>

References


Last updated 2019-07-18
Antifungals

Antimicrobial agents targeting eukaryotic and heterotrophic microbes. Can be divided by class into:

- Azoles
  Inhibit ergosterol synthesis. Subdivided into:
  - Triazoles
    - Fluconazole
    - Itraconazole
    - Voriconazole
    - Posaconazole
  - Imidazoles
    - Ketoconazole

- Echinocandins
  Inhibit glucan synthesis.
  - Caspofungin
  - Micafungin
  - Anidulafungin

- Polyenes
  Disrupt cell membrane.
  - Amphotericin B
  - Nystatin

Common Features

Mechanisms of Antifungal Resistance

Three broad mechanisms:

- Increased efflux
  Increased expression of transport proteins removing drug from cell.

- Alteration of target enzyme
  Changes to protein target prevent drug binding or inactivation.
  - Typically only requires changes in a few amino acids

- Alteration of drug metabolism
  Reduced enzyme activity prevents accumulation of toxic product.

Amphotericin resistance is rare in vivo, and is typically via different mechanisms:

- Decreased ergosterol content
- Altered sterol:phospholipid ratio

Comparison of Antifungals

<table>
<thead>
<tr>
<th>Drug</th>
<th>Fluconazole</th>
<th>Voriconazole</th>
<th>Caspofungin</th>
<th>Amphotericin B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Azole</td>
<td>AzoleEchinocandins</td>
<td>Polyeses</td>
<td>Candida (including azole resistant)</td>
</tr>
</tbody>
</table>

678
### Antifungals

| Spectrum of Activity | Candida albicans (most other species, especially C. glabrata and to a lesser extent C. krusei are resistant), as resistance rapidly develops), Cryptococcus, Coccioides, Histoplasma, Blastomyces, and some Aspergillus (resistance may also develop rapidly). At least as good as amphotericin in susceptible organisms. | C. glabrata and C. krusei and Candida biofilms), Aspergillus. Notably no activity against Cryptococcus, Fusarium, and trichosporon. Additionally, echinocandins typically have no cross-resistance with other antifungals | Effective against many fungi, with notable exceptions being Chromoblastomycosis, Aspergillus terreus, Candida lusitaniae, Scedosporium, and some Fusarium. |
| Pharmaceuticals | Poor water solubility | Poor water solubility | Poor water solubility | Four different formulations, most common is amphotericin B colloidal dispersion (ABCD) |
| Dosing | 100-800mg OD, adjust in renal failure | Typically 70mg loading dose, followed by 50mg daily; dose reduced in hepatic impairment | Load with 0.25-0.5kg.kg⁻¹, followed by 0.25-1.5mg.day⁻¹, reduced in severe renal impairment |
| Route of Administration | IV or PO | IV only (high MW) | IV for systemic indications |
| Absorption | High PO bioavailability, PO absorption at low pH (interaction with antacids, vitamin supplements) | <5% PO bioavailability |
| Distribution | Crosses BBB - good CSF penetration. Very low protein binding (~10%) | Not dialysable due to very high protein binding, VD. Good tissue penetration. | Essentially no CSF penetration, 97% protein bound in serum | Rapid uptake by reticuloendothelial system. Binds to organic anion transporting peptides (important in hepatocyte drug binding), important in key drug interactions (such as tacrolimus) |
| Metabolism | Metabolised by and cause reversible inhibition of multiple hepatic CYP450 enzymes (including 3A4, 2C19, 2C9), leading to increased concentrations of many drugs/metabolites | As fluconazole | Extensive hydrolysis and N-acetylation to inactive metabolites | Minimal metabolism |
| Elimination | 80% of fluconazole renally eliminated unchanged | Mostly cleared via liver. | Renal of metabolites | Renal and faecal elimination of unchanged drug |
| Mechanism of | Inhibit ergosterol synthesis | | Prevent cell wall synthesis | Binds sterols, disrupting osmotic |

**Antifungals**
### Antifungals

<table>
<thead>
<tr>
<th>Action</th>
<th>by inhibiting CYP450 enzyme</th>
<th>As fluconazole</th>
<th>by blocking production of beta-glucan</th>
<th>integrity of the cell membrane</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>HTN</td>
<td>Long QT</td>
<td>Histamine release</td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>Headache, visual disturbances</td>
<td>Hallucinations, psychosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td></td>
<td></td>
<td>AKI via afferent arteriolar constriction and direct tubular toxicity, hypokalaemia, renal tubular acidosis</td>
<td></td>
</tr>
<tr>
<td>GIT</td>
<td>Hepatotoxicity</td>
<td></td>
<td>Mild hepatotoxicity in up to ~15%</td>
<td></td>
</tr>
<tr>
<td>Haeme</td>
<td></td>
<td></td>
<td>Thrombophlebitis, normocytic anaemia</td>
<td></td>
</tr>
</tbody>
</table>

### References

2. Drew RH. Pharmacology of Amphotericin B. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2018.
3. Ashley ED, Perfect JR. Pharmacology of azoles. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2018.
4. Lewis RE. Pharmacology of echinocandins. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2018.

Last updated 2019-07-18
Insulins

Insulins are synthetic polypeptide hormones. They:

- Have a similar mechanism of action and pharmacodynamics of endogenous insulin
- One unit of insulin is defined as the amount required to make a previously healthy 2kg rabbit hypoglycaemic

Types of Insulin

Different insulins are categorised by their time of onset, peak, and duration, and are classified as either:

- Fast acting
- Intermediate acting
- Long acting

Activity Profiles of Different Types of Insulin

![Insulin Profiles Graph]

**Fast Acting**

Fast acting insulins are used for controlling BSL spikes post meals, and for control of hyperglycaemia. Administered subcutaneously they have have an:

- Onset of 5-15 minutes
- Peak at 1-2 hours
- Last 4-6 hours.

Fast acting insulins include:

- Insulin Aspart (Novorapid)
- Insulin Lispro (Humalog)

**Intermediate Acting**
Intermediate acting insulins are used for control of BSL between meals as a pseudo-basal bolus. Administered subcutaneously they have an:

- Onset of 1-2 hours
- Peak at 4-6 hours
- Last >12 hours

Intermediate acting insulins include:

- NPH
- Protaphane

**Long Acting**

Long acting insulins are used for creating a baseline insulin level. Administered subcutaneously they have an:

- Onset of 1-1.5 hours
- Peak at 5 hours
- Last 24 hours

Long-acting insulins include:

- Insulin glargine (Lantus)
- Insulin detemir (Levemir)

### Pharmacokinetics of Exogenous Insulin Preparations

<table>
<thead>
<tr>
<th>Property</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Synthetic polypeptide hormones</td>
</tr>
<tr>
<td>Uses</td>
<td>Diabetes, hyperglycaemia, hyperkalaemia, β-blocker toxicity, Ca(^{2+})-blocker toxicity</td>
</tr>
<tr>
<td>Presentation</td>
<td>Clear colourless solution typically at 100 IU.ml(^{-1})</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>SC, IM, IV</td>
</tr>
<tr>
<td>Absorption</td>
<td>Variable, as described above. Insulin is complexed with different substances (e.g. protamine, zinc), which alter its rate of absorption</td>
</tr>
<tr>
<td>Distribution</td>
<td>Minimal protein binding and minimal redistribution out of ECF - V(_D) 0.075L.kg(^{-1})</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Glutathione insulin transhydrogenase. Metabolism is constant - duration of action is entirely due to different rates of subcutaneous absorption.</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal of inactive metabolites</td>
</tr>
</tbody>
</table>

### References

## Oral Hypoglycaemics

<table>
<thead>
<tr>
<th>Class</th>
<th>Biguanides</th>
<th>Sulfonylureas</th>
<th>Glitazones</th>
<th>Gliflozins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Example</td>
<td>Metformin</td>
<td>Gliclazide</td>
<td>Pioglitazone</td>
<td>Dapagliflozin</td>
</tr>
<tr>
<td>Uses</td>
<td>T2DM</td>
<td>T2DM</td>
<td>T2DM</td>
<td>T2DM</td>
</tr>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Delay glucose absorption, increase peripheral insulin sensitivity, inhibit hepatic gluconeogenesis</td>
<td>Increase insulin secretion from pancreatic β-cells. May increase insulin sensitivity</td>
<td>Activates the intranuclear PPARγ receptor, affecting gene translation and increasing insulin sensitivity</td>
<td>Inhibits glucose reabsorption by the S-GLUT2 co-transporter in the kidney, increasing glucose elimination in urine</td>
</tr>
<tr>
<td>Dosing</td>
<td>500mg-2g BD</td>
<td>40-160mg BD</td>
<td>15-30mg daily</td>
<td>5-10mg daily</td>
</tr>
<tr>
<td>Absorption</td>
<td>Bioavailability 60%</td>
<td>Bioavailability 80%</td>
<td>High bioavailability. Delayed onset and late peak effect given MoA</td>
<td>Bioavailability &gt; 75%</td>
</tr>
<tr>
<td>Distribution</td>
<td>Minimally protein bound</td>
<td>Extensively bound to albumin by non-ionic forces, such that they do not tend to displace other highly protein bound drugs</td>
<td>Low V&lt;sub&gt;D&lt;/sub&gt; (0.6L.kg&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>Not metabolised</td>
<td>Partial hepatic to inactive metabolites</td>
<td>Extensive hepatic phase I to inactive and active metabolites</td>
<td>Extensive hepatic to inactive metabolites</td>
</tr>
<tr>
<td>Elimination</td>
<td>Renal elimination of active drug and inactive metabolites</td>
<td>Renal elimination of active drug and inactive metabolites</td>
<td>Renal and GI elimination of active and inactive metabolites</td>
<td>Renal of inactive drug</td>
</tr>
<tr>
<td>CVS</td>
<td>May precipitate fluid retention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>Contraindicated in renal impairment due to increased risk of lactic acidosis</td>
<td>Contraindicated in renal impairment (&lt;60ml.min&lt;sup&gt;-1&lt;/sup&gt;) as it has no benefit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSK</td>
<td>Photosensitivity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic</td>
<td>↑ Appetite, weight gain, Hypoglycaemia</td>
<td></td>
<td>Weight loss, reduced insulin requirements</td>
<td></td>
</tr>
</tbody>
</table>
### References

5. ANZCA. Severe Euglycaemic Ketoacidosis with SGLT2 Inhibitor Use in the Perioperative Period. 2018.

Last updated 2019-07-18
## Oxytocics

Oxytocics are agents which increase the force of uterine contraction.

<table>
<thead>
<tr>
<th>Property</th>
<th>Oxytocin</th>
<th>Ergometrine</th>
<th>PGF$_2$α (Dinoprost)</th>
<th>Carboprost</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Endogenous (typically synthetic version used) posterior pituitary hormone</td>
<td>Ergot alkaloid</td>
<td>Prostaglandin</td>
<td></td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Augmentation of labour, increase uterine tone (PPH)</td>
<td>PPH</td>
<td>Severe PPH</td>
<td>Severe PPH</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Clear liquid at 5-10 U.ml$^{-1}$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>IV</td>
<td>IV, IM</td>
<td>Intramyometrical injection, IM</td>
<td>Intramyometrical, IM</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>1.5-12mU.min$^{-1}$</td>
<td>250μg IM (IV in emergency via slow push)</td>
<td>500μg IM</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Oxytocinases in liver and kidney</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Oxytocin GPCR in the uterus, increase Ca$^{2+}$ influx. Structurally similar to ADH.</td>
<td>Acts on α and 5HT$_2$ receptors on uterine and vascular smooth muscle</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Resp</strong></td>
<td>Bronchospasm (may be severe)</td>
<td>Bronchospasm (severe if IV so this route is contraindicated)</td>
<td>Bronchospasm, APO due to ↑PVR with subsequent hypoxia</td>
<td></td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>↑ HR, ↓ BP following boluses</td>
<td>↑ SVR, ↑ BP (may cause, ↓ HR) coronary vasoconstriction</td>
<td>↑ SVR, ↑ BP</td>
<td>↑ SVR, ↑ BP (usually transient)</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Headache, nausea, vomiting</td>
<td>Headache, nausea</td>
<td>Nausea, vomiting</td>
<td>Headache</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>↑ UO due to ADH-like effects with prolonged infusions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GU</strong></td>
<td>↑ Uterine tone (↑ frequency at low dose, tetanic contraction at high dose), foetal distress, lactation</td>
<td>↑ Uterine contraction frequency and tone</td>
<td>↑ Uterine contraction frequency and tone</td>
<td>↑ Uterine contraction frequency and tone, contraindicated in pelvic inflammatory disease</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>May be metabolised by oxytocinases in blood products if co-administered on the same line</td>
<td>Contraindicated in pre-eclampsia due to HTN</td>
<td>Depreciated by carboprost, increased body temperature</td>
<td></td>
</tr>
</tbody>
</table>
References


Last updated 2019-07-18
Tocolytics

Tocolytics are agents which decrease uterine tone. Tocolytics include:

- β2-agonists
- Ca2+-channel antagonists
- COX Inhibitors
- MgSO4
- Nitrates
- Volatile anaesthetic agents

All tocolytics are discussed in more detail elsewhere - this covers just the mechanism of action of their uterine effects.

<table>
<thead>
<tr>
<th>Drug</th>
<th>β2-agonists</th>
<th>Ca2+-channel antagonists</th>
<th>COX Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Example</td>
<td>Salbutamol, Terbutaline</td>
<td>Nifedipine</td>
<td>Indomethacin</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>Activate GPCR, ↑ cAMP, which activates protein kinase A and leads to inhibition of myosin light chain kinase and relaxation</td>
<td>Block L-type Ca2+ channels, causing relaxation</td>
<td>Inhibit prostaglandin synthesis, which are vital for uterine contraction</td>
</tr>
</tbody>
</table>

References

1. Diaz, A. Describe the mechanism of action and side effects of three classes of drugs that are used to increase uterine tone, and three classes of drugs used to decrease uterine tone. Primary SAQs.
# Acid Suppression

<table>
<thead>
<tr>
<th>Property</th>
<th>Non-Particulate Antacids</th>
<th>Particulate Antacids</th>
<th>Proton Pump Inhibitors</th>
<th>H₂ receptor antagonists</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Example</strong></td>
<td>Sodium citrate</td>
<td>Aluminium Hydroxide/Calcium carbonate</td>
<td>Omeprazole</td>
<td>Ranitidine</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Aspiration prophylaxis</td>
<td>Aspiration prophylaxis</td>
<td>Aspiration prophylaxis, GORD, peptic ulceration</td>
<td>Aspiration prophylaxis, GORD, peptic ulceration</td>
</tr>
<tr>
<td><strong>Absorption</strong></td>
<td>Rapid absorption due to high water solubility</td>
<td>Lower water solubility results in slower absorption and onset but no risk of alkalosis</td>
<td>Absorbed in small bowel, high PO bioavailability</td>
<td>50% PO bioavailability</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>Low Vₐ of 0.3 L.kg⁻¹</td>
<td>15% protein bound</td>
<td>Renal of metabolites and active drug</td>
<td>Renal of metabolites and active drug</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Prodrug, activated within parietal cell. CYP450 metabolised, inhibits CYP2C19 (reducing, among other things, the antiplatelet effect of clopidogrel)</td>
<td>Partial hepatic by CYP450</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal of metabolites and active drug</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Base reacts with gastric acid to produce salt and water</td>
<td>Base reacts with gastric acid to produce salt and water</td>
<td>Irreversible antagonism of the parietal H⁺/K⁺ ATPase</td>
<td>Competitive antagonism of the (Gs) H₂ receptor, which ↓ cAMP production, ↓ intracellular Ca²⁺, and ↓ activity of the H⁺/K⁺ ATPase</td>
</tr>
<tr>
<td><strong>Resp</strong></td>
<td>Lower risk of pneumonitis if aspirated</td>
<td>Greater risk of pneumonitis if aspirated</td>
<td>Potentially increased severity of pneumonia if aspiration occurs (risk with micro-aspiration in long-term intubated patients)</td>
<td>Pneumonitis/pneumonia as per PPI</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>Potential metabolic alkalosis</td>
<td>No risk of alkalosis</td>
<td>Interstitial nephritis</td>
<td>↓ HR, ↓ BP, and arrhythmogenic with rapid IV administration</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>↑ Gastric pH</td>
<td>↑ Gastric pH</td>
<td>↑ Gastric pH (pH ↑ by ~1), ↑ volume of secretions</td>
<td></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Taste bad</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## References

2. ANZCA Feb/April 2012

Last updated 2019-07-18
Antiemetics

Antiemetic drugs can be classified by their mechanism of action:

- Serotonin antagonists
  - Ondansetron
- Corticosteroids
  - Dexamethasone
    Has additional effects on postsurgical pain and fatigue.
- Dopamine antagonists
  - Phenothiazines
    - Chlorpromazine
    - Prochlorperazine
  - Butyrophenones
    - Droperidol
  - Benzamides
    - Metoclopramide
- Anticholinergics
  - Hyoscine
  - Atropine
- Antihistamines
  - Cyclizine
- NK₁ antagonists
  - Aprepitant
- Others
  - Benzodiazepines
  - Cannabinoids
  - Propofol

Comparison of Antiemetic Drugs

<table>
<thead>
<tr>
<th>Property</th>
<th>Ondansetron</th>
<th>Droperidol</th>
<th>Metoclopramide</th>
<th>Cyclizine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Serotonin antagonist</td>
<td>Benzamide dopamine antagonist</td>
<td>Dopamine antagonist</td>
<td>Piperazine derivative/H₁ antagonist</td>
</tr>
<tr>
<td>Uses</td>
<td>Nausea. Ineffective for vomiting due to motion sickness or dopamine agonism</td>
<td>Antiemetic, sedation, behavioural control</td>
<td>Prokinetic, antiemetic</td>
<td>Antiemetic (including motion sickness and radiation sickness)</td>
</tr>
<tr>
<td>Presentation</td>
<td>Tablet, wafer, clear solution for injection at 4mg.ml⁻¹</td>
<td>Clear solution in brown glass, incompatible with thiopentone and methohexital</td>
<td>Clear solution in plastic</td>
<td>50mg tablets or 50mg.ml⁻¹ light-sensitive solution</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>PO/SL/IV</td>
<td>IV</td>
<td>IV/PO</td>
<td>PO/IV/IM</td>
</tr>
<tr>
<td>Dosing</td>
<td>4-8mg TDS Give on induction for</td>
<td>IV Give at end of surgery for</td>
<td>25-50mg IV (note 10mg has no antiemetic properties</td>
<td>1mg.kg⁻¹ up to 150mg per day</td>
</tr>
</tbody>
</table>
## Antiemetics

<table>
<thead>
<tr>
<th></th>
<th>PONV</th>
<th>PONV</th>
<th>PO bioavailability 80%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Absorption</strong></td>
<td>PO bioavailability 60%</td>
<td>PO bioavailability 30-90%</td>
<td></td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td>90% protein bound, $V_D$ $2L.kg^{-1}$</td>
<td>Minimal protein binding, $V_D$ $3L.kg^{-1}$</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td>Hepatic to inactive metabolites. Dose reduction in hepatic impairment. t1/2 3/24.</td>
<td>Extensive hepatic metabolism</td>
<td>Hepatic metabolism</td>
</tr>
<tr>
<td><strong>Elimination</strong></td>
<td>Renal elimination of inactive metabolites</td>
<td>Renal and hepatic of drug and metabolites</td>
<td>Renal of 20% unchanged drug and remainder as metabolites</td>
</tr>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Central and peripheral antagonism of 5-HT3 receptors, reducing input to the vomiting centre</td>
<td>Central D2 blockade and post-synaptic GABA antagonism</td>
<td>Antiemetic activity via central D2 antagonism, prokinetic activity via muscarinic agonism, peripheral D2 antagonism</td>
</tr>
<tr>
<td><strong>CVS</strong></td>
<td>Bradycardia with rapid IV administration, QT prolongation</td>
<td>QT prolongation, hypotension secondary to α antagonism</td>
<td>↑/↓ HR, ↑/↓ BP</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Headache</td>
<td>Sedation (neurolepsis), extrapyramidal symptoms in ~1%</td>
<td>Extrapyramidal symptoms, neuroleptic malignant syndrome</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>Constipation</td>
<td>Antiemetic</td>
<td>Antiemetic, prokinetic</td>
</tr>
<tr>
<td><strong>Endocrine</strong></td>
<td></td>
<td></td>
<td>Hyperprolactinaemia</td>
</tr>
</tbody>
</table>

### References


Last updated 2017-08-01
Intravenous Contrast

Intravenous contrast may be divided into:

- **X-ray Contrast**
  These agents are all based on a tri-iodinated benzene ring, which absorbs x-ray radiation. Alterations to this ring alter toxicity, lipophilicity, and elimination.
  - Agents are classified by these structural differences into:
    - **Ionic**
      Ionic substances are strong acids and are water soluble due to ionisation. They are further divided into:
      - Monomers
        Typically high molecular weight.
      - Dimers
    - **Non-Ionic**
      Water soluble due to hydrophilic side chains. Lower molecular weight than ionic contrast agents.
      - Monomer
        Agent of choice for angiography.
        - Easy to inject
        - Water soluble at physiologic pH
      - Dimer
        Harder to inject than monomers due to higher viscosity. Typically used for urography.
  - All are renally eliminated, and may be retained in renal dysfunction

- **Gadolinium Contrast**
  Gd\(^{3+}\), due to its seven unpaired electrons, is paramagnetic and alters the magnetic field of an MRI machine.
  - Free gadolinium is nephrotoxic and must be chelated
  - This increases its solubility and allows it to be renally eliminated
  - Gadolinium also attenuates x-rays, but is not used as x-ray contrast as doses required would be toxic

Adverse Reactions

Adverse reactions to low-osmolarity agents are uncommon (3%), with severe reactions being very rare (0.04%) and fatal reactions being extremely rare (1:170,000).

General Adverse Reactions

Adverse reactions include:

- **Chemotoxicity**
  - Platelet inhibition
  - Increased vagal tone
  - Negative inotropy
  - Negative chronotropy

- **Ionic toxicity**
  - Cellular membrane dysfunction
    May worsen myasthenia gravis.

- **Osmotoxicity**
  - Pain
  - Emesis
  - Increased PAP
• Decreased PVR
• Hypersensitivity reaction
  Typically occur within 20 minutes of injection.

Risk factors include:
• Asthma or atopy
• Critically ill
• Cardiac disease
• Renal disease

**Contrast Nephropathy**

Defined as an increase in creatinine by 25% above baseline within three days of IV contrast administration.

• It is theorised that osmotic stress and direct tubular toxic effects lead to renal tubular injury, and may cause acute tubular necrosis
• Typically is benign, with creatinine returning to baseline within 10-14 days
• Significant uncertainty as to whether contrast media do cause acute kidney injury
  IF this risk is present, it is probably only relevant in patients who have:
  • Impaired renal function
  • Arterial contrast
  • Rehydration and volume correction are effective in preventing a rise in creatinine

**References**


Last updated 2019-07-18
Definitions

This appendix is a list of key definitions that are common to many topics.

A

- **Absolute Humidity**
  Mass of water vapour in a given volume of air. Measured in mg.L⁻¹.

- **Absorption**
  The rate at which a drug leaves its site of administration and the extent to which this occurs.

- **Accuracy**
  The ability of a measuring device to match the actual value of the quantity being measured.

- **Acid**
  A proton donor.

- **Acidaemia**
  Arterial blood pH < 7.35.

- **Acidosis**
  A process which leads to an excess of hydrogen ions, and may lead to acidaemia if there is inadequate compensation. Can be subdivided into:
  - **Respiratory acidosis**: PaCO₂ > 45
  - **Metabolic acidosis**: HCO₃⁻ < 22

- **Activity**
  The effective concentration of a substance in a reacting system.

- **Acute Pain**
  Defined as pain of:
  - Recent onset
  - Limited probable duration
  - Identifiable causal and temporal relationship to injury or disease

- **Adiabatic**
  A process that occurs without transfer of heat or matter. For example, gases heat up when compressed (greater than the energy used to compress them), and cool when allowed to expand (adiabatic cooling).

- **Affinity**
  Ability of a drug to bind to a receptor.

- **Afterload**
  Sum of forces, both elastic and kinetic, opposing ventricular ejection.

- **Aging**
  Naturally occurring, physiological decline in the structure and functional reserve of all organ systems.

- **Agonist**
  Drug which produces a maximal response at receptor site.

- **Alkalaemia**
  Arterial blood pH > 7.45.
Alkalosis
A process which leads to a deficit of hydrogen ions, and may lead to alkalaemia if there is inadequate compensation. Can be subdivided into:
- **Respiratory alkalosis**: PaCO\(_2\) < 35
- **Metabolic alkalosis**: HCO\(_3^-\) > 26

Alldynia
Pain caused by a previously non-painful stimulus.

Allosteric Modulator
Substance which binds a receptor distant to the ligand-binding site, and modifies (positively or negatively) the effect of the ligand. Has no activity in absence of a ligand.

Anaesthesia
Without sensation.

Analogue Signal
Where the output of the transducer varies with the input signal.

Anion
Negatively charged ion.

Anode
The electrode which conventional current flows into.

Anrep effect
Method of myocardial autoregulation in which an increase in afterload causes an increase in contractility.

Antagonist
Drug which produces no response at the receptor, but prevents other ligands binding.

Autoregulation
Ability of an organ to maintain homeostasis in the presence of dynamic physiological conditions.

Azeotrope
A mixture of two substances that cannot be separated by fractional distillation, as each component shares same boiling point. This is typically temperature dependent.

Base
Proton acceptor.

Base Excess
Amount of acid that must be added to a solution to lower its pH to 7.4, at 37°C and with a PaCO\(_2\) of 40mmHg.

Bathmotropy
Degree of myocardial excitability. Used with either positive or negative bathmotropy.

Bell-Magendie Law
The principle that in the spinal cord the dorsal roots are sensory and the ventral roots are motor.

Bias
The systematic distortion of the estimated intervention effect away from the "truth", caused by inadequacies in the design, conduct, or analysis of a trial.
● **Black-body radiation**
Electromagnetic radiation given off by all bodies at greater than 0°K. Wavelength of radiation emitted depends on the temperature of the body.

● **Bohr Effect**
An increase in \([H^+]\) or \(PaCO_2\) decreases \(Hb\) affinity for \(O_2\).

● **Boiling Point**
The temperature at which the vapour pressure of a liquid equals the environmental pressure surrounding the liquid.
- Therefore boiling point decreases as environmental pressure falls, as there is less external pressure keeping molecules in their liquid state
- Boiling differs from evaporation as molecules anywhere in the liquid may enter the gaseous phase, whilst evaporation occurs only at the surface

● **Bowditch Effect**
Increase in contractility seen with an increase in \(HR\). Also known as the Treppe effect.

● **Boyle’s Law**
Pressure of a gas is inversely proportional to volume.

● **Buffer**
Solution containing a weak acid and its conjugate base and will resist a change in \(pH\) when a stronger acid of base is added.

## C

● **Calibration**
A process of checking a monitoring device for linearity of correlation between actual and measured values over a given measurement range.

● **Capacitance**
Ability of a system to store electrical charge. Measured in Farads.

● **Central Blood Volume**
Volume of blood in heart and lungs.

● **Central Sensitisation**
Increased responsiveness of nociceptive neurons in the central nervous system (i.e., post-synaptic) to their normal or subthreshold afferent input.

● **Chemotaxis**
Movement of cells along a gradient of increasing concentration of an attracting molecule.

● **Chronic Pain**
Pain that:
- Persists beyond the time of tissue healing
- Frequently has no clearly identifiable cause

● **Clearance**
Volume of plasma completely cleared of a substance per unit time.

● **Coronary Blood Flow**
At rest is ~5% of \(CO\), or 225 ml.min\(^{-1}\), and may increase 3-4\(x\) during exercise.

● **Colloid**
Substance evenly dispersed throughout another solution in which it is insoluble.

● **Colligative Properties**
The properties of a solution that depend on the ratio of solute to solvent, and not on the type of molecules present. These include:

- Vapour pressure
- Boiling point
- Freezing point
- Osmotic pressure

- **Compliance**
  Distensibility of a system. Expressed as the change in volume for a given change in pressure.

- **Concentration Effect**
  Describes the disproportionately rapid rise in Fi/FA ratio of nitrous oxide, as its rapid diffusion across the alveolar membrane increases the concentration of alveolar gas, and also augments respiration by drawing in dead space gas.

- **Context-Sensitive Half-Time**
  Time taken for plasma drug concentration to fall to 50% of its starting value after cessation of a drug infusion aimed to maintain a constant plasma concentration. Varies with the context, or duration, of drug infusion.

- **Contractility**
  Factors affecting myocardial performance, independent of preload and afterload.

- **Critical Length**
  The length of axon which must be blocked in order to prevent action potential transmission. It is dependent on myelination and fibre diameter.

- **Critical Point**
  The point on a phase diagram where the liquid and gas phases of a substance have the same density, and are therefore indistinguishable.
  - This point is where a substance is at both its critical temperature and critical pressure

- **Critical Pressure**
  Pressure required to liquefy a vapour at its critical temperature.

- **Critical Temperature**
  Temperature above which a substance cannot be liquified, irrespective of how much pressure is applied.

- **Critical Volume**
  The volume occupied by a given amount of substance at its critical point.

**D**

- **Dalton**
  Unit of mass equal to $\frac{1}{12}$th of the mass of Carbon-12.

- **Dalton’s Law**
  The partial pressure of a gas in a mixture is equal to the pressure that gas would exert if it occupied the volume alone.

- **Dead Space**
  Inspired gas not participating in gas exchange. Includes:
  - Apparatus dead space
    Gas in the ventilator or breathing circuit.
  - Anatomical dead space
    Gas in the conducting zone of the lung.
  - Alveolar dead space
    Alveolar gas not participating in gas exchange. Also known as West Zone 1.
- **Physiological dead space**
  Sum of alveolar and anatomical dead space.

- **Density**
  Mass per unit of volume.

- **Dependence**
  When a characteristic withdrawal syndrome occurs when a drug is withdrawn, or an antagonist administered.

- **Diffusion**
  Passive movement of a substance down an activity gradient by Brownian motion.

- **Diffusion Hypoxia**
  Fall in alveolar PAO₂ due to dilution of alveolar gas by N₂O diffusing from blood to alveoli.

- **Digestion**
  Process of breaking down macromolecules into readily absorbed compounds.

- **Doppler Effect**
  Alteration in frequency of a signal due to a relative difference in velocity between the emitter and observer. Detected frequencies will be:
  - Higher if the emitter is moving toward the observer
  - Lower if the emitter is moving away from the observer

- **Down regulation**
  Decrease in receptor number due to chronic agonist exposure.

- **Drift**
  A fixed deviation from the true value at all points in the measured range.

- **Drug**
  Substance administered to cause a change in a physiological system.

- **Duplicate Publication**
  Where the same set of results are published in multiple journals. Academically unethical, and will cause a systematic bias in a meta-analyses as the same set of patients are included twice.

- **Dyne**
  Force required to accelerate 1g by 1cm.sec⁻².

---

**E**

- **Efficacy**
  Maximal effect produced by a drug. Analogous to intrinsic activity.

- **Electrocardiogram**
  Graphical recording of the vector sum of cardiac electrical activity, as measured by electrodes on the skin.

- **Emulsion**
  A fine dispersion of minute droplets of one liquid in another in which it is not soluble or miscible.

- **Enzyme**
  Biological catalyst.

- **Eutectic**
  A mixture of substances with the lowest possible melting point than any other mixture of the same substances (and lower than that of either substance).
- **Excitability**
  How rapidly an excitable cell depolarises. Given by the gradient of phase 0 of the action potential, and is dependent on the function of voltage-gated sodium channels.

- **Exponential Function**
  Mathematical function where the rate of change is proportional to the current value.

- **External Validity**
  How well findings from one setting can be applied to another.

**F**

- **Fahraeus-Lindqvist effect**
  Decrease in apparent viscosity that occurs when a suspension (e.g. blood) flows through a tube of smaller diameter.

- **Fasting**
  Metabolic state achieved after complete digestion and absorption of a meal prior to the onset of starvation.

- **Fick Principle**
  Blood flow to an organ equals the uptake of a tracer substance by that organ, divided by the arterio-venous concentration difference.

- **Flow**
  Quantity of fluid passing a point per unit time.

- **Fourier Analysis**
  Deconstruction of a complex waveform by separating it into its constituent sine waves. The slowest component is known as the fundamental frequency.

- **Free radical**
  Extremely reactive molecular constituent carrying an unpaired electron.

- **Freezing point**
  Temperature at which molecular movement begins.

- **Functional Residual Capacity**
  Volume of gas in the lungs at the end of a normal tidal expiration, when the recoil pressure of the lungs equals the expansile pressure of the chest wall.

**G**

- **Galvanometer**
  Device to measure electrical current, usually via deflection of a wire in a magnetic field.

- **Gas**
  Substance above its critical temperature.

- **General anaesthesia**
  Drug induced, controlled, and reversible production of unconsciousness.

- **Gibbs-Donnan Effect**
  Describes the tendency of diffusible ions to distribute themselves such that the ratios of the concentrations are equal when they are in the presence of non-diffusible ions.

- **Grahams Law**
  The speed of diffusion of a gas through a membrane is inversely proportional to the square root of the molecular weight.
Haldane effect
Deoxygenated blood forms carbamino compounds and buffers $H^+$ better than oxygenated blood.

Half-Life
Time taken for drug concentration (typically in plasma) to fall by half.

Heat
Kinetic energy content of a body, as measured in joules.

Henry’s Law
Amount of gas dissolved in a substance is directly proportional to the partial pressure of gas at the gas-liquid interface.

Heterometric autoregulation
Change in ventricular function based on myocardial fibre length. Also known as Starling’s Law.

Homeometric autoregulation
Mechanisms which alter myocardial performance independent of fibre length.

Hormone
Chemical messenger secreted by a ductless gland and has action on a distant target cell.

Hyperalgesia
Greater than normal amount of pain from a noxious stimulus. May be:
- Primary
  Occurring in the region of tissue damage, e.g. in an inflamed area around a wound.
- Secondary
  Extending beyond the region of tissue damage.

Hypoxaemia
When $P_{O_2}$ is less than 60mmHg.

Hypoxia
The point at which inadequate oxygenation of tissues results in anaerobic metabolism.

Hysteresis
When the future state of a system depends not only on its current state, but on the states preceding it.

I

Ideal Gas
A gas which will obey the ideal gas law. An ideal gas must have:
- Negligible intermolecular attraction
- A small molecular volume compared to the space between the molecules

Idiosyncrasy
An effect of a drug affecting only a small number of patients, typically due to the action of a particular metabolite.

Inductance
Property of a conductor by which a change in current induces an electromotive force in the conductor and any nearby conductors.

Inotrope
Drug which alters myocardial contractility.
- **Intrinsic Activity**
  Maximal effect produced by a drug. Analogous to efficacy.

- **Impedance**
  Resistance to alternating current.

- **Internal Validity**
  Where a causal relationship between variables has been properly demonstrated, i.e. a lack of bias.

- **Irritability**
  How easily an excitable cell can be stimulated. Given by how close the resting membrane potential is to threshold potential.

- **Isomer**
  Compound with the same chemical formula, but different chemical structure or arrangement of atoms.

- **Isotherm**
  Line of constant temperature drawn on a pressure-volume graph for a gas, which describes the relationship between pressure, temperature, and volume for a particular gas.

**J**

- **Joule**
  Energy transferred to an object when it is acted on by 1N for 1m.

**L**

- **Laminar Flow**
  Flow occurring smoothly and without turbulence.

- **Local Anaesthetic**
  Drug which reversibly prevents the conduction of the nerve impulse in the region to which it is applied, without affecting consciousness.

**M**

- **MAC**
  The minimal alveolar concentration (measured in % of 1 atm) at steady state which prevents a movement response to a standard surgical stimulus (midline incision) in 50% of a population.

- **Manometer**
  Device which measures gas pressure.

- **Mean Systemic Filling Pressure**
  The pressure measured anywhere in the systemic circulation when all flow of blood is stopped.

- **Mixed Venous Blood**
  Blood from the IVC, SVC and coronary sinus, which has been mixed by the pumping action of the RV and is typically sampled from the pulmonary artery.

- **Mole**
  Amount of a substance which contains as many representative particles as there are atoms in 12g of carbon-12.

- **Molality**
  Number of moles of solute per kg of solvent.
- **Molarity**
  Number of moles of solute per L of solvent. Varies with:
  - Temperature
  - Solvent density
  - Solute volume

N

- **Natural Frequency**
  Frequency at which a system will oscillate if disturbed and left alone.

- **Nausea**
  Unpleasant subjective sensation associated with urge to vomit.

- **Neuropathic Pain**
  Pain caused by a lesion or disease of the somatosensory nervous system.

- **Nociception**
  Neural process of encoding a noxious stimulus.

O

- **Odds Ratio**
  Estimate of risk, where the OR is the ratio of odds of an outcome in those treated vs. those not treated. OR = 1 suggests no effect, ≤1 suggests reduced risk >1 suggests increased risk.

- **Ohm**
  Resistance which will allow one ampere of current to flow per volt of potential difference.

- **Opiate**
  Naturally occurring substance with morphine-like properties.

- **Oncotic Pressure**
  Proportion of osmotic pressure due to colloid.

- **Opioid**
  Describes any substance with activity at opioid receptors, and which can be reversed by naloxone.

- **Osmosis**
  Movement of a solvent across a semipermeable membrane to an area of greater solute concentration.

- **Osmotic Pressure**
  Pressure that must be applied to a solution to prevent the movement of a solvent from entering a solution with higher osmolality.

- **Oxygen Flux**
  Volume of oxygen delivered to the tissues per minute.

P

- **p50**
  The partial pressure at which an oxygen-carrying protein is 50% saturated.
- **Pain**
  Unpleasant sensory and emotional experience associated with actual or potential tissue damage, or expressed in terms of such damage.

- **Partition Coefficient**
  Describe the relative affinity of an agent for two phases. It is defined as the ratio of the concentration of agent in each phase, when both phases are of equal volume and the partial pressures are in equilibrium at **STP**.

- **Pasteur Point**
  PO₂ at which oxidative phosphorylation ceases.

- **PEEP**
  Supra-atmospheric airway pressure at the end of expiration.

- **pH**
  The power of hydrogen. Describes the activity of hydrogen ions in a solution, and is expressed as
  \[ pH = -\log_{10}[H^+] \].

- **Preload**
  Load imposed on a muscle before contraction, and measured as the average myocardial fibre length at the onset of systole. May be approximated clinically using **EDV**.

- **Precision**
  The ability of a measurement device to provide reproducible results upon repeated measurement.

- **Pseudo-critical temperature**
  Temperature at which a gas mixture will separate into its constituent components.

**R**

- **Radiation**
  Transfer of energy via electromagnetic radiation.

- **Receptor**
  Component of a cell which binds to a ligand and results in a change in function.

- **Reduction**
  Reaction which results in a gain of an electron.

- **Reflex**
  Unconscious, predictable response to a stimulus.

- **Regurgitation**
  Passive passage of gastric contents into the mouth.

- **Relative Humidity**
  Ratio of mass of water vapour in a given volume of air, to the mass required to saturate that volume at that temperature. Expressed as a percentage.

- **Respiratory Exchange Ratio**
  Ratio of CO₂ produced to O₂ consumed at any given point.

- **Respiratory Quotient**
  Ratio of CO₂ produced to O₂ consumed at steady-state.

- **Reynolds Number**
  Dimensionless index which predicts the likelihood of turbulent flow.
S

- **Saturated Vapour**
  Vapour which is in equilibrium with its own liquid state, i.e. there are as many molecules entering the vapour phase as there are those condensing into the liquid phase.
  - A saturated vapour contains the least amount of energy possible without condensing

- **Saturated Vapour Pressure**
  Pressure exerted by a vapour which is in equilibrium with its liquid state. Increases with temperature, since as the kinetic energy (heat) content of molecules increase, more of them enter the vapour phase.

- **Second Gas Effect**
  Disproportionately rapid rise in FA/Fi ratio seen when an anaesthetic agent is co-administered with nitrous oxide.

- **Seebeck effect**
  The generation of a potential difference at the junction of two dissimilar metals, with its value dependent on the temperature of the junction.

- **Shivering**
  Involuntary, oscillatory, muscular activity that augments metabolic heat production.

- **Shunt**
  Blood entering the left side of the circulation without being oxygenated via passage through the lungs.

- **Specific Gravity**
  Density of a liquid, in mass per unit volume.

- **Specific Heat Capacity**
  Amount of heat energy required to raise the temperature of 1kg of a substance by 1°K without a change in state.

- **Standard Base Excess**
  The base excess calculated for an Hb of 5g.L⁻¹, and which gives a better representation of ECF pH.

- **Surface Tension**
  Describes the tendency of a fluid to minimise its surface area.

- **Suspension**
  Particles of any phase dispersed in a liquid.

- **Synergism**
  When two drugs interact to produce a greater effect than would be expected.

T

- **Temperature**
  Ability of a body to transfer heat energy to another body, as measured in degrees.

- **Thirst**
  Conscious sensation of the physiological urge to drink.

- **Time constant**
  Time it would take for an exponential function to complete if the initial rate of change continued. A process is:
  - 63% complete at 1T
  - 86.5% complete at 2T
  - 95% complete at 3T
• **Tonicity**
  Effective osmolality of a solution. Given by the osmolality, minus the concentration of freely diffusible osmoles (in plasma, these are urea and glucose).

• **Tonometer**
  Device which measures pressure of liquid.

• **Transducer**
  Device which changes a signal from one energy form to another.

• **Treppe Effect**
  Increase in contractility with an increase in HR. Also known as the Bowditch effect.

• **Turbulent Flow**
  Irregular movement in radial, axial, and circumferential axes.

---

• **Valsalva Manoeuvre**
  Forced expiration against a closed glottis.

• **Vapour**
  Substance in a gaseous phase below its critical temperature.

• **Vapour pressure**
  Pressure exerted by a vapour.

• **Venous admixture**
  Amount of mixed venous blood that must be added to pulmonary end-capillary blood to give the observed arterial oxygen content.

• **Viscosity**
  Describes the tendency of a fluid to resist flow.

• **Volt**
  Potential difference which dissipates 1W of energy per 1A of current.

• **Volume of Distribution**
  Apparent volume into which a drug is distributed to produce the identified plasma concentration.

---

Last updated 2019-07-20
Key Graphs

Graphs:

- Help you to convey knowledge and understanding efficiently in the written
- Are often a feature of the viva as they allow examiners to assess depth of understanding
  - You will be asked to demonstrate how they change under different physiological states

It is easy to get distracted by the curve, and forget the basics (especially in the written). To avoid this, approach them in the same way each time:

- **Axis**
  - First draw the axis.
  - If the axis is continuous (e.g. PaO₂), ensure you place an arrow at the far end
  - If the axis ends at a fixed point (e.g. SpO₂), ensure you place a bar at the end to signify it does not continue indefinitely

- **Labels**
  - Label each axis with what it is representing.

- **Units**
  - Give each label *appropriate units*.
  - In the viva, you can just say this out loud as you’re drawing the axes

- **Curve**
  - Draw the curve.

- **Special Points**
  - Identify the key points of the curve and label these points. These include:
    - Intercepts
    - Inflection points
    - Important values
      - e.g. The mixed venous point.

Pharmacology

**Dose-Response:**

- Dose response curve is a wash-in exponential
- Difficult to compare different drugs using this curve

**LogDose-Response:**
- Log-transform of dose allows different drugs to be compared
- Both red and blue drugs are full agonists (as they both reach 100% response), however the blue drug is more potent as it has a lower $E_{50}$

**Agonists:**

- Partial agonists do not reach 100% response
- Inverse agonists have a negative response

**Antagonists:**

- Non-competitive antagonists prevent maximal response being reached
- Competitive agonists right shift the curve, as they can be overcome with increasing dose of agonist

**Therapeutic Index:**
Can be calculated from the ratio of the LD$_{50}$ and ED$_{50}$

**Models**

**The One-Compartment Model:**

Drug is added to and removed from the single central compartment

- There is no distribution possible.
- $V_1$ is equal to the volume of distribution
- $k_{10}$ is the rate constant for elimination

**Three-Compartment Model:**

Drug is added to and removed from the central compartment

- Drug will also distribute to (and redistribute from) the peripheral compartments
- Plasma concentration will depend on:
  - Rate of drug delivery
  - Rate of drug distribution and redistribution
• Rate of drug elimination

**Effect-Site:**

- Drug distributes to the effect site from the central compartment
- Effect site has no volume, but does have rate constants
- $t_{1/2}k_{e0}$ is generally drawn with drug being eliminated from the effect site, however in reality this does not occur as drug should only be eliminated from the central compartment

**Pharmacokinetics**

**Zero-order kinetics:**

- A constant amount of drug is eliminated per unit time
- Half-life is not a constant value
  
  Half-life progressively shortens, as the time taken to go from 50% to 25% is half the time it took to go from 100% to 50%.

**First-Order Kinetics:**

- A constant proportion of drug is eliminated per unit time
- Half-life is a constant value
Biexponential elimination:

- Note that concentration has been log-transformed
- This describes the elimination of drug from a two compartment model

Pharmacodynamics

Isobologram:

- Plots lines of equal activity versus concentration of two drugs

Plasma-Site Targeting:

TCI graphs are easy to draw if you remember that:

- The pump aims to achieve the targeted concentration:
  - As rapidly as possible
  - Without overshoot
- Effect site concentrations fall slower than plasma site concentrations. Drug can only redistribute back to plasma when effect site concentration is greater than plasma concentration.

Therefore in plasma site targeting:

- Plasma concentration rises rapidly with initial bolus dose
- Does not overshoot
- Effect site concentration rises more slowly
  - Exponential wash in curve as the concentration gradient between plasma and effect site falls over time

**Effect-Site Targeting:**

![Graph showing effect-site and plasma concentrations](image)

- Plasma concentration overshoots effect-site target and then declines rapidly
- Effect site concentration rises rapidly, and is achieved more quickly compared with plasma-site targeted model

**Statistics**

**Boxplot:**

![Boxplot diagram](image)

- Box is defined by the 25th and 75th centiles
- Line in the middle of the box is the median ("50th centile")
- "Whiskers" either side of the box define the 10th and 90th centiles
  - These may also refer to the 5th and 95th centiles
- Results outside of whiskers are defined as outliers, and are represented by single dots

**Respiratory**

**Oxygen**

**Oxygen Cascade:**
Graph of location versus oxygen partial pressure

- Atmospheric (dry) air has a PO$_2$ of 160mmHg
- Tracheal (humidified) gas has a PO$_2$ of 149mmHg
  Reduced due to saturated vapour pressure of water.
- Alveolar gas has a PO$_2$ of 105mmHg
  Reduced to the presence of CO$_2$, as per the alveolar gas equation.
- Arterial blood has a PO$_2$ of ~100mmHg
  Reduced to the Alveolar-arterial oxygen gradient.
- Tissues have a PO$_2$ of ~5mmHg
- Mixed venous blood has a PO$_2$ of ~40mmHg
  Greater than tissue PO$_2$ as not all oxygen in blood diffuses into or is consumed by tissues.

Oxyhaemoglobin Dissociation Curve:

- Graph of PaO$_2$ versus oxygen saturation
- Note that PaO$_2$ is continuous, and so an arrow should be drawn at the tip of the x-axis, whilst saturation is finite and so the y-axis should be capped at 100%
- The curve is a sigmoid shape
- Key points:
  - At 10mmHg, saturation is 10%
- The p50 is at 27mmHg
- The mixed venous point is at 40mmHg, where haemoglobin is 75% saturated
  Note that due to the Haldane effect, the mixed venous point does not technically exist on the arterial curve. This is a small point and is ignored in most graphs (including this one), but may be worth stating if you're feeling confident in the viva.
- The "ICU point" (the upper inflection) is at 60mmHg where haemoglobin is 93% saturated
- The arterial point is 97% saturated at 100mmHg

The curve may be right-shifted by:
- Increased $H^+$
- Increased $\text{PaCO}_2$
- Increased temperature
- Increased 2-3 DPG

These shifts are defined by a movement of the p50

**Double-Bohr Effect:**

- The double Bohr effect can easily become confusing, especially when you are under pressure and only allowed one colour (as in the written exam)
  Here is a straightforward method which minimises the confusion:
  1. Draw an adult curve with a p50 of 27mmHg
  2. Draw a foetal curve with a p50 of 17mmHg
  3. Draw a right-shifted adult curve
  4. Draw a left-shifted foetal curve

**PaO₂ and Minute Ventilation:**
- Exponential curve
- Minute ventilation doubles as PaO₂ decreases from 100mmHg to 60mmHg
- Inflection point is ~50-60mmHg
  Below this there is a large increase in ventilation.
- Hypercapnea leads to a greater minute ventilation for any given PaO₂

**Isoshunt Diagram:**

- Plots the relationship between PAO₂ versus PaO₂ for different (fixed) shunt fractions
- These are known as isoshunt lines
- Key isoshunt lines are:
  - At 50% shunt, PaO₂ is essentially independent of PAO₂
  - At 30% shunt, PaO₂ will not increase above 100mmHg on 100% oxygen at atmospheric pressure

**Carbon Dioxide**

**Carbon Dioxide Dissociation Curve:**

- Graph of carbon dioxide content versus partial pressure
- Key points on this curve:
- Arterial CO\textsubscript{2} content is 48mls.100ml\textsuperscript{-1} of blood at 40mmHg
- Mixed venous CO\textsubscript{2} content is 52.mls.100ml\textsuperscript{-1} of blood at 46mmHg

Note that the mixed venous curve is up-shifted due to the Haldane effect. Remember that 50% of the difference in CO\textsubscript{2} content is due to the Haldane effect. Therefore:
- The mixed venous curve should be drawn such that CO\textsubscript{2} content is 50mls.100ml\textsuperscript{-1} at 40mmHg
- The arterial curve should be drawn such that CO\textsubscript{2} content is 50mls.100ml\textsuperscript{-1} at 46mmHg

**PaCO\textsubscript{2} and Minute Ventilation:**

- Graphs the change in minute ventilation for **primary change in PaCO\textsubscript{2}**
- Remember that minute ventilation increases by ~3L.min\textsuperscript{-1} for every 1mmHg increase in PaCO\textsubscript{2}
  
  From this, the relationship to other states can be derived:
  - Minute ventilation is reduced during sleep, but the central response to CO\textsubscript{2} is only minimally affected
  - The central response to CO\textsubscript{2} is heavily affected during anaesthesia
  - Minute ventilation is increased for any given PaCO\textsubscript{2} in the setting of acidosis

**Alveolar Ventilation and PaCO\textsubscript{2}**:

- Graphs the change in PaCO\textsubscript{2} for a **primary change in minute ventilation**
- Exponential curve as PaCO\textsubscript{2} is inversely proportional to minute ventilation
- Minute ventilation is increased for any given PaCO\textsubscript{2} during exercise

**Anatomical and Physiological Interactions**

**Closing Capacity and Age:**
Note that although FRC increases slightly with age, this is not generally shown on this graph.

Closing capacity increases with increasing age.

Key intersections are:
- Greater than FRC when supine at 44 years of age
- Greater than FRC when erect at 66 years of age

Diffusion and Perfusion Limitation:

Classically drawn as partial pressure versus distance along the capillary.

Time along capillary may also be used, however note that total transit time will change with cardiac output.

- In perfusion limitation, PaO\(_2\) will equal PAO\(_2\) before the end of the capillary
- In diffusion limitation, partial pressures will not be equal at the end of the capillary
- In normal circumstances, PaO\(_2\) equals PAO\(_2\) at ~1/3\(^2\) of the distance along the capillary

If time is being graphed on the x-axis, then this will occur at ~0.25s, as total capillary transit time is ~0.75s.

- Nitrous oxide rapidly diffuses into blood and is and not typically present in mixed venous blood, so this curve begins at the origin and PaN\(_2\)O will rapidly reach PAN\(_2\)O (in this instance 100mmHg)
- Carbon monoxide binds avidly to haemoglobin and so PaCO increases slowly, resulting in diffusion limitation

Regional Ventilation and Perfusion:
- Graph of alveolar ventilation and alveolar blood flow versus rib number in the **erect** person
- Basal alveolar have greater perfusion and ventilation than apical alveoli
- Note the perfusion gradient is steeper than the ventilation gradient
- Note that the V/Q ratio is:
  - ~1 at the 3rd rib
  - ~3.3 at the apex
  - ~0.63 at the base

**Airway Resistance and Airway Generation:**
- Graph of airway resistance versus airway generation
- Airway generations are from 1 to 23, and so this graph should not extend outside these values
- Airway resistance is maximal at the 5th generation
  This has the lowest total cross-sectional area.
- Airway resistance is negligible in the respiratory zone, which exists after the 15th generation

**Airway Resistance and Lung Volume:**
- Airway resistance decreases as lung volume increases as radial tension distends airways, increasing their cross-sectional area and lowering airway resistance
Pulmonary Vascular Resistance and Pulmonary Artery Pressure:

- Pulmonary vascular resistance decreases as pulmonary artery pressure increases
- Arterial pressure has a greater effect on PVR than venous pressure

Lung and Chest Wall Volume and Pressure Relationships:

- Graph of lung volume versus recoil pressure
  - Expressing lung volume as a percentage of total lung capacity may make it easier to remember the key points on this graph
  - Note that recoil pressure is the pressure generated between the lung and the chest wall when they are distended, it is not intrapleural pressure
- This graph is complex and it is easy to draw incorrectly

This is an approach to make it as easy as possible:
1. Draw a sigmoid graph for the pressure-volume relationship of the respiratory system as a whole
   - As recoil pressure is 0 at FRC this will be the y-intercept
   - The graph will asymptote at residual volume, as volume (by definition) cannot become lower than this volume
2. Draw a steep run-away exponential for the pressure-volume relationship of the chest wall
   - Recoil pressure should be ~5cmH₂O at FRC
   - Recoil pressure should be 0cmH₂O at ~75% of TLC
   - Recoil pressure should not exceed ~5cmH₂O at TLC
3. Draw a steep wash-in exponential for the pressure-volume relationship of the lung
   - Remember lung volume cannot fall below residual volume
   - Recoil pressure should be ~5cmH₂O at FRC
     - This should be equal and opposite to the recoil pressure for the chest wall, as the sum of these must be 0 at FRC.
   - Note that this curve should slightly exceed the curve for the respiratory system as recoil pressure increases

Work of Breathing:
Graph of lung volume (above FRC) versus intrapleural pressure.

Note that intrapleural pressure becomes more negative along the x-axis.

The area under different sections of this curve give the work of breathing:
- Elastic inspiratory work of breathing is given the blue triangle.
- Resistive work of expiration is given by the red area.

Note that as this is entirely contained within the area of elastic inspiratory work, expiration is passive and does not require additional energy expenditure.

- Resistive work of inspiration is given by the green area.

**Work of Breathing - Active Expiration:**

When resistive expiratory work exceeds elastic inspiratory work, active expiration must occur.

In this graph, active expiration is given by the red area not contained with the blue triangle.

**Neonatal First Breath:**

This graph describes the pressure-volume changes of the neonate as it takes its first breaths and establishes FRC.

This graph is easy to draw provided you remember that:
- Prior to the first breath, lung volume is 0.
- As the lung initially has very poor compliance, the intrapleural pressure must become very negative more lung volume.
increases substantially
- At the end of each breath, intrathoracic pressure is close to 0
- With each subsequent breath:
  - Lung compliance improves
  - Therefore the magnitude of pressure swings is reduced.
  - FRC increases
  - Lung volume at end-inspiration is increased.

**Spirometry**

**Forced Vital Capacity:**

- Graph of expired volume (vital capacity) over time
- ~80% of total volume is expired within the first second (FEV₁)
- Total FVC is 4.5L in the 70kg Guyton Man
- The gradient of initial expiration is the peak expiratory flow rate

**Spirometry:**

- Graph of lung volume over time
- Includes a normal tidal breath and a vital capacity breath

**Flow-Volume Loops**

**Normal loop:**
- Peak expiratory flow is $\sim 8 \text{L.s}^{-1}$
- Peak inspiratory flow is $\sim 6 \text{L.s}^{-1}$
- Effort independent expiration occurs during expiration

**Obstructive Disease:**

- Residual volume and total lung capacity are increased due to gas trapping
- Peak expiratory flow is reduced
- There is scalloping of the effort-independent portion of the curve
  Also known as a concave curve.

**Restrictive Disease:**

- Total lung capacity is reduced
- Residual volume is normal
- Peak expiratory flow may be reduced (as seen here)
  However the FEV$_1$/FVC ratio will be normal in purely restrictive lung disease.
- Effort-independent expiration is linear and will join with the normal curve

**Fixed Upper Airway Obstruction:**
Obstruction that does not change calibre throughout the respiratory cycle
- Peak expiratory and inspiratory flow rates are limited

**Extrathoracic Obstruction**
- Obstruction worsens during inspiration as it is ‘pulled in’ by negative intrathoracic pressure

**Intrathoracic Obstruction**
- Obstruction worsens during expiration as it is compressed by dynamic airways compression

**Anaesthetic Agents**

F<sub>A</sub>/F<sub>T</sub>: 

- Nitrous Oxide
- Desflurane
- Sevoflurane
- Isoflurane
- Halothane
Key Graphs

- Graph of the alveolar over inspired agent fraction versus time for various volatile agents
- Indicates the relative speed of onset of different agents
- Uptake of agent is proportional to solubility in blood, and therefore is in order of their blood:gas coefficients
  - The exception is nitrous oxide, which has a faster rate of rise than desflurane despite its greater blood:gas coefficient due to the concentration effect

\[ \text{FA/FA0:} \]

- Graph of alveolar agent fraction versus time for a volatile agent
- Note the logarithmic scale on the y-axis
- Exponential washout curve
- Function of two separate washout curves
  - Rapid washout with removal of agent from circuit and FRC
  - Slow washout due to diffusion of agent from tissues into blood, and then alveolus

**Cardiovascular**

**Left Ventricular Coronary Blood Flow:**

- Graph of blood flow to the left ventricle over time
  Systole should be clearly identified.
- Left ventricular flow occurs predominantly in diastole
  Peak flow is $\sim 115 \text{ml.min}^{-1}$.
- There is a brief period of flow reversal during isovolumetric contraction

**Right Ventricular Coronary Blood Flow:**
- Graph of blood flow to the right ventricle over time
- Right ventricular flow occurs throughout the cardiac cycle
  This is because aortic root pressure exceeds cavity pressure throughout the cardiac cycle.
- Peak flow is \( \sim 15 \text{ml.min}^{-1} \)

**Baroreceptor Response:**

- Graph of heart rate versus systolic blood pressure
  Note that the RR interval is inversely proportional to heart rate.
- Heart rate responses asymptote at extremes of blood pressure

**Starling Curve:**

- Typically drawn as a graph of stroke volume (or cardiac output, assuming a constant heart rate) versus preload (typically estimated as end-diastolic volume, but may also be end-diastolic pressure)
- Graph does not cross the origin as EDV is never 0ml

**Starling Curve - Failing:**
Myocardium that has been overloaded by high end-diastolic volumes may lead to a decrease in tension generated by the myocardium.

**Venous Return:**

- Graph of venous return versus right atrial pressure
- The x-intercept is the point of no flow within the circulation (as VR = CO), and therefore is the mean systemic filling pressure
- The curve flattens when RAP becomes negative, as external tissues act as a Starling resistor and prevent further increases in flow

**Venous Return - Compliance and Volume:**

- Decreasing venous compliance or increasing circulating volume results in an increase in mean systemic filling pressure (as for any given compliance, pressure must increase if volume increases) and an increase in venous return for any given right atrial pressure
- The opposite occurs with a decrease in circulating volume or an increase in venous compliance

**Venous Return - Resistance to Venous Return:**
- Altering resistance to venous return (e.g. during pregnancy, or laparoscopic surgery) will alter venous return without changing mean systemic filling pressure

**Circulatory Function Curve:**

- Plotting the venous return curve and the Starling curve on the same axes generates this graph
  - This is only valid at steady state, i.e. when \( CO = VR \)
  - Note that as steady-state exists when \( CO = VR \), the intercept of these two curves is the operating point of the circulation

**Wiggers Diagram:**
Wiggers diagram is a graphical representation of the events during each phase of the cardiac cycle.

Key points to note:
- Aortic diastolic pressure occurs just prior to aortic valve opening.
  A common mistake is to label diastolic pressure at the dicrotic notch.
- Ventricular pressure exceeds aortic pressure during ejection.
- Aortic pressure will slightly exceed ventricular pressure during the last part of ejection.
  This is due to the inertia of ejected blood causing ongoing forward flow despite the pressure gradient.
- The dicrotic notch occurs on the aortic pressure curve.
  A common mistake is to draw this on the ventricular curve.
- CVP slightly exceeds ventricular pressure during ventricular filling.
- The C wave occurs during isovolumetric contraction.
- The V wave begins prior to the T wave, but peaks after the T wave has finished.
- Electrical events slightly proceed ventricular mechanical events.

### Action Potentials

**Pacemaker Potential:**
- The pacemaker potential has only three phases, and notably no ‘resting phase’
  This is due to the funny current.
- Maximal diastolic potential is -65mV
- Peak membrane potential is ~20mV

**Pacemaker Potential - Ion Flux:**

- Demonstrates the timing of electrolyte passage across the cell membrane
- Funny current occurs throughout phase 4 and the early part of phase 0
- T-type calcium current begins in late phase 4 and terminates prior to the onset of phase 0
- L-type calcium current overlaps with the T-type current and continues throughout phase 3
- Outward rectifying potassium current begins during phase 3 and continues during phase 4, restoring membrane potential

**Pacemaker Potential - Autonomic Tone:**

- Alteration to autonomic tone alters the slope of the funny-current
  (Some sources also note a change to maximal diastolic potential, although this is not shown here).

**Ventricular Action Potential:**
The ventricular action potential consists of 5 phases:

- 0: Rapid depolarisation
- 1: Partial repolarisation
  Due to initial efflux of potassium without proportional calcium influx.
- 2: Plateau
  Outward potassium current is matched by inward calcium current.
- 3: Repolarisation
  Note that the absolute refractory period ends when resting membrane potential falls below -50mV, which typically occurs at ~250ms.
- 4: Resting membrane potential
  Note that:
  - Resting Membrane Potential is typically ~-85mV
  - The relative refractory period ends when the membrane potential is at its resting state

### Ventricular Action Potential - Hyperkalaemia:

- In hyperkalaemia:
  - The ventricle is more irritable as resting membrane potential is less negative, bringing it closer to threshold potential
  - The duration of the action potential is shorter, increasing the chance for a re-entrant arrhythmia

### Basic Pressure-Volume Loops

Pressure-volume loops are covered in detail under pressure-volume relationships.

**Left Ventricular P-V Loop:**
Left Ventricular P-V Loop - Increased Preload:

Left Ventricular P-V Loop - Increased Afterload:

Left Ventricular P-V Loop - Increased Contractility:

Advanced-Pressure Volume Loops
When drawing changes to more left-field pressure-volume loops which you may not have seen before approach them in the following way:

- How is preload changed?
- How is afterload changed?
- How is contractility changed?
- How are isovolumetric contraction and isovolumetric relaxation changed?

Advanced pressure-volume loops are covered in detail under pressure-volume relationships.

**Right Ventricular P-V Loop:**

![Right Ventricular P-V Loop](image1)

**Left Ventricular P-V Loop - Aortic Stenosis:**

![Left Ventricular P-V Loop - Aortic Stenosis](image2)

**Left Ventricular P-V Loop - Aortic Regurgitation:**

![Left Ventricular P-V Loop - Aortic Regurgitation](image3)

**Left Ventricular P-V Loop - Mitral Stenosis:**

![Left Ventricular P-V Loop - Mitral Stenosis](image4)
**Left Ventricular P-V Loop - Mitral Regurgitation:**

**Antiarrhythmics**

**Ventricular Action Potential - Class Ia:**

- Prolong the rate of rise of phase 0
- Lengthen the myocardial action potential

**Ventricular Action Potential - Class Ib:**
- Prolong the rate of rise of phase 0
- Shorten the myocardial action potential

**Ventricular Action Potential - Class Ic:**

- Prolong the rate of rise of phase 0
- Do not alter the length of the myocardial action potential

**Pacemaker Potential - Class II (Beta-Blockade):**

- Sympatholytic effect reduces the magnitude of the funny current

**Ventricular Action Potential - Class III:**
- Prolong duration of phase 3 of the myocardial action potential
  This prolongs the refractory period and reduces the chance of a re-entry circuit occurring, and therefore reduces tachyarrhythmias but may increase the risk of *torsade de pointes* due to an increased risk of after depolarisations.

**Pacemaker Potential - Class IV (Calcium Channel Blockade):**

- In the pacemaker cell, reduce the magnitude of T-type and L-type calcium currents, reducing the rate of rise of phase 0 of the pacemaker action potential

**CNS**

**Monroe-Kellie Doctrine:**

- Graphs the intracranial pressure versus the volume of a component (blood, brain, or CSF) in the cranial vault
  - Note that overall volume is *not* correct, as this is unchanged - if overall volume increased the pressure would reduce (e.g. such as a decompressive craniectomy).
  - Note the initial period of compensation, which occurs due to displacement of CSF to the spinal subarachnoid, decreased cerebral blood volume, and a decrease in CSF volume.
  - Once compensatory responses are exhausted ICP will increase rapidly due to the poor elastance of the cranial vault
- Focal ischaemia occurs when ICP exceeds 20mmHg
- Global cerebral ischaemia occurs when ICP exceeds 50mmHg

**Cerebral Blood Flow and Cerebral Perfusion Pressure:**

- Cerebral blood flow is autoregulated for a CPP of 50-150mmHg
  (Note that this classic relationship is probably incorrect, and that CBF is probably only autoregulated across a narrow range of blood pressures).

**Cerebral Blood Flow and PaCO2:**

- CBF increases by ~3% for every 1mmHg increase in CO2
- Below a PaCO2 of 20mmHg, CBF cannot decrease further as the reduced flow results in tissue hypoxia, and metabolic autoregulatory responses
- Above a PaCO2 of 80mmHg, CBF cannot increase further as vessels are maximally dilated

**Cerebral Blood Flow and PaO2:**

- Above a PaO2 of 60mmHg, CBF is essentially independent of PaO2
- Below a PaO2 of 60mmHg, CBF increases rapidly

**Cerebral Blood Flow and Temperature:**
Cerebral metabolic rate falls by ~6% per °C decrease in temperature. This results in a concomitant reduction in CBF. This is an almost linear response.

Renal & Acid-Base

### Ionised potential vs pH - Acids:

- Acids are ionised above their pKa.

### Ionised potential vs pH - Bases:

- Bases are ionised below their pKa.

Glomerular Filtration and Mean Arterial Pressure:
GFR is autoregulated for a MAP between 60 and 160mmHg

Glomerular Filtration Rate and Serum Creatinine:

- At steady-state, GFR and serum creatinine are inversely proportional
- Following a step-change in GFR, it will take ~48 hours before steady-state is achieved again
  During this period, estimates of GFR using serum creatinine will be less accurate.

Glucose Flux:

- As glucose is freely filtered at the glomerulus, filtered plasma glucose will be directly proportional to serum glucose
  This relationship is given by the dotted black line.
- Under normal circumstances, all filtered glucose will be reabsorbed
  This relationship is given by the overlap of the red and dotted black lines.
- When glucose filtration exceeds glucose reabsorption, glucose will begin to be excreted in urine.
  This is given by the dotted blue line.
  - The serum concentration of a substance at which this occurs is known as the transport maximum, or $T_{\text{max}}$
  In reality, some glucose will be filtered before $T_{\text{max}}$ is reached. This is due to the different affinity of S-GLUT channels, and is the cause of the gentle curves seen on the plots of reabsorption and excretion.
  - The serum concentration at which glucose starts to appear in urine is known as the threshold concentration.
The difference between threshold concentration and $T_{\text{max}}$ is known as spay.

**Haematology**

**Coagulation Cascade:**

- **Contact activation (intrinsic) pathway**
  - Damaged surface
  - XII → X IIa → XI → IX → Xa → Va → Thrombin (IIa) → Cross-linked fibrin clot
  - Active Protein C
  - Protein S → Protein C + Thrombomodulin

- **Tissue factor (extrinsic) pathway**
  - Trauma
  - TFPI
  - VIIa → VII
  - Fibrinogen (I) → Fibrin (Ia)
  - Xa → X → V → Va

**Common pathway**

- Thrombin (IIa)
- Cross-linked fibrin clot

- Antithrombin

- TEG/ROTEM can be used to guide coagulopathy treatment as:
  - Prolonged R time
    - Indicates decreased clotting factor concentration; give FFP.

**Thromboelastography:**

- The coagulation cascade is covered in detail under clotting.
- Decreased α-angle/prolonged K time
  Decreased rapidity of fibrinogen cross-linking; **give fibrinogen.**
- Decreased MA (may be associated with prolonged K time)
  Decreased maximal clot strength; **give platelets or DDAVP.**
- Decreased CL 30/CL 60
  Fibrinolysis; **give antifibrinolytic.**

**Other**

**Heat Loss Under Anaesthesia:**

- Heat loss under anaesthesia occurs in three phases:
  1. Rapid reduction: 1-1.5°C in 30 minutes
  2. Gradual reduction: 1°C over 2-3 hours
  3. Plateau: Further heat loss attenuated by metabolic heat reduction
     - Does not occur in neuraxial anaesthesia as vasoconstrictive responses are prevented by sympathectomy

**Equipment & Measurement**

**Einthoven’s Triangle:**

- Einthoven’s triangle demonstrates the relationship between different limb leads and augmented leads on the ECG
- Understanding the triangle means one can identify misplaced ECG electrodes by the changes in ECG morphology
  - e.g. if the RA and LA electrodes are switched:
    - Lead I will invert its polarity
- Lead II and III will be switched
- Leads aVL and aVR will be switched
- Lead aVF will be unchanged

**Damping Coefficients:**

![Graph showing different damping coefficients]

- Following a step-change:
  - An optimally-damped waveform will return to baseline with one overshoot and one undershoot
  - An under-damped waveform returns to baseline rapidly but overshoots and undershoots several times
  - A critically damped waveform returns to baseline as fast as possible without overshooting
  - An over-damped waveform returns to baseline slower than a critically damped waveform, and does not overshoot

**Wheatstone Bridge:**

![Diagram of Wheatstone Bridge]

- Covered in detail under Wheatstone bridge

**Gas Analysis**

**Clark Electrode:**

![Diagram of Clark Electrode]

- Covered in detail under Oxygen Tension

**pH Electrode:**
- Covered in detail under pH Measurement

**Severinghaus Electrode:**

- Covered in detail under Carbon Dioxide Tension

**Capnography**

**Capnograph:**
The capnograph waveform consists of four components:

1. Baseline
   Inspiration and early dead-space expiration (containing no CO₂).
2. Alveolar exhalation
3. Alveolar plateau
   Highest point is defined as E\textsubscript{T}CO₂.
4. Inspiration

Variations on the waveform are covered under E\textsubscript{T}CO₂ Waveform Variations.

References

1. Wigger's Diagram (with some modifications) from Wigger's Diagram. 21/3/2012. (Image). By DanielChangMD (revised original work of DestinyQx); Redrawn as SVG by xavax. CC BY 3.0, via Wikimedia Commons.

Last updated 2019-07-18
Laws and Equations

This appendix is a list of the key laws and equations common to many topics:

### General Laws

- **Fick’s Law of Diffusion**
  
  Diffusion of a substance across a membrane is given by:
  \[
  \dot{V} = \frac{A \times D \times \Delta P}{l'}, \text{ where:}
  \]
  
  - \(A\) = Area of the sheet
  - \(D\) = Diffusion constant, which is proportional to the solubility of the gas and inversely proportional to the square root of the molecular weight, i.e.
  \[
  D \propto \frac{S_{\text{sol}}}{\sqrt{MW}}
  \]
  - \(l'\) = Thickness of the sheet

- **Hagan-Poiseuille Equation**
  
  Calculates the flow for a given pressure different of a particular fluid. May also be rearranged to calculate pressure or resistance.
  
  Given by the equation:
  \[
  Q = \frac{\pi P r^4}{8 \eta l'}, \text{ where:}
  \]
  
  - \(Q\) is the flow
  - \(P\) is the driving pressure
  - \(\eta\) is the dynamic viscosity
  - \(L\) is the length of tubing
  - \(r\) is the radius
  
  Has several limitations:
  - Only models laminar flow
  - Fluid must be incompressible
  - Not technically valid for air, but provides a good approximation when used clinically.
  - Fluid must be Newtonian
  - Fluid must be in a cylindrical pipe of uniform cross-section

- **Reynolds Number**
  
  Reynolds Number is a dimensionless index used to predict the likelihood of turbulent flow. \(R < 2000\) is likely to be laminar, \(R > 2000\) is likely to be turbulent. Given by the equation:
  \[
  R = \frac{v d}{\eta r}, \text{ where:}
  \]
  
  - \(v\) is the linear velocity of fluid in \(m/s\)
  - \(d\) is the fluid density in \(Pa\)
  - \(r\) is the radius in \(m\)
  - \(\eta\) is the viscosity in \(m^2/s\)

### Cell Physiology
**Nernst Equation**
Calculates the electrochemical equilibrium for a given ion:

\[ E (mV) = \frac{R \cdot T}{Z \cdot F} \ln \left( \frac{[con]_{outside}}{[ion]_{inside}} \right) \]

- is the equilibrium potential for the ion
- is the gas constant (8.314 J.deg\(^{-1}\).mol\(^{-1}\))
- is the temperature in Kelvin
- is Faraday's Constant
- is the ionic valency (e.g. +2 for Mg\(^{2+}\), -1 for Cl\(^-\))

**Goldman-Hodgkin-Katz Equation**
Calculates the membrane potential for given values of intracellular and extracellular ionic concentrations:

\[ E (mV) = \frac{R \cdot T}{F} \ln \left( \frac{P_{K} [K^+]_{o} + P_{Na} [Na^+]_{o} + P_{Cl} [Cl^-]_{o}}{P_{K^+} [K^+]_{i} + P_{Na^+} [Na^+]_{i} + P_{Cl^-} [Cl^-]_{i}} \right) \]

- is the permeability constant for the ion, \( P \)
- If the membrane is impermeable to \( x \), then \( P_x = 0 \).

**Henderson-Hasselbalch**
Calculates the pH of a buffer solution:

\[ pH = pK_a + \log \left( \frac{[A^-]}{[HA]} \right) \]

- is the pH of the solution
- is the pKa of the buffer
- is the concentration of base
- is the concentration of acid

**Respiratory Laws**

**Modified Bohr Equation**
The ratio of dead space to tidal volume ventilation equations the arterial - mixed-expired CO2 difference, over the arterial CO2.

\[ V_D \frac{P_a CO_2 - P_e CO_2}{V_t} = P_E CO_2 \]

**La Place’s Law**
The larger the vessel radius, the larger the wall tension required to withstand a given internal fluid pressure. For a thin-walled sphere, Wall Tension (T) is half the product of pressure and radius, i.e.

\[ T = \frac{P \cdot r}{2} \]

**Alveolar Gas Equation**
The alveolar PO2 is equal to the PH2 minus the alveolar CO2/the respiratory quotient, i.e.:

\[ PA_{O_2} = PiO_2 - \frac{PA_{CO_2}}{R} \]

**Gas Laws**

**Boyle’s Law**

\[ PV = K \], i.e. pressure and volume are inversely related at constant temperature and pressure.
- **Boyle's Law** can be used to work out how many litres of gas are remaining in gas cylinder, e.g.:
  - A standard C cylinder is 1.2L in size
  - Normal cylinder pressure is ~137bar, and atmospheric pressure is ~1bar
  \[ P_1 \cdot V_1 = P_2 \cdot V_2 \]
  \[ 137 \cdot 1.2 = 164 \]
  - Therefore, the cylinder contains ~164L of oxygen
  - This can be used to calculate the volume of gas remaining in the cylinder during use, using the volume of the cylinder (fixed) and the current pressure as measured at the regulator

- **Charle’s Law**
  \[ V = kT \], i.e. volume and temperature are linearly related when pressure is constant.

- **Gay-Lussac’s Law/The Third Gas Law** \[ P = k \cdot T \], i.e. pressure and temperature are linearly related when volume is constant.

- **The Universal Gas Equation**
  \[ PV = nRT \], i.e. combination of Boyle’s, Charle’s law combining each variable and the universal gas constant, R (8.13).

- **Henry’s Law**
  The number of molecules of dissolved gas is proportional to the partial pressure of the gas at the surface of the liquid.

- **Graham’s Law of Diffusion**
  Diffusion rates through orifices are inversely proportional to the square root of the molecular weight.

- **Dalton’s Law of Partial Pressures**
  In a mixture of gases, each gas exerts the pressure that it would exert if it occupied the volume alone.

### Cardiovascular Equations

- **Fick’s Principle**
  Flow of blood through an organ equals the uptake of a tracer substance by the organ divided by the concentration difference of the substance across it, i.e.:
  \[ \dot{Q} = \frac{\dot{V}_{O_2}}{C_{aO_2} - C_{vO_2}} \]

- **Starling’s Law of Fluid Exchange**
  Flow of fluid across the capillaries is proportional to the hydrostatic pressure difference and the oncotic pressure difference (times the reflection coefficient), all times by the filtration coefficient, i.e.:
  \[ Net \ flow \ out = K[(P_c - P_t) - \sigma(\pi_c - \pi_t)] \]

- **Venous Admixture**
  Calculates the shunt fraction by identifying how much mixed venous blood must be added to ideal pulmonary capillary blood
  \[ \frac{\dot{Q}_S}{\dot{Q}_R} = \frac{C_{vO_2} - C_{aO_2}}{C_{vO_2} - C_{aO_2}} \]
  to produce the identified arterial oxygen content.

### Equipment

- **Doppler equation**
  Calculates the velocity of an object based on the change in observed frequency when a wave is reflected off (or emitted from)
the object:

\[ V = \frac{\Delta F_s}{2F_0 \cos \theta} \]

where:

- \( V \) = Velocity of object
- \( \Delta F_s \) = Frequency shift
- \( F_0 \) = Speed of sound (in blood)
- \( \theta \) = Frequency of the emitted sound
- \( \theta \) = Angle between the sound wave and the object

**References**


Last updated 2019-07-18
Structures for SAQs

Structured answers are vital:

- Structure aids both learning and recall of information
- A structured format is easy to follow less likely to irritate the drunk/tired/hungover mind of the examiner
- You may get marks for incomplete answers if your structure demonstrates you have an understanding of the topic, even if the details are not filled in

Some questions lend themselves more easily to a particular structure than others, but all questions can be made to fit even a basic structure.

Regulation of Physiological Responses

- Sensor
- Integration
- Effector

Change in Level of a Substance

- Intake
- Distribution
- Elimination

Compare and Contrast (Drugs)

- Class
- Pharmaceutics
  - Uses
  - Chemical
  - Presentation
  - Heat/light stability
  - Routes of administration
  - Doses
- Pharmacokinetics
  - Absorption
  - Distribution
  - Metabolism
  - Elimination
- Pharmacodynamics
  - Main Action
  - Mode of Action
  - Effects (See the physiological approach)
  - Side Effects
  - Toxic effects
    - Allergic
    - Dose-dependent
    - Idiopathic
Drug interactions

Describe Why Two Drugs are Used in Combination

- Definition
  - Brief, of each drug.
  - Consider the components of anaesthesia that each provides
- Pharmacokinetics
  - Interactions
  - Relative onset
  - Metabolism
    - No effect/Induces/Inhibits
  - Elimination
- Pharmacodynamics
  - Isobologram
    - Synergistic/additive/antagonistic.
  - Then list the effects of each drug, and how they are modified by the other
    - e.g. if drugs are synergistic, then decreased doses will be required
      - Increases beneficial effects
      - Decreases adverse effects

Describe the Physiology of...

- Respiratory
  - Bronchodilation/constriction
  - Vasodilation/constriction
  - VT
  - RR
  - Secretion
  - Laryngeal reflexes
- CVS
  - Preload
  - Contractility/Pump effects
    - Inotropy
    - Chronotropy/rhythm
    - Dromotropy
    - Lusitropy
    - Bathmotropy
    - Nodal effects
    - Coronary Blood Flow
  - Afterload/Pipe effects
    - SBP
    - DBP
    - MAP
    - SVR
    - PVR
  - Intraarterial injection
- CNS
  - Sedation
- Analgesia
- Pro/anticonvulsant
- Amnestic
- Cerebral Metabolic Rate
- Cerebral Blood Flow
- ICP
- IOP
- Musculocutaneous
  - Blood Flow
  - NMJ
- Endocrine
  - Gynaecomastia
  - Hair
  - Bone
- Renal and GU
  - Renal Blood Flow
  - Nephrotoxicity
  - Bladder tone
  - Uterine tone
- GIT and Hepatic
  - Hepatotoxicity/LFTs
  - Secretions
  - Gastric emptying
  - N/V/D/C
- Haematological
  - G6PD
  - Porphyrias
  - Bone marrow effects
- Immunological
  - Anaphylaxis
  - Histaminergic
  - Neutrophil function
- Metabolic

**Anatomical Structure**

- Anatomy of the structure
- Relationships
- Relevant surface anatomy
- Layers of dissection

**Physics and Measurement**

- Definition
- Uses
- Physical principles
- Components
- Calibration
- Advantages/Disadvantages
References

- Dr. Podcast
- Wisdom from drunk, tired, and/or hungover examiners.

Last updated 2019-07-18